PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Faulkner, NE; Hilfinger, JM; Markovitz, DM				Faulkner, NE; Hilfinger, JM; Markovitz, DM			Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NF-KAPPA-B; DEK ONCOPROTEIN; OKADAIC ACID; DIFFERENTIAL REGULATION; SP1 PHOSPHORYLATION; TRANSLOCATION 6-9; EXPRESSION; ANTIGEN	Human immunodeficiency virus type 2 (HIV-2) gene expression is regulated by upstream promoter elements, including the peri-Ets (pets) site, which mediate enhancer stimulation following treatment with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), We previously showed that the oncoprotein DEK binds to the pets site in a site-specific manner. In this report, we show that binding to the HIV-2 pets site is modulated by treatment of U937 monocytic cells with TPA, an activator of protein kinase C, TPA treatment resulted in a reduction in the levels of DEK and the formation of a faster migrating pets complex in gel shift assays. We show further that the actions of TPA on pets binding can be duplicated by phosphatase treatment of nuclear proteins and is blocked with okadaic acid, a protein phospatase-2A (PP2A) inhibitor. Finally, we demonstrate that ectopic expression of the catalytic domain of PP2A can activate the HIV-2 enhancer/promoter alone or in synergy with TPA, an effect mediated in part through the pets site. These results suggest that, through an interaction with the protein kinase C pathway, PP2A is strongly involved in regulating HIV-2 enhancer-mediated transcription. This is a consequence of its effects on DEK expression and binding to the pets site, as well as its effects on other promoter elements. These findings have implications not only for HIV-2 transcription but also for multiple cellular processes involving DEK or PP2A.	Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Therapeut Syst Res Labs, Ann Arbor, MI 48108 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markovitz, DM (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, 5220 MSRB3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dmarkov@umich.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036685] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36685] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnaudo JP, 1998, J RHEUMATOL, V25, P1861; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong XW, 1998, ARTHRITIS RHEUM-US, V41, P1505, DOI 10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N; Dong XW, 2000, ARTHRITIS RHEUM-US, V43, P85, DOI 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Fu GK, 1996, J BIOL CHEM, V271, P19599, DOI 10.1074/jbc.271.32.19599; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HANNIBAL MC, 1994, BLOOD, V83, P1839; HILFINGER JM, 1993, J VIROL, V67, P4448, DOI 10.1128/JVI.67.7.4448-4453.1993; KILEY SC, 1995, J CELL SCI, V108, P1003; LI M, 1994, BIOCHEM BIOPH RES CO, V202, P1023, DOI 10.1006/bbrc.1994.2031; MARKOVITZ DM, 1993, ANN INTERN MED, V118, P211, DOI 10.7326/0003-4819-118-3-199302010-00010; MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MEYN MS, 1993, AM J HUM GENET, V53, P1206; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Murray KJ, 1997, J RHEUMATOL, V24, P560; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Oshevski S, 1999, BIOCHEM BIOPH RES CO, V263, P603, DOI 10.1006/bbrc.1999.1425; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; RIECKMANN P, 1992, BIOCHEM BIOPH RES CO, V187, P51, DOI 10.1016/S0006-291X(05)81457-3; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; SEIBENHENER ML, 1993, EXP CELL RES, V207, P183, DOI 10.1006/excr.1993.1178; Slosberg ED, 2000, MOL CARCINOGEN, V27, P166, DOI 10.1002/(SICI)1098-2744(200003)27:3<166::AID-MC3>3.0.CO;2-Z; SOEKARMAN D, 1992, BLOOD, V79, P2990; THEVENIN C, 1990, New Biologist, V2, P793; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wichmann I, 1999, HUM IMMUNOL, V60, P57, DOI 10.1016/S0198-8859(98)00085-8; Wichmann I, 2000, CLIN EXP IMMUNOL, V119, P530, DOI 10.1046/j.1365-2249.2000.01154.x; Wooten Marie W., 1993, Cytobios, V76, P19; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	46	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25804	25812		10.1074/jbc.M006454200	http://dx.doi.org/10.1074/jbc.M006454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11320078	hybrid			2022-12-25	WOS:000169823300024
J	Kremer, L; Dover, LG; Morehouse, C; Hitchin, P; Everett, M; Morris, HR; Dell, A; Brennan, PJ; McNeil, MR; Flaherty, C; Duncan, K; Besra, GS				Kremer, L; Dover, LG; Morehouse, C; Hitchin, P; Everett, M; Morris, HR; Dell, A; Brennan, PJ; McNeil, MR; Flaherty, C; Duncan, K; Besra, GS			Galactan biosynthesis in Mycobacterium tuberculosis - Identification of a bifunctional UDP-galactofuranosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTOCIDA HYALURONAN SYNTHASE; MYCOLIC ACID SYNTHESIS; CAPSULE GENE-CLUSTER; CELL-WALL; ESCHERICHIA-COLI; MASS-SPECTROMETRY; ARABINAN BIOSYNTHESIS; ACTIVE-SITE; ETHAMBUTOL; ARABINOGALACTAN	The cell wall of Mycobacterium tuberculosis and related genera is unique among prokaryotes, consisting of a covalently bound complex of mycolic acids, D-arabinan and D-galactan, which is linked to peptidoglycan via a special linkage unit consisting of Rhap-(1 -->3)-GlcNAc-P. Information concerning the biosynthesis of this entire polymer is now emerging with the promise of new drug targets against tuberculosis. Accordingly, we have developed a galactosyltransferase assay that utilizes the disaccharide neoglycolipid accepters beta -D-Galf-(1 -->5)-beta -Galf-O-C-10:1 and beta -D-Galf-(1 -->6)-beta -D-Galf-O-C-10:1, with UDP-Gal in conjunction with isolated membranes. Chemical analysis of the subsequent reaction products established that the enzymatically synthesized products contained both beta -D-Galf linkages ((1 -->5) and (1 -->6)) found within the mycobacterial cell, as well as in an alternating (1 -->5) and (1 -->6) fashion consistent with the established structure of the cell wall. Furthermore, through a detailed examination of the M. tuberculosis genome, we have shown that the gene product of Rv3808c, now termed glfT is a novel UDP-galactofuranosyltransferase, This enzyme possesses dual functionality in per forming both (1 -->5) and (1 -->6) galactofuranosyltransferase reactions with the above neoglycolipid accepters, using membranes isolated from the heterologous host Escherichia coli expressing Rv3808c, Thus, at a biochemical and genetic level, the polymerization of the galactan region of the mycolyl-arabinogalactan complex has been defined, allowing the possibility of further studies toward substrate recognition and catalysis and assay development. Ultimately, this may also lead to a more rational approach to drug design to be explored in the context of mycobacterial infections.	Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; GlaxoSmithKline Res & Dev Ltd, Stevenage SG1 2NY, Herts, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Newcastle University - UK; Imperial College London; GlaxoSmithKline; Colorado State University	Besra, GS (corresponding author), Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	g.s.besra@newcastle.ac.uk	Dover, Lynn George/Q-6778-2019; McNeil, Michael/G-3325-2019; Kremer, Laurent/M-4935-2017; Dover, Lynn G/F-3021-2010	Dover, Lynn George/0000-0002-4776-2665; Kremer, Laurent/0000-0002-6604-4458; Dover, Lynn G/0000-0002-4776-2665; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038087, R22AI018357, R01AI018357, R37AI018357, N01AI075320, R01AI045317] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-45317, AI-38087, N01-AI-75320, AI-18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Barlow JN, 2000, CARBOHYD RES, V328, P473, DOI 10.1016/S0008-6215(00)00135-X; Barry CE, 1997, BIOCHEM PHARMACOL, V54, P1165, DOI 10.1016/S0006-2952(97)00163-9; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Breton C, 1998, J BIOCHEM, V123, P1000; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DELL A, 1994, METHOD ENZYMOL, V230, P108; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; Hoang TT, 1999, GENE, V237, P361, DOI 10.1016/S0378-1119(99)00331-5; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KILBURN JO, 1981, ANTIMICROB AGENTS CH, V20, P401, DOI 10.1128/AAC.20.3.401; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; KREMER L, 1995, J BACTERIOL, V177, P642, DOI 10.1128/jb.177.3.642-653.1995; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121; Ma YF, 1997, MICROBIOL-SGM, V143, P937, DOI 10.1099/00221287-143-3-937; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; McNeil M, 1999, GENETICS OF BACTERIALS POLYSACCHARIDES, P207; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Mikusova K, 2000, J BIOL CHEM, V275, P33890, DOI 10.1074/jbc.M006875200; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Shibayama K, 1998, J BACTERIOL, V180, P5313, DOI 10.1128/JB.180.20.5313-5318.1998; Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; SUGAWARA F, 1986, AGR BIOL CHEM TOKYO, V50, P1557, DOI 10.1080/00021369.1986.10867583; TAKAYAMA K, 1979, ANTIMICROB AGENTS CH, V16, P240, DOI 10.1128/AAC.16.2.240; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; VEENEMAN GH, 1989, RECL TRAV CHIM PAY B, V108, P344; WARD JB, 1977, FEBS LETT, V78, P151, DOI 10.1016/0014-5793(77)80294-9; WARD JB, 1982, EUR J BIOCHEM, V122, P125; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weston A, 1998, TUBERCLE LUNG DIS, V78, P123, DOI 10.1016/S0962-8479(98)80005-1; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; WOLFROM ML, 1964, J ORG CHEM, V29, P454, DOI 10.1021/jo01025a052; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233; ZUURMOND HM, 1990, RECL TRAV CHIM PAY B, V109, P437	60	141	151	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26430	26440		10.1074/jbc.M102022200	http://dx.doi.org/10.1074/jbc.M102022200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11304545	hybrid			2022-12-25	WOS:000169823300104
J	Cohen, CJ; Graetz, J; Ohman, T; Bergelson, JM				Cohen, CJ; Graetz, J; Ohman, T; Bergelson, JM			Multiple regions within the coxsackievirus and adenovirus receptor cytoplasmic domain are required for basolateral sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STRUCTURAL REQUIREMENTS; APICAL SURFACE; FC-RECEPTORS; B VIRUSES; LOCALIZATION; PROTEIN; MOTIFS; ENDOCYTOSIS; EXPRESSION	The coxsackievirus and adenovirus receptor (CAR) mediates attachment and infection by coxsackie B viruses and many adenoviruses. In human airway epithelia, as well as in transfected Madin-Darby canine kidney cells, CAR is expressed exclusively on the basolateral surface. Variants of CAR that lack the cytoplasmic domain or are attached to the cell membrane by a glycosylphosphatidylinositol anchor are expressed on both the apical and basolateral surfaces, We have examined the localization of CAR variants with progressive truncations of the cytoplasmic domain, as well as with mutations that ablate a potential PDZ (PSD95/dlg/ZO-1) interaction motif and a putative tyrosine-based sorting signal. In addition, we have examined the targeting of two murine CAR isoforms, with different C-terminal sequences. The results suggest that multiple regions within the CAR cytoplasmic domain contain information that is necessary for basolateral targeting.	Childrens Hosp Philadelphia, Div Immunol & Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Cohen, CJ (corresponding author), Childrens Hosp Philadelphia, Div Immunol & Infect Dis, Abramson 1202,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Cohenc@email.chop.edu		Gaetz, Jedidiah/0000-0002-7103-6241	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54734] Funding Source: Medline; NIAID NIH HHS [T32 AI07278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Boucher RC, 1999, J CLIN INVEST, V103, P441, DOI 10.1172/JCI6330; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Keller P, 1997, J CELL SCI, V110, P3001; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Pickles RJ, 2000, J VIROL, V74, P6050, DOI 10.1128/JVI.74.13.6050-6057.2000; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Walters RW, 1999, J BIOL CHEM, V274, P10219, DOI 10.1074/jbc.274.15.10219; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	33	55	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25392	25398		10.1074/jbc.M009531200	http://dx.doi.org/10.1074/jbc.M009531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316797	hybrid			2022-12-25	WOS:000169800700128
J	Aiston, S; Hampson, L; Gomez-Foix, AM; Guinovart, JJ; Agius, L				Aiston, S; Hampson, L; Gomez-Foix, AM; Guinovart, JJ; Agius, L			Hepatic glycogen synthesis is highly sensitive to phosphorylase activity - Evidence from metabolic control analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; GLUCOSE DISPOSAL; RAT-LIVER; GLUCOKINASE; TRANSLOCATION; HEPATOCYTES; INHIBITION; SYNTHASE; GLUCOSE-6-PHOSPHATE; MECHANISM	We used metabolic control analysis to determine the flux control coefficient of phosphorylase on glycogen synthesis in hepatocytes by titration with a specific phosphorylase inhibitor (CP-91149) or by expression of muscle phosphorylase using recombinant adenovirus. The muscle isoform was used because it is catalytically active in the b-state. CP-91149 inactivated phosphorylase with sequential activation of glycogen synthase, It increased glycogen synthesis by 7-fold at 5 mM glucose and by 2-fold at 20 mM glucose with a decrease in the concentration of glucose causing half-maximal rate (S-0.5) from 26 to 19 mM. Muscle phosphorylase was expressed in hepatocytes mainly in the b-state, Low levels of phosphorylase expression inhibited glycogen synthesis by 50%, with little further inhibition at higher enzyme expression, and caused inactivation of glycogen synthase that, was reversed by CP-91149. At endogenous activity, phosphorylase has a very high (greater than unity) negative control coefficient on glycogen synthesis, regardless of whether it is determined by enzyme inactivation or overexpression, This high control is attenuated by glucokinase overexpression, indicating dependence on other enzymes with high control. The high control coefficient of phosphorylase on glycogen synthesis affirms that phosphorylase is a strong candidate target for controlling hyperglycemia in type 2 diabetes in both the absorptive and postabsorptive states.	Newcastle Univ, Sch Med, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona 08028, Spain	Newcastle University - UK; University of Barcelona	Agius, L (corresponding author), Newcastle Univ, Sch Med, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Loranne.Agius@ncl.ac.uk						Agius L, 1998, ADV ENZYME REGUL, V38, P303, DOI 10.1016/S0065-2571(97)00001-0; Agius L, 1997, BIOCHEM J, V325, P667, DOI 10.1042/bj3250667; AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; Aiston S, 1999, DIABETES, V48, P15, DOI 10.2337/diabetes.48.1.15; Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; Aiston S, 2000, DIABETOLOGIA, V43, P589, DOI 10.1007/s001250051348; ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Baque S, 1996, J BIOL CHEM, V271, P2594, DOI 10.1074/jbc.271.5.2594; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bergans N, 2000, DIABETES, V49, P1419, DOI 10.2337/diabetes.49.9.1419; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOARD M, 1995, EUR J BIOCHEM, V228, P753, DOI 10.1111/j.1432-1033.1995.0753m.x; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; CAO YJ, 1993, J BIOL CHEM, V268, P21717; de la Iglesia N, 2000, J BIOL CHEM, V275, P10597, DOI 10.1074/jbc.275.14.10597; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; Fosgerau K, 2000, ARCH BIOCHEM BIOPHYS, V380, P274, DOI 10.1006/abbi.2000.1930; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Guinovart JJ, 1997, BIOCHEM SOC T, V25, P157, DOI 10.1042/bst0250157; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Hoover DJ, 1998, J MED CHEM, V41, P2934, DOI 10.1021/jm980264k; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; Jucker BM, 1999, AM J PHYSIOL-ENDOC M, V277, pE505, DOI 10.1152/ajpendo.1999.277.3.E505; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Oikonomakos NG, 1999, PROTEIN SCI, V8, P1930, DOI 10.1110/ps.8.10.1930; Rath VL, 2000, CHEM BIOL, V7, P677, DOI 10.1016/S1074-5521(00)00004-1; Schulz AR, 1998, ARCH BIOCHEM BIOPHYS, V353, P172, DOI 10.1006/abbi.1998.0643; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SOLLING H, 1979, EUR J BIOCHEM, V94, P231, DOI 10.1111/j.1432-1033.1979.tb12890.x; STALMANS W, 1974, EUR J BIOCHEM, V41, P127, DOI 10.1111/j.1432-1033.1974.tb03252.x; STALMANS W, 1981, BIOCHEM J, V200, P327, DOI 10.1042/bj2000327; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179	46	66	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23858	23866		10.1074/jbc.M101454200	http://dx.doi.org/10.1074/jbc.M101454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309391	hybrid			2022-12-25	WOS:000169531100085
J	Lynch, KW; Weiss, A				Lynch, KW; Weiss, A			A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SEVERE COMBINED IMMUNODEFICIENCY; POINT MUTATION; COMBINATORIAL CONTROL; CELL MATURATION; SR-PROTEINS; T-CELLS; ENHANCER; ACTIVATION; EXPRESSION	Previous studies have identified a single nucleotide polymorphism that significantly increases the splicing of variable exon 4 in transcripts of the human protein-tyrosine phosphatase CD45. Strikingly, the presence of this polymorphism correlates with susceptibility to the autoimmune disease multiple sclerosis. In this study we investigated the mechanism by which the polymorphism enhances splicing of CD45 exon 4. We found that at least four distinct splicing regulatory elements exist within exon 4 and that the strongest of these elements is an exonic splicing silencer (designated ESS1), which is disrupted by the polymorphism. We show that ESS1 normally functions to repress the weak 5' splice site (ss) of CD45 exon 4. The ESS1 sequence also suppresses the splicing of a heterologous 5' ss and associates with a specific complex in nuclear extracts. We further demonstrate that ESS1 is juxtaposed to a purine-rich enhancer sequence that activates the use of the 5' ss of exon 4. Thus, proper functioning of the immune system is dependent on a complex interplay of regulatory activities that mediate the appropriate splicing of CD45 exon 4.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.				NIGMS NIH HHS [R01-GM39553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK DL, 1995, RNA, V1, P763; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Cale CM, 1997, ARCH DIS CHILD, V76, P163, DOI 10.1136/adc.76.2.163; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; EPERON IC, 1994, RNA PROCESSING PRACT, V1, P57; Gooding C, 1998, RNA, V4, P85; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Kung C, 2000, NAT MED, V6, P343; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Lemaire R, 1999, EUR J IMMUNOL, V29, P823, DOI 10.1002/(SICI)1521-4141(199903)29:03<823::AID-IMMU823>3.0.CO;2-C; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Lynch KW, 2000, MOL CELL BIOL, V20, P70, DOI 10.1128/MCB.20.1.70-80.2000; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Maquat LE, 2001, NAT GENET, V27, P5, DOI 10.1038/83759; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; Modafferi EF, 1999, RNA, V5, P687, DOI 10.1017/S1355838299990155; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1997, EUKARYOTIC MRNA PROC, P103; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Sarkissian M, 1996, J BIOL CHEM, V271, P31106, DOI 10.1074/jbc.271.49.31106; Schatzmann M, 1999, ENVIRONM POLLUT SER, V1, P261; SCHWINZER R, 1992, EUR J IMMUNOL, V22, P1095, DOI 10.1002/eji.1830220433; SCHWINZER R, 1990, J EXP MED, V171, P1803, DOI 10.1084/jem.171.5.1803; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; ten Dam GB, 2000, J IMMUNOL, V164, P5287, DOI 10.4049/jimmunol.164.10.5287; THUDE H, 1995, EUR J IMMUNOL, V25, P2101, DOI 10.1002/eji.1830250745; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Wang HY, 2001, MOL CELL, V7, P331, DOI 10.1016/S1097-2765(01)00181-2; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Zilch CF, 1998, EUR J IMMUNOL, V28, P22, DOI 10.1002/(SICI)1521-4141(199801)28:01<22::AID-IMMU22>3.0.CO;2-7	45	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24341	24347		10.1074/jbc.M102175200	http://dx.doi.org/10.1074/jbc.M102175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306584	hybrid			2022-12-25	WOS:000169531100146
J	Wang, N; Silver, DL; Thiele, C; Tall, AR				Wang, N; Silver, DL; Thiele, C; Tall, AR			ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CELLULAR CHOLESTEROL; TANGIER-DISEASE; SCAVENGER RECEPTOR; APOPTOTIC CELLS; DENSITY; LIPOPROTEINS; MUTATIONS; IDENTIFICATION; MECHANISM	ABCA1, an ATP-binding cassette transporter mutated in Tangier disease, promotes cellular phospholipid and cholesterol efflux by loading free apoA-I with these lipids. This process involves binding of apoA-I to the cell surface and phospholipid translocation by ABCA1, The goals of this study were to examine the relationship between ABCA1-mediated lipid efflux and apolipoprotein binding and to determine whether phospholipid and cholesterol efflux are coupled. Inhibition of lipid efflux by glybenclamide treatment or by mutation of the ATP-binding cassette of ABCA1 showed a close correlation between lipid efflux, the binding of apoA-I to cells, and cross-linking of apoA-I to ABCA1, The data suggest that a functionally important apoA-I binding site exists on ABCA1 and that the binding site could also involve lipids. After using cyclodextrin preincubation to deplete cellular cholesterol, ABCA1-mediated cholesterol efflux was abolished but phospholipid efflux and the binding of apoA-I were unaffected, The conditioned media hom cyclodextrin-pretreated, ABCA1-expressing cells readily promoted cholesterol efflux when added to fresh cells not expressing ABCA1, indicating that cholesterol efflux can be dissociated from phospholipid efflux, Further, using a photoactivatable cholesterol analog, we showed that ABCA1 did not bind cholesterol directly, even though several other cholesterol-binding proteins specifically bound the cholesterol analog. The data suggest that the binding of apoA-I to ABCA1 leads to the formation of phospholipid-apoA-I complexes, which subsequently promote cholesterol efflux in an autocrine or paracrine fashion.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Max Planck Inst Mol Biol & Genet, D-01307 Dresden, Germany	Columbia University; Max Planck Society	Wang, N (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.	nw30@columbia.edu	Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NHLBI NIH HHS [HL 58948] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Glomset J A, 1980, Adv Intern Med, V25, P91; Golstein PE, 1999, PFLUG ARCH EUR J PHY, V437, P652, DOI 10.1007/s004240050829; GREEN PHR, 1978, J CLIN INVEST, V61, P528, DOI 10.1172/JCI108963; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARA H, 1991, J BIOL CHEM, V266, P3080; IRIE T, 1982, J PHARMACOBIO-DYNAM, V5, P741; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Vankeerberghen A, 1998, HUM MOL GENET, V7, P1761, DOI 10.1093/hmg/7.11.1761; VAUGHAN DJ, 1980, CAN J BIOCHEM CELL B, V58, P581, DOI 10.1139/o80-080; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WINKLER KE, 1989, J LIPID RES, V30, P979	37	376	390	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23742	23747		10.1074/jbc.M102348200	http://dx.doi.org/10.1074/jbc.M102348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309399	hybrid			2022-12-25	WOS:000169531100070
J	Gaikwad, A; Long, DJ; Stringer, JL; Jaiswal, AK				Gaikwad, A; Long, DJ; Stringer, JL; Jaiswal, AK			In vivo role of NAD(P)H : quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DT-DIAPHORASE; QUINONE OXIDOREDUCTASE; MUTAGENICITY; GENE; RESISTANCE; REDUCTASE; GLYCOGEN; MUSCLE; CELLS; LEAD	NAD(P)H:quinone oxidoreductase 1 (NQO1) is a flavoprotein that utilizes NAD(P)II as an electron donor, catalyzing the two-electron reduction and detoxification of quinones and their derivatives. NQO1-/- mice deficient in NQO1 activity and protein were generated in our laboratory (Rajendirane, V,, Joseph, P., Lee, Y, H., Kimura, S., Klein-Szanto, A. J. P., Gonzalez, F, J., and Jaiswal, A. R. (1998) J. Biol. Chem. 273, 7382-7389). Mice lacking a functional NQO1 gene (NQO1-/-) were born normal and reproduced adeptly as the wild-type NQO1+/+ mice. In the present report, we show that NQO1-/- mice exhibit significantly lower levels of abdominal adipose tissue as compared with the wild-type mice. The NQO1-/- mice showed lower blood levels of glucose, no change in insulin, and higher levels of triglycerides, P-hydroxy butyrate, pyruvate, lactate, and glucagon as compared with wild-type mice. Insulin tolerance test demonstrated that the NQO1-/- mice are insulin resistant. The NQO1-/- mice livers also showed significantly higher levels of triglycerides, lactate, pyruvate, and glucose. The liver glycogen reserve was found decreased in NQO1-/- mice as compared with mild-type mice, The livers and kidneys from NQO1-/- mice also showed significantly lower levels of pyridine nucleotides but an increase in the reduced/oxidized NAD(P)H: NAD(P) ratio. These results suggested that loss of NQO1 activity alters the intracellular redox status by increasing the concentration of NAD(P)H. This leads to a reduction in pyridine nucleotide synthesis and reduced glucose and fatty acid metabolism. The alterations in metabolism due to redox changes result in a significant reduction in the amount of abdominal adipose tissue.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007943] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES07943] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BESSHO M, 1989, ANAL BIOCHEM, V182, P304, DOI 10.1016/0003-2697(89)90599-X; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; DEFLORA S, 1985, CANCER RES, V45, P3188; DUINE JA, 1991, EUR J BIOCHEM, V200, P271, DOI 10.1111/j.1432-1033.1991.tb16183.x; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JOHANN C, 1971, ANAL BIOCHEM, V43, P183, DOI 10.1016/0003-2697(71)90123-0; Joseph P, 1998, BRIT J CANCER, V77, P709, DOI 10.1038/bjc.1998.117; Joseph P, 1998, BRIT J CANCER, V78, P312, DOI 10.1038/bjc.1998.492; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kather B, 2000, J BACTERIOL, V182, P3204, DOI 10.1128/JB.182.11.3204-3209.2000; KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356; LAZZARINO G, 1989, ANAL BIOCHEM, V181, P239, DOI 10.1016/0003-2697(89)90236-4; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P598; Mokuda O, 2000, EXP CLIN ENDOCR DIAB, V108, P353, DOI 10.1055/s-2000-8128; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Radjendirane Venugopal, 1997, P441; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; Roy BD, 1998, J APPL PHYSIOL, V84, P890, DOI 10.1152/jappl.1998.84.3.890; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; TAKASHI M, 1998, P NATL ACAD SCI USA, V95, P10402; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2	27	161	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22559	22564		10.1074/jbc.M101053200	http://dx.doi.org/10.1074/jbc.M101053200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309386	hybrid			2022-12-25	WOS:000169412700079
J	Ishmael, FT; Norcum, MT; Benkovic, SJ; Bond, JS				Ishmael, FT; Norcum, MT; Benkovic, SJ; Bond, JS			Multimeric structure of the secreted meprin A metalloproteinase and characterization of the functional protomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; MAM DOMAIN; METALLOENDOPEPTIDASES; PROTEINASE; PROTEASOME; PEPTIDASES; FORMS; BETA	Meprin A secreted from kidney and intestinal epithe lial cells is capable of cleaving growth factors, extracellular matrix proteins, and biologically active peptides. The secreted form of meprin A is a homo oligomer com posed of ct subunits, a multidomain protease of 582 amino acids coded for near the major histocompatibility complex of the mouse and human genome. Analyses of the recombinant homo-oligomeric form of mouse meprin A by gel filtration, nondenaturing gel electrophoresis, and cross-linking (with disuccinimidyl suberate or N-(4-azido 2,3,5,6-tetraflourobenzyl)-3-maleimidylpropionamide) indicate that the secreted enzyme forms high molecular weight multimers, with a predominance of decamers, The multimers are composed of disulfide-linked dimers attached noncovalently by interactions involving the meprin, A5 protein, receptor protein-tyrosine phosphatase mu (MAM) domain. The active protomer is the noncovalently linked dimer. Linkage of active protomers by disulfide-bonds results in an oligomer of similar to 900 kDa, which is unique among proteases and distinguishes meprin A as the largest known secreted protease. Electron microscopy revealed that the protein was present in two states, a crescent-shaped structure and a closed ring. It is concluded from this and other data that the covalent attachment of the protomers enables noncovalent associations of the native enzyme to form higher oligomers that are critical for hydrolysis of protein substrates.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Penn State Univ, Eberly Coll Sci, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Mississippi; University of Mississippi Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R01DK019691, R37DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alley SC, 2000, J AM CHEM SOC, V122, P6126, DOI 10.1021/ja000591t; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; Johnson G.S., 1998, HDB PROTEOLYTIC ENZY, P1222; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; METZ G, 1977, Z NATURFORSCH C, V32, P929; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	20	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23207	23211		10.1074/jbc.M102654200	http://dx.doi.org/10.1074/jbc.M102654200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301339	hybrid			2022-12-25	WOS:000169412700163
J	Laing, JG; Manley-Markowski, RN; Koval, M; Civitelli, R; Steinberg, TH				Laing, JG; Manley-Markowski, RN; Koval, M; Civitelli, R; Steinberg, TH			Connexin45 interacts with zonula occludens-1 and connexin43 in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; TIGHT JUNCTION; ZO-1	The relative expression of connexin43 and connexin45 modulates gap junctional communication and production of bone matrix proteins in osteoblastic cells, It is likely that changes in gap junction permeability are determined by the interaction between these two proteins. Cx43 interacts with ZO-1, which may be involved in trafficking of Cx43 or facilitating interactions between Cx43 and other proteins. In this study we sought to identify proteins that associate with Cx45 by coprecipitation in non-denaturing conditions. Cx45 was isolated with a 220-kDa protein that we identified as ZO-1. Under the same conditions, Cx43 also was isolated with anti-Cx45 antiserum from Cx45-transfected ROS cells (ROS/Cx45 cells). Cx43 antiserum could also coprecipitate ZO-1 in the transfected and untransfected ROS cells. Double label immunofluorescence studies showed that ZO-1, Cx43, and Cx45 colocalized at appositional membranes in ROS/Cx45 cells suggesting that all three proteins are normally associated in the cells, Additionally, we found that in vitro translated ZO-1 binds to the carboxyl-terminal of Cx45 indicating that there is a direct interaction between the carboxyl-terminal of Cx45 and ZO-1. These studies demonstrate that ZO-1 interacts with Cx45 as well as with Cx43, and suggest that the interaction of connexins with ZO-1 may play a role in regulating the composition of the gap junction and may modulate connexin-connexin interactions.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Washington University (WUSTL); University of Pennsylvania	Laing, JG (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Campus Box 8051,660 S Euclid Ave, St Louis, MO 63110 USA.	laing@id.wustl.edu	Civitelli, Roberto/AAA-8260-2019; Koval, Michael/C-6366-2015	Civitelli, Roberto/0000-0003-4076-4315; Koval, Michael/0000-0002-5422-5614	NIAMS NIH HHS [AR41255] Funding Source: Medline; NIDDK NIH HHS [DK-46686] Funding Source: Medline; NIGMS NIH HHS [GM-54660] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041255, R29AR041255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054660] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUERRIER A, 1995, J CELL SCI, V108, P2609; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987; Koval M, 1997, J CELL BIOL, V137, P847, DOI 10.1083/jcb.137.4.847; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lecanda F, 1998, MOL BIOL CELL, V9, P2249, DOI 10.1091/mbc.9.8.2249; Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; STEINBERG TH, 1993, MOL BIOL CELL, V4, P329; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200	18	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23051	23055		10.1074/jbc.M100303200	http://dx.doi.org/10.1074/jbc.M100303200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11313345	hybrid			2022-12-25	WOS:000169412700142
J	Lim, F; Downey, TP; Peabody, DS				Lim, F; Downey, TP; Peabody, DS			Translational repression and specific RNA binding by the coat protein of the Pseudomonas phage PP7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-Q-BETA; CRYSTAL-STRUCTURE; 3.5-ANGSTROM RESOLUTION; SITE; AERUGINOSA; PLASMID; GA	PP7 is a single strand RNA bacteriophage of Pseudomonas aeroginosa and a distant relative to coliphages like MS2 and Q beta. Here we show that PP7 coat protein is a specific RNA-binding protein, capable of repressing the translation of sequences fused to the translation initiation region of PP7 replicase. Its RNA binding activity is specific since it represses the translational operator of PP7, but does not repress the operators of the MS2 or Q beta phages, Conditions for the purification of coat protein and for the reconstitution of its RNA binding activity from disaggregated virus-like particles were established. Its dissociation constant for PP7 operator RNA in vitro was determined to be about 1 nM. Using a genetic system in which coat protein represses translation of a replicase-beta -galactosidase fusion protein, amino acid residues important for binding of PP7 RNA were identified.	Univ New Mexico, Dept Mol Genet & Microbiol, Sch Med, Albuquerque, NM 87131 USA	University of New Mexico	Peabody, DS (corresponding author), Univ New Mexico, Dept Mol Genet & Microbiol, Sch Med, Albuquerque, NM 87131 USA.							CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; Golmohammadi R, 1996, STRUCTURE, V4, P543, DOI 10.1016/S0969-2126(96)00060-3; GOLMOHAMMADI R, 1993, J MOL BIOL, V234, P620, DOI 10.1006/jmbi.1993.1616; GOTT JM, 1991, NUCLEIC ACIDS RES, V19, P6499, DOI 10.1093/nar/19.23.6499; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LECUYER KA, 1996, EMBO J, V15, P6487; Licis N, 2000, VIROLOGY, V271, P298, DOI 10.1006/viro.2000.0327; LILJAS L, 1994, J MOL BIOL, V244, P279, DOI 10.1006/jmbi.1994.1729; Lim F, 1996, J BIOL CHEM, V271, P31839, DOI 10.1074/jbc.271.50.31839; LIM F, 1994, J BIOL CHEM, V269, P9006; Miller JH., 1972, EXPT MOL GENETICS; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; NI CZ, 1995, STRUCTURE, V3, P255, DOI 10.1016/S0969-2126(01)00156-3; OLSTHOORN RCL, 1995, VIROLOGY, V206, P611, DOI 10.1016/S0042-6822(95)80078-6; PEABODY DS, 1990, J BIOL CHEM, V265, P5684; Peabody DS, 1997, MOL GEN GENET, V254, P358, DOI 10.1007/s004380050427; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tars K, 2000, ACTA CRYSTALLOGR D, V56, P398, DOI 10.1107/S0907444900001232; Tars K, 2000, VIROLOGY, V272, P331, DOI 10.1006/viro.2000.0373; Tars K, 1997, J MOL BIOL, V271, P759, DOI 10.1006/jmbi.1997.1214; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	25	60	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22507	22513		10.1074/jbc.M102411200	http://dx.doi.org/10.1074/jbc.M102411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306589	hybrid			2022-12-25	WOS:000169412700072
J	Ollagnier-de-Choudens, S; Mattioli, T; Tagahashi, Y; Fontecave, M				Ollagnier-de-Choudens, S; Mattioli, T; Tagahashi, Y; Fontecave, M			Iron-sulfur cluster assembly - Characterization of IscA and evidence for a specific and functional complex with ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; 2FE-2S FERREDOXIN; CLOSTRIDIUM-PASTEURIANUM; AZOTOBACTER-VINELANDII; GENE-CLUSTER; PROTEINS; BIOSYNTHESIS; BIOGENESIS	The synthesis of iron-sulfur clusters in Escherichia coli is believed to require a complex protein machinery encoded by the ise (iron-sulfur cluster) operon. The product of one member of this operon, IscA, has been overexpressed, purified, and characterized. It can assemble an air-sensitive [2Fe-2S] cluster as shown by UV-visible and resonance Raman spectroscopy. The metal form but not the apoform of IscA binds ferredoxin, another member of the ise operon, selectively, allowing transfer of iron and sulfide from IscA to ferredoxin and formation of the [2Fe-2S] holoferredoxin. These results thus suggest that IscA is involved in ferredoxin cluster assembly and activation. This is an important function because a functional ferredoxin is required for maturation of other cellular Fe-S proteins.	Univ Grenoble 1, CEA, CNRS,UMR 5047, DBMS,CB,Lab Chim & Biochim, F-38054 Grenoble 09, France; Univ Grenoble 1, CEA, CNRS,UMR 5047, DBMS,CB,Ctr Redox Biol, F-38054 Grenoble, France; CEA, DBCM, Sect Bioenerget, F-91191 Gif Sur Yvette, France; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Universite Paris Saclay; Osaka University	Fontecave, M (corresponding author), Univ Grenoble 1, CEA, CNRS,UMR 5047, DBMS,CB,Lab Chim & Biochim, 17 Ave Martyrs, F-38054 Grenoble 09, France.		Takahashi, Yasuhiro/F-1119-2011	Takahashi, Yasuhiro/0000-0002-0588-6045; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEAN DR, 1993, J BACTERIOL, V175, P6735; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Flint DH, 1996, J BIOL CHEM, V271, P16068; Foster MW, 2000, J AM CHEM SOC, V122, P6805, DOI 10.1021/ja000800+; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; MEYER J, 1984, BIOCHEM BIOPH RES CO, V119, P828, DOI 10.1016/0006-291X(84)90848-9; MEYER J, 1994, BIOCHEMISTRY-US, V33, P13642, DOI 10.1021/bi00250a014; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Pelzer W, 2000, FEBS LETT, V476, P134, DOI 10.1016/S0014-5793(00)01711-7; Spiro T. G., 1988, RESONANCE RAMAN SPEC, P523; SPIRO TG, 2000, PHYSICAL METHODS BIO, P97; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TA DT, 1992, J BIOL CHEM, V267, P11120; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	31	168	172	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22604	22607		10.1074/jbc.M102902200	http://dx.doi.org/10.1074/jbc.M102902200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11319236	hybrid			2022-12-25	WOS:000169412700085
J	Uzel, MI; Scott, IC; Babakhaniou-Chase, H; Palamakumbura, AH; Pappano, WN; Hong, HH; Greenspan, DS; Trackman, PC				Uzel, MI; Scott, IC; Babakhaniou-Chase, H; Palamakumbura, AH; Pappano, WN; Hong, HH; Greenspan, DS; Trackman, PC			Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; AMINO-ACID-SEQUENCE; GENE; COLLAGEN; ENZYME; IDENTIFICATION; EXPRESSION; PRECURSOR; ENCODES; TISSUES	Lysyl oxidase catalyzes the final enzymatic step required for collagen and elastin cross-linking in extracellular matrix biosynthesis, Pro-lysyl oxidase is processed by procollagen C-proteinase activity, which also removes the C-propeptides of procollagens I-III. The Bmp1 gene encodes two procollagen C-proteinases: bone morphogenetic protein 1 (BMP-1) and mammalian Tolloid (mTLD), Mammalian Tolloid-like (mTLL)-1 and -2 are two genetically distinct BMP-l-related proteinases, and mTLL-1 has been shown to have procollagen C-proteinase activity. The present study is the first to directly compare pro-lysyl oxidase processing by these four related proteinases. In vitro assays with purified recombinant enzymes show that all four proteinases productively cleave pro-lysyl oxidase at the correct physiological site but that BMP-1 is 3-, 15, and 20-fold more efficient than mTLL-1, mTLL-2, and mTLD, respectively. To more directly assess the roles of BMP-1 and mTLL-1 in lysyl oxidase activation by connective tissue cells, fibroblasts cultured from Bmp1-null, Till-null, and Bmp2/Tll1 double null mouse embryos, thus lacking BMP-1/mTLD, mTLL I, or all three enzymes, respectively, were assayed for lysyl oxidase enzyme activity and for accumulation of pro-lysyl oxidase and mature similar to 30-kDa lysyl oxidase, Wild type cells or cells singly null for Bmp1 or Till all produced both pro-lysyl oxidase and processed lysyl oxidase at similar levels, indicating apparently normal levels of processing, consistent with enzyme activity data, In contrast, double null Bmp1/Tll1 cells produced predominantly unprocessed 50-kDa prolysyl oxidase and had lysyl oxidase enzyme activity diminished by 70% compared with wild type, Bmp1-null, and Tll1-null cells. Thus, the combination of BMP-1/mTLD and mTLL-1 is shown to be responsible for the majority of processing leading to activation of lysyl oxidase by murine embryonic fibroblasts, whereas in vitro studies identify pro-lysyl oxidase as the first known substrate for mTLL-2.	Boston Univ, Goldman Sch Dent Med, Div Oral Biol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	Boston University; Boston University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Trackman, PC (corresponding author), Boston Univ, Goldman Sch Dent Med, Div Oral Biol, 100 E Newton St,Rm G-07, Boston, MA 02118 USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Pappano, William/0000-0003-2848-2219; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR43621] Funding Source: Medline; NIDCR NIH HHS [DE12425, DE11004, DE12209] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011004, R29DE011004, R03DE012425, R01DE012209] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALMASSIAN B, 1991, CONNECT TISSUE RES, V25, P197, DOI 10.3109/03008209109029156; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; Clark TG, 1999, DEVELOPMENT, V126, P2631; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Jang W, 1999, GENOME RES, V9, P53; Jourdan-Le Saux C, 1998, GENOMICS, V51, P305, DOI 10.1006/geno.1998.5356; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; KAGAN HM, 1995, METHOD ENZYMOL, V258, P122; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1993, J BIOL CHEM, V268, P18435; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kessler E., 1998, HDB PROTEOLYTIC ENZY, P1236; Lathyrism Selye H, 1957, REV CAN BIOL, V16, P3; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uzel MI, 2000, J BONE MINER RES, V15, P1189, DOI 10.1359/jbmr.2000.15.6.1189; VYTASEK R, 1982, ANAL BIOCHEM, V120, P243, DOI 10.1016/0003-2697(82)90342-6	40	189	205	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22537	22543		10.1074/jbc.M102352200	http://dx.doi.org/10.1074/jbc.M102352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11313359	hybrid			2022-12-25	WOS:000169412700076
J	Nelsen, CJ; Hansen, LK; Rickheim, DG; Chen, CS; Stanley, MW; Krek, W; Albrecht, JH				Nelsen, CJ; Hansen, LK; Rickheim, DG; Chen, CS; Stanley, MW; Krek, W; Albrecht, JH			Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2	ONCOGENE			English	Article						cyclins; gene therapy; liver regeneration; polyploidy; skp2	CELL-CYCLE; ECTOPIC EXPRESSION; DEPENDENT KINASES; GROWTH-FACTOR; ADENOVIRUS; REGENERATION; DEGRADATION; PROGRESSION; P27(KIP1); REPLICATION	Cells in culture become competent to replicate in the absence of growth factor after progressing beyond the late G1 restriction point, suggesting that a set of genes expressed during G1 phase is sufficient to trigger completion of the cell cycle. However, this has not been demonstrated in an in vivo system. In this study, we examined whether transfection of genes associated with the G1/S transition could trigger hepatocyte replication. Co-transfection of cyclin E and skp2 synergistically promoted cell cycle progression in cultured primary hepatocytes in the absence of mitogen or in the presence of growth inhibitors. Furthermore, transfection of hepatocytes in vivo with cyclin E and skp2 promoted abundant hepatocyte replication and hyperplasia of the liver. These studies confirm that transfection with a small number of genes can trigger proliferation of quiescent hepatocytes in vivo, and suggest that therapies to enhance liver regeneration by targeting cell cycle control genes may be feasible.	Hennepin Cty Med Ctr, Dept Med 865B, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; FMI, CH-4058 Basel, Switzerland	Hennepin County Medical Center; Hennepin County Medical Center; Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; Friedrich Miescher Institute for Biomedical Research	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr, Dept Med 865B, 701 Pk Ave, Minneapolis, MN 55415 USA.			Hansen, Linda/0000-0003-3651-0419	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056222, R01DK054921] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56222, DK54921] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bilodeau M, 1999, FEBS LETT, V452, P247, DOI 10.1016/S0014-5793(99)00629-8; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chowdhury JR, 1999, SEMIN LIVER DIS, V19, P1, DOI 10.1055/s-2007-1007092; Coelho CM, 2000, J CELL SCI, V113, P2927; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Ehrenfried JA, 1997, SURGERY, V122, P927, DOI 10.1016/S0039-6060(97)90334-2; FANG JWS, 1994, LANCET, V343, P820, DOI 10.1016/S0140-6736(94)92025-7; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gao CH, 1999, HEPATOLOGY, V30, P1405, DOI 10.1002/hep.510300602; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Ginsberg HS, 1996, B NEW YORK ACAD MED, V73, P53; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hansen LK, 1999, J CELL SCI, V112, P2971; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Ilan Y, 1999, SEMIN LIVER DIS, V19, P49, DOI 10.1055/s-2007-1007097; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; KAWASAKI S, 1992, GASTROENTEROLOGY, V102, P1351; Kay MA, 1997, MOL MED TODAY, V3, P108, DOI 10.1016/S1357-4310(96)10062-9; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TARAO K, 1994, CANCER, V73, P1149, DOI 10.1002/1097-0142(19940215)73:4<1149::AID-CNCR2820730405>3.0.CO;2-9; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045	48	47	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1825	1831		10.1038/sj.onc.1204248	http://dx.doi.org/10.1038/sj.onc.1204248			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313930				2022-12-25	WOS:000167908400003
J	Iwai, N; Kitajima, K; Sakai, K; Kimura, T; Nakano, T				Iwai, N; Kitajima, K; Sakai, K; Kimura, T; Nakano, T			Alteration of cell adhesion and cell cycle properties of ES cells by an inducible dominant interfering Myb mutant	ONCOGENE			English	Article						ES cells; cell adhesion; B-Myb	BETA-1 INTEGRIN GENE; EMBRYONIC STEM-CELLS; B-MYB; C-MYB; HEMATOPOIETIC PROGENITORS; S-PHASE; V-MYB; A-MYB; EXPRESSION; DIFFERENTIATION	The Myb transcription factors, c-Myb, A-Myb, and B-Myb, regulate cell differentiation and/or proliferation. To investigate the role of B-Myb in embryogenesis, we introduced an inducible dominant interfering Myb protein (MERT) into embryonic stem (ES) cells, which express B-Myb as an exclusive member of Myb family. Disruption of normal B-Myb function by the conditional activation of MERT caused a drastic morphological alteration of ES cells and G(1)-S cell cycle arrest. The inhibition of B-Myb function by MERT dissociated tightly packed ES cell colonies into dispersed single cells that subsequently detached from the culture dish. Cell adhesion analyses revealed that suppression of B-Myb function reduced the adhesion with extracellular matrix proteins, such as laminin, collagen, and fibronectin, This reduction was presumably due to decreased cell surface expression of beta1 integrin, Embryoid body formation was also severely retarded by the activation of MERT, This impairment was attributed to reduced expression of E-cadherin, which functions as a homophilic intercellular adhesion molecule. Simultaneously, blocking B-Myb function did not alter the expression of differentiation markers. Our data indicate that B-Myb plays important roles in regulating cell adhesion and cell cycle progression. These results are well consistent with the recent report on the phenotype of B-Myb null mice and show that the regulation of cell adhesion is an important B-Myb function that has not yet been assumed.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Osaka 5650871, Japan	Osaka University	Nakano, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Yamadaoka 3-1, Osaka 5650871, Japan.			Kimura, Tohru/0000-0001-9227-0996				ARSURA M, 1992, BLOOD, V79, P2708; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; JOYNER AL, 1993, IRL PRESS, V142, P1121; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kume A, 1999, STEM CELLS, V17, P226, DOI 10.1002/stem.170226; Larue L, 1996, DEVELOPMENT, V122, P3185; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Lipsick JS, 1996, ONCOGENE, V13, P223; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu ZJ, 1998, BLOOD, V92, P4700; Lyon JJ, 1996, GENE, V182, P123, DOI 10.1016/S0378-1119(96)00531-8; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sitzmann J, 1996, ONCOGENE, V12, P1889; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; WILES MV, 1993, METHOD ENZYMOL, V225, P900; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	41	22	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1425	1434		10.1038/sj.onc.1204236	http://dx.doi.org/10.1038/sj.onc.1204236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313886				2022-12-25	WOS:000167595200003
J	Kishi, S; Wulf, G; Nakamura, M; Lu, KP				Kishi, S; Wulf, G; Nakamura, M; Lu, KP			Telomeric protein Pin2/TRF1 induces mitotic entry and apoptosis in cells with short telomeres and is down-regulated in human breast tumors	ONCOGENE			English	Article						apoptosis; cancer; cell cycle; Pin2/TRF1; telomeres; telomeric protein	ATAXIA-TELANGIECTASIA GENE; M-PHASE PHOSPHOPROTEINS; FISSION YEAST; PHOSPHORYLATED EPITOPE; PROLYL ISOMERIZATION; DEFICIENT MICE; FLOW-CYTOMETRY; ATM; LENGTH; INHIBITION	Telomeres are essential for cell survival and have been implicated in the mitotic control. The telomeric protein Pin2/TRF1 controls telomere elongation and its expression is tightly regulated during cell cycle. We previously reported that overexpression of Pin2/TRF1 affects mitotic progression. However, the role of Pin2/TRF1 at the interface between cell division and cell survival remains to be determined. Here we show that overexpression of Pin2 induced apoptosis in cells containing short telomeres, but not in cells with long telomeres, Furthermore, before entering apoptosis, Pin2-expressing cells first accumulated in mitosis and strongly stained with the mitosis-specific MPM2 antibody. Moreover, Pin2-induccd apoptosis is potentiated by arresting cells in mitosis, but suppressed by accumulating cells in G1, In addition, overexpression of Pin2 also resulted in activation of caspase-3, and its proapoptotic activity was significantly reduced by inhibition of caspase-3, These results indicate that up-regulation of Pin2/TRF1 can specifically induce entry into mitosis and apoptosis, likely via a mechanism related to activation of caspase-3, Significantly, we also found that, out of 51 human breast cancer tissues and 10 normal controls examined, protein levels of Pin2/TRF1 in tumors were significantly lower than in normal tissues, as detected by immunoblotting analysis and immunocytochemistry, Since down-regulation of Pin2/TRF1 allows cells to maintain long telomeres, these results suggest that down-regulation of Pin2/TRF1 may be important for cancer cells to extend their proliferative potential.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, HIM 1047,330 Brookline Ave, Boston, MA 02215 USA.		Wulf, Gerburg/AAS-6713-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM56230] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 1999, GENETICS, V151, P1041; Aragona M, 2000, ONCOL REP, V7, P987; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Belloc F, 2000, CYTOMETRY, V40, P151, DOI 10.1002/(SICI)1097-0320(20000601)40:2<151::AID-CYTO9>3.0.CO;2-9; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Douglas RS, 1998, CYTOMETRY, V32, P57, DOI 10.1002/(SICI)1097-0320(19980501)32:1<57::AID-CYTO8>3.0.CO;2-C; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Young AC, 1997, SOMAT CELL MOLEC GEN, V23, P275, DOI 10.1007/BF02674418; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZIV Y, 1989, CANCER RES, V49, P2495	64	50	58	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1497	1508		10.1038/sj.onc.1204229	http://dx.doi.org/10.1038/sj.onc.1204229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313893				2022-12-25	WOS:000167595200010
J	Liu, RG; Li, BL; Qiu, MS				Liu, RG; Li, BL; Qiu, MS			Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha	ONCOGENE			English	Article						superoxide; H-ras; NADPH oxidase; signal transduction; WI-38VA-13 cells; TNF-alpha	CARCINOMA SCC-25 CELLS; REACTIVE OXYGEN; SIGNAL-TRANSDUCTION; NADPH OXIDASE; FREE-RADICALS; CHROMOSOMAL-ABERRATIONS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS	Accumulating evidence has suggested that cellular production of superoxide acts as an intracellular messenger to regulate gene expression and modulate cellular activities, In this report, we set out to investigate the role of active H-ras-mediated superoxide production on tumor cell malignancy in a SV-40 transformed human lung WI-38 VA-13 cell line, Stable transfection and expression of constitutively active mutant V12-H-ras (V12-H-ras) dramatically increased intracellular production of superoxide, The expression of V12-H-ras significantly enhanced cell proliferation, migration and resistance to TNF-alpha treatment compared to that of parental and vector control cells, while expression of wild type H-ras (WT-H-ras) only had modest effects. Upon scavenging by superoxide dismutase and other molecules that decrease the intracellular level of active H-ras mediated superoxide production, cell proliferation, migration and resistance to TNF-alpha were significantly reduced. Furthermore, we demonstrated that the activation of membrane NADPH oxidase activity by expression of active I-P-ras contributed to the intracellular superoxide production. The causal relationship between membrane superoxide production and increased cell proliferation, migration, and resistance to TNF-alpha by the expression of active H-ras, has provided direct evidence to demonstrate that superoxide acts as an intracellular messenger to cascade res oncogenic signal relay and to modulate turner malignant activity.	Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	University of Louisville; Eli Lilly	Liu, RG (corresponding author), Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.							Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bohler T, 2000, CYTOKINE, V12, P986, DOI 10.1006/cyto.1999.0633; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DAGHER MC, 1995, BIOCHIMIE, V77, P651, DOI 10.1016/0300-9084(96)88180-6; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; EMERIT I, 1981, NATURE, V293, P144, DOI 10.1038/293144a0; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Giri U, 1999, CANCER LETT, V135, P53; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IWATA K, 1984, TOXICOL LETT, V22, P75, DOI 10.1016/0378-4274(84)90048-1; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; KENNEDY AR, 1984, CARCINOGENESIS, V5, P1213, DOI 10.1093/carcin/5.10.1213; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li SJ, 2000, CANCER RES, V60, P3927; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Liu RG, 1999, RADIAT RES, V151, P133, DOI 10.2307/3579763; Liu RG, 2000, FREE RADICAL BIO MED, V28, P1197, DOI 10.1016/S0891-5849(00)00237-9; Liu RG, 1998, CELL GROWTH DIFFER, V9, P239; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOSCHEN G, 1974, FEBS LETT, V42, P6874; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; NAKAMURA Y, 1985, CARCINOGENESIS, V6, P229, DOI 10.1093/carcin/6.2.229; OBERLEY LW, 1979, CANCER RES, V39, P1141; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pani G, 2000, CANCER RES, V60, P4654; Pick E, 1986, Methods Enzymol, V132, P407; PRETONE WF, 1980, P NATL ACAD SCI USA, V77, P1159; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; SOFUNI T, 1984, MUTAT RES, V140, P27, DOI 10.1016/0165-7992(84)90067-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; Yan T, 1996, CANCER RES, V56, P2864; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Zhai QW, 2000, J CELL PHYSIOL, V184, P161, DOI 10.1002/1097-4652(200008)184:2<161::AID-JCP3>3.3.CO;2-E; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; ZIMMERMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P2085, DOI 10.1073/pnas.81.7.2085	59	37	39	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1486	1496		10.1038/sj.onc.1204214	http://dx.doi.org/10.1038/sj.onc.1204214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313892				2022-12-25	WOS:000167595200009
J	Slack, JK; Adams, RB; Rovin, JD; Bissonette, EA; Stoker, CE; Parsons, JT				Slack, JK; Adams, RB; Rovin, JD; Bissonette, EA; Stoker, CE; Parsons, JT			Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells	ONCOGENE			English	Article						focal adhesion kinase; Src; cell migration; prostate; signal transduction	PROTEIN-TYROSINE KINASE; SRC FAMILY KINASES; SUBSTRATE P130(CAS); DROSOPHILA HOMOLOG; IN-VIVO; PHOSPHORYLATION; INTEGRIN; CRK; ACTIVATION; PAXILLIN	Focal adhesion kinase (FAK) has been implicated in the regulation of cell migration. In addition, FAK expression is:increased in a number of highly metastatic tumor cell lines. Therefore, we investigated the role of FAK in regulating migration of prostate carcinoma cell lines with increasing metastatic potential. We show that highly tumorigenic PC3 and DU145 cells exhibit intrinsic migratory capacity, while poorly tumorigenic LNCaP cells require a stimulus to migrate, Increased metastatic potential of PC3 and DU145 cells correlates with increased FAK expression, overall tyrosine phosphorylation and activity, as measured by autophosphorylation of tyrosine 397, However, in PC3 and DU145 cells, FAK autophosphorylation is adhesion dependent whereas a second site of tyrosine phosphorylation, tyrosine 861, a Src specific site, is uncoupled from adhesion-dependent signaling events, Finally, inhibiting the FAK/Src signal transduction pathway by over expressing FRNK ((F) under bar ocal adhesion kinase-(R) under bar elated (N) under bar on-(K) under bar inase), an inhibitor of FAK activation, or treatment with PP2, a Src family kinase-inhibitor, significantly inhibited migration of prostate carcinoma cell lines, demonstrating that tumor cell migration continues to be dependent on signals emanating from this pathway.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Parsons, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.		Mordwinkin, Nicholas M/A-4347-2010		NATIONAL CANCER INSTITUTE [P01CA076465] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA76465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Han NM, 1997, ANN SURG ONCOL, V4, P264, DOI 10.1007/BF02306620; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hsu J., 1996, MULTIPLE COMP THEORY; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; KAIGHN ME, 1979, INVEST UROL, V17, P16; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KORNBERG LJ, 1992, J BIOL CHEM, V276, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOHLER JL, 1988, CANCER RES, V48, P4312; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Owen JD, 1999, MOL CELL BIOL, V19, P4806; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Tremblay L, 1996, MOL ENDOCRINOL, V10, P1010, DOI 10.1210/me.10.8.1010; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Zheng DQ, 1999, CANCER RES, V59, P1655	60	175	180	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1152	1163		10.1038/sj.onc.1204208	http://dx.doi.org/10.1038/sj.onc.1204208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313859				2022-12-25	WOS:000167570100002
J	Lewitzky, M; Kardinal, C; Gehring, NH; Schmidt, EK; Konkol, B; Eulitz, M; Birchmeier, W; Schaeper, U; Feller, SM				Lewitzky, M; Kardinal, C; Gehring, NH; Schmidt, EK; Konkol, B; Eulitz, M; Birchmeier, W; Schaeper, U; Feller, SM			The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif	ONCOGENE			English	Article						SH3; Grb2; Gab1; SLP-76	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; SRC HOMOLOGY-3 DOMAIN; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; RAS PATHWAY; CBL PROTOONCOGENE; MOLECULAR-CLONING; EGF-RECEPTOR	The adapter Grb2 is an important mediator of normal cell proliferation and oncogenic signal transduction events. It consists of a central SH2 domain flanked by two SH3 domains, While the binding specificities of the Grb2 SH2 and N-terminal SH3 domain [Grb2 SH3(N)] have been studied in detail, binding properties of the Grb2 SH3(C) domain remained poorly defined. Gab1, a receptor tyrosine kinase substrate which associates with Grb2 and the c-Met receptor, was previously shown to bind Grb2 via a region which lacks a Grb2 SH3(N)-typical motif (P-x-x-P-x-R), Precipitation experiments with the domains of Grb2 shaw now that Gab1 can bind stably to the Grb2 SH3(C) domain. For further analyses, Gab1 mutants mere generated by PCR to test in vivo residues thought to be crucial for Grb2 SH3(C) binding. The Grb2 SH3(C) binding region of Gab1 has significant homology to a region of the adapter protein SLP-76. Peptides corresponding to epitopes SLP-76, Gab1, SoS and other proteins with related sequences, as well as mutant peptides were synthesized and analysed by tryptophan-fluorescence spectrometry and by irt vitro competition experiments. These experiments define a 13 amino acid sequence with the unusual consensus motif P-x-x-x-R-x-x-(K) under bar-(P) under bar as required for a stable binding to the SH3(C) domain of Grb2. Additional analyses point to a distinct binding specificity of the Grb2-homologous adapter protein Mona (Gads), indicating that the proteins of the Grb2 adapter family may have partially overlapping, yet distinct protein binding properties.	Univ Wurzburg, MSZ, Mol Oncol Lab, D-97078 Wurzburg, Germany; GSF, Munich, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Mol Oncol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.							Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; COWBURN D, 1995, J BIOL CHEM, V270, P26738, DOI 10.1074/jbc.270.45.26738; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; KIESS M, 1995, ONCOGENE, V10, P61; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Park RK, 1998, J IMMUNOL, V160, P5018; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takenawa T, 1998, CURR TOP MICROBIOL, V228, P325; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Whisstock JC, 1999, TRENDS BIOCHEM SCI, V24, P132, DOI 10.1016/S0968-0004(99)01366-3; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678	73	83	86	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1052	1062		10.1038/sj.onc.1204202	http://dx.doi.org/10.1038/sj.onc.1204202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314042				2022-12-25	WOS:000167232100005
J	Braliou, GG; Ciana, P; Klaassen, W; Gandrillon, O; Stunnenberg, HG				Braliou, GG; Ciana, P; Klaassen, W; Gandrillon, O; Stunnenberg, HG			The v-ErbA oncoprotein quenches the activity of an erythroid-specific enhancer	ONCOGENE			English	Article						v-ErbA; thyroid hormone; repression; erythroid enhancer; carbonic anhydrase II; GATA-sites	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; DNA-BINDING SPECIFICITY; BETA-GLOBIN GENE; TRANSCRIPTIONAL REPRESSION; C-ERBA; DEPENDENT TRANSACTIVATION; CELL-DIFFERENTIATION; HISTONE DEACETYLASE; ONCOGENE PRODUCT	v-ErbA is a mutated variant of thyroid hormone receptor (TR alpha /NR1A1) borne by the Avian Erythroblastosis virus causing erythroleukemia. TR alpha is known to activate transcription of specific genes in the presence of its cognate ligand, T3 hormone, while in its absence it represses it, v-ErbA is unable to bind ligand, and hence is thought to contribute to leukemogenesis by actively repressing erythroid-specific genes such as the carbonic anhydrase II gene (CA II). In the prevailing model, v-ErbA occludes liganded TR from binding to its cognate elements and constitutively interacts with the corepressors NCoR/ SMRT. We previously identified a v-ErbA responsive element (VRE) within a DNase I hypersensitive region (HS2) located in the second intron of the CA II gene. We now show that HS2 fulfils all the requirements for a genuine enhancer that functions independent of its orientation and position with a profound erythroid-specific activity in normal erythroid progenitors (T2ECs) and in leukemic erythroid cell lines. We find that the HS2 enhancer activity is governed by two adjacent GATA-factor binding sites. v-ErbA as well as unliganded TR prevent HS2 activity by nullifying the positive function of factors bound to GATA-sites. However, v-ErbA, in contrast to TR, does not convey active repression to silence the transcriptional activity intrinsic to a heterologous tk promoter. We propose that depending on the sequence and context of the binding site, v-ErbA contributes to leukomogenesis by occluding liganded TR as well as unliganded TR thereby preventing activation or repression, respectively.	Univ Nijmegen, NCMLS, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands; Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Stunnenberg, HG (corresponding author), Univ Nijmegen, NCMLS, Dept Mol Biol, Geert Groote Pl 26,POB 9101, NL-6500 HB Nijmegen, Netherlands.		Stunnenberg, Hendrik G./D-6875-2012; Ciana, Paolo/F-9224-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; CIANA, PAOLO/0000-0001-5771-5638				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Auwerx J, 1999, CELL, V97, P161; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASINI T, 1995, ONCOGENE, V11, P1019; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEMAGISTRIS L, 1988, NUCLEIC ACIDS RES, V16, P3141, DOI 10.1093/nar/16.8.3141; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Glass CK, 2000, GENE DEV, V14, P121; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; INNIS JW, 1983, MOL CELL BIOL, V3, P2203, DOI 10.1128/MCB.3.12.2203; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; PAIN B, 1990, New Biologist, V2, P284; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RASCLE A, 1994, ONCOGENE, V9, P2853; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHROEDER C, 1992, ONCOGENE, V7, P217; Seraphin B, 1996, NUCLEIC ACIDS RES, V24, P3276, DOI 10.1093/nar/24.16.3276; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; Stunnenberg HG, 1999, BBA-REV CANCER, V1423, pF15, DOI 10.1016/S0304-419X(98)00036-5; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; Thormeyer D, 1999, INT J MOL MED, V4, P351; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wahlstrom GM, 1996, ONCOGENE, V13, P843; Wahlstrom GM, 1998, MOL ENDOCRINOL, V12, P645, DOI 10.1210/me.12.5.645; Wang GF, 1998, MOL CELL BIOL, V18, P6023, DOI 10.1128/MCB.18.10.6023; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 1999, MOL CELL BIOL, V19, P6448	69	5	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					775	787		10.1038/sj.onc.1204159	http://dx.doi.org/10.1038/sj.onc.1204159			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314012	Bronze			2022-12-25	WOS:000166924400001
J	Fluge, O; Haugen, DRF; Akslen, LA; Marstad, A; Santoro, M; Fusco, A; Varhaug, JE; Lillehaug, JR				Fluge, O; Haugen, DRF; Akslen, LA; Marstad, A; Santoro, M; Fusco, A; Varhaug, JE; Lillehaug, JR			Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas	ONCOGENE			English	Article						ret; RNA splicing; ret/ptc; thyroid carcinoma	RET/PTC ONCOGENE ACTIVATION; TYROSINE KINASE; 3'-SPLICING VARIANTS; SIGNAL-TRANSDUCTION; HUMAN KIDNEY; PROTOONCOGENE; RECEPTOR; MUTATIONS; GENE; PHENOTYPES	Somatic rearrangements of the ret receptor tyrosine kinase have been consistently reported in papillary thyroid carcinomas (PTC), It is unclear whether the expression of wild-type c-ret may also be implicated in thyroid tumorigenesis, We studied ret mRNA expression in PTC from Norwegian patients. Using RT-PCR, wild-type ret mRNA was detected in all of 22 PTC and in a PTC cell line. c-ret mRNA was clearly overexpressed in PTC as compared to non-neoplastic thyroid tissue. Hybridization using ret exon DNA dot blot arrays and complex cDNA probes confirmed expression of ret RNA in thyroid biopsies. In accordance with the RNA data, Western immunoblotting showed evidence of wildtype Ret protein in PTC, Rearrangements generating the ret/PTC oncogenes co-existed with c-ret mRNA in PTC, Multiple alternative ret splicing variants were detected in PTC, Four novel I et splicing events were found in the region encoding the extracellular domain. The open reading frames of these transcripts were all in-frame with the Ret tyrosine kinase domain. In the central ret mRNA region encoding the cystein-rich, transmembrane, and main tyrosine kinase domains, no evidence of alternative splicing was detected. Two alternative splice events were detected in the I ct mRNA encoding the C-terminal part of Ret protein harboring tyrosine residues important for Ret signaling, excluding exon 19, or retaining intron 19, respectively. Ribonuclease protection assays confirmed the presence of I et alternative splicing events in thyroid biopsies. We conclude that in addition to ret/PTC rearrangements, wild-type c-ret mRNA and alternatively spliced ret transcripts are present in PTC, Transcriptional up-regulation and post-transcriptional mechanisms of c-l et RNA processing may contribute to differences in expression of Ret protein observed in PTC compared to non-neoplastic thyroid tissue.	Univ Bergen, Dept Mol Biol, N-5020 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway; CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Bergen, Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; University of Bergen; Haukeland University Hospital	Fluge, O (corresponding author), Univ Bergen, Dept Mol Biol, Thormohlens Gt 55, N-5020 Bergen, Norway.		Akslen, Lars A./AAG-6097-2021; Haugen, Dagny R. Faksvåg/AAX-7989-2021; Akslen, Lars A/C-1202-2017	Akslen, Lars A./0000-0003-2710-9543; Akslen, Lars A/0000-0003-2710-9543; Haugen, Dagny Faksvag/0000-0002-8592-4995; Fusco, Alfredo/0000-0003-3332-5197				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; Bunone G, 2000, CANCER RES, V60, P2845; Carson-Walter EB, 1998, ONCOGENE, V17, P367, DOI 10.1038/sj.onc.1201938; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; de Nigris F, 1998, CANCER RES, V58, P4745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; KWOK JBJ, 1993, ONCOGENE, V8, P2575; Lam AKY, 1998, HUM PATHOL, V29, P565, DOI 10.1016/S0046-8177(98)80004-X; Landsvater RM, 1996, HUM GENET, V97, P11, DOI 10.1007/BF00218825; Learoyd DL, 1998, J CLIN ENDOCR METAB, V83, P3631, DOI 10.1210/jc.83.10.3631; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MYERS SM, 1995, ONCOGENE, V11, P2039; Nikiforov YE, 1997, CANCER RES, V57, P1690; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Tallini G, 1998, CLIN CANCER RES, V4, P287; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Visser M, 1996, BRIT J HAEMATOL, V94, P236, DOI 10.1046/j.1365-2141.1996.d01-1789.x; Williams GH, 1996, BRIT J CANCER, V74, P585, DOI 10.1038/bjc.1996.405; Wilson KF, 1999, J BIOL CHEM, V274, P4166, DOI 10.1074/jbc.274.7.4166; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; XING SH, 1994, BIOCHEM BIOPH RES CO, V205, P1526, DOI 10.1006/bbrc.1994.2840	35	32	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					885	892		10.1038/sj.onc.1204161	http://dx.doi.org/10.1038/sj.onc.1204161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314023				2022-12-25	WOS:000166924400013
J	Kuo, ML; Chuang, SE; Lin, MT; Yang, SY				Kuo, ML; Chuang, SE; Lin, MT; Yang, SY			The involvement of PI3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interlenkin-6	ONCOGENE			English	Article						interleukin-6; Mcl-1; apoptosis; PI3-K/Akt pathway	BETA-INDUCED APOPTOSIS; 3-KINASE/AKT SIGNALING PATHWAY; PROTEIN-KINASE CASCADE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; LIVER-REGENERATION; TRANSDUCER GP130; C-JUN; AKT	Interleukin-6 (IL-6) is a pleitrophic cytokine that not only regulates growth and differentiation of many cell types, but also induces production of acute phase proteins (A4P) in hepatocytes. Our previous works have demonstrated that both PI 3-K/Akt and STAT3 pathways mere concomitantly activated and cooperatively mediated the anti-apoptotic effect of IL-6. This investigation reports that IL-6 protected cells against apoptosis induced by a variety of agents including, TGF-beta, Uv and retinoic acid (RA) in Hep3B cells, suggesting that IL-6 is a fundamental determinant of hepatic cell survival. Mel-1, but not other Bcl-2 family members, was rapidly up-regulated by IL-6, with a peak (approximately 3-4-fold) appearing at 4 h. Transient transfection of cells with a mcl-1 antisense vector, resulting in a 50-60% reduction of the anti-apoptotic effect of IL-6, indicating that Mcl-1 is a downstream effector of IL-6. Which signaling pathway transduced by IL-6 responsible for the Mcl-1 up-regulation was further investigated. In Hep3B cells, the JAK/STAT3, ERR, and PI 3-K/Abt pathways mere activated by IL-6 stimulation. Blocking JAK/STAT3 activation with a dominant-negative mutant STAT3F or a JAK inhibitor AG490 could not influence IL-6-mediated Mcl-1 up-regulation. Similarly, PD98059 treatment, a MEK specific inhibitor, also failed to inhibit Mcl-1 expression. However, the IL-6-induced Mcl-1 upregulation was effectively attenuated in the presence of PI 3-K inhibitors, LY294002 and wortmannin. Expression of dominant-negative Akt, but not Etk, could abrogate the IL-6-induced increase of Mcl-1. In conclusion, our results suggest that the anti-apoptotic effect of IL-6 is mediated, at least in part, bai Mcl-1 expression and that is mainly through the PI 3-K/Akt-dependent pathway.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10764, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan; Natl Taiwan Hosp, Dept Surg, Taipei, Taiwan	National Taiwan University; National Health Research Institutes - Taiwan	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10764, Taiwan.		Chuang, Shuang-En/D-2080-2010; Kuo, Min-Liang/C-4872-2009	LIN, MING-TSAN/0000-0001-7313-7057; KUO, MIN-LIANG/0000-0002-7139-0144				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Andrejko KM, 1998, AM J PHYSIOL-GASTR L, V275, pG1423, DOI 10.1152/ajpgi.1998.275.6.G1423; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hockenbery D M, 1992, Semin Immunol, V4, P413; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kuo ML, 1996, CARCINOGENESIS, V17, P815, DOI 10.1093/carcin/17.4.815; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Malaguarnera M, 1997, J GASTROENTEROL, V32, P211, DOI 10.1007/BF02936370; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Minshall C, 1996, J IMMUNOL, V156, P939; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Ogata A, 1997, J IMMUNOL, V159, P2212; Oyanagi Y, 1999, LIVER, V19, P464, DOI 10.1111/j.1478-3231.1999.tb00078.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Toretsky JA, 1999, CANCER RES, V59, P5745; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	50	127	129	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					677	685		10.1038/sj.onc.1204140	http://dx.doi.org/10.1038/sj.onc.1204140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314001				2022-12-25	WOS:000166806000003
J	Lecureur, V; Thottassery, JV; Sun, D; Schuetz, EG; Lahti, J; Zambetti, GP; Schuetz, JD				Lecureur, V; Thottassery, JV; Sun, D; Schuetz, EG; Lahti, J; Zambetti, GP; Schuetz, JD			Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo	ONCOGENE			English	Article						apoptosis; MDR; diethylnitrosamine	WILD-TYPE P53; RESISTANCE GENE-EXPRESSION; DNA-BINDING DOMAIN; RAT HEPATOMA-CELLS; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; LIVER CELLS; APOPTOSIS; PROTEIN; INDUCTION	The mdr1b gene is thought to be a "stress-responsive" gene, however it is unknown if this gene is regulated by p53 in the whole animal. Moreover, it is unknown if overexpression of mdr1b affects cell survival. The dependence of mdr1b upon p53 for upregulation was evaluated in p53 knockout mice. Wild-type (wt) or p53-/- mice were treated singly or in combination with gamma irradiation (IR) and/or the potent DNA damaging agent, diethylnitrosoamine (DEN), Both IR and DEN induced mdr1b in wild-type animals, but not in the p53-/- mice. IR also upregulated endogenous mdr lb in the H35 liver cell line, and the mdr lb promoter was activated by IR and activation correlated with p53 levels; moreover activation required an intact p53 binding site. Colony survival studies revealed that co-transfection of both mdr1b and p53 dramatically reduced colony numbers compared to cells transfected with either p53 or mdr1b alone and cells microinjected with both mdr1b and p53 had a more dramatic loss in viability compared to cells injected with either expression vector alone. Further studies using acridine orange and ethidium bromide to measure apoptosis revealed that mdr1b caused apoptosis and this was enhanced by p53, however the increased apoptosis required a functional p53 transactivation domain. These studies indicate that mdr1b is a downstream target of p53 in the whole animal and expression of mdr1b facilitates p53-mediated cell death.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.		Zambetti, Gerard/N-8093-2018; Schuetz, John D/N-2692-2018; Schuetz, Erin/N-8087-2018; LECUREUR, Valérie/J-9095-2015	Zambetti, Gerard/0000-0002-0929-5007; 	NCI NIH HHS [CA63203] Funding Source: Medline; NIEHS NIH HHS [ES08658, ES05851] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008658, R29ES005851, R01ES005851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; Chin LS, 1997, J NEUROSCI RES, V48, P122, DOI 10.1002/(SICI)1097-4547(19970415)48:2<122::AID-JNR4>3.0.CO;2-E; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DMITRIEVA N, 2000, IN PRESS J BIOL CHEM; Fardel O, 1998, BIOCHEM BIOPH RES CO, V245, P85, DOI 10.1006/bbrc.1998.8388; Furuya KN, 1997, CANCER RES, V57, P3708; Furuya KN, 1997, J BIOL CHEM, V272, P11518; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN J, 1995, GENE DEV, V8, P1235; LOTHSTEIN L, 1989, J BIOL CHEM, V264, P16054; MacCallum DE, 1996, ONCOGENE, V13, P2575; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Ralhan R, 1999, INT J CANCER, V84, P80, DOI 10.1002/(SICI)1097-0215(19990219)84:1<80::AID-IJC15>3.0.CO;2-G; Rasola A, 1999, FASEB J, V13, P1711, DOI 10.1096/fasebj.13.13.1711; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Roemer K, 1996, ONCOGENE, V12, P2069; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; Schrenk D, 1996, BIOCHEM PHARMACOL, V52, P1453, DOI 10.1016/S0006-2952(96)00512-6; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SINGH J, 1991, MUTAGENESIS, V6, P117, DOI 10.1093/mutage/6.2.117; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; SPECTOR DL, 1998, CELLS CULTURE BIOCH; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; Weisburg JH, 1999, J BIOL CHEM, V274, P10877, DOI 10.1074/jbc.274.16.10877; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1998, J BIOL CHEM, V273, P15387, DOI 10.1074/jbc.273.25.15387; Ziemann C, 1999, CARCINOGENESIS, V20, P407, DOI 10.1093/carcin/20.3.407	46	18	18	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					303	313		10.1038/sj.onc.1204065	http://dx.doi.org/10.1038/sj.onc.1204065			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313959				2022-12-25	WOS:000166411000004
J	He, CY; Striepen, B; Pletcher, CH; Murray, JM; Roos, DS				He, CY; Striepen, B; Pletcher, CH; Murray, JM; Roos, DS			Targeting and processing of nuclear-encoded apicoplast proteins in plastid segregation mutants of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; HOST-CELL PENETRATION; PLASMODIUM-FALCIPARUM; APICOMPLEXAN PARASITES; ENDOPLASMIC-RETICULUM; FLUORESCENT PROTEIN; RHOPTRY PROTEIN; TRITON X-114; LOCALIZATION; CHLOROPLASTS	The apicoplast is a distinctive organelle associated with apicomplexan parasites, including Plasmodium sp. (which cause malaria) and Toxoplasma gondii (the causative agent of toxoplasmosis). This unusual structure (acquired by the engulfment of an ancestral alga and retention of the algal plastid) is essential for long-term parasite survival. Similar to other endosymbiotic organelles (mitochondria, chloroplasts), the apicoplast contains proteins that are encoded in the nucleus and post-translationally imported. Translocation across the four membranes surrounding the apicoplast is mediated by an N-terminal bipartite targeting sequence. Previous studies have described a recombinant "poison" that blocks plastid segregation during mitosis, producing parasites that lack an apicoplast and siblings containing a gigantic, nonsegregating plastid. To learn more about this remarkable phenomenon, we examined the localization and processing of the protein produced by this construct. Taking advantage of the ability to isolate apicoplast segregation mutants, we also demonstrated that processing of the transit peptide of nuclear-encoded apicoplast proteins requires plastid-associated activity.	Univ Penn, Dept Biol, Godard Labs 305, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Flow Cytometry Shared Resource, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Roos, DS (corresponding author), Univ Penn, Dept Biol, Godard Labs 305, Philadelphia, PA 19104 USA.		He, Cynthia/H-9789-2012	Roos, David Siker/0000-0001-6725-4089; Striepen, Boris/0000-0002-7426-432X				Ajioka JW, 1998, INT J PARASITOL, V28, P1025, DOI 10.1016/S0020-7519(98)00030-7; Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; DeRocher A, 2000, J CELL SCI, V113, P3969; DUBEY JP, 1988, J AM VET MED ASSOC, V193, P697; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Hager KM, 1999, J CELL SCI, V112, P2631; He CY, 2001, EMBO J, V20, P330, DOI 10.1093/emboj/20.3.330; Jelenska J, 2001, P NATL ACAD SCI USA, V98, P2723, DOI 10.1073/pnas.051629998; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kausch AP, 1999, BIOTECHNIQUES, V26, P336, DOI 10.2144/99262rr04; KELEMEN MV, 1979, J CELL SCI, V35, P431; Kissinger JC, 2001, NUCLEIC ACIDS RES, V29, P66; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MANIATIS T, 1989, MOL CLONING LAB MANU, P18; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; Morrissette NS, 1997, J CELL SCI, V110, P35; NAGEL SD, 1989, J BIOL CHEM, V264, P5569; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; ROIZEN N, 1995, PEDIATRICS, V95, P11; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; SAFFER LD, 1992, J PROTOZOOL, V39, P526, DOI 10.1111/j.1550-7408.1992.tb04844.x; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; Seeber F, 1998, J CELL SCI, V111, P23; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Striepen B, 1998, MOL BIOCHEM PARASIT, V92, P325, DOI 10.1016/S0166-6851(98)00011-5; Striepen B, 2000, J CELL BIOL, V151, P1423, DOI 10.1083/jcb.151.7.1423; Sulli C, 1999, J BIOL CHEM, V274, P457, DOI 10.1074/jbc.274.1.457; Sulli C, 1996, PLANT CELL, V8, P43; Sullivan M, 2000, MOL BIOCHEM PARASIT, V109, P17, DOI 10.1016/S0166-6851(00)00226-7; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1997, MICROBIOL MOL BIOL R, V61, P1; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Zhu G, 2000, MOL BIOCHEM PARASIT, V105, P253, DOI 10.1016/S0166-6851(99)00183-8; Zuther E, 1999, P NATL ACAD SCI USA, V96, P13387, DOI 10.1073/pnas.96.23.13387	46	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28436	28442		10.1074/jbc.M102000200	http://dx.doi.org/10.1074/jbc.M102000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11319231	hybrid			2022-12-25	WOS:000170093400092
J	MacKinnon, AC; Waters, C; Jodrell, D; Haslett, C; Sethi, T				MacKinnon, AC; Waters, C; Jodrell, D; Haslett, C; Sethi, T			Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor - Direct evidence for biased agonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LUNG-CANCER; SWISS 3T3 CELLS; GASTRIN-RELEASING PEPTIDE; STRESS FIBER FORMATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; GROWTH-FACTORS; INDEPENDENT PATHWAY; AP-1 TRANSCRIPTION	Substance P analogues including [D-Arg(1),D-Phe(5),D-Trp(7,) (9),Leu(11)] substance P (SpD) act as "broad spectrum neuropeptide antagonists" and are potential anticancer agents that inhibit the growth of small cell lung cancer cells in vitro and in vivo. However, their mechanism of action is controversial and not fully understood. Although these compounds block bombesin-induced mitogenesis and signal transduction, they also have agonist activity. The mechanism underlying this agonist activity was examined. SpD binds to the ligand-binding site of the bombesin/gastrin-releasing peptide receptor and blocks the bombesin-stimulated increase in [Ca2+](i) within the same concentration range that causes sustained activation of c-Jun N-terminal kinase and extracellular signal-regulated protein kinase (ERK). The activation of e-Jun N-terminal kinase by SpD and bombesin is blocked by dominant negative inhibition of G(alpha 12). The ERK activation by SpD is pertussis toxin-sensitive in contrast to ERK activation by bombesin, which is pertussis toxin-insensitive but dependent on epidermal growth factor receptor phosphorylation. Spl) does not simply act as a partial agonist but differentially modulates the activation of the G-proteins G(alpha 12), G(i), and G(q) compared with bombesin. This unique ability allows the bombesin receptor to couple to Gi and at the same time block receptor activation of G(q). Our results provide direct evidence that Spl) is acting as a "biased agonist" and that this has physiological relevance in small cell lung cancer cells. This validation of the concept of biased agonism has important implications in the development of novel pharmacological agents to dissect receptor-mediated signal transduction and of highly selective drugs to treat human disease.	Univ Edinburgh, Sch Med, Resp Med Unit, Ctr Inflammat Res,Rayne Lab, Edinburgh EH8 9AG, Midlothian, Scotland; Western Gen Hosp, Imperial Canc Res Fund, Med Oncol Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Sethi, T (corresponding author), Univ Edinburgh, Sch Med, Resp Med Unit, Ctr Inflammat Res,Rayne Lab, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.							Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Charlesworth A, 1997, ONCOGENE, V14, P2323, DOI 10.1038/sj.onc.1201075; Charlesworth A, 1996, ONCOGENE, V12, P1337; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Donohue PJ, 1999, BIOCHEMISTRY-US, V38, P9366, DOI 10.1021/bi990544h; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hedin KE, 1999, J BIOL CHEM, V274, P19992, DOI 10.1074/jbc.274.28.19992; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; Kelley MJ, 1997, CHEST, V112, P256, DOI 10.1378/chest.112.1.256; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; MacKinnon AC, 2000, BRIT J CANCER, V83, P941, DOI 10.1054/bjoc.2000.1362; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOODY TW, 1993, LIFE SCI, V52, P1161, DOI 10.1016/0024-3205(93)90098-N; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Perez DM, 1996, MOL PHARMACOL, V49, P112; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; Seckl MJ, 1997, CANCER RES, V57, P51; SECKL MJ, 1995, J CELL PHYSIOL, V163, P87, DOI 10.1002/jcp.1041630110; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Sinnett-Smith J, 2000, J BIOL CHEM, V275, P30644, DOI 10.1074/jbc.M003702200; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; Tsuda T, 1997, MOL PHARMACOL, V51, P721, DOI 10.1124/mol.51.5.721; Wang QMJ, 1996, INT J CANCER, V68, P528, DOI 10.1002/(SICI)1097-0215(19961115)68:4<528::AID-IJC20>3.3.CO;2-Q; Watson C, 2000, MOL PHARMACOL, V58, P1230, DOI 10.1124/mol.58.6.1230; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211	52	48	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28083	28091		10.1074/jbc.M009772200	http://dx.doi.org/10.1074/jbc.M009772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11323408	hybrid			2022-12-25	WOS:000170093400046
J	Tremeau-Bravard, A; Perez, C; Egly, JM				Tremeau-Bravard, A; Perez, C; Egly, JM			A role of the C-terminal part of p44 in the promoter escape activity of transcription factor IIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; FACTOR TFIIH; SSL1 GENES; DNA-REPAIR; HELICASE; CDK7; INITIATION; YEAST; XPD	The p44 subunit plays a crucial role in the overall activity of the transcription/DNA repair factor TFIIH: on the one hand its N-terminal domain interacts with and regulates the XPD helicase (1, 2); on the other hand, as shown in the present study, it participates with the promoter escape reaction. Mutagenesis along with recombinant technology using the baculovirus/insect cells expression system allowed us to define the function of the two structural motifs of the C-terminal moiety of p44: mutations within the C4 zinc finger motif (residues 291-308) prevent incorporation of the p62 subunit within the core TFIIH. Double mutations in the RING finger motif (residues 345-385) allow the synthesis of the first phosphodiester bond by RNA polymerase II, but prevent its escape from the promoter. This highlights the role of transcription factor IIH in the various steps of the transcription initiation process.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.							BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Fribourg S, 2000, J BIOL CHEM, V275, P31963, DOI 10.1074/jbc.M004960200; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; GERARD M, 1991, J BIOL CHEM, V266, P20940; Guzman E, 1999, MOL CELL BIOL, V19, P5652; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Maines S, 1998, GENETICS, V150, P963; MATSUI P, 1995, NUCLEIC ACIDS RES, V23, P767, DOI 10.1093/nar/23.5.767; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; Seroz T, 2000, J BIOL CHEM, V275, P33260, DOI 10.1074/jbc.M004764200; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	34	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27693	27697		10.1074/jbc.M102457200	http://dx.doi.org/10.1074/jbc.M102457200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11319235	hybrid			2022-12-25	WOS:000169966900126
J	Blanpain, C; Wittamer, V; Vanderwinden, JM; Boom, A; Renneboog, B; Lee, B; Le Poul, E; El Asmar, L; Govaerts, C; Vassart, G; Doms, RW; Parmentier, M				Blanpain, C; Wittamer, V; Vanderwinden, JM; Boom, A; Renneboog, B; Lee, B; Le Poul, E; El Asmar, L; Govaerts, C; Vassart, G; Doms, RW; Parmentier, M			Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 CORECEPTOR ACTIVITY; PROTEIN-COUPLED RECEPTOR; 4TH CYTOPLASMIC LOOP; G-BETA-GAMMA; CHEMOKINE RECEPTORS; T-CELLS; POSTTRANSLATIONAL MODIFICATION; BETA(2)-ADRENERGIC RECEPTOR; THYROTROPIN RECEPTOR	CCR5 is a CC chemokine receptor expressed on memory lymphocytes, macrophages, and dendritic cells and also constitutes the main coreceptor for macrophage-tropic (or R5) strains of human immunodeficiency viruses. In the present study, we investigated whether CCR5 as palmitoylated in its carboxyl-terminal do. main by generating alanine substitution mutants for the three cysteine residues present in this region, individually or in combination. We found that wild-type CCR5 was palmitoylated, but a mutant lacking all three Cys residues was not. Through the use of green fluorescent fusion proteins and immunofluorescence studies, we found that the absence of receptor palmitoylation resulted in sequestration of CCR5 in intracellular biosynthetic compartments. By using the fluorescence recovery after photobleaching technique, we showed that the non-palmitoylated mutant had impaired diffusion properties within the endoplasmic reticulum. We next stud led the ability of the mutants to bind and signal in response to chemokines, Chemokines binding and activation of G(i)-mediated signaling pathways, such as calcium mobilization and inhibition of adenylate cyclase, were not affected. However, the duration of the functional response, as measured by a microphysiometer, and the ability to increase [S-35]guanosine 5 ' -3-O(thio)triphosphate binding to membranes were severely affected for the non-palmitoylated mutant. The ability of RANTES (regulated on activation normal T cell expressed and secreted) and aminooxypentane-RANTES to promote CCR5 endocytosis was not altered by cysteine replacements. Finally, we found that the absence of receptor palmitoylation reduced the human immunodeficiency viruses coreceptor function of CCR5, but this effect was secondary to the reduction in surface expression. In conclusion, we found that palmitoylated cysteines play an important role in the intracellular trafficking of CCR5 and are likely necessary for efficient coupling of the receptor to part of its repertoire of signaling cascades.	Euroscreen SA, B-1070 Brussels, Belgium; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium; Free Univ Brussels, Lab Histol Neuroanat & Neuropathol, B-1070 Brussels, Belgium; Free Univ Brussels, Inst Interdisciplianary Res, B-1070 Brussels, Belgium	University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), IRIBHN, ULB Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.		Lee, Benhur/A-8554-2016; Blanpain, Cedric/ABD-8392-2021	Lee, Benhur/0000-0003-0760-1709; Parmentier, Marc/0000-0001-8081-4685; Wittamer, Valerie/0000-0003-0003-2646	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003923] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL03923] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; AXELROD D, 1976, P NATL ACAD SCI USA, V73, P4594, DOI 10.1073/pnas.73.12.4594; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; Blanpain C, 1999, BLOOD, V94, P1899; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; CRISE B, 1992, J BIOL CHEM, V267, P13593; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Faussner A, 1998, J BIOL CHEM, V273, P2617, DOI 10.1074/jbc.273.5.2617; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Garred P, 1998, J RHEUMATOL, V25, P1462; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Hall IP, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03425-X; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; Kawate N, 1997, MOL CELL ENDOCRINOL, V127, P211, DOI 10.1016/S0303-7207(97)04010-0; Kosugi S, 1996, BIOCHEM BIOPH RES CO, V221, P636, DOI 10.1006/bbrc.1996.0648; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mack M, 1999, ARTHRITIS RHEUM, V42, P981, DOI 10.1002/1529-0131(199905)42:5<981::AID-ANR17>3.0.CO;2-4; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nelson S, 1999, ENDOCRINOLOGY, V140, P950, DOI 10.1210/en.140.2.950; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Reynes J, 2000, J INFECT DIS, V181, P927, DOI 10.1086/315315; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; YEUNG DE, 1991, VIROLOGY, V181, P35, DOI 10.1016/0042-6822(91)90467-P; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	76	114	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23795	23804		10.1074/jbc.M100583200	http://dx.doi.org/10.1074/jbc.M100583200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323418	hybrid, Green Submitted			2022-12-25	WOS:000169531100078
J	Nikolopoulos, SN; Turner, CE				Nikolopoulos, SN; Turner, CE			Integrin-linked kinase (ILK) binding to paxillin LD1 motif regulates ILK localization to focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-ADHESION; IDENTIFICATION; GROWTH; ACTIN; SITES	Paxillin is a focal adhesion adapter protein involved in integrin signaling. Paxillin LD motifs bind several focal adhesion proteins including the focal adhesion kinase, vinculin, the Arf-GTPase-activating protein paxillin-kinase linker, and the newly identified actin-binding protein actopaxin, Microsequencing of peptides derived from a 50-kDa paxillin LD1 motif-binding protein revealed 100% identity with integrin-linked kinase (ILK)-1, a serine/threonine kinase that has been implicated in integrin, growth factor, and Wnt signaling pathways. Cloning of ILK from rat smooth muscle cells generated a cDNA that exhibited 99.6% identity at the amino acid level with human ILK-1. A monoclonal antibody raised against a region of the carboxyl terminus of ILK, which is identical in rat and human ILK-1 protein, recognized a 50-kDa protein in all cultured cells and tissues examined. Binding experiments showed that ILK binds directly to the paxillin LD1 motif in vitro, Coimmunoprecipitation from fibroblasts confirmed that the association between paxillin and ILK occurs in vivo in both adherent cells and cells in suspension. Immunofluorescence microscopy of fibroblasts demonstrated that endogenous ILK as well as transfected green fluorescent protein-ILK co-localizes with paxillin in focal adhesions. Analysis of the deduced amino acid sequence of ILK identified a paxillin-binding subdomain in the carboxyl terminus of ILK. In contrast to wild-type ILK, paxillin-binding subdomain mutants of ILK were unable to bind to the paxillin LD1 motif in vitro and failed to localize to focal adhesions. Thus, paxillin binding is necessary for efficient focal adhesion targeting of ILK and may therefore impact the role of ILK in integrin-mediated signal transduction events.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	turnerc@mail.upstate.edu			NIGMS NIH HHS [GM47607, R01 GM047607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Huang Y, 1999, INT J MOL MED, V3, P563; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Li FG, 1997, BBA-MOL CELL RES, V1358, P215, DOI 10.1016/S0167-4889(97)00089-X; Li FG, 1999, J CELL SCI, V112, P4589; Liu SC, 2000, J CELL SCI, V113, P3563; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; WOOD CK, 1994, J CELL SCI, V107, P709; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	27	172	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23499	23505		10.1074/jbc.M102163200	http://dx.doi.org/10.1074/jbc.M102163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11304546	hybrid			2022-12-25	WOS:000169531100038
J	O'Connor, RJ; Schaley, JE; Feeney, G; Hearing, P				O'Connor, RJ; Schaley, JE; Feeney, G; Hearing, P			The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters	ONCOGENE			English	Article						E2F; p107; p130; DNA binding; transcription repression	ADENOVIRUS E4-6/7 PROTEIN; CELLULAR TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; HISTONE DEACETYLASE; DEREGULATED EXPRESSION; COMPLEX-FORMATION; RNA-POLYMERASE; CYCLE; INDUCTION	E2F transcription factors are key players in the regulation of proliferation, apoptosis, and differentiation in mammalian cells. E2Fs are negatively regulated by members of the retinoblastoma protein family, Rb, p107 and p130, During adenovirus infection, viral proteins are expressed that displace Rb family members from E2Fs and recruit E2F complexes to viral and cellular promoter regions. This recruitment of E2F involves the induction of stable E2F binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters and induces both viral and cellular gene expression. The cellular p107 tumor suppressor also displays such regulation of E2F DNA binding activity. p107 induces stable E2F-4/DP binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters. The induction of E2F DNA binding by p107 minimally requires the sequences in p107 that mediate E2F interaction. The related tumor suppressor, p130, also effects this function. p107 levels increase substantially as cells progress through S phase. p107 induction of E2F DNA binding was observed primarily in S phase cells coincident with the increase in p107 protein levels. The results of promoter activity assays directly correlate the induction of E2F DNA binding by p107 with effective transcriptional repression. These results support a model in which p107 and p130 induce the stable binding of E2F complexes to promoters that drive expression of critical regulatory proteins such as E2F-1, Since p107 and p130 bind histone deacetylase complexes (HDACs) which repress promoter activity, p107-E2F and p130-E2F would stably recruit repressor complexes to effect efficient promoter repression.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hearing, P (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Guy CT, 1996, MOL CELL BIOL, V16, P685; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Schaley J, 2000, J VIROL, V74, P2084, DOI 10.1128/JVI.74.5.2084-2093.2000; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	13	13	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1882	1891		10.1038/sj.onc.1204278	http://dx.doi.org/10.1038/sj.onc.1204278			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313936				2022-12-25	WOS:000167908400009
J	Kim, SG; Kim, SN; Jong, HS; Kim, NK; Hong, SH; Kim, SJ; Bang, YJ				Kim, SG; Kim, SN; Jong, HS; Kim, NK; Hong, SH; Kim, SJ; Bang, YJ			Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta 1-induced apoptosis in human gastric cancer cells	ONCOGENE			English	Article						TGF-beta 1; apoptosis; caspase-3; cyclin-dependent kinase-2; p21(cip1); p27(kip1)	DEPENDENT PROTEIN-KINASES; FACTOR-BETA; TGF-BETA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; EPITHELIAL-CELLS; THYMOCYTE APOPTOSIS; HEPATOMA-CELLS; INHIBITION; DEATH	Although TGF-beta1, a growth inhibitor, is known to also induce apoptosis, the molecular mechanism of this apoptosis is largely undefined, Here, we identify the mechanism of TGF-beta1-induced apoptosis in SNU-16 human gastric cancer cells. Cell cycle and TUNEL analysis showed that, upon TGF-beta1 treatment, cells mere initially arrested at the G1 phase and then driven into apoptosis, Of note, caspase-3 was activated in accordance with TGF-beta1-induced G1 arrest, Activated caspase-3 is targeted to cleave p21(cip1), p27(kip1), and Rb, which play important roles in TGF-beta -induced G1 arrest, into;inactive fragments. Subsequently, Cdk2 was aberrantly activated due to the cleavage of p21 and p27, We found that the inhibition of Cdk2 activity efficiently blocks TGF-beta1-induced apoptosis, whereas it did; not prevent caspase-3 activation or the subsequent cleavage of target proteins, In contrast, the suppression of caspase-3 activity inhibited the cleavage of target proteins, the activation of Cdk2, and the induction of apoptosis. Taken together, our results suggest that activation of caspase-3 by TGF-beta1 may initiate the conversion from G1 cell cycle arrest to apoptosis via the cleavage of p21, p27 and Rb, which in turn causes Cdk2 activation and, most significantly, Cdk2 activation as a downstream effector of caspase is a critical step for the execution TGF-beta1-induced apoptosis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Canc Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Canc Res Inst, 28 Yongon Dong, Seoul 110744, South Korea.		Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fan GS, 1996, ONCOGENE, V12, P1909; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GIRARD F, 1991, CELL, V67, P1; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PARK JG, 1990, CANCER RES, V50, P2773; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schrantz N, 1999, ONCOGENE, V18, P3511, DOI 10.1038/sj.onc.1202718; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	45	45	46	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1254	1265		10.1038/sj.onc.1204203	http://dx.doi.org/10.1038/sj.onc.1204203			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313870				2022-12-25	WOS:000167570100013
J	Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H				Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H			Inhibition of NF-kappa B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin	ONCOGENE			English	Article						programmed cell death; DNA-damage; transcription factor; chemotherapy; anthracyclin; phyllotoxin	ALPHA-INDUCED APOPTOSIS; TOPOISOMERASE II-ALPHA; TRANSCRIPTION FACTOR; ACTIVATION; EXPRESSION; TNF; P53; RESISTANCE; CHEMOSENSITIVITY; DIFFERENTIATION	The transcription factor NF-kappaB has anti-apoptotic properties and may confer chemoresistance to cancer cells. Here, me describe human pancreatic carcinoma cell lines that differ in the responsiveness to the topoisomerase-2 inhibitors VP16 (20 muM) and doxorubicin (0.3 muM): Highly sensitive BxPC-3 and PT45-P1 cells, and Capan-1 and A818-4 cells that were almost resistant to both anti cancer drugs. VP16, but not doxorubicin, transiently induced NF-kappaB activity in all cell lines, whereas basal NF-kappaB binding was nearly undetectable in BxPc-3 and PT45-P1 cells, but rather high in Capan-1 and A818-4 cells, as demonstrated by gel-shift and luciferase assays. Treatment with various NF-kappaB inhibitors (Gliotoxin, MG132 and Sulfasalazine), or transfection with the I kappaB alpha super-repressor, strongly enhanced the apoptotic effects of VP16 or doxorubicin on resistant Capan-1 and 818-4 cells. Our results indicate that under certain conditions the resistance of pancreatic carcinoma cells to chemotherapy is due to their constitutive NF-kappaB activity rather than the transient induction of NF-kappaB by some anti-cancer drugs. Blockade of basal NF-kappaB activity by well established drugs efficiently reduces chemoresistance of pancreatic cancer cells and offers the potential for improved therapeutic strategies.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24098 Kiel, Germany; Univ Kiel, Dept Gen Surg, Res Unit Mol Oncol, D-24098 Kiel, Germany; Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, D-4630 Bochum, Germany	University of Kiel; University of Kiel; Ruhr University Bochum	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24098 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019; Kalthoff, Holger/B-1618-2010	Arlt, Alexander/0000-0002-6160-1059; 				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dingemans AMC, 1999, CLIN CANCER RES, V5, P2048; Egawa N, 1996, VIRCHOWS ARCH, V429, P59, DOI 10.1007/BF00196822; ESTIVAL A, 1992, GASTROENTEROLOGY, V103, P1851, DOI 10.1016/0016-5085(92)91444-9; FRY AM, 1991, CANCER RES, V51, P6592; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lam VT, 1999, LEUKEMIA RES, V23, P871, DOI 10.1016/S0145-2126(99)00102-2; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LONG BH, 1991, CANCER RES, V51, P5275; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; MAZO A, 1991, PANCREAS, V6, P37, DOI 10.1097/00006676-199101000-00006; McDade TP, 1999, J SURG RES, V83, P56, DOI 10.1006/jsre.1998.5560; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Ungefroren H, 1998, CANCER RES, V58, P1741; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	31	206	214	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					859	868		10.1038/sj.onc.1204168	http://dx.doi.org/10.1038/sj.onc.1204168			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314019				2022-12-25	WOS:000166924400009
J	Khoury, H; Dankort, DL; Sadekova, S; Naujokas, MA; Muller, WJ; Park, M				Khoury, H; Dankort, DL; Sadekova, S; Naujokas, MA; Muller, WJ; Park, M			Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor	ONCOGENE			English	Article						ErbB-2/Neu; epithelial-mesenchymal transition; morphogenesis; MDCK epithelial cells; Shc	HEPATOCYTE GROWTH-FACTOR; KIDNEY-CELLS REQUIRES; HUMAN BREAST-CANCER; ADAPTER PROTEIN; MAMMARY-GLAND; NEU ONCOGENE; C-MET; KINASE; MORPHOGENESIS; CARCINOMA	Tight control of cell proliferation and morphogenesis is required to ensure normal tissue patterning and prevent cancer formation. Overexpression of the ErbB-2/Neu receptor tyrosine kinase is associated with increased progression in human breast cancer, yet in breast explant cultures, the ErbB-2/Neu receptor contributes to alveolar differentiation. To examine the consequence of deregulated ErbB-2/Neu activation on epithelial morphogenesis, we have expressed a constitutively activated mutant of ErbB-2/Neu in a Madin-Darby canine kidney (MDCK) epithelial cell model. Using two-dimensional cultures we demonstrate that activated ErbB-2/Neu induces breakdown of cell-cell junctions, increased cell motility and dispersal of epithelial colonies. This correlates with reorganization of the actin cytoskeleton and fetal adhesions and loss of insoluble cell-cell junction complexes involving E-cadherin. Interestingly, a constitutively activated ErbB-2/Neu receptor promotes an invasive morphogenic program in MDCK cells in a three-dimensional matrix. We show that two tyrosines in the carboxy-terminal tail of ErbB-2/Neu, involved in the phosphorylation of the Shc adapter protein, are each sufficient to promote epithelial-mesenchymal like transition and enhanced cell motility in two-dimensional culture and cell invasion rather than a morphogenic response in matrix culture. This provides a model system to investigate ErbB-2/Neu induced signaling pathways required for epithelial cell dispersal and invasion versus morphogenesis.	McGill Univ Hosp Ctr, Dept Biochem, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ Hosp Ctr, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ Hosp Ctr, Dept Oncol, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON, Canada	McGill University; McGill University; McGill University; McMaster University	Park, M (corresponding author), McGill Univ Hosp Ctr, Dept Biochem, Mol Oncol Grp, H5-10-687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.			Dankort, David/0000-0002-5862-6829				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Boyer B, 1996, ACTA ANAT, V156, P227; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klapper LN, 2000, CANCER RES, V60, P3384; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Pawson T, 2000, GENE DEV, V14, P1027; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; PELICCI G, 1995, ONCOGENE, V10, P1631; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; RICCI A, 1995, ONCOGENE, V11, P1519; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Selli C, 1997, J UROLOGY, V158, P245, DOI 10.1097/00005392-199707000-00079; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zhang XH, 1997, UROLOGY, V50, P636, DOI 10.1016/S0090-4295(97)00258-6; ZHU H, 1994, J BIOL CHEM, V269, P29943	39	48	50	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					788	799		10.1038/sj.onc.1204166	http://dx.doi.org/10.1038/sj.onc.1204166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314013				2022-12-25	WOS:000166924400002
J	Inga, A; Monti, P; Fronza, G; Darden, T; Resnick, MA				Inga, A; Monti, P; Fronza, G; Darden, T; Resnick, MA			p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	ONCOGENE			English	Article						p53; yeast; enhanced transactivation; dominance	TUMOR-SUPPRESSOR P53; WILD-TYPE; DNA-BINDING; SEQUENCE-SPECIFICITY; GENE-EXPRESSION; TERMINAL DOMAIN; CORE DOMAIN; CELL-LINES; CANCER; MUTATIONS	Changes in promoter specificity and binding affinity that may be associated with p53 mutations or post-translational modifications are useful in understanding p53 structure/ function relationships and categorizing tumor mutations. We have exploited variable expression of human p53 in yeast to identify mutants with novel phenotypes that would correspond to altered promoter selectivity and affinity. The p53 cDNA regions coding for the DNA binding and tetramerization domains were subjected to random PCR mutagenesis and were cloned directly by recombination in yeast into a vector with a GAL1 promoter whose level of expression could be easily varied. p53 variants exhibiting higher than wild type levels of transactivation (supertrans) for the RGC responsive element were identified at low level of p53 protein expression. All the p53 mutants obtained with this screen were located in the DNA binding domain. Two out of 17 supertrans mutants have been found in tumors. Six mutations were in the L1 loop region between amino acids 115 and 124, The transactivation potential of a panel of supertrans p53 mutants on different promoters was evaluated using the p53 responsive elements, RGC, PIG3, p21 and bax. Although all mutants retained some activity with all promoters, we found different patterns of induction based on strength and promoter specificity. In particular none of the mutants was supertrans for the p21 responsive element, Interestingly, further analysis in yeast showed that the transactivation function could be retained even in the presence of dominant-negative p53 tumor mutations that could inhibit wild type p53, Five mutants were also characterized in human cells in terms of growth suppression and transactivation of various promoters. These novel supertrans p53 mutants may be useful in studies aimed at dissecting p53 downstream pathways, understanding specific interactions between p53 and the DNA, and could replace wild type p53 in cancer gene therapy protocols. The approach may also prove useful in identifying p53 tumor mutations.	Natl Inst Environm Hlth Sci, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NCI, IST, Mutagenesis Lab, I-16132 Genoa, Italy; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, Mail Drop D3-01,111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.		Monti, Paola/Y-1118-2019; resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019	Monti, Paola/0000-0002-1978-4998; resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065079, ZIAES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Di Como CJ, 1998, ONCOGENE, V16, P2527; FERRIN TE, 1988, J MOL GRAPHICS, V6, P2, DOI 10.1016/0263-7855(88)80053-5; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREBOURG T, 1994, CANCER RES, V54, P878; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Okaichi K, 1999, INT J RADIAT ONCOL, V45, P975, DOI 10.1016/S0360-3016(99)00285-0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pan Y, 2000, ONCOGENE, V19, P3095, DOI 10.1038/sj.onc.1203663; Prives C, 1999, J PATHOL, V187, P112; Reis AM, 2000, CANCER RES, V60, P1571; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Shimada A, 1999, CANCER RES, V59, P2781; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298	57	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					501	513		10.1038/sj.onc.1204116	http://dx.doi.org/10.1038/sj.onc.1204116			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313981				2022-12-25	WOS:000166562500010
J	Taneja, N; Tjalkens, R; Philbert, MA; Rehemtulla, A				Taneja, N; Tjalkens, R; Philbert, MA; Rehemtulla, A			Irradiation of mitochondria initiates apoptosis in a cell free system	ONCOGENE			English	Article						ionizing radiation; apoptosis; caspase; mitochondria; cytochrome c; Bcl-X-L	RADIATION-INDUCED APOPTOSIS; NF-KAPPA-B; IONIZING-RADIATION; CHEMOTHERAPEUTIC DRUGS; ACTIVATION; APAF-1; GENE; CRMA; FAS; PERMEABILITY	The ability to modulate the sensitivity of mammalian cells to ionizing radiation (IR) (e.g. using chemotherapeutics) is dependent on our understanding of the primary target and biochemical pathway that leads to IR-induced apoptosis. We demonstrate using a cell free assay that irradiation of mitochondria is a primary event that initiates IR-induced apoptosis. IR results in loss of mitochondrial membrane potential, opening of the permeability transition pore (PTP) and the release of cytochrome c (cyto c). Apaf-1 and ATP were required to initiate apoptosis upon release of cyto c from mitochondria, The importance of mitochondrial events in the initiation of IR-induced apoptosis was also supported by the observation that inhibition of caspase-9 by the overexpression of dominant negative mutants resulted in the inhibition of IR-induced apoptosis. In contrast, inhibition of caspase-8 had only a minor impact on IR-induced apoptosis, Over-expression of Bcl-X-L inhibited the initiation of IR-induced apoptosis due to its ability to prevent the loss of mitochondrial membrane potential, PTP opening and cytochrome c release, In a cell free assay for apoptosis, mitochondria as web as cytosol derived from Bcl-X-L over-expressing cells were less efficient at supporting apoptosis in response to IR suggesting multiple roles for Bcl-X-L in the regulation of apoptosis.	Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Toxicol Program, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rehemtulla, A (corresponding author), Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA 78041] Funding Source: Medline; NIEHS NIH HHS [ES 08846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R55ES008846, R01ES008846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Booker JK, 1998, J IMMUNOL, V161, P4536; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Kataoka T, 1998, J IMMUNOL, V161, P3936; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Perkins CL, 2000, CANCER RES, V60, P1645; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rehemtulla Alnawaz, 1999, Neoplasia (New York), V1, P63, DOI 10.1038/sj.neo.7900013; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	40	52	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					167	177		10.1038/sj.onc.1204054	http://dx.doi.org/10.1038/sj.onc.1204054			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313941				2022-12-25	WOS:000166410900004
J	Swaminathan, GJ; Weaver, AJ; Loegering, DA; Checkel, JL; Leonidas, DD; Gleich, GJ; Acharya, KR				Swaminathan, GJ; Weaver, AJ; Loegering, DA; Checkel, JL; Leonidas, DD; Gleich, GJ; Acharya, KR			Crystal structure of the eosinophil major basic protein at 1.8 angstrom - An atypical lectin with a paradigm shift in specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; C-TYPE LECTIN; CARBOHYDRATE-RECOGNITION DOMAIN; HELICAL COILED-COIL; GRANULE PROTEINS; ANIMAL LECTINS; ACTIVATION; PRECURSOR; TOXICITY; PROFORM	The eosinophil major basic protein (EMBP) is the predominant constituent of the crystalline core of the eosinophil primary granule. EMBP is directly implicated in epithelial cell damage, exfoliation, and bronchospasm in allergic diseases such as asthma, Here we report the crystal structure of EMBP at 1.8 Angstrom resolution, and show that it is similar to that of members of the C-type lectin superfamily with which it shares minimal amino acid sequence identity (similar to 15-28%). However, this protein lacks a Ca2+/carbohydrate-binding site. Our analysis suggests that EMBP specifically binds heparin, Based on our results, we propose a possible new function for this protein, which is likely to have implications for EMBP function.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA	University of Bath; Mayo Clinic; Mayo Clinic	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.		Leonidas, Demetres/F-7228-2013; Leonidas, Demetres/AAE-9296-2021	Leonidas, Demetres/0000-0002-3874-2523; Leonidas, Demetres/0000-0002-3874-2523; Swaminathan, Jawahar/0000-0002-0215-4084; Acharya, K. Ravi/0000-0002-3009-4058	NIAID NIH HHS [AI 25230, AI 09728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230, R37AI009728, R01AI009728] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu-Ghazaleh R I, 1992, Immunol Ser, V57, P137; ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; BARKER RL, 1991, J CLIN INVEST, V88, P798, DOI 10.1172/JCI115379; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P456, DOI 10.1042/bst0210456; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; Fischer D, 1996, PROTEIN SCI, V5, P947; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Gleich G.J., 1995, SAMTERS IMMUNOLOGIC, P205; GLEICH GJ, 1974, J EXP MED, V140, P313, DOI 10.1084/jem.140.2.313; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Gronwald W, 1998, BIOCHEMISTRY-US, V37, P4712, DOI 10.1021/bi972788c; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HAMANN KJ, 1987, J PARASITOL, V73, P523, DOI 10.2307/3282130; HAMANN KJ, 1990, J IMMUNOL, V144, P3166; Harp JM, 1998, ACTA CRYSTALLOGR D, V54, P622, DOI 10.1107/S0907444997019008; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P848, DOI 10.1164/arrd.1987.135.4.848; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; JACOBY DB, 1988, AM REV RESPIR DIS, V137, P13, DOI 10.1164/ajrccm/137.1.13; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Llera AS, 2001, J BIOL CHEM, V276, P7312, DOI 10.1074/jbc.M008573200; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MOY JN, 1990, J IMMUNOL, V145, P2626; Natarajan K, 2000, BIOCHEMISTRY-US, V39, P14779, DOI 10.1021/bi0018180; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; PATTHY L, 1989, MOL IMMUNOL, V26, P1151, DOI 10.1016/0161-5890(89)90059-X; PETERS MS, 1986, LAB INVEST, V54, P656; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; POPKENHARRIS P, 1995, J IMMUNOL, V155, P1472; Rochester CL, 1996, J IMMUNOL, V156, P4449; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	61	47	51	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26197	26203		10.1074/jbc.M100848200	http://dx.doi.org/10.1074/jbc.M100848200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319227	hybrid			2022-12-25	WOS:000169823300075
J	Peraldi, P; Filloux, C; Emanuelli, B; Hilton, DJ; Van Obberghen, E				Peraldi, P; Filloux, C; Emanuelli, B; Hilton, DJ; Van Obberghen, E			Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; MICE LACKING SUPPRESSOR; SOCS-BOX MOTIF; DOCKING PROTEINS; STAT3 ACTIVATION; MEDIATE INSULIN; RECEPTOR; BINDS; INHIBITION; MECHANISMS	Suppressor of cytokine signaling (SOCS) proteins were originally described as cytokine-induced molecules involved in negative feedback loops. We have shown that SOCS-3 is also a component of the insulin signaling network (1), Indeed, insulin leads to SOCS-3 expression in 3T3-L1 adipocytes. Once produced, SOCS-3 binds to phosphorylated tyrosine 960 of the insulin receptor and inhibits insulin signaling. Now we show that in 3T3-L1 adipocytes and in transfected COS-7 cells insulin leads to SOCS-3 tyrosine phosphorylation. This phosphorylation takes place on Tyr(204) and is dependent upon a functional SOCS-3 SH2 domain. Purified insulin receptor directly phosphorylates SOCS-3, However, in intact cells, a mutant of the insulin receptor, IRY960F, unable to bind SOCS-3, was as efficient as the wild type insulin receptor to phosphorylate SOCS-3, Importantly, IRY960F is as potent as the wild type insulin receptor to activate janus-activated kinase (Jak) 1 and Jak2, Furthermore, expression of a dominant negative form of Jak2 inhibits insulin-induced SOCS-3 tyrosine phosphorylation, ks transfected Jaks have been shown to cause SOCS-3 phosphorylation, we propose that insulin induces SOCS-3 phosphorylation through Jak activation. Our data indicate that SOCS-3 belongs to a class of tyrosine-phosphorylated insulin signaling molecules, the phosphorylation of which is not dependent upon a direct coupling with the insulin receptor but relies on the Jacks.	Fac Med, INSERM U145, IFR 50, F-06107 Nice 2, France; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factor, Parkville, Vic 3050, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Walter & Eliza Hall Institute	Peraldi, P (corresponding author), Fac Med, INSERM U145, IFR 50, F-06107 Nice 2, France.	peraldi@unice.fr	Peraldi, Pascal/O-4592-2016; Emanuelli, Brice/M-2097-2016; Hilton, Douglas J/C-7250-2013	Peraldi, Pascal/0000-0003-0205-9252; Emanuelli, Brice/0000-0001-5795-5666; Hilton, Douglas J/0000-0002-7698-2392				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GIORGETTI-PERALDI S, 1995, EUR J BIOCHEM, V234, P656, DOI 10.1111/j.1432-1033.1995.656_b.x; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Krebs DL, 2000, J CELL SCI, V113, P2813; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MANIATIS T, 1989, MOL CLONING LAB MANU, P1642; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Saad MJA, 1996, J BIOL CHEM, V271, P22100, DOI 10.1074/jbc.271.36.22100; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White MF, 1998, RECENT PROG HORM RES, V53, P119; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	41	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24614	24620		10.1074/jbc.M102209200	http://dx.doi.org/10.1074/jbc.M102209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325969	hybrid			2022-12-25	WOS:000169800700028
J	Shalak, V; Kaminska, M; Mitnacht-Kraus, R; Vandenabeele, P; Clauss, M; Mirande, M				Shalak, V; Kaminska, M; Mitnacht-Kraus, R; Vandenabeele, P; Clauss, M; Mirande, M			The EMAPII cytokine is released from the mammalian multisynthetase complex after cleavage of its p43/proEMAPII component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ACTIVATING-POLYPEPTIDE-II; CRYSTAL-STRUCTURE; BINDING PROTEIN; CELLS; MONOCYTES; APOPTOSIS; IDENTIFICATION; EXPRESSION; SUBUNIT	Endothelial-monocyte-activating polypeptide II (EMAPII) is an inflammatory cytokine released under apoptotic conditions. Its proEMAPII precursor proved to be identical to the auxiliary p43 component of the aminoacyl-tRNA synthetase complex. We show here that the EMAPII domain of p43 is released readily from the complex after in vitro digestion with caspase 7 and is able to induce migration of human mononuclear phagocytes. The N terminus of in vitro processed EMAPII coincides exactly with that of the mature cytokine isolated from conditioned medium of fibrosarcoma cells. We also show that p43/proEMAPII has a strong tRNA binding capacity (K-D = 0.2 muM) as compared with its isolated N or C domains (7.5 muM and 40 muM, respectively). The potent general RNA binding capacity ascribed to p43/proEMAPII is lost upon the release of the EMAPII domain. This suggests that after onset of apoptosis, the first consequence of the cleavage of p43 is to limit the availability of tRNA for aminoacyl-tRNA synthetases associated within the complex. Translation arrest is accompanied by the release of the EMAPII cytokine that plays a role in the engulfment of apoptotic cells by attracting phagocytes. As a consequence, p43 compares well with a molecular fuse that triggers the irreversible cell growth/ cell death transition induced under apoptotic conditions.	CNRS, Lab Enzymol & Biochim Struct, F-91190 Gif Sur Yvette, France; State Univ Ghent VIB, Dept Mol Biol,Mol Signalling & Cell Death Unit, B-9000 Ghent, Belgium; Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Flanders Institute for Biotechnology (VIB); Ghent University; Max Planck Society	Mirande, M (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	marc.mirande@lebs.cnrs-gif.fr	Shalak, Vyacheslav F/D-3707-2015; Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009	Shalak, Vyacheslav F/0000-0001-6114-6482; Vandenabeele, Peter/0000-0002-6669-8822; Clauss, Matthias/0000-0001-5180-3899				Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; Barnett G, 2000, CANCER RES, V60, P2850; Behrensdorf HA, 2000, FEBS LETT, V466, P143, DOI 10.1016/S0014-5793(99)01777-9; BOYUM A, 1983, SCAND J IMMUNOL, V17, P429, DOI 10.1111/j.1365-3083.1983.tb00809.x; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Kaminska M, 2000, EMBO J, V19, P6908, DOI 10.1093/emboj/19.24.6908; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KELLERMANN O, 1978, EUR J BIOCHEM, V88, P197, DOI 10.1111/j.1432-1033.1978.tb12438.x; KERJAN P, 1992, BIOCHIMIE, V74, P195, DOI 10.1016/0300-9084(92)90046-H; Kim Y, 2000, J BIOL CHEM, V275, P27062; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Kornelyuk Alexander, 1999, Biopolimery i Kletka, V15, P168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marissen WE, 2000, J BIOL CHEM, V275, P9314, DOI 10.1074/jbc.275.13.9314; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1982, J BIOL CHEM, V257, P1056; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Renault L, 2001, EMBO J, V20, P570, DOI 10.1093/emboj/20.3.570; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Swairjo MA, 2000, EMBO J, V19, P6287, DOI 10.1093/emboj/19.23.6287; Tan M, 1999, GENE, V233, P131, DOI 10.1016/S0378-1119(99)00146-8; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147	38	109	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23769	23776		10.1074/jbc.M100489200	http://dx.doi.org/10.1074/jbc.M100489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306575	hybrid			2022-12-25	WOS:000169531100074
J	Basile, JR; Zacny, V; Munger, K				Basile, JR; Zacny, V; Munger, K			The cytokines tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-CYCLE; DEATH DOMAIN; MITOTIC CHECKPOINTS; MEDIATED APOPTOSIS; SIGNALING PATHWAYS; TRAIL RECEPTOR-1; DNA-REPLICATION; PROTEIN; GENE	Keratinocytes are the natural target cells for infection by human papillomaviruses (HPVs), most of which cause benign epithelial hyperplasias (warts), However, a subset of papillomaviruses, the "high risk" HPVs, cause lesions that can progress to carcinomas. Inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand (TRAIL) are produced by cells in response to a viral infection. To determine the effects of TNF-alpha and TRAIL on keratinocytes expressing the high risk HPV-16 oncoprotein E7, human foreskin keratinocytes stably expressing E7 were treated with TNF-alpha and TRAIL. Treatment with TNF-alpha alone, but not TRAIL, induced growth arrest and differentiation in keratinocytes that was almost completely overcome by expression of HPV-16 E7. Both cytokines induced apoptosis when administered in combination with the protein synthesis inhibitor cycloheximide, but the apoptotic response to TRAIL was significantly more rapid and efficient compared with the response seen after TNF-alpha treatment. HPV-16 E7-expressing keratinocytes were more prone to both TNF-alpha- and TRAIL-mediated apoptosis compared with vector-infected controls.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Canc Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave,D2-544A, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [T32CA72320, R01 CA81135] Funding Source: Medline; NIDCR NIH HHS [K16DE00275] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081135, T32CA072320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K16DE000275] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alani RM, 1998, MOL CARCINOGEN, V23, P226, DOI 10.1002/(SICI)1098-2744(199812)23:4<226::AID-MC5>3.0.CO;2-N; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Boyer SN, 1996, CANCER RES, V56, P4620; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; DETMAR M, 1990, ARCH DERMATOL RES, V282, P238, DOI 10.1007/BF00371643; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Jiang YL, 1998, BIOCHEM BIOPH RES CO, V245, P691, DOI 10.1006/bbrc.1998.8390; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; KONO T, 1990, Journal of Dermatology (Tokyo), V17, P409; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KYO S, 1994, VIROLOGY, V200, P130, DOI 10.1006/viro.1994.1171; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ma Y, 1999, CANCER RES, V59, P5341; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PILLAI S, 1989, J CLIN INVEST, V83, P816, DOI 10.1172/JCI113963; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Ruesch MN, 1998, VIROLOGY, V250, P19, DOI 10.1006/viro.1998.9359; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; SYMINGTON FW, 1989, J INVEST DERMATOL, V92, P798, DOI 10.1111/1523-1747.ep12696816; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEMESS BA, 1990, SCIENCE, V248, P76; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WOODWORTH CD, 1990, CANCER RES, V50, P3709; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	75	72	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22522	22528		10.1074/jbc.M010505200	http://dx.doi.org/10.1074/jbc.M010505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306566	hybrid			2022-12-25	WOS:000169412700074
J	Brinkmann, H; Dahler, AL; Popa, C; Serewko, MM; Parsons, PG; Gabrielli, BG; Burgess, AJ; Saunders, NA				Brinkmann, H; Dahler, AL; Popa, C; Serewko, MM; Parsons, PG; Gabrielli, BG; Burgess, AJ; Saunders, NA			Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; DIFFERENTIATION-SPECIFIC GENES; TRANSFORMED-CELL DIFFERENTIATION; CHAIN FATTY-ACIDS; TRANSCRIPTIONAL REPRESSION; ANTITUMOR-ACTIVITY; EPITHELIAL-CELLS; INTERFERON-GAMMA; TRICHOSTATIN-A; RETINOIC ACID	Use of specific histone deacetylase inhibitors has revealed critical roles for the histone deacetylases (HDAC) in controlling proliferation. Although many studies have correlated the function of HDAC inhibitors with the hyperacetylation of histones, few studies have specifically addressed whether the accumulation of acetylated histones, caused by HDAC inhibitor treatment, is responsible for growth inhibition. In the present study we show that HDAC inhibitors cause growth inhibition in normal and transformed keratinocytes but not in normal dermal fibroblasts, This was despite the observation that the HDAC inhibitor, suberic bishydroxamate (SBHA), caused a kinetically similar accumulation of hyperacetylated histones, This cell type-specific response to SBHA was not due to the inactivation of SBHA by fibroblasts, nor was it due to differences in the expression of specific HDAC family members. Remarkably, overexpression of HDACs 1, 4, and 6 in normal human fibroblasts resulted in cells that could be growth-inhibited by SBHA. These data suggest that, although histone acetylation is a major target for HDAC inhibitors, the accumulation of hyperacetylated histones is not sufficient to cause growth inhibition in all cell types, This suggests that growth inhibition, caused by HDAC inhibitors, may be the culmination of histone hyperacetylation acting in concert with other growth regulatory pathways.	Univ Queensland, Princess Alexandra Hosp, Epithelial Pathobiol Grp, Ctr Immunol & Canc Res,Dept Med, Brisbane, Qld 4102, Australia; Queensland Inst Med Res, Canc Unit, Herston, Qld 4006, Australia; Univ Queensland, Dept Pathol, Sch Med, Herston, Qld 4006, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia	University of Queensland; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Epithelial Pathobiol Grp, Ctr Immunol & Canc Res,Dept Med, Ipswich Rd, Brisbane, Qld 4102, Australia.		saunders, nicholas/AAJ-6101-2020; Burgess, Andrew/C-7952-2009; Gabrielli, Brian G/B-3655-2011; McTaggart, Jill/G-4696-2010; Parsons, Peter G/H-8163-2015; Burgess, Andrew/H-3339-2019	saunders, nicholas/0000-0002-2478-3420; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651; McTaggart, Jill/0000-0002-9000-8529; Parsons, Peter G/0000-0002-0473-3346; Burgess, Andrew/0000-0003-4536-9226				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cai RL, 2000, J BIOL CHEM, V275, P27909; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; Kao HY, 2000, GENE DEV, V14, P55; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mariadason JM, 2000, CANCER RES, V60, P4561; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parsons PG, 1997, BIOCHEM PHARMACOL, V53, P1719, DOI 10.1016/S0006-2952(97)00016-6; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Saunders, 1999, Expert Opin Investig Drugs, V8, P1611, DOI 10.1517/13543784.8.10.1611; Saunders N, 1999, CANCER RES, V59, P399; Saunders NA, 1999, J INVEST DERMATOL, V112, P977, DOI 10.1046/j.1523-1747.1999.00611.x; Saunders NA, 1998, CANCER RES, V58, P1646; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	62	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22491	22499		10.1074/jbc.M100206200	http://dx.doi.org/10.1074/jbc.M100206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304533	hybrid			2022-12-25	WOS:000169412700070
J	Sheng, W; Decaussin, G; Sumner, S; Ooka, T				Sheng, W; Decaussin, G; Sumner, S; Ooka, T			N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2	ONCOGENE			English	Article						EBV; malignant transforming activity; Bcl-2; c-myc; rodent fibroblast	LYMPHOCYTE GROWTH TRANSFORMATION; LATENT MEMBRANE-PROTEIN; OPEN READING FRAME; KAPPA-B; NASOPHARYNGEAL CARCINOMA; CELL-DEATH; C-MYC; EMBRYO FIBROBLASTS; EXPRESSION; EBV	The BARF1 gene encoded by the Epstein-Barr virus induces morphological changes, loss of contact inhibition and anchorage independence in established rodent Balb/c3T3 fibroblast, BARF1 gene was also capable of inducing malignant transformation in a human Louckes B cell line. Our recent study showed that BARF1 gene had an ability to immortalize primary epithelial cells. However we do not know which region(s) of BARF1 protein is(are) responsible for inducing malignant transformation in established rodent cells. Using the deletion mutants, we now localized malignant transforming region in N-terminal of BARF1 protein. The mutants lacking this region were unable to transform the cells in malignant state, Furthermore, we demonstrated that only the mutants containing this region rendered the cells resistant to apoptosis induced by serum deprivation. Surprisingly, the BARF1 gene was capable of:activating anti-apoptotic Bcl-2 expression and this activation was due to the N-terminal transforming region. These data suggest that the cooperation of BARF1 with Bcl-2 is essential for the induction of malignant transformation.	Univ Lyon 1, Fac Med RTH Laennec, Mol Virol Lab, CNRS,UMR 5537, F-69372 Lyon 08, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ooka, T (corresponding author), Univ Lyon 1, Fac Med RTH Laennec, Mol Virol Lab, CNRS,UMR 5537, Rue Guillaume Paradin, F-69372 Lyon 08, France.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; de Turenne-Tessier M, 1997, VIRUS RES, V52, P73, DOI 10.1016/S0168-1702(97)00101-9; Decaussin G, 2000, CANCER RES, V60, P5584; DECAUSSIN G, 1995, J VIROL, V69, P7309, DOI 10.1128/JVI.69.11.7309-7314.1995; DETHE G, 1982, HERPESVIRUSES, V1, P25; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY; KLEIN G, 1973, HERPESVIRUSES, P521; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OOKA T, 1991, SPRINGER SEMIN IMMUN, V13, P233, DOI 10.1007/BF00201471; OOKA T, 1983, J VIROL, V46, P187, DOI 10.1128/JVI.46.1.187-195.1983; OOKA T, 1980, VIROLOGY, V104, P219, DOI 10.1016/0042-6822(80)90379-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; RICKINSON AB, 1996, FIELDS VIROLOGY, V2, P2396; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SbihLammali F, 1996, VIROLOGY, V222, P64, DOI 10.1006/viro.1996.0398; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; STOCKBINE LD, 1998, J VIROL, V72, P4015; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; TAO Q, 1994, J CLIN PATHOL, V47, P589, DOI 10.1136/jcp.47.7.589; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988; zur Hausen A, 2000, CANCER RES, V60, P2745	54	62	70	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1176	1185		10.1038/sj.onc.1204217	http://dx.doi.org/10.1038/sj.onc.1204217			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313861				2022-12-25	WOS:000167570100004
J	Mitsutake, N; Namba, H; Shklyaev, SS; Tsukazaki, T; Ohtsuru, A; Ohba, M; Kuroki, T; Ayabe, H; Yamashita, S				Mitsutake, N; Namba, H; Shklyaev, SS; Tsukazaki, T; Ohtsuru, A; Ohba, M; Kuroki, T; Ayabe, H; Yamashita, S			PKC delta mediates ionizing radiation-induced activation of c-Jun NH2-terminal kinase through MKK7 in human thyroid cells	ONCOGENE			English	Article						PKC delta; JNK; MKK7; thyroid cell; ionizing radiation	SIGNAL-TRANSDUCTION PATHWAYS; CERAMIDE-INDUCED APOPTOSIS; N-TERMINAL KINASE; KIDNEY 293 CELLS; PROTEIN-KINASE; MAP KINASE; TYROSINE KINASE; PROTEOLYTIC ACTIVATION; REGULATED KINASE; ISOFORMS	The thyroid gland is one of the most sensitive organs in ionizing radiation (IR)-induced carcinogenesis. To determine, therefore, the specific cascade of IR-induced signal transduction in human thyroid cells, we investigated the functional role of protein kinase C (PKC), especially its interlocking activation of c-Jun NH2-terminal kinase (JNK) pathway. In the present study, using adenovirus expression vectors for diverse dominant-negative (DN) types of PKC isoforms (alpha, beta2, delta, epsilon and zeta) expressed in primary cultured human thyroid cells, only DN/PKC delta suppressed IR-induced JNK activation. In addition, Rottlerin, a PKC delta specific inhibitor, inhibited IR-induced JNK activation. IR-induced activation of transcription factor AP-1, downstream target of JNK, was also attenuated by DN/PKC delta. To examine the involvement of upstream kinases of JNK, we performed immune-complex kinase assays of mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. IR activated MKK7 but not MKK4, and this activation was inhibited by Rottlerin. Furthermore, IR-induced JNK activation was suppressed by overexpression of kinase-deficient MKK7. Our results indicate that IR selectively activates the cascade of PKC delta -MKK7-JNK-AP-1 in human thyroid cells, suggesting a not apoptotic but radio-resistant role of PKC delta in human thyroid cells following IR.	Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Surg 1, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Anat 1, Nagasaki 8528523, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Showa University	Namba, H (corresponding author), Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan.		Mitsutake, Norisato/U-9626-2018; Kuroki, Toshio/A-9500-2011; Yamashita, Shunichi/GVS-9508-2022	Mitsutake, Norisato/0000-0002-2744-8046; Kuroki, Toshio/0000-0001-6369-4351; Yamashita, Shunichi/0000-0001-6399-6261				Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hara T, 1998, BIOCHEM BIOPH RES CO, V244, P41, DOI 10.1006/bbrc.1998.8210; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KAWABE Y, 1989, J CLIN ENDOCR METAB, V68, P1174, DOI 10.1210/jcem-68-6-1174; Kawakami Y, 1998, J IMMUNOL, V161, P1795; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NAMBA H, 1995, CANCER RES, V55, P2075; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sautin Y, 2000, THYROID, V10, P733, DOI 10.1089/thy.2000.10.733; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WANG XD, 1995, THYROID, V5, P137, DOI 10.1089/thy.1995.5.137; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xu X, 1996, ONCOGENE, V13, P135; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	54	58	61	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					989	996		10.1038/sj.onc.1204179	http://dx.doi.org/10.1038/sj.onc.1204179			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314034				2022-12-25	WOS:000167097000010
J	Sablina, AA; Chumakov, PM; Levine, AJ; Kopnin, BP				Sablina, AA; Chumakov, PM; Levine, AJ; Kopnin, BP			p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling	ONCOGENE			English	Article						p53; cell cycle checkpoints; cell adhesion; microtubules	CELL-CYCLE CHECKPOINT; TUMOR-SUPPRESSOR P53; FOCAL ADHESIONS; DNA-DAMAGE; PHOSPHORYLATE P53; PROTEIN-KINASE; BAX GENE; IN-VIVO; PATHWAYS; ARREST	The p53 tumor suppressor is activated in response to various stresses driving the cells into growth arrest or apoptosis. We have addressed the question of how disintegration of microtubule system induces activation of p53. Depolymerization of microtubules by colcemid in rat and human quiescent fibroblasts resulted in accumulation of transcriptionally active p53 that caused cell-cycle arrest at the G1/S boundary. The p53 activation correlated with prominent activation of Erk1/2 MAP kinases that resulted from colcemid-stimulated development of focal adhesions. Inhibition of focal contacts development hy plating of cells onto poly-L-lysine abrogated both Erk1/2 and p53 activations in colcemid-treated cells, while plating of cells onto fibronectin caused transient up-regulation of p53 even in the absence of colcemid. Pre-treatment of cells with the specific MEK1 inhibitor PD098059 also attenuated colcemid-induced p53 activation and G1 cell cycle arrest. Cell types which either failed to develop focal adhesions in response to colcemid treatment (human MCF-7 epithelial cells), or lacked colcemid-induced sustained Erk activation (primary mouse embryo fibroblasts and 12(1) cells) showed virtually no p53 up-regulation in response to disruption of microtubules during G0/G1. Our results indicate that p53 activation is not triggered by disintegration of microtubule system by itself, but rather originates from some of the consequences of such disintegration, in particular, from the development of focal adhesions leading to activation of Erk signaling pathway.	Russian Canc Res Ctr, Inst Cancerogenesis, Moscow, Russia; RAS, VA Engelhardt Mol Biol Inst, Moscow, Russia; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Princeton University	Chumakov, PM (corresponding author), RAS, VA Engelhardt Mol Biol Inst, Moscow, Russia.		Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019; Sablina, Anna/P-2818-2019; Sablina, Anna/B-2217-2017	Kopnin, Boris/0000-0003-3100-2212; Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; Chehab NH, 2000, GENE DEV, V14, P278; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Harris CC, 1996, ENVIRON HEALTH PERSP, V104, P435, DOI 10.2307/3432799; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Khan SH, 1998, CANCER RES, V58, P396; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pletjushkina OJ, 1998, CELL ADHES COMMUN, V5, P121, DOI 10.3109/15419069809040286; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; RITTLING SR, 1992, ONCOGENE, V7, P935; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; Sablina AA, 1998, J CELL SCI, V111, P977; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542	45	51	54	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					899	909		10.1038/sj.onc.1204156	http://dx.doi.org/10.1038/sj.onc.1204156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314025				2022-12-25	WOS:000167097000001
J	Inagaki-Ohara, K; Yada, S; Takamura, N; Reaves, M; Yu, XH; Liu, ER; Rooney, I; Nicholas, S; Castro, A; Ware, CF; Green, DR; Lin, T				Inagaki-Ohara, K; Yada, S; Takamura, N; Reaves, M; Yu, XH; Liu, ER; Rooney, I; Nicholas, S; Castro, A; Ware, CF; Green, DR; Lin, T			p53-dependent radiation-induced crypt intestinal epithelial cells apoptosis is mediated in part through TNF-TNFR1 system	ONCOGENE			English	Article						apoptosis; intestinal epithelial cells; p53; TNF	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; FAS LIGAND EXPRESSION; VERSUS-HOST DISEASE; IN-VIVO; INTRAEPITHELIAL LYMPHOCYTES; GASTROINTESTINAL-TRACT; IONIZING-RADIATION; GAMMA-IRRADIATION; DNA DAMAGE	Radiation induces apoptosis of crypt intestinal epithelial cells (IEC) through a pathway that is largely dependent on p53. However, exactly how p53 mediates IEC apoptosis is unclear, Studies irt vitro suggest that one mechanism by which p53 mediates apoptosis is through its ability to transactivate members of the TNF receptor family of (Death Receptors', Here, we examined the role of one of its member, TNF receptor type 1 (TNFR1), in an in viva model of p53-dependent radiation-induced LEC apoptosis, We demonstrate that mice genetically engineered to be deficient in TNF receptor type 1 (TNFR1(-/-)) and mice injected with TNFR1-fusion chimeric protein (TNFR1-Fc; a competitive inhibitor of TNFR1) were partially protected (30-40%) from p53-dependent radiation-induced IEC apoptosis, However, we found no evidence to support the possibility p53 transcriptionally regulates the expression of TNFR1 nor increases the susceptibility of TEC to TNF-mediated apoptosis, Interestingly, we found that injection of TNF readily induced LEC apoptosis and that radiation induced a p53-dependent increase in the intestinal level of TNF. Furthermore, injection of a neutralizing anti-TNF mAb reduced p53-dependent radiation-induced IEC apoptosis by approximately 60%. Overall, these results suggest that p53-dependent radiation-induced IEC apoptosis is mediated in part through ability of p53 to regulate TNF, which subsequently induces IEC apoptosis through TNFR1.	Northwestern Univ, Sch Med, Dept Med, Gastroenterol Sect, Chicago, IL 60611 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	Northwestern University; La Jolla Institute for Immunology; La Jolla Institute for Immunology	Lin, T (corresponding author), Northwestern Univ, Sch Med, Dept Med, Gastroenterol Sect, Chicago, IL 60611 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI 44828] Funding Source: Medline; NIDDK NIH HHS [DK02445, DK56605-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056605, K08DK002445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; GALLAND RB, 1987, BRIT J SURG, V74, P742, DOI 10.1002/bjs.1800740833; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; Higgins LM, 1999, J IMMUNOL, V162, P486; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; InagakiOhara K, 1997, EUR J IMMUNOL, V27, P2885, DOI 10.1002/eji.1830271121; IWAMOTO KS, 1994, RADIAT RES, V139, P103, DOI 10.2307/3578739; KASTAN MB, 1991, CANCER RES, V51, P6304; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYASHITA T, 1995, CELL, V80, P293; NOVAK JM, 1979, J CLIN GASTROENTEROL, V1, P9, DOI 10.1097/00004836-197903000-00003; Piguet PF, 1998, EUR J IMMUNOL, V28, P3499, DOI 10.1002/(SICI)1521-4141(199811)28:11<3499::AID-IMMU3499>3.0.CO;2-Q; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sheikh MS, 1998, CANCER RES, V58, P1593; Shiraishi M, 1998, WORLD J SURG, V22, P491, DOI 10.1007/s002689900422; VAN AD, 1996, SCIENCE, V274, P787; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	38	22	25	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					812	818		10.1038/sj.onc.1204172	http://dx.doi.org/10.1038/sj.onc.1204172			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314015				2022-12-25	WOS:000166924400004
J	Sibley, K; Cuthbert-Heavens, D; Knowles, MA				Sibley, K; Cuthbert-Heavens, D; Knowles, MA			Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma	ONCOGENE			English	Article						bladder; cancer; FGFR3; mutation	GROWTH-FACTOR RECEPTOR-3; BLADDER-CARCINOMA; URINARY-BLADDER; ACTIVATING MUTATIONS; INCREASED EXPRESSION; CHROMOSOME PATTERN; MULTIPLE-MYELOMA; TISSUE-CULTURE; ALLELIC LOSS; NUDE-MICE	4p16,3 has previously been identified as a region of nonrandom LOH in transitional cell carcinoma, suggesting the presence of a tumour suppressor gene. One candidate within this region is fibroblast growth factor receptor 3 (FGFR3). Germline mutations in FGFR3 are known to cause several autosomal dominant skeletal dysplasias, the severity of which depends on the position and nature of the mutation in the protein. We investigated the frequency and nature of FGFR3 mutations in a panel of transitional cell carcinomas and cell lines and studied the possible link between mutation and loss of heterozygosity (LOH) on 4p16.3. FGFR3 coding sequence from 63 transitional cell carcinomas (TCC) of various stages and grades, and 18 cell lines,vas analysed by fluorescent SSCP, Samples with abnormal migration patterns were sequenced to identify the mutation or polymorphism. Thirty-one of the 63 tumours had previously been assessed to have LOH at 4p16,3, Twenty -six of the 63 tumours (41%) and 4/18 (22%) of the cell lines had missense mutations in FGFR3. All mutations detected in our panel have been reported in the germline where all apart from one cause lethal conditions. One tumour contained K652Q which has recently been identified in less severe cases of skeletal dysplasia. Tumours with and without LOH at 4p16,3 had mutations in FGFR3 suggesting that these tno events are not causally linked. The frequency of FGFR3 mutation indicates that this protein plays an important role in TCC.	St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin Canc, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Imperial Canc Res Fund, Mutat Detect Family, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin Canc, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Heavens, Darren/0000-0001-5418-7868; Knowles, Margaret/0000-0002-9363-8657				Antonarakis SE, 1998, HUM MUTAT, V11, P1; BELLUS GA, 2000, IN PRESS AM J HUM GE; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Caron H, 1996, HUM GENET, V97, P834; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; ELDER PA, 1994, ONCOGENE, V9, P3433; ELLIOTT AY, 1974, JNCI-J NATL CANCER I, V53, P1341, DOI 10.1093/jnci/53.5.1341; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GEY GO, 1952, CANCER RES, V12, P264; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hadano S, 1998, DNA Res, V5, P177, DOI 10.1093/dnares/5.3.177; HASTINGS RJ, 1981, INT J CANCER, V27, P15, DOI 10.1002/ijc.2910270104; *HMSO, 1994, CANC REG STAT; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; KNOWLES MA, 1994, CANCER RES, V54, P531; KYRIAZIS AA, 1984, CANCER RES, V44, P3997; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; Mostofi FK, 1973, HISTOLOGICAL TYPING; NAWROZ H, 1994, CANCER RES, V54, P1152; Onose H, 1999, EUR J ENDOCRINOL, V140, P169, DOI 10.1530/eje.0.1400169; OTOOLE C, 1978, BRIT J CANCER, V38, P64, DOI 10.1038/bjc.1978.164; OTOOLE C, 1976, INT J CANCER, V17, P707, DOI 10.1002/ijc.2910170604; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PAULI BU, 1983, J UROLOGY, V129, P646, DOI 10.1016/S0022-5347(17)52271-5; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; POLASCIK TJ, 1995, CANCER RES, V55, P5396; Pribill I, 1997, SOMAT CELL MOLEC GEN, V23, P413, DOI 10.1007/BF02673751; RASHEED S, 1977, J NATL CANCER I, V58, P881, DOI 10.1093/jnci/58.4.881; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SATO T, 1991, CANCER RES, V51, P5118; Shivapurkar N, 1999, CANCER RES, V59, P3576; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Tartaglia M, 1998, MOL CELL PROBE, V12, P335, DOI 10.1006/mcpr.1998.0189; *UICC, 1978, CLASS MAL TUM BLADD; VILIEN M, 1983, EUR J CANCER CLIN ON, V19, P775, DOI 10.1016/0277-5379(83)90010-X; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WILLIAMS RD, 1980, INVEST UROL, V17, P359; Yustein AS, 1999, CANCER RES, V59, P1437; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149	51	89	92	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					686	691		10.1038/sj.onc.1204110	http://dx.doi.org/10.1038/sj.onc.1204110			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314002				2022-12-25	WOS:000166806000004
J	Hubinger, G; Muller, E; Scheffrahn, I; Schneider, C; Hildt, E; Singer, BB; Sigg, I; Graf, J; Bergmann, L				Hubinger, G; Muller, E; Scheffrahn, I; Schneider, C; Hildt, E; Singer, BB; Sigg, I; Graf, J; Bergmann, L			CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299	ONCOGENE			English	Article						CD30; TNF receptor; cell cycle arrest; anaplastic large cell lymphoma (ALCL)	TNF RECEPTOR SUPERFAMILY; KAPPA-B ACTIVATION; NEGATIVE SELECTION; HODGKINS-DISEASE; FACTORS TRAFS; T-CELLS; DEATH; APOPTOSIS; INDUCTION; CD30	One of the major characteristics of anaplastic large cell lymphomas (ALCL) is the expression of the Ki-1/CD30 antigen. While the receptor mediates NF-kappaB-activation in Hodgkin's lymphomas, some data suggest the CD30-mediated apoptosis of other CD30-expressing cells. We were able to demonstrate that activation of CD30 leads to different effects regarding cell proliferation of the ALCL-derived cell lines Karpas 299 and JB6, Western and Northern blotting analysis re, revealed that CD30-induced growth inhibition of Karpas 299 cells correlated with a strong upregulation of the cell cycle inhibitor p21(CIP1/WAF1). We found a non activating point mutation at codon 273 in exon 8 of the p53 gene in Karpas 299 cells which indicates an p53-independent mechanism for induced p21 expression. Abundant p21 protein expression resulted in hypophosphorylation of the retinoblastoma protein (Rb) and inhibition of the proliferating cell nuclear antigen (PCNA). CD30-stimulated cells showed no indications of apoptotic cell death, like genomic DNA fragmentation or cleavage of the caspase3 target protein poly (ADP-ribose) polymerase (PARP), Our results indicate that CD30 is able to mediate an p21-associated cell cycle arrest in ALCL with possible implications for prognosis and clinical treatment.	Karolinska Inst, Dept Cellular & Mol Biol, Stockholm, Sweden; Robert Koch Inst, Dept Mol Biol, D-1000 Berlin, Germany; Univ Frankfurt, Dept Internal Med 3, D-6000 Frankfurt, Germany; Univ Ulm, Dept Internal Med 3, Ulm, Germany	Karolinska Institutet; Robert Koch Institute; Goethe University Frankfurt; Ulm University	Hubinger, G (corresponding author), Univ Ulm Klinikum, Dept Internal Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.		Singer, Bernhard B./AAP-9999-2020; Hildt, Eberhard/A-1040-2015					Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baker SJ, 1996, ONCOGENE, V12, P1; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chiarle R, 1999, J IMMUNOL, V163, P194; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FALINI B, 1995, BLOOD, V85, P1; Givol I, 1998, ONCOGENE, V16, P3115, DOI 10.1038/sj.onc.1201849; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Marches R, 1999, P NATL ACAD SCI USA, V96, P8711, DOI 10.1073/pnas.96.15.8711; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Singer BB, 2000, CANCER RES, V60, P1236; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	37	51	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					590	598		10.1038/sj.onc.1204128	http://dx.doi.org/10.1038/sj.onc.1204128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313991				2022-12-25	WOS:000166755000006
J	Monaco, C; Visconti, R; Barone, MV; Pierantoni, GM; Berlingieri, MT; De Lorenzo, C; Mineo, A; Vecchio, G; Fusco, A; Santoro, M				Monaco, C; Visconti, R; Barone, MV; Pierantoni, GM; Berlingieri, MT; De Lorenzo, C; Mineo, A; Vecchio, G; Fusco, A; Santoro, M			The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane	ONCOGENE			English	Article						tyrosine kinase; transformation; thyroid; coiled coil; dimerization	THYROID PAPILLARY CARCINOMAS; A ANCHORING PROTEIN; TYROSINE KINASE; MOLECULAR CHARACTERIZATION; REARRANGED FORM; ONCOGENE; GENE; PROTOONCOGENE; RECEPTOR; COACTIVATOR	The RET/PTC3 oncogene arises from the fusion between the N-terminal encoding domain of the RFG gene and the tyrosine kinase encoding domain of RET receptor, RET/PTC3 is,very frequent in papillary thyroid carcinomas, especially in children exposed to the Chernobyl accident. We have studied the functional consequences of the RFG - RET fusion, Here we show, that the N-terminal coiled-coil domain of RGF mediates oligomerization and activation of the kinase and of the transforming capability of RET/PTC3, In addition, the RFG coiled-coil domain mediates a physical association between RET/PTC3 and RGF proteins, rendering RFG a bona fide substrate of RET/PTC3 kinase, Finally, we show that the coiled-coil domain of RGF is essential for the distribution of the RET/PTC3 protein at the membrane/particulate cell compartment level, where also most of the RFG protein is localized. We propose that fusion to the RFG coiled-coil domain provides RET kinase with a scaffold that mediates oligomerization and re-localization of the RET/PTC3 protein, a process that may be crucial for the signalling of this specific RET/PTC variant.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dept Organ & Biol Chem, I-80134 Naples, Italy; Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		Pierantoni, Giovanna Maria/O-7527-2015; Visconti, Roberta/C-5299-2009	Pierantoni, Giovanna Maria/0000-0003-4078-8528; De Lorenzo, Claudia/0000-0002-6195-5631; BARONE, Maria Vittoria/0000-0001-6190-4917; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1998, ONCOGENE, V16, P671, DOI 10.1038/sj.onc.1201526; Klugbauer S, 1998, CANCER RES, V58, P198; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierotti MA, 1998, RECENT RES CANCER, V154, P237; Powell DJ, 1998, CANCER RES, V58, P5523; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Salassidis K, 2000, CANCER RES, V60, P2786; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; Tong Q, 1997, J BIOL CHEM, V272, P9043; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	33	43	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					599	608		10.1038/sj.onc.1204127	http://dx.doi.org/10.1038/sj.onc.1204127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313992				2022-12-25	WOS:000166755000007
J	Stivala, LA; Riva, F; Cazzalini, O; Savio, M; Prosperi, E				Stivala, LA; Riva, F; Cazzalini, O; Savio, M; Prosperi, E			p21(waf1/cip1)-null human fibroblasts are deficient in nucleotide excision repair downstream the recruitment of PCNA to DNA repair sites	ONCOGENE			English	Article						p21(waf1/cip1); nucleotide excision repair; PCNA; p21-null fibroblasts	CELL NUCLEAR ANTIGEN; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION-COUPLED REPAIR; AGENTS 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; ULTRAVIOLET-IRRADIATION; QUIESCENT FIBROBLASTS; GLIOBLASTOMA CELLS; COMPLEX-FORMATION; POLYMERASE-DELTA; BINDING DOMAINS	The cyclin-dependent kinase inhibitor p21(waf1/cip1) is known to impair DNA synthesis by binding to PCNA, the cofactor of DNA polymerases delta and epsilon. However, a positive role for p21 in nucleotide excision repair (NER) has been suggested. In this study, the sensitivity to DNA damage and DNA repair efficiency were investigated in p21-null human fibroblasts obtained by targeted homologous recombination. After UV-C irradiation, p21(sic) cells showed a threefold reduction in clonogenic survival and an increased susceptibility to apoptosis, as compared with parental p21(+/+) cells. Removal of cyclobutane pyrimidine dimers was significantly reduced in p21(-/-) cells both in the whole genome, and at the level of the rDNA gene cluster, as determined by immunoassay and Southern blot, respectively. After DNA damage, the recruitment of PCNA as detergent-insoluble form associated to DNA repair sites in p21(sic) fibroblasts, was comparable to that observed in parental p21(+/+) cells, However, PCNA remained associated with DNA for a longer period in p21(sic) than in p21(+/+) cells, These results suggest that in human cells, p21 is required for NER at a step located downstream the recruitment of PCNA to DNA repair sites.	CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Pavia	Prosperi, E (corresponding author), CNR, Ctr Studio Istochim, Piazza Botta 10, I-27100 Pavia, Italy.		Prosperi, Ennio/A-3439-2014	Prosperi, Ennio/0000-0001-5391-5157				ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fotedar R, 1996, ONCOGENE, V12, P2155; Fritz LK, 1996, J BIOL CHEM, V271, P12972, DOI 10.1074/jbc.271.22.12972; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MITCHELL DL, 1990, BIOESSAYS, V12, P74, DOI 10.1002/bies.950120205; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; Ruan S, 1998, CANCER RES, V58, P1538; Ruan SB, 1999, CLIN CANCER RES, V5, P197; Savio M, 1996, ONCOGENE, V13, P1591; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Van Sloun PPH, 1999, NUCLEIC ACIDS RES, V27, P3276, DOI 10.1093/nar/27.16.3276; VINK AA, 1994, J PHOTOCH PHOTOBIO B, V24, P25, DOI 10.1016/1011-1344(94)07005-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	58	44	44	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					563	570		10.1038/sj.onc.1204132	http://dx.doi.org/10.1038/sj.onc.1204132			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313988				2022-12-25	WOS:000166755000003
J	Champagne, N; Pelletier, N; Yang, XJ				Champagne, N; Pelletier, N; Yang, XJ			The monocytic leukemia zinc finger protein MOZ is is histone acetyltransferase	ONCOGENE			English	Article						histone acetyltransferase; MYST; MOZ; MORF; leukemia	ACUTE MYELOID-LEUKEMIA; CREB-BINDING-PROTEIN; HUMAN GENES; CBP; YEAST; FUSION; MLL; TRANSCRIPTION; TRANSLOCATION; COACTIVATOR	The monocytic leukemia zinc finger protein (MOZ) gene is rearranged in t(8;16)(p11;p13), t(8;22)(p11;q13) and inv(8)(p11q13) associated with acute myeloid leukemia. The other fusion partners involved are CBP, p300 and TIF2, transcriptional coactivators with known or potential histone acetyltransferase (HAT) activity. MOZ itself is a 2004-residue protein containing a putative acetyl CoA-binding motif, so it was hypothesized that MOZ is a HAT. Here we present direct evidence that MOZ has intrinsic HAT activity. Moreover, MOZ possesses a transcriptional repression domain at its N-terminal part and an activation domain at its C-terminal part. The activation domain does not show sequence similarity to any yeast proteins, but when tethered, it is able to activate transcription in yeast. Therefore, MOZ is a HAT with characteristics of a transcriptional coregulator, supporting the hypothesis that aberrant acetylation by abnormal MOZ proteins leads to leukemogenesis.	McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	McGill University	Yang, XJ (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada.							Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; John S, 2000, GENE DEV, V14, P1196; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Thomas T, 2000, DEVELOPMENT, V127, P2537; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	46	95	98	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					404	409		10.1038/sj.onc.1204114	http://dx.doi.org/10.1038/sj.onc.1204114			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313971				2022-12-25	WOS:000166411000016
J	Legare, D; Richard, D; Mukhopadhyay, R; Stierhof, YD; Rosen, BP; Haimeur, A; Papadopoulou, B; Ouellette, M				Legare, D; Richard, D; Mukhopadhyay, R; Stierhof, YD; Rosen, BP; Haimeur, A; Papadopoulou, B; Ouellette, M			The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENITE-RESISTANT LEISHMANIA; INCREASED TRYPANOTHIONE LEVELS; GREEN FLUORESCENT PROTEIN; P-GLYCOPROTEIN GENE; GS-X PUMP; DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; ORNITHINE DECARBOXYLASE; VISCERAL LEISHMANIASIS; PENTAVALENT ANTIMONY	The Leishmania ATP-binding cassette (ABC) transporter PGPA is involved in metal resistance (arsenicals and antimony), although the exact mechanism by which PGPA confers resistance to antimony, the first line drug against Leishmania, is unknown. The results of co-transfection experiments, transport assays, and the use of inhibitors suggest that PGPA recognizes metals conjugated to glutathione or trypanothione, a glutathione-spermidine conjugate present in Leishmania, The HA epitope tag of the influenza hemagglutinin as well as the green fluorescent protein were fused at the COOH terminus of PGPA. Immunofluorescence, confocal, and electron microscopy studies of the fully functional tagged molecules clearly indicated that PGPA is localized in membranes that are close to the flagellar pocket, the site of endocytosis and exocytosis in this parasite. Subcellular fractionation of Leishmania tarentolae PG-PAHA transfectants was performed to further characterize this ABC transporter. The basal PGPA ATPase activity was determined to be 115 nmol/mg/min. Transport experiments using radioactive arsenite-glutathione conjugates clearly showed that PGPA recognizes and actively transports thiol-metal conjugates, Overall, the results are consistent with PGPA being an intracellular ABC transporter that confers arsenite and antimonite resistance by sequestration of the metal-thiol conjugates.	CHU Laval, Ctr Rech Infect, St Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Div Microbiol, St Foy, PQ G1V 4G2, Canada; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Max Planck Inst Biol, D-72076 Tubingen, Germany	Laval University; Laval University; Wayne State University; Max Planck Society	Ouellette, M (corresponding author), CHU Laval, Ctr Rech Infectiol, 2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.		Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646; Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055425, R01GM052216, R01GM055425] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55425, GM52216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CALLAHAN HL, 1994, MOL BIOCHEM PARASIT, V68, P145, DOI 10.1016/0166-6851(94)00154-5; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DETKE S, 1989, EXP CELL RES, V180, P161, DOI 10.1016/0014-4827(89)90220-6; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FarautGambarelli F, 1997, ANTIMICROB AGENTS CH, V41, P827, DOI 10.1128/AAC.41.4.827; FerreiraPinto KC, 1996, CAN J MICROBIOL, V42, P944, DOI 10.1139/m96-121; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P45; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; GRONDIN K, 1993, NUCLEIC ACIDS RES, V21, P1895, DOI 10.1093/nar/21.8.1895; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Haimeur A, 1999, MOL MICROBIOL, V34, P726, DOI 10.1046/j.1365-2958.1999.01634.x; Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P377; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Ishikawa T, 1997, BIOSCIENCE REP, V17, P189, DOI 10.1023/A:1027385513483; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; JACKSON JE, 1990, AM J TROP MED HYG, V43, P464, DOI 10.4269/ajtmh.1990.43.464; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Legare D, 1997, EXP PARASITOL, V87, P275, DOI 10.1006/expr.1997.4222; LEGARE D, 1994, MOL BIOCHEM PARASIT, V68, P81, DOI 10.1016/0166-6851(94)00156-1; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; Mukhopadhyay R, 1996, P NATL ACAD SCI USA, V93, P10383, DOI 10.1073/pnas.93.19.10383; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; Ouellette M, 1998, DRUG RESIST UPDATE, V1, P43, DOI 10.1016/S1368-7646(98)80213-6; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; Papadopoulou B, 1996, BIOCHEM BIOPH RES CO, V224, P772, DOI 10.1006/bbrc.1996.1098; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SINGH AK, 1994, MOL BIOCHEM PARASIT, V66, P161, DOI 10.1016/0166-6851(94)90049-3; STIERHOF YD, 1991, J ELECTRON MICR TECH, V17, P336, DOI 10.1002/jemt.1060170307; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; Weise F, 2000, J CELL SCI, V113, P4587; WHITE TC, 1988, J BIOL CHEM, V263, P16977	57	169	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26301	26307		10.1074/jbc.M102351200	http://dx.doi.org/10.1074/jbc.M102351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11306588	hybrid			2022-12-25	WOS:000169823300088
J	Myles, T; Yun, TH; Hall, SW; Leung, LLK				Myles, T; Yun, TH; Hall, SW; Leung, LLK			An extensive interaction interface between thrombin and factor V is required for factor V activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; DYSTHROMBINS QUICK-I; HUMAN ALPHA-THROMBIN; BINDING EXOSITE-I; CLEAVAGE REQUIREMENTS; CRYSTAL-STRUCTURE; PROTEIN-C; THROMBOMODULIN; HIRUDIN; SITE	The interaction interface between human thrombin and human factor V (FV), necessary for complex formation and cleavage to generate factor Va, was investigated using a site-directed mutagenesis strategy. Fifty-three recombinant thrombins, with a total of 78 solvent-exposed basic and polar residues substituted with alanine, were used in a two-stage clotting assay with human FV, Seventeen mutants with less than 50% of wild-type (WT) thrombin FV activation were identified and mapped to anion-binding exosite I (ABE-I), anion-binding exosite II (ABE-II), the Leu(45)-Asn(57) insertion loop, and the Na+ binding loop of thrombin, Three ABE-I mutants (R68A, R70A, and Y71A) and the ABE-II mutant R98A had less than 30% of WT activity. The thrombin Na+ binding loop mutants, E229A and R233A, and the Leu45-Asn57 insertion loop mutant, W50A, had a major effect on FV activation with 5, 15, and 29% of WT activity, respectively. The K52A mutant, which maps to the S' specificity pocket, had 29% of WT activity. SDS-polyacrylamide gel electrophoresis analysis of cleavage reactions using the thrombin ABE mutants R68A, Y71A, and R98A, the Na+ binding loop mutant E229A, and the Leu(45)-Asn(57) insertion loop mutant W50A showed a requirement for both ABEs and the Na+-bound form of thrombin for efficient cleavage at the FV residue Arg(709) Several basic residues in both ABEs have moderate decreases in FV activation (40-60% of WT activity), indicating a role for the positive electrostatic fields generated by both ABEs in enhancing complex formation with complementary negative electrostatic fields generated by FV, The data show that thrombin activation of FV requires an extensive interaction interface with thrombin, Both ABE-I and ABE-II and the S' subsite are required for optimal cleavage, and the Na+-bound form of thrombin is important for its procoagulant activity.	Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA	Stanford University	Myles, T (corresponding author), Stanford Univ, Sch Med, Div Hematol, CCSR,Rm 1155, Stanford, CA 94305 USA.	tmyles@stanford.edu; lawrence.leung@stanford.edu			NHLBI NIH HHS [R01 HL57530] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BETZ A, 1991, BIOCHEM J, V275, P801, DOI 10.1042/bj2750801; BINNIE CG, 1993, BLOOD, V81, P3186; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; ESMON CT, 1979, J BIOL CHEM, V254, P964; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; HOFSTEENGE J, 1987, EUR J BIOCHEM, V168, P49, DOI 10.1111/j.1432-1033.1987.tb13385.x; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200; LIU LW, 1991, J BIOL CHEM, V266, P16977; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MANN KG, 1990, BLOOD, V76, P1; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; Myles T, 2001, EUR J BIOCHEM, V268, P70, DOI 10.1046/j.1432-1327.2001.01844.x; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1991, BIOCHEMISTRY-US, V30, P6392, DOI 10.1021/bi00240a007; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; WALLACE A, 1989, BIOCHEM J, V257, P191, DOI 10.1042/bj2570191; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1994, J BIOL CHEM, V269, P17965	46	79	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25143	25149		10.1074/jbc.M011324200	http://dx.doi.org/10.1074/jbc.M011324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312264	hybrid			2022-12-25	WOS:000169800700096
J	Manalo, DJ; Liu, AYC				Manalo, DJ; Liu, AYC			Resolution, detection, and characterization of redox conformers of human HSF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; DNA-BINDING ACTIVITY; NITRIC-OXIDE; IN-VITRO; HEAT; ACTIVATION; PROTEIN; OLIGOMERIZATION; THIOREDOXIN; GLUTATHIONE	We describe here an experimental protocol for the resolution, detection, and quantitation of the reduced and oxidized conformers of human heat shock factor 1 (hHSF1) and report on the effects in vitro and in vivo of redox-active agents on the redox status, structure, and function of hHSF1. We showed that diamide, a reagent that promotes disulfide bond formation, caused a loss of immunorecognition of the monomeric hHSF1 protein in a standard Western blot detection procedure. Modification of the Western blot procedure to include dithiothreitol in the equilibration and transfer buffers after gel electrophoresis allowed for the detection of a compact, intramolecularly disulfide cross-linked oxidized hHSF1 (ox-hHSF1) in the diamide-treated sample. The effect of diamide was blocked by pretreatment with N-ethylmaleimide and was reversed by dithiothreitol added to the sample prior to gel electrophoresis. Incubation with nitrosoglutathione at 42 degreesC also promoted the conversion of HSF1 to ox-HSF1; at 25 degreesC, however, nitrosoglutathione was by itself without effect but blocked the formation of ox-hHSF1 in the presence of diamide. The disulfide cross-linked ox-hFPSF1 was monomeric and resistant to the in vitro heat-induced trimerization and activation. The possibility that ox-HSF1 may occur in oxidatively stressed cells was evaluated. Treatment of HeLa cells with 2 mM L-buthionine sulfoximine promoted the formation of ox-HSF1 and blocked the heat-induced activation of HSF DNA binding activity. Our result suggests that hHSF1 may have integrated redox chemistry of cysteine sulfhydryl into its functional responses.	Rutgers State Univ, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; Rutgers State Univ, Grad Program Cell & Dev Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Liu, AYC (corresponding author), Rutgers State Univ, Dept Neurosci & Cell Biol, 604 Allison Rd, Piscataway, NJ 08854 USA.	liu@biology.rutgers.edu		Liu, Alice Y./0000-0002-6984-1671				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; AUSUBEL J, 1990, CURRENT PROTOCOLS MO; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BRANDON C, 1998, INTRO PROTEIN STRUCT, P353; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; FREEMAN ML, 1987, BIOCHEM PHARMACOL, V36, P21; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HUANG LE, 1994, J BIOL CHEM, V269, P30718; JAENICKE R, 1991, CIBA F SYMP, V161, P206; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE KJ, 1988, J CELL PHYSIOL, V136, P411, DOI 10.1002/jcp.1041360304; Lee YK, 1996, BIOL SIGNAL, V5, P180; Lipton SA, 1996, NEUROCHEM INT, V29, P111, DOI 10.1016/0197-0186(95)00150-6; Liu A Y, 1996, EXS, V77, P393; LIU AYC, 1991, J CELL PHYSIOL, V149, P560, DOI 10.1002/jcp.1041490327; LUNBLAD RL, 1995, TECHNIQUES PROTEIN M, P63; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Mercier PA, 1999, J CELL SCI, V112, P2765; Mercier PA, 1997, J BIOL CHEM, V272, P14147, DOI 10.1074/jbc.272.22.14147; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; Park J, 2000, J CELL PHYSIOL, V185, P348, DOI 10.1002/1097-4652(200012)185:3<348::AID-JCP5>3.0.CO;2-3; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Yang F, 1997, CLIN CHEM, V43, P657; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	51	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23554	23561		10.1074/jbc.M011300200	http://dx.doi.org/10.1074/jbc.M011300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320084	hybrid			2022-12-25	WOS:000169531100046
J	Shetzline, SE; Suhadolnik, RJ				Shetzline, SE; Suhadolnik, RJ			Characterization of a 2 ',5 '-oligoadenylate (2-5A)-dependent 37-kDa RNase L - Azido photoaffinity labeling and 2-5A-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC-FATIGUE-SYNDROME; L ANTIVIRAL PATHWAY; ATP-BINDING DOMAIN; SYNTHETASE FAMILY; IDENTIFICATION; SITE; PEPTIDE; PROTEIN	Upregulation of key components of the 2 ' ,5 ' -oligoadenylate (2-5A) synthetase/RNase L pathway have been identified in extracts of peripheral blood mononuclear cells hom individuals with chronic syndrome, including the presence of a low molecular weight form of RNase L. In this study, analysis of 2 ' ,5 ' -Oligoadenylate (2-5A) binding and activation of the 80- and 37-kDa forms of RNase L has been completed utilizing photolabeling/immunoprecipitation and affinity assays, respectively. Saturation of photolabeling of the 80- and the 37-kDa RNase L with the 2-5A azido photoprobe, [P-32]pApAp(8-azidoA), was achieved. Half-maximal photoinsertion of [P-32]pApAp(8-azidoA) occurred at 3.7 x 10(-8) M for the 80-kDa RNase L and at 6.3 x 10(-8) M for the 37-kDa RNase L. Competition experiments using 100-fold excess unlabeled 2-5A photoaffinity probe, pApAp(8-azidoA), and authentic 2-5A (p(3)A(3)) resulted in complete protection against photolabeling, demonstrating that [P-32]pApAp(8-azidoA) binds specifically to the 2-5A-binding site of the 80 and 37-kDa RNase L. The rate of RNA hydrolysis by the 37-kDa RNase L was three times faster than the 80 M)a RNase L. The data obtained from these 2-5A binding and 2-5A-dependent activation studies demonstrate the utility of [P-32]pApAp(8-azidoA) for the detection of the 37-kDa RNase L in peripheral blood mononuclear cell extracts.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Suhadolnik, RJ (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038378] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00349] Funding Source: Medline; NIAID NIH HHS [R01 AI38378] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYARD B, 1994, EUR J BIOCHEM, V223, P403, DOI 10.1111/j.1432-1033.1994.tb19007.x; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; CHARUBALA R, 1989, HELV CHIM ACTA, V72, P1354, DOI 10.1002/hlca.19890720624; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; De Meirleir K, 2000, AM J MED, V108, P99, DOI 10.1016/S0002-9343(99)00300-9; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; Justesen J, 2000, CELL MOL LIFE SCI, V57, P1593, DOI 10.1007/PL00000644; Kon N, 1996, J BIOL CHEM, V271, P19983, DOI 10.1074/jbc.271.33.19983; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHETZLINE SE, 2001, AM ASS CHRON FAT SYN; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suhadolnik R J, 1994, In Vivo, V8, P599; SUHADOLNIK RJ, 1994, CLIN INFECT DIS, V18, pS96, DOI 10.1093/clinids/18.Supplement_1.S96; Suhadolnik RJ, 1997, J INTERF CYTOK RES, V17, P377, DOI 10.1089/jir.1997.17.377; SUHADOLNIK RJ, 1988, BIOCHEMISTRY-US, V27, P8840, DOI 10.1021/bi00424a023; SUHADOLNIK RJ, 1999, J CHRONIC FATIGUE SY, V5, P223; TRAD CH, 1993, ARCH BIOCHEM BIOPHYS, V304, P58, DOI 10.1006/abbi.1993.1321	27	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23707	23711		10.1074/jbc.M101243200	http://dx.doi.org/10.1074/jbc.M101243200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323422	hybrid			2022-12-25	WOS:000169531100065
J	Tomasini-Johansson, BR; Kaufman, NR; Ensenberger, MG; Ozeri, V; Hanski, E; Mosher, DF				Tomasini-Johansson, BR; Kaufman, NR; Ensenberger, MG; Ozeri, V; Hanski, E; Mosher, DF			A 49-residue peptide front adhesin F1 of Streptococcus pyogenes inhibits fibronectin matrix assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; PROTEIN-F; STAPHYLOCOCCUS-AUREUS; LYSOPHOSPHATIDIC ACID; PLASMA FIBRONECTIN; BINDING PROTEIN; CROSS-LINKING; FIBROBLASTS	F1 is an adhesin of Streptococcus pyogenes which binds the N-terminal 70-kDa region of fibronectin with high affinity. The fibronectin binding region of F1 is comprised of a 43-residue upstream domain and a repeat domain comprised of five tandem 37-residue sequences. We investigated the effects of these domains on the assembly of fibronectin matrix by human dermal fibroblasts, MG63 osteosarcoma cells, or fibroblasts derived from fibronectin-null stem cells. Subequimolar or equimolar concentrations of recombinant proteins containing both the upstream and repeat domains or just the repeat domain enhanced binding of fibronectin or its N-terminal 70-kDa fragment to cell layers; higher concentrations of these recombinant proteins inhibited binding. The enhanced binding did not result in greater matrix assembly and was caused by increased ligand binding to substratum. In contrast, recombinant or synthetic protein containing the 43 residues of the upstream domain and the first 6 residues from the repeat domain exhibited monophasic inhibition with an IC50 of similar to 10 nM. Truncation of the 49-residue sequence at its N or C terminus caused loss of inhibitory activity. The 49-residue upstream sequence blocked incorporation of both endogenous cellular fibronectin and exogenous plasma fibronectin into extracellular matrix and inhibited binding of 70-kDa fragment to fibronectin-null cells in a fibronectin-free system. Inhibition of matrix assembly by the 49-mer had no effect on cell adhesion to substratum, cell growth, formation of focal contacts, or formation of stress fibers. These results indicate that the 49-residue upstream sequence of F1 binds in an inhibitory mode to N-terminal parts of exogenous and endogenous fibronectin which are critical for fibronectin fibrillogenesis.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Dana Coll, Dept Biol, Blair, NE 68008 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Clin Microbiol, IL-91010 Jerusalem, Israel	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Hebrew University of Jerusalem	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, 4285 MSC,1300 Univ Ave, Madison, WI 53706 USA.		hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CHERNOUSOV MA, 1985, FEBS LETT, V183, P365, DOI 10.1016/0014-5793(85)80811-5; Cue D, 1998, INFECT IMMUN, V66, P4593, DOI 10.1128/IAI.66.10.4593-4601.1998; GRINNELL F, 1982, EXP CELL RES, V142, P499, DOI 10.1016/0014-4827(82)90398-6; Guzman CA, 1999, J INFECT DIS, V179, P901, DOI 10.1086/314655; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes RO, 1999, P NATL ACAD SCI USA, V96, P2588, DOI 10.1073/pnas.96.6.2588; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PEARLSTEIN E, 1978, INT J CANCER, V22, P32, DOI 10.1002/ijc.2910220108; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; Sottile J, 1998, J CELL SCI, V111, P2933; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	44	94	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23430	23439		10.1074/jbc.M103467200	http://dx.doi.org/10.1074/jbc.M103467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323441	hybrid			2022-12-25	WOS:000169531100029
J	Gaither, LA; Eide, DJ				Gaither, LA; Eide, DJ			The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CONFERS RESISTANCE; METAL TRANSPORTER; MAMMALIAN ZINC; GENE ENCODES; PROTEIN; FAMILY; ARABIDOPSIS	The ZIP superfamily of transporters plays important roles in metal ion uptake in diverse organisms. There are 12 ZIP-encoding genes in humans, and we hypothesize that many of these proteins are zinc transporters. In this study, we addressed the role of one human ZIP gene, hZIP1, in zinc transport. First, we examined Zn-65 uptake activity in K562 erythroleukemia cells overexpressing hZIP1. These cells accumulated more zinc than control cells because of increased zinc influx. Moreover, consistent with its role in zinc uptake, hZIP1 protein was localized to the plasma membrane. Our results also demonstrated that hZIP1 is responsible for the endogenous zinc uptake activity in K562 cells, hZIP1 is expressed in untransfected K562 cells, and the increase in mRNA levels found in hZIP1-overexpressing cells correlated with the increased zinc uptake activity. Furthermore, hZIP1-dependent Zn-65 uptake was biochemically indistinguishable from the endogenous activity. Finally, inhibition of endogenous hZIP1 expression with antisense oligonucleotides caused a marked decrease in endogenous Zn-65 uptake activity. The observation that hZIP1 is the major zinc transporter in K562 cells, coupled with its expression in many normal cell types, indicates that hZIP1 plays an important role in zinc uptake in human tissues.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.	eided@missouri.edu			NATIONAL CANCER INSTITUTE [R01CA079903] Funding Source: NIH RePORTER; NCI NIH HHS [CA79903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Branch AD, 1998, TRENDS BIOCHEM SCI, V23, P45, DOI 10.1016/S0968-0004(97)01155-9; Cleland W W, 1979, Methods Enzymol, V63, P103; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; GAITHER LA, 2001, IN PRESS BIOMETALS; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lioumi M, 1999, GENOMICS, V62, P272, DOI 10.1006/geno.1999.5993; Liuzzi JP, 2001, J NUTR, V131, P46, DOI 10.1093/jn/131.1.46; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MAGNESON GR, 1987, J BIOL CHEM, V262, P11140; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; McMahon RJ, 1998, J NUTR, V128, P667, DOI 10.1093/jn/128.4.667; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Pence NS, 2000, P NATL ACAD SCI USA, V97, P4956, DOI 10.1073/pnas.97.9.4956; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Yamaguchi S, 1995, Kokubyo Gakkai Zasshi, V62, P78; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; Zucker M, 1999, RNA BIOCH BIOTECHNOL	29	210	218	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22258	22264		10.1074/jbc.M101772200	http://dx.doi.org/10.1074/jbc.M101772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301334	hybrid			2022-12-25	WOS:000169412700040
J	Han, J; Kim, N; Kim, E; Ho, WK; Earm, YE				Han, J; Kim, N; Kim, E; Ho, WK; Earm, YE			Modulation of ATP-sensitive potassium channels by cGMP-dependent protein kinase in rabbit ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; PANCREATIC BETA-CELLS; NITRIC-OXIDE; K+-CHANNEL; CYCLIC-GMP; PHARMACOLOGICAL EXPLOITATION; XENOPUS-OOCYTES; SMOOTH-MUSCLE; RAT-HEART; ACTIVATION	This investigation used a patch clamp technique to test the hypothesis that protein kinase G (PKG) contributes to the phosphorylation and activation of ATP-sensitive K+ (K-ATP) channels in rabbit ventricular myocytes. Nitric oxide donors and PKG; activators facilitated pinacidil-induced K-ATP channel activities in a concentration-dependent manner, and a selective PKG inhibitor abrogated these effects. In contrast, neither a selective protein kinase A (PKA) activator nor inhibitor had any effect on K-ATP channels at concentrations up to 100 and 10 muM, respectively. Exogenous PKG, in the presence of both cGMP and ATP, increased channel activity, while the catalytic subunit of PKA had no effect. PKG activity was prevented by heat inactivation, replacing ATP with adenosine 5 ' -O-(thiotriphosphate) (a nonhydrolyzable analog of ATP), removing Mg2+ from the internal solution, applying a PKG inhibitor, or by adding exogenous protein phosphatase 2A The effects of cGMP analogs and PKG were observed under conditions in which PKA was repressed by a selective PKA inhibitor. The results suggest that K-ATP channels are regulated by a PKG-signaling pathway that acts via PKG-dependent phosphorylation. This mechanism may, at least in part, contribute to a signaling pathway that induces ischemic preconditioning in rabbit ventricular myocytes.	Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Natl Res Lab Cellular Signaling, Seoul 110799, South Korea; Inje Univ, Coll Med, Dept Physiol & Biophys, Busan 614735, South Korea	Seoul National University (SNU); Seoul National University (SNU); Inje University	Earm, YE (corresponding author), Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, Yonkeun Dong, Seoul 110799, South Korea.		Ho, Won-Kyung/J-2798-2012					AHLNER J, 1991, PHARMACOL REV, V43, P351; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; AUCHAMPACH JA, 1993, AM J PHYSIOL, V264, pH1327, DOI 10.1152/ajpheart.1993.264.5.H1327; BILLMAN GE, 1990, FASEB J, V4, P1668, DOI 10.1096/fasebj.4.6.2156744; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; Butt E, 1995, BRIT J PHARMACOL, V116, P3110, DOI 10.1111/j.1476-5381.1995.tb15112.x; CAMERON JS, 1994, CARDIOVASC RES, V28, P788, DOI 10.1093/cvr/28.6.788; COHEN MV, 1993, LANCET, V342, P6, DOI 10.1016/0140-6736(93)91878-P; COLQUHOUN D, 1983, FITTING STAT ANAL SI, P191; Duncker DJ, 2000, CARDIOVASC DRUG THER, V14, P7, DOI 10.1023/A:1007866102585; GANOTE C, 1993, CARDIOVASC RES, V27, P1387, DOI 10.1093/cvr/27.8.1387; GENIESER HG, 1992, CARBOHYD RES, V234, P217, DOI 10.1016/0008-6215(92)85050-A; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Han J, 1998, PFLUG ARCH EUR J PHY, V435, P388, DOI 10.1007/s004240050528; HAN J, 1993, PFLUG ARCH EUR J PHY, V425, P546; HAN J, 1995, HEART VESSELS, V9, P94; Iliodromitis EK, 1996, BASIC RES CARDIOL, V91, P234, DOI 10.1007/BF00788909; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; KENNETH DC, 1993, J CLIN INVEST, V91, P2446; Kim EY, 1997, AM J PHYSIOL-HEART C, V272, pH325, DOI 10.1152/ajpheart.1997.272.1.H325; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO M, 1994, CIRC RES, V74, P471, DOI 10.1161/01.RES.74.3.471; Kwak YG, 1996, LIFE SCI, V58, P897, DOI 10.1016/0024-3205(96)00032-X; Light PE, 1996, CIRC RES, V79, P399, DOI 10.1161/01.RES.79.3.399; Maronde E, 1999, J PINEAL RES, V27, P170, DOI 10.1111/j.1600-079X.1999.tb00613.x; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PARRATT JR, 1995, J MOL CELL CARDIOL, V27, P991, DOI 10.1016/0022-2828(95)90068-3; PARRATT JR, 1995, CAN J PHYSIOL PHARM, V73, P837, DOI 10.1139/y95-114; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; Rapundalo ST, 1998, CARDIOVASC RES, V38, P559, DOI 10.1016/S0008-6363(98)00063-7; Ropero AB, 1999, J PHYSIOL-LONDON, V521, P397, DOI 10.1111/j.1469-7793.1999.00397.x; SAKUTA H, 1993, JPN J PHARMACOL, V61, P259, DOI 10.1254/jjp.61.259; SAKUTA H, 1994, EUR J PHARM-MOLEC PH, V267, P281, DOI 10.1016/0922-4106(94)90152-X; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; Shinbo A, 1997, BRIT J PHARMACOL, V120, P1568, DOI 10.1038/sj.bjp.0701069; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; TSUURA Y, 1994, J GEN PHYSIOL, V104, P1079, DOI 10.1085/jgp.104.6.1079; VANWINKLE DM, 1994, AM J PHYSIOL, V266, pH829, DOI 10.1152/ajpheart.1994.266.2.H829; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; WAHLER GM, 1995, AM J PHYSIOL-CELL PH, V268, pC45, DOI 10.1152/ajpcell.1995.268.1.C45; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; Wellman GC, 1998, J PHYSIOL-LONDON, V507, P117, DOI 10.1111/j.1469-7793.1998.117bu.x; Yamaguchi F, 1997, HEART VESSELS, V12, P74, DOI 10.1007/BF02820870; YAO ZH, 1994, CIRCULATION, V89, P1229, DOI 10.1161/01.CIR.89.3.1229; Zhu Z, 2000, PFLUG ARCH EUR J PHY, V439, P808, DOI 10.1007/s004240051008	48	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22140	22147		10.1074/jbc.M010103200	http://dx.doi.org/10.1074/jbc.M010103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303020	hybrid			2022-12-25	WOS:000169412700024
J	Huby, T; Dachet, C; Lawn, RM; Wickings, J; Chapman, MJ; Thillet, J				Huby, T; Dachet, C; Lawn, RM; Wickings, J; Chapman, MJ; Thillet, J			Functional analysis of the chimpanzee and human apo(a) promoter sequences - Identification of sequence variations responsible for elevated transcriptional activity in chimpanzee	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; APOLIPOPROTEIN(A) GENE; LIPOPROTEIN(A) LEVELS; MYOCARDIAL-INFARCTION; SIZE POLYMORPHISM; PLASMA; LP(A); REGION; RISK; ASSOCIATION	Lp(a) concentrations vary considerably among individuals and are primarily determined by the apo(a) gene locus. We have previously shown that mean plasma Lp(a) levels in the chimpanzee are significantly higher than those observed in humans (Doucet, C,, Huby, T., Chapman, J., and Thillet, J, (1994) J, Lipid Res 35, 263-270). To evaluate the possibility that this difference may result from a high level of expression of chimpanzee apo(a), we cloned and sequenced 1.4 kilobase (kb) of the 5 ' -flanking region of the gene and compared promoter activity to that of its human counterpart. Sequence analysis revealed 98% homology between chimpanzee and human apo(a) 5 ' sequences; among the differences observed, two involved polymorphic sites associated with Lp(a) levels in humans, The TTTTA repeat located 1.3 kb 5 ' of the apo(a) gene, present in a variable number of copies (n = 5-12) in humans, is uniquely present as four copies in the chimpanzee sequence, The second position concerns the +93 C >T polymorphism that creates an additional ATG start codon in the human apo(a) gene, thereby impairing translation efficiency. In chimpanzee, this position did not appear polymorphic, and a base difference at position +94 precluded the presence of an additional ATG. In transient transfection assays, the chimpanzee apo(a) promoter exhibited a 5-fold elevation in transcriptional activity as compared with its human counterpart. This marked difference in activity was maintained with either 1.4 kb of 5 ' sequence or the minimal promoter region -98 to +141 of the human and chimpanzee apo(a) genes, Using point mutational analyses, nucleotides present at positions -3, -2, and +8 (relative to the start site of transcription) were found to be essential for the high transcription efficiency of the chimpanzee apo(a) promoter, High transcriptional activity of the chimpanzee apo(a) gene may therefore rep resent a key factor in the elevated plasma Lp(a) levels characteristic of this non-human primate.	Hop Pitie, INSERM Unite 551, F-75651 Paris 13, France; Int Ctr Med Res, Franceville, Gabon; CV Therapeut, Palo Alto, CA 94304 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Thillet, J (corresponding author), Hop Pitie, INSERM Unite 551, 83 Blvd Hop, F-75651 Paris 13, France.		Huby, Thierry/E-6768-2017; chapman, john/Y-2742-2019; HUBY, Thierry/N-4820-2019	Huby, Thierry/0000-0001-6634-551X; HUBY, Thierry/0000-0001-6634-551X				BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BOPP S, 1995, J LIPID RES, V36, P1721; Brazier L, 1999, ATHEROSCLEROSIS, V144, P323, DOI 10.1016/S0021-9150(98)00333-5; Chenivesse X, 1998, BIOCHEMISTRY-US, V37, P7213, DOI 10.1021/bi9721546; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUCET C, 1994, J LIPID RES, V35, P263; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; Hiraga T, 1996, ATHEROSCLEROSIS, V122, P29, DOI 10.1016/0021-9150(95)05743-9; Hixson JE, 1996, J LIPID RES, V37, P2324; JURGENS G, 1995, STROKE, V26, P1841, DOI 10.1161/01.STR.26.10.1841; Keene RG, 1999, J BIOL CHEM, V274, P11526, DOI 10.1074/jbc.274.17.11526; Kraft HG, 1996, ARTERIOSCL THROM VAS, V16, P713, DOI 10.1161/01.ATV.16.6.713; Kraft HG, 1996, EUR J HUM GENET, V4, P74; Kraft HG, 1998, HUM MOL GENET, V7, P257, DOI 10.1093/hmg/7.2.257; KRAFT HG, 1992, HUM GENET, V90, P220; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; Lobentanz EM, 1998, BIOCHEMISTRY-US, V37, P5417, DOI 10.1021/bi972761t; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MOOSER V, 1995, HUM MOL GENET, V4, P173, DOI 10.1093/hmg/4.2.173; RAINWATER DL, 1988, ATHEROSCLEROSIS, V73, P23, DOI 10.1016/0021-9150(88)90159-1; SANDHOLZER C, 1991, HUM GENET, V86, P607; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schreiner PJ, 1996, ARTERIOSCL THROM VAS, V16, P471, DOI 10.1161/01.ATV.16.3.471; Suzuki K, 1997, J CLIN INVEST, V99, P1361, DOI 10.1172/JCI119295; TROMMSDORFF M, 1995, J CLIN INVEST, V96, P150, DOI 10.1172/JCI118015; Utermann G, 1999, CURR OPIN LIPIDOL, V10, P133, DOI 10.1097/00041433-199904000-00007; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WADE DP, 1994, J BIOL CHEM, V269, P19757; Wade DP, 1997, J BIOL CHEM, V272, P30387, DOI 10.1074/jbc.272.48.30387; WADE DP, 1993, P NATL ACAD SCI USA, V90, P1369, DOI 10.1073/pnas.90.4.1369; White AL, 1997, J BIOL CHEM, V272, P5048, DOI 10.1074/jbc.272.8.5048; Yang ZY, 1998, J BIOL CHEM, V273, P891, DOI 10.1074/jbc.273.2.891; ZYSOW BR, 1995, ARTERIOSCL THROM VAS, V15, P58, DOI 10.1161/01.ATV.15.1.58	38	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22209	22214		10.1074/jbc.M102204200	http://dx.doi.org/10.1074/jbc.M102204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301336	hybrid			2022-12-25	WOS:000169412700033
J	Knoop, LL; Baker, SJ				Knoop, LL; Baker, SJ			EWS/FLI alters 5 '-splice site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; EWINGS-SARCOMA TRANSLOCATION; SPLICING IN-VIVO; TRANSCRIPTION FACTOR; CHROMOSOME-TRANSLOCATION; MYXOID LIPOSARCOMA; POLYMERASE-II; GROWTH-FACTOR; GENE FUSION; CELL LINE	The chimeric gene EWS/FLI is present in at least 85% of Ewing's sarcomas as a result of chromosomal translocations, The resulting fusion protein contains the N terminus of the RNA-binding protein EWS and the ETS DNA-binding domain of the transcription factor FLI-1, Although EWS/FLI binds DNA and activates transcription, both EWS and EWS/FLI also interact with SF1 and U1C, essential components of the splicing machinery. Therefore, we tested the ability of EWS and EWS/FLI to alter 5'-splice site selection using an E1A gene in vivo splicing assay. We found that EWS/FLI, but not EWS, interfered with heterogeneous nuclear ribonucleoprotein Al-dependent splice site selection of E1A, Mutational analysis of EWS/FLI revealed that the ability to affect pre-mRNA splicing coincided with transforming activity. Therefore, EWS/FLI has the ability to influence splicing as well as transcription.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Baker, SJ (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale, Memphis, TN 38105 USA.				NCI NIH HHS [P01-CA-71907, P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; Hosokawa Y, 1997, CANCER LETT, V113, P123, DOI 10.1016/S0304-3835(97)04605-3; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Jang JH, 2000, CANCER RES, V60, P4049; JEON IS, 1995, ONCOGENE, V10, P1229; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LESSNICK SL, 1995, ONCOGENE, V10, P423; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Poleev A, 2000, EUR J BIOCHEM, V267, P4002, DOI 10.1046/j.1432-1327.2000.01431.x; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WANG J, 1995, RNA, V1, P335; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zhang HT, 2000, BRIT J CANCER, V83, P63; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	39	78	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22317	22322		10.1074/jbc.M008950200	http://dx.doi.org/10.1074/jbc.M008950200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301318	hybrid			2022-12-25	WOS:000169412700048
J	Lee, BC; Croonquist, PA; Sosnick, TR; Hoff, WD				Lee, BC; Croonquist, PA; Sosnick, TR; Hoff, WD			PAS domain receptor photoactive yellow protein is converted to a molten globule state upon activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-COUMARIC ACID; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOCYCLE; CHROMOPHORE; PHOTORECEPTOR; INTERMEDIATE; RHODOPSIN; FOLD	Biological signaling generally involves the activation of a receptor protein by an external stimulus followed by protein-protein interactions between the activated receptor and its downstream signal transducer. The current paradigm for the relay of signals along a signal transduction chain is that it occurs by highly specific interactions between fully folded proteins. However, recent results indicate that many regulatory proteins are intrinsically unstructured, providing a serious challenge to this paradigm and to the nature of structure-function relationships in signaling. Here we study the structural changes that occur upon activation of the blue light receptor photoactive yellow protein (PYP). Activation greatly reduces the tertiary structure of PYP but leaves the level secondary structure largely unperturbed. In addition, activated PYP exposes previously buried hydrophobic patches and allows significant solvent penetration into the core of the protein. These traits are the distinguishing hallmarks of molten globule states, which have been intensively studied for their role in protein folding. Our results show that receptor activation by light converts PYP to a molten globule and indicate stimulus-induced unfolding to a partially unstructured molten globule as a novel theme in signaling.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Hoff, WD (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.		Freed, Karl F/J-7764-2018	Freed, Karl F/0000-0001-6240-2599				Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Craven CJ, 2000, BIOCHEMISTRY-US, V39, P14392, DOI 10.1021/bi001628p; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; France RM, 2000, BIOCHEM BIOPH RES CO, V269, P709, DOI 10.1006/bbrc.2000.2346; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Ptitsyn Oleg B., 1992, P243; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a	25	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20821	20823		10.1074/jbc.C100106200	http://dx.doi.org/10.1074/jbc.C100106200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11319215	hybrid			2022-12-25	WOS:000169297900005
J	Masumi, A; Ozato, K				Masumi, A; Ozato, K			Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLATION; DNA-BINDING; GENE-TRANSCRIPTION; ONCOPROTEIN E1A; FACTOR-II; PCAF; PHOSPHORYLATION; ACTIVATION; CBP; ACETYLTRANSFERASE	Interferon regulatory factor-2 (IRF-2) is at transcription factor of the IRF family that represses interferon-mediated gene expression. In the present study, we show that human monocytic U937 cells express truncated forms of IRF-2 containing the DNA binding do main but lacking much of the C-terminal regulatory domain. U937 cells are shown to respond to phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) to induce expression of histone acetylases p300 and p300/CBP-associated factor (PCAF), In addition, TPA treatment led to the appearance of full-length IRF-2, along with a reduction of the truncated protein. interestingly, full-length IRF-2 in TPA-treated U937 cells occurred as a complex with p300 as well as PCAF and was itself acetylated. Consistent with these results, recombinant IRF-2 was acetylated by p300 and to a lesser degree by PCAF in vitro. Another IRF member, IRF-1, an activator of interferon-mediated transcription, was also acetylated in vitro by these acetylases, Finally, we demonstrate that the addition of IRF-2 but not IRF-1. inhibits core histone acetylation by p300 in vitro, The addition of IRF-2 also inhibited acetylation of nucleosomal histones in TPA-treated U937 cells. Acetylated IRF-2 may affect local chromatin structure in vivo by inhibiting core histone acetylation and may serve as a mechanism by which IRF-2 negatively regulates interferon-inducible transcription.	Natl Inst Infect Dis, Dept Safety Res Biol, Tokyo 2080011, Japan; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institute of Infectious Diseases (NIID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Masumi, A (corresponding author), Natl Inst Infect Dis, Dept Safety Res Biol, 4-7-1 Gakuen,Musashimurayama Shi, Tokyo 2080011, Japan.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Burysek L, 1999, J VIROL, V73, P7334; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Colle JH, 1997, J IMMUNOL METHODS, V210, P175, DOI 10.1016/S0022-1759(97)00186-5; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Liu L, 1999, MOL CELL BIOL, V19, P1202; Magnaghi-Jaulin L, 1999, SEMIN CELL DEV BIOL, V10, P197, DOI 10.1006/scdb.1999.0301; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masumi A, 1999, MOL CELL BIOL, V19, P1810; MASUMIFUKAZAWA A, 1995, EUR J BIOCHEM, V232, P134, DOI 10.1111/j.1432-1033.1995.tb20791.x; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; WAYS K, 1991, J BIOL CHEM, V266, P1258; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Xi HK, 1999, ONCOGENE, V18, P5889, DOI 10.1038/sj.onc.1202969; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhou Q, 2000, J BIOL CHEM, V275, P35256, DOI 10.1074/jbc.M003106200	51	45	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20973	20980		10.1074/jbc.M101707200	http://dx.doi.org/10.1074/jbc.M101707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11304541	hybrid			2022-12-25	WOS:000169297900025
J	Benedit, P; Paciucci, R; Thomson, TM; Valeri, M; Nadal, M; Caceres, C; de Torres, I; Estivill, X; Lozano, JJ; Morote, J; Reventos, J				Benedit, P; Paciucci, R; Thomson, TM; Valeri, M; Nadal, M; Caceres, C; de Torres, I; Estivill, X; Lozano, JJ; Morote, J; Reventos, J			PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks	ONCOGENE			English	Article						prostate; prostate adenocarcinoma; androgens; molecular markers	DIFFERENTIALLY EXPRESSED GENES; INTRAEPITHELIAL NEOPLASIA; SERINE-PROTEASE; ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; CARCINOMA; TISSUE; DISPLAY; SEARCH; FAMILY	In a search for molecular markers of progression in prostate cancer by means of differential display, me have identified a new gene, which we have designated PTO VI, Semiquantitative RT-PCR has established that nine out of 11 tumors overexpress PTOV1 at levels significantly higher than benign prostatic hyperplasia or normal prostate tissue. The human PTOV1 protein consists almost entirely of two repeated blocks of homology of 151 and 147 amino acids, joined by a short linker peptide, and is encoded by a 12-exon gene localized in chromosome 19q13.3, A Drosophila melanogaster PTOV1 homolog also contains two tandemly arranged PTOV blocks. A second gene, PTOV2, was identified in humans and Drosophila, coding for proteins with a single PTOV homology block and unrelated amino- and carboxyl-terminal extensions. A 1.8-Kb PTOV1 transcript was detected abundantly in normal human brain, heart, skeletal muscle, kidney and liver, and at low levels in normal prostate. Immunocytochemical analysis and expression of chimeric GFP-PTOV1 proteins in cultured cells showed a predominantly perinuclear localization of PTOV1, In normal prostate tissue and in prostate adenomas, PTOV1 was undetectable or expressed at low levels, whereas nine out of 11 prostate adenocarcinomas showed a strong immunoreactivity, with a focal distribution in areas of carcinoma and prostatic intraepithelial neoplasia, Therefore, PTOV1 is a previously unknown gene, overexpressed in early and late stages of prostate cancer. The PTOV homology block represents a new class of conserved sequence blocks present in human, rodent and fly proteins.	Hosp Gen Valle Hebron, Hosp Materno Infantil, Unitat Rec Biomed, Barcelona, Spain; CSIC, Inst Mol Biol, Barcelona, Spain; Inst Rec Oncol, Ctr Genet Mol, Barcelona, Spain; Hosp Gen Valle Hebron, Serv Anat Patol, Barcelona, Spain; Inst Municipal Invest Med, Inst Rec Informat Med, Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Hosp Gen Valle Hebron, Urol Serv, Barcelona, Spain	Hospital Universitari Vall d'Hebron; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Hospital Universitari Vall d'Hebron; Pompeu Fabra University; Hospital Universitari Vall d'Hebron	Thomson, TM (corresponding author), Hosp Gen Valle Hebron, Hosp Materno Infantil, Unitat Rec Biomed, Barcelona, Spain.		Estivill, Xavier/E-2957-2012; Paciucci, Rosanna/AGP-3844-2022; Reventos, Jaume/I-1633-2012; Morote, Juan/M-6914-2017; Estivill, Xavier/A-3125-2013; Thomson, Timothy/Z-6271-2019	Paciucci, Rosanna/0000-0001-5651-5933; Morote, Juan/0000-0002-2168-323X; Estivill, Xavier/0000-0002-0723-2256; Thomson, Timothy/0000-0002-4670-9440; Lozano, Juan Jose/0000-0001-7613-3908; Nadal, Marga/0000-0002-5739-1693				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLOK LJ, 1995, PROSTATE, V26, P213, DOI 10.1002/pros.2990260407; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W; Bostwick DG, 1997, PROSTATE, V33, P32, DOI 10.1002/(SICI)1097-0045(19970915)33:1<32::AID-PROS6>3.0.CO;2-B; Brooks JD, 1996, CANCER RES, V56, P3814; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chang GTG, 1997, CANCER RES, V57, P4075; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fernandez PL, 1999, J PATHOL, V187, P563, DOI 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; Goyal J, 1998, CANCER RES, V58, P4782; Guate JL, 1999, BJU INT, V84, P495; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; Harper ME, 1998, J PATHOL, V186, P169, DOI 10.1002/(SICI)1096-9896(1998100)186:2<169::AID-PATH164>3.0.CO;2-W; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Jenster G, 1999, SEMIN ONCOL, V26, P407; Johnson MI, 1998, PROSTATE, V37, P223, DOI 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO;2-O; Kallioniemi OP, 1996, ADV CANCER RES, V68, P225, DOI 10.1016/S0065-230X(08)60355-3; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin BY, 1999, CANCER RES, V59, P4180; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Lucas S, 1998, CANCER RES, V58, P743; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; Montironi R, 1999, J CLIN PATHOL, V52, P350, DOI 10.1136/jcp.52.5.350; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Rondinelli RH, 1999, CLIN CANCER RES, V5, P1595; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stubbs AP, 1999, AM J PATHOL, V154, P1335, DOI 10.1016/S0002-9440(10)65387-4; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; Sun YL, 1997, CANCER RES, V57, P18; TROYER JK, 1995, INT J CANCER, V62, P552, DOI 10.1002/ijc.2910620511; Wang FL, 1996, CANCER RES, V56, P3634; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yousef GM, 2000, GENOMICS, V63, P88, DOI 10.1006/geno.1999.6072; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; ZHAU HYE, 1992, MOL CARCINOGEN, V5, P320, DOI 10.1002/mc.2940050413	43	53	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2001	20	12					1455	1464		10.1038/sj.onc.1204233	http://dx.doi.org/10.1038/sj.onc.1204233			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313889				2022-12-25	WOS:000167595200006
J	Maeda, R; Mood, K; Jones, TL; Aruga, J; Buchberg, AM; Daar, IO				Maeda, R; Mood, K; Jones, TL; Aruga, J; Buchberg, AM; Daar, IO			Xmeis1, a protooncogene involved in specifying neural crest cell fate in Xenopus embryos	ONCOGENE			English	Article						Xmeis1; neural crest; homeodomain; Xenopus	HEDGEHOG SIGNALING PATHWAY; COOPERATIVE DNA-BINDING; HOMEOBOX GENES; FLOOR PLATE; MESSENGER-RNA; GLI PROTEINS; NUCLEAR-LOCALIZATION; ZIC FAMILY; HOX GENES; EXPRESSION	Meis1 (Myeloid Ecotropic viral Integration Site 1) is a homeobox gene that was originally isolated as a common site of viral integration in myeloid tumors of the BXH-2 recombinant inbred mice strain. We previously isolated a Xenopus homolog of Meis1 (Xmeis1), Here we show that Xmeis1 may play a significant role in neural crest development. In developing Xenopus embryos, Xmeis1 displays a broad expression pattern, but strong expression is observed in tissue of neural cell fate, such as midbrain, hindbrain, the dorsal portion of the neural tube, and neural crest derived branchial arches. In animal cap explants, overexpression of Xmeis1b, an alternatively spliced form of Ymeis1, induces expression of neural crest marker genes in the absence of mesoderm, Moreover, Xmeis1b induces XGli-3 and XZic3, pre-pattern genes involved at the earliest stages of neural crest development, and like these two genes, can induce ectopic pigmented cell masses when overexpressed in developing embryos. Misexpression of Ymeis1b also induces ectopic expression of neural crest markers along the antero-posterior axis of the neural tube in developing Xenopus embryos. In contrast, Xmeis1a, another splice variant, is much less effective at inducing these effects. These data suggest that Xmeis1b is involved in neural crest cell fate specification during embryogenesis, and can functionally intersect with the Gli/Zic signal transduction pathway.	NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); RIKEN; Jefferson University	Daar, IO (corresponding author), NCI, Regulat Cell Growth Lab, Bldg 560 Room 22-3, Frederick, MD 21702 USA.		Aruga, Jun/H-5837-2011	Aruga, Jun/0000-0001-7936-1375; Buchberg, Arthur/0000-0002-0543-5631; Daar, Ira/0000-0003-2657-526X	NCI NIH HHS [N01-CO-5600] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Ding Q, 1998, DEVELOPMENT, V125, P2533; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kurant E, 1998, DEVELOPMENT, V125, P1037; LaBonne C, 1999, ANNU REV CELL DEV BI, V15, P81, DOI 10.1146/annurev.cellbio.15.1.81; LaBonne C, 1998, DEVELOPMENT, V125, P2403; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LU QA, 1995, MOL CELL BIOL, V15, P3786; Maeda R, 1997, DEVELOPMENT, V124, P2553; Mancilla A, 1996, DEV BIOL, V177, P580, DOI 10.1006/dbio.1996.0187; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mayor R, 1999, CURR TOP DEV BIOL, V43, P85; MAYOR R, 1995, DEVELOPMENT, V121, P767; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; MIYATANI S, 1986, J CELL BIOL, V103, P1957, DOI 10.1083/jcb.103.5.1957; Mizuseki K, 1998, NEURON, V21, P77, DOI 10.1016/S0896-6273(00)80516-4; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; Nakata K, 2000, MECH DEVELOP, V99, P83, DOI 10.1016/S0925-4773(00)00480-9; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; Salzberg A, 1999, MECH DEVELOP, V80, P3, DOI 10.1016/S0925-4773(98)00187-7; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; SUZUKI A, 1993, ZOOL SCI, V10, P175; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Tada M, 1997, DEVELOPMENT, V124, P2225; Theil T, 1998, DEVELOPMENT, V125, P443; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wallingford JB, 1999, TRENDS GENET, V15, P385, DOI 10.1016/S0168-9525(99)01800-4; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005; Yang SS, 1998, J BIOL CHEM, V273, P13746, DOI 10.1074/jbc.273.22.13746; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	81	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1329	1342		10.1038/sj.onc.1204250	http://dx.doi.org/10.1038/sj.onc.1204250			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313877				2022-12-25	WOS:000167495000007
J	Stepczynska, A; Lauber, K; Engels, IH; Janssen, O; Kabelitz, D; Wesselborg, S; Schulze-Osthoff, K				Stepczynska, A; Lauber, K; Engels, IH; Janssen, O; Kabelitz, D; Wesselborg, S; Schulze-Osthoff, K			Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation	ONCOGENE			English	Article						anticancer drugs; apoptosis; caspase; staurosporine; CD95	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CYTOCHROME-C; CELL-DEATH; AKT PHOSPHORYLATION; WILD-TYPE; CD95; FAS; PROTEASE; RELEASE; MITOCHONDRIA	Apoptosis can be induced by various stimuli including DNA-damaging anticancer drugs and the protein kinase inhibitor staurosporine, It is generally believed that the molecular events during execution of apoptosis are shared, as both anticancer drugs and staurosporine derivatives induce mitochondrial damage, cytochrome c release and the activation of the caspase-9 proteolytic cascade. In the present study we show that overexpression of a dominant-negative caspase-9 mutant abolished the activation of endogenous caspase-9, caspase-3 and the cleavage of the caspase substrate Bid in response to anticancer drug treatment, Surprisingly, however, only marginal effects were observed during staurosporine-induced apoptosis, Furthermore, we describe a Jurkat T-cell clone that is completely resistant towards different anticancer drugs, but remains sensitive towards staurosporine-induced apoptosis, In these cells only staurosporine, but neither anti-CD95 nor anticancer drugs were able to trigger caspase activity and the cleavage of caspase substrates. Our results therefore suggest that the mechanism of staurosporine-induced apoptosis is more complex and at least partially differs from anticancer drug-induced caspase activation. These distinct features of staurosporine may allow to bypass chemoresistance of tumor cells and may encourage further clinical trials for the use of staurosporine derivatives in antitumor therapy.	Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Tubingen, Dept Internal Med 1, D-72074 Tubingen, Germany; Univ Kiel, Inst Immunol, D-24098 Kiel, Germany	University of Munster; Eberhard Karls University of Tubingen; University of Kiel	Schulze-Osthoff, K (corresponding author), Univ Munster, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013; Kabelitz, Dieter/AAB-4199-2021; Janssen, Ottmar/E-9735-2010; Janssen, Ottmar/N-8769-2019; Kabelitz, Dieter/A-2757-2010	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Janssen, Ottmar/0000-0002-9612-8900; Janssen, Ottmar/0000-0002-9612-8900; Wesselborg, Sebastian/0000-0002-5236-942X				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Fulda S, 1997, CANCER RES, V57, P3823; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Gescher A, 1998, GEN PHARMACOL, V31, P721, DOI 10.1016/S0306-3623(98)00069-X; Han Z, 2000, CELL DEATH DIFFER, V7, P521, DOI 10.1038/sj.cdd.4400681; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Janssen O, 1996, IMMUNOL LETT, V49, P63, DOI 10.1016/0165-2478(95)02482-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Villunger A, 1997, CANCER RES, V57, P3331; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	54	118	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1193	1202		10.1038/sj.onc.1204221	http://dx.doi.org/10.1038/sj.onc.1204221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313863				2022-12-25	WOS:000167570100006
J	Droin, N; Rebe, C; Bichat, F; Hammann, A; Bertrand, R; Solary, E				Droin, N; Rebe, C; Bichat, F; Hammann, A; Bertrand, R; Solary, E			Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization	ONCOGENE			English	Article						apoptosis; caspase-2 isoforms; nuclear changes	CELL-DEATH; DNA FRAGMENTATION; ADAPTER MOLECULE; MESSENGER-RNA; UP-REGULATION; CASPASE-2; ACTIVATION; EXPRESSION; PROTEIN; ANTIGEN	Procaspase-2 is one of the cysteine aspartate proteases involved in apoptotic cell death. Alternative splicing of CASP-2 messenger RNA generates a long isoform, procaspase-2L, whose overexpression induces cell death and a truncated isoform, procaspase-2S, whose function remains poorly defined. The present study explored the consequences of procaspase-2S overexpression in U937 human leukemic cells exposed to the topoisomerase If inhibitor etoposide as an apoptotic stimulus, Overexpression of procaspase-2S in U937 cells partially prevented nuclear changes associated with etoposide-induced cell death, as determined by Hoechst 33342 staining of nuclear chromatin and electron microscopy studies, Procaspase-2S also prevented the maturation of apoptotic bodies, delayed phosphatidylserine externalization on the plasma membrane and prevented the cleavage and activation of procaspase-2L, These effects were not observed when the cysteine 289 in the consensus QACRG motif was mutated into a serine. Wild-type procaspase-2S overexpression did not influence the cleavage of procaspase-3, procaspase-7 and poly(ADP-ribose)polymerase nor the fragmentation of nuclear DNA into nucleosome-sized fragments. Altogether, these results indicate that the short isoform of procaspase-2 negatively interferes with selective features of apoptosis, an activity that is suppressed by mutation of the cysteine 289.	Fac Med, INSERM U517, F-21033 Dijon, France; Fac Pharm, INSERM U517, F-21033 Dijon, France; Ctr Univ Montreal Hosp Ctr, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Montreal	Solary, E (corresponding author), Fac Med, INSERM U517, 7 Blvd Jeanne Arc, F-21033 Dijon, France.		REBE, Cédric/AAD-4316-2019; Droin, Nathalie M/Y-5506-2018	REBE, Cédric/0000-0001-8831-145X; Droin, Nathalie M/0000-0002-6099-5324; Solary, Eric/0000-0002-8629-1341				Ahmad M, 1997, CANCER RES, V57, P615; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BERTRAND R, 1991, CANCER RES, V51, P6280; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; Buendia B, 1999, J CELL SCI, V112, P1743; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fujimura M, 1999, J CANCER RES CLIN, V125, P389, DOI 10.1007/s004320050291; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kojima M, 1998, NEUROSCI RES, V31, P211, DOI 10.1016/S0168-0102(98)00039-X; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; McIlroy D, 2000, GENE DEV, V14, P549; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pelassy C, 2000, BIOCHEM PHARMACOL, V59, P855, DOI 10.1016/S0006-2952(99)00383-4; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Ronchetti A, 1999, J IMMUNOL, V163, P130; Rovere P, 1998, J IMMUNOL, V161, P4467; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1999, CANCER RES, V59, P999; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99	56	33	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					260	269		10.1038/sj.onc.1204066	http://dx.doi.org/10.1038/sj.onc.1204066			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313953				2022-12-25	WOS:000166410900013
J	Skalsky, YM; Ajuh, PM; Parker, C; Lamond, AI; Goodwin, G; Cooper, CS				Skalsky, YM; Ajuh, PM; Parker, C; Lamond, AI; Goodwin, G; Cooper, CS			PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors	ONCOGENE			English	Article						TFE3; PRCC; transcription activation; pre-mRNA splicing	HELIX-LOOP-HELIX; ACTIVATOR INHIBITOR-1 GENE; BETA-INDUCED TRANSCRIPTION; CELL CARCINOMA; BINDING PROTEIN; SMAD PROTEINS; RNA-BINDING; DNA-BINDING; TRANSLOCATION; P54(NRB)	In papillary renal cell carcinomas the TFE3 transcription factor becomes fused to the PSF and NonO pre-mRNA splicing factors and most commonly to a protein of unknown function designated PRCC, In this: study we have examined the ability of the resulting PRCC-TFE3 and NonO-TFE3 fusions to activate transcription from the plasminogen activator inhibitor-1 (PAI-1) promoter. The results shea that only fusion to PRCC enhanced transcriptional activation, indicating that the ability to enhance the level of transcription from endogenous TFE3 promoters is not a consistent feature of TFE3 fusions, In investigations of the normal function of PRCC,ve observed that PRCC expressed as a green fluorescent fusion protein colocalizes within the nucleus with Sm pre-RNA splicing factors. It was also found that endogenous PRCC is coimmunoprecipitated by antibodies that recognize a variety of pre-mRNA splicing factors including SC35, PRL1 and CDC5. Association with the cellular splicing machinery is therefore, a common feature of the proteins that become fused to TFE3 in papillary renal cell carcinomas.	Inst Canc Res, Mol Carcinogenesis Sect, Haddow Labs, Sutton SM2 5NG, Surrey, England; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	University of London; Institute of Cancer Research - UK; University of Dundee	Skalsky, YM (corresponding author), Inst Canc Res, Mol Carcinogenesis Sect, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Lamond, Angus/0000-0001-6204-6045				ANGLARD P, 1992, CANCER RES, V52, P348; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Basu A, 1997, MOL CELL BIOL, V17, P677, DOI 10.1128/MCB.17.2.677; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; Groenen PMA, 1998, GENOMICS, V49, P218, DOI 10.1006/geno.1998.5254; Groenen PMA, 1996, GENOMICS, V38, P141, DOI 10.1006/geno.1996.0609; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kreivi JP, 1996, CURR BIOL, V6, P802, DOI 10.1016/S0960-9822(02)00599-7; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; REEVES BR, 1989, ONCOGENE, V4, P373; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Shinozaki A, 1999, INT J BIOCHEM CELL B, V31, P1279, DOI 10.1016/S1357-2725(99)00101-6; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Tian G, 1999, MOL CELL BIOL, V19, P2946; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593	44	49	50	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					178	187		10.1038/sj.onc.1204056	http://dx.doi.org/10.1038/sj.onc.1204056			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313942				2022-12-25	WOS:000166410900005
J	Stephanou, A; Scarabelli, TM; Brar, BK; Nakanishi, Y; Matsumura, M; Knight, RA; Latchman, DS				Stephanou, A; Scarabelli, TM; Brar, BK; Nakanishi, Y; Matsumura, M; Knight, RA; Latchman, DS			Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-DEATH; SIGNAL-TRANSDUCTION; REPERFUSION INJURY; PHOSPHORYLATION; INVOLVEMENT; INHIBITION; ISCHEMIA; PATHWAY; STRESS	Previously we reported that ischemia results in apoptosis and is accompanied by phosphorylation on Tyr-701 and increased expression and transcriptional activity of the signal transducer and activator of transcription-1 (STAT-1). In the present study, we show that exposure of cardiomyocytes to ischemia induced the phosphorylation of STAT-1 at another site, Ser-727. Moreover, STAT-1 is critical for the induction of Fas receptor and Fas ligand expression by ischemia/reperfusion (I/R). Transcriptional activation of Fas and FasL was dependent on Ser-727 of STAT-1 but was independent of Tyr-701. Similarly, Ser-727 but not Tyr-701 was required for enhancement of cardiomyocyte cell death by STAT-1 during I/R. In addition, inhibition of the p38 pathway prevented the induction and transcriptional activation of Fas and FasL in cardiac cells exposed to I/R, whereas inhibition of p42/p44 MAPK had no effect. Finally, I/R also induced phosphorylation of STAT-1 on Ser-727 and expression of Fas/FasL in ventricular myocytes in the intact heart ex vivo. These results indicate that Fas/FasL genes and apoptosis are activated by STAT-1 in cardiac myocytes exposed to I/R and these effects are dependent on the Ser-727 but not the Tyr-701 phosphorylation sites of STAT-1.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Royal Brompton Hosp, Natl Heart & Lung Inst, London WC1N 1EH, England	University of London; University College London; Kanazawa University; Imperial College London; Royal Brompton Hospital	Stephanou, A (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	A.Stephanou@ich.ucl.ac.uk	Nakanishi, Yoshinobu/D-4602-2014	Nakanishi, Yoshinobu/0000-0002-8767-3587				Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; BRAR B, 2001, IN PRESS CARDIOVASCU; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; He HP, 1999, CELL DEATH DIFFER, V6, P987, DOI 10.1038/sj.cdd.4400572; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITOH G, 1995, AM J PATHOL, V146, P1325; Jeremias I, 2000, CIRCULATION, V102, P915; Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365-2249.1997.4191324.x; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano A, 2000, CIRC RES, V86, P144, DOI 10.1161/01.RES.86.2.144; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Scarabelli TM, 1999, J IMMUNOL METHODS, V228, P23, DOI 10.1016/S0022-1759(99)00090-3; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Stoiber D, 1999, J IMMUNOL, V163, P2640; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; UMANSKY SR, 1995, CELL DEATH DIFFER, V2, P235; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Xu XL, 1998, CANCER RES, V58, P2832; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	40	147	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28340	28347		10.1074/jbc.M101177200	http://dx.doi.org/10.1074/jbc.M101177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11309387	hybrid			2022-12-25	WOS:000170093400080
J	Woodring, PJ; Hunter, T; Wang, JYJ				Woodring, PJ; Hunter, T; Wang, JYJ			Inhibition of c-Abl tyrosine kinase activity by filamentous actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TERMINAL REPEATED DOMAIN; DNA-DAMAGE; CELL-CYCLE; APOPTOTIC RESPONSE; PROTEIN; BINDING; SRC; PHOSPHORYLATION; GROWTH	The catalytic activity of c-Abl tyrosine kinase is reduced in fibroblasts that are detached from the extracellular matrix. We report here that a deletion of the extreme C terminus of c-Abl (DeltaF-actin c-Abl) can partially restore kinase activity to c-Abl from detached cells. Because the extreme C terminus of c-Abl contains a consensus F-actin binding motif, we investigated the effect of F-actin on c-Abl tyrosine kinase activity. We found that F-actin can inhibit the kinase activity of purified c-Abl protein. Mutations of the extreme C-terminal region of c-Abl disrupted both the binding of c-Abl to F-actin and the inhibition of c-Abl by F-actin. Mutations of the SH3, SH2, and DNA binding domains did not abolish the inhibition of c-Abl kinase by F-actin. Catalytic domain substitutions that affect the regulation of c-Abl by the retinoblastoma protein or the ataxia telangiectasia-mutated kinase also did not abolish the inhibition of c-Abl by F-actin. Interestingly, among these c-Abl mutants, only the DeltaF-actin c-Abl retained kinase activity in detached cells. Taken together, the data suggest that F-actin is an inhibitor of the c-Abl tyrosine kinase and that this inhibition contributes in part to the reduced Abl kinase activity in detached cells.	Salk Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Woodring, PJ (corresponding author), Salk Inst, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R37CA043054, F32CA076710, R01CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER; NCI NIH HHS [CA82863, R37 CA043054, CA76710, R01 CA043054] Funding Source: Medline; NHLBI NIH HHS [P01 HL057900, HL57900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agami R, 1999, NATURE, V399, P809; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Gong JG, 1999, NATURE, V399, P806; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	46	91	93	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27104	27110		10.1074/jbc.M100559200	http://dx.doi.org/10.1074/jbc.M100559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11309382	hybrid			2022-12-25	WOS:000169966900051
J	Zhou, AW; Carrell, RW; Huntington, JA				Zhou, AW; Carrell, RW; Huntington, JA			The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INHIBITORS; C1 INHIBITOR; COWPOX VIRUS; COMPLEXES; TRYPSIN; SERINE; ENZYME; ALPHA-2-ANTIPLASMIN; ALPHA-1-ANTITRYPSIN; INSERTION	The recent crystallographic structure of a serpin-protease complex revealed that protease inactivation results from a disruption of the catalytic site architecture caused by the displacement of the catalytic serine, We hypothesize that inhibition depends on the length of the N-terminal portion of the reactive center loop, to which the active serine is covalently attached, To test this, alpha (1)-antitrypsin Pittsburgh variants were prepared with lengthened and shortened reactive center loops. The rates of inhibition of factor Xa and of complex dissociation were measured. The addition of one residue reduced the stability of the complex more than 200,000-fold, and the addition of two residues reduced it by more than 1,000,000-fold, whereas the deletion of one or two residues lowered the efficiency of inhibition and increased the stability of the complex (a-fold), The deletion of more than two residues completely converted the serpin into a substrate. Similar results were obtained for the alpha (1)-antitrypsin variants with thrombin and for PAI-1 and PAI-2 with their common target tissue plasminogen activator. We conclude that the length of the serpin reactive center loop is critical for its mechanism of inhibition and is precisely regulated to balance the efficiency of inhibition and stability of the final complex.	Univ Cambridge, Dept Haematol, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge	Huntington, JA (corresponding author), Univ Cambridge, Dept Haematol, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.			ZHOU, Aiwu/0000-0002-2555-5091				Bottomley SP, 1998, PROTEIN ENG, V11, P1243, DOI 10.1093/protein/11.12.1243; CARTER PE, 1988, EUR J BIOCHEM, V173, P163, DOI 10.1111/j.1432-1033.1988.tb13980.x; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HOLMES WE, 1987, J BIOL CHEM, V262, P1659; HOLMES WE, 1987, SCIENCE, V238, P209, DOI 10.1126/science.2958938; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JESTY J, 1979, J BIOL CHEM, V254, P44; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; OLSON ST, 1995, J BIOL CHEM, V270, P30007; Olson ST, 1997, J BIOL CHEM, V272, P13338, DOI 10.1074/jbc.272.20.13338; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200; Zhou AW, 1997, J BIOCHEM, V121, P930	28	121	127	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27541	27547		10.1074/jbc.M102594200	http://dx.doi.org/10.1074/jbc.M102594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11325972	hybrid			2022-12-25	WOS:000169966900106
J	Carretero, J; Obrador, E; Esteve, JM; Ortega, A; Pellicer, JA; Sempere, FV; Estrela, JM				Carretero, J; Obrador, E; Esteve, JM; Ortega, A; Pellicer, JA; Sempere, FV; Estrela, JM			Tumoricidal activity of endothelial cells - Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; EXPERIMENTAL METASTASIS; GENE-TRANSCRIPTION; OXIDATIVE STRESS; H2O2 PRODUCTION; CANCER-CELLS; GLUTATHIONE; OXYGEN; SUPEROXIDE; RELEASE	The mechanism of NO- and H2O2-induced tumor cytotoxicity was examined during B16 melanoma (B16M) adhesion to the hepatic sinusoidal endothelium (HSE) in vitro. We used endothelial nitric-oxide synthetase gene disruption and NO-nitro-L-arginine methyl ester-induced inhibition of nitric-oxide synthetase activity to study the effect of HSE-derived NO on B16M cell viability. Extracellular H2O2 was removed by exogenous catalase, H2O2 was not cytotoxic in the absence of NO, However, NO-induced tumor cytotoxicity was increased by H2O2 due to the formation of potent oxidants, likely (OH)-O-. and -OONO radicals, via a trace metal-dependent process. B16M cells cultured to low density (LD cells), with high GSH content, were more resistant to NO and H2O2 than B16M cells cultured to high density (HD cells; with similar to 25% of the GSH content found in LD cells). Resistance of LD cells decreased using buthionine sulfoximine, a specific GSH synthesis inhibitor, whereas resistance increased in HD cells using GSH ester, which delivers free intracellular GSH, Because NO and H2O2 were particularly cytotoxic in HD cells, we investigated the enzyme activities that degrade H2O2, NO and H2O2 caused an similar to 75% (LD cells) and a 60% (HD cells) decrease in catalase activity without affecting the GSH peroxidase/GSH reductase system. Therefore, B16M resistance to the HSE-induced cytotoxicity appears highly dependent on GSH and GSH peroxidase, which are both required to eliminate H2O2, In agreement with this fact, ebselen, a GSH peroxidase mimic, abrogated the increase in NO toxicity induced by H2O2.	Univ Valencia, Fac Med & Odontol, Dept Fisiol, Valencia 46010, Spain; Univ Valencia, Hosp La Fe, Serv Anat Patol, Valencia, Spain	University of Valencia; Hospital Universitari i Politecnic La Fe; University of Valencia	Estrela, JM (corresponding author), Univ Valencia, Fac Med & Odontol, Dept Fisiol, Av Blasco Ibanez 17, Valencia 46010, Spain.	jose.m.estrela@uv.es	MARTINEZ, ANTONIO PELLICER/C-4832-2015; Carretero, Julian/N-5214-2014; OBRADOR, ELENA/H-4069-2015; Estrela, Jose/H-4449-2015; Vera-Sempere, Francisco/AAG-4726-2019; Ortega, Angel L./A-4113-2014	Carretero, Julian/0000-0001-7269-8506; OBRADOR, ELENA/0000-0002-5934-5543; Estrela, Jose/0000-0002-2540-9190; Vera-Sempere, Francisco/0000-0003-1838-5466; Ortega, Angel L./0000-0002-9901-3383				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Ahmed A, 1997, LAB INVEST, V76, P779; Akerboom T P, 1981, Methods Enzymol, V77, P373; ALBERTSSON PA, 1995, CLIN EXP METASTAS, V13, P269, DOI 10.1007/BF00133482; Anasagasti MJ, 1997, HEPATOLOGY, V25, P840, DOI 10.1002/hep.510250410; Anasagasti MJ, 1996, J CELL PHYSIOL, V167, P314, DOI 10.1002/(SICI)1097-4652(199605)167:2<314::AID-JCP16>3.0.CO;2-7; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; ARRICK BA, 1984, CANCER RES, V44, P4224; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; Bayon LG, 1996, HEPATOLOGY, V23, P1224, DOI 10.1002/hep.510230542; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BUTTERY LDK, 1993, J PATHOL, V171, P311, DOI 10.1002/path.1711710412; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; Chiang KT, 2000, TOXICOL APPL PHARM, V167, P30, DOI 10.1006/taap.2000.8970; CLANCY RM, 1990, ANAL BIOCHEM, V191, P138, DOI 10.1016/0003-2697(90)90400-4; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DONG ZY, 1994, CANCER RES, V54, P789; ESKENAZI AE, 1993, J NATL CANCER I, V85, P711, DOI 10.1093/jnci/85.9.711; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FIDLER IJ, 1990, CANCER RES, V50, P6130; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GIAVAZZI R, 1990, CANCER RES, V50, P4771; GLAVES D, 1986, INVAS METAST, V6, P101; Gupta MP, 1997, AM J PHYSIOL-LUNG C, V272, pL1133, DOI 10.1152/ajplung.1997.272.6.L1133; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; Jessup JM, 1999, CANCER RES, V59, P1825; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAFRENIE R, 1992, CANCER METAST REV, V11, P377, DOI 10.1007/BF01307188; LI L, 1991, CANCER RES, V51, P245; LI LM, 1991, CANCER RES, V51, P2531; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MCCLOSKEY TW, 1992, HEPATOLOGY, V16, P191, DOI 10.1002/hep.1840160130; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Nishikawa M, 1998, HEPATOLOGY, V27, P422, DOI 10.1002/hep.510270216; NORONHADUTRA AA, 1993, FEBS LETT, V321, P59, DOI 10.1016/0014-5793(93)80621-Z; OROSZ P, 1993, J EXP MED, V177, P1391, DOI 10.1084/jem.177.5.1391; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; RICE GE, 1988, AM J PATHOL, V133, P204; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; SELLAK H, 1994, BLOOD, V83, P2669; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Sies H, 2000, FREE RADICAL BIO MED, V28, P1451, DOI 10.1016/S0891-5849(00)00253-7; Uppu RM, 1996, METHOD ENZYMOL, V269, P322; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; WALKER MW, 1995, PEDIATR RES, V37, P41, DOI 10.1203/00006450-199501000-00010; Wang HM, 2000, CANCER RES, V60, P5862; WEISS L, 1988, FASEB J, V2, P12, DOI 10.1096/fasebj.2.1.3275560; Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	68	43	45	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25775	25782		10.1074/jbc.M101148200	http://dx.doi.org/10.1074/jbc.M101148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313348	hybrid			2022-12-25	WOS:000169823300020
J	Carter, RS; Geyer, BC; Xie, MH; Acevedo-Suarez, CA; Ballard, DW				Carter, RS; Geyer, BC; Xie, MH; Acevedo-Suarez, CA; Ballard, DW			Persistent activation of NF-kappa B by the tax transforming protein involves chronic phosphorylation of I kappa B kinase subunits IKK beta and IKK gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; COMPLEX; ALPHA; EXPRESSION; INHIBITION; TYPE-1	The Tax transforming protein encoded by human T-cell leukemia virus type 1 (HTLV1) persistently activates transcription factor NF-kappaB and deregulates the expression of downstream genes that mediate cell cycle entry. We recently found that Tax binds to and chronically stimulates the catalytic function of I kappaB kinase (IKK), a cellular enzyme complex that phosphorylates and inactivates the I kappaB inhibitory subunit of NF-kappaB, We now demonstrate that the IKK beta catalytic subunit and IKK gamma regulatory subunit of IKK are chronically phosphorylated in HTLV1-infected and Tax-transfected cells. Alanine substitutions at Ser-177 and Ser-181 in the T loop of IKK beta protect both of these IKK subunits from Tax-directed phosphorylation and prevent the induction of I kappaB kinase activity. Each of these inhibitory effects is recapitulated in Tax transfectants expressing the bacterial protein YopJ, a potent in vivo agonist of T loop phosphorylation, Moreover, ectopically expressed forms of IKK beta that contain glutamic acid substitutions at Ser-177 and Ser-181 have the capacity to phosphorylate a recombinant lKK gamma substrate in vitro, We conclude that Tax-induced phosphorylation of IKK beta is required for IKK beta activation, phosphoryl group transfer to IKK gamma, and acquisition of the deregulated IKK phenotype.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, A4301 Med Ctr N, Nashville, TN 37232 USA.				NCI NIH HHS [R01 CA 82556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	19	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24445	24448		10.1074/jbc.C000777200	http://dx.doi.org/10.1074/jbc.C000777200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325957	hybrid			2022-12-25	WOS:000169800700004
J	Maroney, AC; Finn, JP; Connors, TJ; Durkin, JT; Angeles, T; Gessner, G; Xu, ZH; Meyer, SL; Savage, MJ; Greene, LA; Scott, RW; Vaught, JL				Maroney, AC; Finn, JP; Connors, TJ; Durkin, JT; Angeles, T; Gessner, G; Xu, ZH; Meyer, SL; Savage, MJ; Greene, LA; Scott, RW; Vaught, JL			CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; PROGRAMMED CELL-DEATH; PROTEIN-KINASE; C-JUN; JNK PATHWAY; SYMPATHETIC NEURONS; MOLECULAR-CLONING; INDUCED APOPTOSIS; ACTIVATION; IDENTIFICATION	CEP-1347 (KT7515) promotes neuronal survival at dosages that inhibit activation of the c-Jun amino-terminal kinases (JNKs) in primary embryonic cultures and differentiated PC12 cells after trophic withdrawal and in mice treated with 1-methyl-4-phenyl tetrahydropyridine. In an effort to identify molecular target(s) of CEP-1347 in the JNK cascade, JNK1 and known upstream regulators of JNK1 were co-expressed in Cos-7 cells to determine whether CEP-1347 could modulate JNK1 activation. CEP-1347 blocked JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase), The response was selective because CEP-1347 did not inhibit JNK1 activation in cells induced by kinases independent of the MLK cascade. CEP-1347 inhibition of recombinant MLK members in vitro was competitive with ATP, resulting in IC,, values ranging from 23 to 51 nM, comparable to inhibitory potencies observed in intact cells. In addition, overexpression of MLK3 led to death in Chinese hamster ovary cells, and CEP-1347 blocked this death at doses comparable to those that inhibited MLK3 kinase activity. These results identify MLKs as targets of CEP-1347 in the JNK signaling cascade and demonstrate that CEP-1347 can block MLK-induced cell death.	Cephalon Inc, W Chester, PA 19380 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Teva Pharmaceutical Industries; Cephalon Inc.; Columbia University; Columbia University	Maroney, AC (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.	amaroney@cephalon.com		Xu, Zhiheng/0000-0002-4809-2851				Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bergeron P, 1997, BIOCHEM BIOPH RES CO, V231, P153, DOI 10.1006/bbrc.1997.6073; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Borasio GD, 1998, NEUROREPORT, V9, P1435, DOI 10.1097/00001756-199805110-00034; Cleland W W, 1979, Methods Enzymol, V63, P103; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEIJARD B, 1995, SCIENCE, V267, P682; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Eilers A, 1998, J NEUROSCI, V18, P1713; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; EZOE K, 1994, ONCOGENE, V9, P935; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Glicksman MA, 1998, J NEUROBIOL, V35, P361, DOI 10.1002/(SICI)1097-4695(19980615)35:4<361::AID-NEU3>3.3.CO;2-G; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hartkamp J, 1999, CANCER RES, V59, P2195; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ING YL, 1994, ONCOGENE, V9, P1745; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kaneko M, 1997, J MED CHEM, V40, P1863, DOI 10.1021/jm970031d; KATOH M, 1995, ONCOGENE, V10, P1447; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOIDE K, 1995, CHEM BIOL, V2, P601, DOI 10.1016/1074-5521(95)90124-8; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 1998, J NEUROSCI, V18, P104; MARONEY AC, 1995, J NEUROCHEM, V64, P540; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; MEYER SL, 1994, J NEUROCHEM, V62, P825; Michel PP, 1999, CLIN NEUROPHARMACOL, V22, P137; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Pitt A.M., 1996, J BIOMOL SCREEN, V1, P47, DOI [10.1177/108705719600100115, DOI 10.1177/108705719600100115]; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Rasmussen RK, 1998, ELECTROPHORESIS, V19, P809, DOI 10.1002/elps.1150190535; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 1998, NEUROSCIENCE, V86, P461, DOI 10.1016/S0306-4522(98)00059-1; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; SCHLINGENSIEPEN KH, 1994, CELL MOL NEUROBIOL, V14, P487, DOI 10.1007/BF02088833; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Waggie KS, 1999, LAB ANIM SCI, V49, P358; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	75	184	191	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25302	25308		10.1074/jbc.M011601200	http://dx.doi.org/10.1074/jbc.M011601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325962	hybrid			2022-12-25	WOS:000169800700116
J	Poser, I; Dominguez, D; de Herreros, AG; Varnai, A; Buettner, R; Bosserhoff, AK				Poser, I; Dominguez, D; de Herreros, AG; Varnai, A; Buettner, R; Bosserhoff, AK			Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor snail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVASION-SUPPRESSOR GENE; EPITHELIAL TUMOR-CELLS; LOBULAR BREAST CANCERS; GASTRIC CARCINOMAS; ADHESION MOLECULE; DOWN-REGULATION; MALIGNANT-MELANOMA; FACTOR AP-2; MUTATIONS; METASTASIS	Malignant transformation of melanocytes frequently coincides with loss of E-cadherin expression. Here we show that loss of E-cadherin in melanoma cell lines does not involve mutations in the E-cadherin gene, promoter methylation, or alterations in expression of AP-2 transcription factors as suggested previously. In a panel of different melanoma cell lines, E-cadherin expression was negatively regulated by up-regulation of the transcription factor Snail. In comparison with primary human melanocytes, where Snail expression was not detected by reverse transcription-polymerase chain reaction, significant expression was found in all eight melanoma cell lines. In parallel, Western blot and reverse transcription-polymerase chain reaction analysis revealed strong reduction of E-cadherin expression in the melanoma cells. Consistently, transient transfection of a Snail expression plasmid into human primary melanocytes led to significant down-regulation of E-cadherin, whereas transient and stable transfection of an antisense Snail construct induced reexpression of E-cadherin in Mel Ju and Mel Im melanomas. In summary, we conclude that activation of Snail expression plays an important role in down-regulation of E-cadherin and tumorigenesis of malignant melanomas.	Rhein Westfal TH Aachen, Inst Pathol, Sch Med, D-52074 Aachen, Germany; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona 08003, Spain	RWTH Aachen University; Pompeu Fabra University	Bosserhoff, AK (corresponding author), Rhein Westfal TH Aachen, Inst Pathol, Sch Med, Pauwelsstr 30, D-52074 Aachen, Germany.	bosserhoff@pat.rwth-aachen.de	Bosserhoff, Anja/GNH-4801-2022; de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808; Bosserhoff, Anja/0000-0001-8147-394X				Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1998, CELL ADHES COMMUN, V6, P171, DOI 10.3109/15419069809004474; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; Danen EHJ, 1996, EUR J CELL BIOL, V70, P69; Danen EHJ, 1996, MELANOMA RES, V6, P127, DOI 10.1097/00008390-199604000-00007; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gayther SA, 1998, CANCER RES, V58, P4086; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; Mbalaviele G, 1996, CANCER RES, V56, P4063; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Melki JR, 2000, BLOOD, V95, P3208; Mintz-Weber CS, 2000, J BIOL CHEM, V275, P34672, DOI 10.1074/jbc.M003812200; MOLL R, 1993, AM J PATHOL, V143, P1731; MOSER M, 1995, DEVELOPMENT, V121, P2779; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; Seline PC, 1996, J INVEST DERMATOL, V106, P1320, DOI 10.1111/1523-1747.ep12349048; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tamura S, 1996, BRIT J SURG, V83, P1608, DOI 10.1002/bjs.1800831138; VANDENBOSSCHE GMR, 1994, INT J CANCER, V57, P73, DOI 10.1002/ijc.2910570114; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	56	225	237	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24661	24666		10.1074/jbc.M011224200	http://dx.doi.org/10.1074/jbc.M011224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323412	hybrid			2022-12-25	WOS:000169800700034
J	Agarwal-Mawal, A; Paudel, HK				Agarwal-Mawal, A; Paudel, HK			Neuronal Cdc2-like protein kinase (Cdk5/p25) is associated with protein phosphatase 1 and phosphorylates inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CYCLIN-DEPENDENT KINASE-5; CATALYTIC SUBUNIT; GLYCOGEN-SYNTHASE; SYNERGISTIC PHOSPHORYLATION; MOLECULAR MECHANISM; BRAIN; TAU; IDENTIFICATION; PURIFICATION	Protein phosphatase 1 (PP1) is complexed with inhibitor 2 (I-2) in the cytosol,In rabbit muscle extract PP1 .I-2 is activated upon preincubation with ATP/Mg. This activation is caused by phosphorylation of I-2 on Thr(72) by glycogen synthase kinase 3 (GSK3). We have found that PP1 LB in bovine brain extract is also activated upon preincubation with ATP/Mg. However, blocking GSK3 action by LiCl inhibited only similar to 29% of PP1 activity and indicated that GSI(3 is not the sole PP1 .I-2 activator in the brain. When bovine brain extract was analyzed by gel filtration PPI .I-2 and neuronal CdcS-like protein kinase (NCLK), a heterodimer of Cdk5 and the regulatory p25 subunit, co-eluted as a similar to 450-kDa size species. The NCLK. from the eluted column fractions bound to PP1-specific microcystin-Sepharose and glutathione S-transferase (GST)-I-2-coated glutathione-agarose beads. Similarly, PPI from the eluted column fractions was pulled down with GST-Cdk5-coated glutathione-agarose beads. In vitro, NCLK( phosphorylated I-2 on Thr72 and activated PPI I-S in an ATP/Mg-dependent manner. NCLK bound to PP1 through its CdkS subunit and the PP1 binding region was localized to CdkS residues 28-41. Our data demonstrate that in brain extract PP1 .I-2 and NCLK are associated within a complex of similar to 450 kDa and suggest that NCLK is one of the PPI I-8-activating kinases in the mammalian brain.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Paudel, HK (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca						Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; GERVASI C, 1995, MOL BRAIN RES, V33, P192, DOI 10.1016/0169-328X(95)00109-6; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HELLMICH MR, 1994, FEBS LETT, V356, P317, DOI 10.1016/0014-5793(94)01298-9; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HOLMES CFB, 1987, BIOCHIM BIOPHYS ACTA, V929, P208, DOI 10.1016/0167-4889(87)90178-9; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LEE EYC, 1999, FRONT BIOSCI, V4, P270; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; PARK IK, 1994, J BIOL CHEM, V269, P944; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; WANG QM, 1994, J BIOL CHEM, V269, P14566; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANG SD, 1981, J BIOL CHEM, V256, P231; YANG SD, 1985, J BIOL CHEM, V260, P3464; YANG SD, 1980, J BIOL CHEM, V255, P1759; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	46	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23712	23718		10.1074/jbc.M010002200	http://dx.doi.org/10.1074/jbc.M010002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320080	hybrid			2022-12-25	WOS:000169531100066
J	Chang, JW; Mechling, DE; Bachinger, HP; Burrows, GG				Chang, JW; Mechling, DE; Bachinger, HP; Burrows, GG			Design, engineering, and production of human recombinant T cell receptor ligands derived from human leukocyte antigen DR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BOUND SINGLE PEPTIDES; MULTIPLE-SCLEROSIS; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; STRUCTURAL BASIS	Major histocompatibility complex (MHC) class II molecules are membrane-anchored heterodimers on the surface of antigen-presenting cells that bind the T cell receptor, initiating a cascade of interactions that results in antigen-specific activation of clonal populations of T cells. Susceptibility to multiple sclerosis is associated with certain MHC class II haplotypes, including human leukocyte antigen (HLA) DR2. Two DRB chains, DRB5*0101 and DRB1*1501, are co-expressed in the HLA-DR2 haplotype, resulting in the formation of two functional cell surface heterodimers, HLA-DR2a (DRA*0101, DRB5*0101) and HLA-DR2b (DRA*0101(al, DRB1*1501). Both isotypes can present an immunodominant peptide of myelin basic protein (MBP-(84-102)) to MBP-specific T cells from multiple sclerosis patients. We have previously demonstrated that the peptide binding/T cell recognition domains of rat MHC class II (alpha1 and pi domains) could be expressed as a single exon for structural and functional characterization; Burrows, G. G., Chang, J. m,, Bachinger, H.-P., Bourdette, D. N., Wegmann, K, W, Offner H, and Vandenbark A. A. (1999) Protein Eng. 12, 711-778; Burrows, G. G., Adlard, K. L., Bebo, B. F., Jr., Chang, J. W., Tenditnyy, K., Vandenbark, A. A, and Offner, H. (2000) J. Immunol 164, 6366-6371). Single-chain human recombinant T cell receptor ligands (RTLs) of similar to 200 amino acid residues derived from HLA-DR2b were designed using the same principles and have been produced in Escherichia coli with and without amino-terminal extensions containing antigenic peptides. Structural characterization using circular dichroism predicted that these molecules retained the antiparallel beta -sheet platform and antiparallel alpha -helices observed in the native HLA-DR2 heterodimer. The proteins exhibited a cooperative two-state thermal unfolding transition, and DR2-derived RTLs with a covalently linked MBP peptide (MBP-(85-99)) showed increased stability to thermal unfolding relative to the empty DR2-derived RTLs. These novel molecules represent a new class of small soluble ligands for modulating the behavior of T cells and provide a platform technology for developing potent and selective human diagnostic and therapeutic agents for treatment of autoimmune disease.	Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Burrows, GG (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, L-219,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	ggb@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010554] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43960] Funding Source: Medline; NIEHS NIH HHS [ES10554] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Burrows GG, 2000, J IMMUNOL, V164, P6366, DOI 10.4049/jimmunol.164.12.6366; Burrows GG, 1998, J IMMUNOL, V161, P5987; Burrows GG, 1999, PROTEIN ENG, V12, P771, DOI 10.1093/protein/12.9.771; Chen G C, 1973, Biophys Chem, V1, P62; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; CONNOLLY ML, 1986, BIOPOLYMERS, V25, P1229, DOI 10.1002/bip.360250705; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CUSH JJ, 1988, ARTHRITIS RHEUM-US, V31, P1230, DOI 10.1002/art.1780311003; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; Li YL, 2000, J MOL BIOL, V304, P177, DOI 10.1006/jmbi.2000.4198; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PATERSON PY, 1973, J CHRON DIS, V26, P119, DOI 10.1016/0021-9681(73)90085-4; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; QUILL H, 1987, J IMMUNOL, V138, P3704; Schafer P H, 1995, Semin Immunol, V7, P389, DOI 10.1006/smim.1995.0043; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; SWANBORG RH, 1983, J IMMUNOL, V130, P1503; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VANDENBARK AA, 1994, J IMMUNOL, V153, P852; WEINBERG AD, 1992, J IMMUNOL, V148, P2109; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZHAO BG, 1992, J MOL BIOL, V227, P239, DOI 10.1016/0022-2836(92)90694-F; ZinnJustin S, 1996, BIOCHEMISTRY-US, V35, P8535, DOI 10.1021/bi960466n	37	30	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24170	24176		10.1074/jbc.M101808200	http://dx.doi.org/10.1074/jbc.M101808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319230	hybrid			2022-12-25	WOS:000169531100125
J	De Ferrari, GV; Mallender, WD; Inestrosa, NC; Rosenberry, TL				De Ferrari, GV; Mallender, WD; Inestrosa, NC; Rosenberry, TL			Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORSIONAL RELAXATION; SUBSTRATE-BINDING; ANIONIC SITE; INHIBITION; PROPIDIUM; LIGANDS; PROTEIN; GORGE; SPECIFICITY; TRANSITION	Three-dimensional structures of acetylcholinesterase (AChE) reveal a narrow and deep active site gorge with two sites of ligand binding, an acylation site at the base of the gorge, and a peripheral site near the gorge entrance. Recent studies have shown that the peripheral site contributes to catalytic efficiency by transiently binding substrates on their way to the acylation site, but the question of whether the peripheral site makes other contributions to the catalytic process remains open. A possible role for ligand binding to the peripheral site that has long been considered is the initiation of a conformational change that is transmitted allosterically to the acylation site to alter catalysis, However, evidence for conformational interactions between these sites has been difficult to obtain, Here we report that thioflavin T, a fluorophore widely used to detect amyloid structure in proteins, binds selectively to the AChE peripheral site with an equilibrium dissociation constant of 1.0 mum. The fluorescence of the bound thioflavin T is increased more than 1000-fold over that of unbound thioflavin T, the greatest enhancement of fluorescence for the binding of a fluorophore to AChE yet observed. Furthermore, when the acylation site ligands edrophonium or m-(N, N,N-trimethylammonio)trifluoroacetophenone form ternary complexes with AChE and thioflavin T, the fluorescence is quenched by factors of 2.7-4.2. The observation of this partial quenching of thioflavin T fluorescence is a major advance in the study of AChE, for two reasons. First, it allows thioflavin T to be used as a reporter for ligand reactions at the acylation site. Second, it indicates that ligand binding to the acylation site initiates a change in the local AChE conformation at the peripheral site that quenches the fluorescence of bound thioflavin T, The data provide strong evidence in support of a conformational interaction between the two AChE sites.	Mayo Clin Jacksonville, Dept Pharmacol, Mayo Fdn Med Educ & Res, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Program Neurosci, Mayo Fdn Med Educ & Res, Jacksonville, FL 32224 USA; Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Regulac Celular & Patol, Dept Biol Celular & Mol, Santiago 114D, Chile	Mayo Clinic; Mayo Clinic; Pontificia Universidad Catolica de Chile	Rosenberry, TL (corresponding author), Mayo Clin Jacksonville, Dept Pharmacol, Mayo Fdn Med Educ & Res, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.			De Ferrari, Giancarlo/0000-0003-0932-125X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-16577] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BRODBECK U, 1979, BIOCHIM BIOPHYS ACTA, V567, P357, DOI 10.1016/0005-2744(79)90122-0; Camps P, 2000, MOL PHARMACOL, V57, P409; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HUCHO F, 1991, TRENDS PHARMACOL SCI, V12, P422; KITZ RJ, 1970, MOL PHARMACOL, V6, P108; KUNG CE, 1986, BIOCHEMISTRY-US, V25, P6114, DOI 10.1021/bi00368a042; LeVine H, 1999, METHOD ENZYMOL, V309, P274; LOUTFY RO, 1982, J PHYS CHEM-US, V86, P4205, DOI 10.1021/j100218a023; Mallender WD, 2000, BIOCHEMISTRY-US, V39, P7753, DOI 10.1021/bi000210o; Mallender WD, 1999, J BIOL CHEM, V274, P8491, DOI 10.1074/jbc.274.13.8491; NAIR HK, 1993, J AM CHEM SOC, V115, P9939, DOI 10.1021/ja00075a009; Radic Z, 1999, CHEM-BIOL INTERACT, V119, P111, DOI 10.1016/S0009-2797(99)00019-8; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Sentjurc M, 1999, BBA-PROTEIN STRUCT M, V1430, P349, DOI 10.1016/S0167-4838(99)00018-7; SHARP TR, 1982, J BIOCHEM BIOPH METH, V6, P159, DOI 10.1016/0165-022X(82)90062-8; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; Tara S, 1998, BIOPOLYMERS, V46, P465; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TAYLOR P, 1974, MOL PHARMACOL, V10, P703	31	117	122	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23282	23287		10.1074/jbc.M009596200	http://dx.doi.org/10.1074/jbc.M009596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313335	hybrid			2022-12-25	WOS:000169531100011
J	El Nemer, W; Gane, P; Colin, Y; D'Ambrosio, AM; Callebaut, I; Cartron, JP; Le van Kim, C				El Nemer, W; Gane, P; Colin, Y; D'Ambrosio, AM; Callebaut, I; Cartron, JP; Le van Kim, C			Characterization of the laminin binding domains of the Lutheran blood group glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL ADHESION; LU-A/LU-B; GROUP ANTIGENS; IMMUNOGLOBULIN SUPERFAMILY; MOLECULAR-BASIS; GROUP PROTEIN; IDENTIFICATION; EXPRESSION; RECEPTOR; INTEGRINS	Lutheran (Lu) blood group antigens and the basal cell adhesion molecule antigen reside on two glycoproteins that belong to the Ig superfamily (IgSF) and carry five Ig-like extracellular domains. These glycoproteins act as widely expressed adhesion molecules and represent the unique receptors for laminin-10/11 in erythroid cells. Here, we report the mapping of IgSF domains responsible for binding to laminin, In plasmonic resonance surface experiments, only recombinant Lu proteins containing the N-terminal IgSF domains 1-3 were able to bind laminin-10/11 and to inhibit binding of laminin to Lu-expressing K562 cells. Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3, Altogether, these results indicate that IgSF domains 1-3 are involved in laminin binding and that a specific spatial arrangement of these three first domains is most probably necessary for interaction. Nei ther the RGD nor the N-glycosylation motifs present in IgSF domain 3 were involved in laminin binding.	Inst Natl Transfus Sanguine, INSERM U76, F-75015 Paris, France; Univ Paris 06, CNRS UMR7590, F-75005 Paris, France; Univ Paris 07, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite	Le van Kim, C (corresponding author), Inst Natl Transfus Sanguine, INSERM U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.		colin, yves/O-1910-2017; Nemer, Wassim El/N-4247-2017	colin, yves/0000-0001-5196-4254; Nemer, Wassim El/0000-0001-8184-427X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bailly P, 1995, EUR J IMMUNOL, V25, P3316, DOI 10.1002/eji.1830251217; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; CHESAGARIN P, 1994, INT J ONCOL, V5, P1261; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; El Nemer W, 1998, J BIOL CHEM, V273, P16686; El Nemer W, 1999, J BIOL CHEM, V274, P31903, DOI 10.1074/jbc.274.45.31903; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; Ferletta M, 1999, J CELL SCI, V112, P1; Freigang J, 2000, CELL, V101, P425, DOI 10.1016/S0092-8674(00)80852-1; GANE P, 2001, IN PRESS BR J HAEMAT, V113; Gu YC, 1999, BLOOD, V93, P2533, DOI 10.1182/blood.V93.8.2533.408k22_2533_2542; Hebbel RP, 1997, J CLIN INVEST, V99, P2561, DOI 10.1172/JCI119442; Hermand P, 2000, J BIOL CHEM, V275, P26002, DOI 10.1074/jbc.M002823200; JOHNSON JP, 1993, MELANOMA RES, V3, P337, DOI 10.1097/00008390-199310000-00006; Lee SP, 1998, BLOOD, V92, P2951, DOI 10.1182/blood.V92.8.2951.420k30_2951_2958; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Parsons SF, 1997, BLOOD, V89, P4219, DOI 10.1182/blood.V89.11.4219; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; Parsons SF, 2001, BLOOD, V97, P312, DOI 10.1182/blood.V97.1.312; Rahuel C, 1996, BLOOD, V88, P1865; Rahuel C, 1999, IMMUNOGENETICS, V50, P271, DOI 10.1007/s002510050602; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435; TERRANOVA VP, 1982, CANCER RES, V42, P2265; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; Wick T M, 1996, Curr Opin Hematol, V3, P118; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YURCHENKO PD, 1993, MOL CELLULAR ASPECTS, P121; Zen Q, 1999, J BIOL CHEM, V274, P728, DOI 10.1074/jbc.274.2.728; Zen Q, 1999, FASEB J, V13, pA1360	38	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23757	23762		10.1074/jbc.M102978200	http://dx.doi.org/10.1074/jbc.M102978200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319237	hybrid			2022-12-25	WOS:000169531100072
J	Gonzalez, LC; Weis, WI; Scheller, RH				Gonzalez, LC; Weis, WI; Scheller, RH			A novel SNARE N-terminal domain revealed by the crystal structure of Sec22b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; SYNAPTIC EXOCYTOSIS; GAF DOMAIN; PROTEIN; PROFILIN; COMPLEX; TRANSPORT; SYNTAXIN	Intra-cellular membrane fusion is facilitated by the association of SNAREs from opposite membranes into stable alpha -helical bundles. Many SNAREs, in addition to their alpha -helical regions, contain N-terminal domains that likely have essential regulatory functions. To better understand this regulation, we have determined the 2.4-Angstrom crystal structure of the 130-amino acid N-terminal domain of mouse Sec22b (mSec22b), a SNARE involved in endoplasmic reticulum/Golgi membrane trafficking. The domain consists of a mixed alpha -helical/beta -sheet fold that resembles a circular permutation of the actin/polyproline binding protein, profilin, and the GAF/PAS family of regulatory modules. The structure is distinct from the previously characterized N-terminal domain of syn taxin 1A, and, unlike syntaxin 1A, the N-terminal domain of mSec22b has no effect on the rate of SNARE assembly in vitro. An analysis of surface conserved residues reveals a potential protein interaction site. Key residues in this site are distinct in two mammalian Sec22 variants that lack SNARE domains, Finally, sequence analysis indicates that a similar domain is likely present in the endosomal/lysosomal SNARE VAMP7.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011; Gonzalez, Lino/E-4102-2012	Weis, William I/0000-0002-5583-6150; Gonzalez, Lino/0000-0003-3817-6450	NIMH NIH HHS [MH58570] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; Grosse-Kunstleve RW, 1999, ACTA CRYSTALLOGR D, V55, P1568, DOI 10.1107/S0907444999007763; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Neiman AM, 2000, GENETICS, V155, P1643; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pevsner J, 1996, GENE, V183, P7, DOI 10.1016/S0378-1119(96)00367-8; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SOHN RH, 1995, J BIOL CHEM, V270, P21114, DOI 10.1074/jbc.270.36.21114; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tang BL, 1998, BIOCHEM BIOPH RES CO, V243, P885, DOI 10.1006/bbrc.1998.8194; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Womble D D, 2000, Methods Mol Biol, V132, P3; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	53	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24203	24211		10.1074/jbc.M101584200	http://dx.doi.org/10.1074/jbc.M101584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309394	hybrid			2022-12-25	WOS:000169531100129
J	Gu, SM; Roderick, HL; Camacho, P; Jiang, JX				Gu, SM; Roderick, HL; Camacho, P; Jiang, JX			Characterization of an N-system amino acid transporter expressed in retina and its involvement in glutamine transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; FUNCTIONAL-CHARACTERIZATION; NITROGEN-METABOLISM; RAT-LIVER; CLONING; IDENTIFICATION; CALRETICULIN; ORGANIZATION; ASC	We report here on the characterization of a mouse N-system amino acid transporter protein, which is involved in the transport of glutamine. This protein of 485 amino acids shares 52% sequence homology with an N-system amino acid transporter, mouse N-system amino acid transporter (mNAT) and its orthologs. Because this protein shares a high degree of sequence homology and functional similarity to mNAT, we named it mNAT2. mNAT2 is predominately expressed in the retina and to a slightly lesser extent in the brain. In the retina, it is located in the axons of ganglion cells in the nerve fiber layer and in the bundles of the optic nerve. Functional analysis of mNAT2 expressed in Xenopus oocytes revealed that the strongest transport activities were specific for L-glutamine. In addition, mNAT2 is a Na+- and pH-dependent, high affinity transporter and partially tolerates substitution of Na+ by Li+. Additionally, mNAT2 functions as a carrier-mediated transporter that facilitates efflux. The unique expression pattern and selective glutamine transport properties of mNAT2 suggest that it plays a specific role in the uptake of glutamine involved in the generation of the neurotransmitter glutamate in retina.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Mail Code,7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Jiang, Jean/0000-0002-2185-5716; Roderick, Hywel/0000-0001-7065-3523				BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BENDER DA, 1975, AMINO ACID METABOLIS, P1; Broer A, 1999, J NEUROCHEM, V73, P2184; BURGER HJ, 1989, HEPATOLOGY, V9, P22, DOI 10.1002/hep.1840090105; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Castagna M, 1997, J EXP BIOL, V200, P269; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; Derouiche A, 1996, VISION RES, V36, P3875, DOI 10.1016/S0042-6989(96)00140-X; Fei YJ, 2000, J BIOL CHEM, V275, P23707, DOI 10.1074/jbc.M002282200; FISHMAN RA, 1992, CEREBROSPINAL FLUID, P233; Gu SM, 2000, P NATL ACAD SCI USA, V97, P3230, DOI 10.1073/pnas.050318197; GUIDOTTI GG, 1992, MAMMALIAN AMINO ACID TRANSPORT, P3; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; Imamura Y, 1998, GENOMICS, V51, P293, DOI 10.1006/geno.1998.5357; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kalloniatis M, 1999, PROG RETIN EYE RES, V18, P811, DOI 10.1016/S1350-9462(98)00036-6; KENNEDY AJ, 1974, NATURE, V252, P50, DOI 10.1038/252050a0; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1979, BIOCHEM BIOPH RES CO, V88, P744, DOI 10.1016/0006-291X(79)92110-7; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MARC RE, 1995, J NEUROSCI, V15, P5106; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MCDONNELL JM, 1994, RETINA, P5; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Poitry S, 2000, J NEUROSCI, V20, P1809; Rauen T, 1996, CELL TISSUE RES, V286, P325, DOI 10.1007/s004410050702; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; TAYLOR PM, 1992, J BIOL CHEM, V267, P3873; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VANDENBE.CJ, 1971, BIOCHEM J, V123, P211, DOI 10.1042/bj1230211; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; VOADEN MJ, 1978, J NEUROCHEM, V31, P1069, DOI 10.1111/j.1471-4159.1978.tb00149.x; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	43	38	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24137	24144		10.1074/jbc.M009003200	http://dx.doi.org/10.1074/jbc.M009003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11325958	Green Published, hybrid			2022-12-25	WOS:000169531100121
J	Lukashova, V; Asselin, C; Krolewski, JJ; Rola-Pleszczynski, M; Stankova, J				Lukashova, V; Asselin, C; Krolewski, JJ; Rola-Pleszczynski, M; Stankova, J			G-protein-independent activation of Tyk2 by the platelet-activating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II AT(1) RECEPTOR; NF-KAPPA-B; INTERFERON-ALPHA RECEPTOR; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; JAK/STAT PATHWAY; CYTOPLASMIC DOMAINS; HUMAN MONOCYTES	Platelet-activating factor (PAF) is a potent pro-inflammatory phospholipid with multiple physiological and pathological effects. PAF exerts its activity through a specific heptohelical G-protein coupled receptor, expressed on a variety of cell types, including leukocytes. In this study, we showed that PAF induced a rapid tyrosine phosphorylation of the Tyk2 kinase in the monocytic cell lines U937 and MonoMac-1. PAF-initiated Tyk2 phosphorylation was also observed in COS-7 cells transiently transfected with the human PAF receptor (PAFR) and Tyk2 cDNAs. In addition, we found that Tyk2 co-immunoprecipitated and co-localized with PAFR, independently of ligand binding. Deletion mutants of Tyk2 indicated that the N terminus of the kinase was important for the binding to PAFR. Activation of Tyk2 was followed by a time-dependent 2-4-fold increase in the level of tyrosine phosphorylation of signal transducers and activators of transcription 1 (STAT1), STAT2, and STAT3 and a sustained 2.5-fold increase in STAT5 tyrosine phosphorylation. In MonoMac-1 cells, STAT1 and STAT3 translocated to the nucleus following PAF stimulation, and their translocation in transiently transfected COS-7 cells was shown to be dependent on the presence of Tyk2. In addition, when COS-7 cells were transfected with PAFR and constructs containing PAFR promoter 1, coupled to the luciferase reporter gene, PAF induced a 3.6-fold increase in promoter activation in the presence of Tyk2. Finally, PAFR mutants that could not couple to G-proteins were found to effectively mediate Tyk2 activation and signaling. Taken together, these findings suggest an important role for the Janus kinase/STAT pathway in PAFR signaling, independent of G-proteins, and in the regulation of PAF receptor expression by its ligand.	Univ Sherbrooke, Fac Med, Div Immunol, Dept Pediat, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Anat & Cell Biol, Sherbrooke, PQ J1H 5N4, Canada; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	University of Sherbrooke; University of Sherbrooke; University of California System; University of California Irvine	Stankova, J (corresponding author), Univ Sherbrooke, Fac Med, Div Immunol, Dept Pediat, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.							Ali MS, 2000, J BIOL CHEM, V275, P15586, DOI 10.1074/jbc.M908931199; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; BRAQUET P, 1987, PHARMACOL REV, V39, P97; Calcerrada MC, 1999, BRAIN RES, V835, P275, DOI 10.1016/S0006-8993(99)01612-1; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Chaqour B, 1999, J MOL CELL CARDIOL, V31, P1345, DOI 10.1006/jmcc.1999.0967; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Dagenais P, 1997, INFLAMM RES, V46, pS161; Dagenais P, 1997, J LEUKOCYTE BIOL, V61, P106, DOI 10.1002/jlb.61.1.106; DHAR A, 1994, J BIOL CHEM, V269, P9123; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; HUANG SJ, 1988, BIOCHEM J, V249, P839, DOI 10.1042/bj2490839; Hunt RA, 1999, HYPERTENSION, V34, P603, DOI 10.1161/01.HYP.34.4.603; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; Le Gouill C, 1999, J BIOL CHEM, V274, P12548, DOI 10.1074/jbc.274.18.12548; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Mellado M, 1998, J IMMUNOL, V161, P805; Mutoh H, 1996, P NATL ACAD SCI USA, V93, P774, DOI 10.1073/pnas.93.2.774; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1130, DOI 10.1006/bbrc.1994.2783; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; OUELLET S, 1994, J IMMUNOL, V152, P5092; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; PARENT JL, 1993, BIOCHEM BIOPH RES CO, V197, P1443, DOI 10.1006/bbrc.1993.2639; Parent JL, 1996, BIOCHEM BIOPH RES CO, V219, P968, DOI 10.1006/bbrc.1996.0341; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Rezaul K, 1997, BIOCHEM BIOPH RES CO, V239, P23, DOI 10.1006/bbrc.1997.7419; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; ROLAPLESZCZYNSKI M, 1993, J LIPID MEDIATOR, V6, P175; Shimizu T, 1996, ADV EXP MED BIOL, V416, P79; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; Snyder F., 1990, AM J PHYSIOL, V259, P697; Soldi R, 1996, ONCOGENE, V13, P515; THIVIERGE M, 1993, J BIOL CHEM, V268, P17457; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VENABLE ME, 1993, J LIPID RES, V34, P691; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang H, 1999, IMMUNOLOGY, V97, P447, DOI 10.1046/j.1365-2567.1999.00784.x; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Yan H, 1998, J BIOL CHEM, V273, P4046, DOI 10.1074/jbc.273.7.4046; Yang HH, 1997, J IMMUNOL, V158, P2771; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	58	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24113	24121		10.1074/jbc.M100720200	http://dx.doi.org/10.1074/jbc.M100720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309383	hybrid			2022-12-25	WOS:000169531100118
J	Ono, K; Ohtomo, T; Sato, S; Sugamata, Y; Suzuki, M; Hisamoto, N; Ninomiya-Tsuji, J; Tsuchiya, M; Matsumoto, K				Ono, K; Ohtomo, T; Sato, S; Sugamata, Y; Suzuki, M; Hisamoto, N; Ninomiya-Tsuji, J; Tsuchiya, M; Matsumoto, K			An evolutionarily conserved motif in the TAB1 C-terminal region is necessary for interaction with and activation of TAK1 MAPKKK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE KINASE KINASE; BETA SIGNAL-TRANSDUCTION; PROTEIN-KINASES; PATHWAY; SPECTROSCOPY; JNK; PHOSPHORYLATION; INHIBITOR; EXCHANGE; MEDIATOR	TAK1, a member of the MAPKKK family, is involved in the intracellular signaling pathways mediated by transforming growth factor beta, interleukin 1, and Wnt, TAK1 kinase activity is specifically activated by the TAK1-binding protein TAB1. The C-terminal 68-amino acid sequence of TAB1 (TAB1-C68) is sufficient for TAX1 interaction and activation Analysis of various truncated versions of TAB1-C68 defined a C-terminal 30-amino acid sequence (TAB1-C30) necessary for TAK1 binding and activation. NMR studies revealed that the TAB1-C30 region has a unique cu-helical structure. We identified a conserved sequence motif, PYVDXA/TXF, in the C-terminal domain of mammalian TAB1, Xenopus TAB1, and its Caenorhabditis elegans homolog TAP-I, suggesting that this motif constitutes a specific TAK1 docking site. Alanine substitution mutagenesis showed that, TAB1 Phe484, located in the conserved motif, is crucial for TAK1 binding and activation. The C, elegans homolog of TAB1, TAP-1, was able to interact with and activate the C. elegans homolog of TAK1, MOM-4. However, the site in TAP-1 corresponding to Phe-484 of TAB1 is an alanine residue (Ala-364), and changing this residue to Phe abrogates the ability of TAP-1 to interact with and activate MOM-4. These results suggest that the Phe or Ala residue within the conserved motif of the TAB1-related proteins is important for interaction with and activation of specific TAK1 MAPKKK family members in vivo.	Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka 4128513, Japan; Nagoya Univ, Dept Mol Biol, Grad Sch Sci, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Nagoya, Aichi 4648602, Japan	Chugai Pharmaceutical Co., Ltd.; Roche Holding; Nagoya University; Japan Science & Technology Agency (JST)	Tsuchiya, M (corresponding author), Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, 1-135 Komakado, Shizuoka 4128513, Japan.			Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Bartel P. L., 1993, CELLULAR INTERACTION, P153; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRUENGER AT, 1992, X POLAR MANUAL VERSI; BRUENGER AT, 1986, P NATL ACAD SCI USA, V74, P4130; CLORE G, 1986, J MOL BIOL, V205, P201; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miller J.H., 1972, EXPT MOL GENETICS; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDFIELD AG, 1975, J MAGN RESON, V19, P250, DOI 10.1016/0022-2364(75)90073-6; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WUTHICH K, 1983, J MOL BIOL, V1369, P949; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	36	58	62	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24396	24400		10.1074/jbc.M102631200	http://dx.doi.org/10.1074/jbc.M102631200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323434	hybrid			2022-12-25	WOS:000169531100154
J	Xiao, WH; Wang, LH; Yang, XY; Chen, TS; Hodge, D; Johnson, PF; Farrar, W				Xiao, WH; Wang, LH; Yang, XY; Chen, TS; Hodge, D; Johnson, PF; Farrar, W			CCAAT/enhancer-binding protein beta mediates interferon-gamma-induced p48 (ISGF3-gamma) gene transcription in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED DISRUPTION; ISGF3 COMPONENTS; MELANOMA-CELLS; DNA-BINDING; IFN-BETA; ACTIVATION; EXPRESSION; INDUCTION; RESISTANT; FAMILY	Previous studies have identified a novel interferon-stimulated response element-like element, termed gamma -interferon-activating transcription element, within the interferon-stimulating gene factor-3 gamma (p48) promoter region that is bound by novel transcription factors in response to stimulation with interferons (IFNs) (Weihua, X,, Kolla, V., and Kalvakolanu, D, V. (1997) Proc. Natl. Acad, Sci. U. S. A. 94, 103-108), In the present study, we have identified CCAAT/enhancer-binding protein beta (C/EBP-beta) as one of the gamma -interferon-activating transcription element cognate transcription factors by screening a human monophage-derived cDNA library in a yeast one-hybrid system. Electrophoretic mobility shift assay studies suggest that C/EBP-beta dynamically regulates p48 gene expression upon IFN-gamma stimulation by undergoing changes in its heterodimerization partners. Transient transfection studies demonstrate that overexpression of C/EBP-beta strongly enhanced IFN-gamma -induced transcription from the p48 promoter. However, deletion mutants of C/EBP-beta that lack the N-terminal transactivation domain were unable to stimulate the p48 promoter. Western blotting revealed that C/EBP-beta is induced by IFN-gamma stimulation in THP-1-derived macrophages. Collectively, these results suggest that C/EBP-beta plays an important role in the human IFN-gamma signaling pathway by transcriptional regulation of p48 gene expression, an essential component in the IFN signaling pathway.	NCI, Frederick Canc Res & Dev Ctr, Intramural Res Program, SAIC Frederick,NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Cytokine Mol Mech Sect,NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Xiao, WH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Intramural Res Program, SAIC Frederick,NIH, POB B,Bldg 560,Rm 31-76, Frederick, MD 21702 USA.	xiaow@mail.ncifcrf.gov	Xiao, Weihua/N-2775-2013; Chen, Taosheng/I-6351-2013; Johnson, Peter/A-1940-2012	Xiao, Weihua/0000-0001-9102-6326; Chen, Taosheng/0000-0001-6420-3809; Johnson, Peter/0000-0002-4145-4725	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N0 1-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; Berger LC, 1997, J INTERF CYTOK RES, V17, P757, DOI 10.1089/jir.1997.17.757; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cross JC, 1999, BIOL REPROD, V60, P312, DOI 10.1095/biolreprod60.2.312; Dai WJ, 1997, J IMMUNOL, V158, P5297; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dlaska M, 1999, J IMMUNOL, V162, P6171; GAO PQ, 1993, J BIOL CHEM, V268, P12380; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Masumoto M, 1999, J IMMUNOL, V163, P5039; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Nakao K, 1999, J BIOL CHEM, V274, P28075, DOI 10.1074/jbc.274.40.28075; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nishiya T, 1997, FEBS LETT, V408, P33, DOI 10.1016/S0014-5793(97)00383-9; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Suzuki Y, 1997, INFECT IMMUN, V65, P2339, DOI 10.1128/IAI.65.6.2339-2345.1997; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Wang LH, 1999, J IMMUNOL, V162, P3897; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wong LH, 1998, J IMMUNOL, V160, P5475; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Xiao WH, 1999, ANTIVIR RES, V40, P145, DOI 10.1016/S0166-3542(98)00056-4; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103; XU B, 1994, BLOOD, V84, P1942	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23275	23281		10.1074/jbc.M010047200	http://dx.doi.org/10.1074/jbc.M010047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312260	hybrid			2022-12-25	WOS:000169531100010
J	Nielsen, MS; Vorum, H; Lindersson, E; Jensen, PH				Nielsen, MS; Vorum, H; Lindersson, E; Jensen, PH			Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; AXONAL-TRANSPORT; LEWY BODIES; CALCIUM; EXPRESSION; IDENTIFICATION; SYNAPTOTAGMIN	alpha -Synuclein is a protein normally involved in presynaptic vesicle homeostasis. It participates in the development of Parkinson's disease, in which the nerve cell lesions, Lewy bodies, accumulate alpha -synuclein filaments. The synaptic neurotransmitter release is primarily dependent on Ca2+-regulated processes. A microdialysis technique was applied showing that alpha -synuclein binds Ca2+ with an IC,, of about 2-300 muM and in a reaction uninhibited by a 50 fold excess of Mg2+. The Ca2+-binding site consists of a novel C-terminally localized acidic 32-amino acid domain also present in the homologue beta -synuclein, as shown by Ca2+ binding to truncated recombinant and synthetic alpha -synuclein peptides. Ca2+ binding affects the functional properties of alpha -synuclein, First, the ligand binding of I-125-labeled bovine microtubule-associated protein 1A is stimulated by Ca2+ ions in the 1-500 muM. range and is dependent on an intact Ca2+ binding site in alpha -synuclein. Second, the Ca2+ binding stimulates the proportion of I-125-alpha -synuclein-containing oligomers, This suggests that Ca2+ ions may both participate in normal alpha -synuclein functions in the nerve terminal and exercise pathological effects involved in the formation of Lewy bodies.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark	Aarhus University	Jensen, PH (corresponding author), Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark.	phj@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Jensen, Poul Henning/0000-0002-4439-9020				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Bayer TA, 1999, NEUROREPORT, V10, P2799, DOI 10.1097/00001756-199909090-00019; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P22; Buchman VL, 1998, NAT NEUROSCI, V1, P101, DOI 10.1038/349; Caillard O, 2000, P NATL ACAD SCI USA, V97, P13372, DOI 10.1073/pnas.230362997; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fink JK, 1996, GENOMICS, V35, P577, DOI 10.1006/geno.1996.0400; Fukuda M, 2000, J BIOL CHEM, V275, P28180; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Goda Y, 1997, CURR OPIN CELL BIOL, V9, P513, DOI 10.1016/S0955-0674(97)80027-0; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hsu LJ, 1998, J NEUROCHEM, V71, P338; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1999, EUR J NEUROSCI, V11, P3369, DOI 10.1046/j.1460-9568.1999.00754.x; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; KRAGHHANSEN U, 1993, CLIN CHEM, V39, P202; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; NIXON RA, 1990, J CELL BIOL, V110, P437, DOI 10.1083/jcb.110.2.437; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; Petersen K, 1999, NEUROSCIENCE, V91, P651, DOI 10.1016/S0306-4522(98)00596-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Vorum H, 1996, ELECTROPHORESIS, V17, P1787, DOI 10.1002/elps.1150171118; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	56	119	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22680	22684		10.1074/jbc.M101181200	http://dx.doi.org/10.1074/jbc.M101181200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312271	hybrid			2022-12-25	WOS:000169412700095
J	Ren, XQ; Furukawa, T; Aoki, S; Nakajima, T; Sumizawa, T; Haraguchi, M; Chen, ZS; Kobayashi, M; Akiyama, S				Ren, XQ; Furukawa, T; Aoki, S; Nakajima, T; Sumizawa, T; Haraguchi, M; Chen, ZS; Kobayashi, M; Akiyama, S			Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLINE-BASED DRUG; P-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; LEUKOTRIENE C-4; TUMOR-CELLS; PHARMACOLOGICAL CHARACTERIZATION; MEMBRANE-VESICLES; INSECT CELLS; EXPORT PUMP; MRP	MRP1 is a 190-kDa membrane glycoprotein that confers multidrug resistance (MDR) to tumor cells. MRP1 is characterized by an N-terminal transmembrane domain (TMD0), which is connected to a P-glycoprotein-like core region (Delta MRP) by a cytoplasmic Linker domain zero (L-0). It has been demonstrated that GSH plays an important role in MRP1-mediated MDR. However, the mechanism by which GSH mediates MDR and the precise roles of TMD0 and L-0 are not known. We synthesized [I-125]11-azidophenyl agosterol A ([I-125]azidoAG-A), a photoaffinity analog of the MDR-reversing agent, agosterol A (AGA), to photolabel MRP1, and found that the analog photolabeled the C-proximal molecule of MRP1 (C932-1531) in a manner that was GSH-dependent. The photolabeling was inhibited by anticancer agents, reversing agents and leukotriene C-4. Based on photolabeling studies in the presence and absence of GSH using membrane vesicles expressing various truncated, co-expressed, and mutated MRP1s, we found that L-0 is the site on MRP1 that interacts with GSH. This study demonstrated that GSH is required for the binding of an unconjugated agent to MRP1 and suggested that GSH interacts with L-0 of MRP1. The photoanalog of AG-A will be useful for identifying the drug binding site within MRP1, and the role of GSH in transporting substrates by MRP1.	Kagoshima Univ, Fac Med, Canc Res Inst, Dept Canc Chemotherapy, Kagoshima 8908520, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan	Kagoshima University; Osaka University	Akiyama, S (corresponding author), Kagoshima Univ, Fac Med, Canc Res Inst, Dept Canc Chemotherapy, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.			Chen, Zhe-Sheng/0000-0002-8289-097X; Furukawa, Tatsuhiko/0000-0003-1655-4123				AKIYAMA SI, 1989, MOL PHARMACOL, V36, P730; Aoki S, 1998, TETRAHEDRON LETT, V39, P6303, DOI 10.1016/S0040-4039(98)01336-7; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Chen ZS, 1999, MOL PHARMACOL, V55, P921; CHEN ZS, 2001, INT J CANC; CHOWDHRY V, 1979, ANNU REV BIOCHEM, V48, P293, DOI 10.1146/annurev.bi.48.070179.001453; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; DEBENHAM PG, 1982, MOL CELL BIOL, V2, P881, DOI 10.1128/MCB.2.8.881; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; FLENS MJ, 1994, CANCER RES, V54, P4557; FOJO A, 1985, CANCER RES, V45, P3002; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Jedlitschky G, 1996, CANCER RES, V56, P988; Latli B, 1997, BIOCONJUGATE CHEM, V8, P7, DOI 10.1021/bc960066c; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1998, CANCER RES, V58, P5130; Nagayama S, 1998, CANCER LETT, V130, P175, DOI 10.1016/S0304-3835(98)00132-3; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; Ren XQ, 2000, BIOCHEM BIOPH RES CO, V270, P608, DOI 10.1006/bbrc.2000.2483; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Sumizawa T, 1997, MOL PHARMACOL, V51, P399; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; Vezmar M, 1998, BIOCHEM PHARMACOL, V56, P733, DOI 10.1016/S0006-2952(98)00217-2; Vezmar M, 1997, BIOCHEM BIOPH RES CO, V241, P104, DOI 10.1006/bbrc.1997.7634; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	51	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23197	23206		10.1074/jbc.M101554200	http://dx.doi.org/10.1074/jbc.M101554200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301332	hybrid			2022-12-25	WOS:000169412700162
J	Stivala, LA; Savio, M; Carafoli, F; Perucca, P; Bianchi, L; Maga, G; Forti, L; Pagnoni, UM; Albini, A; Prosperi, E; Vannini, V				Stivala, LA; Savio, M; Carafoli, F; Perucca, P; Bianchi, L; Maga, G; Forti, L; Pagnoni, UM; Albini, A; Prosperi, E; Vannini, V			Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; DNA-POLYMERASE; POLYPHENOLIC COMPOUND; PLATELET-AGGREGATION; PHENOLIC-COMPOUNDS; TRANS-RESVERATROL; VITIS-VINIFERA; GRAPE BERRIES; RED WINE; CANCER	Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a natural phytoalexin found in grapes and wine, which shows antioxidant and antiproliferative activities. In this study we have investigated whether these properties are dependent on similar or different structural determinants of the molecule. To this purpose, resveratrol derivatives, in which all or each single hydroxylic function were selectively substituted with methyl groups, were synthesized. Analogues with the stilbenic double bond reduced or with the stereoisomery modified were also investigated. The antioxidant activity of these compounds was evaluated by measuring the inhibition of citronellal thermo-oxidation, or the reduction of 2,2 diphenyl-1-picrylhydrazyl radical. In addition, the protection against lipid peroxidation was determined in rat liver microsomes, and in human primary cell cultures. The antiproliferative activity was evaluated by a clonogenic assay, and by analysis of cell cycle progression and DNA synthesis. The results showed that the hydroxyl group in 4' position is not the sole determinant for antioxidant activity. In contrast, the presence of 4'-OH together with stereoisomery in the trans conformation (4'-hydroxystyryl moiety) was absolutely required for inhibition of cell proliferation. Enzymatic assays in vitro demonstrated that inhibition of DNA synthesis was induced by a direct interaction of resveratrol with DNA polymerases alpha and delta.	Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen C Golgi, I-27100 Pavia, Italy; CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; CNR, IGBE, I-27100 Pavia, Italy; Univ Modena, Dipartimento Chim, I-41100 Modena, Italy	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Universita di Modena e Reggio Emilia	Stivala, LA (corresponding author), Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen C Golgi, Piazza Botta 10, I-27100 Pavia, Italy.	l.stivala@botta.unipv.it	Prosperi, Ennio/A-3439-2014; Forti, Luca/AAY-9976-2021; Luca, Forti/C-9876-2015; Maga, Giovanni/C-5409-2009	Prosperi, Ennio/0000-0001-5391-5157; Forti, Luca/0000-0002-5662-7756; Luca, Forti/0000-0002-5662-7756; Maga, Giovanni/0000-0001-8092-1552; Albini, Adriana/0000-0002-9624-5103; ALBINI, ANGELO/0000-0003-4036-4290				ARICHI H, 1982, CHEM PHARM BULL, V30, P1766; Babich H, 2000, TOXICOL LETT, V114, P143, DOI 10.1016/S0378-4274(99)00288-X; Belguendouz L, 1997, BIOCHEM PHARMACOL, V53, P1347, DOI 10.1016/S0006-2952(96)00820-9; Bertelli AAE, 1996, DRUG EXP CLIN RES, V22, P61; Bocco A, 1998, SCI ALIMENT, V18, P13; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Carbo N, 1999, BIOCHEM BIOPH RES CO, V254, P739, DOI 10.1006/bbrc.1998.9916; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Goldberg DM, 1996, ANAL CHEM, V68, P1688, DOI 10.1021/ac951083i; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; HAIN R, 1990, PLANT MOL BIOL, V15, P325, DOI 10.1007/BF00036918; Hsieh TC, 1999, INT J ONCOL, V15, P245; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jang DS, 1999, BIOCHEM PHARMACOL, V57, P705, DOI 10.1016/S0006-2952(98)00350-5; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; JEANDET P, 1991, AM J ENOL VITICULT, V42, P41; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kerry NL, 1997, ATHEROSCLEROSIS, V135, P93, DOI 10.1016/S0021-9150(97)00156-1; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; KURECHI T, 1980, CHEM PHARM BULL, V28, P2089; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; Liu M, 1999, CARCINOGENESIS, V20, P1869, DOI 10.1093/carcin/20.9.1869; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Orsini F, 1997, CARBOHYD RES, V301, P95, DOI 10.1016/S0008-6215(97)00087-6; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; PEZET R, 1988, PLANT PHYSIOL BIOCH, V26, P603; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; Rotondo S, 1998, BRIT J PHARMACOL, V123, P1691, DOI 10.1038/sj.bjp.0701784; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Stivala LA, 2000, EUR J BIOCHEM, V267, P2290, DOI 10.1046/j.1432-1327.2000.01236.x; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Tadolini B, 2000, FREE RADICAL RES, V33, P105, DOI 10.1080/10715760000300661; WEISER T, 1991, J BIOL CHEM, V266, P10420; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; Zi XL, 1998, CANCER RES, V58, P1920; Zou JG, 1999, INT J ONCOL, V15, P647	52	406	427	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22586	22594		10.1074/jbc.M101846200	http://dx.doi.org/10.1074/jbc.M101846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11316812	hybrid			2022-12-25	WOS:000169412700083
J	Doan, TN; Ali, MS; Bernstein, KE				Doan, TN; Ali, MS; Bernstein, KE			Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PROTEIN; CELLS; PHOSPHORYLATION; TRANSDUCTION; PATHWAY; DOMAIN	The angiotensin II type 1 (AT(1)) receptor signals via heterotrimeric G-proteins and intracellular tyrosine kinases, Here, we investigate a modified AT(1) receptor, termed M5, where the last five tyrosines (residues 292, 302, 312, 319, and 339) within the intracellular carboxyl tail have been mutated to phenylalanine. This receptor did not elevate cytosolic free calcium or inositol phosphate production in response to angiotensin II, suggesting an uncoupling of the receptor from G-protein activation. Despite this, the M5 receptor still activated tyrosine kinases, induced STAT1 tyrosine phosphorylation, and stimulated cell proliferation. We also studied another AT(1) mutant receptor, D74E, stably expressed in Chinese hamster ovarian cells and a fibroblast cell line from mice with a genetic inactivation of G alpha (q/11). Both cell lines have a deficit in calcium signaling and in G-protein activation, and yet in both cell lines, angiotensin II induced the time-dependent tyrosine phosphorylation of STAT1, These studies are the first to show the ability of a seven-transmembrane receptor to activate intracellular tyrosine kinase pathways in the absence of a G-protein-coupled rise in intracellular calcium.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Bernstein, KE (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Woodruff Mem Bldg,Rm 7107A,1639 Pierce Dr, Atlanta, GA 30322 USA.			Bernstein, Kenneth/0000-0001-8097-3272	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010269, R01HL061710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039777, R01DK044280, R01DK051445, R01DK039777] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61710, F32 HL10269] Funding Source: Medline; NIDDK NIH HHS [DK39777, DK51445, DK44280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI MS, 1997, J BIOL CHEM, V272, P5592; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BODART V, 1995, J STEROID BIOCHEM, V54, P55, DOI 10.1016/0960-0760(95)00077-D; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Harp JB, 1997, BIOCHEM BIOPH RES CO, V232, P540, DOI 10.1006/bbrc.1997.6322; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1996, AM J PHYSIOL-CELL PH, V270, pC1834, DOI 10.1152/ajpcell.1996.270.6.C1834; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; SADOSHIMA J, 1995, CIRC RES, V76, P1; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; SCHORB W, 1994, J BIOL CHEM, V269, P19626; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677	19	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20954	20958		10.1074/jbc.C100199200	http://dx.doi.org/10.1074/jbc.C100199200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11319216	hybrid			2022-12-25	WOS:000169297900022
J	Shah, N; Thomas, TJ; Lewis, JS; Klinge, CM; Shirahata, A; Gelinas, C; Thomas, T				Shah, N; Thomas, TJ; Lewis, JS; Klinge, CM; Shirahata, A; Gelinas, C; Thomas, T			Regulation of estrogenic and nuclear factor kappa B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells	ONCOGENE			English	Review						polyamines; nuclear factor kappa B; estrogen receptor; breast cancer	SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; CREB-BINDING PROTEIN; ORNITHINE DECARBOXYLASE; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASES; INDUCIBLE CHEMORESISTANCE; GROWTH-INHIBITION; RESPONSE ELEMENT; CARCINOMA-CELLS; GENE-EXPRESSION	The natural polyamines -putrescine, spermidine, and spermine- are essential for cell growth and differentiation. Polyamines are involved in several gene regulatory functions, although their mechanism(s) of action has not been elucidated. We investigated the role of polyamines in the function of NF-kappaB and estrogen receptor-alpha (ER alpha), two transcription factors implicated in breast cancer cell proliferation and cell survival, using MCF-7 breast cancer cells. We found that spermine facilitated the binding of ER alpha and NF-kappaB to estrogen response element (ERE)- and NF-kappaB response element (NRE), respectively, and enhanced ER alpha -mediated transcriptional activation in transient transfection experiments. We also found that the association of the co-regulatory protein CBP/p300 with ER alpha and NF-kappaB was increased by spermine treatment of MCF-7 cells. Spermine also increased the nuclear translocation of NF-kappaB compared to the control. In contrast, treatment of MCF-7 cells with polyamine analogs, BE-3-4-3 and BE-3-3-3, resulted in transcriptional inhibition of both ERE- and NRE-driven reporter plasmids, in addition, polyamine analogs inhibited the association of ER alpha and NF-kappaB with CBP/p300 and were unable to facilitate nuclear translocation of NF-kappaB, APO-BRDU assay demonstrated that polyamine analogs induced apoptosis, with a loss of the anti-apoptotic protein Bcl-2, These data show a gene regulatory function of polyamines involving transcriptional activation of ER alpha and NF-kappaB, potentially leading to the up-regulation of genes involved in breast cancer cell proliferation. Our results with BE-3-4-3 and BE-3-3-3 suggest that down-regulation of ER alpha- and NF-kappaB-regulated genes is a possible mechanism for the action of polyamine analogs in inducing apoptosis of breast cancer cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Community Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, New Brunswick, NJ 08903 USA; Rutgers State Univ, Nutr Sci Grad Program, New Brunswick, NJ 08903 USA; Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA; Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 35002, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Louisville; Josai University	Thomas, T (corresponding author), 125 Paterson St,Clin Acad Bldg,Room 7090, New Brunswick, NJ 08901 USA.			Klinge, Carolyn/0000-0002-3358-4378; Shah, Neha/0000-0002-9286-3801	NCI NIH HHS [CA 42439, CA 80163, CA 73058] Funding Source: Medline; NIDDK NIH HHS [DK 53220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA042439, R01CA080163, R01CA042439, R01CA073058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berchtold CM, 1998, J CELL PHYSIOL, V174, P380, DOI 10.1002/(SICI)1097-4652(199803)174:3<380::AID-JCP12>3.0.CO;2-D; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BISWAD SK, 2000, P NATL ACAD SCI USA, V97, P8542; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryans M, 1996, BIOCHEM BIOPH RES CO, V226, P618, DOI 10.1006/bbrc.1996.1405; Canizares F, 1999, CLIN CANCER RES, V5, P2035; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CELANO P, 1989, J BIOL CHEM, V264, P8922; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Cusack JC, 2000, CANCER RES, V60, P2323; DAVIDSON NE, 1993, CANCER RES, V53, P2071; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; Delzenne NM, 2000, J NUTR, V130, P2456, DOI 10.1093/jn/130.10.2456; Desiderio MA, 1999, FEBS LETT, V455, P149, DOI 10.1016/S0014-5793(99)00873-X; Doerre S, 1999, J IMMUNOL, V163, P269; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Faaland CA, 2000, BIOCHEM CELL BIOL, V78, P415, DOI 10.1139/bcb-78-4-415; FAALAND CA, 1995, CELL GROWTH DIFFER, V6, P115; FEUERSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271, DOI 10.1093/nar/18.5.1271; Gabrielson EW, 1999, CLIN CANCER RES, V5, P1638; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; IGARASHI K, 1995, CANCER RES, V55, P2615; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Kramer DL, 1997, CANCER RES, V57, P5521; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurebayashi S, 1997, J STEROID BIOCHEM, V60, P11, DOI 10.1016/S0960-0760(96)00175-6; Leveque J, 1999, ANTICANCER RES, V19, P2275; Leveque J, 2000, BREAST CANCER RES TR, V60, P99, DOI 10.1023/A:1006319818530; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MANNI A, 1995, CANCER LETT, V92, P49, DOI 10.1016/0304-3835(95)03763-M; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MUNOZ E, 1994, J VIROL, V68, P8035; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; OBRIEN MJ, 1992, CANCER-AM CANCER SOC, V70, P1317, DOI 10.1002/1097-0142(19920901)70:3+<1317::AID-CNCR2820701519>3.0.CO;2-X; OBrien TG, 1997, CANCER RES, V57, P2630; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PANAGIOTIDIS CA, 1995, NUCLEIC ACIDS RES, V23, P1800, DOI 10.1093/nar/23.10.1800; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PERA PJ, 1986, CANCER RES, V46, P1148; Porter C W, 1988, Adv Exp Med Biol, V250, P677; PORTER CW, 1994, CANCER RES, V54, P5917; PORTER CW, 1990, BIOCHEM J, V268, P207, DOI 10.1042/bj2680207; Rauch BH, 2000, FEBS LETT, V481, P3, DOI 10.1016/S0014-5793(00)01957-8; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Rouet-Benzineb P, 2000, J MOL CELL CARDIOL, V32, P1767, DOI 10.1006/jmcc.2000.1211; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P37, DOI 10.1016/0303-7207(91)90057-Y; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Sharma A, 1997, CLIN CANCER RES, V3, P1239; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TABIB A, 1994, BIOCHEM BIOPH RES CO, V202, P720, DOI 10.1006/bbrc.1994.1990; Tabib A, 1999, INT J BIOCHEM CELL B, V31, P1289, DOI 10.1016/S1357-2725(99)00098-9; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; THOMAS T, 1995, J STEROID BIOCHEM, V54, P89, DOI 10.1016/0960-0760(95)00126-K; Thomas T, 1999, J MOL ENDOCRINOL, V22, P131, DOI 10.1677/jme.0.0220131; Thomas T, 1997, NUCLEIC ACIDS RES, V25, P2396, DOI 10.1093/nar/25.12.2396; THOMAS T, 1993, BREAST CANCER RES TR, V29, P189; Thomas TJ, 1998, BREAST CANCER RES TR, V47, P181, DOI 10.1023/A:1005925931215; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang GJ, 1998, ONCOL REP, V5, P1211; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	112	45	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1715	1729		10.1038/sj.onc.1204247	http://dx.doi.org/10.1038/sj.onc.1204247			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313919				2022-12-25	WOS:000167750900005
J	Teckchandani, AM; Feshchenko, EA; Tsygankov, AY				Teckchandani, AM; Feshchenko, EA; Tsygankov, AY			c-Cbl facilitates fibronectin matrix production by v-Abl-transformed NIH3T3 cells via activation of small GTPases	ONCOGENE			English	Article						c-Cbl; fibronectin; adhesion; morphology; tyrosine phosphorylation; ubiquitination	NUCLEOTIDE-RELEASING FACTOR; INTEGRIN SIGNALING PATHWAY; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; DEPENDENT ACTIVATION; NEGATIVE REGULATOR	The protooncogenic protein c-Cbl has been shown to act as a multivalent adaptor and a negative regulator of protein tyrosine kinase-mediated signaling, Recent studies have implicated it in the regulation of cell adhesion-related events. We have previously shown that c-Cbl facilitates adhesion and spreading of v-Abl-transformed fibroblasts, and that these effects are dependent on its tyrosine phosphorylation, However, the mechanisms mediating effects of c-Cbl on fibroblast adhesion remain poorly understood. In this study we demonstrate that the tyrosine phosphorylation-dependent effect of c-Cbl on adhesion of v-Abl-transformed fibroblasts is primarily mediated by an increase in fibronectin matrix deposition by these cells. This increase in fibronectin matrix deposition and, hence, in cell adhesion is dependent on cytoskeletal rearrangements induced by RhoA, Rad and, possibly, Rapt activation caused by c-Cbl, The observed activation of these GTPases is mediated by the recruitment of phosphatidylinositol-3' kinase, CrkL and Vav2 to the C-terminal tyrosine residues of c-Cbl, The results of this study also demonstrate that ubiquitination is essential for the observed effects of c-Cbl on fibronectin matrix production and cell adhesion.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, Rm 506,3400 N Broad St, Philadelphia, PA 19140 USA.		Tsygankov, Alexander Y/K-6205-2017	Teckchandani, Anjali/0000-0002-2237-9598	NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu H, 1996, CANCER RES, V56, P4541; Akiyama S K, 1996, Hum Cell, V9, P181; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Andoniou CE, 1996, ONCOGENE, V12, P1981; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Christopher RA, 1997, J CELL SCI, V110, P569; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Herzhoff K, 1999, BRIT J DERMATOL, V141, P218; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; Kumar CC, 1999, ANN NY ACAD SCI, V886, P122, DOI 10.1111/j.1749-6632.1999.tb09407.x; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu KS, 1999, TERR ATMOS OCEAN SCI, V10, P377, DOI 10.3319/TAO.1999.10.2.377(T); Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Marengere LEM, 1997, J IMMUNOL, V159, P70; MCKILLOP DFA, 1994, J MUSCLE RES CELL M, V15, P309; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RAJARAMAN R, 1983, EXP CELL BIOL, V51, P9; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scardigli R, 1996, EXP CELL RES, V227, P223, DOI 10.1006/excr.1996.0271; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; VAHERI A, 1978, BIOCHIM BIOPHYS ACTA, V516, P1, DOI 10.1016/0304-419X(78)90002-1; Vaheri A, 1978, Ann N Y Acad Sci, V312, P343, DOI 10.1111/j.1749-6632.1978.tb16812.x; VOLBERG T, 1994, CELL MOTIL CYTOSKEL, V29, P321, DOI 10.1002/cm.970290405; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WALSH A, 1997, ONCOGENE, V16, P2553; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	73	16	17	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1739	1755		10.1038/sj.onc.1204246	http://dx.doi.org/10.1038/sj.onc.1204246			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313921				2022-12-25	WOS:000167750900007
J	Agathanggelou, A; Honorio, S; Macartney, DP; Martinez, A; Dallol, A; Radar, J; Fullwood, P; Chauhan, A; Walker, R; Shaw, JA; Hosoe, S; Lerman, MI; Minna, JD; Maher, ER; Latif, F				Agathanggelou, A; Honorio, S; Macartney, DP; Martinez, A; Dallol, A; Radar, J; Fullwood, P; Chauhan, A; Walker, R; Shaw, JA; Hosoe, S; Lerman, MI; Minna, JD; Maher, ER; Latif, F			Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours	ONCOGENE			English	Article						3p; tumour suppressor gene; methylation; lung cancer; breast cancer	HUMAN-CHROMOSOME 3P21.3; SUPPRESSOR GENE; HOMOZYGOUS DELETION; SMALL-CELL; SHORT ARM; CANCER; IDENTIFICATION; 3P; LOCUS; CARCINOMA	Previously we analysed overlapping homozygous deletions in lung and breast tumours/tumour lines and defined a small region of 120 kb (part of LCTSGR1) at 3p21.3 that contained putative lung and breast cancer tumour suppressor gene(s) (TSG), Eight genes including RASSF1 were isolated from the minimal region. However, extensive mutation analysis in lung tumours and tumour lines revealed only rare inactivating mutations. Recently, de novo methylation at a CpG island associated with isoform A of RASSF1 (RASSF1A) was reported in lung tumours and tumour lines. To investigate RASSF1A as a candidate TSG for various cancers, we investigated: (a) RASSF1A methylation status in a large series of primary tumour and tumour lines; (b) chromosome 3p allele loss in lung tumours and (c) RASSF1 mutation analysis in breast tumours, RASSF1A promoter region CpG island methylation was detected in 72% of SCLC, 34% of NSCLC, 9% of breast, 10% of ovarian and 0% of primary cervical tumours and in 72% SCLC, 36% NSCLC, 80% of breast and 40% of ovarian tumour lines. In view of the lower frequency of RASSF1 methylation in primary breast cancers me proceeded to RASSF1 mutation analysis in 40 breast cancers. No mutations were detected, but six single nucleotide polymorphisms were identified. Twenty of 26 SCLC tumours with 3p21.3 allelic loss had RASSF1A methylation, while only six out of 22 NSCLC with 3p21.3 allele loss had RASSF1A methylation (P = 0.0012), one out of five ovarian and none out of six cervical tumours with 3p21.3 loss had RASSF1A methylation. These results suggest that (a) RASSF1A inactivation by two hits (methylation and loss) is a critical step in SCLC tumourigenesis and (b) RASSF1A inactivation is of lesser importance in NSCLC, breast, ovarian and cervical cancers in which other genes within LCTSGR1 are likely to be implicated.	Univ Birmingham, Sch Med, Dept Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Univ Leicester, Glenfield Hosp, Breast Canc Res Unit, Leicester, Leics, England; Natl Kinki Chuo Hosp, Dept Internal Med, Osaka, Japan; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21701 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	University of Birmingham; Washington University (WUSTL); University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008; Dallol, Ashraf/H-8661-2012	MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X; Shaw, Jacqui/0000-0003-4227-503X; Macartney-Coxson, Donia/0000-0002-1051-537X	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline; Breast Cancer Now [1999:98] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Now		BURBEE DG, 2001, IN PRESS J NATL CANC; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Fullwood P, 1999, CANCER RES, V59, P4662; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lerman MI, 2000, CANCER RES, V60, P6116; Partridge M, 1999, INT J CANCER, V83, P318, DOI 10.1002/(SICI)1097-0215(19991029)83:3<318::AID-IJC6>3.0.CO;2-V; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Reed AL, 1996, CANCER RES, V56, P3630; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; VOS MD, 2000, IN PRESS J BIOL CHEM; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349	32	343	381	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2001	20	12					1509	1518		10.1038/sj.onc.1204175	http://dx.doi.org/10.1038/sj.onc.1204175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313894				2022-12-25	WOS:000167595200011
J	Luo, JC; Shibuya, M				Luo, JC; Shibuya, M			A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1 alpha, 2 alpha and 3 alpha)	ONCOGENE			English	Article						nuclear localization signal; hypoxia inducible factor; ubiquitin-proteasome system; von hippellindau tumor suppressor; protein stability	TUMOR-SUPPRESSOR PROTEIN; ARYL-HYDROCARBON RECEPTOR; HIPPEL-LINDAU PROTEIN; EXPORT SIGNALS; EXPRESSION; BINDING; DOMAIN; ALPHA; FACTOR-1-ALPHA; STABILIZATION	Hypoxia inducible factors (HTF1, 2 and 3), consisting of alpha and beta subunits, play an essential role in various responses to hypoxia. Nuclear entry of alpha subunits is a necessary step for the formation of DNA-binding complex with beta subunit, which is constitutively localized in the nucleus. We show here that the nuclear accumulation of HIF2 alpha induced by hypoxia is mediated through a novel variant of bipartite-type nuclear localization signal (NLS) in the C-terminus of the protein, which has an unusual length of spacer sequence between two adjacent basic domains. We further show that when the ubiquitin-proteasome system was deficient or inhibited, HIF2a accumulated in the nucleus even under normoxia, also mediated through the bipartite NLS, These findings indicate that the protein stability is critical for the nuclear localization of HIF2a and hypoxia is not a necessary factor for the process. Importantly, the NLS of HIF2a is also conserved in the other HIF family members, HIF1 alpha and HIF3 alpha. Mutational analyses proved that the NLS mediating the nuclear localization of HIF1 alpha is indeed bipartite-, but not monopartite-type as thought before, Our results suggest that the newly identified NLS is crucial for the functional regulation of HIF family.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan.		Jin Cai, Luo/A-7900-2011					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bear J, 1999, MOL CELL BIOL, V19, P6306; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; Chilov D, 1999, J CELL SCI, V112, P1203; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Luo JC, 1998, CANCER RES, V58, P2652; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	28	65	68	2	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1435	1444		10.1038/sj.onc.1204228	http://dx.doi.org/10.1038/sj.onc.1204228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313887				2022-12-25	WOS:000167595200004
J	Acquati, F; Morelli, C; Cinquetti, R; Bianchi, MG; Porrini, D; Varesco, L; Gismondi, V; Rocchetti, R; Talevi, S; Possati, L; Magnanini, C; Tibiletti, MG; Bernasconi, B; Daidone, MG; Shridhar, V; Smith, DI; Negrini, M; Barbanti-Brodano, G; Taramelli, R				Acquati, F; Morelli, C; Cinquetti, R; Bianchi, MG; Porrini, D; Varesco, L; Gismondi, V; Rocchetti, R; Talevi, S; Possati, L; Magnanini, C; Tibiletti, MG; Bernasconi, B; Daidone, MG; Shridhar, V; Smith, DI; Negrini, M; Barbanti-Brodano, G; Taramelli, R			Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27	ONCOGENE			English	Article						ovarian carcinoma; senescence; chromosome 6q27; Class II tumor suppressor gene; ribonuclease	NON-HODGKIN-LYMPHOMA; 2 DISTINCT REGIONS; CANCER CELL-LINES; SELF-INCOMPATIBILITY; NICOTIANA-ALATA; LONG ARM; BREAST CARCINOMAS; ALLELIC IMBALANCE; EPITHELIAL-CELLS; FREQUENT LOSS	Cytogenetic, molecular and functional analysis has shown that chromosome region 6q27 harbors a senescence inducing gene and a tumor suppressor gene involved in several solid and hematologic malignancies. We have cloned at 6q27 and characterized the RNASE6PL gene which belongs to a family of cytoplasmic RNases highly conserved from plants, to man. Analysis of 55 primary ovarian tumors and several ovarian tumor cell lines indicated that the RNASE6PL gene is not mutated in tumor tissues, but its expression is significantly reduced in 30% of primary ovarian tumors and: in 75% of ovarian tumor cell lines. The promoter region of the gene was unaffected in tumors cell lines. Transfection of RNASE6PL cDNA into HEY4 and SG10G ovarian tumor cell lines suppressed tumorigenicity in nude mice. When tumors were induced by RNASE6PL-transfected cells, they completely lacked expression of RNASE6PL cDNA. Tumorigenicity was suppressed also in RNASE6PL-transfected pRPcT1/ H6c12T cells, derived from a human/mouse monochromosomic hybrid carrying a human chromosome 6 deleted at 6q27. Moreover, 63.6% of HEY4 clones and 42.8% of the clones of XP12ROSV, a Xeroderma pigmentosum SV40-immortalized cell line, transfected with RNASE6PL cDNA, developed a marked senescence process during in vitro growth. We therefore propose that RNASE6PL may be a candidate for the 6q27 senescence inducing and class II tumor suppressor gene in ovarian cancer.	Univ Insubria, Dipartimento Biol Strutturale & Funz, Varese, Italy; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Ancona, Ist Sci Biomed, I-60131 Ancona, Italy; Osped Circolo, Lab Anat Patol, Varese, Italy; Ist Nazl Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA	University of Insubria; University of Ferrara; University of Genoa; IRCCS AOU San Martino IST; Marche Polytechnic University; Ospedale Circolo & Fondazione Macchi; Fondazione IRCCS Istituto Nazionale Tumori Milan; Mayo Clinic	Taramelli, R (corresponding author), Univ Insubria, Dipartimento Biol Strutturale & Funz, Varese, Italy.		Negrini, Massimo/J-2377-2016; smith, jeremy c/B-7287-2012; Varesco, Liliana/AAF-6521-2019; Daidone, Maria Grazia/E-9232-2017	Negrini, Massimo/0000-0002-0007-1920; smith, jeremy c/0000-0002-2978-3227; Varesco, Liliana/0000-0003-4871-6668; Daidone, Maria Grazia/0000-0002-4786-1321; Gismondi, Viviana/0000-0002-1115-0325				Abdollahi A, 1997, CANCER RES, V57, P2029; ACQUATI F, 2000, IN PRESS METH MOL BI; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; ARDELT W, 1991, J BIOL CHEM, V266, P245; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bruening W, 1999, CANCER RES, V59, P4973; BUICK RN, 1985, CANCER RES, V45, P3668; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; COOKE I, 1996, GENE CHROMOSOME CANC, V15, P13; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVELLE P, 1991, ONCOGENE, V6, P1705; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FRANCESCONI M, 1984, CANCER, V53, P1927, DOI 10.1002/1097-0142(19840501)53:9<1927::AID-CNCR2820530920>3.0.CO;2-#; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Garzetti G. G., 1992, European Journal of Gynaecological Oncology, V13, P514; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Hauptschein RS, 1998, GENOMICS, V50, P170, DOI 10.1006/geno.1998.5321; HAYASHI Y, 1990, BLOOD, V76, P1626; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIME G, 1995, GENE, V158, P203, DOI 10.1016/0378-1119(94)00896-Z; Honchel R, 1996, CANCER RES, V56, P145; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lin HC, 1999, CANCER RES, V59, P807; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MEADOR J, 1990, GENE, V95, P1, DOI 10.1016/0378-1119(90)90406-H; MILLIKIN D, 1991, CANCER RES, V51, P5449; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Mok SC, 1996, ONCOGENE, V12, P1895; MORITA R, 1991, CANCER RES, V51, P5817; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; Queimado L, 1998, ONCOGENE, V16, P83, DOI 10.1038/sj.onc.1201480; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; SIMON L, 1981, CARCINOGENESIS, V2, P567, DOI 10.1093/carcin/2.6.567; Smith MR, 1999, EXP CELL RES, V247, P220, DOI 10.1006/excr.1998.4317; Tahara H, 1996, CANCER RES, V56, P599; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1997, BRIT J CANCER, V75, P1831, DOI 10.1038/bjc.1997.312; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214	55	59	65	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					980	988		10.1038/sj.onc.1204178	http://dx.doi.org/10.1038/sj.onc.1204178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314033				2022-12-25	WOS:000167097000009
J	Nip, J; Strom, DK; Eischen, CM; Cleveland, JL; Zambetti, GP; Hiebert, SW				Nip, J; Strom, DK; Eischen, CM; Cleveland, JL; Zambetti, GP; Hiebert, SW			E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation	ONCOGENE			English	Article						E2F-1; p53; stability; cell cycle progression; apoptosis	WILD-TYPE P53; S-PHASE ENTRY; TRANSCRIPTION FACTOR E2F-1; ARF TUMOR-SUPPRESSOR; CELL-CYCLE CONTROL; E1B 19K PROTEIN; RETINOBLASTOMA PROTEIN; GENE-PRODUCT; DNA-SYNTHESIS; P53-DEPENDENT APOPTOSIS	E2F-1 induces p53 accumulation and E2F-1 and p53 form a physical complex, which affects the ability of E2F-1 to activate transcription. We mapped the domains on E2F-1 that interact with p53 and found two p53-binding domains. To understand the functional consequences of the E2F-1/p53 association on p53 activities we identified the domains of E2F-1 that were responsible for the accumulation of p53. Unexpectedly, we found that the E2F-1 transactivation domain was dispensable for p53 induction. By contrast, further deletion of the DP-1 interaction/'marked' box domain eliminated p53 accumulation. Radiolabeling pulse/chase analysis demonstrated that E2F-1 caused post-translational stabilization of p53. Although E2F-1 caused the stabilization of p53, E2F-1 expression impaired p53-dependent transactivation. Thus, the E2F-1:p53 interaction may provide a checkpoint function to inactivate overactive E2F-1, but the association may also inactivate p53 transactivation to allow cell cycle progression.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	Vanderbilt University; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.		Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007	NATIONAL CANCER INSTITUTE [R01CA063230, R01CA064140, R01CA077274, R01CA076379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013726] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA27165, CA76379, CA64140, CA77274, CA63230] Funding Source: Medline; NIA NIH HHS [AG13726] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline; PHS HHS [C09346] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; OLSON DC, 1993, ONCOGENE, V8, P2353; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SALA A, 1994, CANCER RES, V54, P1402; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	83	37	37	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					910	920		10.1038/sj.onc.1204171	http://dx.doi.org/10.1038/sj.onc.1204171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314026				2022-12-25	WOS:000167097000002
J	Stoneley, M; Spencer, JP; Wright, SC				Stoneley, M; Spencer, JP; Wright, SC			An internal ribosome entry segment in the 5 ' untranslated region of the mnt gene	ONCOGENE			English	Article						mnt; 5 ' UTR; internal initiation; IRES	MESSENGER-RNA; C-MYC; TRANSLATION; INITIATION; PROTEIN; REPRESSION; CELLS; SITES; MAX; BIP	Mnt is a transcriptional repressor related to the Myc/ Mad family of transcription factors. It is expressed in proliferating, resting and differentiating cells and is believed to antagonize the function of Myc. Here we have characterized the major transcription initiation site of the mnt gene. In doing so we noted a remarkable level of sequence conservation between the murine and human 5' untranslated regions, Our experiments revealed that this sequence contains an internal ribosome entry segment (IRES), In addition, we show that sequences at both the 5' and 3' end of the IRES are essential for its function. These findings indicate that mnt can be translated by internal initiation. Such a mechanism may allow efficient Mnt synthesis when cap-dependent translation initiation is reduced.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Wright, SC (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.							Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	17	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					893	897		10.1038/sj.onc.1204157	http://dx.doi.org/10.1038/sj.onc.1204157			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314024				2022-12-25	WOS:000166924400014
J	Dihlmann, S; Siermann, A; Doeberitz, MV				Dihlmann, S; Siermann, A; Doeberitz, MV			The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling	ONCOGENE			English	Article						WNT; NSAID; colorectal cancer; transcriptional regulation; tumor prevention	NF-KAPPA-B; BETA-CATENIN; CYCLOOXYGENASE-2 INHIBITORS; COLORECTAL-CANCER; SULINDAC SULFIDE; COLON-CANCER; CYCLIN D1; APC; TARGET; CELLS	Increasing epidemiological and experimental evidence implicates non-steroidal anti-inflanmatory drugs (NSAIDs) as anti-tumorigenic agents. The precise mechanisms whereby NSAIDs exert their anti-neoplastic effects remain poorly understood. Studies from hereditary and sporadic colorectal cancer (CRC) patients suggest that NSAIDs may interfere with initiating steps of carcinogenesis, i.e. disturbances,within the beta -catenin signaling pathway. We therefore investigated beta -catenin/ TCF signaling in response to aspirin or indomethacin, respectively, in four CRC cell lines (SW948, SW480, HCT116, LoVo). Both, aspirin and indomethacin inhibited transcription of a beta -catenin/TCF-responsive reporter gene In a dose dependent manner, In addition, the beta -catenin/TCF transcriptional target cyclin D1 was downregulated by both drugs, Endogenous beta -catenin levels remained unaffected by either drug. Moreover, indirect immunofluorescence studies revealed no significant changes of subcellular beta -catenin localization in either cell line after NSAID treatment, Likewise, binding of the beta -catenin/TCF complex to its specific DNA-binding sites was not altered, as demonstrated by electrophoretic mobility shift assay (EMSA) of nuclear extracts derived from NSAID treated cells, These results strongly suggest that aspirin and indomethacin attenuate the transcription of beta -catenin/TCF-responsive gents, by modulating TCF activity without disrupting beta -catenin/ TCF complex formation.	Heidelberg Univ, Dept Surg, Div Mol Diagnost & Therapy, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Dept Surg, Div Mol Diagnost & Therapy, D-69120 Heidelberg, Germany.			Dihlmann, Susanne/0000-0002-3737-7755				AHNEN DJ, 1988, EUR J SURG S, V582, P111; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bordonaro M, 1999, CELL GROWTH DIFFER, V10, P713; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dihlmann S, 1999, CANCER RES, V59, P1857; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Goodman L. S., 1996, PHARM BASIS THERAPEU; Goppelt-Struebe M, 2000, N-S ARCH PHARMACOL, V361, P636, DOI 10.1007/s002100000231; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Mahmoud NN, 1997, CANCER RES, V57, P5045; Mahmoud NN, 1998, SURGERY, V124, P225, DOI 10.1016/S0039-6060(98)70124-2; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McEntee MF, 1999, CARCINOGENESIS, V20, P635, DOI 10.1093/carcin/20.4.635; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Patten EJ, 1999, CANCER LETT, V147, P95, DOI 10.1016/S0304-3835(99)00282-7; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ricchi P, 1997, INT J CANCER, V73, P880; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Subbegowda R, 1998, CANCER RES, V58, P2772; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	45	163	172	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					645	653		10.1038/sj.onc.1204123	http://dx.doi.org/10.1038/sj.onc.1204123			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313997				2022-12-25	WOS:000166755000012
J	Offer, H; Milyavsky, M; Erez, N; Matas, D; Zurer, I; Harris, CC; Rotter, V				Offer, H; Milyavsky, M; Erez, N; Matas, D; Zurer, I; Harris, CC; Rotter, V			Structural and functional involvement of p53 in BER in vitro and in vivo	ONCOGENE			English	Article						p53; BER; transactivation; DNA repair	NUCLEOTIDE-EXCISION-REPAIR; INHIBITS DNA-REPLICATION; TATA-BINDING PROTEIN; CELL NUCLEAR ANTIGEN; TRANSCRIPTIONAL ACTIVATION; TERMINAL DOMAIN; 3'-TO-5' EXONUCLEASE; WILD-TYPE; IN-VIVO; APOPTOSIS	p53 is involved in several DNA repair pathways. Some of these require the specific transactivation of p53-dependent genes and others involve direct interactions between the p53 protein and DNA repair associated proteins. Previously, we have shown that p53 acts directly in Base Excision Repair (BER) when assayed under in vitro conditions. Our present data indicate that this involvement is independent of the transcriptional activity of the p53 molecule. We found that under both in vitro and in vivo conditions, a p53 transactivation-deficient molecule, p53-22-23,was more efficient in BER activity than was wild type p53. However, mutations in the core domain or C-terminal alterations strongly reduced p53-mediated BER activity, These results are consistent with the hypothesis that the involvement of p53 in BER activity, a housekeeping DNA repair pathway, is a prompt and immediate one that does not involve the activation of D53 transactivation-dependent mechanisms, but rather concerns with the p53 protein itself. In an endogenous DNA damage status p53 is active in BER pathways as a protein and not as a transcription factor.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20896 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Milyavsky, Michael/E-8306-2011	Erez, Neta/0000-0001-6506-9074				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN IT, 1995, ONCOGENE, V11, P1931; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HENDERSON EE, 1989, MUTAT RES, V220, P151, DOI 10.1016/0165-1110(89)90021-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNGER HD, 1994, ANAL BIOCHEM, V217, P98, DOI 10.1006/abio.1994.1088; Hussain SP, 1998, CANCER RES, V58, P4023; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; KANEKO Y, 1995, CANCER LETT, V91, P11, DOI 10.1016/0304-3835(95)03709-6; KASTAN MB, 1991, CANCER RES, V51, P4279; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lloyd DR, 2000, CANCER RES, V60, P517; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Miller DL, 1997, WETLANDS, V17, P31, DOI 10.1007/BF03160716; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Myung K, 1998, P NATL ACAD SCI USA, V95, P7664, DOI 10.1073/pnas.95.13.7664; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Peled A, 1996, CANCER RES, V56, P2148; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang W, 1999, CANCER RES, V59, P2562; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Yokote H, 1998, MUTAT RES-DNA REPAIR, V409, P147, DOI 10.1016/S0921-8777(98)00052-4; Zhou XL, 1999, CANCER RES, V59, P843	48	63	64	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					581	589		10.1038/sj.onc.1204120	http://dx.doi.org/10.1038/sj.onc.1204120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313990	Bronze			2022-12-25	WOS:000166755000005
J	Yu, PW; Huang, B; Shen, M; Lau, C; Chan, E; Michel, J; Xiong, Y; Payan, DG; Luo, Y				Yu, PW; Huang, B; Shen, M; Lau, C; Chan, E; Michel, J; Xiong, Y; Payan, DG; Luo, Y			p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues	ONCOGENE			English	Article						PCNA; p21; tumor; PIP box	CELL NUCLEAR ANTIGEN; C-TERMINAL REGION; D-TYPE CYCLINS; DNA-REPLICATION; BINDING; P21; P21(WAF1/CIP1); PROGNOSIS; INHIBITOR; CARCINOMA	Proliferating cell nuclear antigen (PCNA) is an essential protein in both DNA replication and DNA damage repair. A novel 15 kD protein, p15(PAF), was identified as a PCNA-associated factor in a yeast two-hybrid screen using PCNA as the bait, p15(PAF) is localized primarily in the nucleus. p15(PAF) shares the conserved PCNA binding motif with several other PCNA binding proteins including CDK inhibitor p21. Overexpression of p15(PAF) competes with p21-PCNA binding. Mutation of this motif in p15(PAF) abolished its PCNA-binding activity. Notably, p15(PAF) expression in several types of tumor tissues was significantly increased, especially in esophageal tumors. Like PCNA, p15(PAF) may possess prognostic significance in a broad array of human cancers.	Rigel Pharmaceut Inc, S San Francisco, CA 94080 USA; Univ N Carolina, Lineberger Canc Ctr 22012, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Luo, Y (corresponding author), Rigel Pharmaceut Inc, 240 E Grand Ave, S San Francisco, CA 94080 USA.							Baekelandt M, 1999, CLIN CANCER RES, V5, P2848; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kuwahara M, 1999, DIS ESOPHAGUS, V12, P116, DOI 10.1046/j.1442-2050.1999.00034.x; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Natsugoe S, 1999, CLIN CANCER RES, V5, P2445; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Russell A, 1999, ONCOGENE, V18, P6454, DOI 10.1038/sj.onc.1203030; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	26	90	98	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					484	489		10.1038/sj.onc.1204113	http://dx.doi.org/10.1038/sj.onc.1204113			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313979				2022-12-25	WOS:000166562500008
J	Desbois-Mouthon, C; Cadoret, A; Blivet-Van Eggelpoel, MJ; Bertrand, F; Cherqui, G; Perret, C; Capeau, J				Desbois-Mouthon, C; Cadoret, A; Blivet-Van Eggelpoel, MJ; Bertrand, F; Cherqui, G; Perret, C; Capeau, J			Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3 beta inhibition and Ras activation	ONCOGENE			English	Article						insulin; IGF-1; beta-catenin; PI 3-kinase; GSK-3 beta; Ras	GLYCOGEN-SYNTHASE KINASE-3; GROWTH-FACTOR-II; RECEPTOR SUBSTRATE-1 OVEREXPRESSION; HUMAN HEPATOCELLULAR CARCINOMAS; INTEGRIN-LINKED KINASE; APC TUMOR-SUPPRESSOR; HEPATITIS-B; INCREASED EXPRESSION; SIGNALING PATHWAY; GENE-PRODUCT	We examined the interplay between the insulin/LGF-1- and beta -catenin-regulated pathways, both of which are suspected to play a role in hepatocarcinogenesis. Insulin and IGF-1 stimulated the transcription of a Lef/Tcf-dependent luciferase reporter gene by 3-4-fold in HepG2 cells, This stimulation was mediated through the activation of phosphatidylinositol 3-kinase (PI 3-K)/Akt and the inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) since the effects of insulin and IGF-I were inhibited by dominant-negative mutants of PI 3-K or Akt and an uninhibitable GSK-3 beta. Together with inhibiting GSK-3 beta, insulin and IGF-I increased the cytoplasmic levels of beta -catenin, The PI 3-K/Akt/GSK-3 beta pathway was not the sole to mediate insulin and IGF-1 stimulation of Lef/Tcf-dependent transcription. The Ras signalling pathway was also required as (i) the stimulatory effects of insulin and IGF-I were inhibited by dominant-negative Ras or the MEK1 inhibitor PD98059 and (ii) activated Ha-Res or constitutively active MEK synergized with catalytically inactive GSK-3 beta to stimulate Lef/Tcf-dependent transcription. This study provides the first evidence that insulin and IGF-I stimulate the beta -catenin pathway through tw a signalling cascades bifurcating downstream of PI 3-K and involving GSK-3 beta inhibition and Ras activation. These findings demonstrate for the first time the ability of insulin and IGF-I to activate the beta -catenin pathway in hepatoma cells and thereby provide new insights into the role of these factors in hepatocarcinogenesis.	Univ Paris 06, INSERM U402, F-75571 Paris 12, France; INSERM, U129, ICGM, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Desbois-Mouthon, C (corresponding author), Univ Paris 06, INSERM U402, 27 Rue Chaligny, F-75571 Paris 12, France.		Perret-Mayeux, Christine/L-3297-2017; Cadoret, Axelle/L-2529-2017; Desbois-Mouthon, Christele/M-7076-2017	Cadoret, Axelle/0000-0002-4283-6864; Desbois-Mouthon, Christele/0000-0002-0772-1711; perret, christine/0000-0003-4710-7051				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Buchmann A, 1999, CELL DEATH DIFFER, V6, P190, DOI 10.1038/sj.cdd.4400475; CARIANI E, 1988, CANCER RES, V48, P6844; CARIANI E, 1991, HEPATOLOGY, V13, P644, DOI 10.1002/hep.1840130406; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kim SO, 1996, CANCER RES, V56, P3831; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moradpour D, 1994, J Viral Hepat, V1, P17, DOI 10.1111/j.1365-2893.1994.tb00058.x; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogawa K, 1999, CANCER RES, V59, P1830; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Tanaka S, 1996, CANCER RES, V56, P3391; Tanaka S, 1997, HEPATOLOGY, V26, P598; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Tsujiuchi T, 1999, CANCER RES, V59, P3904; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Weihl CC, 1999, J NEUROSCI, V19, P5360; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	52	265	273	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					252	259		10.1038/sj.onc.1204064	http://dx.doi.org/10.1038/sj.onc.1204064			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313952				2022-12-25	WOS:000166410900012
J	Huang, L; Jacob, RJ; Pegg, SCH; Baldwin, MA; Wang, CC; Burlingame, AL; Babbitt, PC				Huang, L; Jacob, RJ; Pegg, SCH; Baldwin, MA; Wang, CC; Burlingame, AL; Babbitt, PC			Functional assignment of the 20 S proteasome from Trypanosoma brucei using mass spectrometry and new bioinformatics approaches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SUBSTITUTION MATRICES; PROTEIN IDENTIFICATION; ELECTROSPRAY IONIZATION; RAPID IDENTIFICATION; SEQUENCE DATABASES; ALIGNMENT; INFORMATION; GENERATION; PEPTIDES	As experimental technologies for characterization of proteomes emerge, bioinformatic analysis of the data becomes essential. Separation and identification technologies currently based on two-dimensional gels/mass spectrometry provide the inherent analytical power required. This strategy involves protein spot digestion and accurate mass mapping together with computational interrogation of available data bases for protein functional identification. When either no exact match is found or when the possible matches only partially account for molecular weights actually observed, peptide sequencing by tandem mass spectrometry has emerged as the methodology of choice to provide the basic additional information required. To evaluate the capabilities of bioinformatics methods employed for identifying homologs of a protein of interest, we attempted to identify the major proteins from the 20 S proteasome of Trypanosoma brucei using sequence information determined using mass spectrometry. The results suggest that neither the traditional query engines, BLAST and FASTA, nor specialized software developed for analysis of sequence information obtained by mass spectrometry are able to identify even closely related sequences at statistically significant scores. To address this deficit, new bioinformatics approaches were developed for concomitant use of the multiple fragments of short sequence typically available from methods of tandem mass spectrometry. These approaches rely on the occurrence of congruence across searches of multiple fragments from a single protein. This method resulted in sharply better statistical significance values for correct hits in the data base output relative to that achieved for independent searches using single sequence fragments.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Babbitt, PC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	babbitt@cgl.ucsf.edu	Huang, Lan/C-3618-2011	Jacob, Richard/0000-0003-0910-5282	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060595] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614] Funding Source: Medline; NIAID NIH HHS [R01 AI21786] Funding Source: Medline; NIGMS NIH HHS [R01 GM60595] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baker AS, 1998, BIOCHEMISTRY-US, V37, P9305, DOI 10.1021/bi972677d; BAKER P, PROTEIN PROSPECTOR V; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; Chang WWP, 2000, PLANT PHYSIOL, V122, P295, DOI 10.1104/pp.122.2.295; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 2000, CURR OPIN CHEM BIOL, V4, P489, DOI 10.1016/S1367-5931(00)00121-6; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Hua SB, 1996, MOL BIOCHEM PARASIT, V78, P33, DOI 10.1016/S0166-6851(96)02599-6; Huang L, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P217; Huang L, 1999, MOL BIOCHEM PARASIT, V102, P211, DOI 10.1016/S0166-6851(99)00096-1; JAMES P, 1993, BIOCHEM BIOPH RES CO, V195, P58, DOI 10.1006/bbrc.1993.2009; JIMENEZ CR, 1998, CURRENT PROTOCOLS PR; Johnson RS, 2000, METH MOL B, V146, P41, DOI 10.1385/1-59259-045-4:41; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Lander ES, 2000, SCIENCE, V287, P1777, DOI 10.1126/science.287.5459.1777; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Medzihradszky Katalin F., 1994, Methods (Orlando), V6, P284, DOI 10.1006/meth.1994.1030; Medzihradszky KF, 2000, ANAL CHEM, V72, P552, DOI 10.1021/ac990809y; Medzihradszky KF, 2001, J AM SOC MASS SPECTR, V12, P215, DOI 10.1016/S1044-0305(00)00214-2; Monaco JJ, 1995, ANNU REV GENET, V29, P729, DOI 10.1146/annurev.ge.29.120195.003501; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pegg SCH, 1999, BIOINFORMATICS, V15, P729, DOI 10.1093/bioinformatics/15.9.729; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qin J, 1997, ANAL CHEM, V69, P3995, DOI 10.1021/ac970488v; Qiu YC, 1998, J BIOL CHEM, V273, P17940, DOI 10.1074/jbc.273.28.17940; QU K, 2000, CURRENTS COMPUTATION, P139; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; Taylor JA, 1997, RAPID COMMUN MASS SP, V11, P1067, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1067::AID-RCM953>3.0.CO;2-L; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vestal M, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P1; Xu L, 1999, BIOCHEMISTRY-US, V38, P7659, DOI 10.1021/bi990103y; YATES JR, 1993, ANAL BIOCHEM, V214, P397, DOI 10.1006/abio.1993.1514	49	68	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28327	28339		10.1074/jbc.M008342200	http://dx.doi.org/10.1074/jbc.M008342200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11309374	hybrid			2022-12-25	WOS:000170093400079
J	Dupont, J; Fernandez, AM; Glackin, CA; Helman, L; LeRoith, D				Dupont, J; Fernandez, AM; Glackin, CA; Helman, L; LeRoith, D			Insulin-like growth factor 1 (IGF-1)-induced Twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE-ACTIVITY; BHLH PROTEIN TWIST; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; INHIBITS APOPTOSIS; CELL-DEATH; ANNEXIN-V; ACTIVATION; DIFFERENTIATION	In this study we investigated the molecular mechanisms whereby insulin-like growth factor 1 (IGF-1) induced Twist gene expression and the role of Twist in the anti-apoptotic actions of the IGF-1 receptor. In NIH-3T3 fibroblasts overexpressing the human IGF-1 receptor (NWTb3), treatment with IGF-1 (10(-8) M) for 1 and 4 h increased the level of Twist mRNA as well as protein by 3-fold. In contrast, insulin at physiological concentrations did not stimulate Twist expression in NIH-3T3 fibroblasts overexpressing the human insulin receptor. The IGF-1 effect was specific for the IGF-1 receptor since, in cells overexpressing a dominant negative IGF-1 receptor, IGF-1 failed to increase Twist expression. Preincubation with the ERK1/2 inhibitor U0126 or expression of a dominant negative MEK-1 abolished the effect of IGF-1 on Twist mRNA expression in NWTb3 cells, suggesting that Twist induction by IGF-1 occurs via the mitogen-activated protein kinase signaling pathway. In vivo, IGF-1 injection increased the mRNA level of Twist in mouse skeletal muscle, the major site of Twist expression. Finally, using an antisense strategy, we demonstrated that a reduction of 40% in Twist expression decreased significantly the ability of IGF-1 to rescue NWTb3 cells from etoposide-induced apoptosis, Taken together, these results define Twist as an important factor involved in the anti-apoptotic actions of the IGF-1 receptor.	NIDDK, Clin Endocrinol Branch, Sect Mol & Cell Physiol, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City of Hope; Beckman Research Institute of City of Hope	LeRoith, D (corresponding author), NIDDK, Clin Endocrinol Branch, Sect Mol & Cell Physiol, NIH, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.	derek@helix.nih.gov		Fernandez, Ana M./0000-0001-5160-3854				Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; Bourez RLJH, 1997, J CRANIOFAC SURG, V8, P441, DOI 10.1097/00001665-199711000-00002; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1997, CANCER RES, V57, P3264; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; Dunn SE, 1997, CANCER RES, V57, P2687; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Harrrison M, 1998, FEBS LETT, V435, P207, DOI 10.1016/S0014-5793(98)01051-5; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Hsing AY, 1996, CANCER RES, V56, P5146; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; KATO H, 1993, J BIOL CHEM, V268, P2655; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leshem Y, 2000, J CELL PHYSIOL, V184, P101, DOI 10.1002/(SICI)1097-4652(200007)184:1<101::AID-JCP11>3.0.CO;2-D; LEVYTOLEDANO R, 1993, BIOCHIM BIOPHYS ACTA, V1220, P1, DOI 10.1016/0167-4889(93)90090-C; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V273, P322, DOI 10.1006/bbrc.2000.2934; Mooney A, 1997, J IMMUNOL, V159, P3949; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Parrizas M, 1997, J BIOL CHEM, V272, P154; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SELL C, 1995, CANCER RES, V55, P303; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang SM, 1997, GENE, V187, P83, DOI 10.1016/S0378-1119(96)00727-5; Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	56	85	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26699	26707		10.1074/jbc.M102664200	http://dx.doi.org/10.1074/jbc.M102664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11323435	Green Submitted, hybrid			2022-12-25	WOS:000169823300137
J	Imbriano, C; Bolognese, F; Gurtner, A; Piaggio, G; Mantovani, R				Imbriano, C; Bolognese, F; Gurtner, A; Piaggio, G; Mantovani, R			HSP-CBF is an NF-Y-dependent coactivator of the heat shock promoters CCAAT boxes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE-CELL LINES; BINDING-FACTOR; TRANSCRIPTIONAL ACTIVATION; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; REGULATORY ELEMENT; GRP78/BIP PROMOTER; IN-VIVO; C-MYC; GENE	The cellular response to toxic stimuli is elicited through the expression of heat shock proteins, a transcriptional process that relies upon conserved DNA elements in the promoters: the Heat Shock Elements, activated by the heat shock factors, and the CCAAT boxes. The identity of the CCAAT activator(s) is unclear because two distinct entities, NF-Y and HSP-CBF, have been implicated in the HSP70 system, The former is a conserved ubiquitous trimer containing histone-like subunits, the latter a 110-kDa protein with an acidic N-terminal, We analyzed two CCAAT-containing promoters, HSP70 and HSP40, with recombinant NF-Y and HSP-CBF using electrophoretic mobility shift assay, protein-protein interactions, transfections and chromatin immunoprecipitation assays (ChIP) assays. Both recognize a common DNA-binding protein in nuclear extracts, identified in vitro and in vivo as NF-Y, Both CCAAT boxes show high affinity for recombinant NF-Y but not for HSP-CBF, However, HSP-CBF does activate HSP70 and HSP40 transcription under basal and heat shocked conditions; for doing so, it requires an intact NF-Y trimer as judged by cotransfections with a diagnostic NF-YA dominant negative vector. HSP-CBF interacts in solution and on DNA with the NF-Y trimer through an evolutionary conserved region. In yeast two-hybrid assays HSP-CBF interacts with NF-YB, These data implicate HSP-CBF as a non-DNA binding coactivator of heat shock genes that act on a DNA-bound NF-Y.	Univ Modena, Dipartimento Biol Anim, I-41100 Modena, Italy; Univ Milan, Dipartimento Genet & Biol Microorganismi, I-20133 Milan, Italy; Ist Regina Elena, Ctr Ricerca Sperimentale, I-00161 Rome, Italy	Universita di Modena e Reggio Emilia; University of Milan; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Mantovani, R (corresponding author), Univ Modena, Dipartimento Biol Anim, Via Campi 213-D, I-41100 Modena, Italy.		Gurtner, Aymone/J-7217-2018; Imbriano, Carol/C-9376-2015; Piaggio, Giulia/J-7214-2018; Imbriano, Carol/ABD-8204-2021; gurtner, aymone/AAB-8843-2020; Piaggio, Giulia/AAD-7336-2022	Gurtner, Aymone/0000-0002-7661-9059; Imbriano, Carol/0000-0003-2864-4820; Piaggio, Giulia/0000-0003-2114-1892; Imbriano, Carol/0000-0003-2864-4820; gurtner, aymone/0000-0002-7661-9059; 				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; AGOFF SN, 1994, ONCOGENE, V9, P3707; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BONNYCASTLE LLC, 1994, GENOMICS, V23, P85, DOI 10.1006/geno.1994.1462; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Dix DJ, 1996, DEV BIOL, V174, P310, DOI 10.1006/dbio.1996.0076; Edskes HK, 1998, J BIOL CHEM, V273, P28912, DOI 10.1074/jbc.273.44.28912; GORZOWSKI JJ, 1995, J BIOL CHEM, V270, P26940, DOI 10.1074/jbc.270.45.26940; GREENE JM, 1990, MOL CELL BIOL, V10, P1319, DOI 10.1128/MCB.10.4.1319; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Hata M, 1998, BBA-GENE STRUCT EXPR, V1397, P43, DOI 10.1016/S0167-4781(97)00208-X; Hoeppner MA, 1996, NUCLEIC ACIDS RES, V24, P1091, DOI 10.1093/nar/24.6.1091; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; James P, 1996, GENETICS, V144, P1425; Jayasena SMT, 1999, INT J PARASITOL, V29, P581, DOI 10.1016/S0020-7519(99)00002-8; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LEJOHN HB, 1994, J BIOL CHEM, V269, P4513; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Lis JT, 2000, GENE DEV, V14, P792; LISOWSKA K, 1994, BBA-GENE STRUCT EXPR, V1219, P64, DOI 10.1016/0167-4781(94)90247-X; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Mayer MP, 1998, BIOL CHEM, V379, P261; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Molina A, 2000, FEBS LETT, V474, P5, DOI 10.1016/S0014-5793(00)01538-6; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MORIMOTO RI, 1986, J BIOL CHEM, V261, P2692; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; MULLER FW, 1992, GENE, V111, P165, DOI 10.1016/0378-1119(92)90684-H; Ohtsuka K, 2000, INT J HYPERTHER, V16, P231, DOI 10.1080/026567300285259; OVSENEK N, 1990, DEV GENET, V11, P97, DOI 10.1002/dvg.1020110111; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; RIEPING M, 1992, MOL GEN GENET, V231, P226, DOI 10.1007/BF00279795; ROY B, 1995, MOL CELL BIOL, V15, P2263; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Tom M, 1999, BIOCHEM BIOPH RES CO, V262, P103, DOI 10.1006/bbrc.1999.1165; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; Yasuda K, 1999, BIOCHEM BIOPH RES CO, V256, P75, DOI 10.1006/bbrc.1999.0283; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	59	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26332	26339		10.1074/jbc.M101553200	http://dx.doi.org/10.1074/jbc.M101553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11306579	hybrid			2022-12-25	WOS:000169823300092
J	Nakajima, J; Tanaka, Y; Yamazaki, M; Saito, K				Nakajima, J; Tanaka, Y; Yamazaki, M; Saito, K			Reaction mechanism from leucoanthocyanidin to anthocyanidin 3-glucoside, a key reaction for coloring in anthocyanin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETUNIA-HYBRIDA; UDP-GLUCOSE; FLAVANONE 3-BETA-HYDROXYLASE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR-CLONING; ANTIRRHINUM-MAJUS; FLAVONOL SYNTHASE; GENES; EXPRESSION; ENZYMES	In the conversion from colorless leucoanthocyanidin to colored anthocyanidin 5-glucoside, at least two enzymes, anthocyanidin synthase (ANS) and UDP-glucose: flavonoid 3-O-glucosyltransferase (3-GT), are postulated to be involved. Despite the importance of this reaction sequence for coloring in anthocyanin biosynthesis, the biochemical reaction mechanism has not been clarified, and the possible involvement of a dehydratase has not been excluded. Here we show that recombinant ANSs from several model plant species, snapdragon, petunia, torenia, and maize, catalyze the formation of anthocyanidin in vitro through a 2-oxoglutarate-dependent oxidation of leucoanthocyanidin, Crude extracts of Escherichia coli, expressing recombinant ANSs from these plant species, and purified recombinant enzymes of petunia and maize catalyzed the formation of anthocyanidin in the presence of ferrous ion, 8-oxoglutarate, and ascorbate, The in vitro formation of colored cyanidin 5-glucoside from leucocyanidin, via a cyanidin intermediate, was demonstrated using petunia ANS and 3-GT, The entire reaction sequence did not require any additional dehydratase but was dependent on moderate acidic pH conditions following the enzymatic steps. The present study indicated that the in vivo cytosolic reaction sequence involves an ANS-catalyzed 8-oxogiutarate-dependent conversion of leucoanthocyanidin (flavan3,4-cis-diol) to 3-flaven-2,3-diol (pseudobase), most probably through 2,3-desaturation and isomerization, followed by glucosylation at the C-3 position by 3-GT.	Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Inage Ku, Chiba 2638522, Japan; Suntory Ltd, Inst Fundamental Res, Mishima, Osaka 6188503, Japan	Chiba University; Suntory Holdings Ltd	Saito, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.	ksaito@p.chiba-u.ac.jp	Yamazaki, Mami/A-9050-2010; Saito, Kazuki/D-2670-2009	Yamazaki, Mami/0000-0001-6157-5287; Saito, Kazuki/0000-0001-6310-5342				AKHTAR M, 1991, NAT PROD REP, V8, P527, DOI 10.1039/np9910800527; ATTWOOD MR, 1983, J CHEM SOC PERK T 1, P2229, DOI 10.1039/p19830002229; BALDWIN JE, 1987, J CHEM SOC CHEM COMM, P1654, DOI 10.1039/c39870001654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V282, P152, DOI 10.1016/0003-9861(90)90099-K; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V276, P348, DOI 10.1016/0003-9861(90)90731-D; BRITSCH L, 1992, J BIOL CHEM, V267, P5380; BROUILLARD R, 1990, CAN J CHEM, V68, P755, DOI 10.1139/v90-119; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; DAVIES KM, 1993, PLANT PHYSIOL, V103, P1015, DOI 10.1104/pp.103.3.1015; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; DOONER HK, 1977, P NATL ACAD SCI USA, V74, P5623, DOI 10.1073/pnas.74.12.5623; Ebel J., 1982, FLAVONOIDS ADV RES, P641; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; HELLER W, 1988, FLAVONOIDS ADV RES 1, P399; HELLER W, 1986, FLAVONOIDS ADV RES S, P499; HOLTON TA, 1993, PLANT J, V4, P1003, DOI 10.1046/j.1365-313X.1993.04061003.x; HOLTON TA, 1995, PLANT CELL, V7, P1071, DOI 10.1105/tpc.7.7.1071; KAMSTEEG J, 1978, BIOCHEM GENET, V16, P1045, DOI 10.1007/BF00484525; KHO KFF, 1978, Z PFLANZENPHYSIOL, V88, P449, DOI 10.1016/S0044-328X(78)80261-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN C, 1991, PLANT J, V1, P37, DOI 10.1111/j.1365-313X.1991.00037.x; Martin C, 1992, MOL BIOL FLOWERS, P219; MENSSEN A, 1990, EMBO J, V9, P3051, DOI 10.1002/j.1460-2075.1990.tb07501.x; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; NAKAJIMA J, 2000, PLANT BIOTECHNOL-NAR, V17, P331; Nakanishi K., 1999, COMPREHENSIVE NATURA, V1, P713; Pelletier MK, 1997, PLANT PHYSIOL, V113, P1437, DOI 10.1104/pp.113.4.1437; Prescott AG, 1996, ANNU REV PLANT PHYS, V47, P245, DOI 10.1146/annurev.arplant.47.1.245; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; REDDY GM, 1962, SCIENCE, V138, P149, DOI 10.1126/science.138.3537.149; Rosati C, 1999, PLANT SCI, V149, P73, DOI 10.1016/S0168-9452(99)00146-6; RUHNAU B, 1988, PHYTOCHEMISTRY, V27, P1035, DOI 10.1016/0031-9422(88)80268-1; Saito K, 1999, PLANT J, V17, P181, DOI 10.1046/j.1365-313X.1999.00365.x; SPARVOLI F, 1994, PLANT MOL BIOL, V24, P743, DOI 10.1007/BF00029856; STAFFORD HA, 1985, PHYTOCHEMISTRY, V24, P333; STAFFORD HA, 1984, PLANT PHYSIOL, V76, P184, DOI 10.1104/pp.76.1.184; STEAHELIN LA, 2000, BIOCH MOL BIOL PLANT, P2; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; Tanaka Y, 1998, PLANT CELL PHYSIOL, V39, P1119, DOI 10.1093/oxfordjournals.pcp.a029312; WEISS D, 1993, PLANT MOL BIOL, V22, P893, DOI 10.1007/BF00027374	42	110	139	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25797	25803		10.1074/jbc.M100744200	http://dx.doi.org/10.1074/jbc.M100744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316805	hybrid			2022-12-25	WOS:000169823300023
J	Kang, Q; Cao, Y; Zolkiewska, A				Kang, Q; Cao, Y; Zolkiewska, A			Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85 alpha activates phosphatidylinositol 3-kinase in C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; CYSTEINE-RICH DOMAIN; MELTRIN-ALPHA; PHOSPHOINOSITIDE 3-KINASES; SIGNALING PATHWAYS; MYOBLAST FUSION; MUSCLE-CELLS; DIFFERENTIATION; MYOGENESIS; BINDING	ADAM 12, a member of the ADAM family of transmembrane metalloprotease-disintegrins, has been implicated previously in the differentiation of skeletal myoblasts. In the present study, we show that the cytoplasmic tail of mouse ADAM 12 interacts in vitro and in vivo with the Src homology 3 domain of the p85 alpha regulatory subunit of phosphatidylinositol (PI) 3-kinase, By site-directed mutagenesis, we have identified three p85 alpha -binding sites in ADAM 12 involving PXXP motifs located at amino acids 825-828, 833-836, and 884-887, Using green fluorescent protein (GFP)-pleckstrin homology (PH) domain fusion protein as a probe for PI 3-kinase lipid products, we have further demonstrated that expression of ADAM 12 in C2C12 cells resulted in translocation of c;FP-PH to the plasma membrane. This suggests that transmembrane ADAM 12, by providing docking sites for the Src homology 3 domain of p85 alpha, activates PI 3-kinase by mediating its recruitment to the membrane. Because PI 3-kinase is critical for terminal differentiation of myoblasts, and because expression of ADAM 12 is up-regulated at the onset of the differentiation process, ADAM 12-mediated activation may constitute one of the regulatory mechanisms for PI I-kinase during myoblast differentiation.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Zolkiewska, A (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.	zolkiea@ksu.edu			NIAMS NIH HHS [AR 45787] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045787] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Bornemann A, 2000, J MUSCLE RES CELL M, V21, P475, DOI 10.1023/A:1005657607591; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Schlondorff J, 1999, J CELL SCI, V112, P3603; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	37	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24466	24472		10.1074/jbc.M101162200	http://dx.doi.org/10.1074/jbc.M101162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313349	hybrid			2022-12-25	WOS:000169800700008
J	Aro, N; Saloheimo, A; Ilmen, M; Penttila, M				Aro, N; Saloheimo, A; Ilmen, M; Penttila, M			ACEII, a novel transcriptional activator involved in regulation of cellulase and xylanase genes of Trichoderma reesei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; SACCHAROMYCES-CEREVISIAE; AFLATOXIN BIOSYNTHESIS; CELLOBIOHYDROLASE I; AMDS GENE; EXPRESSION; NIGER; XLNR; TRANSFORMATION; ENDOGLUCANASE	A novel yeast-based method to isolate transcriptional activators was applied to clone regulators binding to the cellulase promoter cbh1 of the filamentous fungus Trichoderma reesei (Hypocrea jecorina). This led to the isolation of the cellulase activator ace2 encoding for a protein belonging to the class of zinc binuclear cluster proteins found exclusively in fungi. The DNA-binding domain of ACEII was expressed as a glutathione S-transferase fusion protein in Escherichia coli, and ACEII was shown to bind in vitro to the 5'-GGCTAATAA site present in the cbh1 promoter. This site also contains the proposed binding sequence of the xylanase activator XlnR of Aspergillus niger. Mutation of the GGC triplet abolished ACEII binding. The function of ACEII was studied by analyzing the effects of ace2 deletion in the hypercellulolytic T. reesei strain ALKO2221. Deletion of the ace2 gene led to lowered induction kinetics of mRNAs encoding the major cellulases cellobiohydrolases I and II and endoglucanases I and II and to 30-70% reduced cellulase activity when the fungus was grown on medium containing Solka flee cellulose. The expression level of the gene encoding xylanase was also affected. ace2 deletion led to lowered xyn2 expression in cellulose-induced cultivation. Cellulase induction by so. phorose was not affected by ace2 deletion.	VTT Biotechnol, FIN-02044 Espoo, Finland	VTT Technical Research Center Finland	Aro, N (corresponding author), VTT Biotechnol, Tietotie 2,POB 1500, FIN-02044 Espoo, Finland.	nina.aro@vtt.fi	Penttilä, Merja E/A-4710-2013	Penttila, Merja/0000-0002-6929-1032				BAILEY MJ, 1981, ENZYME MICROB TECH, V3, P153, DOI 10.1016/0141-0229(81)90076-4; CHANG PK, 1995, APPL ENVIRON MICROB, V61, P2372, DOI 10.1128/AEM.61.6.2372-2377.1995; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; DURAND H, 1988, ENZYME MICROB TECH, V10, P341, DOI 10.1016/0141-0229(88)90012-9; Gielkens MMC, 1999, APPL ENVIRON MICROB, V65, P4340; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gritzali M., 1979, HYDROLYSIS CELLULOSE, V181, P237, DOI DOI 10.1021/BA-1979-0181.CH012; HenriqueSilva F, 1996, BIOCHEM BIOPH RES CO, V228, P229, DOI 10.1006/bbrc.1996.1646; Ilmen M, 1996, MOL GEN GENET, V251, P451, DOI 10.1007/s004380050189; Ilmen M, 1997, APPL ENVIRON MICROB, V63, P1298; Ilmen M, 1996, MOL GEN GENET, V253, P303, DOI 10.1007/s004380050326; KUBICEK CP, 1998, REGULATION PRODUCTIO; LITTLEJOHN TG, 1992, MOL GEN GENET, V235, P81, DOI 10.1007/BF00286184; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH RL, 1994, CURR GENET, V25, P567, DOI 10.1007/BF00351679; MANDELS M, 1962, J BACTERIOL, V83, P400, DOI 10.1128/JB.83.2.400-408.1962; MargollesClark E, 1997, J BIOTECHNOL, V57, P167, DOI 10.1016/S0168-1656(97)00097-7; Narendja FM, 1999, MOL CELL BIOL, V19, P6523; NISIZAWA T, 1971, J BIOCHEM-TOKYO, V70, P375, DOI 10.1093/oxfordjournals.jbchem.a129652; PENTTILA M, 1987, GENE, V61, P155, DOI 10.1016/0378-1119(87)90110-7; PENTTILA ME, 1988, GENE, V63, P103, DOI 10.1016/0378-1119(88)90549-5; PENTTILA ME, 1987, YEAST, V3, P175; SAARELAINEN R, 1993, MOL GEN GENET, V241, P497, DOI 10.1007/BF00279891; Saloheimo A, 2000, J BIOL CHEM, V275, P5817, DOI 10.1074/jbc.275.8.5817; SALOHEIMO M, 1988, GENE, V63, P11, DOI 10.1016/0378-1119(88)90541-0; SHERMAN F, 1981, GUIDE YEAST GENETICS; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Todd RB, 1997, MOL GEN GENET, V254, P495, DOI 10.1007/s004380050444; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; TORRONEN A, 1992, BIO-TECHNOL, V10, P1461, DOI 10.1038/nbt1192-1461; VAHERI M, 1979, BIOTECHNOLOGY, V1, P696; van Peij NNME, 1998, MOL MICROBIOL, V27, P131, DOI 10.1046/j.1365-2958.1998.00666.x; van Peij NNME, 1998, APPL ENVIRON MICROB, V64, P3615; VANHANEN S, 1989, CURR GENET, V15, P181, DOI 10.1007/BF00435504; VANTILBEURGH H, 1982, FEBS LETT, V149, P152, DOI 10.1016/0014-5793(82)81092-2; WOLOSHUK CP, 1994, APPL ENVIRON MICROB, V60, P2408, DOI 10.1128/AEM.60.7.2408-2414.1994; Zeilinger S, 1996, J BIOL CHEM, V271, P25624, DOI 10.1074/jbc.271.41.25624	38	241	293	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24309	24314		10.1074/jbc.M003624200	http://dx.doi.org/10.1074/jbc.M003624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11304525	hybrid			2022-12-25	WOS:000169531100142
J	Benson, MA; Newey, SE; Martin-Rendon, E; Hawkes, R; Blake, DJ				Benson, MA; Newey, SE; Martin-Rendon, E; Hawkes, R; Blake, DJ			Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; NITRIC-OXIDE SYNTHASE; ALPHA-DYSTROBREVIN; BETA-DYSTROBREVIN; SYNTROPHIN; TORPEDO; LOCALIZATION; SARCOLEMMA; COMPLEX; BINDING	The dystrophin-associated protein complex (DPC) is required for the maintenance of muscle integrity during the mechanical stresses of contraction and relaxation. In addition to providing a membrane scaffold, members of the DPC such as the alpha -dystrobrevin protein family are thought to play an important role in intracellular signal transduction. To gain additional insights into the function of the DPC, we performed a yeast two-hybrid screen for dystrobrevin-interacting proteins. Here we describe the identification of a dysbindin, a novel dystrobrevin-binding protein. Dysbindin is an evolutionary conserved 40-kDa coiled-coil-containing protein that binds to alpha- and beta -dystrobrevin in muscle and brain. Dystrophin and alpha -dystrobrevin are co-immunoprecipitated with dysbindin, indicating that dysbindin is DPC-associated in muscle. Dysbindin co-localizes with alpha -dystrobrevin at the sarcolemma and is up-regulated in dystrophin-deficient muscle. In the brain, dysbindin is found primarily in axon bundles and especially in certain axon terminals, notably messy fiber synaptic terminals in the cerebellum and hippocampus. These findings have implications for the molecular pathology of Duchenne muscular dystrophy and may provide an alternative route for anchoring dystrobrevin and the DPC to the muscle membrane.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Calgary, Fac Med, Dept Cell Biol & Anat & Genes, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dev Res Grp, Calgary, AB T2N 4N1, Canada	University of Oxford; University of Oxford; University of Calgary; University of Calgary		dblake@enterprise.molbiol.ox.ac.uk	Hawkes, Richard/F-7971-2011	Benson, Matthew/0000-0003-4459-0439				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong CL, 2000, J COMP NEUROL, V416, P383, DOI 10.1002/(SICI)1096-9861(20000117)416:3<383::AID-CNE9>3.0.CO;2-M; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; Blank M, 1999, EUR J NEUROSCI, V11, P2121, DOI 10.1046/j.1460-9568.1999.00636.x; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; Crosbie RH, 2000, HUM MOL GENET, V9, P2019, DOI 10.1093/hmg/9.13.2019; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Gee SH, 1998, J NEUROSCI, V18, P128; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Jaarsma D, 1997, PROG BRAIN RES, V114, P67; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; Knuesel I, 2000, J COMP NEUROL, V422, P594, DOI 10.1002/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; Michalak M, 1997, CURR OPIN NEUROL, V10, P436, DOI 10.1097/00019052-199710000-00014; Nawrotzki R, 1998, J CELL SCI, V111, P2595; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; NGUYEN TM, 1992, BIOCHEM J, V288, P663, DOI 10.1042/bj2880663; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SCHOFIELD JN, 1994, HUM MOL GENET, V3, P1309; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; UEDA H, 1995, INVEST OPHTH VIS SCI, V36, P2318; Ueda H, 2000, NEUROSCI LETT, V283, P121, DOI 10.1016/S0304-3940(00)00925-3; Vainzof M, 1996, HUM MOL GENET, V5, P1963, DOI 10.1093/hmg/5.12.1963; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R	52	256	270	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24232	24241		10.1074/jbc.M010418200	http://dx.doi.org/10.1074/jbc.M010418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316798	hybrid			2022-12-25	WOS:000169531100132
J	Bregoli, L; Baldassare, JJ; Raben, DM				Bregoli, L; Baldassare, JJ; Raben, DM			Nuclear diacylglycerol kinase-theta is activated in response to alpha-thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; RAT-LIVER NUCLEI; SWISS 3T3 CELLS; PHOSPHOLIPASE-D; LYMPHOCYTE-PROLIFERATION; INDUCED TRANSLOCATION; CULTURED FIBROBLASTS; SIGNAL-TRANSDUCTION; CALCIUM-BINDING; GROWTH-FACTOR	Currently, there is substantial evidence that nuclear lipid metabolism plays a critical role in a number of signal transduction cascades. Previous work from our laboratory showed that stimulation of quiescent fibroblasts with Lu-thrombin leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate phosphatidic acid. Diacylglycerol kinase (DGK) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component. There is substantial evidence that this activity is indeed regulated in a number of signaling cascades (reviewed by van Blitterswijk, W.J., and Houssa, B. (1999) Chem. Phys. Lipids 98, 95-108). In this report, we show that the addition of cr-thrombin to quiescent IIC9 fibroblasts results in an increase in nuclear DGK activity. The examination of nuclei isolated from quiescent IIC9 cells indicates that DGK-theta and DGK-delta are both present. We took advantage of the previous observations that phosphatidylserine inhibits DGK-delta (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol. Chem. 271, 8394-8401), and constitutively active RhoA inhibits DGK-theta (reviewed by Houssa, B., de Widt, J., Kranenburg, O., Moolenaar, W. H., and van Blitterswijk, W. J. (1999) J. Biol Chem. 274, 6820-6822) to identify the activity induced by Lv-thrombin. Constitutively active RhoA inhibited the nuclear stimulated activity, whereas phosphatidylserine did not have an inhibitory effect. In addition, a monoclonal anti-DGK-theta antibody inhibited the alpha -thrombin-stimulated nuclear activity in vitro. These results demonstrate that DGK-theta is the isoform responsive to alpha -thrombin stimulation. Western blot and immunofluorescence microscopy analyses showed that cr-thrombin induced the translocation of DGK-theta to the nucleus, implicating that this translocation is at least partly responsible for the increased nuclear activity. Taken together, these data are the first to demonstrate an agonist-induced activity of nuclear DGK-theta activity and a nuclear localization of DGK-delta.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Johns Hopkins University; Saint Louis University	Raben, DM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.			Bregoli, Lisa/0000-0001-9376-1914	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059251] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSSEL C, 1992, CELL IMMUNOL, V139, P333, DOI 10.1016/0008-8749(92)90075-Z; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; BROCK TG, 1994, J BIOL CHEM, V269, P22059; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P526, DOI 10.1021/bi00168a018; JIMENEZ B, 1988, BIOCHEM BIOPH RES CO, V150, P118, DOI 10.1016/0006-291X(88)90494-9; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KATO H, 1988, BIOCHEM BIOPH RES CO, V154, P959, DOI 10.1016/0006-291X(88)90233-1; KATO M, 1989, FEBS LETT, V247, P247, DOI 10.1016/0014-5793(89)81345-6; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Liu ZT, 2001, J BIOL CHEM, V276, P5900, DOI 10.1074/jbc.M007311200; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MARONEY AC, 1989, J CELL BIOCHEM, V40, P165, DOI 10.1002/jcb.240400205; Martelli AM, 2000, CANCER RES, V60, P815; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; Nobe K, 1997, BIOCHEM PHARMACOL, V53, P1683, DOI 10.1016/S0006-2952(97)82454-9; NOBE K, 1995, BIOCHEM PHARMACOL, V50, P591, DOI 10.1016/0006-2952(95)00184-2; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; OHANIAN J, 1994, BIOCHEM J, V300, P51, DOI 10.1042/bj3000051; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PREVIATI M, 1994, CELL SIGNAL, V6, P393, DOI 10.1016/0898-6568(94)90086-8; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; Raben DM, 2000, ADV ENZYME REGUL, V40, P97, DOI 10.1016/S0065-2571(99)00023-0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; SMITH CD, 1983, J BIOL CHEM, V258, P9368; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; VANDERKLIS FRM, 1993, INT J BIOCHEM, V25, P575, DOI 10.1016/0020-711X(93)90666-3; Wada I, 1996, FEBS LETT, V393, P48, DOI 10.1016/0014-5793(96)00857-5; Walker AJ, 2001, BIOCHEM J, V353, P129, DOI 10.1042/bj3530129; WANG YL, 1993, J BIOL CHEM, V268, P5899; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	49	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23288	23295		10.1074/jbc.M101501200	http://dx.doi.org/10.1074/jbc.M101501200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309392	hybrid			2022-12-25	WOS:000169531100012
J	Cunnick, JM; Mei, L; Doupnik, CA; Wu, J				Cunnick, JM; Mei, L; Doupnik, CA; Wu, J			Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; TANDEM SH2 DOMAINS; PHOSPHATASE SH-PTP2; DOCKING PROTEIN; GRB2-ASSOCIATED BINDER-1; PHOSPHORYLATION SITES; ADAPTER PROTEIN; EGF-RECEPTOR; INSULIN	A major Grb2-associated binder-1 (Gab1) binding partner in epidermal growth factor (EGF)-stimulated cells is protein-tyrosine phosphatase (PTPase) SHP2, which contains tandem SH2 domains. The SHP2 PTPase activity is required for activation of the extracellular signal-regulated kinase (ERK) subfamily of mitogen-activated protein (MAP) kinase by EGF, To investigate the mechanism by which Gab1 and SHP2 mediate ERK activation, me characterized the Gab1-SHP2 interaction. We found that both Tyr-627 and Tyr-659 of Gab1 were required for SHP2 binding to Gab1 and for ERK2 activation by EGF, Far Western blot analysis suggested that the tandem SH2 domains of SHP2 bind to Gab1 in a specific orientation, in which the N-SH2 domain binds to phosphotyrosine (Tyr(P))-627 and the C-SH2 domain binds to Tyr(P)-659, When assayed with peptide substrates, SHP2 PTPase was activated by a bisphosphopeptide containing both Tyr(P)-627 and Tyr(P)-659, but not by monophosphopeptides containing Tyr(P)-627 or Tyr(P)-659 or a mixture of these monophosphopeptides. These results suggest that Tyr(P)-627 and Tyr(P)-659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) that binds and activates SHP2, Remarkably while a constitutively active SHPB (SHP2 DeltaN) could not rescue the defect of a SHP2-binding defective Gab1 (Gab1FF) in ERK2 activation, expression of a Gab1FF-SHP2 DeltaN chimera resulted in constitutive activation of ERK2 in transfected cells. Thus, physical association of activated SHPB with Gab1 is necessary and sufficient to mediate the ERK mitogen-activated protein kinase activation. Phosphopeptides derived from Gab1 were dephosphorylated by active SHP2 in vitro. Consistently, substrate-trapping experiments with a SHPB catalytic inactive mutant suggested that Gab1 was a SRPB PTPase substrate in the cells. Therefore, Gab1 not only is a SHPB activator but also is a target of its PTPase.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 3E, Tampa, FL 33612 USA; Univ S Florida, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Immunol & Med Microbiol, Tampa, FL 33612 USA; Univ S Florida, Dept Physiol & Biophys, Tampa, FL 33612 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Alabama System; University of Alabama Birmingham	Wu, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 3E, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Doupnik, Craig A/I-3617-2012; Wu, Jie/R-2404-2019; Mei, Lin/G-8755-2012; Cunnick, Jess/F-1715-2018	Doupnik, Craig A/0000-0002-7314-0747; Wu, Jie/0000-0002-2864-1606; 	NCI NIH HHS [R29 CA077467, CA77467] Funding Source: Medline; NINDS NIH HHS [NS40480, NS34062] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA077467, R01CA077467, R29CA077467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062, R01NS040480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HASEGAWA H, 1982, ANAL BIOCHEM, V120, P360, DOI 10.1016/0003-2697(82)90358-X; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; MEI L, 1994, J BIOL CHEM, V269, P12254; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	34	128	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24380	24387		10.1074/jbc.M010275200	http://dx.doi.org/10.1074/jbc.M010275200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323411	hybrid			2022-12-25	WOS:000169531100152
J	Diamond, TL; Kimata, J; Kim, B				Diamond, TL; Kimata, J; Kim, B			Identification of a simian immunodeficiency virus reverse transcriptase variant with enhanced replicational fidelity in the late stage of viral infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMICS IN-VIVO; GENETIC-VARIATION; ERROR SPECIFICITY; ESCHERICHIA-COLI; DRUG-RESISTANCE; DNA-SYNTHESIS; MUTATION-RATE; TYPE-1; HIV-1; POLYMERASE	Genomic hypermutation of human and simian immunodeficiency viruses (HIV and SIV) enables these viruses to adapt and escape from various types of antiviral selection by altering the molecular properties of viral gene products. In this study, we examined whether the biochemical and catalytic properties of SIV DNA polymerases (reverse transcriptases; RT) can change during the course of viral infection. For this test, we analyzed RTs obtained from two SIV clones, SIVMNE CL8 and SIVMNE 170. SIVMNE 170 was isolated during the late symptomatic phase of infection with the parental strain, SIVMNE CL8, We found these two RTs have identical DNA polymerase specific activities and kinetics with three different DNA and RNA templates. In addition, the processivity of these two SIV RT proteins mere also similar. However, as demonstrated by a misincorporation assay, the SIVMNE 170 RT showed much higher fidelity than SIVMNE CL8, The fidelity difference between these two SIV RTs was also confirmed by a steady state kinetic fidelity assay. These findings suggest that the fidelity of lentiviral RTs may change during the course of viral infection, possibly in response to alterations of host anti-viral immune capability. In addition, our sequence analysis of these two RT genes proposes possible structural strategies that the virus may employ to alter RT fidelity.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14672 USA; SW Fdn Biomed Res, Dept Virol & Immunol, San Antonio, TX 78245 USA	University of Rochester; Texas Biomedical Research Institute	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14672 USA.			Kimata, Jason/0000-0002-0504-0090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI047725, R01AI047725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055500] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI047725, AI 47725] Funding Source: Medline; NIGMS NIH HHS [GM55500] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BATTULA N, 1974, J BIOL CHEM, V249, P4086; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Cherry E, 1997, ANTIMICROB AGENTS CH, V41, P2763, DOI 10.1128/AAC.41.12.2763; Cheynier R, 1997, AIDS RES HUM RETROV, V13, P985, DOI 10.1089/aid.1997.13.985; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COFFIN JM, 1992, CURR TOP MICROBIOL I, V176, P156; Douglas NW, 1997, J MOL BIOL, V273, P122, DOI 10.1006/jmbi.1997.1277; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; GOUDSMIT J, 1991, FASEB J, V5, P2427, DOI 10.1096/fasebj.5.10.2065891; Hirsch VM, 1999, NAT MED, V5, P488, DOI 10.1038/8369; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; Kimata JT, 1997, J VIROL, V71, P7629, DOI 10.1128/JVI.71.10.7629-7639.1997; Kimata JT, 1999, NAT MED, V5, P535, DOI 10.1038/8414; Kimata JT, 1999, J VIROL, V73, P1655, DOI 10.1128/JVI.73.2.1655-1660.1999; KIRCHHOFF F, 1994, J VIROL, V68, P3682, DOI 10.1128/JVI.68.6.3682-3692.1994; Mansky LM, 2000, J VIROL, V74, P9532, DOI 10.1128/JVI.74.20.9532-9539.2000; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; Quinones-Mateu ME, 1998, J VIROL, V72, P9002; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; Rezende LF, 1998, J VIROL, V72, P2890, DOI 10.1128/JVI.72.4.2890-2895.1998; RUDENSEY LM, 1995, VIROLOGY, V207, P528, DOI 10.1006/viro.1995.1113; Shahs FS, 2000, J BIOL CHEM, V275, P27037; SHIODA T, 1994, J VIROL, V68, P7689, DOI 10.1128/JVI.68.12.7689-7696.1994; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; Vartanian JP, 1997, J MOL BIOL, V270, P139, DOI 10.1006/jmbi.1997.1104; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; WILLIAMS KJ, 1992, CURR TOP MICROBIOL, V176, P165; Zhang LQ, 1997, AIDS RES HUM RETROV, V13, P1357, DOI 10.1089/aid.1997.13.1357	40	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23624	23631		10.1074/jbc.M102496200	http://dx.doi.org/10.1074/jbc.M102496200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11325971	hybrid			2022-12-25	WOS:000169531100054
J	Gentil, BJ; Delphin, C; Mbele, GO; Deloulme, JC; Ferro, M; Garin, J; Baudier, J				Gentil, BJ; Delphin, C; Mbele, GO; Deloulme, JC; Ferro, M; Garin, J; Baudier, J			The giant protein AHNAK is a specific target for the calcium- and zinc-binding S100B protein - Potential implications for Ca2+ homeostasis regulation by S100B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GENE AHNAK; YEAST 2-HYBRID SYSTEM; DESMOYOKIN/AHNAK PROTEIN; ALZHEIMER-DISEASE; S100-BETA PROTEIN; PLASMA-MEMBRANE; DNA-BINDING; KINASE-C; IN-VIVO; P53	Transformation of rat embryo fibroblast clone 6 cells by ras and temperature sensitive p53val(135) is reverted by ectopic expression of the calcium- and zinc-binding protein S100B. In an attempt to define the molecular basis of the S100B action, we have identified the giant phosphoprotein AHNAK as the major and most specific Ca2+ dependent S100B target protein in rat embryo fibroblast cells. We next characterized AHNAK as a major Ca2+-dependent S100B target protein in the rat glial C6 and human U-87MG astrocytoma cell lines. AHNAK binds to S100B-Sepharose beads and is also recovered in anti-S100B immunoprecipitates in a strict Ca2+- and Zn2+-dependent manner. Using truncated AHNAK fragments, we demonstrated that the domains of AHNAK responsible for interaction with S100B correspond to repeated motifs that characterize the AHNAK molecule. These motifs show no binding to calmodulin or to S100A6 and S100A11, We also provide evidence that the binding of 2 Zn2+ equivalents/mol S100B enhances Ca2+-dependent S100B-AHNAK interaction and that the effect of Zn2+. relies on Zn2+-dependent regulation of S100B affinity for Ca2+. Taking into consideration that AHNAK is a protein implicated in calcium flux regulation, we propose that the S100B-AHNAK interaction may participate in the S100B-mediated regulation of cellular Ca2+ homeostasis.	Ctr Etud Nucl Grenoble, Dept Biol Mol & Struct, INSERM EPI 0104, F-38054 Grenoble 9, France; CEN Grenoble, Lab Chim Prot DBMS CP, F-38054 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA	Baudier, J (corresponding author), Ctr Etud Nucl Grenoble, Dept Biol Mol & Struct, INSERM EPI 0104, EPI-0104,17 Rue Martyrs, F-38054 Grenoble 9, France.		GENTIL, Benoit/B-9459-2012; Baudier, Jacques/O-2183-2016; FERRO, Myriam/O-6588-2014; Deloulme, Jean Christophe/P-6858-2017; Christian, Delphin/P-9284-2017	FERRO, Myriam/0000-0002-4222-6847; Deloulme, Jean Christophe/0000-0002-2234-5865; jacques, baudier/0000-0001-8427-4444; Christian, Delphin/0000-0003-3240-8695; GENTIL, Benoit/0000-0003-2022-1890				ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BAUDIER J, 1986, BIOCHEMISTRY-US, V25, P6934, DOI 10.1021/bi00370a029; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; COCHRAN AJ, 1983, MELANOMA RES, V53, P325; Deloulme JC, 2000, J BIOL CHEM, V275, P35302, DOI 10.1074/jbc.M003943200; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; GANNON JV, 1991, NATURE, V349, P802; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Heierhorst J, 1997, EUR J BIOCHEM, V249, P127, DOI 10.1111/j.1432-1033.1997.00127.x; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Maler L, 1999, J BIOMOL NMR, V13, P233, DOI 10.1023/A:1008315517955; MARSHAK DR, 1981, P NATL ACAD SCI USA, V11, P6793; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; Pozdnyakov N, 1997, BIOCHEMISTRY-US, V36, P14159, DOI 10.1021/bi971792l; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHENG JG, 1994, J NEUROSCI RES, V39, P398, DOI 10.1002/jnr.490390406; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; STANLEY LC, 1994, J NEUROPATH EXP NEUR, V53, P231, DOI 10.1097/00005072-199405000-00003; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tsoporis JN, 1998, J CLIN INVEST, V102, P1609, DOI 10.1172/JCI3077; Tsoporis JN, 1997, J BIOL CHEM, V272, P31915, DOI 10.1074/jbc.272.50.31915; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; Yang Q, 1999, EXP CELL RES, V246, P501, DOI 10.1006/excr.1998.4314; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	45	85	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23253	23261		10.1074/jbc.M010655200	http://dx.doi.org/10.1074/jbc.M010655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312263	hybrid			2022-12-25	WOS:000169531100007
J	Muenzner, P; Naumann, M; Meyer, TF; Gray-Owen, SD				Muenzner, P; Naumann, M; Meyer, TF; Gray-Owen, SD			Pathogenic Neisseria trigger expression of their carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1; previously CD66a) receptor on primary endothelial cells by activating the immediate early response transcription factor, nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; TUMOR-NECROSIS-FACTOR; GONOCOCCAL OPACITY PROTEINS; CROSS-REACTING ANTIGEN; EPITHELIAL-CELLS; BILIARY GLYCOPROTEIN; SOLUBLE CD14; OPA PROTEINS; C-CAM; GONORRHOEAE	Neisseria gonorrhoeae express opacity-associated (Opa) protein adhesins that mediate binding to various members of the carcinoembryonic antigen-related cellular adhesion molecule (CEACAM; previously CD66) receptor family. Although human umbilical vein endothelial cells express little CEACAM receptor in vitro, we found neisserial infection to induce expression of CEACAM1, CEACAM1-3L, and CECAM1-4L splice variants. This mediates an increased Opa(52)-dependent binding of gonococci by these cells. The induced receptor expression did not require bacterial Opa expression, but it was more rapid with adherent bacteria. Because the time course of induction was similar to that seen for induced proinflammatory cytokines, we tested whether CEACAM1 expression could be controlled by a similar mechanism. Gonococcal infection activated a nuclear factor-kappaB (NF-kappaB) heterodimer consisting of p50 and p65, and inhibitors that prevent the nuclear translocation of activated NF-kappaB complex inhibited CEACAM1 transcript expression. Each of these effects could be mimicked by using culture filtrates or purified lipopolysaccharide instead of intact bacteria. Together, our results support a model whereby the outer membrane "blebs" that are actively released by gonococci trigger a Toll-like receptor-4-dependent activation of NF-kappaB, which up-regulates the expression of CEACAM1 to allow Opa(52)-mediated neisserial binding. The regulation of CEACAM1 expression by MF-kappaB also implies a broader role for this receptor in the general inflammatory response to infection.	Max Planck Inst Biol, Infekt Biol Abt, D-72076 Tubingen, Germany; Max Planck Inst Infekt Biol, Abt Molekulare BIol, D-21122 Berlin, Mitte, Germany; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Max Planck Society; Max Planck Society; University of Toronto	Meyer, TF (corresponding author), Max Planck Inst Biol, Infekt Biol Abt, Spemannstr 34, D-72076 Tubingen, Germany.	meyer@mpiib-berlin.mpg.de	Gray-Owen, Scott/AAG-7337-2022; Gray-Owen, Scott/AFL-7380-2022; Meyer, Thomas F. F/J-2485-2013; Naumann, Michael/B-5285-2011	Meyer, Thomas F. F/0000-0002-6120-8679; Naumann, Michael/0000-0002-8060-2313; Gray-Owen, Scott D./0000-0002-1477-3616				ACHTMAN M, 1988, J EXP MED, V168, P507, DOI 10.1084/jem.168.2.507; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beauchemin N, 1999, EXP CELL RES, V252, P243; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Billker O, 2000, TRENDS MICROBIOL, V8, P258, DOI 10.1016/S0966-842X(00)01771-6; Bos MP, 1997, INFECT IMMUN, V65, P2353, DOI 10.1128/IAI.65.6.2353-2361.1997; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; Chen T, 1997, J EXP MED, V185, P1557, DOI 10.1084/jem.185.9.1557; Chen T, 1996, P NATL ACAD SCI USA, V93, P14851, DOI 10.1073/pnas.93.25.14851; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Dehio C, 1997, J CELL SCI, V110, P2141; Dehio M, 1998, FEBS LETT, V424, P84, DOI 10.1016/S0014-5793(98)00144-6; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; Duensing TD, 1997, INFECT IMMUN, V65, P964, DOI 10.1128/IAI.65.3.964-970.1997; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; Gray-Owen SD, 1997, MOL MICROBIOL, V26, P971, DOI 10.1046/j.1365-2958.1997.6342006.x; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; Hauck CR, 1997, INFECT IMMUN, V65, P1863, DOI 10.1128/IAI.65.5.1863-1869.1997; HEFTA SA, 1990, J BIOL CHEM, V265, P8618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; HSIEH JT, 1995, CANCER RES, V55, P190; Kammerer R, 1998, EUR J IMMUNOL, V28, P3664, DOI 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D; Klein ML, 1996, INFECT IMMUN, V64, P4574, DOI 10.1128/IAI.64.11.4574-4579.1996; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; Kunath T, 1995, ONCOGENE, V11, P2375; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; Lorenzen DR, 1999, J EXP MED, V190, P1049, DOI 10.1084/jem.190.8.1049; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; MAJURI ML, 1994, APMIS, V102, P432, DOI 10.1111/j.1699-0463.1994.tb04895.x; MCGEE ZA, 1983, REV INFECT DIS, V5, pS708; Means TK, 1999, J IMMUNOL, V163, P3920; Muenzner P, 2000, INFECT IMMUN, V68, P3601, DOI 10.1128/IAI.68.6.3601-3607.2000; NASSIF X, 1992, MOL MICROBIOL, V6, P591, DOI 10.1111/j.1365-2958.1992.tb01505.x; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; Popp A, 1999, CELL MICROBIOL, V1, P169, DOI 10.1046/j.1462-5822.1999.00017.x; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; Virji M, 1999, MOL MICROBIOL, V34, P538, DOI 10.1046/j.1365-2958.1999.01620.x; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355; Wang J, 1998, MOL MICROBIOL, V30, P657, DOI 10.1046/j.1365-2958.1998.01102.x; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	62	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24331	24340		10.1074/jbc.M006883200	http://dx.doi.org/10.1074/jbc.M006883200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306560	hybrid			2022-12-25	WOS:000169531100145
J	Yamauchi, J; Tsujimoto, G; Kaziro, Y; Itoh, H				Yamauchi, J; Tsujimoto, G; Kaziro, Y; Itoh, H			Parallel regulation of mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 in G(q)-signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; BETA-GAMMA-SUBUNITS; KIDNEY 293 CELLS; C-JUN KINASE; COUPLED RECEPTORS; SIGNALING PATHWAY; TYROSINE KINASE; NH2-TERMINAL KINASES; MAJOR ACTIVATOR; P38	Heterotrimeric G protein G, stimulates the activity of p38 mitogen-activated protein kinase (MAPK) in mammalian cells. To investigate the signaling mechanism whereby ct and py subunits of G,activate p38 MAPK, we introduced kinase-deficient mutants of mitogen-activated protein kinase kinase 3 (MKK3), MKK4, and MKK6 into human embryonal kidney 293 cells. The activation of p38 MAPK. by Get, and G beta gamma was blocked by kinase-deficient MKK3 and MKK6 but not by kinase-deficient MKK4. In addition, G alpha (q) and G beta gamma stimulated MKK3 and MKK6 activities. The MKK3 and MMK6 activations by G alpha (q), but not by G beta gamma, were dependent on phospholipase C and c-Src. G alpha (q) stimulated MKK3 in a Rac- and Cdc42-dependent manner and MKK6 in a Rho-dependent manner. On the other hand, G beta gamma activated MKK3 in a Rac-and Cdc42-dependent manner and MMK6 in a Rho-, Rac-, and Cdc42-dependent manner. G beta gamma -induced MKK3 and MKK6 activations were dependent on a tyrosine kinase other than c-Src. These results suggest that G alpha (q) and G beta gamma stimulate the activity of p38 MAPK by regulating MKK3 and MKK6 through parallel signaling pathways.	Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Sanyo Gakuen Univ & Coll, Okayama 7038501, Japan; Japan Sci & Technol Corp, Kawasaki, Kanagawa 3320012, Japan; Childrens Natl Med Ctr, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1541809, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Itoh, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito M, 1999, MOL CELL BIOL, V19, P7539; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; VAN AL, 1997, GENE DEV, V11, P2295; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	59	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23362	23372		10.1074/jbc.M011752200	http://dx.doi.org/10.1074/jbc.M011752200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11304531	hybrid			2022-12-25	WOS:000169531100021
J	Mester, T; Ambert-Balay, K; Ciofi-Baffoni, S; Banci, L; Jones, AD; Tien, M				Mester, T; Ambert-Balay, K; Ciofi-Baffoni, S; Banci, L; Jones, AD; Tien, M			Oxidation of a tetrameric nonphenolic lignin model compound by lignin peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHANEROCHAETE-CHRYSOSPORIUM BURDS; SUBSTRATE INTERACTION SITES; MANGANESE PEROXIDASE; VERATRYL ALCOHOL; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; DEGRADATION; ROT; BIODEGRADATION	The present study maps the active site of lignin peroxidase in respect to substrate size using either fungal or recombinant wild type, as well as mutated, recombinant lignin peroxidases. A nonphenolic tetrameric lignin model was synthesized that contains beta -O-4 linkages. The fungal and recombinant wild type lignin peroxidase both oxidized the tetrameric model forming four products, The four products were identified by mass spectral analyses and compared with synthetic standards. They were identified as tetrameric, trimeric, dimeric, and monomeric carbonyl compounds. Ah four of these products were also formed from single turnover experiments. This indicates that lignin peroxidase is able to attack any of the C-alpha-C-beta linkages in the tetrameric compound and that the substrate-binding site is well exposed. Mutation of the recombinant lignin peroxidase (isozyme H8) in the heme access channel, which is relatively restricted and was previously proposed to be the veratryl alcohol-binding site (E146S), had little effect on the oxidation of the tetramer. In contrast, mutation of a Trp residue (W171S) in the alternate proposed substrate-binding site completely inhibited the oxidation of the tetrameric model. These results are consistent with lignin peroxidase having an exposed active site capable of directly interacting with the lignin polymer without the advent of low molecular weight mediators.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Univ Florence, Dept Chem, I-50121 Florence, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Florence	Tien, M (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.		Jones, Arthur D/C-2670-2013; Ciofi-Baffoni, Simone/AAH-9778-2021	Ciofi Baffoni, Simone/0000-0002-2376-3321; BANCI, LUCIA/0000-0003-0562-5774; Jones, A. Daniel/0000-0002-7408-6690; Ambert-Balay, Katia/0000-0002-2624-712X				Ambert-Balay K, 1998, BIOCHEM BIOPH RES CO, V251, P283, DOI 10.1006/bbrc.1998.9454; Blodig W, 1998, BIOCHEMISTRY-US, V37, P8832, DOI 10.1021/bi9727186; Camarero S, 1999, J BIOL CHEM, V274, P10324, DOI 10.1074/jbc.274.15.10324; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; Ciofi-Baffoni S, 1998, J CHEM SOC PERK T 1, P3207, DOI 10.1039/a805027i; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; FENN P, 1984, J WOOD CHEM TECHNOL, V4, P131, DOI 10.1080/02773818408081148; FLOURNOY DS, 1993, HOLZFORSCHUNG, V47, P297, DOI 10.1515/hfsg.1993.47.4.297; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HAMMEL KE, 1991, ENZYME MICROB TECH, V13, P15, DOI 10.1016/0141-0229(91)90182-A; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; Johjima T, 1999, P NATL ACAD SCI USA, V96, P1989, DOI 10.1073/pnas.96.5.1989; Khindaria A, 1996, BIOCHEMISTRY-US, V35, P6418, DOI 10.1021/bi9601666; KIRK TK, 1986, BIOCHEM J, V236, P279, DOI 10.1042/bj2360279; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KIRK TK, 1986, ENZYME MICROB TECH, V8, P27, DOI 10.1016/0141-0229(86)90006-2; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; KUAN IC, 1993, J BIOL CHEM, V268, P20064; MESSNER K, 1994, FEMS MICROBIOL REV, V13, P351, DOI 10.1111/j.1574-6976.1994.tb00054.x; Mester T, 1998, J BIOL CHEM, V273, P15412, DOI 10.1074/jbc.273.25.15412; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; ORTH AB, 1993, APPL ENVIRON MICROB, V59, P4017, DOI 10.1128/AEM.59.12.4017-4023.1993; PAICE MG, 1995, J PULP PAP SCI, V27, pJ280; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; PASZCZYNSKI A, 1991, BIOCHEM BIOPH RES CO, V178, P1056, DOI 10.1016/0006-291X(91)90999-N; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; SARKANEN S, 1991, J BIOL CHEM, V266, P3636; Schoemaker HE, 1996, PURE APPL CHEM, V68, P2089, DOI 10.1351/pac199668112089; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; Timofeevski SL, 1999, BIOCHEM BIOPH RES CO, V256, P500, DOI 10.1006/bbrc.1999.0360; Timofeevski SL, 2000, ARCH BIOCHEM BIOPHYS, V373, P147, DOI 10.1006/abbi.1999.1562	37	59	59	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22985	22990		10.1074/jbc.M010739200	http://dx.doi.org/10.1074/jbc.M010739200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304528	hybrid			2022-12-25	WOS:000169412700134
J	Pagano, M; Anand-Srivastava, MB				Pagano, M; Anand-Srivastava, MB			Cytoplasmic domain of natriuretic peptide receptor C constitutes G(i) activator sequences that inhibit adenylyl cyclase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; SIGNAL-TRANSDUCTION SYSTEM; GUANYLATE-CYCLASE; CLEARANCE RECEPTOR; SMOOTH-MUSCLE; PORCINE BRAIN; CYCLIC-GMP; NPR-C; ATRIAL; CELLS	We have recently demonstrated that a 37-amino acid peptide corresponding to the cytoplasmic domain of the natriuretic peptide receptor C (NPR-C) inhibited adenylyl cyclase activity via pertussis toxin (PT)-sensitive G(i) protein. In the present studies, we have used seven different peptide fragments of the cytoplasmic domain of the NPR-C receptor with complete, partial, or no G(i) activator sequence to examine their effects on adenylyl cyclase activity. The peptides used were KKYRITIER-RNH (peptide 1), RRNHQEESNIGK (peptide 2), HRELREDSIRSH (peptide 3), RRNHQEESNIGKHRELR (peptide 4), QEESNIGK (peptide X), ITIERRNH (peptide Y), and ITYKRRNHRE (peptide Z). Peptides 1, 3, and 4 have complete G(i) activator sequences, whereas peptides 2 and Y have partial G(i) activator sequences with truncated carboxyl or amino terminus, respectively. Peptide X has no structural specificity, whereas peptide Z is the scrambled peptide control for peptide 1. Peptides 1, 3, and 4 inhibited adenylyl cyclase activity in a concentration-dependent manner with apparent K-i between 0.1 and 1 nm; however, peptide 2 inhibited adenylyl cyclase activity with a higher K-i of about 10 nM, and peptides X, Y, and Z were unable to inhibit adenylyl cyclase activity. The maximal inhibitions observed were between 30 and 40%. The inhibition of adenylyl cyclase activity by peptides 1-4 was absolutely dependent on the presence of guanine nucleotides and was completely attenuated by PT treatment. In addition, the stimulatory effects of isoproterenol, glucagon, and forskolin on adenylyl cyclase activity were inhibited to different degrees by these peptides. These results suggest that the small peptide fragments of the cytoplasmic domain of the NPR-C receptor containing 12 or 17 amino acids were sufficient to inhibit adenylyl cyclase activity through a PT-sensitive G(i) protein. The peptides having complete structural specificity of G(i) activator sequences at both amino and carboxyl termini were more potent to inhibit adenylyl cyclase activity as compared with the peptides having a truncated carboxyl terminus, whereas the truncation of the amino-terminal motif completely attenuates adenylyl cyclase inhibition.	Univ Montreal, Fac Med, Dept Physiol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Anand-Srivastava, MB (corresponding author), Univ Montreal, Fac Med, Dept Physiol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.							AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324; ANANDSRIVASTAVA MB, 1986, AM J PHYSIOL, V251, pF417, DOI 10.1152/ajprenal.1986.251.3.F417; ANANDSRIVASTAVA MB, 1991, BIOCHEM J, V278, P211, DOI 10.1042/bj2780211; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1986, BIOCHEM BIOPH RES CO, V138, P427, DOI 10.1016/0006-291X(86)90299-8; ANANDSRIVASTAVA MB, 1984, BIOCHEM BIOPH RES CO, V121, P855, DOI 10.1016/0006-291X(84)90756-3; ANANDSRIVASTAVA MB, 1985, LIFE SCI, V36, P1873, DOI 10.1016/0024-3205(85)90161-4; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; ANANDSRIVASTAVA MB, 1992, BIOCHEM J, V288, P79, DOI 10.1042/bj2880079; ANANDSRIVASTAVA MB, 1985, FEBS LETT, V181, P199, DOI 10.1016/0014-5793(85)80259-3; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; BIANCHI C, 1986, CURR EYE RES, V5, P283, DOI 10.3109/02713688609020054; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLAVELL AL, 1993, AM J PHYSIOL, V264, P290; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DEBOLD AJ, 1982, P SOC EXP BIOL MED, V170, P133; FULLER F, 1988, J BIOL CHEM, V263, P9395; HAMET P, 1984, BIOCHEM BIOPH RES CO, V123, P515, DOI 10.1016/0006-291X(84)90260-2; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; KAMBAYASHI Y, 1990, FEBS LETT, V259, P341, DOI 10.1016/0014-5793(90)80043-I; Kanwal S, 1999, ENDOCRINOLOGY, V140, P1118, DOI 10.1210/en.140.3.1118; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Murthy KS, 1999, J BIOL CHEM, V274, P17587, DOI 10.1074/jbc.274.25.17587; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Palaparti A, 1999, ARCH BIOCHEM BIOPHYS, V365, P113, DOI 10.1006/abbi.1999.1153; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SCHENK DB, 1985, J BIOL CHEM, V260, P4887; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SOLOMON Y, 1974, ANAL BIOCHEM, V58, P541; STINGO AJ, 1992, AM J PHYSIOL, V262, P308; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; WALDMAN S, 1984, J BIOL CHEM, V259, P15332	38	74	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22064	22070		10.1074/jbc.M101587200	http://dx.doi.org/10.1074/jbc.M101587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303026	hybrid			2022-12-25	WOS:000169412700012
J	Ma, WB; Xia, CZ; Ling, P; Qiu, MS; Luo, Y; Tan, TH; Liu, MY				Ma, WB; Xia, CZ; Ling, P; Qiu, MS; Luo, Y; Tan, TH; Liu, MY			Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes	ONCOGENE			English	Article						adaptor protein Grap2; HPK1; JNK; T-cells	N-TERMINAL KINASE; CELL ANTIGEN RECEPTOR; GERMINAL CENTER KINASE; TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVITY; LINKER PROTEIN; RAS PATHWAY	Immune cell-specific adaptor proteins create various combinations of multiprotein complexes and integrate signals from cell surface receptors to the nucleus, modulating the specificity and selectivity of intracellular signal transduction, Grap2 is a newly identified adaptor protein specifically expressed in lymphoid tissues. This protein shares 40-50% sequence homology in the SH3 and the SH2 domain with Grb2 and Grap, However, the Grap2 protein has a unique 120-amino acid glutamine-and proline-rich domain between the SH2 and C-terminal SH3 domains, The expression of Grap2 is highly restricted to lymphoid organs and T lymphocytes. In order to understand the role of this specific adaptor protein in immune cell signaling and activation, we searched for the Grap2 interacting protein in T lymphocytes. We found that Grap2 interacted with the hematopoietic progenitor kinase 1 (HPK1) in vitro and in Jurkat T cells. The interaction was mediated by the carboxyl-terminal SH3 domain of Grap2 with the second proline-rich motif of HPK1, Coexpression of Grap2 with HPK1 not only increased the kinase activity of HPK1 in the cell, but also had an additive effect on HPK1 mediated JNK activation. Furthermore, over expression of Grap2 and HPK1 induced significant transcriptional activation of c-Jun in the JNK signaling pathway and IL-2 gene reporter activity in stimulated Jurkat T cells, Therefore, our data suggest that the hematopoietic specific proteins Grap2 and HPK1 form a signaling complex to mediate the c-Jun NH2-terminal kinase (JNK) signaling pathway in T cells.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Ctr Canc Biol & Nutr,Inst Biosci & Technol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Univ Louisville, Dept Anat Sci & Neurobiol, Sch Med, Louisville, KY 40202 USA; Shanghai Genom Inc, Shanghai 201204, Peoples R China	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Louisville	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Ctr Canc Biol & Nutr,Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Ma, Wenbin/0000-0001-8774-7593	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649, R01AI042532] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI42532, R01-AI38649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell DA, 1996, CANCER SURV, V27, P165; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen YR, 2000, INT J ONCOL, V16, P651; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHOI KY, 1994, CELL, V78, P499; Clements JL, 1998, J IMMUNOL, V161, P3880; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hua SB, 1997, PLASMID, V38, P91, DOI 10.1006/plas.1997.1305; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LOWE VPW, 1991, ENVIRON POLLUT, V70, P1, DOI 10.1016/0269-7491(91)90128-J; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	65	43	46	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1703	1714		10.1038/sj.onc.1204224	http://dx.doi.org/10.1038/sj.onc.1204224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313918				2022-12-25	WOS:000167750900004
J	Lee, YJ; Lee, KH; Kim, HRC; Jessup, JM; Seol, DW; Kim, TH; Billiar, TR; Song, YK				Lee, YJ; Lee, KH; Kim, HRC; Jessup, JM; Seol, DW; Kim, TH; Billiar, TR; Song, YK			Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells	ONCOGENE			English	Article						TRAIL; apoptosis; SNP; nitric oxide; mitochondria; caspase; cytochrome c; Bcl-2	CYTOCHROME-C RELEASE; OXIDE-MEDIATED APOPTOSIS; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; DEATH DOMAIN; PERMEABILITY TRANSITION; CASPASE ACTIVATION; DECOY RECEPTORS; CANCER-CELLS; IN-VIVO	The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo-2L) is a recently characterized member of the family of programmed cell death-inducing ligands that includes TNF-alpha and CD95L (FasL), It is well known that TRAIL binds to the death signaling receptors, DR4 and DR5, and initiates the TRAIL death pathway, Activation of this pathway, mediated through a caspase cascade, causes apoptosis, In this study, we hypothesized that oxidative stress facilitates TRAIL-induced apoptosis by promoting caspase activity through cytochrome c release from mitochondria, Human colorectal carcinoma CX-1 cells were treated with various concentrations of TRAIL (12.5-200 ng/ml) and/or sodium nitroprusside (SNP; 0.03-1 mM) for 12 h, SNP, a nitric oxide donor, which had little toxic effect by itself, enhanced TRAIL-induced cytotoxicity, For example, TRAIL-induced apoptosis (200 ng/ml) was increased by a factor of 2.5-fold in the presence of 1 mM SNP. The combined treatment also caused an increase in cytochrome c release, caspase-3 activity, and PARR cleavage, Overexpression of Bcl-2 completely blocked the SNP-promoting effects, but only moderately inhibited TRAIL-induced apoptosis, Similar results were observed in the presence of hydrogen peroxide or peroxynitrite. Taken together, the present studies suggest that SNP enhances TRAIL-induced cytotoxicity by facilitating the mitochondria-mediated caspase signal transduction pathway.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Inst Canc, Pittsburgh, PA 15213 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wayne State University; University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Inst Canc, E1056 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA064139, R29CA064139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NCI NIH HHS [CA48000, CA64139] Funding Source: Medline; NIGMS NIH HHS [GM44100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bal-Price A, 1999, ANN NY ACAD SCI, V893, P376, DOI 10.1111/j.1749-6632.1999.tb07859.x; BIANCO FJ, 1995, AM J PATHOL, V146, P75; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; IRMIER M, 1997, NATURE, V388, P190; ITOH N, 1993, J IMMUNOL, V151, P621; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Nagane M, 2000, CANCER RES, V60, P847; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhou YW, 1998, CELL IMMUNOL, V186, P103, DOI 10.1006/cimm.1998.1297; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	53	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1476	1485		10.1038/sj.onc.1204225	http://dx.doi.org/10.1038/sj.onc.1204225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313891				2022-12-25	WOS:000167595200008
J	Machado, JC; Oliveira, C; Carvalho, R; Soares, P; Berx, G; Caldas, C; Seruca, R; Carneiro, F; Sobrinho-Simoes, M				Machado, JC; Oliveira, C; Carvalho, R; Soares, P; Berx, G; Caldas, C; Seruca, R; Carneiro, F; Sobrinho-Simoes, M			E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma	ONCOGENE			English	Article						E-cadherin; mutation; methylation; gastric cancer; stomach; diffuse cancer	LOBULAR BREAST CANCERS; MUTATIONS PROVIDE; EXPRESSION; HYPERMETHYLATION; CELLS; PROGRESSION; PATTERNS; ADHESION; ISLAND	In diffuse gastric carcinoma, despite common E-cadherin gene (CDH1) mutations, tumors show absence of CDH1 loss of heterozigosity (LOH) in most cases. This observation challenges the classical two-hit model of tumor suppresser gene inactivation. In order to investigate whether or not CDH1 promoter methylation may function as the second hit we analysed a series of 23 sporadic gastric carcinomas for the presence of CDH1 mutations, CDH1 promoter methylation, LOH and E-cadherin expression. CDH1 mutations were detected in nine of the 16 (56.3%) diffuse gastric carcinomas and in none of the seven intestinal gastric carcinomas. In diffuse gastric carcinomas harboring CDH1 mutations, LOH was observed in a single case. Loss of plasma membrane E-cadherin expression was consistently found in all nine cases with CDH1 mutation, suggesting that tumors inactivated the remaining CDH1 allele via a different mechanism. CDH1 promoter methylation was observed in nine of the 16 (56.3%) diffuse-type gastric carcinoma cases, including six of the nine cases (66.7%) harboring CDH1 mutations. CDH1 promoter methylation was also seen in two (28.6%) intestinal-type cases. Our results show that CDH1 promoter methylation is the second hit in more than half of the sporadic diffuse gastric carcinoma cases harboring CDH1 mutations.	IPATIMUP, P-4200 Oporto, Portugal; Univ Cambridge, Dept Oncol, Cambridge CB2 2XY, England; VIB Ghent Univ, KL, Dept Mol Biol, B-9000 Ghent, Belgium; Univ Porto, Fac Med, P-4200 Oporto, Portugal	University of Cambridge; Flanders Institute for Biotechnology (VIB); Ghent University; Universidade do Porto	Machado, JC (corresponding author), IPATIMUP, Rua Roberto Frias S-N, P-4200 Oporto, Portugal.		Soares, Paula/B-6054-2008; Caldas, Carlos/U-7250-2019; Carneiro, Fatima/J-6432-2013; Caldas, Carlos/A-7543-2008; Oliveira, Carla/F-8188-2011; Carneiro, Fatima/AAV-8677-2021; Machado, Jose Carlos/C-5907-2009; seruca, raquel/F-8187-2011; Sobrinho-Simões, Manuel/J-8290-2013	Soares, Paula/0000-0001-9607-6998; Caldas, Carlos/0000-0003-3547-1489; Carneiro, Fatima/0000-0002-1964-1006; Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; Machado, Jose Carlos/0000-0003-4741-8415; Seruca, Raquel/0000-0002-8851-4166; Berx, Geert/0000-0001-5770-2458; Sobrinho-Simoes, Manuel/0000-0003-1613-1235				BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Gayther SA, 1998, CANCER RES, V58, P4086; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Lee YY, 1997, CANCER, V80, P1889, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1889::AID-CNCR3>3.0.CO;2-J; Leung SY, 1999, CANCER RES, V59, P159; Luber B, 2000, CELL ADHES COMMUN, V7, P391, DOI 10.3109/15419060009109021; Machado JC, 1998, INT J SURG PATHOL, V6, P135, DOI 10.1177/106689699800600302; Machado JC, 1999, LAB INVEST, V79, P459; Shin JY, 2000, CANCER RES, V60, P262; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569	23	215	234	0	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1525	1528		10.1038/sj.onc.1204234	http://dx.doi.org/10.1038/sj.onc.1204234			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313896				2022-12-25	WOS:000167595200013
J	Eymin, B; Karayan, L; Seite, P; Brambilla, C; Brambilla, E; Larsen, CJ; Gazzeri, S				Eymin, B; Karayan, L; Seite, P; Brambilla, C; Brambilla, E; Larsen, CJ; Gazzeri, S			Human ARF binds E2F1 and inhibits its transcriptional activity	ONCOGENE			English	Article						ARF; E2F1; mdm2; tumour suppressor; transcription regulation	P19(ARF) TUMOR-SUPPRESSOR; CELL LUNG-CANCER; P53-DEPENDENT APOPTOSIS; RETINOBLASTOMA PROTEIN; NUCLEOLAR LOCALIZATION; BETA-TRANSCRIPT; STABILIZES P53; DNA-SYNTHESIS; GENE-PRODUCT; MDM2	The INK4a/ARF locus which is frequently inactivated in human tumours encodes two different tumour suppressive proteins, p16(INK4a) and ARF, p16(INK4a) is a major component of the RE pathway. ARF is part of an ARF-mdm2-p53 network that exerts a negative control on hyperproliferative signals emanating from oncogenic stimuli. Among these is the transcription factor E2F1, a final effector of the RE pathway, that induces ARF expression. Recent data suggest that ARF function is not restricted to the p53 pathway. However, ARF target(s) implicated in this p53-independent function remains to be identified. We show that ARF is able to inhibit the proliferation of human cell lines independently of their p53 status. In this context, we demonstrate that ARF interacts physically with E2F1 and inhibits its transcriptional activity. Moreover, we show that mdm2 is required for the modulation of E2F1 activity by ARF, Beside the well-known p53 and mdm2 partners, these results identify E2F1 as a new ARF target. Thus, ARF can be viewed as a dual-acting tumour suppressor protein in both the p53 and RE pathways, further emphasizing its role in tumour surveillance.	Inst Albert Bonniot, INSERM EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France; CHU La Miletrie, CNRS ESA 6031, Lab Immunol & Biochim Prot, F-86021 Poitiers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CHU Poitiers; Universite de Poitiers	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019	gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; Seite, Paule/0000-0002-7809-7610				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EYMIN B, 2001, IN PRESS ONCOGENE; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Gazzeri S, 1998, CANCER RES, V58, P3926; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTIN F, 1995, NATURE, V373, P691; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; NEVINS JR, 1992, SCIENCE, V258, P424; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	37	148	154	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1033	1041		10.1038/sj.onc.1204220	http://dx.doi.org/10.1038/sj.onc.1204220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314038	Green Submitted, Bronze			2022-12-25	WOS:000167232100003
J	Habuchi, T; Takahashi, T; Kakinuma, H; Wang, LZ; Tsuchiya, N; Satoh, S; Akao, T; Sato, K; Ogawa, O; Knowles, MA; Kato, T				Habuchi, T; Takahashi, T; Kakinuma, H; Wang, LZ; Tsuchiya, N; Satoh, S; Akao, T; Sato, K; Ogawa, O; Knowles, MA; Kato, T			Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer	ONCOGENE			English	Article						bladder cancer; methylation; DBCCR1; chromosome 9q	DNA METHYLATION; HOMOZYGOUS DELETION; CELL CARCINOMA; CPG ISLANDS; GENE; INACTIVATION; LOCUS	Transcriptional silencing by CpG island hypermethylation of gene regulatory regions is one mechanism for inactivation of tumour suppressor genes. Chromosome 9q deletion is frequently found in transitional cell carcinoma (TCC) of the bladder and upper urinary tract and one of the putative tumour suppressor loci has been mapped to 9q32-33, A gene designated as DBCCR1 was identified in the candidate region and its mRNA expression is thought to be suppressed by hypermethylation, To understand the role of hypermethylation in TCC, we evaluated the methylation status of 20 CpG sites of the DBCCR1 5'-CpG island region in a total of 69 tumours from 45 patients, 21 normal urothelial specimens, and six bladder cancer cell lines. Aberrant hypermethylation levels mere found in 36 (52%) of 69 tumours without any association with tumour grade or stage. Methylation was weakly detected in the normal urothelium in association with ageing. Although recurrent tumours tended to have higher methylation levels than the initial tumours, the methylation pattern was mostly maintained between multifocal TCCs in individual patients. The results suggest that hypermethylation of the DBCCR1 region is one of the earliest alterations in the development of TCCs and there may be an age-related hypermethylation-based field defect in normal urothelium. Methylator or methylation-resistant phenotype seems to be maintained during multifocal development or recurrence of most TCCs.	Akita Univ, Sch Med, Dept Urol, Akita 0108543, Japan; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan; St Jamess Univ Hosp, ICRF, Canc Med Unit, Leeds, W Yorkshire, England	Akita University; Kyoto University; Saint James's University Hospital; University of Leeds	Kato, T (corresponding author), Akita Univ, Sch Med, Dept Urol, 1-1-1 Hondo, Akita 0108543, Japan.		Wang, Lizhong/J-4268-2019; Tsuchiya, Norihiko/H-6538-2019	Wang, Lizhong/0000-0003-1980-4730; Knowles, Margaret/0000-0002-9363-8657				Ahuja N, 1998, CANCER RES, V58, P5489; CEDER H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1; Choi EK, 1996, MUTAT RES-FUND MOL M, V354, P123, DOI 10.1016/0027-5107(96)00056-5; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hermanek P, 1992, TNM CLASSIFICATION M; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1997, CANCER RES, V57, P1678; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; KNOWLES MA, 1994, CANCER RES, V54, P531; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; Maesawa C, 1996, CANCER RES, V56, P3875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESSING EM, 1998, CAMPBELLS UROLOGY, P2327; Mostofi FK, 1973, HISTOLOGICAL TYPING; Muto S, 2000, CANCER RES, V60, P4021; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; SAKAI T, 1991, AM J HUM GENET, V48, P880; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; Takahashi T, 1998, CANCER RES, V58, P5835; Toyota M, 1999, CANCER RES, V59, P5438; van Tilborg AAG, 1999, BRIT J CANCER, V80, P489, DOI 10.1038/sj.bjc.6690383	34	59	64	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					531	537		10.1038/sj.onc.1204122	http://dx.doi.org/10.1038/sj.onc.1204122			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313984				2022-12-25	WOS:000166562500013
J	Langland, G; Kordich, J; Creaney, J; Goss, KH; Lillard-Wetherell, K; Bebenek, K; Kunkel, TA; Groden, J				Langland, G; Kordich, J; Creaney, J; Goss, KH; Lillard-Wetherell, K; Bebenek, K; Kunkel, TA; Groden, J			The Bloom's syndrome protein (BLM) interacts with MLH1 but is not required for DNA mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; SACCHAROMYCES-CEREVISIAE; HOLLIDAY JUNCTIONS; TOPOISOMERASE-III; HELICASE ACTIVITY; SYNDROME CELLS; REPLICATION; RECOMBINATION; ASSOCIATION	Bloom's syndrome (BS) is a rare autosomal recessive disorder characterized by pre- and postnatal growth deficiency, immunodeficiency, and a tremendous predisposition to a wide variety of cancers. Cells from BS individuals are characterized by a high incidence of chromosomal gaps and breaks, elevated sister chromatid exchange, quadriradial formations, and locus-specific mutations. BS is the consequence of mutations that lead to loss of function of BLM, a gene encoding a helicase with homology to the RecQ helicase family. To delineate the role of BLM in DNA replication, recombination, and repair we used a yeast two-hybrid screen to identify potential protein partners of the BLM helicase. The C terminus of BLM interacts directly with MLH1 in the yeast-two hybrid assay; far Western analysis and co-immunoprecipitations confirmed the interaction. Cell extracts deficient in BLM were competent for DNA mismatch repair. These data suggest that the BLM helicase and MLH1 function together in replication, recombination, or DNA repair events independent of single base mismatch repair.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Cincinnati, OH 45267 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	University System of Ohio; University of Cincinnati; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Groden, J (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.		Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Goss, Kathleen/0000-0002-7379-5639	NCI NIH HHS [CA59268-06A1, CA63507] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063507, R29CA063507, T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, Z01ES065089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Chakraverty RK, 1999, BIOESSAYS, V21, P286; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, J CELL SCI, V113, P2641; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; GRODEN J, 1990, P NATL ACAD SCI USA, V87, P4315, DOI 10.1073/pnas.87.11.4315; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Johnson FB, 2000, CANCER RES, V60, P1162; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; LONN U, 1990, CANCER RES, V50, P3141; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	29	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30031	30035		10.1074/jbc.M009664200	http://dx.doi.org/10.1074/jbc.M009664200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11325959	hybrid			2022-12-25	WOS:000170558000057
J	Perez-Moreno, MA; Locascio, A; Rodrigo, I; Dhondt, G; Portillo, F; Nieto, MA; Cano, A				Perez-Moreno, MA; Locascio, A; Rodrigo, I; Dhondt, G; Portillo, F; Nieto, MA; Cano, A			A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SNAIL; INVASION-SUPPRESSOR GENE; LOOP-HELIX PROTEINS; DNA-BINDING; E2A GENE; TUMOR PROGRESSION; CELL-ADHESION; PROMOTER; E47; HEB	Down-regulation of E-cadherin expression is a determinant of tumor cell invasiveness, an event frequently associated with epithelial-mesenchymal transitions. Here we show that the mouse E12/E47 basic helix-loop-helix transcription factor (the E2A gene product) acts as a repressor of E-cadherin expression and triggers epithelial-mesenchymal transitions. The mouse E47 factor was isolated in a one-hybrid system designed to isolate repressors of the mouse E-cadherin promoter. Epithelial cells ectopically expressing E47 adopt a fibroblastic phenotype and acquire tumorigenic and migratory/invasive properties, concomitant with the suppression of E-cadherin expression. Suppression of E-cadherin expression under stable or inducible expression of E47 in epithelial cells occurs at the transcriptional level and is dependent on the E-boxes of the E-cadherin promoter. Interestingly, analysis of endogenous E2A expression in murine and human cell lines illustrated its presence in E-cadherin-deficient, invasive carcinoma cells but its absence from epithelial cell lines. This expression pattern is consistent with that observed in early mouse embryos, where E2A mRNA is absent from epithelia but strongly expressed in the mesoderm. These results implicate E12/E47 as a repressor of E-cadherin expression during both development and tumor progression and indicate its involvement in the acquisition and/or maintenance of the mesenchymal phenotype.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; CSIC, Inst Cajal, E-28002 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Cano, A (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.		Locascio, Annamaria/E-8714-2015; Perez-Moreno, Mirna/I-3687-2015; Nieto, M. Angela/A-6531-2008	Locascio, Annamaria/0000-0001-6956-2157; Perez-Moreno, Mirna/0000-0002-0170-6406; Nieto, M. Angela/0000-0002-3538-840X; Portillo Perez, Francisco/0000-0003-4922-346X				ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; ARONHEIM A, 1993, NUCLEIC ACIDS RES, V21, P1601, DOI 10.1093/nar/21.7.1601; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Behrens J, 1992, Semin Cell Biol, V3, P169; Bellairs R., 1987, P123; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cook DM, 1996, ONCOGENE, V13, P1789; Engel I, 1999, CURR OPIN GENET DEV, V9, P575, DOI 10.1016/S0959-437X(99)00008-8; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Ramain P, 2000, MOL CELL, V6, P781, DOI 10.1016/S1097-2765(05)00079-1; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sefton M, 1998, DEVELOPMENT, V125, P3111; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WATADA H, 1995, GENE, V153, P255, DOI 10.1016/0378-1119(94)00765-K; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	56	362	369	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27424	27431		10.1074/jbc.M100827200	http://dx.doi.org/10.1074/jbc.M100827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11309385	hybrid, Green Published			2022-12-25	WOS:000169966900092
J	Jonas-Straube, E; Hutin, C; Hoffman, NE; Schunemann, D				Jonas-Straube, E; Hutin, C; Hoffman, NE; Schunemann, D			Functional analysis of the protein-interacting domains of chloroplast SRP43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; THYLAKOID MEMBRANES; CHROMO DOMAIN; POSTTRANSLATIONAL INTEGRATION; 54-KDA SUBUNIT; ANKYRIN REPEAT; BINDING; HOMOLOG; INSERTION; HP1	The chloroplast signal recognition particle (cpSRP) consists of an evolutionarily conserved 54-kDa subunit (cpSRP54) and a dimer of a unique 43-kDa subunit (cpSRP43), cpSRP binds light-harvesting chlorophyll proteins (LHCPs) to form a cpSRP/LHCP transit complex, which targets LHCP to the thylakoid membrane. Previous studies showed that transit complex formation is mediated through the binding of the L18 domain of LHCP to cpSRP43, cpSRP43 is characterized by a four-ankyrin repeat domain at the N terminus and two chromodomains at the C terminus. in the present study we used the yeast two-hybrid system and in vitro binding assays to analyze the function of different domains of cpSRP43 in protein complex formation. We report here that the first ankyrin repeat binds to the Is-amino acid domain on LHCP that binds to cpSRP43, whereas the third and fourth ankyrin repeats are involved in the dimerization of cpSRP43. We show further that the interaction of cpSRP43 with cpSRP54 is mediated via binding of the methionine-rich domain of cpSRP54 to the C-terminally located chromodomains of cpSRP43, Both chromodomains contain essential elements for binding cpSRP54, indicating that the closely spaced chromodomains together create a single binding site for cpSRP54. In addition, our data demonstrate that the interaction of cpSRP54 with the chromodomains of cpSRP43 is enhanced indirectly by the dimerization motif of cpSRP43.	Rhein Westfal TH Aachen, Inst Biol 2, D-52074 Aachen, Germany; Dept Ecohphysiol Vegetale & Microbiol, F-13108 St Paul Durance, France; Paradigm Genet, Res Triangle Pk, NC 27709 USA	RWTH Aachen University	Schunemann, D (corresponding author), Rhein Westfal TH Aachen, Inst Biol 2, Worringerweg 1, D-52074 Aachen, Germany.			Hoffman, Neil/0000-0002-4057-555X; Schuenemann, Danja/0000-0001-8894-7685				AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Amin P, 1999, PLANT PHYSIOL, V121, P61, DOI 10.1104/pp.121.1.61; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CLINE K, 1989, J BIOL CHEM, V264, P14225; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Lin JH, 1999, J BIOL CHEM, V274, P14706, DOI 10.1074/jbc.274.21.14706; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Schuenemann D, 1999, BIOCHEM BIOPH RES CO, V254, P253, DOI 10.1006/bbrc.1998.9923; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Tu CJ, 2000, J BIOL CHEM, V275, P13187, DOI 10.1074/jbc.C000108200; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	32	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24654	24660		10.1074/jbc.M100153200	http://dx.doi.org/10.1074/jbc.M100153200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11306572	hybrid			2022-12-25	WOS:000169800700033
J	Shafirovich, V; Dourandin, A; Huang, WD; Geacintov, NE				Shafirovich, V; Dourandin, A; Huang, WD; Geacintov, NE			The carbonate radical is a site-selective oxidizing agent of guanine in double-stranded oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER FLASH-PHOTOLYSIS; AQUEOUS-SOLUTION; ELECTRON-TRANSFER; NITRIC-OXIDE; EPR-DETECTION; CU,ZN-SUPEROXIDE DISMUTASE; 2-PHOTON PHOTOIONIZATION; TYROSINE NITRATION; REACTIVE OXYGEN; RATE CONSTANTS	The carbonate radical anion (CO3.-) is believed to be an important intermediate oxidant derived from the oxidation of bicarbonate anions and nitrosoperoxocarboxylate anions (formed in the reaction of CO2 with ONOO-) in cellular environments. Employing nanosecond laser flash photolysis methods, we show that the CO3.- anion can selectively oxidize guanines in the self-complementary oligonucleotide duplex d(AACGCGAATTCGCGTT) dissolved in air-equilibrated aqueous buffer solution (pH 7.5), In these time-resolved transient absorbance experiments, the CO3.- radicals are generated by one-electron oxidation of the bicarbonate anions (HCO3-) with sulfate radical anions (SO4.-) that, in turn, are derived from the photodissociation of persulfate anions (S2O82-) initiated by 308-nm XeCl excimer laser pulse excitation. The kinetics of the CO3.- anion and neutral guanine radicals, G(-H)(.), arising from the rapid deprotonation of the guanine radical cation, are monitored via their transient absorption spectra (characteristic maxims at 600 and 315 nm, respectively) on time scales of microseconds to seconds. The bimolecular rate constant of oxidation of guanine in this oligonucleotide duplex by CO3.- is (1.9 +/- 0.2) x 10(7) M-1 s(-1). The decay of the CO3.- anions and the formation of G(-H)(.) radicals are correlated with one another on the millisecond time scale, whereas the neutral guanine radicals decay on time scales of seconds. Alkali-labile guanine lesions are produced and are revealed by treatment of the irradiated oligonucleotides in hot piperidine solution. The DNA fragments thus formed are identified by a standard polyacrylamide gel electrophoresis assay, showing that strand cleavage occurs at the guanine sites only, The biological implications of these oxidative processes are discussed.	NYU, Dept Chem, New York, NY 10003 USA; NYU, Radiat & Solid State Lab, New York, NY 10003 USA	New York University; New York University	Shafirovich, V (corresponding author), NYU, Dept Chem, 31 Washington Pl, New York, NY 10003 USA.							ADAMS GE, 1972, RADIAT RES, V49, P278, DOI 10.2307/3573266; ALSHEIKHLY M, 1994, RADIAT PHYS CHEM, V44, P297, DOI 10.1016/0969-806X(94)90007-8; ALTMAN P, 1971, BLOOD OTHER BODY FLU; BACHLER V, 1992, RADIAT PHYS CHEM, V40, P59; BAVERSTOCK K, 1974, INT J RADIAT BIOL, V26, P39, DOI 10.1080/09553007414550921; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; BIELSKI BHJ, 1978, PHOTOCHEM PHOTOBIOL, V28, P645, DOI 10.1111/j.1751-1097.1978.tb06986.x; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Candeias LP, 2000, CHEM-EUR J, V6, P475, DOI 10.1002/(SICI)1521-3765(20000204)6:3<475::AID-CHEM475>3.0.CO;2-E; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Czapski G, 1999, J PHYS CHEM A, V103, P3447, DOI 10.1021/jp984769y; DOGLIOTTI L, 1967, J PHYS CHEM-US, V71, P2511, DOI 10.1021/j100867a019; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; Epperlein MM, 1998, J AM SOC NEPHROL, V9, P457; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Goldstein S, 1999, J AM CHEM SOC, V121, P2444, DOI 10.1021/ja9822254; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; HILDENBRAND K, 1990, FREE RADICAL RES COM, V11, P195, DOI 10.3109/10715769009088916; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; HUIE RE, 1991, RADIAT PHYS CHEM, V38, P477; HUIE RE, 1990, J PHYS CHEM-US, V94, P8561, DOI 10.1021/j100386a015; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Ivanov KL, 2000, J PHOTOCH PHOTOBIO A, V133, P99, DOI 10.1016/S1010-6030(00)00218-5; JONSSON M, 1995, J CHEM SOC PERK T 2, P67, DOI 10.1039/p29950000067; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Kuzmin VA, 2000, PHYS CHEM CHEM PHYS, V2, P1531, DOI 10.1039/b000212g; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LILIE J, 1978, RADIAT PHYS CHEM, V11, P225, DOI 10.1016/0146-5724(78)90101-2; Lymar SV, 2000, RADIAT PHYS CHEM, V59, P387, DOI 10.1016/S0969-806X(00)00277-2; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; LYMAR SV, 1995, CHEM RES TOXICOL, V8, P833, DOI 10.1021/tx00048a003; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MCELROY WJ, 1990, J PHYS CHEM-US, V94, P2435, DOI 10.1021/j100369a044; Merenyi G, 1997, CHEM RES TOXICOL, V10, P1216, DOI 10.1021/tx970101j; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; NETA P, 1988, J PHYS CHEM REF DATA, V17, P1027, DOI 10.1063/1.555808; ONEILL P, 1987, INT J RADIAT BIOL, V52, P577, DOI 10.1080/09553008714552071; PATEL DJ, 1982, SCIENCE, V216, P581, DOI 10.1126/science.6280281; PATEL DJ, 1982, BIOCHEMISTRY-US, V21, P428, DOI 10.1021/bi00532a002; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Schiemann O, 2000, J PHYS CHEM B, V104, P7214, DOI 10.1021/jp000725p; SCHINDLER S, 1993, INORG CHEM, V32, P4200, DOI 10.1021/ic00072a009; Shafirovich V, 2000, J CHEM SOC PERK T 2, P271, DOI 10.1039/a907995e; Shafirovich V, 2000, PHYS CHEM CHEM PHYS, V2, P4399, DOI 10.1039/b004896h; Shafirovich V, 1999, J PHYS CHEM B, V103, P10924, DOI 10.1021/jp992002f; Shafirovich V, 2001, CHEM RES TOXICOL, V14, P233, DOI 10.1021/tx000204t; Shafirovich V, 2001, J PHYS CHEM B, V105, P586, DOI 10.1021/jp0029055; SHAFIROVICH VY, 1995, J AM CHEM SOC, V117, P4920, DOI 10.1021/ja00122a024; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Steenken S, 2000, J AM CHEM SOC, V122, P2373, DOI 10.1021/ja993508e; Tien M, 1999, P NATL ACAD SCI USA, V96, P7809, DOI 10.1073/pnas.96.14.7809; Tretyakova NY, 2000, CHEM RES TOXICOL, V13, P658, DOI 10.1021/tx000083x; Tretyakova NY, 2000, MUTAT RES-FUND MOL M, V447, P287, DOI 10.1016/S0027-5107(99)00221-3; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; WEAST RC, 1984, CRC HDB CHEM PHYSICS, pD167; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; WOLCOTT RG, 1994, J BIOL CHEM, V269, P9721; Yermilov V, 1996, FEBS LETT, V399, P67, DOI 10.1016/S0014-5793(96)01288-4; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038	74	125	127	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24621	24626		10.1074/jbc.M101131200	http://dx.doi.org/10.1074/jbc.M101131200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320091	hybrid			2022-12-25	WOS:000169800700029
J	Wintjens, R; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Buee, L; Lippens, G; Landrieu, I				Wintjens, R; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Buee, L; Lippens, G; Landrieu, I			H-1 NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE PIN1; WW DOMAIN; REGULATORY MECHANISM; STRUCTURAL-ANALYSIS; LIGAND-BINDING; TAU-PROTEINS; BETA-SHEET; PHOSPHORYLATION; PROLINE; RECOGNITION	The recent crystal structure of Pin1 protein bound to a doubly phosphorylated peptide from the C-terminal domain of RNA polymerase II revealed that binding interactions between Pin1 and its substrate take place through its Trp-Trp (WW) domain at the level of the loop Ser(11)-Arg(12) and the aromatic pair Tyr(18)-Trp(29), and showed a trans conformation for both pSer-Pro peptide bonds. However, the orientation of the ligand in the aromatic recognition groove still could be sequence-specific, as previously observed in SH3 domains complexed by peptide ligands or for different class of WW domains (Zarrinpar, A, and Lim, W, A (2000) Nat, Struct, Riot, 7, 611-613), Because the bound peptide conformation could also differ as observed for peptide ligands bound to the 14-3-3 domain, ligand orientation and conformation for two other biologically relevant monophosphate substrates, one derived from the Cdc25 phosphatase of Xenopus laevis (EQPLpTPVTDL) and another from the human tau protein (KVSVVRpTPPKSPS) in complex with the WW domain are here studied by solution NMR methods. First, the proton resonance perturbations on the WW domain upon complexation with both peptide ligands were determined to be essentially located in the positively charged beta -hairpin Ser(11)-Gly(15) and around the aromatic Trp(29). Dissociation equilibrium constants of 117 and 230 muM for Cdc25 and tau peptides, respectively, were found. Several intermolecular nuclear Overhauser effects between WW domain and substrates were obtained from a ligand-saturated solution and were used to determine the structures of the complexes in solution. We found a similar N to C orientation as the one observed in the crystal complex structure of Pin1 and a trans conformation for the pThr-Pro peptidic bond in both peptide ligands, thereby indicating a unique binding scheme for the Pin1 WW domain to its multiple substrates.	Inst Pasteur Lille, Inst Biol Lille, CNRS UMR 8525, F-59021 Lille, France; Unite INSERM 422, F-59045 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Landrieu, I (corresponding author), Inst Pasteur Lille, Inst Biol Lille, CNRS UMR 8525, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.		Landrieu, Isabelle/AAF-8495-2019; BUEE, Luc/B-3126-2010; Rousselot-Pailley, Pierre/E-4151-2015	Landrieu, Isabelle/0000-0002-4883-2637; BUEE, Luc/0000-0002-6261-4230; Lippens, Guy/0000-0002-8236-0901; Drobecq, Herve/0000-0002-4081-1575				BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BAX A, 1985, J MAGN RESON, V53, P521; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brunger A. T, 1993, XPLOR MANUAL VERSION; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Crane JC, 2000, J MOL BIOL, V298, P283, DOI 10.1006/jmbi.2000.3665; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Daly NL, 2000, BIOCHEMISTRY-US, V39, P9039, DOI 10.1021/bi0004807; Delacourte A, 1997, INT REV CYTOL, V171, P167; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Fletcher R, 1980, PRACTICAL METHODS OP, V1; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAPLAN JI, 1995, ENCY NUCL MAGNETIC R, V2, P1247; Karaiskou A, 1999, J CELL SCI, V112, P3747; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Landrieu I, 2001, J BIOL CHEM, V276, P1434, DOI 10.1074/jbc.M006420200; Landrieu I, 2000, J BIOL CHEM, V275, P10577, DOI 10.1074/jbc.275.14.10577; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MAPLE JR, 1988, P NATL ACAD SCI USA, V85, P5350, DOI 10.1073/pnas.85.15.5350; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; WILLIAMSON MP, 1995, J MOL BIOL, V247, P541, DOI 10.1006/jmbi.1995.0160; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	47	112	117	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25150	25156		10.1074/jbc.M010327200	http://dx.doi.org/10.1074/jbc.M010327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313338	hybrid			2022-12-25	WOS:000169800700097
J	Caldwell, SR; Hill, KJ; Cooper, AA				Caldwell, SR; Hill, KJ; Cooper, AA			Degradation of endoplasmic reticulum (ER) quality control substrates requires transport between the ER and Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN-RESPONSE; COPII-COATED VESICLES; DI-LYSINE MOTIF; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN; MEMBRANE GLYCOPROTEIN; PROTEASOME; COMPONENT; PATHWAY; COMPLEX	Endoplasmic reticulum (ER) quality control (ERQC) components retain and degrade misfolded proteins, and our results have found that the degradation of the soluble ERQC substrates CPY* and PrA* but not membrane spanning ERQC substrates requires transport between the ER and Golgi. Stabilization of these misfolded soluble proteins was seen in cells lacking Erv29p, a probable Golgi localized protein that cycles through the ER by means of a di-lysine ER retrieval motif (KKKIY). Cells lacking Erv29p also displayed severely retarded ER exit kinetics for a subset of correctly folded proteins. We suggest that Erv29p is likely involved in cargo loading of a subset of proteins, including soluble misfolded proteins, into vesicles for ER exit. The stabilization of soluble ERQC substrates in both erv29 Delta cells and sec mutants blocked in either ER exit (sec12) or vesicle delivery to the Golgi (sec18) suggests that ER-Golgi transport is required for ERQC and reveals a new aspect of the degradative mechanism.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Cooper, AA (corresponding author), Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA.	coopera@umkc.edu		Cooper, Antony/0000-0002-6027-2353	NIGMS NIH HHS [GM55848] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055848] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BONIFACINO JS, 1994, MODERN CELL BIOL CEL; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brigance WT, 2000, MOL BIOL CELL, V11, P171, DOI 10.1091/mbc.11.1.171; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEONORA FC, 2000, J BIOL CHEM, V275, P8382; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1991, METHOD ENZYMOL, V194, P195; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	54	139	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23296	23303		10.1074/jbc.M102962200	http://dx.doi.org/10.1074/jbc.M102962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316816	hybrid			2022-12-25	WOS:000169531100013
J	Friedhoff, P; Lurz, R; Luder, G; Pingoud, A				Friedhoff, P; Lurz, R; Luder, G; Pingoud, A			Sau3AI, a monomeric type II restriction endonuclease that dimerizes on the DNA and thereby induces DNA loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; 2 RECOGNITION SITES; ESCHERICHIA-COLI; MISMATCH REPAIR; HOMING ENDONUCLEASE; CRYSTAL-STRUCTURE; STRUCTURE PREDICTION; PI-SCEI; PROTEIN; CLEAVAGE	Here, we report that Sau3AI, an unusually large type II restriction enzyme with sequence homology to the mismatch repair protein MutH, is a monomeric enzyme as shown by gel filtration and ultracentrifugation. Structural similarities in the N- and C-terminal halves of the protein suggest that Sau3AI is a pseudo-dimer, i.e. a polypeptide with two similar domains. Since Sau3AI dis plays a nonlinear dependence of cleavage activity on enzyme concentration and a strong preference for substrates with two recognition sites over those with only one, it is likely that the functionally active form of Sau3AI is a dimer of a pseudo-dimer. Indeed, electron microscopy studies demonstrate that two distant recognition sites are brought together through DNA looping induced by the simultaneous binding of two Sau3AI molecules to the DNA. We suggest that the dimeric form of Sau3AI supplies two DNA-binding sites, one that is associated with the catalytic center and one that serves as an effector site.	Univ Giessen, Inst Biochem FB8, D-35392 Giessen, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Justus Liebig University Giessen; Max Planck Society	Pingoud, A (corresponding author), Univ Giessen, Inst Biochem FB8, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	Alfred.M.Pingoud@chemie.bio.uni-giessen.de	Friedhoff, Peter/G-7905-2012	Friedhoff, Peter/0000-0003-1946-1117				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; Bilcock DT, 1999, MOL MICROBIOL, V31, P1243, DOI 10.1046/j.1365-2958.1999.01266.x; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; Bron S, 1980, Methods Enzymol, V65, P112; Bujnicki JM, 2001, PROTEIN SCI, V10, P352, DOI 10.1110/ps.40501; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Fischer D, 2000, Pac Symp Biocomput, P119; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Hadden JM, 2001, NAT STRUCT BIOL, V8, P62; Halford SE, 2000, NAT STRUCT BIOL, V7, P705, DOI 10.1038/78911; Halford SE, 1999, BIOCHEM SOC T, V27, P696, DOI 10.1042/bst0270696; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hickman AB, 2000, MOL CELL, V5, P1025, DOI 10.1016/S1097-2765(00)80267-1; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; KARPLUS K, 1999, PROTEINS STRUCT FU S, V3, P121; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, GENE, V157, P165, DOI 10.1016/0378-1119(95)00699-7; KUPPER D, 1995, GENE, V157, P97, DOI 10.1016/0378-1119(95)00700-G; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mucke M, 2000, J BIOL CHEM, V275, P30631, DOI 10.1074/jbc.M003904200; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PETRAUSKENE OV, 1994, BIOCHEM BIOPH RES CO, V198, P885, DOI 10.1006/bbrc.1994.1126; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; PINGOUD A, 2001, IN PRESS NUCL ACIDS; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Roberts R, 1993, NUCLEASES, P35; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; Stahl F, 1998, BIOL CHEM, V379, P467, DOI 10.1515/bchm.1998.379.4-5.467; SYDDALL R, 1985, BIOCHIM BIOPHYS ACTA, V825, P236, DOI 10.1016/0167-4781(85)90108-3; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; Weigel C, 1997, EMBO J, V16, P6574, DOI 10.1093/emboj/16.21.6574; WELSH KM, 1987, J BIOL CHEM, V262, P15624; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123; Wentzell LM, 1998, J MOL BIOL, V281, P433, DOI 10.1006/jmbi.1998.1967; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6	59	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23581	23588		10.1074/jbc.M101694200	http://dx.doi.org/10.1074/jbc.M101694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316811	hybrid			2022-12-25	WOS:000169531100049
J	Jiang, SW; Dong, MQ; Trujillo, MA; Miller, LJ; Eberhardt, NL				Jiang, SW; Dong, MQ; Trujillo, MA; Miller, LJ; Eberhardt, NL			DNA binding of TEA/ATTS domain factors is regulated by protein kinase C phosphorylation in human choriocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; SOMATOMAMMOTROPIN GENE ENHANCER; HEAVY-CHAIN PROMOTER; PHORBOL ESTER; CARDIAC MYOCYTES; TRANSCRIPTION FACTOR; SV40 ENHANCER; EXPRESSION; ACTIVATION; ELEMENTS	Transcription enhancer factor 1 (TEF-1) controls the expression of a diverse set of genes. Previous studies implicated protein kinase C (PKC)-mediated signal transduction in modulating TEF function. We demonstrate that in human choriocarcinoma BeWo cells, the PKC activator 12-O-tetradecanoyl phorbol 13-acetate and PHC inhibitor bisindolylmaleimide reciprocally down- and up-regulate, respectively, TEF-mediated GGAATG core enhancer activity. In vitro TEF-1 phosphorylation with several PKC isozymes and phosphoamino acid analysis confirmed that TEF-1 is a potential PKC substrate. TEF-1(.)DNA complexes formed by BeWo nuclear extracts are supershifted by phosphoserine- and phosphothreonine- but not phosphotyrosine-specific antibodies, indicating that TEF-1 is phosphorylated in vivo at serine and threonine residues. The TEF-1 phosphorylation domain was localized to the third alpha -helix of the DNA binding domain and adjacent hinge region by phosphopeptide analysis. TEF-1 phosphorylation significantly reduced its DNA binding activity both in vitro and in vivo, providing a possible mechanism for the inhibitory action of PKC. Finally, BeWo cells contained abundant levels of gamma and delta PKC isoforms, and their overexpression resulted in even greater inhibition of GGAATG core enhancer activity after 12-O-tetradecanoyl phorbol 13-acetate treatment. These data strongly suggest that PKC-mediated phosphorylation is a key factor controlling TEF function.	Mayo Clin, Dept Med, Div Endocrinol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Div Endocrinol, Rochester, MN 55905 USA; Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Jiang, SW (corresponding author), St Marys Hosp, Mayo Clin, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bamberger AM, 1997, ENDOCRINE, V6, P111, DOI 10.1007/BF02738953; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Cabell CH, 1996, P ASSOC AM PHYSICIAN, V108, P37; CARTER AN, 1997, CURRENT PROTOCOLS MO; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; COURAGE C, 1995, BRIT J CANCER, V71, P697, DOI 10.1038/bjc.1995.137; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 1999, MOL ENDOCRINOL, V13, P879, DOI 10.1210/me.13.6.879; Jiang SW, 2000, DNA CELL BIOL, V19, P507, DOI 10.1089/10445490050128430; JIANG SW, 1995, NUCLEIC ACIDS RES, V23, P3607, DOI 10.1093/nar/23.17.3607; Jiang SW, 1996, J BIOL CHEM, V271, P9510, DOI 10.1074/jbc.271.16.9510; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; JIANG SW, 1994, J BIOL CHEM, V269, P10384; Jiang SW, 2000, BIOCHEMISTRY-US, V39, P3505, DOI 10.1021/bi991048w; Kaneko KJ, 1998, DEV GENET, V22, P43, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;43::AID-DVG5&gt;3.0.CO;2-7; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 1998, FASEB J, V12, P35; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; Ruzycky AL, 1996, PLACENTA, V17, P461, DOI 10.1016/S0143-4004(96)90028-4; SchmitzPeiffer C, 1996, BIOCHEM J, V320, P207, DOI 10.1042/bj3200207; TERTRINCLARY C, 1991, ANN ENDOCRINOL-PARIS, V52, P327; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727	46	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23464	23470		10.1074/jbc.M010934200	http://dx.doi.org/10.1074/jbc.M010934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313339	hybrid			2022-12-25	WOS:000169531100033
J	Kim, M; Spelta, V; Sim, J; North, RA; Surprenant, A				Kim, M; Spelta, V; Sim, J; North, RA; Surprenant, A			Differential assembly of rat purinergic P2X(7) receptor in immune cells of the brain and periphery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-LYMPHOCYTES; GATED ION-CHANNEL; MICROGLIAL CELLS; XENOPUS OOCYTES; PURINOCEPTORS; EXPRESSION; SUBUNITS; RELEASE	ATP-gated P2X(7) purinoceptors are found in most immune cells of the periphery and the brain where their activation leads to multiple downstream events such as cell permeabilization, apoptosis, and/or cytokine release. P2X(7) receptors do not form heteromeric receptors with any of the other six P2X subunits, and it is not known what type of homomeric assemblies the P2X(7) subunit makes. We constructed and purified an ectodomain protein of the rat P2X(7) receptor (amino acids 60-323) and used this to generate a monoclonal antibody (Ab) with which to probe P2X(7) receptors in central and peripheral immune cells. In HEK cells expressing rat P2X(7) receptors, the Ab increased the maximum current evoked by BzATP by 3-8-fold with a 5-fold leftward shift in EC50 concentration. This Ab recognized only a nondenatured, multimeric form of the receptor on blue native-PAGE but did not recognize the denatured form on SDS-PAGE. A C-terminaI polyclonal P2X(7) Ab recognized both monomeric subunits on SDS-PAGE and a multimeric complex on blue native-PAGE in this heterologous expression system. With Western blotting using these two Abs, native P2X(7) receptors in peritoneal macrophage and bone marrow cells are shown to exist as a strongly bound multimeric complex, whereas P2X(7) receptors in brain glia and/or astrocytes appear to form only as monomeric subunits.	Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Surprenant, A (corresponding author), Univ Sheffield, Inst Mol Physiol, Alfred Denny Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		North, Richard/GQA-6156-2022					Boucsein C, 2000, EUR J NEUROSCI, V12, P2049, DOI 10.1046/j.1460-9568.2000.00100.x; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BUTTNER C, 2000, PUR 2000 INT S NUCL; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F, 1999, PROG BRAIN RES, V120, P355; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Gudipaty L, 2001, AM J PHYSIOL-CELL PH, V280, pC943, DOI 10.1152/ajpcell.2001.280.4.C943; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Inoue K, 1998, BRIT J PHARMACOL, V123, P1304, DOI 10.1038/sj.bjp.0701732; KENNENMANN H, 1999, ADV NEUROL, V79, P565; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; Klapperstuck M, 2000, BBA-BIOMEMBRANES, V1467, P444, DOI 10.1016/S0005-2736(00)00245-5; MacKenzie AB, 1999, ANN NY ACAD SCI, V868, P716, DOI 10.1111/j.1749-6632.1999.tb11351.x; Markwardt E, 1999, PROG BRAIN RES, V120, P345; Markwardt F, 1997, J PHYSIOL-LONDON, V498, P143, DOI 10.1113/jphysiol.1997.sp021847; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Pannicke T, 2000, J NEUROSCI, V20, P5965, DOI 10.1523/JNEUROSCI.20-16-05965.2000; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x	34	93	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23262	23267		10.1074/jbc.M102253200	http://dx.doi.org/10.1074/jbc.M102253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313357	hybrid			2022-12-25	WOS:000169531100008
J	Wu, HJ; Lima, WF; Crooke, ST				Wu, HJ; Lima, WF; Crooke, ST			Investigating the structure of human RNase H1 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; BINDING; PURIFICATION; SUBUNIT; SPECIFICITY; EXPRESSION; RESOLUTION; ENZYME	In this study we examine for the first time the roles of the various domains of human RNase H1 by site-directed mutagenesis. The carboxyl terminus of human RNase H1 is highly conserved with Escherichia coli RNase H1 and contains the amino acid residues of the putative catalytic site and basic substrate binding do. main of the E. coli RNase enzyme. The amino terminus of human RNase H1 contains a structure consistent with a double-strand RNA (dsRNA) binding motif that is separated from the conserved E. coli RNase H1 region by a Ga-amino acid sequence. These studies showed that although the conserved amino acid residues of the putative catalytic site and basic substrate-binding domain are required for RNase H activity, deletion of either the catalytic site or the basic substrate-binding domain did not ablate binding to the heteroduplex substrate. Deletion of the region between the dsRNA-binding domain and the conserved E. coli RNase H1 domain resulted in a significant loss in the RNase H activity. Furthermore, the binding affinity of this deletion mutant for the heteroduplex substrate was similar to2-fold tighter than the wildtype enzyme suggesting that this central ga-amino acid region does not contribute to the binding affinity of the enzyme for the substrate. The dsRNA-binding domain was not required for RNase H activity, as the dsRNA-deletion mutants exhibited catalytic rates similar to2-fold faster than the rate observed for wild-type enzyme. Comparison of the dissociation constant of human RNase H1 and the dsRNA-deletion mutant for the heteroduplex substrate indicates that the deletion of this region resulted in a 5-fold loss in binding affinity. Finally, comparison of the cleavage patterns exhibited by the mutant proteins with the cleavage pattern for the wild-type enzyme indicates that the dsRNA-binding domain is responsible for the observed strong positional preference for cleavage exhibited by human RNase H1.	ISIS Pharmaceut, Dept Biol Mol & Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Lima, WF (corresponding author), ISIS Pharmaceut, Dept Biol Mol & Struct, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	wlima@isisph.com						Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAMARA RA, 1997, J BIOL CHEM, V272, P4647; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497; CERRITELLI SM, 1995, RNA, V1, P246; Crouch R. J., 1982, NUCLEASES, P211; Dabora JM, 1996, BIOCHEMISTRY-US, V35, P11951, DOI 10.1021/bi9611671; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P392; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRANK P, 1994, NUCLEIC ACIDS RES, V22, P5247, DOI 10.1093/nar/22.24.5247; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	34	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23547	23553		10.1074/jbc.M009676200	http://dx.doi.org/10.1074/jbc.M009676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319219	hybrid			2022-12-25	WOS:000169531100045
J	Strathdee, G; Sansom, OJ; Sim, A; Clarke, AR; Brown, R				Strathdee, G; Sansom, OJ; Sim, A; Clarke, AR; Brown, R			A role for mismatch repair in control of DNA ploidy following DNA damage	ONCOGENE			English	Article						mismatch repair; cell cycle; polyploidy; p53; DNA damage	CELL-CYCLE CHECKPOINT; MICROSATELLITE INSTABILITY; TUMOR-CELLS; SPINDLE CHECKPOINT; DRUG-RESISTANCE; P53 PROTEIN; APOPTOSIS; MUTATION; CISPLATIN; MICE	Many reports have shown a link between mismatch repair (MMR) deficiency and loss of normal cell cycle control, particularly loss of G2 arrest. However almost all of these studies utilized transformed cell lines, and thus the involvement of other genes in this phenotype cannot be excluded. We have examined the effects of cisplatin treatment on primary embryo fibroblasts (MEFs) derived from mice in which the MMR gene Msh2 had been inactivated (Msh2(-/-)). This analysis determined that both primary Msh2(-/-) and wild type (WT) fibroblasts exhibited an essentially identical G2 arrest following cisplatin treatment. Similarly, we observed a cisplatin-induced G2 arrest in immortalized MMR deficient (Mlh1 (/) and Pms2(-/-)) and WT MEFs, p53 deficient primary MEFs (p53(-/-)) exhibited both a clear G2 arrest and an increase in cells with a DNA content of 8N in response to cisplatin, When the Msh2 and p53 defects were combined (p53(-/-)/Msh2(-/-)) the G2 arrest was essentially identical to the p53(-/-) fibroblasts. However, the p53(-/-)/Msh2(-/-) fibroblasts demonstrated a further increase in cells with an 8N DNA content, above that seen in the p53 (/) fibroblasts, These results suggest that loss of MMR on its own is not enough to overcome G2 arrest following exposure to cisplatin but does play a role in preventing polyploidization, or aberrant DNA reduplication, in the absence of functional p53.	Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Beatson Institute; University of Glasgow; University of Edinburgh; Cardiff University	Brown, R (corresponding author), Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Brown, Robert/0000-0001-7960-5755; Sansom, Owen J./0000-0001-9540-3010; Strathdee, Gordon/0000-0001-9681-8429; Clarke, Alan/0000-0002-4281-426X				Anthoney DA, 1996, CANCER RES, V56, P1374; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davis TW, 1998, CANCER RES, V58, P767; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fink D, 1998, CLIN CANCER RES, V4, P1; Gong JG, 1999, NATURE, V399, P806; HAWN MT, 1995, CANCER RES, V55, P3721; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KOI M, 1994, CANCER RES, V54, P4308; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Nehme A, 1997, CANCER RES, V57, P3253; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687	28	29	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1923	1927		10.1038/sj.onc.1204276	http://dx.doi.org/10.1038/sj.onc.1204276			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313940				2022-12-25	WOS:000167908400013
J	Yang, W; Shen, J; Wu, M; Arsura, M; FitzGerald, M; Suldan, Z; Kim, DW; Hofmann, CS; Pianetti, S; Romieu-Mourez, R; Freedman, LP; Sonenshein, GE				Yang, W; Shen, J; Wu, M; Arsura, M; FitzGerald, M; Suldan, Z; Kim, DW; Hofmann, CS; Pianetti, S; Romieu-Mourez, R; Freedman, LP; Sonenshein, GE			Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc	ONCOGENE			English	Article						c-Myc; Max; p27(Kip1); WEHI 231 cells; smooth muscle cells; breast cancer	RECEPTOR-MEDIATED APOPTOSIS; GROWTH-FACTOR-BETA; B-CELL LYMPHOMAS; PRIMARY BREAST-CANCER; CD40 LIGAND RESCUE; FACTOR-KAPPA-B/REL; PROGNOSTIC-SIGNIFICANCE; CONTACT INHIBITION; MESSENGER-RNA; CDK INHIBITOR	Upon engagement of the B Cell Receptor (BCR) of WEHI 231 immature B cells, a drop in c-Myc expression is followed by activation of the cyclin-dependent kinase inhibitor (CKI) p27(kip1), which induces growth arrest and apoptosis, Here, we report inverse patterns of p27 and c-Myc protein expression follow BCR engagement, We present evidence demonstrating, for the first time, that the p27(Kip1) gene is a target of transcriptional repression by c-Myc, Specifically, the changes in p27 protein levels correlated with changes in p27 mRNA levels, and gene transcription, Induction of p27 promoter activity followed BCR engagement of WEHI 231 cells, and this induction could be repressed upon co-transfection of a c-Myc expression vector. Inhibition of the TATA-less p27 promoter by c-Myr was also observed in Jurkat T cells, vascular smooth muscle, and Hs578T breast canter cells, extending the observation beyond immune cells, Consistent with putative Inr element CC (A) under bar GACC (where +1 is underlined) at the start site of transcription in the p27 promoter, deletion of Myc homology box II reduced the extent of repression, Furthermore, enhanced repression was observed upon transfection of the c-Myc 'super-repressor', with mutation of Phe115 to Leu, The sequences mediating transcriptional activity and c-Myc repression were mapped to bp -20 to +20 of the p27 gene, Finally, binding of Max was shown to facilitate c-Myc binding and repression of p27 promoter activity, Overall, these studies identify the p27 CKI gene as a new target whereby c-Myc can control cell proliferation, survival and neoplastic transformation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Boston University; Memorial Sloan Kettering Cancer Center	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.				NATIONAL CANCER INSTITUTE [R01CA082742, T32CA064070, R01CA036355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NCI NIH HHS [CA64070, CA 82742, CA 36355] Funding Source: Medline; NHLBI NIH HHS [HL13262, HL07429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Arsura M, 2000, BLOOD, V96, P1013, DOI 10.1182/blood.V96.3.1013.015k06_1013_1020; ARSURA M, 2001, TRANSCRIPTION FACTOR, P521; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BERNS EMJJ, 1992, CANCER RES, V52, P1107; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BOYD AW, 1981, J IMMUNOL, V126, P2466; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; CLARK HM, 1994, CANCER RES, V54, P3383; Dang CV, 1999, MOL CELL BIOL, V19, P1; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FitzGerald MJ, 1999, ONCOGENE, V18, P2489, DOI 10.1038/sj.onc.1202611; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Kamesaki H, 1998, J IMMUNOL, V160, P770; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lee CCR, 1999, CARCINOGENESIS, V20, P1697, DOI 10.1093/carcin/20.9.1697; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; NORVELL A, 1995, J IMMUNOL, V154, P4404; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Runge D, 1997, BIOL CHEM, V378, P873, DOI 10.1515/bchm.1997.378.8.873; Schauer SL, 1998, J IMMUNOL, V160, P4398; Schauer SL, 1996, J IMMUNOL, V157, P81; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; Steiner P, 1996, Prog Cell Cycle Res, V2, P73; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsuchiya A, 1999, J SURG ONCOL, V70, P230, DOI 10.1002/(SICI)1096-9098(199904)70:4<230::AID-JSO6>3.0.CO;2-I; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang W, 1999, J IMMUNOL, V162, P314; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wu M, 1999, J IMMUNOL, V163, P6530; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yanagisawa K, 1999, J BIOCHEM-TOKYO, V125, P36, DOI 10.1093/oxfordjournals.jbchem.a022265; YANO T, 1993, ONCOGENE, V8, P2741; Yi AK, 1996, J IMMUNOL, V157, P4918	93	218	230	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1688	1702		10.1038/sj.onc.1204245	http://dx.doi.org/10.1038/sj.onc.1204245			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313917				2022-12-25	WOS:000167750900003
J	Yolcu, E; Sayan, BS; Yagci, T; Cetin-Atalay, R; Soussi, T; Yurdusev, N; Ozturk, M				Yolcu, E; Sayan, BS; Yagci, T; Cetin-Atalay, R; Soussi, T; Yurdusev, N; Ozturk, M			A monoclonal antibody against DNA binding helix of p53 protein	ONCOGENE			English	Article						p53; hybridoma; DNA binding helix	MUTATIONS; MUTANTS; REGION; CANCER; CELLS	Three monoclonal antibodies (Mabs) were generated against p53 DNA-binding core domain. When tested by immunoprecipitation, Western blot and immunofluorescence techniques, Mab 9E4, as well as 7D3 and 6B10 reacted with both wild-type and various mutant p53 proteins. The epitopes recognized by Mabs 7D3, 9E4 and 6B10 were located respectively within the amino acid residues 211-220, 281-290 and 291-300 of human p53 protein. The epitope recognized by 9E4 Mab coincides with helix 2, also called p53 DNA binding helix, which allows the direct contact of the protein with its target DNA sequences. This antibody may be useful to study transcription-dependent and transcription-independent activities of wild-type and mutant p53 proteins.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey; Bilkent Univ, BilGen Genet & Biotechnol Ctr, TR-06533 Ankara, Turkey; TUBITAK MRC, Res Inst Genet Engn & Biotechnol, Dept Mol Oncol, Gebze, Kocaeli, Turkey; Inst Curie, Paris, France	Ihsan Dogramaci Bilkent University; Ihsan Dogramaci Bilkent University; Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014; Cetin-Atalay, Rengul/O-9826-2014; Cetin-Atalay, Rengul/F-5780-2013	OZTURK, MEHMET/0000-0002-6092-9706; Cetin-Atalay, Rengul/0000-0003-2408-6606; Cetin-Atalay, Rengul/0000-0003-2408-6606; soussi, thierry/0000-0001-8184-3293				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	15	5	6	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1398	1401		10.1038/sj.onc.1204240	http://dx.doi.org/10.1038/sj.onc.1204240			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313883	Green Published			2022-12-25	WOS:000167495000013
J	Barette, C; Jariel-Encontre, I; Piechaczyk, M; Piette, J				Barette, C; Jariel-Encontre, I; Piechaczyk, M; Piette, J			Human cyclin C protein is stabilized by its associated kinase cdk8, independently of its catalytic activity	ONCOGENE			English	Article						cyclin C; cdk8; degradation; proteasome; ubiquitin	RNA-POLYMERASE-II; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; TRANSCRIPTIONAL CONTROL; RAPID DEGRADATION; MEDIATOR COMPLEX; MAMMALIAN-CELLS; MESSENGER-RNA; CLN FUNCTION; DNA-REPAIR	Cyclin C belongs to the cyclin family of proteins that control cell cycle transitions through activation of specific catalytic subunits, the cyclin-dependent kinases (CDKs), However, there is as yet no evidence, for any role of cyclin C and its partner, cdk8, in cell cycle regulation. Rather, the cyclin C-cdk8 complex was found associated with the RNA polymerase II transcription machinery. The periodic degradation of bona fide cyclins is crucial for cell-cycle progression and depends on the catalytic activity of the associated CDK. Here we,ve show that endogenous cyclin C protein is quite stable with a half-life of 4 h, In contrast, exogenously expressed cyclin C is very unstable (half-life 15 min) and degraded by the ubiquitin-proteasome pathway. Co-expression with its associated cdk, however, strongly stabilizes cyclin C and results in a protein half-life near that of endogenous cyclin C. In stark contrast to data reported for other members of the cyclin family, both catalytically active and inactive cdk8 induce cyclin C stabilization. Moreover, this stabilization is accompanied in both cases by phosphorylation of the cyclin,which is not detectable when unstable. Our results indicate that cyclin C has apparently diverged from other cyclins in the regulation of its stability by its CDK partner.	CNRS, UMR 5535, Inst Genet Mol, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piette, J (corresponding author), CNRS, UMR 5535, Inst Genet Mol, IFR24,1919 Route Mende, F-34293 Montpellier 5, France.		PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; BARETTE, Caroline/0000-0003-0999-7751				Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; CARLSON M, 1984, GENETICS, V107, P19; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hautbergue G, 1999, MOL CELL BIOL, V19, P2527; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Rickert P, 1996, ONCOGENE, V12, P2631; Sambrook J., 2002, MOL CLONING LAB MANU; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158	53	28	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					551	562		10.1038/sj.onc.1204129	http://dx.doi.org/10.1038/sj.onc.1204129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313987				2022-12-25	WOS:000166755000002
J	Lee, SH; Shin, MS; Kim, HS; Lee, HK; Park, WS; Kim, SY; Lee, JH; Han, SY; Park, JY; Oh, RR; Kang, CS; Kim, KM; Jang, JJ; Nam, SW; Lee, JY; Yoo, NJ				Lee, SH; Shin, MS; Kim, HS; Lee, HK; Park, WS; Kim, SY; Lee, JH; Han, SY; Park, JY; Oh, RR; Kang, CS; Kim, KM; Jang, JJ; Nam, SW; Lee, JY; Yoo, NJ			Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma	ONCOGENE			English	Article						mutation; TRAIL-receptor 1; TRAIL-receptor 2; non-Hodgkin's lymphoma	TRAIL-INDUCED APOPTOSIS; FAS APO-1/CD95 GENE; LIGAND TRAIL; RECEPTOR; DEATH; CELLS; REGIONS; FADD; DNA	Tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. TRAIL-RI and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL), Because TRAIL/TRAIL, receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-RI and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL, In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-RI gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-RI gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-RI and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-RI and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R2 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL.	Catholic Univ Korea, Coll Med, Dept Pathol, Socho Gu, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110799, South Korea; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	Catholic University of Korea; Catholic University of Korea; Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Socho Gu, 505 Banpo Dong, Seoul 137701, South Korea.		Jang, JaJune/F-6647-2011; Yoo, Nam Jin/GNM-9060-2022; kim, Hong Sug/G-2731-2014					Arai T, 1998, CANCER LETT, V133, P197, DOI 10.1016/S0304-3835(98)00230-4; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; EMI M, 1992, CANCER RES, V52, P5368; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gronbaek K, 1998, BLOOD, V92, P3018; HARRIS NL, 1994, BLOOD, V84, P1361; KAGAN J, 1995, ONCOGENE, V11, P2121; Keane MM, 1999, CANCER RES, V59, P734; Kim KH, 2000, CLIN CANCER RES, V6, P335; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 1999, CANCER RES, V59, P3068; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Monni O, 1996, BLOOD, V87, P5269, DOI 10.1182/blood.V87.12.5269.bloodjournal87125269; Mori S, 1999, J IMMUNOL, V162, P5616; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Thomas WD, 1998, J IMMUNOL, V161, P2195; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wistuba II, 1999, CANCER RES, V59, P1973; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhang XD, 1999, CANCER RES, V59, P2747	37	121	125	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					399	403		10.1038/sj.onc.1204103	http://dx.doi.org/10.1038/sj.onc.1204103			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313970				2022-12-25	WOS:000166411000015
J	Cohen, SB; Waha, A; Gelman, IH; Vogt, PK				Cohen, SB; Waha, A; Gelman, IH; Vogt, PK			Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts	ONCOGENE			English	Article						oncogenic transformation; differential gene expression; DNA micro-array; tumor suppressor	KINASE-C SUBSTRATE; PROTEIN-KINASE; RETROVIRAL VECTORS; GENE-TRANSFER; EMBRYO CELLS; ACTIVATION; IDENTIFICATION; FOS; SRC; MYC	Line 10T1/2 mouse fibroblast overexpressing the v-Jun oncoprotein mere morphologically altered, grew into multilayered foci in culture and formed colonies when suspended in agar, The growth rate of the v-Jun-transformed 10T1/2 cells was not changed significantly from that of the untransformed parental cells, but the saturation density of the transformed cultures exceeded that of normal controls by a factor of 2, mRNA extracted from v-Jun-transformed 10T1/2 cells was analysed for differential gene expression with DNA micro-array technology. One of the targets downregulated by v-Jun was identified as SSeCKS (Src-suppressed C kinase substrate). Re-expression of SSeCKS in v-Jun-transformed fibroblasts reversed the transformed phenotype of the cells. Their ability to form foci was reduced to background levels, the number and size of agar colonies was lowered by a factor of 10 and the saturation density was significantly diminished. However, expression of SSeCKS had little effect on the morphology of v-Jun-transformed 10T1/2 cells. These data suggest that the SSeCKS protein has growth-attenuating properties. Down-regulation of SSeCKS may be essential for Jun-induced transformation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Gen Probe Inc, San Diego, CA 92121 USA	Scripps Research Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA42564] Funding Source: Medline; NIDDK NIH HHS [5 T23 DK 07022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; ALT M, 1993, ONCOGENE, V8, P1421; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; COLLEDGE WH, 1989, ONCOGENE, V4, P753; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GRODEN J, 1995, CANCER RES, V55, P1531; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; MORGAN IM, 1994, ONCOGENE, V9, P2793; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NISHIMURA T, 1988, ONCOGENE, V3, P659; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; Xu JC, 2000, CANCER RES, V60, P1677; ZHANG M, 1995, CANCER RES, V55, P2537	39	22	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					141	146		10.1038/sj.onc.1204077	http://dx.doi.org/10.1038/sj.onc.1204077			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313943				2022-12-25	WOS:000166410900001
J	Kodama, E; Baba, T; Yokosawa, H; Sawada, H				Kodama, E; Baba, T; Yokosawa, H; Sawada, H			cDNA cloning and functional analysis of ascidian sperm proacrosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACROSIN-LIKE ENZYME; ZONA-PELLUCIDA; HALOCYNTHIA-RORETZI; CUB DOMAIN; FERTILIZATION; PROTEINS; SEQUENCE; IDENTIFICATION; SPERMADHESINS; PARTICIPATION	cDNA cloning and functional analysis of proacrosin from the ascidian Halocynthia roretzi were undertaken. The isolated cDNA of the ascidian preproacrosin consists of 2367 nucleotides, and an open reading frame encodes 505 amino acids, which corresponds to the molecular mass of 55,003 De. The mRNA of proacrosin was found to be specifically expressed in the gonad by Northern blotting and in the spermatocytes or spermatids by in situ hybridization, The amino acid sequences around His(76), Asp(132), and Ser(227), which make up a catalytic triad, showed high homology to those of the trypsin family. Ascidian acrosin has paired basic residues (Lys(56)-His(57)) in the N-terminal region, which is one of the most characteristic features of mammalian acrosin, This region seems to play a key role in the binding of (pro)acrosin to the vitelline coat, because the peptide containing the paired basic residues, but not the peptide substituted with Ale, was capable of binding to the vitelline coat. Unlike mammalian proacrosin, ascidian proacrosin contains two CUB domains in the C-terminal region, in which CUB domain 1 seems to be involved in its binding to the vitelline coat. Four components of the vitelline coat that are capable of binding to CUB domain 1 in proacrosin were identified. In response to sperm activation, acrosin was released from sperm into the surrounding seawater, suggesting that ascidian acrosin plays a key role in sperm penetration through the coat. These results indicate that ascidian sperm contains a mammalian acrosin homologue, a multi-functional protein working in fertilization.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	Hokkaido University; University of Tsukuba	Sawada, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan.							Adham IM, 1997, MOL REPROD DEV, V46, P370, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;370::AID-MRD16&gt;3.0.CO;2-2; BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1994, J BIOL CHEM, V269, P31845; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CALVETE JJ, 1993, FEBS LETT, V334, P37, DOI 10.1016/0014-5793(93)81675-P; CLAVETE JJ, 1995, FEBS LETT, V365, P179; DELGADILLOREYNOSO MG, 1989, J MOL EVOL, V29, P314, DOI 10.1007/BF02103619; DOSTALOVA Z, 1994, BIOL CHEM H-S, V375, P457, DOI 10.1515/bchm3.1994.375.7.457; HOSHI M, 1981, DEV BIOL, V86, P117, DOI 10.1016/0012-1606(81)90322-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT CC, 1979, DEV BIOL, V69, P296, DOI 10.1016/0012-1606(79)90293-8; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MULLERESTERL W, 1981, METHOD ENZYMOL, V80, P621; OLAND R, 1986, ADV EXP MED BIOL, V205, P131; Richardson RT, 1996, J BIOL CHEM, V271, P24069, DOI 10.1074/jbc.271.39.24207; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Sambrook J., 2002, MOL CLONING LAB MANU; Sawada H, 1996, BIOCHEM BIOPH RES CO, V222, P499, DOI 10.1006/bbrc.1996.0773; SAWADA H, 1984, J BIOL CHEM, V259, P2900; SAWADA H, 1982, GAMETE RES, V5, P291, DOI 10.1002/mrd.1120050309; SAWADA H, 1984, DEV BIOL, V105, P246, DOI 10.1016/0012-1606(84)90281-1; Topfer-Petersen E, 1996, J Reprod Fertil Suppl, V50, P55; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; URCH UA, 1991, DEVELOPMENT, V111, P1165; URCH UA, 1985, J EXP ZOOL, V233, P479, DOI 10.1002/jez.1402330317; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470	28	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24594	24600		10.1074/jbc.M011370200	http://dx.doi.org/10.1074/jbc.M011370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313341	hybrid			2022-12-25	WOS:000169800700025
J	van Roosmalen, ML; Jongbloed, JDH; Dubois, JYF; Venema, G; Bron, S; van Dijl, JM				van Roosmalen, ML; Jongbloed, JDH; Dubois, JYF; Venema, G; Bron, S; van Dijl, JM			Distinction between major and minor Bacillus signal peptidases based on phylogenetic and structural criteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPORALLY CONTROLLED EXPRESSION; MULTIPLE SEQUENCE ALIGNMENT; SUBTILIS; IDENTIFICATION; SECRETION; SIPS; MECHANISM; PROTEINS; CLEAVAGE; SITE	The processing of secretory preproteins by signal peptidases (SPases) is essential for cell viability. As previously shown for Bacillus subtilis, only certain SPases of organisms containing multiple paralogous SPases are essential. This allows a distinction between SPases that are of major and minor importance for cell viability. Notably, the functional difference between major and minor SPases is not reflected clearly in sequence alignments. Here, we have successfully used molecular phylogeny to predict major and minor SPases, The results were verified with SPases from various bacilli, As predicted, the latter enzymes behaved as major or minor SPases when expressed in B. subtilis. Strikingly, molecular modeling indicated that the active site geometry is not a critical parameter for the classification of major and minor Bacillus SPases, Even though the substrate binding site of the minor SPase SipV is smaller than that of other known SPases, SipV could be converted into a major SPase without changing this site. Instead, replacement of amino-terminal residues of SipV with corresponding residues of the major SPase SipS was sufficient for conversion of SipV into a major SPase, This suggests that differences between major and minor SPases are based on activities other than substrate cleavage site selection.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	J.M.VAN.DIJL@FARM.RUG.NL	van Dijl, Jan Maarten/G-1205-2013					Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; BRON S, 1972, MUTAT RES, V15, P395, DOI 10.1016/0027-5107(72)90004-8; Carlos JL, 2000, J BIOL CHEM, V275, P38813, DOI 10.1074/jbc.M007093200; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; HOANG V, 1995, BBA-MOL CELL RES, V1269, P64, DOI 10.1016/0167-4889(95)00101-W; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 2000, PHARMACOL THERAPEUT, V87, P27, DOI 10.1016/S0163-7258(00)00064-4; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stover AG, 1999, J BACTERIOL, V181, P7065; Stover AG, 1999, J BACTERIOL, V181, P1664; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjalsma H, 1999, J BACTERIOL, V181, P2448, DOI 10.1128/JB.181.8.2448-2454.1999; Tjalsma H, 2000, J BIOL CHEM, V275, P25102, DOI 10.1074/jbc.M002676200; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; van Roosmalen ML, 2001, MICROBIOL-UK, V147, P909, DOI 10.1099/00221287-147-4-909; van Roosmalen ML, 2000, J BACTERIOL, V182, P5765, DOI 10.1128/JB.182.20.5765-5770.2000; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	28	12	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25230	25235		10.1074/jbc.M102099200	http://dx.doi.org/10.1074/jbc.M102099200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309398	hybrid			2022-12-25	WOS:000169800700107
J	Minic, Z; Simon, V; Penverne, B; Gaill, F; Herve, G				Minic, Z; Simon, V; Penverne, B; Gaill, F; Herve, G			Contribution of the bacterial endosymbiont to the biosynthesis of pyrimidine nucleotides in the deep-sea tube worm Riftia pachyptila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA SEQUENCES; ESCHERICHIA-COLI; GLUTAMINE-SYNTHETASE; CHEMOAUTOTROPHIC SYMBIONTS; ASPARTATE-TRANSCARBAMYLASE; MULTIFUNCTIONAL PROTEIN; NITRATE RESPIRATION; CELLS; JONES; PURIFICATION	The deep-sea tube worm Riftia pachyptila (Vestimentifera) from hydrothermal vents lives in an intimate symbiosis with a sulfur-oxidizing bacterium. That involves specific interactions and obligatory metabolic exchanges between the two organisms. In this work, we analyzed the contribution of the two partners to the biosynthesis of pyrimidine nucleotides through both the "de novo" and "salvage" pathways. The first three enzymes of the de novo pathway, carbamyl-phosphate synthetase, aspartate transcarbamylase, and dihydroorotase, were present only in the trophosome, the symbiont-containing tissue. The study of these enzymes in terms of their catalytic and regulatory properties in both the trophosome and the isolated symbiotic bacteria provided a clear indication of the microbial origin of these enzymes. In contrast, the succeeding enzymes of this de novo pathway, dihydroorotate dehydrogenase and orotate phosphoribosyltransferase, were present in all body parts of the worm. This finding indicates that the animal is fully dependent on the symbiont for the de novo biosynthesis of pyrimidines. In addition, it suggests that the synthesis of pyrimidines in other tissues is possible from the intermediary metabolites provided by the trophosomal tissue and from nucleic acid degradation products since the enzymes of the salvage pathway appear to be present in all tissues of the worm. Analysis of these salvage pathway enzymes in the trophosome strongly suggested that these enzymes belong to the worm. In accordance with this conclusion, none of these enzyme activities was found in the isolated bacteria. The enzymes involved in the production of the precursors of carbamyl phosphate and nitrogen assimilation, glutamine synthetase and nitrate reductase, were also investigated, and it appears that these two enzymes are present in the bacteria.	Univ Paris 06, CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, F-75006 Paris, France; Univ Paris 06, CNRS UPR Roscoff 9042, Inst Natl Sci Univers, Biol Marine Lab, F-75252 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Herve, G (corresponding author), Univ Paris 06, CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, 96 Blvd Raspail, F-75006 Paris, France.		Minic, Zoran/AAH-2091-2021					AITKEN DM, 1975, CAN J BIOCHEM CELL B, V53, P721, DOI 10.1139/o75-099; ARP AJ, 1981, SCIENCE, V213, P342, DOI 10.1126/science.213.4505.342; BENDER RA, 1977, J BACTERIOL, V129, P1001, DOI 10.1128/JB.129.2.1001-1009.1977; BOSH C, 1984, C R ACAD SCI 3, V299, P413; BOSH C, 1984, C R ACAD SCI 3, V299, P371; Boza JJ, 2000, EUR J NUTR, V39, P38, DOI 10.1007/s003940050074; Bright M, 2000, MAR BIOL, V136, P621, DOI 10.1007/s002270050722; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DARROW RA, 1977, BIOCHEM BIOPH RES CO, V78, P554, DOI 10.1016/0006-291X(77)90214-5; De Cian MC, 2000, J EXP BIOL, V203, P2907; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; DISTEL DL, 1987, MAR BIOL, V96, P97; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; EVANS DR, 1993, BIOCHEM SOC T, V21, P186, DOI 10.1042/bst0210186; FELBECK H, 1981, SCIENCE, V213, P336, DOI 10.1126/science.213.4505.336; Felbeck Horst, 1988, Oceanologica Acta Special Issue, V8, P131; FOX RM, 1971, ANAL BIOCHEM, V41, P578, DOI 10.1016/0003-2697(71)90180-1; HENTSCHEL U, 1993, MAR ECOL PROG SER, V94, P35, DOI 10.3354/meps094035; HENTSCHEL U, 1993, NATURE, V366, P338, DOI 10.1038/366338a0; HUGUES DS, 1997, APPL ENVIRON MICROB, V63, P3494; IVES DH, 1969, ANAL BIOCHEM, V28, P192, DOI 10.1016/0003-2697(69)90170-5; JARROLL EL, 1983, J PARASITOL, V69, P846, DOI 10.2307/3281043; Jones M.L., 1981, Proceedings of the Biological Society of Washington, V93, P1295; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Jones Meredith L., 1988, Oceanologica Acta Special Issue, V8, P69; JONES ML, 1981, SCIENCE, V213, P333, DOI 10.1126/science.213.4505.333; KALMAN SM, 1966, J BIOL CHEM, V241, P1871; Kochevar Randall E., 1993, Molecular Marine Biology and Biotechnology, V2, P10; Lee RW, 1999, J EXP BIOL, V202, P289; LEGER D, 1988, BIOCHEMISTRY-US, V27, P4293, DOI 10.1021/bi00412a015; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; LINDMARK DG, 1982, MOL BIOCHEM PARASIT, V5, P291, DOI 10.1016/0166-6851(82)90036-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundegaard C, 1999, BIOCHEMISTRY-US, V38, P3327, DOI 10.1021/bi982279q; McCauley R, 1998, JPEN-PARENTER ENTER, V22, P105, DOI 10.1177/0148607198022002105; Miller R W, 1978, Methods Enzymol, V51, P63; Nelson D.C., 1995, DEEP SEA HYDROTHERMA, P125; ODONOVAN GA, 1970, BACTERIOL REV, V34, P278, DOI 10.1128/MMBR.34.3.278-343.1970; Ogawa J, 1995, ARCH MICROBIOL, V164, P353; Orengo A, 1978, Methods Enzymol, V51, P299; PERBAL B, 1972, J MOL BIOL, V70, P511, DOI 10.1016/0022-2836(72)90556-6; ROBIN JP, 1989, EUR J BIOCHEM, V183, P519, DOI 10.1111/j.1432-1033.1989.tb21080.x; ROGERS LE, 1972, EXPERIENTIA, V28, P1258, DOI 10.1007/BF01946211; ROGERS LE, 1968, PEDIATRICS, V42, P423; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SANDER EG, 1965, J BIOL CHEM, V240, P3628; Shigenobu S, 2000, NATURE, V407, P81, DOI 10.1038/35024074; Simon V, 2000, MAR BIOL, V136, P115, DOI 10.1007/s002270050014; STAHL DA, 1984, SCIENCE, V224, P409, DOI 10.1126/science.224.4647.409; STEUART CD, 1971, NATURE-NEW BIOL, V233, P109, DOI 10.1038/newbio233109a0; STEWART V, 1994, ANTON LEEUW INT J G, V66, P37, DOI 10.1007/BF00871631; TAYLOR WH, 1976, J BACTERIOL, V127, P863, DOI 10.1128/JB.127.2.863-873.1976; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; TUNNICLIFFE V, 1992, AM SCI, V80, P334; WANG CC, 1984, MOL BIOCHEM PARASIT, V10, P171, DOI 10.1016/0166-6851(84)90005-7; Weinfeld H, 1978, Methods Enzymol, V51, P84	57	19	19	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23777	23784		10.1074/jbc.M102249200	http://dx.doi.org/10.1074/jbc.M102249200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306586	hybrid			2022-12-25	WOS:000169531100075
J	Estrada, M; Cardenas, C; Liberona, JL; Carrasco, MA; Mignery, GA; Allen, PD; Jaimovich, E				Estrada, M; Cardenas, C; Liberona, JL; Carrasco, MA; Mignery, GA; Allen, PD; Jaimovich, E			Calcium transients in 1B5 myotubes lacking ryanodine receptors are related to inositol trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNELS; MYOGENIC CELL-LINE; SKELETAL-MUSCLE; 1,4,5-TRISPHOSPHATE RECEPTOR; GENE-EXPRESSION; NUCLEUS; UNITS; MEMBRANES; PATHWAYS; PROTEIN	Potassium depolarization of skeletal myotubes evokes slow calcium waves that are unrelated to contraction and involve the cell nucleus (Jaimovich, E., Reyes, R., Liberona, J. L., and Powell, J. A. (2000) Am. J. Physiol. 278, C998-C1010). Studies were done in both the 1B5 (Ry53-/-) murine "dyspedic" myoblast cell line, which does not express any ryanodine receptor isoforms (Moore, R. A, Nguyen, H., Galceran, J., Pessah, I. N., and Alien, P. D. (1998) J. Cell Biol. 140, 843-851), and C2C12 cells, a myoblast cell line that expresses all three isoforms. Although 1B5 cells lack ryanodine binding, they bind tritiated inositol (1,4,5)-trisphosphate. Both type 1 and type 3 inositol trisphosphate receptors were immune-located in the nuclei of both cell types and were visualized by Western blot analysis. After stimulation with 47 mM K+, inositol trisphosphate mass raised transiently in both cell types. Both fast calcium increase and slow propagated calcium signals were seen in C2C12 myotubes. However, 1B5 myotubes (as well as ryanodine-treated C2C12 myotubes) displayed only a long-lasting, non-propagating calcium increase, particularly evident in the nuclei. Calcium signals in 1B5 myotubes were almost completely blocked by inhibitors of the inositol trisphosphate pathway: U73122, 2-aminoethoxydiphenyl berate, or xestospongin C. Results support the hypothesis that inositol trisphosphate mediates slow calcium signals in muscle cell ryanodine receptors, having a role in their time course and propagation.	Univ Chile, Fac Med, Inst Ciencias Biomed, Santiago 70005, Chile; Loyola Univ, Dept Physiol, Maywood, IL 60153 USA; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA	Universidad de Chile; Loyola University Chicago; Harvard University; Brigham & Women's Hospital	Jaimovich, E (corresponding author), Casilla 70005, Santiago 6530499, Chile.		Estrada, Manuel/C-1269-2014; Estrada, Manuel/AAS-5605-2020; Jaimovich, Enrique/AAY-7632-2020	Estrada, Manuel/0000-0001-7877-8160; Estrada, Manuel/0000-0001-7877-8160; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR43140] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; Buck ED, 1997, J BIOL CHEM, V272, P7360, DOI 10.1074/jbc.272.11.7360; CASTLEMAN KR, 1989, DIGITAL IMAGE PROCES; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Estrada M, 2000, AM J PHYSIOL-ENDOC M, V279, pE132, DOI 10.1152/ajpendo.2000.279.1.E132; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P496; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1, DOI 10.1007/s004240050098; Guihard G, 1997, FEBS LETT, V414, P89, DOI 10.1016/S0014-5793(97)00949-6; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; JAIMOVICH E, 1994, CELL CALCIUM, V15, P356, DOI 10.1016/0143-4160(94)90011-6; Jaimovich E, 2000, AM J PHYSIOL-CELL PH, V278, pC998, DOI 10.1152/ajpcell.2000.278.5.C998; JAIMOVICH E, 1986, BIOCHIM BIOPHYS ACTA, V855, P89, DOI 10.1016/0005-2736(86)90192-6; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Liberona JL, 1997, J MUSCLE RES CELL M, V18, P587, DOI 10.1023/A:1018671520294; Liberona JL, 1998, MUSCLE NERVE, V21, P902, DOI 10.1002/(SICI)1097-4598(199807)21:7<902::AID-MUS8>3.0.CO;2-A; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MINTA A, 1989, J BIOL CHEM, V264, P8171; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; Ward CW, 2000, J PHYSIOL-LONDON, V525, P91, DOI 10.1111/j.1469-7793.2000.t01-2-00091.x; Wojcikiewicz RJH, 1998, MOL PHARMACOL, V53, P656, DOI 10.1124/mol.53.4.656	34	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22868	22874		10.1074/jbc.M100118200	http://dx.doi.org/10.1074/jbc.M100118200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301324	hybrid			2022-12-25	WOS:000169412700119
J	Gombos, Z; Jeromin, A; Mal, TK; Chakrabartty, A; Ikura, M				Gombos, Z; Jeromin, A; Mal, TK; Chakrabartty, A; Ikura, M			Calexcitin B is a new member of the sarcoplasmic calcium binding protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CIRCULAR-DICHROISM; DROSOPHILA-MELANOGASTER; ANGSTROM RESOLUTION; KINASE-C; GTP; MEMORY; DOMAIN; PURIFICATION; CONFORMATION	Calexcitin (CE) is a calcium sensor protein that has been implicated in associative learning. The CE gene was previously cloned from the long-finned squid, Loligo pealei, and the gene product was shown to bind GTP and modulate K+ channels and ryanodine receptors in a Ca2+-dependent manner. We cloned a new gene from L. pealei, which encodes a CE like protein, here named calexcitin B (CEB). CEB has 95% amino acid identity to the original form. Our sequence analyses indicate that CEs are homologous to the sarcoplasmic calcium binding protein subfamily of the EF-hand superfamily. Far and near UV circular dichroism and nuclear magnetic resonance studies demonstrate that CEB binds Ca2+ and undergoes a conformational change. CEB is phosphorylated by protein kinase C, but not by casein kinase II. CEB does not bind GTP. Western blot experiments using polyclonal antibodies generated against CEB showed that CEB is expressed in the L. pealei optic lobe, Taken together, the neuronal protein CE represents the first example of a Ca2+ sensor in the sarcoplasmic calcium-binding protein family.	Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ikura, M (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, Rm 7-723,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	mikura@uhnres.utoronto.ca	Mal, Tapas K/A-9453-2011	Mal, Tapas K/0000-0002-0625-2095; Ikura, Mitsuhiko/0000-0002-9524-1303; Chakrabartty, Avi/0000-0001-7002-8381				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Ascoli GA, 1997, J BIOL CHEM, V272, P24771, DOI 10.1074/jbc.272.40.24771; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAMPBELL JA, 1991, BIOCHEM SOC T, V19, pS53, DOI 10.1042/bst019053s; Cavallaro S, 1997, P NATL ACAD SCI USA, V94, P9669, DOI 10.1073/pnas.94.18.9669; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLOSSET J, 1975, BIOCHIM BIOPHYS ACTA, V405, P228, DOI 10.1016/0005-2795(75)90089-6; COLLINS JH, 1983, BIOCHEMISTRY-US, V22, P341, DOI 10.1021/bi00271a017; COOK WJ, 1993, J MOL BIOL, V229, P461, DOI 10.1006/jmbi.1993.1046; COX JA, 1981, BIOCHIM BIOPHYS ACTA, V670, P441, DOI 10.1016/0005-2795(81)90119-7; COX JA, 1979, BIOCHIMIE, V61, P601, DOI 10.1016/S0300-9084(79)80157-1; COX JA, 1991, NOVEL CALCIUM BINDIN, P447; Craescu CT, 1998, J BIOMOL NMR, V12, P565, DOI 10.1023/A:1008361202496; Cuvillier A, 2000, J CELL SCI, V113, P2065; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P2394, DOI 10.1021/bi00060a034; ETCHEBERRIGARAY R, 1994, ANN NY ACAD SCI, V747, P245; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Gribenko A, 1998, PROTEIN SCI, V7, P211, DOI 10.1002/pro.5560070123; HERMANN A, 1995, COMP BIOCHEM PHYS B, V111, P337, DOI 10.1016/0305-0491(94)00218-J; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1985, BIOCHEMISTRY-US, V24, P4264, DOI 10.1021/bi00337a002; Kato M, 1998, BIOCHEM J, V331, P871, DOI 10.1042/bj3310871; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; Kelly LE, 1997, INSECT BIOCHEM MOLEC, V27, P783, DOI 10.1016/S0965-1748(97)00062-3; KERSCHBAUM HH, 1992, BRAIN RES, V597, P339, DOI 10.1016/0006-8993(92)91491-V; KIM CS, 1995, P NATL ACAD SCI USA, V92, P3060, DOI 10.1073/pnas.92.7.3060; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KOHLER L, 1978, MOL CELL BIOCHEM, V20, P85; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Kuzirian AM, 1998, BIOL BULL, V195, P198, DOI 10.2307/1542837; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MANSER E, 1995, METHOD ENZYMOL, V256, P130; Mitchell J, 1998, BIOCHEMISTRY-US, V37, P9064, DOI 10.1021/bi972768a; Nelson TJ, 1996, P NATL ACAD SCI USA, V93, P13808, DOI 10.1073/pnas.93.24.13808; NELSON TJ, 1990, SCIENCE, V247, P1479, DOI 10.1126/science.2108498; Nelson TJ, 1999, BIOCHEM J, V341, P423, DOI 10.1042/0264-6021:3410423; NELSON TJ, 1991, J NEUROCHEM, V57, P2065, DOI 10.1111/j.1471-4159.1991.tb06423.x; NELSON TJ, 1994, P NATL ACAD SCI USA, V91, P9287, DOI 10.1073/pnas.91.20.9287; NELSON TJ, 1995, J NEUROCHEM, V65, P2350; PAIN R, 1996, CURRENT PROTOCOLS PR, P761; PAULS TL, 1993, EUR J NEUROSCI, V5, P549, DOI 10.1111/j.1460-9568.1993.tb00520.x; PAULS TL, 1993, J BIOL CHEM, V268, P20897; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Sun MK, 1999, P NATL ACAD SCI USA, V96, P7023, DOI 10.1073/pnas.96.12.7023; TAKAGI T, 1990, EUR J BIOCHEM, V192, P387, DOI 10.1111/j.1432-1033.1990.tb19239.x; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VIJAYKUMAR S, 1992, J MOL BIOL, V224, P413, DOI 10.1016/0022-2836(92)91004-9; WILLIAMS TC, 1986, BIOCHEMISTRY-US, V25, P1835, DOI 10.1021/bi00355a057; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	66	15	15	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22529	22536		10.1074/jbc.M010508200	http://dx.doi.org/10.1074/jbc.M010508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306567	Green Published, hybrid			2022-12-25	WOS:000169412700075
J	Knight, JS; Cotter, MA; Robertson, ES				Knight, JS; Cotter, MA; Robertson, ES			The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAVITY-BASED LYMPHOMA; EPSTEIN-BARR-VIRUS; HTERT GENE PROMOTER; DNA-SEQUENCES; C-MYC; CELL-LINES; MAMMALIAN TELOMERASE; ENDOTHELIAL-CELLS; RNA COMPONENT; ACTIVATION	Telomerase is a multi-subunit ribonucleoprotein holoenzyme that stabilizes telomere length through the addition of new repeat sequence to the ends of chromosomes. Telomerase reverse transcriptase is the subunit of this complex responsible for the enzymatic activity of telomerase. Expression of the reverse transcriptase is regulated at the level of transcription through the action of transcription factors that target its promoter. Most Kaposi's sarcoma tumor cells are latently infected with the Kaposi's sarcoma-associated herpesvirus, and the constitutive expression of a viral-encoded latency-associated nuclear antigen has been shown to be important for the maintenance of the viral episome. The proliferative nature of Kaposi's sarcoma suggests that this antigen may also play a critical role in viral-mediated oncogenesis. In this study telomerase reverse transcriptase promoter elements cloned into a luciferase reporter plasmid were analyzed to determine the ability of the latency associated nuclear antigen to regulate transcription. The latency associated nuclear antigen transactivated the fall-length promoter in 293T, 293, and BJAB cell. lines. Furthermore, truncation promoter studies implicated sequence from -130 to +5 in viral mediated activation. This region contains five Spl transcription factor-binding sites. Electrophoretic mobility shift assays indicated that the latency-associated nuclear antigen targets and affects the Sp1-DNA complex in the context of BJAB nuclear extracts.	Univ Michigan, Med Ctr, Sch Med, Med Scientist Training Program, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Cell & Mol Biol Grad Program, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Comprehens Canc & Geriatr Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Robertson, ES (corresponding author), Univ Michigan, Med Ctr, Sch Med, Med Scientist Training Program, CCGC 3217, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [T32 GM07863] Funding Source: Medline; PHS HHS [C072150-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIELLO L, 1979, VIROLOGY, V94, P460, DOI 10.1016/0042-6822(79)90476-8; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; BATSCHE E, 1994, ONCOGENE, V9, P2235; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Callahan J, 1999, VIROLOGY, V262, P18, DOI 10.1006/viro.1999.9876; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; DIGIOVANNA JJ, 1981, AM J MED, V71, P779, DOI 10.1016/0002-9343(81)90364-8; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Gao SJ, 1999, J INFECT DIS, V180, P1466, DOI 10.1086/315098; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Gunes C, 2000, CANCER RES, V60, P2116; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Horikawa I, 1999, CANCER RES, V59, P826; Ito H, 1998, CLIN CANCER RES, V4, P1603; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, INT J CANCER, V80, P804; Lim C, 2000, J GEN VIROL, V81, P2645, DOI 10.1099/0022-1317-81-11-2645; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; Nakabayashi K, 1997, EXP CELL RES, V235, P345, DOI 10.1006/excr.1997.3678; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NAMBA M, 1985, INT J CANCER, V35, P275, DOI 10.1002/ijc.2910350221; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Renne R, 1998, J VIROL, V72, P5182, DOI 10.1128/JVI.72.6.5182-5188.1998; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 1998, CANCER RES, V58, P1558; TAPPERO JW, 1993, J AM ACAD DERMATOL, V28, P371, DOI 10.1016/0190-9622(93)70057-Z; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	68	94	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22971	22978		10.1074/jbc.M101890200	http://dx.doi.org/10.1074/jbc.M101890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11313352	hybrid			2022-12-25	WOS:000169412700132
J	Miranda, M; Allen, KE; Pardo, JP; Slayman, CW				Miranda, M; Allen, KE; Pardo, JP; Slayman, CW			Stalk segment 5 of the yeast plasma membrane H+-ATPase - Mutational evidence for a role in glucose regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; NA,K-ATPASE ALPHA-SUBUNIT; SINGLE-POINT MUTATIONS; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE DOMAIN; DIRECTED MUTAGENESIS; CALCIUM-PUMP; SECRETORY VESICLES; TERMINAL REGION; PHOSPHORYLATION	In P-2-type ATPases, a stalk region connects the cytoplasmic part of the molecule, which binds and hydrolyzes ATP, to the membrane-embedded part through which cations are pumped. The present study has used cysteine scanning mutagenesis to examine structure-function relationships within stalk segment 5 (S5) of the yeast plasma-membrane H+-ATPase. Of 29 Cys mutants that were made and examined, two (G670C and R682C) were blocked in biogenesis, presumably due to protein misfolding, In addition, one mutant (S681C) had very low ATPase activity, and another (F685C) displayed a 40-fold decrease in sensitivity to orthovanadate, reflecting a shift in equilibrium from the E-2 conformational state toward E-1. By far the most striking group of mutants (F666C, L671C, I674C, A677C, I684C, R687C, and Y689C) were constitutively activated even in the absence of glucose, with rates of ATP hydrolysis and kinetic properties normally seen only in glucose-metabolizing cells. Previous work has suggested that activation of the wild-type H+-ATPase results from kinase-mediated phosphorylation in the auto-inhibitory C-terminal region of the 100-kDa polypeptide, The seven residues identified in the present study are located on one face of the S5 alpha -helix, consistent with the idea that mutations along this face serve to release the auto inhibition.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Miranda, M (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 2000, J BIOL CHEM, V275, P20545, DOI 10.1074/jbc.M001682200; Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; Carafoli E, 2000, CURR OPIN CHEM BIOL, V4, P152, DOI 10.1016/S1367-5931(99)00069-1; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Curran AC, 2000, J BIOL CHEM, V275, P30301, DOI 10.1074/jbc.M002047200; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; Dutra MB, 1998, J BIOL CHEM, V273, P17411, DOI 10.1074/jbc.273.28.17411; ERASO P, 1994, J BIOL CHEM, V269, P10393; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fiske CH, 1925, J BIOL CHEM, V66, P375; Garnett C, 1996, BIOCHEMISTRY-US, V35, P11019, DOI 10.1021/bi960718k; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mason AB, 1998, BBA-BIOMEMBRANES, V1372, P261, DOI 10.1016/S0005-2736(98)00065-0; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; Petrov VV, 2000, J BIOL CHEM, V275, P15709, DOI 10.1074/jbc.M000546200; Portillo F, 2000, BBA-REV BIOMEMBRANES, V1469, P31, DOI 10.1016/S0304-4157(99)00011-8; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sen Gupta S, 1998, J BIOL CHEM, V273, P34328; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	46	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22485	22490		10.1074/jbc.M102332200	http://dx.doi.org/10.1074/jbc.M102332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306587	hybrid			2022-12-25	WOS:000169412700069
J	Vatamaniuk, OK; Bucher, EA; Ward, JT; Rea, PA				Vatamaniuk, OK; Bucher, EA; Ward, JT; Rea, PA			A new pathway for heavy metal detoxification in animals - Phytochelatin synthase is required for cadmium tolerance in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS; YEAST; GLUTATHIONE; RESISTANCE; PROTEIN; GENES	Increasing emissions of heavy metals such as cadmium, mercury, and arsenic into the environment pose an acute problem for all organisms. Considerations of the biochemical basis of heavy metal detoxification in animals have focused exclusively on two classes of peptides, the thiol tripeptide, glutathione (GSH, gamma -Glu Cys-Gly), and a diverse family of cysteine-rich low molecular weight proteins, the metallothioneins. Plants and some fungi, however, not only deploy GSH and metallothioneins for metal detoxification but also synthesize another class of heavy metal binding peptides termed phytochelatins (PCs) from GSH. Here we show that PC-mediated heavy metal detoxification is not restricted to plants and some fungi but extends to animals by demonstrating that the ce-pcs-l gene of the nematode worm Caenorhabditis elegans encodes a functional PC synthase whose activity is critical for heavy metal tolerance in the intact organism.	Univ Penn, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu			NHLBI NIH HHS [R01-HL 59680-0] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059680] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; Costa Max, 1998, Science Progress, V81, P329; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GIEST RD, 1991, YEAST, V7, P253; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HONG L, 2001, IN PRESS J CELL BIOL; Hu H, 2000, PRIMARY CARE, V27, P983, DOI 10.1016/S0095-4543(05)70185-8; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; Koga M, 2000, EMBO J, V19, P5148, DOI 10.1093/emboj/19.19.5148; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; Mello C, 1995, METHOD CELL BIOL, V48, P451; NORTHROPCLEWES CA, 1998, BR MED B, V56, P193; PARISH RW, 1975, ARCH MICROBIOL, V105, P187, DOI 10.1007/BF00447136; Sambrook J, 1989, MOL CLONING; Svoboda P, 2000, DEVELOPMENT, V127, P4147; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110	23	161	170	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20817	20820		10.1074/jbc.C100152200	http://dx.doi.org/10.1074/jbc.C100152200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11313333	hybrid			2022-12-25	WOS:000169297900004
J	Okan, E; Drewett, V; Shaw, PE; Jones, P				Okan, E; Drewett, V; Shaw, PE; Jones, P			The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism	ONCOGENE			English	Article						RalA; c-Src; c-Jun; ATF2; uPAR; Ras	GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; SIGNALING PATHWAY; PROTEIN-KINASE; CELLULAR-TRANSFORMATION; HA-RAS; CELLS; FAMILY; JUN; PHOSPHORYLATION	The urokinase plasminogen activator receptor (uPAR) focuses extracellular protease activity to the cell surface, modulates cell adhesion and activates intracellular signal transduction pathways. In a range of cancers uPAR expression often has a negative correlation with prognosis, Here we show that uPAR transcription is stimulated by V12 H-Ras, the effector loop mutant V12 H-Ras G37 and constitutively-active RalA 72L, RalA-dependent transcription required the presence of the ATF2-like AP1-site at -70 bp and the c-Jun binding motif at -184 bp in the uPAR promoter. Consistent with this, both Ga14-c-Jun- and Ga14-ATF2-fusion proteins were activated by RalA signalling through phosphorylation of their activation domains at Ser63 and Ser73 of c-Jun or Thr69 and Thr71 of ATF2, A transdominant inhibitory mutant of c-Jun N-terminal kinase (JNK) failed to inhibit uPAR transcription demonstrating that JNK activation is not a prerequisite for RalA-dependent uPAR transcription, A dominant negative inhibitor of c-Src effectively inhibited RalA-dependent uPAR transcription identifying it as a downstream effector in the RalA signalling pathway. These data provide evidence for the existence of a novel signalling pathway that links RalA to the activation of uPAR transcription via a c-Src intermediate and activation of AP1.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Jones, P (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.			SHAW, Peter/0000-0002-2598-4283				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; de Bruyn KMT, 2000, J BIOL CHEM, V275, P29761, DOI 10.1074/jbc.M001160200; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JANKUN J, 1991, CANCER RES, V51, P1221; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kindzelskii AL, 1997, BIOPHYS J, V73, P1777, DOI 10.1016/S0006-3495(97)78208-0; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Koshelnick Y, 1999, THROMB HAEMOSTASIS, V82, P305, DOI 10.1055/s-0037-1615847; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muller SM, 2000, BIOCHEM BIOPH RES CO, V270, P892, DOI 10.1006/bbrc.2000.2531; Murai H, 1997, J BIOL CHEM, V272, P10483; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xue W, 1997, CANCER RES, V57, P1682; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	57	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1816	1824		10.1038/sj.onc.1204260	http://dx.doi.org/10.1038/sj.onc.1204260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313929				2022-12-25	WOS:000167908400002
J	Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E				Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E			Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma	ONCOGENE			English	Article						carcinogenesis; cell cycle; E2F1; expression; lung tumour	S-PHASE ENTRY; ACTIVE TRANSCRIPTIONAL REPRESSION; NUCLEAR ACCUMULATION; P53; GENE; RETINOBLASTOMA; PROTEIN; DEGRADATION; APOPTOSIS; P16(INK4A)	The transcription factor E2F1 is a keg component of cell cycle that acts to transactivate genes required for S phase entry. Thus, it plays an important role in cellular proliferation, oncogenesis and differentiation. In order to investigate its potential implication in human lung carcinogenesis, we studied E2F1 protein expression by Western blotting and immunohistochemistry in a series of 58 human lung tumours of all histological types. We showed that E2F1 product was overexpressed in 92% (24/26) of small cell lung carcinoma (SCLC) and in 50% (5/10) of large cell neuroendocrine carcinoma (LCNEC) whereas it was undetectable in 90% (10/11) of adenocarcinoma and 82% (9/11) of squamous carcinoma when compared to corresponding normal lung. No amplification was found but an increase in E2F1 mRNA expression was detected in 75% (18/24) of SCLC overexpressing E2F1 product. In these tumours and in contrast with NSCLC, upregulation of E2F1 product was associated with its nuclear accumulation and with overexpression of several of its target-genes. Moreover, E2F1 overexpression in NE lung tumours was significantly associated with a high K167 index (P < 0.0001) as well as a Bcl-2:Bax ratio >1 (P<0.001), Overall, these results demonstrate a distinct pattern of E2F1 expression in human lung tumours and suggest that its deregulation could be involved in the carcinogenesis of SCLC.	Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Brambilla, E (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France.		Eymin, Beatrice/M-1962-2013; Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013; gazzeri, sylvie/U-4669-2019; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810				Allen KE, 1997, J CELL SCI, V110, P2819; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Brambilla E, 1996, AM J PATHOL, V149, P1941; BRAMBILLA E, 1997, J PATHOL, V188, P351; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P18, DOI 10.1165/ajrcmb.19.1.3077; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GERDES J, 1984, J IMMUNOL, V133, P1710; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KELLEY MJ, 1997, J NATL CANCER I, V87, P756; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Travis W. D., 1999, WHO INT HISTOLOGICAL; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Volm M, 1998, INT J CANCER, V79, P294, DOI 10.1002/(SICI)1097-0215(19980619)79:3<294::AID-IJC15>3.3.CO;2-0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yatabe Y, 1998, CANCER RES, V58, P1042; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	55	108	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1678	1687		10.1038/sj.onc.1204242	http://dx.doi.org/10.1038/sj.onc.1204242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313916	Green Submitted			2022-12-25	WOS:000167750900002
J	Arevalo, JC; Conde, B; Hempstead, BI; Chao, MV; Martin-Zanca, D; Perez, P				Arevalo, JC; Conde, B; Hempstead, BI; Chao, MV; Martin-Zanca, D; Perez, P			A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation	ONCOGENE			English	Article						receptor; tyrosine kinases; dimerization; cell transformation	NERVE GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; FACTOR BINDING-SITE; LEUCINE-RICH MOTIF; LIGAND-BINDING; SIGNAL-TRANSDUCTION; DIMERIZATION; DELETIONS; SPECIFICITY; ONCOGENES	The TrkA NGF receptor extracellular region contains three leucine repeats flanked by cysteine clusters and two immunoglobulin-like domains that are required for specific ligand binding. Deletion of the immunoglobulinlike domains abolishes NGF binding and causes ligand independent activation of the receptor. Here we report a specific mutation that increases the binding affinity of the TrkA receptor for NGF, A change of proline 203 to alanine (P203A) in the linker region between the leucine repeats and the first Ig-like domain increased NGF binding by decreasing the ligand rate of dissociation, This mutated receptor was appropriately expressed on the cell surface and promoted ligand-independent neurite outgrowth in PC12nnr5 cells. The mutant receptor was capable of spontaneous dimerization and was constitutively phosphorylated in the absence of ligand, Moreover, expression of TrkA-P203A receptor in fibroblasts induced DNA synthesis and transformation and generated tumours in nude mice. These data suggest that domains outside of the immunoglobulin-like structure contribute to ligand binding and constitutive activation of Trk receptors.	Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca 37007, Spain; Univ Zaragoza, Dept Ciencias Morfol, E-50009 Zaragoza, Spain; Cornell Univ, Coll Med, Div Hematol Oncol, New York, NY 10021 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Physiol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Neurosci, New York, NY 10016 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Zaragoza; Cornell University; New York University; New York University; New York University	Perez, P (corresponding author), Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca 37007, Spain.		Arévalo, Juan Carlos/J-8154-2014; Perez, Pilar/B-4948-2010	Arévalo, Juan Carlos/0000-0003-1994-3095; Perez, Pilar/0000-0003-3557-2247; Chao, Moses/0000-0002-6969-3744				Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; EZOE K, 1995, AM J HUM GENET, V56, P58; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Greco A, 1997, GENE CHROMOSOME CANC, V19, P112, DOI 10.1002/(SICI)1098-2264(199706)19:2<112::AID-GCC7>3.0.CO;2-1; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Smith DK, 1997, J MOL BIOL, V274, P530, DOI 10.1006/jmbi.1997.1432; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; WETTERS TV, 1992, EMBO J, V11, P551, DOI 10.1002/j.1460-2075.1992.tb05086.x; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	35	36	37	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1229	1234		10.1038/sj.onc.1204215	http://dx.doi.org/10.1038/sj.onc.1204215			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313867				2022-12-25	WOS:000167570100010
J	Ciullo, I; Diez-Roux, G; Di Domenico, M; Migliaccio, A; Avvedimento, EV				Ciullo, I; Diez-Roux, G; Di Domenico, M; Migliaccio, A; Avvedimento, EV			cAMP signaling selectively influences Ras effectors pathways	ONCOGENE			English	Article						transduction; cAMP-dependent kinase; Ras and GTP binding proteins; PI3-kinases; growth; thyroid differentiation	DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; THYROTROPIN RECEPTOR; THYROID-CELLS; DNA-SYNTHESIS; CELLULAR RAS; INHIBITION; ACTIVATION; PROLIFERATION; GROWTH	Thyrotropin (TSH) stimulates survival and growth of thyroid cells via a seven transmembrane G protein-coupled receptor. TSH elevates the intracellular cyclic AMP (cAMP) levels activating protein kinase A (PKA), Recent evidence indicates that p21 Ras is required for TSH-induced mitogenesis, but the molecular mechanism(s) is not known. Here we report that Ras p21 activity is necessary for the Go- G1 transition in TSH induced cycle and that the downstream effector of Ras upon TSH signaling is p85-p110 PI3K, We show that PI3K inhibitors block TSH-induced DNA synthesis, cAMP-PKA stimulate the formation of the complex PI3K-p21 Ras and reduce the complex Ras-Raf1 in thyroid and other cells types. Moreover, PKA phosphorylates immunoprecipitated p85 and PKA phosphorylation of cell extracts significantly stimulates the formation of the complex PI3K-Ras, We suggest that PKA phosphorylates p85 and stabilizes the complex p110-p85, enhancing the interaction PI3K and p21 Ras, Simultaneously, cAMP inhibits Raf-1-ERK signaling by decreasing Raf1 availability to Ras, Under these circumstances PI3K signaling is favored. These results indicate that PI3K is an important mediator of Ras effects in cAMP-induced proliferation and illustrates how cAMP can selectively influence Ras effector pathways.	Univ Naples Federico II, Fac Med,Policlin 2, Dipartimento Biol & Patol Mol & Cellulare, CNR, I-80131 Naples, Italy; Univ Catanzaro, Fac Med, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Naples 2, Ist Patol Gen, I-80138 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita della Campania Vanvitelli	Avvedimento, EV (corresponding author), Univ Naples Federico II, Fac Med,Policlin 2, Dipt Biol & Patol Mol & Cell, CNR, Via S Pansini 5, I-80131 Naples, Italy.		Migliaccio, Antimo/AAB-3376-2019	Di Domenico, Marina/0000-0002-6201-4200; Migliaccio, Antimo/0000-0002-4197-2055				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BONAPACE IM, 1990, MOL CELL BIOL, V10, P1033, DOI 10.1128/MCB.10.3.1033; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHEATHAM B, 1997, MOL CELL BIOL, V14, P4902; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DEVITA G, 2000, IN PRESS CANC RES; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MEINKOTH JL, 1991, THYROIDOLOGY, V3, P97; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; PORCELLINI A, 1995, ONCOGENE, V11, P1089; PORCELLINI A, 1997, ONCOGENE, V14, P2233; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	84	86	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1186	1192		10.1038/sj.onc.1204219	http://dx.doi.org/10.1038/sj.onc.1204219			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313862				2022-12-25	WOS:000167570100005
J	Goldstone, S; Pavey, S; Forrest, A; Sinnamon, J; Gabrielli, B				Goldstone, S; Pavey, S; Forrest, A; Sinnamon, J; Gabrielli, B			Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR	ONCOGENE			English	Article						cell cycle checkpoint; DNA damage; ATM/ATR	DNA-DAMAGE CHECKPOINT; CDC25B PHOSPHATASE; G(2) CHECKPOINT; TYROSINE DEPHOSPHORYLATION; DEPENDENT KINASE-2; HUMAN FIBROBLASTS; PROTEIN-KINASE; HELA-CELLS; S-PHASE; PHOSPHORYLATION	Cyclin A/cdk2 is active during S and G2 phases of the cell cycle, but its regulation and function during G2 phase is poorly understood. In this study we have examined the regulation of cyclin A/cdk2 activity during normal G2 phase progression and in genotoxin-induced G2 arrest. We show that cyclin A/cdk2 is activated in early G2 phase by a cdc25 activity. In the G2 phase checkpoint arrest initiated in response to various forms of DNA damage, the cdc25-dependent activation of both cyclin A/cdk2 and cyclin B1/cdc2 is blocked. Ectopic expression of cdc25B, but not cdc25C, in G2 phase arrested cells efficiently activated both cyclin A/cdk2 and cyclin B1/cdc2. Finally, we demonstrate that the block in cyclin A/cdk2 activation in the G2 checkpoint arrest is independent of ATM/ATR. We speculate that the ATM/ ATR-independent block in G2 phase cyclin A/cdk2 activation may act as a further layer of checkpoint control, and that blocking G2 phase cyclin A/cdk2 activation contributes to the G2 phase checkpoint arrest.	Univ Queensland, Queensland Inst Med Res, Queensland Canc Fund Res Unit, Brisbane, Qld, Australia; Univ Queensland, Dept Pathol, Joint Expt Oncol Program, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Queensland Inst Med Res, Queensland Canc Fund Res Unit, Brisbane, Qld, Australia.		Pavey, Sandra/B-3662-2011; Forrest, Alistair/A-6597-2008; Gabrielli, Brian G/B-3655-2011	Pavey, Sandra/0000-0003-4519-5932; Forrest, Alistair/0000-0003-4543-1675; Gabrielli, Brian G/0000-0003-3933-1651				Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HERZINGER T, 1995, ONCOGENE, V11, P2151; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lammer C, 1998, J CELL SCI, V111, P2445; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; Maity A, 1996, ONCOGENE, V13, P1647; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; Ramsay J, 1998, BRIT J CANCER, V77, P11, DOI 10.1038/bjc.1998.2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Tamura K, 2000, CANCER RES, V60, P1317; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Wang XQ, 1996, CANCER RES, V56, P2510	45	74	78	2	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					921	932		10.1038/sj.onc.1204177	http://dx.doi.org/10.1038/sj.onc.1204177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314027				2022-12-25	WOS:000167097000003
J	Kumar, A; Jasmin, A; Eby, MT; Chaudhary, PM				Kumar, A; Jasmin, A; Eby, MT; Chaudhary, PM			Cytotoxicity of tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines	ONCOGENE			English	Article						Ewing's sarcoma; TRAIL; Apo2L; apoptosis; MRIT; NF-kappa B	NF-KAPPA-B; L929 CELLS; TRAIL; DEATH; ACTIVATION; SENSITIVITY; INHIBITION; RECEPTOR; PATHWAY; FAMILY	Death ligands of the Tumor Necrosis Factor (TNF) family are known to induce apoptosis upon binding to their cognate receptors. However, the clinical utility of these cytokines as anticancer agents has been limited due to unacceptable toxicity. TRAIL is a recently isolated death ligand that possesses selective anti-tumor activity against a number of cancer cell lines without significant systemic toxicity. In this report we present evidence that cell lines derived from Ewing's Sarcoma (ES) are uniformly sensitive to TRAIL-mediated apoptosis. Furthermore, unlike TNF-alpha, treatment with TRAIL fails to induce the anti-apoptotic and pro-inflammatory NF-kappaB pathway in the ES cell lines. Our results suggest that TRAIL may prove to be a useful agent for the treatment of Ewing's sarcoma and related peripheral neuroectodermal tumors.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Kumar, Arvind/B-6094-2009; Chaudhary, Preet/E-1970-2018					Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Griffith TS, 1998, J IMMUNOL, V161, P2833; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HENGERER B, 1996, PROMEGA NOTES, V58, P40; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Leverkus M, 2000, CANCER RES, V60, P553; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386	18	22	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					1010	1014		10.1038/sj.onc.1204154	http://dx.doi.org/10.1038/sj.onc.1204154			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314037				2022-12-25	WOS:000167097000013
J	Chen, YR; Shrivastava, A; Tan, TH				Chen, YR; Shrivastava, A; Tan, TH			Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate	ONCOGENE			English	Article						JNK; phosphatase; oxidation; metal ions	TUMOR-NECROSIS-FACTOR; PROTEIN-KINASES; SIGNAL-TRANSDUCTION; INTRACELLULAR LEVEL; GAMMA-RADIATION; CELL-DEATH; METAL-IONS; APOPTOSIS; PATHWAY; STRESS	Oxidative stress activates the c-Jun N-terminal kinase (JNK) pathway. However, the exact mechanisms by which reactive oxygen species (ROS) activate JNK are unclear. We found that the ability of hydrogen peroxide (H2O2) to induce JNK activation varied in different cell types. Pyrrolidine dithiocarbamate (PDTC), a presumed antioxidant, induced JNK activation on its own and enhanced JNK activation by H2O2 in many cell types, including Jurkat, HEK293, and LNCaP and Tsu-Prl prostate cancer cells. The activation of JNK by PDTC, in the presence or absence of exogenous H2O2, was dependent on its chelating ability to metal ions, most likely copper ions, Despite the strong JNK-activating ability, H2O2 plus PDTC did not induce significant activation of the upstream kinases, SEK1/MKK4 and MKK7. However, the JNK inactivation rate was slower in cells treated with H2O2 pins PDTC compared with the rate in cells treated with ultraviolet C CUV-C), Treatment of H2O2 pins PDTC significantly decreased the expression levels of a JNK phosphatase, M3/6 (also named hVH-5), but not the levels of other phosphatases (PP2A and PP4), In contrast, UV-C irradiation did not cause the down-regulation of M3/6, These results suggest that JNK activation by H2O2 plus PDTC resulted from the down-regulation of JNK phosphatases. Our data also reveal a necessity to carefully evaluate the pharmacological and biochemical properties of PDTC.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.		Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/E-3991-2010; Tan, Tse-Hua/ABD-7080-2021	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170	NCI NIH HHS [P50-CA58204] Funding Source: Medline; NIAID NIH HHS [R01-AI38649, R01-AI42532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; delArco PG, 1996, J BIOL CHEM, V271, P26335; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fuchs D, 1997, OXIDATIVE STRESS MOL, P139; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1635; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAUPTMANN N, 1997, OXIDATIVE STRESS MOL, P1; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kim CH, 1999, FEBS LETT, V449, P28, DOI 10.1016/S0014-5793(99)00390-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENTNER C, 1984, GEIGY SCI TABLES, V3, P85; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	41	70	78	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					367	374		10.1038/sj.onc.1204105	http://dx.doi.org/10.1038/sj.onc.1204105			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313966				2022-12-25	WOS:000166411000011
J	NicAmhlaoibh, R; Shtivelman, E				NicAmhlaoibh, R; Shtivelman, E			Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro	ONCOGENE			English	Article						angiogenesis; metastasis; CC3	TAT-ACTIVATED TRANSCRIPTION; LUNG-CARCINOMA; THROMBOSPONDIN; ANGIOPOIETIN-1; PROLIFERATION; CHEMOKINE; APOPTOSIS; COFACTOR; GROWTH; FAMILY	Resistance to apoptosis and ability to promote angiogenesis are integral features of the metastatic phenotype. Human gene CC3 is a metastasis suppressor for variant small cell lung carcinoma and a mouse melanoma in vivo. We have shown previously that metastasis-suppressing function of CC3 might be due at least in part to the ability of CC3 protein to predispose tumor cells to apoptosis, Here we demonstrate that CC3 has a previously unidentified effect on the ability of tumor cells to induce angiogenesis in vitro. Expression of CC3 in three different tumor cell lines significantly diminished their angiogenic character as manifested in the in vitro proliferation and migration assays with endothelial cells of both macro- and microvascular origin. Expression of CC3 induced changes in RNA levels of several angiogenic modulators consistent with the overall reduction in angiogenic properties. These results indicate that expression of CC3 has a dual effect on phenotype of tumor cells ultimately inhibiting their metastatic potential.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Shtivelman, E (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA071422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Addison CL, 2000, HUM GENE THER, V11, P247, DOI 10.1089/10430340050015996; Baker ME, 1999, CURR BIOL, V9, pR471, DOI 10.1016/S0960-9822(99)80297-8; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; Gentilini G, 1999, BLOOD, V93, P25, DOI 10.1182/blood.V93.1.25.401a47_25_33; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Liu Y, 1999, J BIOL CHEM, V274, P13338, DOI 10.1074/jbc.274.19.13338; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Whitman S, 2000, MOL CELL BIOL, V20, P583, DOI 10.1128/MCB.20.2.583-593.2000; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	24	46	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					270	275		10.1038/sj.onc.1204075	http://dx.doi.org/10.1038/sj.onc.1204075			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313954				2022-12-25	WOS:000166410900014
J	Gargalovic, P; Dory, L				Gargalovic, P; Dory, L			Caveolin-1 and caveolin-2 expression in mouse macrophages - High density lipoprotein 3-stimulated secretion and a lack of significant subcellular co-localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; APOLIPOPROTEIN-E; GOLGI-COMPLEX; IN-VIVO; CHOLESTEROL TRANSPORT; PROTEIN CAVEOLIN; BINDING PROTEIN; GENE FAMILY; IDENTIFICATION; CELLS	Evidence for caveolin expression in macrophages is scarce and conflicting. We therefore examined caveolin-1 and caveolin-2 expression in resident and thioglycollate-elicited mouse peritoneal macrophages (tg-MPM) and in the J774 mouse macrophage cell line by RT-PCR, ribonuclease protection assay, immunoblotting, and immunofluorescence. We found that relative to 3T3 cells, resident MPM and tg-MPM express low amounts of caveolin-1 (45 and 15% of those in 3T3 fibroblasts, respectively), while J774.A1 cells do not express any. Caveolin-2, on the other hand, is expressed in all cells examined, with highest expression in tg-MPM and the lowest in J774 cells. The relative levels of caveolin expression in the various cells correspond well with their respective mRNA levels, as measured by ribonuclease protection assay. Caveolin-1, present primarily on the cell surface, does not co-localize significantly with caveolin-2, which is present primarily in the Golgi compartment in all macrophages studied. Loading of tg-MPM with cholesterol or variations in unesterified cholesterol content appear to have little effect on the level of caveolin-1 or -2 expression or their distribution. Stimulation of cholesterol efflux by HDL, leads to caveolin-1 and caveolin-2 secretion to the cell culture medium, a process not detected in the absence of HDL,, The lack of significant co-localization of the two caveolin isoforms in primary macrophages and their secretion in the presence of HDL, provides an interesting and physiologically relevant model system to study additional aspects of caveolin function.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Dory, L (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.				NHLBI NIH HHS [HL 45513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAM R, 1989, BIOCHIM BIOPHYS ACTA, V1004, P292, DOI 10.1016/0005-2760(89)90076-3; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DENG JT, 1995, J LIPID RES, V36, P2129; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; DORY L, 1991, J LIPID RES, V32, P783; DORY L, 1989, J LIPID RES, V30, P809; Fielding CJ, 1997, J LIPID RES, V38, P1503; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Hailstones D, 1998, J LIPID RES, V39, P369; HO MK, 1982, J IMMUNOL, V128, P1221; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lei MG, 2000, INFECT IMMUN, V68, P5084, DOI 10.1128/IAI.68.9.5084-5089.2000; Li SW, 1996, J BIOL CHEM, V271, P3863; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Matveev S, 1999, J LIPID RES, V40, P1647; Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Sengelov H, 1998, J LEUKOCYTE BIOL, V63, P563, DOI 10.1002/jlb.63.5.563; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TAKEMURA R, 1984, AM J PHYSIOL, V246, P1; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; van Reyk DM, 1999, J LEUKOCYTE BIOL, V66, P557, DOI 10.1002/jlb.66.4.557	42	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26164	26170		10.1074/jbc.M011291200	http://dx.doi.org/10.1074/jbc.M011291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316799	hybrid			2022-12-25	WOS:000169823300071
J	Jang, GF; Kuksa, V; Filipek, S; Bartl, F; Ritter, E; Gelb, MH; Hofmann, KP; Palczewski, K				Jang, GF; Kuksa, V; Filipek, S; Bartl, F; Ritter, E; Gelb, MH; Hofmann, KP; Palczewski, K			Mechanism of rhodopsin activation as examined with ring-constrained retinal analogs and the crystal structure of the ground state protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-STABLE RHODOPSIN; BETA-IONONE RING; VISUAL PIGMENT; TRANSDUCIN ACTIVATION; BOVINE RHODOPSIN; 9-METHYL GROUP; BINDING-SITE; CHROMOPHORE; SPECTROSCOPY; FTIR	The guanine nucleotide-binding protein (G-protein)coupled receptor superfamily (GPCR) is comprised of a large group of membrane proteins involved in a wide range of physiological signaling processes. The functional switch from a quiescent to an active conformation is at the heart of GPCR action. The GPCR rhodopsin has been studied extensively because of its key role in scotopic vision. The ground state chromophore, Il-cis-retinal, holds the transmembrane region of the protein in the inactive conformation, Light induces cis-trans isomerization and rhodopsin activation. Here we show that rhodopsin regenerated with a ring-constrained 11-cis-retinal analog undergoes photoisomerization; however, it remains marginally active because isomerization occurs without the chromophore-induced conformational change of the opsin moiety, Modeling the locked chromophore analogs in the active site of rhodopsin suggests that the beta -ionone ring rotates but is largely confined within the binding site of the natural Il-cis-retinal chromophore, This constraint is a result of the geometry of the stable 11-cis-locked configuration of the chromophore analogs. These results suggest that the native chromophore cis-trans isomerization is merely a mechanism for repositioning of the beta -ionone ring which ultimately leads to helix movements and determines receptor activation.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Warsaw, Dept Chem, PL-02093 Warsaw, Poland; Humboldt Univ, Univ Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Warsaw; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.		Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858; gelb, michael/0000-0001-7000-5219	NEI NIH HHS [R01 EY009339] Funding Source: Medline; NIEHS NIH HHS [ES09339] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKITA A, 1980, J AM CHEM SOC, V102, P6372; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Grobner G, 2000, NATURE, V405, P810, DOI 10.1038/35015604; Han M, 1997, P NATL ACAD SCI USA, V94, P13442, DOI 10.1073/pnas.94.25.13442; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HUANG MJ, 1994, J AM CHEM SOC, V116, P2515; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P6257, DOI 10.1021/bi9519359; ITO M, 1992, PHOTOCHEM PHOTOBIOL, V56, P915, DOI 10.1111/j.1751-1097.1992.tb09713.x; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; Jang GF, 2000, J BIOL CHEM, V275, P28128; KHORANA HG, 1999, J BIOMOL STRUCT DES, V1, P1; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; LIU RSH, 1988, J AM CHEM SOC, V110, P8617, DOI 10.1021/ja00234a007; MAPLE JR, 1994, J COMPUT CHEM, V15, P162, DOI 10.1002/jcc.540150207; MATSUMOTO H, 1975, NATURE, V258, P523, DOI 10.1038/258523a0; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rao VR, 1996, ANNU REV BIOPH BIOM, V25, P287; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SHEVES M, 1986, J AM CHEM SOC, V108, P6440, DOI 10.1021/ja00280a081; SHICHIDA Y, 1988, BIOCHEMISTRY-US, V27, P6495, DOI 10.1021/bi00417a044; TELLER DC, 2001, IN PRESS BIOCHEMISTR; VANDERSTEEN R, 1989, RECL TRAV CHIM PAY B, V108, P20; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0; ZANKEL T, 1990, J AM CHEM SOC, V112, P5387, DOI 10.1021/ja00169a077; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	38	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26148	26153		10.1074/jbc.M102212200	http://dx.doi.org/10.1074/jbc.M102212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316815	Green Accepted, hybrid			2022-12-25	WOS:000169823300069
J	Takei, K; Sakakibara, H; Sugiyama, T				Takei, K; Sakakibara, H; Sugiyama, T			Identification of genes encoding adenylate isopentenyltransferase, a cytokinin biosynthesis enzyme, in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; PROTEIN; DNA; EXPRESSION; BINDING	The initial step in the de novo biosynthesis of cytokinin in higher plants is the formation of isopentenyladenosine 5 ' -monophosphate (iPMP) from AMP and dimethylallylpyrophosphate (DMAPP), which is catalyzed by adenylate isopentenyltransferase (IPT). Although cytokinin is an essential hormone for growth and development, the nature of the enzyme for its biosynthesis in higher plants has not been identified. Herein, we describe the molecular cloning and biochemical identification of IPTs from Arabidopsis thaliana. Eight cDNAs encoding putative IPT, designated as AtIPT1 to AtIPT8, were picked up from A. thaliana, The Escherichia coli transformants expressing the recombinant proteins excreted cytokinin species into the culture medium except for that expressing AtIPT2 that is a putative tRNA IPT. A purified recombinant AtIPT1 catalyzed the formation of iPMP from DMAPP and AMP. These results indicate that the small multigene family contains both types of isopentenyltransferase, which could synthesize cytokinin and mature tRNA.	RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Wako, Saitama 3510198, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Biol Mech & Funct, Nagoya, Aichi 4648601, Japan	RIKEN; Nagoya University	Sakakibara, H (corresponding author), RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Hirosawa 2-1, Wako, Saitama 3510198, Japan.		Sakakibara, Hitoshi/A-6040-2010; Ding, Cheng-Qiang/B-6287-2011	Sakakibara, Hitoshi/0000-0001-5449-6492; 				AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; Astot C, 2000, P NATL ACAD SCI USA, V97, P14778, DOI 10.1073/pnas.260504097; BARTZ JK, 1972, BIOCHIMIE, V54, P31, DOI 10.1016/S0300-9084(72)80035-X; BLACKWELL JR, 1994, PHYTOCHEMISTRY, V35, P339, DOI 10.1016/S0031-9422(00)94760-5; BLACKWELL JR, 1993, PHYTOCHEMISTRY, V34, P1477, DOI 10.1016/S0031-9422(00)90831-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; CHEN CM, 1979, FEBS LETT, V107, P15, DOI 10.1016/0014-5793(79)80452-4; CHEN CM, 1994, CYTOKININS CHEM ACTI, P81; CHONG S, 1995, BIOCHEMISTRY-US, V34, P3695; CRESPI M, 1992, EMBO J, V11, P795, DOI 10.1002/j.1460-2075.1992.tb05116.x; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; Feldman L. J., 1975, The development and function of roots (Third Cabot Symposium)., P55; FUJIWARA T, 1992, PLANT PHYSIOL, V99, P263, DOI 10.1104/pp.99.1.263; Golovko A, 2000, GENE, V258, P85, DOI 10.1016/S0378-1119(00)00421-2; HOLTZ J, 1978, H-S Z PHYSIOL CHEM, V359, P89; HOLTZ J, 1975, H-S Z PHYSIOL CHEM, V356, P1459; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; KLAMBT D, 1992, PHYSIOLOGY AND BIOCHEMISTRY OF CYTOKININS IN PLANTS, P25; KLINE KL, 1969, BIOCHEMISTRY-US, V8, P4361; KODA Y, 1980, PHYSIOL PLANTARUM, V49, P193, DOI 10.1111/j.1399-3054.1980.tb02651.x; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; LICHTER A, 1995, J BACTERIOL, V177, P4457, DOI 10.1128/jb.177.15.4457-4465.1995; MASUI Y, 1983, EXPT MANIPULATION GE, P15; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; POWELL GK, 1986, NUCLEIC ACIDS RES, V14, P2555, DOI 10.1093/nar/14.6.2555; ROSENBAUM N, 1972, J BIOL CHEM, V247, P5675; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shudo K., 1994, CYTOKININS CHEM ACTI, P35; Suzuki K, 1998, BBA-GENE STRUCT EXPR, V1396, P1, DOI 10.1016/S0167-4781(97)00182-6; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P107, DOI 10.1093/pcp/pce037; SWAMINATHAN S, 1977, BIOCHEMISTRY-US, V16, P1355, DOI 10.1021/bi00626a018; Takei K, 2001, PLANT CELL PHYSIOL, V42, P85, DOI 10.1093/pcp/pce009; WADSWORTH GJ, 1988, ANAL BIOCHEM, V172, P279, DOI 10.1016/0003-2697(88)90443-5	38	334	388	3	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26405	26410		10.1074/jbc.M102130200	http://dx.doi.org/10.1074/jbc.M102130200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313355	hybrid			2022-12-25	WOS:000169823300101
J	Blobe, GC; Schiemann, WP; Pepin, MC; Beauchemin, M; Moustakas, A; Lodish, HF; O'Connor-McCourt, MD				Blobe, GC; Schiemann, WP; Pepin, MC; Beauchemin, M; Moustakas, A; Lodish, HF; O'Connor-McCourt, MD			Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; GENE-EXPRESSION; LIGAND-BINDING; I RECEPTOR; BETAGLYCAN; ENDOGLIN; COMPLEX; FORM; RESPONSIVENESS; PATHWAY	Transforming growth factor beta (TGF-beta) signals through three high affinity cell surface receptors, TGF-beta type I, type II, and type III receptors, The type III receptor, also known as betaglycan, binds to the type II receptor and is thought to act solely by "presenting" the TGF-beta ligand to the type II receptor. The short cytoplasmic domain of the type III receptor is thought to have no role in TGF-beta signaling because deletion of this domain has no effect on association with the type II receptor, or with the presentation role of the type III receptor. Here we demonstrate that the cytoplasmic domains of the type III and type II receptors interact specifically in a manner dependent on the kinase activity of the type II receptor and the ability of the type II receptor to autophosphorylate, This interaction results in the phosphorylation of the cytoplasmic domain of the type III receptor by the type II receptor, The type III receptor with the cytoplasmic domain deleted is able to bind TGF-beta, to bind the type II receptor, and to enhance TGF-beta binding to the type II receptor but is unable to enhance TGF-beta signaling, determining that the cytoplasmic domain is essential for some functions of the type III receptor. The type III receptor functions by selectively binding the autophosphorylated type II receptor via its cytoplasmic domain, thus promoting the preferential formation of a complex between the autophosphorylated type II receptor and the type I receptor and then dissociating from this active signaling complex. These studies, for the first time, elucidate important functional roles of the cytoplasmic domain of the type III receptor and demonstrate that these roles are essential for regulating TGF-beta signaling.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Biotechnol Res Inst, Cell Surface Recognot Grp, Montreal, PQ H4P 2R2, Canada; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Research Council Canada; Ludwig Institute for Cancer Research	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 2631, Durham, NC 27710 USA.		Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NCI NIH HHS [CA63260, CA73161-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA073161, R01CA063260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fink SP, 2001, CANCER RES, V61, P256; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LIN HY, 1994, CELL MOL BIOL, V40, P337; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; MORELLO JP, 1995, J CELL PHYSIOL, V165, P201, DOI 10.1002/jcp.1041650123; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; PEPIN MC, 1994, P NATL ACAD SCI USA, V91, P6997, DOI 10.1073/pnas.91.15.6997; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	30	104	118	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24627	24637		10.1074/jbc.M100188200	http://dx.doi.org/10.1074/jbc.M100188200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323414	hybrid			2022-12-25	WOS:000169800700030
J	Lin, YC; Hsu, CL; Shih, JW; Lin, JJ				Lin, YC; Hsu, CL; Shih, JW; Lin, JJ			Specific binding of single-stranded telomeric DNA by Cdc13p of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYTRICHA MACRONUCLEAR DNA; REPLICATION ORIGIN; IN-VITRO; INITIATOR PROTEIN; HUMAN-CHROMOSOMES; EST1 PROTEIN; 3' TERMINUS; YEAST; END; MAINTENANCE	Cdc13p is a single strand telomere-binding protein of Saccharomyces cerevisiae; its telomere-binding region is within amino acids 451-693, Cdc13(451-693)p, In this study, we used purified Cdc13p and Cdc13(451-693)p to characterize their telomere binding activity, We found that the binding specificity of single-stranded TC,, DNA by these two proteins is similar. However, the affinity of Cdc13(451-693)p to DNA was slightly lower than that of Cdc13p, The binding of telomeric DNA by these two proteins was disrupted at NaCl concentrations higher than 0.3 M, indicating that electrostatic interaction contributed significantly to the binding process. Because both proteins bound to strand TG,, DNA positioned at the 3 ' end, the 5 ' end, or in the middle of the oligonucleotide substrates, our results indicated that the location of TG,, in single-stranded DNA does not appear to be important for Cdc13p binding. Moreover, using DNase I footprint analysis, the structure of the telomeric DNA complexes of Cdc13p and Cdc13(451693)p was analyzed. The DNase I footprints of these two proteins to three different telomeric DNA substrates were virtually identical, indicating that the telomere contact region of Cdc13p is within Cdc13(451-693)p, Together, the binding properties of Cdcl3p and its binding domain support the theory that the specific binding of Cdcl3p to telomeres is an important feature of telomeres that regulate telomerase access and/or differentiate natural telomeres from broken ends.	Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lin, JJ (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Shih Pai, Taipei 112, Taiwan.	jjlin@ym.edu.tw	Lin, Jing-Jer/G-8068-2015; Shih, Jing-Wen/J-4555-2017	Shih, Jing-Wen/0000-0002-0417-9015; LIN, JING-JER/0000-0001-8250-7398				Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LIN JJ, 1993, BIOESSAYS, V15, P555, DOI 10.1002/bies.950150809; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; Qi HY, 2000, GENE DEV, V14, P1777; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SHUEY DJ, 1986, NATURE, V323, P459, DOI 10.1038/323459a0; Steiner BR, 1996, P NATL ACAD SCI USA, V93, P2817, DOI 10.1073/pnas.93.7.2817; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Wang MJ, 2000, NUCLEIC ACIDS RES, V28, P4733, DOI 10.1093/nar/28.23.4733; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x	48	18	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24588	24593		10.1074/jbc.M101642200	http://dx.doi.org/10.1074/jbc.M101642200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309395	hybrid			2022-12-25	WOS:000169800700024
J	Robin, MA; Anandatheerthavarada, HK; Fang, JK; Cudic, M; Otvos, L; Avadhani, NG				Robin, MA; Anandatheerthavarada, HK; Fang, JK; Cudic, M; Otvos, L; Avadhani, NG			Mitochondrial targeted cytochrome p450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BETA-NAPHTHOFLAVONE; ENDOPLASMIC-RETICULUM; FORMS; PURIFICATION; METABOLISM; SYSTEM; PHOSPHORYLATION; ACTIVATION; FERREDOXIN	Hepatic mitochondria contain an inducible cytochrome P450, referred to as P450 MT5, which cross-reacts with antibodies to microsomal cytochrome P450 2E1, In the present study, we purified, partially sequenced, and determined enzymatic properties of the rat liver mitochondrial form, The mitochondrial cytochrome P450 2E1 was purified from pyrazole-induced rat livers using a combination of hydrophobic and ion-exchange chromatography. Mass spectrometry analysis of tryptic fragments of the purified protein further ascertained its identity, N-terminal sequencing of the purified protein showed that its N terminus is identical to that of the microsomal cytochrome P450 2E1, In reconstitution experiments, the mitochondrial cytochrome P450 2E1 displayed the same catalytic activity as the microsomal counterpart, although the activity of the mitochondrial enzyme was supported exclusively by adrenodoxin and adrenodoxin reductase, Mass spectrometry analysis of tryptic fragments and also immunoblot analysis of proteins with anti-serine phosphate antibody demonstrated that the mitochondrial cytochrome P450 2E1 is phosphorylated at a higher level compared with the microsomal counterpart. A different conformational state of the mitochondrial targeted cytochrome P450 2E1 (P450 MT5) is likely to be responsible for its observed preference for adrenodoxin and adrenodoxin reductase electron transfer proteins.	Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; The Wistar Institute	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Biol Anim, 3800 Spruce St, Philadelphia, PA 19104 USA.				NIGMS NIH HHS [GM 34883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Anandatheerthavarada HK, 2001, EMBO J, V20, P2394, DOI 10.1093/emboj/20.10.2394; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; Boopathi E, 2000, J BIOL CHEM, V275, P34415, DOI 10.1074/jbc.M004431200; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; Fataccioli V, 1999, HEPATOLOGY, V29, P14, DOI 10.1002/hep.510290106; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KOCH JA, 1991, METHOD ENZYMOL, V206, P305; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEPER J, 1990, HEPATOLOGY, V11, P850, DOI 10.1002/hep.1840110521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUBARA T, 1976, ANAL BIOCHEM, V75, P596, DOI 10.1016/0003-2697(76)90114-7; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1988, J BIOL CHEM, V263, P6038; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; OMURA T, 1991, METHOD ENZYMOL, V206, P75; RAZA H, 1988, J BIOL CHEM, V263, P9533; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; Robin MA, 2000, J PHARMACOL EXP THER, V294, P1063; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; SHAYIQ RM, 1991, METHOD ENZYMOL, V206, P587; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Tanaka E, 2000, J CLIN PHARM THER, V25, P165; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TU YY, 1983, CANCER RES, V43, P623; Von Wachenfeldt Claes, 1995, P183	41	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24680	24689		10.1074/jbc.M100363200	http://dx.doi.org/10.1074/jbc.M100363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325963	hybrid			2022-12-25	WOS:000169800700037
J	Azizan, A; Holaday, N; Neame, PJ				Azizan, A; Holaday, N; Neame, PJ			Post-translational processing of bovine chondromodulin-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-MODULATING FACTOR; PSEUDOMONAS EXOTOXIN-A; MOLECULAR-CLONING; GENE-EXPRESSION; CARTILAGE; CELLS; FURIN	Chondromodulin-I (ChM-I) is a small. glycoprotein that is abundant in fetal cartilage. Mature chondromodulin-I is processed from a larger precursor form, presumably at a proteolytic site RERR-ELVR. The precursor, mature chondromodulin-I and two processed products, the remnant left after removal of mature chondromodulin-I and a smaller, unglycosylated form, were identified using antipeptide antisera. The products of chondromodulin-I precursor processing were seen in cultured chondrocytes, a stable long-term culture chondrosarcoma cell line, as well as Chinese hamster ovary (CHO) cells transfected with an expression plasmid that contained cDNA coding for the chondromodulin-I precursor, Pulse-chase analysis allowed a processing pathway to be analyzed for chonaromodulin-I. To further dissect the processing events, three constructs that express recombinant wild-type or mutant chondromodulin-I were transfected into CHO cells. We showed that chondromodulin-I is cleaved intracellularly at the predicted cleavage site, and that the mature glycopeptide is rapidly secreted immediately after processing. The chondromodulin-1 precursor has a short half-life and is not readily apparent in tissue samples, suggesting that chondromodulin is not a member of the juxtacrine family of growth factors, despite some similarities, The smaller unglycosylated form of chondromodulin-I was only observed in cartilage and not in short-term cultures or transfected cells, suggesting an extracellular processing event. No processing occurred when the precursor cleavage site was mutated to RERQ-SLVR or when precursor chondromodulin-I was expressed in the furin-deficient CHO cell line, suggesting the involvement of furin in processing.	Shriners Hosp Children, Ctr Res Skeletal Dev & Pediat Orthoped, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Neame, PJ (corresponding author), Shriners Hosp Children, Ctr Res Skeletal Dev & Pediat Orthoped, 12502 N Pine Dr, Tampa, FL 33612 USA.		Azizan, Azliyati/A-6774-2009					Azizan A, 2000, MATRIX BIOL, V19, P521, DOI 10.1016/S0945-053X(00)00110-4; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Brandau O, 2001, DEV DYNAM, V221, P72, DOI 10.1002/dvdy.1126; Dietz UH, 1999, DEV DYNAM, V216, P233, DOI 10.1002/(SICI)1097-0177(199911)216:3<233::AID-DVDY2>3.0.CO;2-G; Hering Thomas M., 1999, Frontiers in Bioscience, V4, pd743, DOI 10.2741/Hering; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hiraki Y, 1999, EUR J BIOCHEM, V260, P869, DOI 10.1046/j.1432-1327.1999.00227.x; Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419; Hiraki Y, 2000, PEDIATR NEPHROL, V14, P602, DOI 10.1007/s004670000339; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KUCHARSKA A, 1990, J ORTHOPAED RES, P781; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NEAME PJ, 1990, J BIOL CHEM, V265, P9628; Neame PJ, 1999, CELL MOL LIFE SCI, V55, P1327, DOI 10.1007/s000180050373; Shukunami C, 1999, INT J DEV BIOL, V43, P39; Shukunami C, 1999, FEBS LETT, V456, P165, DOI 10.1016/S0014-5793(99)00931-X; Shukunami C, 2001, BIOCHEM BIOPH RES CO, V280, P1323, DOI 10.1006/bbrc.2001.4271; Suzuki F, 1999, BIOCHEM BIOPH RES CO, V259, P1, DOI 10.1006/bbrc.1999.0610; Yamana K, 2001, BIOCHEM BIOPH RES CO, V280, P1101, DOI 10.1006/bbrc.2000.4245	21	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23632	23638		10.1074/jbc.M009967200	http://dx.doi.org/10.1074/jbc.M009967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323410	hybrid			2022-12-25	WOS:000169531100055
J	Berger, CEM; Fagnant, PM; Heizmann, S; Trybus, KM; Geeves, MA				Berger, CEM; Fagnant, PM; Heizmann, S; Trybus, KM; Geeves, MA			ADP binding induces an asymmetry between the heads of unphosphorylated myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; HEAVY-MEROMYOSIN; KINESIN ATPASE; 2 HEADS; ACTIN; SUBFRAGMENT-1; TROPOMYOSIN; CONTRACTION; MECHANISM	Light chain phosphorylation is the key event that regulates smooth and non-muscle myosin II ATPase activity. Here we show that both heads of smooth muscle heavy meromyosin (HMM) bind tightly to actin in the absence of nucleotide, irrespective of the state of light chain phosphorylation. In striking contrast, only one of the two heads of unphosphorylated HMM binds to actin in the presence of ADP, and the heads have different affinities for ADP. This asymmetry suggests that phosphorylation alters the mechanical coupling between the heads of HMM. A model that incorporates strain between the two heads is proposed to explain the data, which have implications for how one head of a motor protein can gate the response of the other.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Kent; University of Vermont	Geeves, MA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.		Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38113] Funding Source: Medline; NIAMS NIH HHS [P01-AR41637] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENNETT AJ, 1986, BIOCHEM J, V233, P179, DOI 10.1042/bj2330179; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Cross RA, 1999, CURR BIOL, V9, pR854, DOI 10.1016/S0960-9822(00)80045-7; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GREENE LE, 1981, BIOCHEMISTRY-US, V20, P2120, DOI 10.1021/bi00511a008; HACKNEY DD, 1984, P NATL ACAD SCI-BIOL, V81, P5345, DOI 10.1073/pnas.81.17.5345; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MCKILLOP DFA, 1990, BIOCHEM SOC T, V18, P585, DOI 10.1042/bst0180585; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	20	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23240	23245		10.1074/jbc.M100524200	http://dx.doi.org/10.1074/jbc.M100524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11301326	hybrid			2022-12-25	WOS:000169531100005
J	Musial, A; Eissa, NT				Musial, A; Eissa, NT			Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; INHIBITORS; CALMODULIN; MECHANISMS; REQUIRES; SUBUNIT; RELEASE; CLONING; DOMAIN	Inducible nitric-oxide synthase (iNOS) is responsible for nitric oxide (NO) synthesis from L-arginine in response to inflammatory mediators. To determine the degradation pathway of iNOS, human epithelial kidney HEK293 cells with stable expression of human iNOS were incubated in the presence of various degradation pathway inhibitors. Treatment with the proteasomal inhibitors lactacystin, MG132, and N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal resulted in the accumulation of iNOS, indicating that these inhibitors blocked its degradation. Moreover proteasomal inhibition blocked iNOS degradation in a dose- and time-dependent manner as well as when NO synthesis was inhibited by N-omega-nitro-L-arginine methyl ester. Furthermore, proteasomal inhibition blocked the degradation of an iNOS splice variant that lacked the capacity to dimerize and of an iNOS mutant that lacks L-arginine binding ability, suggesting that iNOS is targeted by proteasomes, notwithstanding its capacity to produce NO, dimerize, or bind the substrate. In contrast to proteasomal inhibitors, the calpain inhibitor calpastatin and the lysosomal inhibitors transepoxysuccinyl-L-leucylamido-4-guanidino butane, leupeptin, pepstatin-A chloroquine, and NH4Cl did not lead to significant accumulation of iNOS. Interestingly, when cytokines were used to induce iNOS in RT4 human epithelial cells, the effect of proteasomal inhibition was dichotomous. Lactacystin added prior to cytokine stimulation prevented iNOS induction by blocking the degradation of the NF-KB inhibitor I kappaB-alpha, thus preventing activation of NF-kappaB. In contrast, lactacystin added 48 h after iNOS induction led to the accumulation of iNOS. Similarly in murine macrophage cell line RAW 264.7, lactacystin blocked iNOS degradation when added 48 h after MOS induction by Lipopolysaccharide. These data identify the proteasome as the primary degradation pathway for iNOS.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Eissa, NT (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,FBRN-B567, Houston, TX 77030 USA.	teissa@bcm.tmc.edu						ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Eissa NT, 2001, AM J RESP CELL MOL, V24, P616, DOI 10.1165/ajrcmb.24.5.4324; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Konur A, 1996, J IMMUNOL, V157, P2109; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; NAKANE M, 1995, MOL PHARMACOL, V47, P831; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	32	131	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24268	24273		10.1074/jbc.M100725200	http://dx.doi.org/10.1074/jbc.M100725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312270	hybrid			2022-12-25	WOS:000169531100136
J	Pacek, M; Konopa, G; Konieczny, I				Pacek, M; Konopa, G; Konieczny, I			DnaA box sequences as the site for helicase delivery during plasmid RK2 replication initiation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTANTLY RELATED BACTERIA; HOST-RANGE; CHROMOSOMAL REPLICATION; BACILLUS-SUBTILIS; NUCLEOTIDE-SEQUENCE; PROTEIN COMPLEX; GENE-PRODUCT; ORIGIN; BINDING; REGION	DnaA box sequences are a common motif present within the replication origin region of a diverse group of bacteria and prokaryotic extrachromosomal genetic elements. Although the origin opening caused by binding of the host DnaA protein has been shown to be critical for the loading of the DnaB helicase, to date there has been no direct evidence presented for the formation of the DnaB complex at the DnacA box site. For these studies, we used the replication origin of plasmid RK2 (oriV), containing a cluster of four DnaA boxes that bind DnaA proteins isolated from different bacterial species (Caspi, R., Helinski, D. R., Pacek, M,, and Konieczny, I. (2000) J. Biol. Chem. 275, 18454-18461). Size exclusion chromatography, surface plasmon resonance, and electron microscopy experiments demonstrated that the DnaB helicase is delivered to the DnaA box region, which is localized similar to 200 base pairs upstream hom the region of Origin opening and a potential site for helicase entry. The DnaABC complex was formed on both double-stranded superhelical and linear RK2 templates. A strict DnaA box sequence requirement for stable formation of that nucleoprotein structure was confirmed. In addition, our experiments provide evidence for interaction between the plasmid initiation protein TrfA and the DnaABC prepriming complex, formed at DnaA box region. This interaction is facilitated via direct contact between TrfA and DnaB proteins.	Univ Gdansk, Dept Mol & Cellular Biol, Fac Biotechnol, PL-80822 Gdansk, Poland; Univ Gdansk, Fac Biol, Dept Mol Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; University of Gdansk	Konieczny, I (corresponding author), Univ Gdansk, Dept Mol & Cellular Biol, Fac Biotechnol, 24 Kladki, PL-80822 Gdansk, Poland.			Konieczny, Igor/0000-0002-1588-5601				ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Caspi R, 2000, J BIOL CHEM, V275, P18454, DOI 10.1074/jbc.M000552200; COWAN P, 1982, PLASMID, V8, P164, DOI 10.1016/0147-619X(82)90054-3; CROSS MA, 1986, PLASMID, V15, P132, DOI 10.1016/0147-619X(86)90049-1; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; Doran KS, 1999, MOL MICROBIOL, V33, P490, DOI 10.1046/j.1365-2958.1999.01491.x; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; FUJITA MQ, 1989, MOL GEN GENET, V215, P381, DOI 10.1007/BF00427033; FUKUOKA T, 1990, J BIOCHEM-TOKYO, V107, P732, DOI 10.1093/oxfordjournals.jbchem.a123117; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Kornberg A., 1992, DNA REPLICATION; Krause M, 1997, J MOL BIOL, V274, P365, DOI 10.1006/jmbi.1997.1404; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Majka J, 1997, J BACTERIOL, V179, P2426, DOI 10.1128/jb.179.7.2426-2432.1997; Majka J, 1999, EUR J BIOCHEM, V260, P325, DOI 10.1046/j.1432-1327.1999.00168.x; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; NIETO C, 1992, J MOL BIOL, V223, P415, DOI 10.1016/0022-2836(92)90661-3; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PERRI S, 1991, J BIOL CHEM, V266, P12536; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; VOCKE C, 1983, CELL, V35, P495, DOI 10.1016/0092-8674(83)90183-6; VOCKE C, 1983, P NATL ACAD SCI-BIOL, V80, P6557, DOI 10.1073/pnas.80.21.6557; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YEE TW, 1990, P NATL ACAD SCI USA, V87, P1278, DOI 10.1073/pnas.87.4.1278; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	56	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23639	23644		10.1074/jbc.M100255200	http://dx.doi.org/10.1074/jbc.M100255200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316803	hybrid			2022-12-25	WOS:000169531100056
J	Bureau, C; Bernad, J; Chaouche, N; Orfila, C; Beraud, M; Gonindard, C; Alric, L; Vinel, JP; Pipy, B				Bureau, C; Bernad, J; Chaouche, N; Orfila, C; Beraud, M; Gonindard, C; Alric, L; Vinel, JP; Pipy, B			Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD MONONUCLEAR-CELLS; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; REACTIVE OXYGEN; RESPIRATORY BURST; NS3 PROTEIN; INFECTED PATIENTS; CYCLIC-AMP; KINASE; EXPRESSION	It has been shown that oxidative stress occurs in chronic hepatitis C. Release of reactive oxygen species (ROS) from sequestered phagocytes and activated resident macrophages represents the predominant component of oxidative stress in the liver. However, little is known about the ability of the monocyte to produce ROS in response to protein of hepatitis C virus. In this study, we investigated the ROS production in human monocytes stimulated by several viral proteins of hepatitis C virus. Human monocytes from healthy blood donors were incubated with recombinant viral protein: Core, NS3, NS4, and NS5. ROS production was measured by chemiluminescence. Only NS3 triggered ROS production in human monocytes. Generated ROS were mainly the anion superoxide. NS3 also induced a rapid and transient increase in intracellular calcium concentration measured by a video digital microscopy technique. By using different metabolic inhibitors, we showed that ROS production requires calcium influx, tyrosine kinases, and the stress-activated protein kinase, p38. The study of p47(PHOX) phosphorylation and translocation showed that NADPH oxidase was activated and involved in ROS production induced by NS3. In a second experiment, NS3 inhibited the oxidative burst induced by phorbol 12-myristate 13-acetate. These results indicate that NS3 activates NADPH oxidase and modulates ROS production, which may be involved in the natural history of hepatitis C infection.	Univ Toulouse 3, Inst Louis Bugnard, UPRES EA 2405, CHU Rangueil,IFR31, F-31403 Toulouse 04, France; CHU Purpan, Federat Digest, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Pipy, B (corresponding author), Univ Toulouse 3, Inst Louis Bugnard, UPRES EA 2405, CHU Rangueil,IFR31, Batiment L1,1 Ave Jean Poulhes, F-31403 Toulouse 04, France.			Pipy, Bernard/0000-0001-8060-7029				ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barbaro G, 1999, AM J GASTROENTEROL, V94, P2198, DOI 10.1111/j.1572-0241.1999.01294.x; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BIRONAITE DA, 1992, ARCH BIOCHEM BIOPHYS, V297, P253, DOI 10.1016/0003-9861(92)90669-N; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Borowski P, 1997, J VIROL, V71, P2838, DOI 10.1128/JVI.71.4.2838-2843.1997; Borowski P, 1999, J BIOL CHEM, V274, P30722, DOI 10.1074/jbc.274.43.30722; BOUFFARD P, 1992, J INFECT DIS, V166, P1276, DOI 10.1093/infdis/166.6.1276; Boya P, 1999, J HEPATOL, V31, P808, DOI 10.1016/S0168-8278(99)80281-5; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; DeMaria N, 1996, FREE RADICAL BIO MED, V21, P291, DOI 10.1016/0891-5849(96)00044-5; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fujita T, 1996, BIOCHEM BIOPH RES CO, V229, P825, DOI 10.1006/bbrc.1996.1887; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; Ishido S, 1997, BIOCHEM BIOPH RES CO, V230, P431, DOI 10.1006/bbrc.1996.5980; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kaul N, 1996, FREE RADICAL BIO MED, V21, P401, DOI 10.1016/0891-5849(96)00178-5; Lachgar A, 1999, J VIROL, V73, P1447, DOI 10.1128/JVI.73.2.1447-1452.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lal AS, 1999, BIOCHEM BIOPH RES CO, V259, P465, DOI 10.1006/bbrc.1999.0759; Larrea E, 1998, FREE RADICAL BIO MED, V24, P1235, DOI 10.1016/S0891-5849(97)00437-1; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MULLER HM, 1993, J GEN VIROL, V74, P669, DOI 10.1099/0022-1317-74-4-669; Muratori L, 1996, BLOOD, V88, P2768, DOI 10.1182/blood.V88.7.2768.bloodjournal8872768; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; PACE GW, 1995, FREE RADICAL BIO MED, V19, P523, DOI 10.1016/0891-5849(95)00047-2; Rane MJ, 1997, J IMMUNOL, V159, P5070; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; Sansonno D, 1996, CLIN EXP IMMUNOL, V103, P414; SOZZANI P, 1995, J BIOL CHEM, V270, P5084, DOI 10.1074/jbc.270.10.5084; SUNO M, 1984, BIOCHEM BIOPH RES CO, V125, P1046, DOI 10.1016/0006-291X(84)91389-5; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; TAUBER AI, 1982, BLOOD, V60, P333; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666; VONJAGOW G, 1981, FEBS LETT, V136, P19, DOI 10.1016/0014-5793(81)81206-9; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464	46	130	131	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23077	23083		10.1074/jbc.M100698200	http://dx.doi.org/10.1074/jbc.M100698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304537	hybrid			2022-12-25	WOS:000169412700145
J	Harris, VK; Kagan, BL; Ray, R; Coticchia, CM; Liaudet-Coopman, ED; Wellstein, A; Riegel, AT				Harris, VK; Kagan, BL; Ray, R; Coticchia, CM; Liaudet-Coopman, ED; Wellstein, A; Riegel, AT			Serum induction of the fibroblast growth factor-binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP-regulated transcription	ONCOGENE			English	Article						FGF-BP; serum; p38 MAPK; C/EBP; transcription	SIGNAL-TRANSDUCTION PATHWAYS; GENE-EXPRESSION; PHOSPHORYLATION; ISOFORMS; ELEMENT	The fibroblast growth factor-binding protein (FGF-BP) modulates FGF activity through binding and release from the extracellular matrix, Consequently, the expression of FGF-BP in certain tumor types is a rate-limiting regulator of FGF-mediated angiogenesis. FGF-BP is upregulated in squamous cell carcinoma by treatment with mitogens such as EGF or TPA, In this study, we investigated the regulation of FGF-BP gene expression by serum. Treatment of serum-starved ME-180 cells with fetal bovine serum (FBS) resulted in a rapid increase in steady-state levels of FGF-BP mRNA and in the rate of FGF-BP gene transcription. Serum induction of FGF-BP mRNA was not mediated through EGF receptor activation but was dependent on PKC, as well as ERK kinase (MEK) and p38 MAP kinase activation. Promoter analysis showed that C/EBP is the main promoter element required for the serum response. Unlike EGF-activation of FGF-BP, transcriptional induction by serum is not significantly regulated through the AP-I or E-box sites in the promoter. These results illustrate differences between the mechanism of induction in response to serum and EGF.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Harris, VK (corresponding author), CUNY, Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, 1425 Madison Ave,Box 1130,East Bldg,Rm 15-52, New York, NY 10029 USA.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA71508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Harris VK, 2000, J BIOL CHEM, V275, P28539, DOI 10.1074/jbc.M001677200; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU DQ, 1991, J BIOL CHEM, V266, P16778	24	21	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1730	1738		10.1038/sj.onc.1204249	http://dx.doi.org/10.1038/sj.onc.1204249			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313920				2022-12-25	WOS:000167750900006
J	Chai, YL; Chipitsyna, G; Cui, JQ; Liao, BS; Liu, S; Aysola, K; Yezdani, M; Reddy, ESP; Rao, VN				Chai, YL; Chipitsyna, G; Cui, JQ; Liao, BS; Liu, S; Aysola, K; Yezdani, M; Reddy, ESP; Rao, VN			c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells	ONCOGENE			English	Article						c-Fos; BRCA1/BRCA1a/1b; Elk-1; growth suppression; breast cancer; protein-protein interaction	ETS TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; DNA-BINDING; PROTEIN ELK-1; IN-VIVO; EXPRESSION; ACTIVATION; GENE; DOMAINS; COMPLEX	Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain family of transcriptional factors, plays an important role in the induction of immediate early gene expression in response to a variety of extracellular signals. In this study, we demonstrate for the first time the in, vitro and in vivo interaction of Elk-1 with BRCA1 splice variants BRCA1a and BRCA1b using GST-pull down assays, co-imunoprecipitations/Western blot analysis of cell extracts from breast cancer cells and mammalian two-hybrid assays. We have localized the BRCA1 interaction domain of Elk-1 protein to the conserved ETS domain, a motif involved in DNA binding and protein-protein interactions. We also observed binding of BRCA1 proteins to other ETS-domain transcription factors SAP1, ETS-1, ERG-2 and Fli-1 but not to Elk-1 splice variant Delta Elk-1 and c-Fos protooncogene, Both BRCA1a and BRCA1b splice variants function as growth suppressors of human breast cancer cells. interestingly, our studies reveal that although both Elk-1 and SAP-1 are highly homologous members of a subfamily of ETS domain proteins called ternary complex factors, it is only Elk-1 but not SAP-I that can augment the growth suppressive function of BRCA1a/1b proteins in breast cancer cells, Thus Elk-1 could be a potential downstream target of BRCA1 in its growth control pathway, Furthermore, we hare observed inhibition of c-Fos promoter activity in BRCA1a transfected stable breast cancer cells and over expression of BRCA1a/1b attenuates MEK-induced SRE activation in vivo. These results demonstrate for the first time a link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 protein, All these results taken together suggest that one of the mechanisms by which BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos.	Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, 245 N 15th St,New Coll Bldg,MS 481, Philadelphia, PA 19102 USA.				NATIONAL CANCER INSTITUTE [R01CA085343, R01CA058642, R01CA057322] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA58642, 1RO1CA85343, 1RO1CA57322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1995, AM J HUM GENET, V57, P1457; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Katsama A, 2000, CANCER LETT, V150, P165, DOI 10.1016/S0304-3835(99)00386-9; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Lu ML, 1996, CANCER RES, V56, P4578; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; Ozcelik H, 1998, INT J CANCER, V77, P1; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SHYAM E, 1990, CANCER RES, V50, P5013; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	59	45	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1357	1367		10.1038/sj.onc.1204256	http://dx.doi.org/10.1038/sj.onc.1204256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313879				2022-12-25	WOS:000167495000009
J	Decesse, JT; Medjkane, S; Datto, MB; Cremisi, CE				Decesse, JT; Medjkane, S; Datto, MB; Cremisi, CE			RB regulates transcription of the p21/WAF1/CIP1 gene	ONCOGENE			English	Article						RB; p21(WAF1/CIP); Spl; epithelial cells; differentiation	CDK-INHIBITOR P21(WAF1/CIP1); SV40 T-ANTIGEN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; SP1-MEDIATED TRANSCRIPTION; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; PRODUCT RB; EXPRESSION; DIFFERENTIATION	We have previously shown that RB plays an important role in the maintenance of the epithelial phenotype, p21 is also involved in several terminal differentiation systems including keratinocytes. We report here that p21 is an RB target gene in epithelial cells, but not in fibroblasts where RB is unable to transactivate p21 transcriptional expression. In epithelial cells, when RB family factors were inactivated by SV40 T antigen (LT), p21 expression was strongly repressed, whereas its expression was not affected when the cells were transformed by a mutated LT leaving RB active but inactivating p53. Moreover, retransformation by RB of LT transformed epithelial cells totally restored p21 expression. By cotransfection experiments and using deletions and point mutations of the p21 promoter, we show that the minimal region required for the RB-mediated transcriptional activation maps to a GC-rich region located between -83 and -74. This region is shown to interact specifically with the transcription factor Sp1 and Sp3. Thus for the first time, we show a positive transcriptional relationship between RB and p21 in epithelial cells. Since p21 keeps RB in a hypophosphorylated state important for its transcriptional activity during differentiation, our results imply an auto-loop of regulation between RB and p21 that may be essential for the maintenance of the differentiation state. We propose that this transcriptional relationship might be necessary of their roles in cell cycle arrest and in several differentiation pathways.	Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, F-94801 Villejuif, France; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); Duke University	Cremisi, CE (corresponding author), Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.			Medjkane, Souhila/0000-0001-7973-7707				Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUCHS E, 1993, J CELL SCI, P197; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; JIANG HP, 1994, ONCOGENE, V9, P3397; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martel C, 1997, CELL GROWTH DIFFER, V8, P165; Martel C, 1996, CELL DEATH DIFFER, V3, P285; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	43	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					962	971		10.1038/sj.onc.1204169	http://dx.doi.org/10.1038/sj.onc.1204169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314031				2022-12-25	WOS:000167097000007
J	Fukuchi, Y; Kizaki, H; Yamato, K; Kawamura, C; Umezawa, A; Hata, J; Nishihara, T; Ikeda, Y				Fukuchi, Y; Kizaki, H; Yamato, K; Kawamura, C; Umezawa, A; Hata, J; Nishihara, T; Ikeda, Y			Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells	ONCOGENE			English	Article						activin A; CML apoptosis; differentiation; Mcl-1	GLOBIN GENE-EXPRESSION; FSH-RELEASING PROTEIN; BCL-2 FAMILY-MEMBERS; ERYTHROID-DIFFERENTIATION; SIGNALING PATHWAY; PROLIFERATION; LEUKEMIA; INHIBIN; PURIFICATION; DELAYS	Activin A, one member of the transforming grow th factor (TGF)-beta superfamily, is known to be a commitment factor for cell death and differentiation. In the present study, we demonstrate that human chronic myeloid leukemia (CML) cell lines, KU812 and K562 cells, either induced apoptosis or differentiation, respectively, by treatment with activin A. During these cell fate decisive events caused by activin A, rapid and transient up-regulation of Mcl-1 nas observed in both cell lines, In activin A-induced apoptosis of KU812 cells, continuous up-regulation of Bas was observed. After the decrease in Mcl-1 expression had occurred, activation of caspase-9 and caspase-3 and cleavage of DFF45 were shown to take place in KU812 cells, resulting in the fragmentation of the genomic DNA of the cells. In contrast, the dean-regulation of Mcl-1 without up-regulation of Bas caused accumulation of hemoglobin (Hb) contents in activin A-treated K562 cells. Interestingly, erythropoietin (EPO) prevented activin A-induced apoptosis with continuous expression of Mcl-1 and caused KU812 cells to undergo erythroid differentiation. To address the role of Mcl-1 in activin A-treated CML cells, KU812 and K562 cells were stably transfected with cDNA encoding Mcl-1 (designated as KU812/mcl and K562/mcl cells). As in combined effect of activin A and EPO on the parental KU812 cells, activin A induced differentiation, but not apoptosis, of KU812/mcl cells without modulating Bas levels. Activin A-treated K562/mcl cells, as well as parental cells, were only differentiated to erythroid cells, These results suggest that Mcl-1 is an early inducible gene activated by the activin A signaling pathway for both cellular differentiation and apoptosis, and continuous expression of Mcl-1 mag be contributed to differentiation signals to the erythroid lineage in CML cells.	Keio Univ, Sch Med, Div Hematol, Dept Internal Med & Pathol,Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci,Dept Oral Funct, Sect Mol Cellular Oncol Microbiol, Tokyo 1138519, Japan; Kyushu Dent Coll, Dept Oral Microbiol, Kitakyushu, Fukuoka 8038580, Japan	Keio University; Tokyo Medical & Dental University (TMDU); Kyushu Dental University	Kizaki, H (corresponding author), Keio Univ, Sch Med, Div Hematol, Dept Internal Med & Pathol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							Ando T, 1998, JPN J CANCER RES, V89, P1326, DOI 10.1111/j.1349-7006.1998.tb00530.x; BILEZIKJIAN LM, 1992, TRENDS ENDOCRIN MET, V3, P218, DOI 10.1016/1043-2760(92)90031-U; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; CHAMPLIN RE, 1985, BLOOD, V65, P1039; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; DEPAOLO LV, 1991, P SOC EXP BIOL MED, V198, P500; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FRIGON NL, 1992, BLOOD, V79, P765; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MIYAMOTO Y, 1990, BIOCHEM BIOPH RES CO, V168, P1149, DOI 10.1016/0006-291X(90)91149-M; MIZUGUCHI T, 1993, BLOOD, V81, P2891; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; NISHIMURA M, 1991, BIOCHEM BIOPH RES CO, V181, P1042, DOI 10.1016/0006-291X(91)92042-I; Peters R, 1998, BLOOD, V92, P2041, DOI 10.1182/blood.V92.6.2041.418k34_2041_2052; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SHAO LE, 1992, BLOOD, V79, P773; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shiozaki M, 1998, BIOCHEM BIOPH RES CO, V242, P631, DOI 10.1006/bbrc.1997.8020; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; TALPAZ M, 1995, ANN INTERN MED, V122, P728, DOI 10.7326/0003-4819-122-9-199505010-00013; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang JM, 1999, MOL CELL BIOL, V19, P6195; YAMASHITA T, 1991, J BIOL CHEM, V266, P3888; Yamato K, 1997, MOL ENDOCRINOL, V11, P1044, DOI 10.1210/me.11.8.1044; YAMATO K, 1996, JPN J CLIN HEMATOL, V37, P564; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YU J, 1989, BLOOD, V73, P952; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	45	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					704	713		10.1038/sj.onc.1204142	http://dx.doi.org/10.1038/sj.onc.1204142			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314004				2022-12-25	WOS:000166806000006
J	Liu, JM; Yuan, Y; Huan, J; Shen, ZY				Liu, JM; Yuan, Y; Huan, J; Shen, ZY			Inhibition of breast and brain cancer cell growth by BCCIP alpha, an evolutionarily conserved nuclear protein that interacts with BRCA2	ONCOGENE			English	Article						BRCA2; calcium-binding protein; BCCIP	SUSCEPTIBILITY GENE BRCA2; TUMOR-SUPPRESSOR LOCI; LONG ARM; RADIATION HYPERSENSITIVITY; TERMINAL DELETION; HUMAN GLIOMAS; ALLELIC LOSS; RAD51; CHROMOSOME-10; 10Q	BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis, Although important functions have been assigned to a few conserved domains of BRCA2, little is known about the longest internal conserved domain encoded by exons 14-24.,We identified a novel protein, designated BCCIP alpha, that interacts with part of the internal conserved region of human BRCA2, Human BCCIP represents a family of proteins that are evolutionarily conserved, and contain three distinct domains: an N-terminus acidic domain (NAD) of 30-60 amino acids, an internal conserved domain (ICD) of 180-220 amino acids, and a C-terminus variable domain (CVD) of 30-60 amino acids, The N-terminal half of the human BCCIP ICD shares moderate homology with regions of calmodulin and ill-calpain, suggesting that BCCIP may also bind Ca. Human cells express both a longer, BCCIP alpha, and a shorter, BCCIP beta, form of the protein, which differ in their CVD, BCCIP is a nuclear protein highly expressed in testis, Although BCCIP beta expression is relatively consistent in cancer cells, the expression of BCCIP alpha varies in cancer cell Lines. The BCCIP alpha gene is located at chromosome 10q25.3-26.2, a region frequently altered in brain and other cancers. Furthermore, expression of BCCIP alpha inhibits breast and brain cancer cell growth,but fails to inhibit HT1080 cells and a non-transformed human skin fibroblast, These results suggest that BCCIP alpha is an important cofactor for BRCA2 in tumor suppression.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ Illinois, Coll Med, Grad Program Mol Genet, Chicago, IL 60607 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shen, ZY (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008353, R01ES008353] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08353] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Gayther SA, 1998, DIS MARKERS, V14, P1; Ittmann M, 1996, CANCER RES, V56, P2143; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Koul A, 1999, GENE CHROMOSOME CANC, V24, P207, DOI 10.1002/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nordling M, 1998, CANCER RES, V58, P1372; PEAR WS, 1997, GENE THERAPY PROTLCO, P41; PEIFFER SL, 1995, CANCER RES, V55, P1922; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; Pontremoli S, 1999, CALCIUM AS A CELLULAR REGULATOR, P371; RASHEED BKA, 1991, CANCER METAST REV, V10, P289; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Robertson GP, 1999, CANCER RES, V59, P3596; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shen ZY, 1996, MUTAT RES-DNA REPAIR, V364, P81, DOI 10.1016/0921-8777(96)00025-0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanabe S, 1999, PEDIATR INT, V41, P565, DOI 10.1046/j.1442-200x.1999.01105.x; TAYSI K, 1982, ANN GENET-PARIS, V25, P141; VIDAL M, 1997, YEAST 2 HYBRID SYSTE, P109; Waggoner DJ, 1999, AM J MED GENET, V86, P1; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; YJANDRA N, 1999, CALCIUM CELL REGULAT, P152; Yuan SSF, 1999, CANCER RES, V59, P3547	37	76	80	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					336	345		10.1038/sj.onc.1204098	http://dx.doi.org/10.1038/sj.onc.1204098			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313963				2022-12-25	WOS:000166411000008
J	Cebrian, C; Areste, C; Nicolas, A; Olive, P; Carceller, A; Piulats, J; Meseguer, A				Cebrian, C; Areste, C; Nicolas, A; Olive, P; Carceller, A; Piulats, J; Meseguer, A			Kidney androgen-regulated protein interacts with cyclophilin B and reduces cyclosporine A-mediated toxicity in proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA; GENE-EXPRESSION; MOUSE KIDNEY; CALCINEURIN-BINDING; THYROID-HORMONE; NEPHROTOXICITY; MECHANISMS; SEQUENCE; LINES	The gene for kidney androgen-regulated protein (KAP) is the most abundant and specific gene expressed in mouse kidney proximal tubule cells, where it is tightly regulated by steroid and thyroid hormones in different tubule segments. Despite the cell-specific expression, strict regulatory mechanisms, and relative abundance, nothing is known of the function of its encoded protein, which does not exhibit known structural or functional domains, or homologies with other sequences in the data bases. We raised monoclonal antibodies against KAP, which specifically recognize a protein with an apparent molecular mass of 20 kDa in crude kidney homogenates, the distribution and regulation of which parallel that of its m-RNA. To gain insight into its function, we performed a yeast two hybrid screen and determined that KAP specifically interacts with cyclophilin B. Furthermore, cyclosporine A (CsA)-treated mice exhibited a significant decrease in KAP levels, and tetracycline-controlled overexpression of KAP in stably transfected proximal tubule cells significantly decreased the toxic effects of CsA. Taken together, these results indicate a functional relationship among KAP-, cyclophilin B-, and CsA-mediated nephrotoxicity and suggest an important role of KAP in renal physiology, providing new data on the molecular mechanisms implied in the toxic effects of CsA.	Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona 08035, Spain; Merck Farma & Quim SA, Lab Bioinvest, Barcelona 08010, Spain	Hospital Universitari Vall d'Hebron	Meseguer, A (corresponding author), Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Pg Vall dHebron 119-129,Plta 14, Barcelona 08035, Spain.	meseguer@hg.vhebron.es	Cebrian, Cristina/ABE-1974-2021; Navarro, Anna Meseguer/M-2222-2014; Cebrian, Cristina/E-2185-2012	Navarro, Anna Meseguer/0000-0003-3833-2249; Cebrian, Cristina/0000-0002-1297-6591				Ader JL, 1998, CURR OPIN NEPHROL HY, V7, P539, DOI 10.1097/00041552-199809000-00009; ANDERSON R, 1994, TOXICOL APPL PHARM, V125, P176, DOI 10.1006/taap.1994.1062; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BENNETT WM, 1994, MINER ELECTROL METAB, V20, P214; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Buetler TM, 2000, TRENDS PHARMACOL SCI, V21, P288, DOI 10.1016/S0165-6147(00)01508-X; CARTIER N, 1993, J CELL SCI, V104, P695; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Mattos AM, 2000, AM J KIDNEY DIS, V35, P333, DOI 10.1016/S0272-6386(00)70348-9; Denys A, 1998, TRANSPLANTATION, V65, P1076, DOI 10.1097/00007890-199804270-00012; El-Meanawy MA, 2000, AM J PHYSIOL-RENAL, V279, pF383, DOI 10.1152/ajprenal.2000.279.2.F383; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; Healy E., 1994, British Journal of Pharmacology, V112, p142P; HEALY E, 1995, J AM SOC NEPHROL, V6, P999; Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x; Kainer DB, 2000, HYPERTENSION, V35, P958, DOI 10.1161/01.HYP.35.4.958; KASIK JW, 1993, MOL CELL ENDOCRINOL, V90, P239, DOI 10.1016/0303-7207(93)90157-F; KOPP JB, 1990, J AM SOC NEPHROL, V1, P162; LACAVE R, 1993, J CELL SCI, V104, P705; Lally C, 1999, KIDNEY INT, V56, P1254, DOI 10.1046/j.1523-1755.1999.00696.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Melia MJ, 1998, ENDOCRINOLOGY, V139, P688, DOI 10.1210/en.139.2.688; MESEGUER A, 1987, MOL ENDOCRINOL, V1, P535, DOI 10.1210/mend-1-8-535; MESEGUER A, 1989, MOL ENDOCRINOL, V3, P962, DOI 10.1210/mend-3-6-962; MESEGUER A, 1990, MOL ENDOCRINOL, V4, P1240, DOI 10.1210/mend-4-8-1240; MESEGUER A, 1992, MOL CELL ENDOCRINOL, V89, P153, DOI 10.1016/0303-7207(92)90221-Q; MIHATSCH MJ, 1986, CLIN NEPHROL, V25, pS2; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; OTSUKA M, 1994, KIDNEY INT, V45, P1340, DOI 10.1038/ki.1994.175; Ouar Z, 1998, KIDNEY INT, V53, P59, DOI 10.1046/j.1523-1755.1998.00721.x; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; Ruhlmann A, 1997, IMMUNOBIOLOGY, V198, P192; Runic R, 1996, ENDOCRINOLOGY, V137, P729, DOI 10.1210/en.137.2.729; SCHNEIDER H, 1994, BIOCHEMISTRY-US, V33, P8218, DOI 10.1021/bi00193a007; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shihab FS, 1996, KIDNEY INT, V49, P1141, DOI 10.1038/ki.1996.165; Shihab FS, 1997, KIDNEY INT, V52, P660, DOI 10.1038/ki.1997.380; Shihab FS, 1999, KIDNEY INT, V56, P2147, DOI 10.1046/j.1523-1755.1999.00794.x; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SOLE E, 1994, ENDOCRINOLOGY, V135, P2120, DOI 10.1210/en.135.5.2120; Sole E, 1996, MOL CELL ENDOCRINOL, V119, P147, DOI 10.1016/0303-7207(96)03603-9; SUZUKI S, 1987, TRANSPLANTATION, V44, P363, DOI 10.1097/00007890-198709000-00008; Takenaka M, 1998, KIDNEY INT, V53, P562, DOI 10.1046/j.1523-1755.1998.00808.x; TAKESHI F, 1997, SEMIN NEPHROL, V17, P34; TOOLE JJ, 1979, CELL, V17, P441, DOI 10.1016/0092-8674(79)90170-3; Virlon B, 1999, P NATL ACAD SCI USA, V96, P15286, DOI 10.1073/pnas.96.26.15286; VONWILLEBRAND E, 1983, LANCET, V2, P189; Wang L, 2000, KIDNEY INT, V58, P528, DOI 10.1046/j.1523-1755.2000.00199.x; WOLF G, 1995, TRANSPLANTATION, V60, P237, DOI 10.1097/00007890-199508000-00005; Zhang H, 1999, KIDNEY INT, V56, P549, DOI 10.1046/j.1523-1755.1999.00561.x	57	21	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29410	29419		10.1074/jbc.M102916200	http://dx.doi.org/10.1074/jbc.M102916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11323438	hybrid			2022-12-25	WOS:000170346000103
J	Goodwin, AJ; McInerney, JM; Glander, MA; Pomerantz, O; Lowrey, CH				Goodwin, AJ; McInerney, JM; Glander, MA; Pomerantz, O; Lowrey, CH			In vivo formation of a human beta-globin locus control region core element requires binding sites for multiple factors including GATA-1, NF-E2, erythroid Kruppel-like factor, and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; CHROMATIN REMODELING COMPLEX; TRANSCRIPTION FACTOR; HYPERSENSITIVE SITES; MINIMAL REQUIREMENTS; FACTOR EKLF; GENE; PROMOTER; ACTIVATION; ENHANCER	The active elements of the beta -globin locus control region (LCR) are located within domains of unique chromatin structure. These nuclease hypersensitive sites (HSs) are characterized by high DNase I sensitivity, erythroid specificity, similar nucleosomal structure, and evolutionarily conserved clusters of cis-acting elements that are required for the formation and function of the core elements. To determine the requirements for HS core formation in the setting of nuclear chromatin, we constructed a series of artificial HS cores containing binding sites for GATA-1, NF-E2, and Sp1, In contrast to the results of previous in vitro experiments, we found that when constructs were stably integrated in mouse erythroleukemia cells the binding sites for NF-E2, GATA-1, or Sp1 alone or in any combination were unable to form core HS structures, We subsequently identified two new cis-acting elements from the LCR HS4 core that, when combined with the NF-ES, Sp1, and tandem inverted GATA elements, result in core structure formation. Both new cis-acting elements bind Sp1, and one binds erythroid Kruppel-like factor (EKLF). We conclude that in vivo beta -globin LCR HS core formation is more complex than previously thought and that several factors are required for this process to occur.	Dartmouth Coll, Sch Med, Dept Med, HB 7650, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Lowrey, CH (corresponding author), Dartmouth Coll, Sch Med, Dept Med, HB 7650, Hanover, NH 03755 USA.	c.lowrey@dartmouth.edu			NHLBI NIH HHS [F32 HL10083, HL 52243] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052243, F32HL010083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BAIYONG L, 1994, J BIOL CHEM, V269, P7756; Bender MA, 2000, BLOOD, V95, P3600, DOI 10.1182/blood.V95.11.3600.011k42_3600_3604; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; DHAR V, 1990, MOL CELL BIOL, V10, P4324, DOI 10.1128/MCB.10.8.4324; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; HARDISON R, 1995, MOL BIOL HEMOGLOBIN, P405; JONGSTRA J, 1984, NATURE, V307, P708, DOI 10.1038/307708a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; LAYON ME, 1998, BLOOD CELL MOL DIS, V24, P499; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; McDowell JC, 1999, MOL CELL BIOL, V19, P7600; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Navas PA, 1998, MOL CELL BIOL, V18, P4188, DOI 10.1128/MCB.18.7.4188; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PAWLIK KM, 1995, DEV BIOL, V169, P728, DOI 10.1006/dbio.1995.1182; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; Pomerantz O, 1998, NUCLEIC ACIDS RES, V26, P5684, DOI 10.1093/nar/26.24.5684; PONDEL MD, 1995, P NATL ACAD SCI USA, V92, P7237, DOI 10.1073/pnas.92.16.7237; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; Shelton DA, 1997, BLOOD, V89, P3457, DOI 10.1182/blood.V89.9.3457; Stamatoyannopoulos G., 2000, MOL BASIS BLOOD DIS, P135; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638; ZON LI, 1991, J BIOL CHEM, V266, P22948	64	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26883	26892		10.1074/jbc.M008410200	http://dx.doi.org/10.1074/jbc.M008410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11304527	hybrid			2022-12-25	WOS:000169966900022
J	Ramamurthy, V; Tucker, C; Wilkie, SE; Daggett, V; Hunt, DM; Hurley, JB				Ramamurthy, V; Tucker, C; Wilkie, SE; Daggett, V; Hunt, DM; Hurley, JB			Interactions within the coiled-coil domain of RetGC-1 guanylyl cyclase are optimized for regulation rather than for high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE-ROD DYSTROPHY; ADENYLYL-CYCLASE; CATALYTIC MECHANISM; CA2+-BINDING PROTEINS; MOLECULAR-DYNAMICS; ACTIVATING PROTEIN; ESCHERICHIA-COLI; NUCLEIC-ACIDS; CALCIUM; MUTATIONS	RetGC-1, a member of the membrane guanylyl cyclase family of proteins, is regulated in photoreceptor cells by a Ca2+-binding protein known as GCAP-1, Proper regulation of RetGC-1 is essential in photoreceptor cells for normal light adaptation and recovery to the dark state. In this study we show that cGMP synthesis by RetGC-1 requires dimerization, because critical functions in the catalytic site must be provided by each of the two polypeptide chains of the dimer, We also show that an intact cy-helical coiled-coil structure is required to provide dimerization strength for the catalytic domain of RetGC-1, However, the dimerization strength of this domain must be precisely optimized for proper regulation by GCAP-1, We found that Arg(838) within the dimerization domain establishes the Ca2+ sensitivity of RetGC-1 by determining the strength of the coiled-coil interaction. Arg(838) substitutions dominantly enhance cGMP synthesis even at the highest Ca2+ concentrations that occur in normal dark-adapted photoreceptor cells, Molecular dynamics simulations suggest that Arg(838) substitutions disrupt a small network of salt bridges to allow an abnormal extension of coiled-coil structure. Substitutions at Arg(838) were first identified by linkage to the retinal degenerative disease, autosomal dominant cone rod dystrophy (adCORD). Consistent with the characteristics of this disease, the Arg(898)-substituted RetGC-1 mutants exhibit a dominant biochemical phenotype, We propose that accelerated cGMP synthesis in humans with adCORD is the primary cause of cone-rod degeneration.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; UCL, Inst Ophthalmol, Dept Visual Sci, London EC1V 9EL, England; UCL, Dept Mol Genet, London EC1V 9EL, England; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of London; University College London; University of London; University College London; University of Washington; University of Washington Seattle	Hurley, JB (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	jbhhh@u.washington.edu	Hunt, David M/K-6024-2012; Tucker, Chandra/F-6842-2011	Hunt, David M/0000-0002-9264-3948; Tucker, Chandra/0000-0003-3033-1786	NEI NIH HHS [EY06641] Funding Source: Medline; NIGMS NIH HHS [GM50789] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050789, R29GM050789] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; COETZER TL, 1991, J CLIN INVEST, V88, P743, DOI 10.1172/JCI115371; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Duda T, 1999, BIOCHEMISTRY-US, V38, P13912, DOI 10.1021/bi9915972; Duda T, 2000, BIOCHEMISTRY-US, V39, P12522, DOI 10.1021/bi001514d; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; Gregory-Evans K, 2000, OPHTHALMOLOGY, V107, P55, DOI 10.1016/S0161-6420(99)00038-X; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; HOVNANIAN A, 1993, NAT GENET, V3, P327, DOI 10.1038/ng0493-327; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Hu JC, 2000, METHODS, V20, P80, DOI 10.1006/meth.1999.0908; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Jappelli R, 1999, BIOCHEM BIOPH RES CO, V266, P243, DOI 10.1006/bbrc.1999.1806; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KABSCH W, 1983, FEBS LETT, V155, P179, DOI 10.1016/0014-5793(82)80597-8; Kelsell RE, 1998, HUM MOL GENET, V7, P1179, DOI 10.1093/hmg/7.7.1179; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; Levitt M, 1997, J PHYS CHEM B, V101, P5051, DOI 10.1021/jp964020s; LEVITT M, 1995, COMPUT PHYS COMMUN, V91, P215, DOI 10.1016/0010-4655(95)00049-L; LEVITT M, 1990, ENCAD COMPUTER PROGR; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Lucas KA, 2000, PHARMACOL REV, V52, P375; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Tucker CL, 1999, P NATL ACAD SCI USA, V96, P9039, DOI 10.1073/pnas.96.16.9039; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; van den Akker F, 2000, NATURE, V406, P101, DOI 10.1038/35017602; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Weigell-Weber M, 2000, ARCH OPHTHALMOL-CHIC, V118, P300; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Yang JM, 1997, J INVEST DERMATOL, V109, P692, DOI 10.1111/1523-1747.ep12338320; Yang RB, 1999, J NEUROSCI, V19, P5889, DOI 10.1523/JNEUROSCI.19-14-05889.1999; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Yu H, 1999, J BIOL CHEM, V274, P15547, DOI 10.1074/jbc.274.22.15547; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	70	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26218	26229		10.1074/jbc.M010495200	http://dx.doi.org/10.1074/jbc.M010495200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11306565	hybrid			2022-12-25	WOS:000169823300078
J	Sun, Y; Savanenin, A; Reddy, PH; Liu, YF				Sun, Y; Savanenin, A; Reddy, PH; Liu, YF			Polyglutamine-expanded Huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE MUTATION; PROTEIN; PSD-95; MICE; ACTIVATION; LOCALIZATION; EXPRESSION; PLASTICITY; APOPTOSIS; LENGTH	increased glutamate-mediated excitotoxicity seems to play an important role in the pathogenesis of Huntington's disease (Tabrizi, S, J., Cleeter, M, W,, Xuereb, J,, Taaman, J. W., Cooper, J. M., and Schapira, A. H. (1999) Ann, Neurol, 45, 25-32), However, how polyglutamine expansion in huntingtin promotes glutamate-mediated excitotoxicity remains a mystery. In this study we provide evidence that (i) normal huntingtin is associated with N-methyl-D-aspartate (NMDA) and kainate receptors via postsynaptic density 95 (PSD-95), (ii) the SH3 domain of PSD-95 mediates its binding to huntingtin, and (iii) polyglutamine expansion interferes with the ability of huntingtin to interact with PSD-95, The expression of polyglutamine-expanded huntingtin causes sensitization of NMDA receptors and promotes neuronal apoptosis induced by glutamate, The addition of the NMDA receptor antagonist significantly attenuates neuronal toxicity induced by glutamate and polyglutamine-expanded huntingtin, The overexpression of normal huntingtin significantly inhibits neuronal toxicity mediated by NMDA or kainate receptors, Our results demonstrate that polyglutamine expansion impairs the ability of huntingtin to bind PSD-95 and inhibits glutamate-mediated excitotoxicity, These changes may be essential for the pathogenesis of Huntington's disease.	Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA; Oregon Hlth Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA	Northeastern University; Oregon Health & Science University	Liu, YF (corresponding author), Boston Univ, Dept Pharmacol, 715 Albany St, Boston, MA 02118 USA.							BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chen Q, 1996, BRAIN RES, V743, P346, DOI 10.1016/S0006-8993(96)01098-0; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HARPER PS, 1996, HUNTINGTONS DIS, V31; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207; Levine MS, 1999, J NEUROSCI RES, V58, P515, DOI 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; Murphy KPSJ, 2000, J NEUROSCI, V20, P5115; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0	30	218	226	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24713	24718		10.1074/jbc.M103501200	http://dx.doi.org/10.1074/jbc.M103501200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319238	hybrid			2022-12-25	WOS:000169800700041
J	Wang, HY; Maechler, P; Ritz-Laser, B; Hagenfeldt, KA; Ishihara, H; Philippe, J; Wollheim, CB				Wang, HY; Maechler, P; Ritz-Laser, B; Hagenfeldt, KA; Ishihara, H; Philippe, J; Wollheim, CB			Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE; BETA-CELLS; TRANSCRIPTIONAL ACTIVATION; ISLET CELLS; ALPHA-CELL; HOMEODOMAIN; PROTEIN; PAX4; REPRESSION; REVEALS	The absence of Pdx1 and the expression of brain-4 distinguish alpha -cells from other pancreatic endocrine cell lineages. To define the transcription factor responsible for pancreatic cell differentiation, we employed the reverse tetracycline-dependent transactivator system in INS-I cell-derived subclones INSr alpha beta and INSr beta to achieve tightly controlled and conditional expression of wild type Pdx1 or its dominant-negative mutant, as well as brain-4, INSr alpha beta cells express not only insulin but also glucagon and brain-4, while INSr beta cells express only insulin. Overexpression of Pdx1 eliminated glucagon mRNA and protein in INSr alpha beta cells and promoted the expression of beta -cell-specific genes in INSr beta cells. Induction of dominant-negative Pdx1 in INSr alpha beta cells resulted in differentiation of insulin-producing beta -cells into glucagon-containing alpha -cells without altering brain4 expression. Loss of Pdx1 function alone in INSr beta cells, which do not express endogenous brain-4 and glucagon, was also sufficient to abolish the expression of genes restricted to beta -cells and to cause alpha -cell differentiation. in contrast, induction of brain-4 in INSr beta cells initiated detectable expression of glucagon but did not affect beta -cell-specific gene expression. In conclusion, Pdx1 confers the expression of pancreatic beta -cell-specific genes, such as genes encoding insulin, islet amyloid polypeptide, Glut2, and Nkx6.1. Pdx1 defines pancreatic cell lineage differentiation. Loss of Pdx1 function rather than expression of brain4 is a prerequisite for alpha -cell differentiation.	Univ Geneva, Ctr Med, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland; Univ Geneva, Ctr Med, Dept Internal Med, Diabet Unit, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Wollheim, CB (corresponding author), Ctr Med Univ Geneva, Dept Med Interne, Div Biochim Clin & Diabetol Expt, CH-1211 Geneva 4, Switzerland.	Haiyan.Wang@medicine.unige.ch; Claes.Wollheim@medicine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hessabi B, 1999, EUR J BIOCHEM, V263, P170, DOI 10.1046/j.1432-1327.1999.00481.x; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Larsson LI, 1996, MECH DEVELOP, V60, P175, DOI 10.1016/S0925-4773(96)00609-0; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; MADSEN OD, 1993, ENDOCRINOLOGY, V133, P2022, DOI 10.1210/en.133.5.2022; MADSEN OD, 1988, P NATL ACAD SCI USA, V85, P6652, DOI 10.1073/pnas.85.18.6652; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Seijffers R, 1999, ENDOCRINOLOGY, V140, P3311, DOI 10.1210/en.140.7.3311; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; TRIMBLE ER, 1982, J CLIN INVEST, V69, P405, DOI 10.1172/JCI110464; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang HY, 2000, EMBO J, V19, P4257, DOI 10.1093/emboj/19.16.4257; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200	57	149	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25279	25286		10.1074/jbc.M101233200	http://dx.doi.org/10.1074/jbc.M101233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309388	hybrid, Green Published			2022-12-25	WOS:000169800700113
J	Chen, S; Inamdar, KV; Pfeiffer, P; Feldmann, E; Hannah, MF; Yu, Y; Lee, JW; Zhou, T; Lees-Miller, SP; Povirk, LF				Chen, S; Inamdar, KV; Pfeiffer, P; Feldmann, E; Hannah, MF; Yu, Y; Lee, JW; Zhou, T; Lees-Miller, SP; Povirk, LF			Accurate in vitro end joining of a DNA double strand break with partially cohesive 3 '-overhangs and 3 '-phosphoglycolate termini - Effect of Ku on repair fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RAY-SENSITIVE MUTANTS; XENOPUS EGG EXTRACTS; CELL-FREE-EXTRACTS; IONIZING-RADIATION; CATALYTIC SUBUNIT; IN-VITRO; MAMMALIAN-CELLS; NUCLEAR FOCI; MECHANISMS	To examine determinants of fidelity in DNA end joining, a substrate containing a model of a staggered free radical-mediated double-strand break, with cohesive phosphoglycolate-terminated 3'-overhangs and a one-base gap in each strand, was constructed. In extracts of Xenopus eggs, human lymphoblastoid cells, hamster CHO-K1 cells, and a Chinese hamster ovary (CHO) derivative lacking the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), the predominant end joining product was that corresponding to accurate restoration of the original sequence. In extracts of the Ku-deficient CHO derivative xrs6, a shorter product, consistent with 3' --> 5' resection before ligation, was formed. Similar results were seen for a substrate with 5'-overhangs and recessed S'-phosphoglycolate ends. Supplementation of the xrs6 extracts with purified Ku restored accurate end joining. In Xenopus and human extracts, but not in hamster extracts, gap filling and ligation were blocked by wortmannin, consistent with a requirement for DNA-PKcs activity. The results suggest a Ku-dependent pathway, regulated by DNA-PKcs, that can accurately restore the original DNA sequence at sites of free radical-mediated double-strand breaks, by protecting DNA termini from degradation and maintaining the alignment of short partial complementarities during gap filling and ligation.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Essen Gesamthsch Klinikum, Inst Zellbiol, D-45122 Essen, Germany; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	Virginia Commonwealth University; University of Duisburg Essen; University of Calgary	Povirk, LF (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980230, Richmond, VA 23298 USA.	LPOVIRK@hsc.vcu.edu		Lees-Miller, Susan/0000-0001-5809-2516	NATIONAL CANCER INSTITUTE [R01CA040615] Funding Source: NIH RePORTER; NCI NIH HHS [CA40615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bennett RAO, 1996, INT J RADIAT BIOL, V70, P623; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chen S, 2001, ANAL BIOCHEM, V289, P274, DOI 10.1006/abio.2000.4936; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; Errami A, 1998, NUCLEIC ACIDS RES, V26, P3146, DOI 10.1093/nar/26.13.3146; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Gottlich B, 1998, EUR J BIOCHEM, V258, P387, DOI 10.1046/j.1432-1327.1998.2580387.x; Gu XY, 1998, BIOCHEMISTRY-US, V37, P9827, DOI 10.1021/bi980198o; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENNER WD, 1983, J BIOL CHEM, V258, P711; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Labhart P, 1999, MOL CELL BIOL, V19, P2585; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LeRomancer M, 1996, J CELL SCI, V109, P3121; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; MEUTH M, 1989, MOBILE DNA, P833; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; OBE G, 1992, MUTAGENESIS, V7, P3, DOI 10.1093/mutage/7.1.3; Pang DL, 1997, CANCER RES, V57, P1412; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SCHAAL H, 1993, GENE, V124, P275, DOI 10.1016/0378-1119(93)90405-R; Smith GCM, 1999, BIOCHEM SOC SYMP, P91; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; Ting NSY, 1999, RADIAT RES, V151, P414, DOI 10.2307/3579828; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WARD JF, 1981, RADIAT RES, V86, P185, DOI 10.2307/3575500; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679	62	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24323	24330		10.1074/jbc.M010544200	http://dx.doi.org/10.1074/jbc.M010544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309379	hybrid			2022-12-25	WOS:000169531100144
J	Yam, A; Hyun, T; Li, WQ				Yam, A; Hyun, T; Li, WQ			Characterization of insulin-like growth factor I (IGF-I) receptor mutants for their effects on IGF-I- and interleukin 4-mediated DNA synthesis of 32D cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; TRANSFORMING ACTIVITIES; TUMOR-GROWTH; MITOGENESIS; SUBSTRATE-1; MUTATIONS; DIFFERENTIATION; PROLIFERATION; ACTIVATION; STATS	Recently we demonstrated that overexpression of the wild type insulin-like growth factor I receptor (IGF-IRWT) in 32D myeloid progenitor cells led to cell proliferation in response to interleukin 4 (IL-4) as well as insulin-like growth factor I (IGF-I) in the absence of insulin receptor substrate expression (Soon, L,, Flechner, L., Gutkind, J, S., Wang, L, H,, Baserga, R,, Pierce, J, H,, and Li, W. (1999)Mol. Cell. Biol. 19, 3816-3828), To understand the structural importance of insulin-like growth factor I receptor (IGF-IR) in mediating IL-4- and IGF-I-induced DNA synthesis, we transfected various mutants of IGF-IR to 32D cells. Our results show that most mutants, including Y1250F, Y1251F, Y1250F/Y1251F, S1280A/S1281A/S1282A/S1283A, Y1316F, and 1245d, still retained mitogenic response toward IGF-I or IL-4. However, the Y950F, Y1131F, and Y1135F mutants were not able to respond to either ligand, The H1293F/K1294R and 1293d mutants reduced response toward IGF-I but not to IL-4, Phosphorylation of She was greatly reduced in those three mutants that lost mitogenic response. The MAPK activity was much lower in Y1131F and Y1135F mutants, indicating the importance of the Shc/MAPK pathway in IGF-I-induced mitogenesis. Importantly, the synergistic effect of these two factors on DNA synthesis was not affected in cells expressing most of the mutants, even in those three that had lower mitogenic response toward a single ligand, These results suggest that an unidentified pathway(s) may be induced upon co-addition of IGF-I and IL-4 that sustains the intact mitogenesis.	Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, New Res Bldg,E407,3970 Reservoir Rd, Washington, DC 20007 USA.			Hyun, Teresa/0000-0002-9350-2733	NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; BASERGA R, 1995, CANCER RES, V55, P249; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Hongo A, 1996, ONCOGENE, V12, P1231; Ihle JN, 1998, CANCER J SCI AM, V4, pS84; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; LI SW, 1994, J BIOL CHEM, V269, P32558; Li WQ, 2000, CANCER RES, V60, P3909; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Soon L, 1999, MOL CELL BIOL, V19, P3816; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423	27	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24409	24413		10.1074/jbc.M102358200	http://dx.doi.org/10.1074/jbc.M102358200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323432	hybrid			2022-12-25	WOS:000169531100156
J	Anusaksathien, O; Laplace, C; Li, X; Ren, Y; Peng, L; Goldring, SR; Galson, DL				Anusaksathien, O; Laplace, C; Li, X; Ren, Y; Peng, L; Goldring, SR; Galson, DL			Tissue-specific and ubiquitous promoters direct the expression of alternatively spliced transcripts from the calcitonin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MESSENGER-RNA; PEPTIDE RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; LIGAND-BINDING; TRANSMEMBRANE DOMAIN; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; PHOSPHOLIPASE-C	The gene encoding the murine calcitonin receptor (mCTR) was isolated, and the exon/intron structure was determined. Analysis of transcripts revealed novel cDNA sequences, new alternative exon splicing in the 5'- untranslated region, and three putative promoters (P1, P2, and P3). The longest transcription unit is greater than 67 kilobase pairs, and the location of introns within the coding region of the mCTR gene (exons E3-E14) are identical to those of the porcine and human CTR genes. We have identified novel cDNA sequences that form three new exons as well as others that add 512 base pairs to the 5' side of the previously published cDNA, thereby extending exon El to 682 base pairs. Two of these novel exons are upstream of exon E2 and form a tripartite exon E2 (E2a, E2b, and E2c) in which E2a is utilized by promoter P2 with variable splicing of E2b. The third new exon (E3b') lies between E3a and E3b and is utilized by promoter P3. Analysis of mCTR mRNAs has revealed that the three alternative promoters give rise to at least seven mCTR isoforms in the 5' region of the gene and generate 5'-untranslated regions of very different lengths. Analysis by reverse transcription-polymerase chain reaction shows that promoters P1 and P2 are utilized in osteoclasts, brain, and kidney, whereas promoter P3 appears to be osteoclast-specific. Using transiently transfected reporter constructs, promoter P2 has activity in both a murine kidney cell line (MDCT209) and a chicken osteoclastlike cell line (HD-11EM), whereas promoter P3 is active only in the osteoclast-like cell. line. These transfection data confirm the osteoclast specificity of promoter P3 and provide the first evidence that the CTR gene is regulated in a tissue specific manner by alternative promoter utilization.	Harvard Inst Med, Beth Israel Deaconess Med Ctr, New England Baptist & Bone Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New England Baptist Hospital; Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School	Galson, DL (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, New England Baptist & Bone Joint Inst, Rm 247,4 Blackfan Circle, Boston, MA 02115 USA.		Galson, Deborah L./E-9370-2010	Galson, Deborah L./0000-0002-2045-8807	NIAMS NIH HHS [R01 AR045421, AR45421] Funding Source: Medline; NIDDK NIH HHS [DK46773] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046773] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRANDT K, 1995, ENDOCRINOLOGY, V136, P5377, DOI 10.1210/en.136.12.5377; ALBRANDT K, 1993, FEBS LETT, V325, P225, DOI 10.1016/0014-5793(93)81078-E; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Antequera F, 1993, MOL BIOL BIOL SIGNIF, P169; Beesley AH, 1999, AM J PHYSIOL-CELL PH, V276, pC585, DOI 10.1152/ajpcell.1999.276.3.C585; Bettoun JD, 1998, J CLIN INVEST, V102, P958, DOI 10.1172/JCI3678; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Deftos Leonard J., 1996, P82; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; FEN Z, 1991, ONCOGENE, V6, P953; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; FRIEDMAN J, 1965, SCIENCE, V150, P1465, DOI 10.1126/science.150.3702.1465; GALSON DL, 1997, J BONE MINER RES S1, V12, pS323; GALSON DL, 1996, J BONE MINER RES  S1, V11, pS203; Gebauer F, 1998, RNA, V4, P142; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; GOLDRING S, 1996, PRINCIPLES BONE BIOL, P462; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; HSIA YJ, 1995, J BONE MINER RES, V10, pS424; IKEGAME M, 1995, J BONE MINER RES, V10, P59; Inoue D, 1999, ENDOCRINOLOGY, V140, P1060, DOI 10.1210/en.140.3.1060; Jagger C, 1999, ENDOCRINOLOGY, V140, P492, DOI 10.1210/en.140.1.492; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOUN H, 1995, J BONE MINER RES, V10, pS488; Kel A, 1999, J MOL BIOL, V288, P353, DOI 10.1006/jmbi.1999.2684; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; KUESTNER RE, 1994, MOL PHARMACOL, V46, P246; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LEE SK, 1995, ENDOCRINOLOGY, V136, P4572, DOI 10.1210/en.136.10.4572; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MCCUAIG KA, 1995, NUCLEIC ACIDS RES, V23, P1948, DOI 10.1093/nar/23.11.1948; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; MITSUHASHI T, 1989, J BIOL CHEM, V264, P8900; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Naro F, 1998, ENDOCRINOLOGY, V139, P3241, DOI 10.1210/en.139.7.3241; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; Nishikawa T, 1999, FEBS LETT, V458, P409, DOI 10.1016/S0014-5793(99)01176-X; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAISZ LG, 1967, AM J MED, V43, P684, DOI 10.1016/0002-9343(67)90110-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Steinbeck MJ, 1998, J CELL PHYSIOL, V176, P574, DOI 10.1002/(SICI)1097-4652(199809)176:3<574::AID-JCP14>3.0.CO;2-#; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TETI A, 1995, J BIOL CHEM, V270, P16666, DOI 10.1074/jbc.270.28.16666; THEISEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3202; Turner CW, 1998, BRIT J HAEMATOL, V103, P326, DOI 10.1046/j.1365-2141.1998.01003.x; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; WARSHAWSKY H, 1980, J CELL BIOL, V85, P682, DOI 10.1083/jcb.85.3.682; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; YAMIN M, 1994, ENDOCRINOLOGY, V135, P2635, DOI 10.1210/en.135.6.2635; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	75	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22663	22674		10.1074/jbc.M007104200	http://dx.doi.org/10.1074/jbc.M007104200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309373	hybrid			2022-12-25	WOS:000169412700093
J	Van Valkenburgh, H; Shern, JF; Sharer, JD; Zhu, XJ; Kahn, RA				Van Valkenburgh, H; Shern, JF; Sharer, JD; Zhu, XJ; Kahn, RA			ADP-ribosylation factors (ARFs) and ARF-like 1 (ARL1) have both specific and shared effectors - Characterizing ARL1-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; GUANINE-NUCLEOTIDE-EXCHANGE; COILED-COIL PROTEINS; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-D; CHOLERA-TOXIN; GOLGI-COMPLEX; DELTA-SUBUNIT; MOLECULAR CHARACTERIZATION; DOWNSTREAM EFFECTOR	Despite the 40-60% identity between ADP-ribosylation factors (ARFs) and ARE-like (ARL) proteins, distinct functional roles have been inferred from findings that ARLs lack the biochemical or genetic activities characteristic of ARFs. The potential for functional overlap between ARFs and ARLs was examined by com paring effects of expression on intact cells and the ability to bind effecters. Expression of [Q71L]ARL1 in mammalian cells led to altered Golgi structure similar to, but less dramatic than, that reported previously for [Q71L]ARF1 (1). Two previously identified partners of ARFs, MKLP1 and Arfaptin2/POR1, also bind ARL1 but not ARL2 or ARL3. Two-hybrid screens of human cDNA libraries with dominant active mutants of human ARL1, ARL2, and ARL3 identified eight different but overlapping sets of binding partners. Specific interactions between ARL1 and two binding proteins, SCOCO and Golgin-245, are defined and characterized in more detail. Like ARFs and ARL1, the binding of SCOCO to Golgi membranes is rapidly reversed by brefeldin A, suggesting the presence of a brefeldin A-sensitive ARL1 exchange factor. These data reveal a complex network of interactions between GTPases in the ARF family and their effecters and reveal a potential for cross-talk not demonstrated previously.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Kahn, Richard/ABD-2666-2020; Shern, Jack/V-4002-2019	Kahn, Richard/0000-0002-0259-0601; 				Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boman AL, 1999, CELL MOTIL CYTOSKEL, V44, P119, DOI 10.1002/(SICI)1097-0169(199910)44:2<119::AID-CM4>3.3.CO;2-3; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOTSTEIN D, 1988, COLD SPRING HARB SYM, V53, P629, DOI 10.1101/SQB.1988.053.01.072; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHAN EKL, 1998, ELECTRON J BIOTECHN, V1, P1; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; Hall A, 1995, GUIDEBOOK SMALL GTPA, P3; Higashide T, 1996, J BIOL CHEM, V271, P1797, DOI 10.1074/jbc.271.3.1797; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KAHN RA, 1995, GUIDEBOOK SMALL GTPA, P443; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1992, J BIOL CHEM, V267, P24441; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Li N, 1998, FEBS LETT, V440, P454, DOI 10.1016/S0014-5793(98)01501-4; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; Lowe SL, 1996, J CELL SCI, V109, P209; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; MURTAGH JJ, 1993, BIOCHEMISTRY-US, V32, P6011, DOI 10.1021/bi00074a012; Nothwang HG, 1998, GENOMICS, V47, P383, DOI 10.1006/geno.1997.5119; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; ROTH MG, 2000, GTPASES; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Sharer JD, 1999, J BIOL CHEM, V274, P27553, DOI 10.1074/jbc.274.39.27553; Sherman F., 1974, METHODS YEAST GENETI; Shin OH, 1999, J BIOL CHEM, V274, P36609, DOI 10.1074/jbc.274.51.36609; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; Swanson DA, 1998, INVEST OPHTH VIS SCI, V39, P2085; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465; Zhu XJ, 2001, BIOCHEMISTRY-US, V40, P4560, DOI 10.1021/bi002628s	71	118	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22826	22837		10.1074/jbc.M102359200	http://dx.doi.org/10.1074/jbc.M102359200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303027	hybrid			2022-12-25	WOS:000169412700113
J	Zeng, HY; Moise, L; Grant, MA; Hawrot, E				Zeng, HY; Moise, L; Grant, MA; Hawrot, E			The solution structure of the complex formed between alpha-bungarotoxin and an 18-mer cognate peptide derived from the alpha 1 subunit of the nicotinic acetylcholine receptor from Torpedo californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL SOLUTION STRUCTURE; QUANTITATIVE J-CORRELATION; BINDING-SITE; NMR-SPECTROSCOPY; LONG NEUROTOXIN; AMINO-ACIDS; J-COUPLINGS; PROTON NMR; SENSITIVITY	The region encompassing residues 181-98 on the alpha1 subunit of the muscle-type nicotinic acetylcholine receptor forms a major determinant for the binding of cu neurotoxins. We have prepared an N-15-enriched (18)-amino acid peptide corresponding to the sequence in this region to facilitate structural elucidation by multidimensional NMR. Our aim was to determine the structural basis for the high affinity, stoichiometric complex formed between this cognate peptide and cu-bungarotoxin, a long cu-neurotoxin. Resonances in the complex were assigned through heteronuclear and homonuclear NMR experiments, and the resulting interproton distance constraints were used to generate ensemble structures of the complex. Thr(8), Pro(10), Lys(38), Val(39), Val(40), and pro(69) in alpha -bungarotoxin and Tyr(189), Tyr(190), Thr(191), Cys(192), Asp(195), and Thr(196) in the peptide participate in major intermolecular contacts. A comparison of the free and bound Lu-bungarotoxin structures reveals significant conformational rearrangements in flexible regions of alpha -bungarotoxin, mainly loops I, II, and the C-terminal tail. Furthermore, several of the calculated structures suggest that cation-pi interactions may be involved in binding. The root mean square deviation of the polypeptide backbone in the complex is 2.07 Angstrom. This structure provides, to date, the highest resolution description of the contacts between a prototypic alpha -neurotoxin and its cognate recognition sequence.	Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University	Hawrot, E (corresponding author), Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.	Edward_Hawrot@brown.edu	Moise, Lenny/AAE-7448-2019	Moise, Lenny/0000-0002-4410-865X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034348] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08240] Funding Source: Medline; NIGMS NIH HHS [GM32629] Funding Source: Medline; NINDS NIH HHS [NS34348] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BASUS VJ, 1988, BIOCHEMISTRY-US, V27, P2763, DOI 10.1021/bi00408a016; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1994, METHOD ENZYMOL, V239, P79; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Connolly PJ, 1996, BIOCHEMISTRY-US, V35, P418, DOI 10.1021/bi9520287; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GENTILE LN, 1995, ANN NY ACAD SCI, V757, P222, DOI 10.1111/j.1749-6632.1995.tb17479.x; GODDARD TD, 2000, SPARKY 3 95; Goldenberg DP, 2001, PROTEIN SCI, V10, P538, DOI 10.1110/ps.30701; Grutter T, 2000, BIOCHEMISTRY-US, V39, P3034, DOI 10.1021/bi992393o; KACHALSKY SG, 1995, P NATL ACAD SCI USA, V92, P10801, DOI 10.1073/pnas.92.23.10801; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; LABHARDT AM, 1988, EUR J BIOCHEM, V177, P295, DOI 10.1111/j.1432-1033.1988.tb14376.x; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; Michalet S, 2000, J BIOL CHEM, V275, P25608, DOI 10.1074/jbc.M002362200; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PEARCE SFA, 1990, P ROY SOC B-BIOL SCI, V241, P207, DOI 10.1098/rspb.1990.0087; Peng SS, 1997, J BIOL CHEM, V272, P7817, DOI 10.1074/jbc.272.12.7817; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rolz C, 2001, BIOPHYS CHEM, V89, P119, DOI 10.1016/S0301-4622(00)00222-2; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scherf T, 1997, P NATL ACAD SCI USA, V94, P6059, DOI 10.1073/pnas.94.12.6059; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; Thompson GS, 2000, PROTEIN SCI, V9, P846, DOI 10.1110/ps.9.5.846; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1994, J BIOMOL NMR, V4, P193; WILSON PT, 1988, MOL PHARMACOL, V34, P643; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WU SH, 1983, ARCH BIOCHEM BIOPHYS, V227, P111, DOI 10.1016/0003-9861(83)90353-3; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	51	41	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22930	22940		10.1074/jbc.M102300200	http://dx.doi.org/10.1074/jbc.M102300200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312275	hybrid			2022-12-25	WOS:000169412700127
J	Brodie, SG; Xu, XL; Li, CL; Kuo, A; Leder, P; Deng, CX				Brodie, SG; Xu, XL; Li, CL; Kuo, A; Leder, P; Deng, CX			Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis	ONCOGENE			English	Article						p53; erbB2; cyclin D1; tumorigenesis; cooperation; parotid gland	TRANSGENIC MICE; BREAST-CANCER; CELL-CYCLE; CARCINOMAS; AMPLIFICATION; EXPRESSION; NEOPLASMS; HER-2/NEU; DEATH; D1	Transgenic mice expressing specific oncogenes usually develop tumors in a stochastic fashion suggesting that tumor progression is a multi-step process. To gain further understanding of the interactions between oncogenes and tumor suppressor genes during tumorigenesis, we have crossed a transgenic strain (TG,NK) carrying an activated c-neu oncogene driven by the MMTV enhancer/promoter with p53-deficient mice. c-neu transgenic mice have stochastic breast tumor formation and normal appearing salivary glands. However, c-neu mice heterozygous for a p53 deletion develop parotid gland tumors and loose their wild type p53 allele, c-neu mice with a homozygous p53 deletion have increased rates of parotid tumor onset suggesting that inactivation of p53 is required and sufficient for parotid gland transformation in the presence of activated c-neu. In contrast to the dramatic effect of p53 in parotid gland transformation, p53 loss has little effect on the rate or stochastic appearance of mammary tumors. In addition, p53 loss was accompanied by the down regulation of p21 in parotid gland tumors but not breast tumors, The parotid gland tumors were aneuploid and demonstrated increased levels of Cyclin D1 expression. These observations suggest that in c-neu transgenic mice, p53 alterations have differential tissue effects and may be influenced by the tissue specific expression of genes influencing p53 activity.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Califano J, 1999, OTOLARYNG CLIN N AM, V32, P861, DOI 10.1016/S0030-6665(05)70178-X; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSON A, 1995, ONCOGENE, V11, P181; EVANS E P, 1987, P93; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Hand AR, 1999, ARCH ORAL BIOL, V44, pS3, DOI 10.1016/S0003-9969(99)00042-4; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Hynes NE, 1996, J MAMMARY GLAND BIOL, V1, P199, DOI 10.1007/BF02013643; Isola J, 1999, CLIN CANCER RES, V5, P4140; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez RE, 2000, MODERN PATHOL, V13, P37, DOI 10.1038/modpathol.3880007; Kamio N, 1996, VIRCHOWS ARCH, V428, P75; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1997, CANCER RES, V57, P1171; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MULLER S, 1994, MODERN PATHOL, V7, P628; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OSWALD F, 1994, ONCOGENE, V9, P2029; Pignataro L, 1998, ANTICANCER RES, V18, P1287; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRESS MF, 1994, CANCER RES, V54, P5675; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Rice DH, 1999, OTOLARYNG CLIN N AM, V32, P875, DOI 10.1016/S0030-6665(05)70179-1; Samuelson LC, 1996, ANNU REV PHYSIOL, V58, P209, DOI 10.1146/annurev.physiol.58.1.209; SCHULZE A, 1994, ONCOGENE, V9, P3475; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; Tonin PN, 2000, SEMIN SURG ONCOL, V18, P281, DOI 10.1002/(SICI)1098-2388(200006)18:4<281::AID-SSU2>3.0.CO;2-Q; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P	57	23	23	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1445	1454		10.1038/sj.onc.1204222	http://dx.doi.org/10.1038/sj.onc.1204222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313888				2022-12-25	WOS:000167595200005
J	Huang, YP; Ohtani, K; Iwanaga, R; Matsumura, Y; Nakamura, M				Huang, YP; Ohtani, K; Iwanaga, R; Matsumura, Y; Nakamura, M			Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I	ONCOGENE			English	Article						cell cycle; CREB; HTLV-I; NF-kappa B; tax; cyclin D2	EXPRESSION; PROTEIN; E2F; CANCER; LINES; ESTABLISHMENT; TRANSCRIPTION; ACCUMULATION; LYMPHOCYTES; PROGRESSION	Cyclins are one of the pivotal determinants regulating cell cycle progression. We previously reported that the trans-activator Tax of human T-cell leukemia virus type I(HTLV-I) induces endogenous cyclin D2 expression along with cell cycle progression in a resting human T-cell line, Kit 225, suggesting a role of cyclin D2 in Tax-mediated cell cycle progression, The cyclin D2 gene has a typical E2F binding element, raising the possibility that induction of cyclin D2 expression is a consequence of cell cycle progression. In this study, we examined the role and molecular mechanism of induction of the endogenous human cyclin D2 gene by Tax. Introduction of p19(INK4d), a cyclin dependent kinase (CDK) inhibitor of the INK4 family specific for D-type CDK, inhibited Tax-mediated activation of E2F, indicating requirement of D-type CDK in Tax-mediated activation of E2F, Previously indicated E2F binding element and, two NF-kappaB-like binding elements in the 1.6 kbp cyclin D2 promoter fragment had little, if any, effect on responsiveness to Tax, We found that trans-activation of the cyclin D2 promoter by Tax was mainly mediated by a newly identified NF-kappaB-like element with auxiliary contribution of a CRE-like element residing in sequences downstream of -444 which were by themselves sufficient for transactivation by Tax. These results indicate that Tax directly trans-activates the cyclin D2 gene, resulting in growth promotion and perhaps leukemogenesis through activation of D-type CDK.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HORI T, 1987, BLOOD, V70, P1069; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takano Y, 1999, J PATHOL, V189, P194; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	31	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1094	1102		10.1038/sj.onc.1204198	http://dx.doi.org/10.1038/sj.onc.1204198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314046	Bronze			2022-12-25	WOS:000167232100009
J	Kokontis, JM; Wagner, AJ; O'Leary, M; Liao, S; Hay, N				Kokontis, JM; Wagner, AJ; O'Leary, M; Liao, S; Hay, N			A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function	ONCOGENE			English	Article						p53; apoptosis; transactivation; transrepression; cell cycle arrest	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; MYC-MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; EXPRESSION; GROWTH; BCL-2; IDENTIFICATION; REPRESSION	The tumor suppressor p53 is an inducer of cell cycle arrest and programmed cell death (apoptosis), The ability of p53 to induce cell cycle arrest is linked to its ability to induce transcription of genes such as the cyclin-dependent kinase inhibitor p21, However, the dependence of p53-mediated apoptosis on transcriptional activation remains control versial. Ectopic expression of a temperature-sensitive (ts) p53 allele induced expression of p53 target genes and elicited both G1 and G2/M cell cycle arrest upon shift to the permissive temperature. Ectopic expression of the same ts p53 allele with two additional point mutations (Gln22, Ser23) that abolish p53-transcriptional activation did not induce p53 target genes and G1 nor G2/M cell cycle arrest. In HCT116 colon carcinoma cells ectopic expression of wild type p53 does not elicit apoptosis whereas p53 mutant deficient in trans-activation induces apoptosis, The ability of wild type p53 to induce apoptosis is restored in HCT116 cells that are null for p21, However, the trans-activation deficient mutant of p53 is still more potent mediator of apoptosis than wild type p53 in the p21 null cells. Although the ability of Gln22,Ser23 to trans-activate p53 target genes is diminished, it retains the ability to repress Bcl-2 expression. Thus, we conclude that while ectopic expression of wild type p53 can induce both G1 and G2/M;I arrest, in a p21 dependent manner, without apoptosis, a p53 mutant defective in transactivation elicits apoptosis without inducing cell cycle arrest. Further, the anti-apoptotic function of p53 is dependent on trans-activation and is linked to cell cycle arrest. The results strongly suggest that the transactivation deficient mutant is a more potent inducer of apoptosis because it lost its anti-apoptotic function and retains its ability to repress pro-apoptotic genes such as Bcl-2, Taken together, the results imply that employing a trans-activation deficient p53 in gene therapy approaches or the use of drugs that convert mutant p53 to a transactivation-independent mediator of apoptosis may be much more efficient therapeutic approaches than current approaches that employ wild type p53.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Hay, N (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA058073, U24CA078174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78174, CA-58073] Funding Source: Medline; NIA NIH HHS [AG-16927] Funding Source: Medline; NIDDK NIH HHS [DK-41670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANNON JV, 1990, EMBO J, V9, P1595; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TA, 2000, GENE DEV, V14, P1584; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Harn HJ, 1996, HISTOPATHOLOGY, V28, P317, DOI 10.1046/j.1365-2559.1996.d01-431.x; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; ISAACS WB, 1991, CANCER RES, V51, P4716; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	40	71	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					659	668		10.1038/sj.onc.1204139	http://dx.doi.org/10.1038/sj.onc.1204139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11313999				2022-12-25	WOS:000166806000001
J	Blyth, K; Terry, A; Mackay, N; Vaillant, F; Bell, M; Cameron, ER; Neil, JC; Stewart, M				Blyth, K; Terry, A; Mackay, N; Vaillant, F; Bell, M; Cameron, ER; Neil, JC; Stewart, M			Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging	ONCOGENE			English	Article						Runx2; Cbfa1; Myc; oncogene collaboration; retroviral tagging; runt domain	MURINE LEUKEMIA-VIRUS; PROVIRAL INSERTION SITE; T-CELL LYMPHOMAGENESIS; PIM-1 TRANSGENIC MICE; ZINC-FINGER PROTEIN; C-MYC; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; P53-DEFICIENT MICE; NERVOUS-SYSTEM	The Runx2 (Cbfa1, Pebp2 alphaA, Aml3) gene was previously identified as a frequent target for transcriptional activation by proviral insertion in T-cell lymphomas of CD2-MYC transgenic mice. We have recently shown that over-expression of the full-length, most highly expressed Runx2 isoform in the thymus perturbs T-cell development, leads to development of spontaneous lymphomas at low frequency and is strongly synergistic with MSc. To gain further insight into the relationship of Runx2 to other lymphomagenic pathways, me tested the effect of combining the CD2-Runx2 transgene either with a Pim1 transgene (E mu -Pim1) or with the p53 null genotype, as each of these displays independent synergy with Myc, In both cases we observed synergistic tumour development. However, Runx2 appeared to have a dominant effect on the tumour phenotype in each case, with most tumours conforming to the CD3(+), CD8(+), CD4(+/-) phenotype seen in CD2-Runx2 mice, Neonatal infection of CD2-Runx2 mice with Moloney murine leukaemia virus (Moloney MLV) also led to a dramatic acceleration of tumour onset. Analysis of known Moloney MLV target genes in these lymphomas showed a high frequency of rearrangement at c-Myc or N-Myc (82%), and a significant number at Pim1 or Pim2 (23%), and at Pal1/Gfi1 (18%), These results indicate that Runx2 makes a distinct contribution to T-cell lymphoma development which does not coincide with any of the oncogene complementation groups previously identified by retroviral tagging.	Univ Glasgow, Sch Vet, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Stewart, M (corresponding author), Univ Glasgow, Sch Vet, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Baxter EW, 1996, J VIROL, V70, P2095, DOI 10.1128/JVI.70.4.2095-2100.1996; Berns A, 1999, CANCER RES, V59, p1773S; BLYTH K, 1995, ONCOGENE, V10, P1717; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; BLYTH K, 1996, THESIS U GLASGOW VET; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; CUYPERS HT, 1984, CELL, V37, P141; DEPINHO R, 1999, ONCOGENE REV MOUSE M, pRG21; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAZO PA, 1990, J VIROL, V64, P3948, DOI 10.1128/JVI.64.8.3948-3959.1990; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LILLY M, 1997, CANCER RES, V57, P5248; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Meyers S, 1996, ONCOGENE, V13, P303; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; STEWART M, 1993, INT J CANCER, V53, P1023; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VIJAYA S, 1987, J VIROL, V61, P1164, DOI 10.1128/JVI.61.4.1164-1170.1987; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	50	89	90	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					295	302		10.1038/sj.onc.1204090	http://dx.doi.org/10.1038/sj.onc.1204090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313958				2022-12-25	WOS:000166411000003
J	Gual, P; Giordano, S; Anguissola, S; Parker, PJ; Comoglio, PM				Gual, P; Giordano, S; Anguissola, S; Parker, PJ; Comoglio, PM			Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling	ONCOGENE			English	Article						HGF; Gab1; Ser/Thr phosphorylation; negative regulation; invasive growth; PKC	HEPATOCYTE GROWTH-FACTOR; PROTEIN-KINASE-C; FACTOR SCATTER FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; INSULIN-RECEPTOR; DOCKING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; EPITHELIAL MORPHOGENESIS; MET RECEPTOR	Signal transduction by HGF receptor, the tyrosine kinase encoded by the MET oncogene, switches on a genetic program called 'invasive growth' inducing epithelial cell dissociation, migration, growth? and ultimately leading to differentiation into branched tubular structures. Sustained tyrosine phosphorylation of the downstream adaptor protein Gab1 is required for the HGF response, Here we show that serine/threonine phosphorylation of Gab1 provides a control mechanism for negative regulation. Treatment,vith okadaic acid, a potent inhibitor of the serine/threonine protein phosphatases PP1 and PP2A, was followed by activation of a number of serine/threonine kinases, hyper-phosphorylation in serine and threonine of Gab1 and se, ere inhibition of the HGF-induced biological responses, Under these conditions, Gab1 nas found to be concomitantly hypophosphorylated in tyrosine, and thus endowed with reduced ability to recruit SH2 containing signal transducers such as PI3 kinase. Among the serine-threonine kinases activated bg PP1 and PP2A inhibition, we found that PKC-alpha and PKC-beta1 are required for negative regulation of Gab1, These data pro,ide a novel negative mechanism for the HGF receptor signaling pathways and highlight a potentially useful target for inhibitors of invasive growth.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Cancer Research UK	Gual, P (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Gual, Philippe/P-9833-2019; Giordano, Silvia/J-9858-2018; Parker, Peter j/D-5192-2013; Comoglio, Paolo/G-6323-2011	Gual, Philippe/0000-0001-7393-8356; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; parker, peter/0000-0002-6218-2933				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, CIBA F SYMP, V212, P133; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BARON V, 1992, J BIOL CHEM, V267, P23290; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; CHIN JE, 1993, J BIOL CHEM, V268, P6338; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUAL P, 1995, ENDOCRINOLOGY, V136, P5298, DOI 10.1210/en.136.12.5298; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Machide M, 1998, J NEUROCHEM, V71, P592; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Taylor BK, 2000, AM J PHYSIOL-LUNG C, V278, pL1062, DOI 10.1152/ajplung.2000.278.5.L1062; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	72	36	36	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					156	166		10.1038/sj.onc.1204047	http://dx.doi.org/10.1038/sj.onc.1204047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313945				2022-12-25	WOS:000166410900003
J	Vashee, S; Simancek, P; Challberg, MD; Kelly, TJ				Vashee, S; Simancek, P; Challberg, MD; Kelly, TJ			Assembly of the human origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; FISSION YEAST; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOME-REPLICATION; DROSOPHILA HOMOLOG; ORC1 HOMOLOG; IDENTIFICATION; PROTEINS; XENOPUS	The six-subunit origin recognition complex (ORC) was originally identified in the yeast Saccharomyces cerevisiae, Yeast ORC binds specifically to origins of replication and serves as a platform for the assembly of additional initiation factors, such as Cdc6 and the Mcm proteins. Human homologues of all six ORC subunits have been identified by sequence similarity to their yeast counterparts, but little is known about the biochemical characteristics of human ORC (HsORC), We have extracted HsORC from HeLa cell chromatin and probed its subunit composition using specific antibodies. The endogenous HsORC, identified in these experiments, contained homologues of Orc1-Orc5 but lacked a putative homologue of Orc6, By expressing HsORC subunits in insect cells using the baculovirus system, we were able to identify a complex containing all six subunits, To explore the subunit-subunit interactions that are required for the assembly of HsORC, we carried out extensive co-immunoprecipitation experiments with recombinant ORC subunits expressed in different combinations. These studies revealed the following binary interactions: HsOrc2-HsOrc3, HsOrc2-HsOrc4, HsOrc3-HsOrc4, HsOrc2-HsOrc6, and HsOrc3-HsOrc6. HsOrc5 did not form stable binary complexes with any other HsORC subunit but interacted with sub-complexes containing any two of subunits HsOrc2, HsOrc3, or HsOrc4, Complex formation by HsOrc1 required the presence of HsOrc2, HsOrc3, HsOrc4, and HsOrc5 subunits, These results suggest that the subunits HsOrc2, HsOrc3, and HsOrc4 form a core upon which the ordered assembly of HsOrc5 and HsOrc1 takes place. The characterization of HsORC should facilitate the identification of human origins of DNA replication.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kelly, TJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.	tkelly@jhmi.edu			NCI NIH HHS [CA40414] Funding Source: Medline; NIGMS NIH HHS [GM19675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040414, R01CA040414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, V1, P41; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kornberg A., 1992, DNA REPLICATION; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0	45	120	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26666	26673		10.1074/jbc.M102493200	http://dx.doi.org/10.1074/jbc.M102493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11323433	hybrid			2022-12-25	WOS:000169823300132
J	Silver, DL; Wang, N; Xiao, X; Tall, AR				Silver, DL; Wang, N; Xiao, X; Tall, AR			High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; TARGETED MUTATION; APOLIPOPROTEIN-E; LDL CHOLESTEROL; APICAL DOMAIN; LIPID UPTAKE; CELLS; RAT; IDENTIFICATION; METABOLISM	High density lipoprotein (HDL) mediates reverse transport of cholesterol from atheroma foam cells to the liver, but the mechanisms of hepatic uptake and trafficking of HDL particles are poorly understood. In contrast to its accepted role as a cell surface receptor, scavenger receptor class B type 1 (SR-BI) is shown to be an endocytic receptor that mediates HDL particle uptake and recycling, but not degradation, in both transfected Chinese hamster ovary cells and hepatocytes. Confocal microscopy of polarized primary hepatocytes shows that HDL particles enter both the endocytic recycling compartment and the apical canalicular region paralleling the movement of SR-BI. In polarized epithelial cells (Madin-Darby canine kidney) expressing SR-BI, HDL protein and cholesterol undergo selective sorting with recycling of HDL protein from the basolateral membrane and secretion of HDL-derived cholesterol through the apical membrane. Thus, HDL particles, internalized via SR-BI, undergo a novel process of selective transcytosis, leading to polarized cholesterol transport. A distinct process not mediated by SR-BI is involved in uptake and degradation of apoE-free HDL in hepatocytes.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15219 USA	Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Silver, DL (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.	dls51@columbia.edu	Tall, Alan/AAT-8528-2021; Eckhardt, Erik/G-1567-2010	Silver, David/0000-0002-7289-9890	NHLBI NIH HHS [HL22682, HL09928] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009928, R01HL022682, R37HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Azhar S, 1998, J LIPID RES, V39, P1616; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOYER JL, 1993, ISOLATED RAT HEPATOC, P597; BRAVO E, 1989, BIOCHIM BIOPHYS ACTA, V1003, P315, DOI 10.1016/0005-2760(89)90238-5; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; CABRAL DJ, 1989, PHYSICAL CHEM BILE H, P621; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; DELAMATRE JG, 1990, J LIPID RES, V31, P191; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fidge NH, 1999, J LIPID RES, V40, P187; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Glomset J A, 1973, Adv Lipid Res, V11, P1; GOLDSTEIN JL, 1992, EUR HEART J, V13, P34, DOI 10.1093/eurheartj/13.suppl_B.34; Hemery I, 1996, J CELL SCI, V109, P1215; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; KAMBOURIS AM, 1990, ARTERIOSCLEROSIS, V10, P582, DOI 10.1161/01.ATV.10.4.582; KOO C, 1985, J BIOL CHEM, V260, P1934; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; McGwire GB, 1999, J BIOL CHEM, V274, P31632, DOI 10.1074/jbc.274.44.31632; MELLMAN I, 1993, J CELL SCI, P1; Miller N. E., 1980, Atherosclerosis 5. Proceedings of the Fifth International Symposium, P500; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PORTMAN OW, 1980, BIOCHIM BIOPHYS ACTA, V619, P545, DOI 10.1016/0005-2760(80)90106-X; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Roelofsen H, 1998, J CELL SCI, V111, P1137; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCHWARTZ CC, 1978, J CLIN INVEST, V61, P408, DOI 10.1172/JCI108952; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Subtil A, 1997, J CELL SCI, V110, P2441; TAKATA K, 1988, J LIPID RES, V29, P1117; Tall AR, 1998, EUR HEART J, V19, pA31; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Vilhardt F, 1999, MOL BIOL CELL, V10, P179, DOI 10.1091/mbc.10.1.179; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241	51	192	196	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25287	25293		10.1074/jbc.M101726200	http://dx.doi.org/10.1074/jbc.M101726200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11301333	hybrid			2022-12-25	WOS:000169800700114
J	Zhang, XA; Bontrager, AL; Hemler, ME				Zhang, XA; Bontrager, AL; Hemler, ME			Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PHC to specific beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; BINDING PROTEINS; TM4SF PROTEINS; CROSS-LINKING; GROWTH-FACTOR; CDNA CLONE; RECEPTOR; ADHESION; COMPLEXES; MOLECULES	Translocation of conventional protein kinases C (PKCs) to the plasma membrane leads to their specific association with transmembrane-4 superfamily (TM4SF; tetraspanin) proteins (CD9, CD53, CD81, CD82, and CD151), as demonstrated by reciprocal co-immunoprecipitation and covalent cross-linking experiments. Although formation and maintenance of TM4SF-PKC complexes are not dependent on integrins, TM4SF proteins can act as linker molecules, recruiting PKC into proximity with specific integrins. Previous studies showed that the extracellular large loop of TM4SF proteins determines integrin associations. In contrast, specificity for PKC association probably resides within cytoplasmic tails or the first two transmembrane domains of TM4SF proteins, as seen from studies with chimeric CD9 molecules, Consistent with a TM4SF linker function, only those integrins (alpha (3)beta (1), alpha (6)beta (1), and a chimeric "X3TC5" alpha (3) mutant) that associated strongly with tetraspanins were found in association with PKC, We propose that PKC-TM4SF-integrin structures represent a novel type of signaling complex. The simultaneous binding of TM4SF proteins to the extracellular domains of the integrin alpha (3) subunit and to intracellular PKC helps to explain why the integrin alpha (3) extracellular domain is needed for both intracellular PKC recruitment and PKC-dependent phosphorylation of the alpha (3) integrin cytoplasmic tail.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hemler, ME (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Rm D-1430,44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA86712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; AMIOT M, 1995, LEUKOCYTE TYPING, V5, P556; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; CARMO AM, 1995, EUR J IMMUNOL, V25, P2090, DOI 10.1002/eji.1830250743; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHUN JS, 1993, MOL BIOL CELL, V3, P1863; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DUMONT JA, 1994, BIOCHEM BIOPH RES CO, V204, P264, DOI 10.1006/bbrc.1994.2454; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EMI N, 1993, IMMUNOGENETICS, V37, P193; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HEMLER ME, 1983, J IMMUNOL, V131, P334; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Kitadokoro K, 2001, EMBO J, V20, P12, DOI 10.1093/emboj/20.1.12; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu SC, 2000, J CELL SCI, V113, P3563; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MANGER B, 1987, J IMMUNOL, V139, P2755; Mannion BA, 1996, J IMMUNOL, V157, P2039; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mochly-Rosen D, 1998, FASEB J, V12, P35; Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WOODS A, 1992, J CELL SCI, V101, P277; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	68	286	306	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25005	25013		10.1074/jbc.M102156200	http://dx.doi.org/10.1074/jbc.M102156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325968	hybrid			2022-12-25	WOS:000169800700077
J	Jacquelin, B; Rozenshteyn, D; Kanaji, S; Koziol, JA; Nurden, AT; Kunicki, TJ				Jacquelin, B; Rozenshteyn, D; Kanaji, S; Koziol, JA; Nurden, AT; Kunicki, TJ			Characterization of inherited differences in transcription of the human integrin alpha(2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN RECEPTOR; REGULATORY ELEMENTS; YOUNGER PATIENTS; CODING SEQUENCE; PROMOTER; EXPRESSION; BINDING; SP1; POLYMORPHISMS; PROTEIN	Inherited, single-base substitutions are found at only two positions, C-52T and C(-92)G, within the proximal 5 ' -regulatory region (within -1096 to +48) of the human integrin alpha (2) gene. We recently reported that the T-52 substitution results in decreased binding of transcription factor Spl to adjacent binding sites, decreased transcription of the alpha (2) gene, and reduced densities of platelet alpha (2)beta (1). In this study, we identify an additional Sp1-binding site at position -107 to -99 and show that the adjacent dimorphic sequence C(-92)G also influences the rate of gene transcription. In the erythroleukemia cell line Dami, transfected promoter-luciferase constructs bearing the G(-92) sequence exhibit roughly a 3-fold decrease in activity relative to the C-92 constructs. In transfected CHRF-288-11 megakaryocytic cells, the corresponding activity decreases by 5-fold. DNase I footprinting of the promoter region with Dami nuclear extracts showed a protected segment at -107 to -99 that can be deprotected by coincubation with molar excess of a consensus Sp1 oligonucleotide, Gel mobility shift assays and supershift assays with specific antibodies indicate that Sp1 binds to this region of the cu, gene promoter. Mutation of the Sp1 binding element within -107 to -99 in constructs containing either (C-92 or G(-92) abolishes basal promoter activity and eliminates the binding of Sp. The G(-92) sequence has a gene frequency of 0.15 in a typical Caucasian population, and the presence of this allele correlates with reduced densities of platelet alpha (1)beta (2). The combined substitution G(-92)/T-52 has an additive influence on gene transcription, resulting in an 8-fold decrease in transfected Dami cells or a 20 fold decrease in transfected CRRF-288-11 cells. In summary, the natural dimorphism C(-92)G within the proximal 5 ' -regulatory region of the human integrin alpha (2) gene contributes to the regulation of integrin alpha (2)beta (1) expression on megakaryocytes and blood platelets and must thereby modulate collagen-related platelet function in vivo.	Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Hop Cardiol, CNRS, UMR 5533, F-33604 Pessac, France	Scripps Research Institute; Scripps Research Institute; Centre National de la Recherche Scientifique (CNRS); CHU Bordeaux	Kunicki, TJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, 10550 N Torrey Pines Rd,Maildrop MEM150, La Jolla, CA 92037 USA.			JACQUELIN, Beatrice/0000-0002-1896-5092	NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NHLBI NIH HHS [HL54203, HL46979] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054203, R01HL046979] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brunekreef GA, 1997, EXP EYE RES, V64, P295, DOI 10.1006/exer.1996.0289; Carlsson LE, 1999, BLOOD, V93, P3583, DOI 10.1182/blood.V93.11.3583.410k34_3583_3586; Corral J, 1999, THROMB HAEMOSTASIS, V81, P951, DOI 10.1055/s-0037-1614605; Corral J, 1999, TRANSFUSION, V39, P372, DOI 10.1046/j.1537-2995.1999.39499235668.x; Di Paola J, 1999, BLOOD, V93, P3578, DOI 10.1182/blood.V93.11.3578.410k18_3578_3582; FUGMAN DA, 1990, BLOOD, V75, P1252; Jacquelin B, 2001, BLOOD, V97, P1721, DOI 10.1182/blood.V97.6.1721; JASPERS M, 1991, SOMAT CELL MOLEC GEN, V17, P505, DOI 10.1007/BF01233174; Kim S, 1999, MOL VIS, V5, pU1; Kritzik M, 1998, BLOOD, V92, P2382, DOI 10.1182/blood.V92.7.2382; Kunicki TJ, 1997, BLOOD, V89, P1939, DOI 10.1182/blood.V89.6.1939; KUNICKI TJ, 1993, BLOOD, V82, P2693; Matsubara Y, 2000, BLOOD, V95, P1560, DOI 10.1182/blood.V95.5.1560.005k43_1560_1564; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Noti JD, 1996, MOL CELL BIOL, V16, P2940; RANEY AK, 1989, J VIROL, V63, P3919, DOI 10.1128/JVI.63.9.3919-3925.1989; ROEST M, 2000, BLOOD, V101, P67; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santoso S, 1999, BLOOD, V93, P2449, DOI 10.1182/blood.V93.8.2449.408k34_2449_2453; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Wang ZY, 1999, BLOOD, V93, P4208, DOI 10.1182/blood.V93.12.4208.412k17_4208_4221; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; YE J, 1966, MOL CELL BIOL, V16, P6178; Ye JP, 1996, MOL CELL BIOL, V16, P157; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689; ZUTTER MM, 1994, J BIOL CHEM, V269, P463; ZUTTER MM, 1990, AM J PATHOL, V137, P113; ZUTTER MM, 1995, BLOOD, V86, P3006; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	36	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23518	23524		10.1074/jbc.M102019200	http://dx.doi.org/10.1074/jbc.M102019200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313353	hybrid			2022-12-25	WOS:000169531100041
J	Maroto, R; Hamill, OP				Maroto, R; Hamill, OP			Brefeldin a block of integrin-dependent mechanosensitive ATP release from Xenopus oocytes reveals a novel mechanism of mechanotransduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CFTR; GOLGI; CELLS; TRANSPORT; PROTEINS; MICROTUBULES; TRAFFICKING; INHIBITION; ACTIVATION	Many animal cells release ATP into the extracellular medium, and often this release is mechanosensitive, However, the mechanisms underlying this release are not well understood. Using the luciferin-luciferase bi. oluminescent assay we demonstrate that a Xenopus oocyte releases ATP at a basal rate similar to0.01 fmol/s, and gentle mechanical stimulation can increase this to 50 fmol/s. Brefeldin A, nocodazole, and progesterone-induced-maturation block basal and mechanosensitive ATP release. These treatments share the common feature of disrupting the Golgi complex and vesicle trafficking to the cell surface and thereby block protein secretion and membrane protein insertion. We propose that ATP release occurs when protein transport vesicles enriched in ATP fuse with the plasma membrane. Collagenase, integrin-binding peptides, and cytochalasin D also block ATP release, indicating that extracellular, membrane and cytoskeletal elements are involved in the release process. Elevation of intracellular Ca2+ does not evoke ATP release but potentiates mechanosensitive ATP release. Our study indicates a novel mechanism of mechanotransduction that would allow cells to regulate membrane trafficking and protein transport/secretion in response to mechanical loading.	Univ Texas, Med Branch, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Hamill, OP (corresponding author), Univ Texas, Med Branch, 301 Univ Blvd, Galveston, TX 77550 USA.	ohamill@utmb.edu						ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; Bodas E, 2000, J BIOL CHEM, V275, P20268, DOI 10.1074/jbc.M000894200; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Cantiello HF, 1998, AM J PHYSIOL-CELL PH, V274, pC799, DOI 10.1152/ajpcell.1998.274.3.C799; Chen BM, 1997, J NEUROSCI, V17, P904; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; DHO S, 1993, BIOCHIM BIOPHYS ACTA, V1225, P78, DOI 10.1016/0925-4439(93)90125-K; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Fisher RS, 1996, AM J PHYSIOL-CELL PH, V270, pC138, DOI 10.1152/ajpcell.1996.270.1.C138; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HAMILL OP, 1992, P NATL ACAD SCI USA, V89, P7462, DOI 10.1073/pnas.89.16.7462; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; LUNDIN A, 1976, ANAL BIOCHEM, V75, P611, DOI 10.1016/0003-2697(76)90116-0; Maroto R, 2000, J PHYSIOL-LONDON, V527, p45P; Mayerhofer A, 1998, P NATL ACAD SCI USA, V95, P10990, DOI 10.1073/pnas.95.18.10990; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; Nakamura F, 1996, P NATL ACAD SCI USA, V93, P10465, DOI 10.1073/pnas.93.19.10465; PEREZSAMARTIN AL, 2000, J PHYSL, P721; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; Roman RM, 1999, AM J PHYSIOL-GASTR L, V277, pG1222, DOI 10.1152/ajpgi.1999.277.6.G1222; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Samartsev VN, 1997, FEBS LETT, V412, P179, DOI 10.1016/S0014-5793(97)00667-4; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; VERREY F, 1995, J MEMBRANE BIOL, V145, P193; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Xu J, 1996, J CELL SCI, V109, P1605; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; Zhang Y, 1998, J PHYSIOL-LONDON, V508, P763, DOI 10.1111/j.1469-7793.1998.763bp.x; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P83, DOI 10.1111/j.1469-7793.2000.t01-2-00083.x; ZHANG Y, 2000, J PHYSL, P117; ZHANG Y, 2000, J PHYSL, P101; ZIGANSHIN AU, 1995, PFLUG ARCH EUR J PHY, V429, P412, DOI 10.1007/BF00374157	57	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23867	23872		10.1074/jbc.M101500200	http://dx.doi.org/10.1074/jbc.M101500200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320093	hybrid			2022-12-25	WOS:000169531100086
J	Parada, Y; Banerji, L; Glassford, J; Lea, NC; Collado, M; Rivas, C; Lewis, JL; Gordon, MY; Thomas, NSB; Lam, EWF				Parada, Y; Banerji, L; Glassford, J; Lea, NC; Collado, M; Rivas, C; Lewis, JL; Gordon, MY; Thomas, NSB; Lam, EWF			BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27(Kip1) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; IN-VIVO; PROTEIN; ONCOGENE; INHIBITOR; G1; TRANSFORMATION; TRANSCRIPTION; FAMILY; GROWTH	Although it is evident that BGR-ABL can rescue cytokine-deprived hematopoietic progenitor cells from cell cycle arrest and apoptosis, the exact mechanism of action of BCR/ABL and interleukin (IL)-3 to promote proliferation and survival has not been established. Using the pro-B cell line BaF3 and a BaF3 cell line stably overexpressing BCR-ABL (BaF3-p210), we investigated the proliferative signals derived from BCR-ABL and IL-3, The results indicate that both IL-3 and BCR-ABE target the expression of cyclin Ds and down-regulation of p27(Kip1) mediate pRB-related pocket protein phosphorylation, E2F activation, and thus S phase progression. These findings were further confirmed in a BaF3 cell line (TonB.210) where the BCR-ABL expression is inducible by doxycyclin and by using the drug STI571 to inactivate BCR-ABL activity in BaF3-p210. To establish the functional significance of cyclin D2 and p27(Kip1) expression in response to IL-3 and BCR-ABL expression, me studied the effects of ectopic expression of cyclin D2 and p27(Kip1) On cell proliferation and survival. Our results demonstrate that both cyclin D2 and p27(Kip1) have a role in BaF3 cell proliferation and survival, as ectopic expression of cyclin D2 is sufficient to abolish the cell cycle arrest and apoptosis induced by IL-3 withdrawal or by BCR-ABL inactivation, while overexpression of p27(Kip1) can cause cell cycle arrest and apoptosis in the BaF3 cells. Furthermore, our data also suggest that cyclin D2 functions upstream of p27(Kip1), cyclin E, and cyclin D3, and therefore, plays an essential part in integrating the signals from IL-3 and BCR-ABL with the pRB/ESF pathway.	Hammersmith Hosp, Imperial Coll, Sch Med, CRC Labs, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, Sect Canc Cell Biol, London W12 0NN, England; Ludwig Inst Canc Res, London W2 1PG, England; St Marys Hosp, Sch Med, Imperial Coll, Sect Virol & Cell Biol, London W2 1PG, England; Imperial Coll, Sch Med, Dept Haematol, Royal Postgrad Med Sch,LRF Ctr Adult Leukaemia, London W12 0NN, England; Guys Kings St Thomas Sch Med, Rayne Inst, Dept Haematol Med, London SE5 9NU, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Imperial College London; University of London; King's College London	Lam, EWF (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, CRC Labs, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Collado, Manuel/K-8140-2014; Lam, Eric W-F/AAW-8566-2020; Rivas, Carmen/L-3162-2017; Rivas, Carmen/AAB-6278-2019	Collado, Manuel/0000-0002-0330-0880; Lam, Eric W-F/0000-0003-1274-3576; Rivas, Carmen/0000-0002-0518-7199; Rivas, Carmen/0000-0002-0518-7199				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BEDI A, 1994, BLOOD, V83, P2038; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Buchdunger E, 1996, CANCER RES, V56, P100; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eder M, 1997, STEM CELLS, V15, P327, DOI 10.1002/stem.150327; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gordon MY, 1999, LEUKEMIA, V13, pS65, DOI 10.1038/sj.leu.2401281; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kato Jun-ya, 1999, Frontiers in Bioscience, V4, pd787, DOI 10.2741/Kato; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KONOPKA JB, 1986, P NATL ACAD SCI USA, V83, P4049, DOI 10.1073/pnas.83.11.4049; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Maguer-Satta V, 1998, ONCOGENE, V16, P237, DOI 10.1038/sj.onc.1201533; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; ROSENBERG N, 1990, CANCER CELL-MON REV, V2, P284; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiotsu Y, 2000, BLOOD, V96, P2284, DOI 10.1182/blood.V96.6.2284; STRIFE A, 1988, CANCER RES, V48, P1035; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	58	97	101	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23572	23580		10.1074/jbc.M101885200	http://dx.doi.org/10.1074/jbc.M101885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323429	hybrid			2022-12-25	WOS:000169531100048
J	Govaerts, C; Lefort, A; Costagliola, S; Wodak, SJ; Ballesteros, JA; Van Sande, J; Pardo, L; Vassart, G				Govaerts, C; Lefort, A; Costagliola, S; Wodak, SJ; Ballesteros, JA; Van Sande, J; Pardo, L; Vassart, G			A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LEUCINE-RICH REPEATS; HYPERFUNCTIONING THYROID ADENOMAS; FOLLICLE-STIMULATING-HORMONE; SOMATIC MUTATIONS; GERMLINE MUTATIONS; MOLECULAR-CLONING; TSH RECEPTOR; DEVELOPMENTAL REGULATION; DROSOPHILA-MELANOGASTER	The thyrotropin (TSH) receptor is an interesting model to study G protein-coupled receptor activation as many point mutations can significantly increase its ba sal activity. Here, we identified a molecular interaction between Asp(633) in transmembrane helix 6 (TM6) and Asn(674) in TM7 of the TSHr that is crucial to maintain the inactive state through conformational constraint of the Asn. We show that these residues are perfectly conserved in the glycohormone receptor family, except in one case, where they are exchanged, suggesting a direct interaction. Molecular modeling of the TSHr, based on the high resolution structure of rhodopsin, strongly favors this hypothesis. Our approach combining site-directed mutagenesis with molecular modeling shows that mutations disrupting this interaction, like the D633A mutation in TM6, lead to high constitutive activation. The strongly activating N674D (TM7) mutation, which in our modeling breaks the TM6-TM7 link, is reverted to wild type-like behavior by an additional D633N mutation (TM6), which would restore this link. Moreover, we show that the Asn of TM7 (conserved in most G protein-coupled receptors) is mandatory for ligand-induced cAMP accumulation, suggesting an active role of this residue in activation. In the TSHr, the conformation of this Asn residue of TM7 would be constrained, in the inactive state, by its Asp partner in TM6.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Univ Autonoma Barcelona, Fac Med, Lab Med Computac, Unitat Bioestadist, Bellaterra 08193, Spain; Free Univ Brussels, Serv Conformat Macromol Biol, B-1050 Brussels, Belgium; Novasite Pharmaceut Inc, San Diego, CA 92121 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Autonomous University of Barcelona; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vassart, G (corresponding author), Free Univ Brussels, IRIBHN, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.		costagliola, sabine/D-4864-2012	wodak, shoshana/0000-0002-0701-6545; Pardo, Leonardo/0000-0003-1778-7420				Angelova K, 2000, MOL ENDOCRINOL, V14, P459, DOI 10.1210/me.14.4.459; Aqvist J, 2000, NATURE, V404, P881, DOI 10.1038/35009114; AQVIST J, 2000, NATURE, V20, P404; ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; CASE DA, 1997, AMBERS5; CHAN T, 1992, J BIOL CHEM, V267, P9478; Chelvanayagam G, 1997, PROTEIN ENG, V10, P307, DOI 10.1093/protein/10.4.307; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Costagliola S, 1998, FEBS LETT, V436, P427, DOI 10.1016/S0014-5793(98)01177-6; Costagliola S, 1998, J IMMUNOL, V160, P1458; Da Costa CR, 1998, J BIOL CHEM, V273, P11874, DOI 10.1074/jbc.273.19.11874; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; Donnelly D, 1999, BIOCHEM J, V339, P55, DOI 10.1042/0264-6021:3390055; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Eriksen KK, 2000, GENOME RES, V10, P924, DOI 10.1101/gr.10.7.924; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Fahmy K, 2000, BIOCHEMISTRY-US, V39, P10607, DOI 10.1021/bi000912d; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2000, J BIOL CHEM, V275, P3121, DOI 10.1074/jbc.275.5.3121; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; Hauser F, 1997, J BIOL CHEM, V272, P1002, DOI 10.1074/jbc.272.2.1002; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MCGREGOR MJ, 1987, J MOL BIOL, V20, P198; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Perlman JH, 1997, J BIOL CHEM, V272, P11937, DOI 10.1074/jbc.272.18.11937; RATH P, 1993, BIOCHEMISTRY-US, V32, P10277, DOI 10.1021/bi00090a001; Refetoff S, 2001, METABOLIC MOL BASES, P4029; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; VANSANDE J, 1995, EUR J BIOCHEM, V229, P338; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	64	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22991	22999		10.1074/jbc.M102244200	http://dx.doi.org/10.1074/jbc.M102244200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312274	hybrid			2022-12-25	WOS:000169412700135
J	Jahns, P; Wehner, A; Paulsen, H; Hobe, S				Jahns, P; Wehner, A; Paulsen, H; Hobe, S			De-epoxidation of violaxanthin after reconstitution into different carotenoid binding sites of light-harvesting complex II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHOPHYLL-CYCLE; PLANTS; PROTEINS; IDENTIFICATION; DEPENDENCE; DYNAMICS	In higher plants, the de-epoxidation of violaxanthin (Vx) to antheraxanthin and zeaxanthin is required for the pH-dependent dissipation of excess light energy as heat and by that process plays an important role in the protection against photo-oxidative damage. The de epoxidation reaction was investigated in an in vitro system using reconstituted light-harvesting complex II (LHCII) and a thylakoid raw extract enriched in the enzyme Vx de-epoxidase. Reconstitution of LHCII with varying carotenoids was performed to replace lutein and/or neoxanthin, which are bound to the native complex, by Vx. Recombinant LHCII containing either 2 lutein and 1 Vx or 1.6 Vx and 1.1 neoxanthin or 2.8 Vx per monomer were studied. Vx de epoxidation was inducible for all complexes after the addition of Vx de epoxidase but to different extents and with different kinetics in each complex. Analysis of the kinetics indicated that the three possible Vx binding sites have at least two, and perhaps three, specific rate constants for de-epoxidation. In particular, Vx bound to one of the two lutein binding sites of the native complex, most likely L1, was not at all or only at a slow rate convertible to Zx. In reisolated LHCII, newly formed Zx almost stoichiometrically replaced the transformed Vx, indicating that LHCII and Vx de-epoxidase stayed in close contact during the de-epoxidation reactions and that no release of carotenoids occurred.	Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany; Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55128 Mainz, Germany	Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz	Jahns, P (corresponding author), Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany.	pjahns@uni-duesseldorf.de	Paulsen, Harald/D-3742-2011					Arvidsson PO, 1996, PHOTOSYNTH RES, V49, P119, DOI 10.1007/BF00117662; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; Farber A, 1997, PLANT PHYSIOL, V115, P1609, DOI 10.1104/pp.115.4.1609; FRYER MJ, 1992, PLANT CELL ENVIRON, V15, P381, DOI 10.1111/j.1365-3040.1992.tb00988.x; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; Hartel H, 1996, PLANT PHYSIOL, V110, P471, DOI 10.1104/pp.110.2.471; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2000, PLANT PHYSIOL, V124, P273, DOI 10.1104/pp.124.1.273; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; JAHNS P, 1995, PLANT PHYSIOL, V108, P149, DOI 10.1104/pp.108.1.149; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; PFUNDEL EE, 1993, PLANT PHYSIOL, V101, P65, DOI 10.1104/pp.101.1.65; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SIEFERMANN D, 1974, BIOCHIM BIOPHYS ACTA, V357, P144, DOI 10.1016/0005-2728(74)90119-4; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; YAMAMOTO HY, 1996, OXYGENIC PHOTOSYNTHE, P539, DOI DOI 10.1007/0-306-48127-8_30	32	56	57	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22154	22159		10.1074/jbc.M102147200	http://dx.doi.org/10.1074/jbc.M102147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301335	hybrid			2022-12-25	WOS:000169412700026
J	Kim, DH; Nelson, HH; Wiencke, JK; Christiani, DC; Wain, JC; Mark, EJ; Kelsey, KT				Kim, DH; Nelson, HH; Wiencke, JK; Christiani, DC; Wain, JC; Mark, EJ; Kelsey, KT			Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer	ONCOGENE			English	Article						DAP-kinase; k-ras; p53; methylation; nonsmall cell lung cancer	TUMOR-SUPPRESSOR GENES; DNA METHYLATION; CPG ISLAND; SIGNALING PATHWAY; HYPERMETHYLATION; METHYLTRANSFERASE; PROTEIN; DEATH; IDENTIFICATION; APOPTOSIS	Death associated protein (DAP)-kinase is a 16 kDa calmodulin-dependent serine/threonine kinase that carries a death domain at its C-terminus. DAP-kinase functions as a positive mediator of apoptosis that is induced by interferon-gamma. Recent studies suggest that DAP-kinase is involved in tumor metastasis and that it can be inactivated by methylation of CpG islands in the promoter region of the gene in some human tumors. However, little is known about the factors that are associated with the occurrence of DAP-kinase promoter methylation. We investigated both the possible associations of tobacco carcinogen and asbestos exposure with DAP-kinase promoter methylation, and the demographic and clinical factors associated with DAP-kinase promoter methylation in non-small cell lung cancer (NSCLC), One hundred and eighty-five patients diagnosed with NSCLC undergoing surgical resection from June, 1992 through December, 1996 at Massachusetts General Hospital participated in this study, Methylation-Specific PCR (MSP), performed using fresh-frozen tissue, was used to determine the methylation status of the promoter region of the DAP-kinase gene. Forty-seven (25%) of 185 tumors showed DAP-kinase promoter methylation. There was a significant association between methylation and an advanced pathologic stage (P=0.003, Fisher's exact test). Methylation of the DAP-kinase promoter was also associated with an increase in tumor size (P=0.009, Fisher's exact test) and lymph node involvement (P=0.04), No association was found between promoter methylation of DAP-kinase and k-ras or p53 mutation. In addition there was no association with a history of exposure to tobacco or asbestos. Controlling for age, sex, and histology, the odds ratios describing the association of DAP-kinase hypermethylation with stage were 2.70 (1.13-6.45), 3.11 (1.37-7.08) and 7.77 (1.21-50.03) in stages II, III and IV, respectively. Stage I cases with DAP-kinase promoter methylation had worse overall survival, but with the small sample size and limited follow-up this did not reach statistical significance. Our findings suggest that methylation of the promoter region of the DAP-kinase gene is not associated with exposure to tobacco or asbestos. However, they strongly suggest that DAP-kinase may be important in the progression of non-small cell lung cancer from early to late stage disease.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, Lab Mol Epidemiol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Thorac Surg Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Rm 207, Boston, MA 02115 USA.		Kelsey, Karl T/I-1252-2014	Nelson, Heather/0000-0003-1901-9513	NATIONAL CANCER INSTITUTE [R01CA074386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006409, P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA74386, CA08357, CA06717] Funding Source: Medline; NIEHS NIH HHS [ES00002, ES/CA 06409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Eguchi K, 1997, CANCER RES, V57, P4913; ELDEIRY WA, 1990, P NATL ACAD SCI USA, V88, P3470; Esteller M, 1999, CANCER RES, V59, P67; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; NELSON HH, 1999, CANCER RES, V20, P667; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543; WU J, 1990, P NATL ACAD SCI USA, V90, P8891	29	123	133	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1765	1770		10.1038/sj.onc.1204302	http://dx.doi.org/10.1038/sj.onc.1204302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313923				2022-12-25	WOS:000167750900009
J	Argentini, M; Barboule, N; Wasylyk, B				Argentini, M; Barboule, N; Wasylyk, B			The contribution of the acidic domain of MDM2 to p53 and MDM2 stability	ONCOGENE			English	Article						ring finger domain; ubiquitylation; nuclear export; p300; NES	RING-FINGER DOMAIN; NUCLEAR EXPORT; IN-VIVO; NUCLEOLAR-LOCALIZATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; UBIQUITIN LIGASE; ONCOPROTEIN MDM2; DNA-DAMAGE; CELL-LINE	p53 and MDM2 are both degraded by the ubiquitin-proteasome pathway, MDM2 binds p53 and promotes its rapid degradation, MDM2 is an E3 ligase that activates self and p53 ubiquitylation, Moreover, MDM2 nuclear-cytoplasmic shuttling contributes to p53 degradation in the cytoplasm, We have identified a new region of MDM2 which regulates the stability of both p53 and MDM2, The first 50 amino-acids of the MDM2 acidic domain (222-272) contribute to MDM2 and MDM2-mediated p53 degradation by a mechanism which is independent of either MDM2 E3-ligase activity or MDM2 nucleo-cytoplasmic shuttling, The transcriptional coactivator p300 could have been involved, since it binds to the MDM2 acidic domain, Howe, er, we found that p300 stabilises MDM2, even in absence of an intact acidic domain, indicating that the MDM2 acidic region contributes to proteolysis independently of p300, We propose that the MDM2 acidic domain is required for unbiquitylated MDM2 and p53 to be degraded by cytoplasmic proteasomes.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Argentini M, 2000, ONCOGENE, V19, P3849, DOI 10.1038/sj.onc.1203737; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haas AL, 1997, FASEB J, V11, P1257; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; KASTAN MB, 1991, CANCER RES, V51, P6304; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSER FG, 1975, J CELL BIOL, V66, P676, DOI 10.1083/jcb.66.3.676; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Pickart CM, 2000, NAT CELL BIOL, V2, pE139, DOI 10.1038/35019610; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STRACK PR, 1992, INT J BIOCHEM, V24, P887, DOI 10.1016/0020-711X(92)90093-G; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	65	69	69	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1267	1275		10.1038/sj.onc.1204241	http://dx.doi.org/10.1038/sj.onc.1204241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313871				2022-12-25	WOS:000167495000001
J	Forgacs, E; Wren, JD; Kamibayashi, C; Kondo, M; Xu, XL; Markowitz, S; Tomlinson, GE; Muller, CY; Gazdar, AF; Garner, HR; Minna, JD				Forgacs, E; Wren, JD; Kamibayashi, C; Kondo, M; Xu, XL; Markowitz, S; Tomlinson, GE; Muller, CY; Gazdar, AF; Garner, HR; Minna, JD			Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers	ONCOGENE			English	Article						microsatellite instability; mutation; repetitive DNA sequences	NONPOLYPOSIS COLON-CANCER; GENETIC INSTABILITY; MUTATOR PHENOTYPE; REPEAT EXPANSION; CELL-LINES; PROTEIN; HMLH1; IDENTIFICATION; TRANSCRIPTION; CONSEQUENCES	RepX represents a new informatics approach to probe the UniGene database for potentially polymorphic repeat sequences in the open reading frame (ORF) of genes, 56% of which were found to be actually polymorphic. We now have performed mutational analysis of 17 such sites in genes not found to be polymorphic (<0.03 frequency) in a large panel of human cancer genomic DNAs derived from 31 lung, 21 breast, seven ovarian, 21 (13 microsatellite instability (MSI)+ and eight MS-) colorectal cancer cell lines. In the lung, breast and ovarian tumor DNAs we found no mutations (<0.03-0.04 rate of tumor associated open reading frame mutations) in these sequences, BS contrast, 18 MSI+ colorectal cancers (13 cancer cell lines and five primary tumors) with mismatch repair defects exhibited six mutations in three of the 17 genes (SREBP-2, TAN-1, GR6) (P<0.000003 compared to all other cancers tested). We conclude that coding region microsatellite alterations are rare in lung, breast, ovarian carcinomas and MSI(-) colorectal cancers, but are relatively frequent in MSI (+) colorectal cancers with mismatch repair deficits.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Program Genet & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Biomed Invent, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Howard Hughes Medical Institute	Minna, JD (corresponding author), Univ Texas, Med Ctr, Hamon Ctr Therapeut Oncol, 6000 Harry Hines Blvd,NB 8-206, Dallas, TX 75390 USA.		Kondo, Masashi/I-7378-2014; Wren, Jonathan D/E-5611-2011	Wren, Jonathan D/0000-0003-2776-3545	NCI NIH HHS [P50 CA70907, CA 67409] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gurin CC, 1999, CANCER RES, V59, P462; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; King BL, 1997, CANCER RES, V57, P209; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Liu T, 1999, HUM GENET, V105, P437, DOI 10.1007/s004390051127; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PARSONS R, 1995, CANCER RES, V55, P5548; Pekarsky Y, 1997, CANCER RES, V57, P3914; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; Wren JD, 2000, AM J HUM GENET, V67, P345, DOI 10.1086/303013; Yamamoto H, 1997, CANCER RES, V57, P4420	26	17	21	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					1005	1009		10.1038/sj.onc.1204211	http://dx.doi.org/10.1038/sj.onc.1204211			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314036				2022-12-25	WOS:000167097000012
J	Fillippovich, I; Sorokina, N; Gatei, M; Haupt, Y; Hobson, K; Moallem, E; Spring, K; Mould, M; McGuckin, MA; Lavin, MF; Khanna, KK				Fillippovich, I; Sorokina, N; Gatei, M; Haupt, Y; Hobson, K; Moallem, E; Spring, K; Mould, M; McGuckin, MA; Lavin, MF; Khanna, KK			Transactivation-deficient p73 alpha (p73 Delta exon2) inhibits apoptosis and competes with p53	ONCOGENE			English	Article						p53; p73; apoptosis; breast cancer; transactivation	APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; KINASE C-ABL; P73 GENE; MEDIATED APOPTOSIS; DNA-DAMAGE; PROTEIN; ACTIVATION; EXPRESSION; INDUCTION	p73 has recently been identified as a structural and functional homolog of the tumor suppressor protein p53. Overexpression of p53 activates transcription of p53 effector genes, causes growth inhibition and induced apoptosis. We describe here the effects of a tumor-derived truncated transcript of p73 alpha (p73 Delta exon2) on p53 function and on cell death. This transcript, which lacks the acidic N-terminus corresponding to the transactivation domain of p53, was initially detected in a neuroblastoma cell line. Overexpression of p73 Delta exon2 partially protects lymphoblastoid cells against apoptosis induced by anti-Fas antibody or cisplatin. By cotransfecting p73 Delta exon2 with wild-type p53 in the p53 null line Saos 2, we found that this truncated transcript reduces the ability of wild-type p53 to promote apoptosis. This anti-apoptotic effect was also observed when p73 Delta exon2 was co-transfected with full-length p73 (p73 alpha). This was further substantiated by suppression of p53 transactivation of the effector gene p21-Waf1 in p73 Delta exon2 transfected cells and by inhibition of expression of a reporter gene under the control of the p53 promoter. Thus, this truncated form of p73 can act as a dominant-negative agent towards transactivation by p53 and p73 alpha, highlighting the potential implications of these findings for p53 signaling pathway. Furthermore, we demonstrate the existence of a p73 Delta exon2 transcript in a very significant proportion (46%) of breast cancer cell lines. However, a large spectrum of normal and malignant tissues need to be surveyed to determine whether this transdominant p73 variant occurs in a tumor-specific manner.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Russian Minist Hlth, Inst Biophys, Lab Mol Radiobiol, Moscow 123182, Russia; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Mater Med Res Inst, Brisbane, Qld 4101, Australia; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Ministry of Health of the Russian Federation; Hebrew University of Jerusalem; Mater Research; Royal Brisbane & Women's Hospital; University of Queensland	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.		Khanna, Kum Kum/I-1747-2013; Hobson, Keith/Q-9306-2019; Lavin, Martin F/F-5961-2014; McGuckin, Michael/G-2310-2010	Lavin, Martin F/0000-0002-5940-4769; McGuckin, Michael/0000-0002-8375-2675; Spring, Kevin/0000-0003-0601-924X; Khanna, Kum Kum/0000-0001-8650-5381				ALLDAY MJ, 1993, J GEN VIROL, V74, P361, DOI 10.1099/0022-1317-74-3-361; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gong JG, 1999, NATURE, V399, P806; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Miyake H, 1998, INT J ONCOL, V12, P469; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; POZNIAK CD, 2000, NATURE, V289, P304; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAMURA T, 1995, ONCOGENE, V11, P1939; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	43	113	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					514	522		10.1038/sj.onc.1204118	http://dx.doi.org/10.1038/sj.onc.1204118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313982				2022-12-25	WOS:000166562500011
J	Sakamoto, N; Larson, JE; Iyer, RR; Montermini, L; Pandolfo, M; Wells, RD				Sakamoto, N; Larson, JE; Iyer, RR; Montermini, L; Pandolfo, M; Wells, RD			GGA center dot TCC-interrupted triplets in long GAA center dot TTC repeats inhibit the formation of tripler and sticky DNA structures, alleviate transcription inhibition, and reduce genetic instabilities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICHS-ATAXIA; SUPERCOILED PLASMIDS; MISMATCH REPAIR; EXPANSION; SEQUENCES; REPLICATION; LENGTH; DETERMINES; STABILITY; FRATAXIN	Large expansions of GAA.TTC repeats in the first intron of the frataxin (X25) gene are the principal mutation responsible for Friedreich's ataxia (FRDA). Sticky DNA, based on R.R.Y triplexes, was found at the expanded GAA.TTC repeats from FRDA patients. The (GAAGGA.TCCTTC)(65) repeat occurs in the same frataxin locus but is nonpathogenic and does not form sticky DNA. To elucidate the behavior of sticky DNA, we introduced various extents of GGA.TCC interruptions into the long GAA.TTC repeat, More than 20% of GGA.TCC interruptions abolished the formation of sticky DNA. However, the GAA.TTC repeats with less than 11% of GGA.TCC interruptions formed triplexes and/or sticky DNA similar to the uninterrupted repeat sequence. These triplexes showed different P1 nuclease sensitivities, and the GGA.TCC interruptions were slightly more sensitive than the surrounding GAA.TTC repeats. Furthermore, genetic instability investigations in Escherichia coli revealed that a small number (4%) of interruptions substantially stabilized the long GAA.TTC tracts. Furthermore, the greater the extent of interruptions of the GAA.TTC repeats, the less inhibition of in vitro transcription was observed, as expected, based on the capacity of interruptions to inhibit the formation of sticky DNA We propose that the interruptions introduce base mismatches into the R.R.Y triplex, which explains the observed chemical and biological properties.	Texas A&M Univ Syst, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr,Hlth Sci Ctr, Houston, TX 77030 USA; Ctr Hosp Univ Montreal, Montreal, PQ H2L 4M1, Canada	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Universite de Montreal	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	Pandolfo, Massimo/B-2853-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554, R01NS034192] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS34192, NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cossee M, 1997, P NATL ACAD SCI USA, V94, P7452, DOI 10.1073/pnas.94.14.7452; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Epplen C, 1997, HUM GENET, V99, P834, DOI 10.1007/s004390050458; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; RICH A, 1961, J MOL BIOL, V3, P71, DOI 10.1016/S0022-2836(61)80009-0; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	31	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27178	27187		10.1074/jbc.M101852200	http://dx.doi.org/10.1074/jbc.M101852200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11325966	hybrid			2022-12-25	WOS:000169966900061
J	Zhang, T; Hong, WJ				Zhang, T; Hong, WJ			Ykt6 forms a SNARE complex with syntaxin 5, GS28, and Bet1 and participates in a late stage in endoplasmic reticulum-Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; MEMBRANE-FUSION; INTERMEDIATE COMPARTMENT; SECRETORY PATHWAY; PRENYLATED SNARE; CIS-GOLGI; APPARATUS; ER; VESICLES; YEAST	The yeast SNARE Ykt6p has been implicated in several trafficking steps, including vesicular transport from the endoplasmic reticulum (ER) to the Golgi, intra-Golgi transport, and homotypic vacuole fusion. The functional role of its mammalian homologue (Ykt6) has not been established. Using antibodies specific for mammalian Ykt6, it is revealed that it is found mainly in Golgi-enriched membranes. Three SNAREs, syntaxin 5, GS28, and Bet1, are specifically associated with Ykt6 as revealed by co-immunoprecipitation, suggesting that these four SNAREs form a SNARE complex. Double labeling of Ykt6 and the Golgi marker mannosidase II or the ER-Golgi recycling marker KDEL receptor suggests that Ykt6 is primarily associated with the Golgi apparatus. Unlike the KDEL receptor, Ykt6 does not cycle back to the peripheral ER exit sites. Antibodies against Ykt6 inhibit in vitro ER-Golgi transport of vesicular stomatitis virus envelope glycoprotein (VSVG) only when they are added before the EGTA-sensitive stage. ER-Golgi transport of VSVG in vitro is also inhibited by recombinant Ykt6. In the presence of antibodies against Ykt6, VSVG accumulates in peri-Golgi vesicular structures and is prevented from entering the mannosidase II compartment, suggesting that Ykt6 functions at a late stage in ER-Golgi transport. Golgi apparatus marked by mannosidase II is fragmented into vesicular structures in cells microinjected with Ykt6 antibodies. It is concluded that Ykt6 functions in a late step of ER-Golgi transport, and this role may be important for the integrity of the Golgi complex.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010					ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Catchpoole DR, 1999, DNA CELL BIOL, V18, P141, DOI 10.1089/104454999315529; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hauri HP, 2000, J CELL SCI, V113, P587; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HAY JC, 1997, CELL, V89, P147; HONG W, 1996, PROTEIN TRAFFICKING; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; Lowe SL, 1996, J CELL SCI, V109, P209; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; McNew JA, 1998, FEBS LETT, V435, P89, DOI 10.1016/S0014-5793(98)01044-8; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Mironov A, 1998, FASEB J, V12, P249; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RICHARD CL, 2000, ANNU REV CELL DEV BI, V16, P19; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stephens DJ, 2001, J CELL SCI, V114, P1053; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TANG BL, 1995, EUR J CELL BIOL, V68, P199; Tsui MMK, 2001, MOL BIOL CELL, V12, P521, DOI 10.1091/mbc.12.3.521; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Xu Y, 1998, J BIOL CHEM, V273, P21783, DOI 10.1074/jbc.273.34.21783; Yang W, 1998, MOL BIOL CELL, V9, P191, DOI 10.1091/mbc.9.1.191; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	64	97	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27480	27487		10.1074/jbc.M102786200	http://dx.doi.org/10.1074/jbc.M102786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11323436	hybrid			2022-12-25	WOS:000169966900099
J	Chipuk, JE; Bhat, M; Hsing, AY; Ma, JJ; Danielpour, D				Chipuk, JE; Bhat, M; Hsing, AY; Ma, JJ; Danielpour, D			Bcl-xL, blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; RAT VENTRAL PROSTATE; HUMAN HEPATOMA-CELLS; TGF-BETA; IMMUNOHISTOCHEMICAL ANALYSIS; ANIMAL DEVELOPMENT; CANCER CELLS; BCL-X(L); DEATH; EXPRESSION	The mechanism by which transforming growth factor-pi (TGF-beta1) induces apoptosis of prostate epithelial cells was studied in the NRP-154 rat prostate epithelial cell line. TGF-beta1 down-regulates expression of Bcl-xL and poly(ADP-ribosyl)polymerase (PARP), promotes cytochrome c release, up-regulates expression of latent caspase-3, and activates caspases 3 and 9, We tested the role of Bcl-xL in this cascade by stably overexpressing Bcl-xL to prevent loss by TGF-beta1, Clones overexpressing Bcl-xL are resistant to TGF-beta1 with respect to induction of apoptosis, cytochrome c release, activation of caspases 9 and 3, and cleavage of PARP; yet they remain sensitive to TGF-beta1 by cell cycle arrest, induction of both fibronectin and latent caspase-3 expression, and loss of PARP expression, We show that Bcl-xL associates with Apaf-1 in NRP-154 cells; but this association does not inhibit the activation of caspases 9 and 3 by cytochrome c, Together, our data suggest that TGF-beta1 induces apoptosis through loss of Bcl-xL, leading to cytochrome c release and the subsequent activation of caspases 9 and 3, Moreover, our data demonstrate that the antiapoptotic effect of Bcl-xL occurs by inhibition of mitochondrial cytochrome c release and not through antagonizing Apaf-1-dependent processing of caspases 9 and 3.	Case Western Reserve Univ, Ireland Canc Ctr, Dept Pharmacol, Res Labs,Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Dept Physiol & Biophys, Res Labs,Univ Hosp Cleveland, Cleveland, OH 44106 USA; NCI, Lab Cell Regualt & Carcinogensis, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Danielpour, D (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Dept Pharmacol, Res Labs, Samuel Gerber Bldg,Suite 200,Lab 3,11001 Cedar Rd, Cleveland, OH 44106 USA.	dxd49@po.cwru.edu		Chipuk, Jerry Edward/0000-0002-1337-842X	NCI NIH HHS [1R01-CA30369-01, P30CA43703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; Brodin G, 1999, CANCER RES, V59, P2731; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Buchmann A, 1999, CELL DEATH DIFFER, V6, P190, DOI 10.1038/sj.cdd.4400475; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Carthy CM, 1999, LAB INVEST, V79, P953; Chao DT, 1997, INT IMMUNOL, V9, P1375, DOI 10.1093/intimm/9.9.1375; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 1999, J CELL SCI, V112, P169; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Freathy C, 2000, HEPATOLOGY, V32, P750, DOI 10.1053/jhep.2000.18329; Gao CL, 2000, INT J CANCER, V88, P191, DOI 10.1002/1097-0215(20001015)88:2<191::AID-IJC7>3.3.CO;2-1; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo YP, 1999, CANCER RES, V59, P1366; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; HARTLEYASP B, 1982, J UROLOGY, V127, P818, DOI 10.1016/S0022-5347(17)54057-4; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsing AY, 1996, CANCER RES, V56, P5146; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hung WC, 1998, CELL SIGNAL, V10, P511, DOI 10.1016/S0898-6568(97)00189-7; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; Kokontis J, 1991, Receptor, V1, P271; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marcelli M, 2000, PROSTATE, V42, P260, DOI 10.1002/(SICI)1097-0045(20000301)42:4<260::AID-PROS3>3.0.CO;2-0; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; Massague J, 2000, GENE DEV, V14, P627; MICKEY DD, 1977, CANCER RES, V37, P4049; Milligan CE, 1997, BRIT MED BULL, V53, P570; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; Nunez G, 1996, ADV EXP MED BIOL, V406, P75; Ohta S, 1997, BIOCHEM J, V324, P777, DOI 10.1042/bj3240777; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pollard M, 1998, PROSTATE, V37, P1, DOI 10.1002/(SICI)1097-0045(19980915)37:1<1::AID-PROS1>3.0.CO;2-L; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SCHUURMANS ALG, 1991, J STEROID BIOCHEM, V40, P193, DOI 10.1016/0960-0760(91)90182-5; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; SPORN MB, 1991, CIBA F SYMP, V157, P1; Takahashi N, 2000, PROSTATE, V44, P328, DOI 10.1002/1097-0045(20000901)44:4<328::AID-PROS10>3.0.CO;2-8; Tang BW, 1999, CANCER RES, V59, P4834; Tang DG, 1998, CANCER RES, V58, P3466; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tu HC, 1996, INT J CANCER, V69, P357, DOI 10.1002/(SICI)1097-0215(19961021)69:5<357::AID-IJC1>3.0.CO;2-4; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zhang HC, 1996, PROSTATE, V29, P69	89	87	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26614	26621		10.1074/jbc.M100913200	http://dx.doi.org/10.1074/jbc.M100913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11320089	hybrid			2022-12-25	WOS:000169823300126
J	Rusnati, M; Urbinati, C; Caputo, A; Possati, L; Lortat-Jacob, H; Giacca, M; Ribatti, D; Presta, M				Rusnati, M; Urbinati, C; Caputo, A; Possati, L; Lortat-Jacob, H; Giacca, M; Ribatti, D; Presta, M			Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; IMMUNODEFICIENCY-VIRUS TYPE-1; PHASE-I TRIAL; SULFATED POLYSACCHARIDES; HEPARAN SULFATES; TUMOR-GROWTH; PROTEIN; CELLS; SARCOMA; ANGIOGENESIS	HIV-1 Tat protein, released from HIV-infected cells, may act as a pleiotropic heparin-binding growth factor. From this observation, extracellular Tat has been implicated in the pathogenesis of AIDS and of AIDS-associated pathologies. Here we demonstrate that the heparin analog pentosan polysulfate (PPS) inhibits the interaction of glutathione S-transferase (GST)-Tat protein with heparin immobilized to a BIAcore sensor chip. Competition experiments showed that Tat-PPS interaction occurs with high affinity (K-d = 9.0 nM). Also, GST.Tat prevents the binding of [H-3]heparin to GST Tat immobilized to glutathione-agarose beads. In vitro, PPS inhibits GST Tat internalization and, consequently, HIV-1 long terminal repeat transactivation in HL3T1 cells. Also, PPS inhibits cell surface interaction and mitogenic activity of GST Tat in murine adenocarcinoma T53 Tat-less cells. In all assays, PPS exerts its Tat antagonist activity with an ID50 equal to similar to1.0 nM. In vivo, PPS inhibits the neovascularization induced by GST Tat or by Tat overexpressing T53 cells in the chick embryo chorioallantoic membrane. In conclusion, PPS binds Tat protein and inhibits its cell surface interaction, internalization, and biological activity in vitro and in vivo. PPS may represent a prototypic molecule for the development of novel Tat antagonists with therapeutic implications in AIDS and AIDS-associated pathologies, including Kaposi's sarcoma.	Univ Brescia, Dept Biomed Sci & Biotechnol, Sch Med, I-25123 Brescia, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, I-44100 Ferrara, Italy; Inst Biol Struct, F-38027 Grenoble, France; Univ Ancona, Inst Biomed Sci, I-60131 Ancona, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Bari, Inst Anat Histol & Embryol, I-70124 Bari, Italy	University of Brescia; University of Ferrara; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Marche Polytechnic University; International Center for Genetic Engineering & Biotechnology (ICGEB); Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Sch Med, Via Valsabbina 19, I-25123 Brescia, Italy.	presta@med.unibs.it	Rusnati, Marco/F-1168-2010; Caputo, Antonella/ABE-7851-2020; Giacca, Mauro/J-9287-2016; Presta, Marco/B-4345-2010	Rusnati, Marco/0000-0001-9968-5908; Caputo, Antonella/0000-0002-1241-0299; Giacca, Mauro/0000-0003-2927-7225; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871				Albini A, 1996, ONCOGENE, V12, P289; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Corallini A, 1998, AIDS RES HUM RETROV, V14, P1561, DOI 10.1089/aid.1998.14.1561; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Gatignol A, 2000, Adv Pharmacol, V48, P209; HATTON MWC, 1980, ANAL BIOCHEM, V106, P417, DOI 10.1016/0003-2697(80)90542-4; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marshall JL, 1997, CLIN CANCER RES, V3, P2347; McLeskey SW, 1996, BRIT J CANCER, V73, P1053, DOI 10.1038/bjc.1996.204; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; Noonan D, 2000, Adv Pharmacol, V48, P229; PARKER BW, 1993, J NATL CANCER I, V85, P1068, DOI 10.1093/jnci/85.13.1068; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173; Possati L, 1999, CLIN EXP METASTAS, V17, P575, DOI 10.1023/A:1006737029616; Prakash O, 2000, JNCI-J NATL CANCER I, V92, P721, DOI 10.1093/jnci/92.9.721; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Rusnati M, 1997, AIDS, V11, P727, DOI 10.1097/00002030-199706000-00005; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 2000, FASEB J, V14, P1917, DOI 10.1096/fj.99-0902com; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; Schwartsmann G, 1996, TUMORI, V82, P360, DOI 10.1177/030089169608200412; SWAIN SM, 1995, INVEST NEW DRUG, V13, P55, DOI 10.1007/BF02614221; SYDOW G, 1987, BIOMED BIOCHIM ACTA, V46, P527; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Watson K, 1999, BIOCHEM PHARMACOL, V57, P775, DOI 10.1016/S0006-2952(98)00352-9; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WITVROUW M, 1994, ANTIVIR CHEM CHEMOTH, V5, P345, DOI 10.1177/095632029400500601; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; Zugmaier G, 1999, ANN NY ACAD SCI, V886, P243, DOI 10.1111/j.1749-6632.1999.tb09427.x; ZUGMAIER G, 1992, J NATL CANCER I, V84, P1716, DOI 10.1093/jnci/84.22.1716	42	71	74	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22420	22425		10.1074/jbc.M010779200	http://dx.doi.org/10.1074/jbc.M010779200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304529	hybrid			2022-12-25	WOS:000169412700061
J	Hardwick, JCH; van den Brink, GR; Offerhaus, GJ; van Deventer, SJH; Peppelenbosch, MP				Hardwick, JCH; van den Brink, GR; Offerhaus, GJ; van Deventer, SJH; Peppelenbosch, MP			NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps	ONCOGENE			English	Article						polyp; JNK; NF-kappaB; p38 MAPK; COX-2; NSAIDs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TERMINAL KINASE; PROTEIN-KINASE; SODIUM-SALICYLATE; CYCLOOXYGENASE 2; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; B ACTIVATION; CANCER CELLS; INHIBITION	The factors that govern the progression from colonic adenomatous polyp to colon cancer are poorly understood. The observation that NSAIDs act as chemopreventative agents and reduce the size of colonic polyps suggests the involvement of inflammatory signalling, but inflammatory signalling in colonic polyps has not been studied. We investigated the expression of the active forms of NF-kappaB, JNK and p38 MAPK using immunohistochemistry with activation specific antibodies in human colonic adenomas, We show that active NF-kappaB is seen in stromal macrophages that also express COX-2 and TNF-alpha, active JNK is seen in stromal and intraepithelial T-lymphocytes and periendothelial cells of new blood vessels, and active p38 MAPK is most highly expressed in macrophages and other stromal cells. These results demonstrate the presence of active inflammatory signal transduction in colonic polyps and that these are predominantly in the stroma, In the case of NF-kappaB this coincides with the cellular localisation of COX-2. These results support evidence that NSAIDs may act through effects on stromal cells rather than epithelial cells.	Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Hardwick, JCH (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Hardwick, James/J-4862-2013	Hardwick, James/0000-0002-9575-5099; Peppelenbosch, Maikel/0000-0001-9112-6028				Bak AW, 1998, LIFE SCI, V62, pPL367; Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; Chiu CH, 1997, CANCER RES, V57, P4267; DIGIORGIO A, 1992, INT SURG, V77, P256; Gaweco AS, 2000, HEPATOLOGY, V31, P1183, DOI 10.1053/he.2000.6983; Hakansson L, 1997, BRIT J CANCER, V75, P374, DOI 10.1038/bjc.1997.61; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Licato LL, 1998, DIGEST DIS SCI, V43, P1454, DOI 10.1023/A:1018894227169; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piazza GA, 1997, CANCER RES, V57, P2452; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; SANO H, 1995, CANCER RES, V55, P3785; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; SVENNEVIG JL, 1984, BRIT J CANCER, V49, P375, DOI 10.1038/bjc.1984.60; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van den Brink GR, 2000, J IMMUNOL, V164, P3353, DOI 10.4049/jimmunol.164.6.3353; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	44	94	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					819	827		10.1038/sj.onc.1204162	http://dx.doi.org/10.1038/sj.onc.1204162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314016				2022-12-25	WOS:000166924400005
J	Yang, HS; Jansen, AP; Nair, R; Shibahara, K; Verma, AK; Cmarik, JL; Colburn, NH				Yang, HS; Jansen, AP; Nair, R; Shibahara, K; Verma, AK; Cmarik, JL; Colburn, NH			A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappa B or ODC transactivation	ONCOGENE			English	Article						pdcd4; AP-1; NF-kappa B; transformation	MOUSE EPIDERMAL-CELLS; NEOPLASTIC TRANSFORMATION; TUMOR PROMOTION; JB6 CELLS; TRANSCRIPTIONAL REGULATION; ANCHORAGE INDEPENDENCE; HUMAN KERATINOCYTES; TRANSGENIC MICE; EXPRESSION; ACTIVATION	Pdcd4 is a novel transformation suppressor that is highly expressed in promotion-resistant (P-) mouse epidermal JB6 cells but not in susceptible (P+) cells. Overexpression of pdcd4 cDNA in stably transfected P+ cells rendered cells resistant to tumor promoter-induced transformation, indicating that elevated expression of Pdcd4 protein is sufficient to suppress neoplastic transformation. To determine whether Pdcd4 suppresses neoplastic transformation through inhibiting known transformation required events, se examined the possibility that pdcd4 inhibited the activation of AP-1 or NF-kappaB dependent transcription or of ornithine decarboxylase (ODC) activity. Activation of AP-1-dependent transcriptional activity mas inhibited bai pdcd4 expression in a concentration dependent manner. In contrast, Pdcd4 slightly increased NF-kappaB-dependent transcription and did not alter ODC enzymatic activity. Previous studies suggested that activation of AP-1 was required for P+ cell transformation as well as for tumor promotion in vivo. These results indicate that Pdcd4 functions as a transformation suppressor, possibly through inhibiting AP-1 activation in combination with other factors such as enhancing NF-kappaB activation. Pdcd4 may thus constitute a useful molecular target for cancer prevention.	NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD 21702 USA; Univ Wisconsin, Sch Med, Dept Human Oncol, Madison, WI 53792 USA; Kyoto Univ, Sakyo Ku, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison; Kyoto University	Yang, HS (corresponding author), NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD 21702 USA.		Yang, Hsin-Sheng/AAF-6793-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036				AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Azzoni L, 1998, J IMMUNOL, V161, P3493; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang PL, 2000, J CELL BIOCHEM, V78, P8, DOI 10.1002/(SICI)1097-4644(20000701)78:1<8::AID-JCB2>3.3.CO;2-J; Cmarik J.L., 1997, FOOD FACTORS CANC PR, P67, DOI [10.1007/978-4-431-67017-9_13, DOI 10.1007/978-4-431-67017-9_13]; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1980, CARCINOGENESIS, V1, P951, DOI 10.1093/carcin/1.11.951; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DEBENEDETTI F, 1990, PROG LEUC B, V10, P275; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Foo SY, 1999, TRENDS GENET, V15, P229; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Jansen AP, 1999, ONCOGENE, V18, P5806, DOI 10.1038/sj.onc.1202965; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; OBrien TG, 1997, CANCER RES, V57, P2630; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; TAKAHASHI K, 1986, CANCER RES, V46, P5923; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	41	163	169	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					669	676		10.1038/sj.onc.1204137	http://dx.doi.org/10.1038/sj.onc.1204137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314000				2022-12-25	WOS:000166806000002
J	He, W; Cao, TY; Smith, DA; Myers, TE; Wang, XJ				He, W; Cao, TY; Smith, DA; Myers, TE; Wang, XJ			Smads mediate signaling of the TGF beta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis	ONCOGENE			English	Article						keratinocytes; growth inhibition; skin chemical carcinogenesis; transforming growth factor beta; tumor progression	GROWTH-FACTOR-BETA; GROWTH-FACTOR-BETA-1 MESSENGER-RNA; NF-KAPPA-B; TRANSGENIC MICE; MOUSE SKIN; DPC4 GENE; VITAMIN-D; TRANSFORMING GROWTH-FACTOR-BETA-1; TUMOR-SUPPRESSOR; IN-VIVO	The Smads are the signaling mediators of the TGF beta superfamily, In the present study, we examined Smad expression in mouse epidermis and chemically-induced skin tumors. Mutations in Smad2 and -4 genes were also screened. Transcripts of Smad1 through -5 were constantly expressed in the epidermis regardless of changes in TGF beta signaling, state of differentiation and stages of carcinogenesis. Smad7 transcripts were barely detectable in keratinocytes, but were induced by TGF beta1 treatment and in chemically-induced skin tumors. At the protein level, Smad1 was detected throughout the epidermis, whereas Smad2 through -5 exhibited greater levels in suprabasal layers than basal keratinocytes. In cultured keratinocytes, Smad2, -3 and -4 underwent nuclear translocation upon TGF beta1 treatment. Furthermore, nuclear translocation of Smads correlated with decreased BrdU labeling in proliferative keratinocytes. Although no mutations mere detected in the Smad2 and -4 genes in tumors, proteins of Smad1 through -5 were partially or completely lost in carcinomas. These data document that Smads are expressed at high levels in the epidermis and mediate signaling of the TGF beta superfamily. During skin carcinogenesis, loss of Smad1 through -5 and overexpression of Smad7 may contribute to the loss of growth inhibition mediated by TGF beta superfamily members, thus resulting in tumor progression.	Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wang, XJ (corresponding author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA.		Wikramanayake, Tongyu/A-9759-2013		NCI NIH HHS [CA 87849, CA79998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087849, R01CA079998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; Barrett MT, 1996, CANCER RES, V56, P4351; BIKLE DD, 1988, ANN NY ACAD SCI, V548, P27, DOI 10.1111/j.1749-6632.1988.tb18790.x; BLESSING M, 1995, TERATOGEN CARCIN MUT, V15, P11, DOI 10.1002/tcm.1770150103; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Chang H, 1999, DEVELOPMENT, V126, P1631; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Devereux TR, 1997, CARCINOGENESIS, V18, P1751, DOI 10.1093/carcin/18.9.1751; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Go C, 1999, CANCER RES, V59, P2861; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hejlik DP, 1997, CANCER RES, V57, P3779; Heldin CH, 1999, NAT CELL BIOL, V1, pE195, DOI 10.1038/70223; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kong XT, 1997, CANCER RES, V57, P3772; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Ma SH, 1997, GENE EXPRESSION, V6, P361; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Nadeau A, 1997, J HISTOCHEM CYTOCHEM, V45, P107, DOI 10.1177/002215549704500114; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; ROBERTS AB, 1987, NUCL MED BIOL, V14, P435, DOI 10.1016/0883-2897(87)90020-1; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; Rougui Z, 1996, J CELL PHYSIOL, V168, P385, DOI 10.1002/(SICI)1097-4652(199608)168:2<385::AID-JCP17>3.0.CO;2-2; Rozenblum E, 1997, CANCER RES, V57, P1731; Rundhaug JE, 1997, MOL CARCINOGEN, V18, P115, DOI 10.1002/(SICI)1098-2744(199702)18:2<115::AID-MC7>3.0.CO;2-F; Schutte M, 1996, CANCER RES, V56, P2527; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHERMAN JH, 1993, MOL CARCINOGEN, V8, P264, DOI 10.1002/mc.2940080409; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Uchida K, 1996, CANCER RES, V56, P5583; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zavadil J, 1997, LEUKEMIA, V11, P1187, DOI 10.1038/sj.leu.2400750; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	64	68	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					471	483		10.1038/sj.onc.1204117	http://dx.doi.org/10.1038/sj.onc.1204117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313978				2022-12-25	WOS:000166562500007
J	Kim, KW; Chung, HH; Chung, CW; Kim, IK; Miura, M; Wang, SY; Zhu, H; Moon, KD; Rha, GB; Park, JH; Jo, DG; Woo, HN; Song, YH; Kim, BJ; Yuan, JY; Jung, YK				Kim, KW; Chung, HH; Chung, CW; Kim, IK; Miura, M; Wang, SY; Zhu, H; Moon, KD; Rha, GB; Park, JH; Jo, DG; Woo, HN; Song, YH; Kim, BJ; Yuan, JY; Jung, YK			Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: Cleavage of the common alpha subunit during apoptosis	ONCOGENE			English	Article						apoptosis; caspase; farnesyltransferase; geranylgeranyltransferase	FARNESYL TRANSFERASE INHIBITORS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; PROTEIN FARNESYLTRANSFERASE; CELL-DEATH; H-RAS; TRANSFORMED-CELLS; TRANSGENIC MICE; GROWTH-FACTOR; ACTIVATION; SUPPRESSION	Caspase plays an important role in apoptosis. We report here that farnesyltransferase(geranylgeranyltransferase (FTase/GGTase)-alpha, a common subunit of FTase (alpha/beta (FTase)) and GGTase I (alpha/beta (GGTase)), was cleaved by caspase-3 during apoptosis, FTase/GGTase-alpha (49 kDa) was cleaved to 35 kDa (p35) in the Rat-2/H-ras, W4 and Rat-1 cells treated with FTase inhibitor (LB42708), anti-Fas antibody and etoposide, respectively. This cleavage was inhibited by caspase-inhibitors (YVAD-cmk, DEVID-cho), Serial N-terminal deletions and site-directed mutagenesis showed that Asp59 of FTase/GGTase-alpha was cleaved by caspase-3. The common FTase/GGTase-alpha subunit, but not the beta subunits, of the FTase or GGTase I protein complexes purified from baculovirus-infected SF-9 cells was cleaved to be inactivated by purified caspase-3. In contrast, FTase mutant protein complex [(D(59)A)alpha/beta (FTase)] was resistant to caspase-3. Expression of either the cleavage product (60-379) or anti-sense of FTase/GGTase-alpha induced cell death in Rat-2/H-ras cells. Furthermore, expression of (D(59)A)FTase/GCTase-alpha mutant significantly desensitized cells to etoposide-induced death. Taken together, we suggest that cleavage of prenyltransferase by caspase contributes to the progression of apoptosis.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Biotech Res Inst, LG Chem, Taejon, South Korea; Osaka Univ, Sch Med, Dept Neuroanat, Osaka, Japan; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Gwangju Institute of Science & Technology (GIST); LG Chem; Osaka University; Harvard University; Harvard Medical School	Jung, YK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.		Jo, Dong-Gyu/AAN-9278-2021	Jo, Dong-Gyu/0000-0003-2271-1076; Kim, Ki Woo/0000-0002-7790-1515; Zhu, Hong/0000-0002-2575-4031; Jung, Yong-Keun/0000-0002-9686-3120; Woo, Ha-Na/0000-0002-6771-8151				Ahmad M, 1998, CANCER RES, V58, P5201; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, CANCER RES, V59, P4208; Feldkamp MM, 1999, ONCOGENE, V18, P7514, DOI 10.1038/sj.onc.1203105; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; GULBILNS E, 1996, J BIOL CHEM, V271, P26390; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JANSEN B, 1997, CANCER RES, V57, P1846; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lebowitz PF, 1997, CANCER RES, V57, P708; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; McKenna WG, 1996, ONCOGENE, V12, P237; Miquel K, 1997, CANCER RES, V57, P1846; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; O'Reilly LA, 1999, INFLAMM RES, V48, P5, DOI 10.1007/s000110050369; Park HW, 1997, CURR OPIN STRUC BIOL, V7, P873; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; SUMMERS MD, 1998, TEXAS AGR EXP ST B, V1555, P29; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	49	15	16	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					358	366		10.1038/sj.onc.1204099	http://dx.doi.org/10.1038/sj.onc.1204099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313965				2022-12-25	WOS:000166411000010
J	Sung, JY; Kim, J; Paik, SR; Park, JH; Ahn, YS; Chung, KC				Sung, JY; Kim, J; Paik, SR; Park, JH; Ahn, YS; Chung, KC			Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; SPORADIC PARKINSONS-DISEASE; AMYLOID PRECURSOR PROTEIN; MULTIPLE SYSTEM ATROPHY; ALZHEIMERS-DISEASE; LEWY BODIES; CEREBROSPINAL-FLUID; NACP/ALPHA-SYNUCLEIN; PRESYNAPTIC PROTEIN; MEMBRANE-FUSION	The presynaptic alpha -synuclein is a prime suspect for contributing to Lewy pathology and clinical aspects of diseases, including Parkinson's disease, dementia with Lewy bodies, and a Lewy body variant of Alzheimer's disease. Here we examined the pathogenic mechanism of neuronal cell death induced by alpha -synuclein. The exogenous addition of alpha -synuclein caused a marked decrease of cell viability in primary and immortalized neuronal cells. The neuronal cell death appeared to be correlated with the Rab5A-specific endocytosis of alpha -synuclein that subsequently caused the formation of Lewy body-like intracytoplasmic inclusions. This was further supported by the fact that the expression of GTPase-deficient Rab5A resulted in a significant decrease of its cytotoxicity as a result of incomplete endocytosis of alpha -synuclein.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Res Inst, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Inha Univ, Dept Biochem, Coll Med, Inchon 402751, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Inha University	Chung, KC (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Shinchon Dong 134, Seoul 120752, South Korea.			Kim, Jongsun/0000-0002-3149-669X; Park, Jeon Han/0000-0001-9604-3205				Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Arima K, 1999, BRAIN RES, V843, P53, DOI 10.1016/S0006-8993(99)01848-X; Arima K, 2000, ACTA NEUROPATHOL, V100, P115, DOI 10.1007/s004010050002; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; Chung KC, 2000, J NEUROCHEM, V75, P9, DOI 10.1046/j.1471-4159.2000.0750009.x; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; DICARLO V, 1993, CAN J NEUROL SCI S, V4, pS80; DICARLO V, 2000, ABSTR SOC NEUROSCI, V26, P1547; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Gai WP, 1995, BRAIN, V118, P1447, DOI 10.1093/brain/118.6.1447; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Ho SL, 1998, MOVEMENT DISORD, V13, P970, DOI 10.1002/mds.870130619; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Ikin AF, 1996, J BIOL CHEM, V271, P31783, DOI 10.1074/jbc.271.50.31783; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Kim HJ, 1999, NEUROREPORT, V10, P1427, DOI 10.1097/00001756-199905140-00008; Kim J, 1997, MOL CELLS, V7, P78; Ko LW, 2000, J NEUROCHEM, V75, P2546, DOI 10.1046/j.1471-4159.2000.0752546.x; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Lin JJ, 1999, EUR NEUROL, V42, P217, DOI 10.1159/000008110; Lin X, 1999, NEURON, V24, P499, DOI 10.1016/S0896-6273(00)81104-6; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; Masliah E, 1996, AM J PATHOL, V148, P201; McLean PJ, 2000, J NEURAL TRANSM-SUPP, P53; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakamura S, 2000, CLIN NEUROPATHOL, V19, P51; Neve RL, 1998, J NEUROSCI, V18, P7757; NISHIMURA M, 1994, BRAIN RES, V634, P339, DOI 10.1016/0006-8993(94)91940-2; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Troncoso JC, 1998, ANN NEUROL, V43, P673, DOI 10.1002/ana.410430519; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Vaughan J, 1998, ANN NEUROL, V44, P270, DOI 10.1002/ana.410440221; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang WW, 1998, ARCH NEUROL-CHICAGO, V55, P1521, DOI 10.1001/archneur.55.12.1521; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	62	154	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27441	27448		10.1074/jbc.M101318200	http://dx.doi.org/10.1074/jbc.M101318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11316809	hybrid			2022-12-25	WOS:000169966900094
J	Domino, SE; Zhang, L; Lowe, JB				Domino, SE; Zhang, L; Lowe, JB			Molecular cloning, genomic mapping, and expression of two secretor blood group alpha(1,2)fucosyltransferase genes differentially regulated in mouse uterine epithelium and gastrointestinal tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; HEPARIN HEPARAN-SULFATE; EARLY-PREGNANCY; DEVELOPMENTAL REGULATION; CHROMOSOMAL ASSIGNMENT; CARBOHYDRATE ANTIGENS; HORMONAL-CONTROL; MENSTRUAL-CYCLE; BINDING-SITES; ATTACHMENT	Fucosylated oligosaccharides have been proposed to be involved in multiple cell-cell interactions, including mouse blastocyst adhesion and intestine-microbe interactions. To begin to define the regulation and function of terminal alpha (1,2)fucosylated carbohydrates in these and other tissues, we isolated and characterized a 85-kilobase (kb) genomic region of mouse chromosome 7, 23.2 centimorgans analogous to human chromosome 19q13.3 that encodes three alpha (1,2) fucosyltransferases. Gene-specific DNA probes from the open reading frames of the mouse fucosyltransferase genes corresponding to human FUT1, FUT2, and SEC1 demonstrate distinct tissue-specific expression patterns by Northern blot analyses. Flow cytometry profiles of cultured cells transfected with DNA segments containing the open reading frames of the mouse genes confirm that, each encodes an alpha (1,2)fucosyltransferase. In uterus and colon, a 3.3-kb FUT2 mRNA represents the major fucosyltransferase gene expressed. Steady-state FUT2 mRNA levels are cyclically regulated during the estrus cycle, increasing 10-fold from early diestrus to a relative maximum in proestrus. In contrast, SEC1 and FUT1 do not show prominently regulated expression in uterus, FUT2 expression localizes to luminal uterine epithelium by in situ hybridization, implying that this gene determines expression of cell surface Fuc alpha1 --> 2Gal beta epitopes proposed to mediate blastocyst adhesion.	Univ Michigan, Dept Obstet & Gynecol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Domino, SE (corresponding author), Univ Michigan, Dept Obstet & Gynecol, Sch Med, 6428 Med Sci Bldg 1,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	sedomino@med.umich.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001195] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932] Funding Source: Medline; NICHD NIH HHS [K08 HD01195] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMANT DR, 1986, DEV BIOL, V116, P519, DOI 10.1016/0012-1606(86)90152-1; ARMANT DR, 1986, P NATL ACAD SCI USA, V83, P6751, DOI 10.1073/pnas.83.18.6751; BARBIAZ BS, 1988, BIOL REPROD, V39, P699; BENNETT G, 1978, AM J ANAT, V152, P223, DOI 10.1002/aja.1001520205; BIOL MC, 1992, BIOCHIM BIOPHYS ACTA, V1133, P206, DOI 10.1016/0167-4889(92)90070-R; BLOCH KD, 1987, CURRENT PROTOCOLS MO; BROWN T, 1993, CURRENT PROTOCOLS MO; Brown T., 1997, CURRENT PROTOCOLS MO; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; CARSON DD, 1994, INT J BIOCHEM, V26, P1269, DOI 10.1016/0020-711X(94)90096-5; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CHAVEZ DJ, 1985, BIOL REPROD, V32, P1135, DOI 10.1095/biolreprod32.5.1135; CLARK MA, 1995, CELL TISSUE RES, V282, P455, DOI 10.1007/BF00318877; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DAS SK, 1994, DEVELOPMENT, V120, P1071; Domino SE, 1997, BIOCHEM J, V327, P105, DOI 10.1042/bj3270105; DUTT A, 1987, DEV BIOL, V119, P27, DOI 10.1016/0012-1606(87)90203-X; DUTT A, 1988, J BIOL CHEM, V263, P2270; Enders AC, 1976, J REPROD FERTIL    S, V25, P1; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FARR AG, 1985, J IMMUNOL, V134, P2971; FEINBERG RF, 1991, AM J PATHOL, V138, P537; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HARPER MJK, 1992, BAILLIERE CLIN OB GY, V6, P351, DOI 10.1016/S0950-3552(05)80092-6; Hitoshi S, 1996, J BIOL CHEM, V271, P16975, DOI 10.1074/jbc.271.28.16975; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; Hokke CH, 1998, GLYCOBIOLOGY, V8, P393, DOI 10.1093/glycob/8.4.393; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KIMBER SJ, 1988, J REPROD IMMUNOL, V12, P297, DOI 10.1016/0165-0378(88)90015-0; KIMBER SJ, 1990, J REPROD FERTIL, V89, P13, DOI 10.1530/jrf.0.0890013; KIMBER SJ, 1995, J REPROD FERTIL, V103, P75; KLIMAN HJ, 1995, AM J PATHOL, V146, P166; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LENOIR D, 1995, BBA-BIOMEMBRANES, V1234, P29, DOI 10.1016/0005-2736(94)00254-M; LESSEY BA, 1994, FERTIL STERIL, V62, P497; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; LINDENBERG S, 1988, J REPROD FERTIL, V83, P149; LINDENBERG S, 1990, J REPROD FERTIL, V89, P431, DOI 10.1530/jrf.0.0890431; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; ROY MJ, 1987, CELL TISSUE RES, V248, P483, DOI 10.1007/BF00216473; RUGGIEROLOPEZ D, 1991, BIOCHEM J, V279, P801, DOI 10.1042/bj2790801; SADLER JE, 1984, BIOL CARBOHYDRATES, P200; Sidhu SS, 1999, BIOL REPROD, V60, P147, DOI 10.1095/biolreprod60.1.147; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; SURVEYOR GA, 1995, ENDOCRINOLOGY, V136, P3639, DOI 10.1210/en.136.8.3639; SUTHERLAND AE, 1988, J CELL BIOL, V106, P1331, DOI 10.1083/jcb.106.4.1331; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; SVALANDER PC, 1990, J REPROD FERTIL, V88, P213; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; WHITE S, 1994, BIOL REPROD, V50, P73, DOI 10.1095/biolreprod50.1.73; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; YAMAGATA T, 1991, BIOCHEM BIOPH RES CO, V181, P1004, DOI 10.1016/0006-291X(91)92036-J	60	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23748	23756		10.1074/jbc.M100735200	http://dx.doi.org/10.1074/jbc.M100735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323419	hybrid			2022-12-25	WOS:000169531100071
J	Tiffany, HL; Lavigne, MC; Cui, YH; Wang, JM; Leto, TL; Gao, JL; Murphy, PM				Tiffany, HL; Lavigne, MC; Cui, YH; Wang, JM; Leto, TL; Gao, JL; Murphy, PM			Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; SCAVENGER RECEPTOR; MICROGLIAL CELLS; HUMAN MONOCYTE; INTERFERON-GAMMA; GENE-CLUSTER; MOUSE; NEUROTOXICITY	Amyloid-beta, the pathologic protein in Alzheimer's disease, induces chemotaxis and production of reactive oxygen species in phagocytic cells, but mechanisms have not been fully defined. Here me provide three lines of evidence that the phagocyte G protein-coupled receptor (N-formylpeptide receptor 2 (FPR2)) mediates these amyloid-beta -dependent functions in phagocytic cells. First, transfection of FPR2, but not related receptors, including the other known N-formylpeptide receptor FPR, reconstituted amyloid-beta -dependent chemotaxis and calcium flux in HEK 293 cells. Second, amyloid-beta induced both calcium flux and chemotaxis in mouse neutrophils (which express endogenous FPR2) with similar potency as in FPR2-transfected HEK 293 cells, This activity could be specifically desensitized in both cell types by preincubation with a specific FPR2 agonist, which desensitizes the receptor, or with pertussis toxin, which uncouples it from G(i)-dependent signaling. Third, specific and reciprocal desensitization of superoxide production was observed when N-formylpeptides and amyloid-beta were used to sequentially stimulate neutrophils from FPR -/- mice, which express FPR2 normally. Potential biological relevance of these results to the neuroinflamma. tion associated with Alzheimer's disease was suggested by two additional findings: first, FPR2 mRNA could be detected by PCR in mouse brain; second, induction of FPR2 expression correlated with induction of calcium flux and chemotaxis by amyloid-beta in the mouse microglial cell line N9, Further, in sequential stimulation experiments with N9 cells, N-formylpeptides and amyloid-beta were able to reciprocally cross-desensitize each other. Amyloid-beta was also a specific agonist at the human counterpart of FPR2, the FPR-like 1 receptor. These results suggest a unified signaling mechanism for linking amyloid-beta to phagocyte chemotaxis and oxidant stress in the brain.	NIAID, Mol Signaling Sect, NIH, Bethesda, MD 20892 USA; NIAID, Genet Immunotherapy Sect, Host Def Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Murphy, PM (corresponding author), NIAID, Mol Signaling Sect, NIH, Bldg 10,Rm 11N113, Bethesda, MD 20892 USA.		Gao, Ji-Liang/Y-4397-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614, ZIAAI000614, ZIAAI000615, Z01AI000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Antic A, 2000, EXP NEUROL, V161, P96, DOI 10.1006/exnr.1999.7265; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T; Bonaiuto C, 1997, J NEUROIMMUNOL, V77, P51, DOI 10.1016/S0165-5728(97)00054-4; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Cotter RL, 1999, J LEUKOCYTE BIOL, V65, P416, DOI 10.1002/jlb.65.4.416; Cowburn RF, 1997, NEUROCHEM RES, V22, P1437, DOI 10.1023/A:1021942109490; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; DURSTIN M, 1994, BIOCHEM BIOPH RES CO, V201, P174, DOI 10.1006/bbrc.1994.1685; ElKhoury J, 1996, NATURE, V382, P716; Ferrari D, 1996, J IMMUNOL, V156, P1531; Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Flynn BL, 1999, ANN PHARMACOTHER, V33, P840, DOI 10.1345/aph.17093; GAO JL, 1993, J BIOL CHEM, V268, P25395; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hartt JK, 2000, BIOCHEM BIOPH RES CO, V272, P699, DOI 10.1006/bbrc.2000.2846; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Liang TS, 2000, BIOCHEM BIOPH RES CO, V270, P331, DOI 10.1006/bbrc.2000.2416; Liu Y, 1997, BIOCHEM BIOPH RES CO, V237, P37, DOI 10.1006/bbrc.1997.7068; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; Lorton D, 1997, MECH AGEING DEV, V94, P199, DOI 10.1016/S0047-6374(96)01847-7; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McDonald DR, 1997, J NEUROSCI, V17, P2284; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; ROGERS J, 1996, NEUROBIOL AGING, V17, P661; SABO S, 1995, NEUROSCI LETT, V184, P25, DOI 10.1016/0304-3940(94)11159-G; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; Schulz JG, 1998, EUR J NEUROSCI, V10, P2085, DOI 10.1046/j.1460-9568.1998.00220.x; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Su SB, 1999, J IMMUNOL, V162, P5924; Sutton E. T., 1999, Journal of Submicroscopic Cytology and Pathology, V31, P313; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; TAKENOUCHI T, 1995, PEPTIDES, V16, P1019, DOI 10.1016/0196-9781(95)00084-W; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Van Muiswinkel FL, 1999, J NEUROIMMUNOL, V96, P121, DOI 10.1016/S0165-5728(99)00019-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y	62	132	136	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23645	23652		10.1074/jbc.M101031200	http://dx.doi.org/10.1074/jbc.M101031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316806	hybrid			2022-12-25	WOS:000169531100057
J	Boulay, A; Regnier, CH; Anglard, P; Stoll, I; Tomasetto, C; Rio, MC				Boulay, A; Regnier, CH; Anglard, P; Stoll, I; Tomasetto, C; Rio, MC			Transcription regulation and protein subcellular localization of the truncated basic hair keratin hHb1-Delta N in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE SKIN; LEUKOSIALIN CD43 GENE; HUMAN TYPE-I; INTERMEDIATE FILAMENTS; CHROMOSOMAL LOCALIZATION; EXPRESSION; FOLLICLE; HHB1; IDENTIFICATION; STROMELYSIN-3	An aberrant truncated hHb1 hair keratin transcript, named hHb1-DeltaN, was previously identified in breast carcinomas. No normal tissue tested so far, including hairy skin, expressed hHb1-DeltaN, indicating that hHb1-DeltaN is related to carcinogenesis. In the present study, we investigated the mechanism by which such truncated transcript was generated in breast cancer cell lines. We found that hHb1-DeltaN transcription is initiated at an unusual cryptic promoter within the fourth intron of the hHb1 gene and is dependent on two proximal Spl binding sites for its baseline activity, Moreover, hHb1-DeltaN transcription is increased in response to DNA demethylation by the 5-aza-2 ' -deoxycytidine drug. This induction is dependent on protein neosynthesis, indicating that an additional factor is required, In addition, we showed that the hHb1-DeltaN transcript is translated in vivo as a truncated hHb1 protein that is missing the 270 amino-terminal residues. The hHb1-DeltaN protein exhibits a filament pattern throughout the cytoplasm and partially co-localizes with cytokeratin filaments, indicating its participation in the cytoskeleton network, hHb1-DeltaN might alter the adhesive properties of cancer cells.	Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM U184, ULP, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rio, MC (corresponding author), Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM U184, ULP, BP 163, F-67404 Illkirch Graffenstaden, France.	rio@igbmc.u-strasbg.fr	Tomasetto, Catherine Laure/J-2783-2014; Anglard, Patrick/M-6618-2019	Tomasetto, Catherine Laure/0000-0002-1811-5848; Anglard, Patrick/0000-0001-5701-441X; Regnier, Catherine/0000-0002-4386-1324				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BLOEMENDAL H, 1989, BIOCHIM BIOPHYS ACTA, V1007, P245, DOI 10.1016/0167-4781(89)90144-9; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; Cribier B, 1999, BRIT J DERMATOL, V140, P600; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Fuchs E, 1997, MOL BIOL CELL, V8, P189, DOI 10.1091/mbc.8.2.189; Galou M, 1997, BIOL CELL, V89, P85, DOI 10.1016/S0248-4900(99)80068-9; Hutton E, 1998, J CELL BIOL, V143, P487, DOI 10.1083/jcb.143.2.487; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Korge BP, 1999, J INVEST DERMATOL, V113, P607, DOI 10.1046/j.1523-1747.1999.00722.x; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; Luo DC, 1999, J BIOL CHEM, V274, P37177, DOI 10.1074/jbc.274.52.37177; MILLER RK, 1993, J CELL BIOL, V122, P123, DOI 10.1083/jcb.122.1.123; MULLER D, 1993, CANCER RES, V53, P165; NATHRATH WBJ, 1994, INT CONGR SER, V1050, P57; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Paladini RD, 1999, J CELL BIOL, V146, P1185, DOI 10.1083/jcb.146.5.1185; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Regnier CH, 1998, BRIT J CANCER, V78, P1640, DOI 10.1038/bjc.1998.736; Regnier CH, 1997, EXP DERMATOL, V6, P87, DOI 10.1111/j.1600-0625.1997.tb00152.x; ROGERS GE, 1993, J INVEST DERMATOL, V101, pS50, DOI 10.1111/1523-1747.ep12362626; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683; Rogers MA, 2000, J INVEST DERMATOL, V114, P464, DOI 10.1046/j.1523-1747.2000.00910.x; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Windoffer R, 1999, J CELL SCI, V112, P4521; Winter H, 1997, HUM GENET, V101, P165, DOI 10.1007/s004390050607; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; YU DW, 1991, J INVEST DERMATOL, V97, P354, DOI 10.1111/1523-1747.ep12480706; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	42	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22954	22964		10.1074/jbc.M101687200	http://dx.doi.org/10.1074/jbc.M101687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304540	hybrid			2022-12-25	WOS:000169412700130
J	Floyd, ZE; Trausch-Azar, JS; Reinstein, E; Ciechanover, A; Schwartz, AL				Floyd, ZE; Trausch-Azar, JS; Reinstein, E; Ciechanover, A; Schwartz, AL			The nuclear ubiquitin-proteasome system degrades MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; SUBCELLULAR-LOCALIZATION; CONJUGATING ENZYME; PROTEIN-DEGRADATION; ACTIVATING ENZYME; RAPID DEGRADATION; 26-S PROTEASOME; DNA-BINDING; IN-VIVO; CELLS	Many short-lived nuclear proteins are targeted for degradation by the ubiquitin-proteasome pathway. The role of the nucleus in regulating the turnover of these proteins is not well defined, although many components of the ubiquitin-proteasome system are localized in the nucleus. We have used nucleoplasm from highly purified HeLa nuclei to examine the degradation of a physiological substrate of the ubiquitin-proteasome system (MyoD). lit vitro studies using inhibitors of the system demonstrate MyoD is degraded via the ubiquitin-proteasome pathway in HeLa nucleoplasm. Purified nucleoplasm in vitro also supports the generation of high molecular mass MyoD-ubiquitin adducts. In addition, in vivo studies, using leptomycin B to inhibit nuclear export, demonstrate that MyoD is degraded in HeLa cells by the nuclear ubiquitin-proteasome system.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat & Mol Biol & Phar, St Louis, MO 63110 USA; St Louis Childrens Hosp, Div Pediat Hematol Oncol, St Louis, MO 63110 USA; Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat & Mol Biol & Phar, St Louis, MO 63110 USA.	schwartz@kids.wustl.edu	Floyd, Elizabeth/N-1962-2017; Ciechanover, Aaron J/C-9166-2017; Floyd, Elizabeth/W-2758-2019	Floyd, Elizabeth/0000-0002-3002-6186; Floyd, Elizabeth/0000-0002-3002-6186				Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; GRENFELL SJ, 1994, BIOCHEM J, V300, P701, DOI 10.1042/bj3000701; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Raymond F, 2000, J CELL SCI, V113, P1687; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; Tansey WP, 1999, MOL MED, V5, P773, DOI 10.1007/BF03401990; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TRAUSCH JS, 1993, AM J PHYSIOL, V264, pC93, DOI 10.1152/ajpcell.1993.264.1.C93; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465	63	61	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22468	22475		10.1074/jbc.M009388200	http://dx.doi.org/10.1074/jbc.M009388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309375	hybrid			2022-12-25	WOS:000169412700067
J	Glazner, GW; Camandola, S; Geiger, JD; Mattson, MP				Glazner, GW; Camandola, S; Geiger, JD; Mattson, MP			Endoplasmic reticulum D-myo-inositol 1,4,5-trisphosphate-sensitive stores regulate nuclear factor-kappa B binding activity in a calcium-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; BACKPROPAGATING ACTION-POTENTIALS; HIPPOCAMPAL SYNAPTIC PLASTICITY; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; INTRACELLULAR CALCIUM; PHOSPHATE FORMATION; CEREBRAL-ISCHEMIA	The transcription factor nuclear factor-kappaB (NF-kappaB) plays critical roles in neuronal survival and plasticity and in activation of immune responses. The activation of NF-kappaB has been closely associated with changes in intracellular calcium levels, but the relationship be tween the two remains unclear. Here we report that inhibition of endoplasmic reticulum (ER) D-myo-inositol 1,4,5-trisphosphate (IP3)-gated calcium release caused decreased basal NF-kappaB DNA-binding activity in cultured rat cortical neurons. Activation of NF-kappaB in response to tumor necrosis factor-alpha and glutamate was completely abolished when IP3 receptors were blocked, and NF-kappaB activation in response to depletion of ER calcium by thapsigargin treatment was also decreased by IP3 receptor blockade, We further investigated the relationship between IP3 receptor activation and NF-kappaB activity using a cell-free system. Microsomes enriched in the ER were isolated from adult rat cerebral cortex, resuspended, and treated with agents that induce or inhibit ER calcium release, They were then recentrifuged, and the supernatant was added to cytoplasmic extract isolated from the same source tissue. We found that microsomes released an NF-kappaB stimulating signal in response to activation of IP3 receptors or inhibition of the ER Ca2+-ATPase, but not in response to ryanodine. Studies of intact cells and cell-free preparations indicated that the signal released from the ER was not calcium and was heat- and trypsin sensitive. Our data suggest that activation of IP3 receptors is required for a major component of both constitutive and inducible NF-kappaB binding activity in neurons and that decreasing ER intraluminal calcium levels triggers release of a diffusible NF-kappaB-activating signal from the ER.	NIA, Neurosci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Univ Manitoba, Fac Med, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Manitoba; Johns Hopkins University	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, NIH, GRC 4F02,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Mattson, Mark P/F-6038-2012		NINDS NIH HHS [NS39184] Funding Source: Medline; NINR NIH HHS [NRSA467305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000313, Z01AG000313, Z01AG000312, ZIAAG000314, Z01AG000314, ZIAAG000312] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Albensi BC, 2000, SYNAPSE, V35, P151; AMRANI Y, 1995, BRIT J PHARMACOL, V114, P4, DOI 10.1111/j.1476-5381.1995.tb14896.x; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barger SW, 1996, MOL BRAIN RES, V40, P116; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BOUCHELOUCHE PN, 1990, CELL SIGNAL, V2, P479; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DELRIO E, 1994, J NEUROCHEM, V63, P535; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Glazner GW, 2000, J NEUROSCI, V20, P3641, DOI 10.1523/JNEUROSCI.20-10-03641.2000; Glazner GW, 2000, J NEUROCHEM, V75, P101, DOI 10.1046/j.1471-4159.2000.0750101.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Guerrini L, 1997, J NEUROSCI, V17, P6057; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Harris KM, 1999, P NATL ACAD SCI USA, V96, P12213, DOI 10.1073/pnas.96.22.12213; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Huang EP, 1998, ESSAYS BIOCHEM, V33, P165, DOI 10.1042/bse0330165; HUGHES AR, 1990, ENVIRON HEALTH PERSP, V84, P141, DOI 10.2307/3430715; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Kanno T, 1996, J IMMUNOL, V157, P5277; Kato BM, 1999, J NEUROPHYSIOL, V81, P1587, DOI 10.1152/jn.1999.81.4.1587; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Lazaar AL, 1998, J IMMUNOL, V161, P3120; Liu HN, 1997, EUR J PHARMACOL, V338, P277, DOI 10.1016/S0014-2999(97)81931-0; Liu JSH, 2000, J NEUROSCI, V20, P5292, DOI 10.1523/JNEUROSCI.20-14-05292.2000; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MAY W, 1998, BRAIN RES, V797, P243; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; Nakamura T, 2000, J NEUROSCI, V20, P8365, DOI 10.1523/JNEUROSCI.20-22-08365.2000; Nakamura T, 1999, NEURON, V24, P727, DOI 10.1016/S0896-6273(00)81125-3; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; Quinlan KL, 1999, J IMMUNOL, V163, P5656; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; RECASENS M, 1995, ANN NY ACAD SCI, V757, P418, DOI 10.1111/j.1749-6632.1995.tb17501.x; Reyes M, 1996, J NEUROSCI, V16, P5951; Rong YQ, 1996, J NEUROCHEM, V67, P662; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SEI Y, 1995, IMMUNOL LETT, V45, P75, DOI 10.1016/0165-2478(94)00250-U; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; Shatrov VA, 1997, BIOCHEM BIOPH RES CO, V234, P121, DOI 10.1006/bbrc.1997.6598; STEVENS CF, 1994, NEURON, V13, P769, DOI 10.1016/0896-6273(94)90244-5; SWINGLER S, 1992, AIDS RES HUM RETROV, V8, P487, DOI 10.1089/aid.1992.8.487; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; Yao CJ, 1999, J NEUROCHEM, V73, P457, DOI 10.1046/j.1471-4159.1999.0730457.x; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	82	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22461	22467		10.1074/jbc.M101315200	http://dx.doi.org/10.1074/jbc.M101315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309390	hybrid			2022-12-25	WOS:000169412700066
J	Belsches-Jablonski, AP; Biscardi, JS; Peavy, DR; Tice, DA; Romney, DA; Parsons, SJ				Belsches-Jablonski, AP; Biscardi, JS; Peavy, DR; Tice, DA; Romney, DA; Parsons, SJ			Src family kinases and HER2 interactions in human breast cancer cell growth and survival	ONCOGENE			English	Article						Src family kinases; heregulin; breast cancer; HER2/neu; cell growth; apoptosis	PROTEIN-TYROSINE KINASES; ERBB SIGNALING NETWORK; FACTOR RECEPTOR; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIATION FACTOR; NEU PROTOONCOGENE; EPITHELIAL-CELLS; OVARIAN-CANCER; A431 CELLS	Evidence from murine fibroblast models and human breast cancer cells indicates that c-Src and human EGF receptor (HER1) synergize to enhance neoplastic growth of mammary epithelial cells, To investigate whether interactions between c-Src and other HER members may also play a role in breast tumor progression, we characterized 13 human breast carcinoma cell lines and 13 tumor samples for expression of HER family members and c-Src and examined a subset of the cell lines for Src-dependent, heregulin (HRG)-augmented, anchorage-dependent and independent growth. By immunoblotting, we found that all cell lines overexpressed one or more HER family member, and 60% overexpressed c-Src, Seventy-five per cent of the tumor tissues overexpressed HER2, while 64% overexpressed c-Src, Colony formation in soft agar was enhanced by HRG in three of five cell lines tested, a response that correlated,vith the presence of a c-Src/HER2 heterocomplex, This result suggests that HRG may act through both HER2 and c-Src to facilitate anchorage-independent growth. In contrast, HRG had little effect on anchorage-dependent growth in any of the cell lines tested. PP1, a Src family kinase inhibitor, reduced or ablated HRG-dependent and independent soft agar growth or anchorage dependent growth, and triggered apoptosis in all cell lines tested. The apoptotic effect of PP1 could be partially or completely reversed by HRG, depending on the cell line. These results suggest that while Src family kinases may cooperate with HRG to promote the survival and growth of human breast tumor cells, they also function independently of HER2/HRG in these processes.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Lynchburg Coll, Biol Program, Lynchburg, VA 24501 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NCI NIH HHS [CA71449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; BERCHUCK A, 1990, CANCER RES, V50, P4087; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KAMEDA T, 1990, CANCER RES, V50, P8002; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPERS GJL, 1991, BRIT J CANCER, V64, P469, DOI 10.1038/bjc.1991.333; KERN JA, 1990, CANCER RES, V50, P5184; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; LINSLEY PS, 1980, J SUPRAMOL STR CELL, V14, P441, DOI 10.1002/jss.400140404; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MAGUIRE HC, 1992, PATHOBIOLOGY, V60, P117; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PIERCE JH, 1991, ONCOGENE, V6, P1189; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SAINSBURY JRC, 1987, LANCET, V1, P1398; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VILLANUEVA A, 1984, HISTOCHEMISTRY, V81, P103, DOI 10.1007/BF00495409; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	63	153	157	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1465	1475		10.1038/sj.onc.1204205	http://dx.doi.org/10.1038/sj.onc.1204205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313890				2022-12-25	WOS:000167595200007
J	Suen, TC; Goss, PE				Suen, TC; Goss, PE			Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene	ONCOGENE			English	Article						BRCA1; breast cancer; transcriptional regulation; intron; repressor	SPORADIC BREAST-CANCER; RNA-POLYMERASE-II; OVARIAN-CANCER; CELL-CYCLE; MESSENGER-RNA; NUCLEAR PHOSPHOPROTEIN; GROWTH-RETARDATION; SOMATIC MUTATIONS; EPITHELIAL-CELLS; PROMOTER REGION	Loss or lowered expression of BRCA1 in non-familial breast cancer has been shown in several recent studies. Understanding how BRCA1 expression is regulated should provide new insights into the role of BRCA1 in sporadic breast cancer. We have recently identified a critical 18-base pair (bp) DNA element within the minimal BRCA1 promoter whereupon the formation of a specific protein-DNA complex and transcription of BRCA1 is dependent. We now report a non tissue-specific transcriptional repressor activity, located more than 500 bp into the first intron of BRCA1. Progressive deletions from the 3'-end of intron I and reporter gene assays localized the repressor activity to an 83-bp region. Electrophoretic mobility shift assays with this 83 bp DNA and various sub-fragments of it showed binding of nuclear proteins to a 36 bp BstNI-BseRI fragment. Functional transcriptional repression by this 36 bp DNA could be conferred on a heterologous thymidine kinase promoter. Analysis of multiple reporter gene constructs containing the BRCA1 genomic region driving transcription in both directions suggests that the putative negative regulatory element functions to block transcription only in the BRCA1 direction, although the promoter is shared by the divergently transcribed NBR2 gene.	Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Goss, PE (corresponding author), Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Toronto, ON M5G 2M9, Canada.							Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YM, 1996, CANCER RES, V56, P3168; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobrovic A, 1997, CANCER RES, V57, P3347; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Husain A, 1998, CANCER RES, V58, P1120; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rao VN, 1996, ONCOGENE, V12, P523; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Suen TC, 2000, J BIOL CHEM, V275, P6600, DOI 10.1074/jbc.275.9.6600; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; van der Looij M, 2000, GENE CHROMOSOME CANC, V27, P295, DOI 10.1002/(SICI)1098-2264(200003)27:3<295::AID-GCC10>3.0.CO;2-F; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	64	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					440	450		10.1038/sj.onc.1204078	http://dx.doi.org/10.1038/sj.onc.1204078			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313975				2022-12-25	WOS:000166562500004
J	Tsuiki, H; Nitta, M; Tada, M; Inagaki, M; Ushio, Y; Saya, H				Tsuiki, H; Nitta, M; Tada, M; Inagaki, M; Ushio, Y; Saya, H			Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines	ONCOGENE			English	Article						hyperploidy; spindle assembly checkpoint; glioma; microtubule inhibitor; staurosporine	PROTEIN-KINASE; SPINDLE DISRUPTION; CYCLE CHECKPOINT; MAMMALIAN-CELLS; MITOTIC EXIT; P53; STAUROSPORINE; MITOSIS; PROGRESSION; ARREST	Checkpoint mechanism plays a crucial role in ensuring genomic integrity during cell cycle. Loss of checkpoint function is known to induce genomic instability and to alter ploidy of dividing cells. In this study, we examined mechanisms of hyperploid formation in glioma cells by treatment with nocodazole, which activates spindle assembly checkpoint by inhibiting microtubule polymerization. By prolonged nocodazole treatment, U251MG human glioma cell, which has a p53 mutation, underwent transient arrest at mitosis, and subsequently exited from mitotic arrest (termed 'mitotic slippage') followed by DNA replication without cytokinesis, resulting in hyperploid formation. Additionally, the heterogeneity in the number of centrosomes per cell increased during the hyperploid formation, suggesting that these hyperploid cells have genomic instability. By employing LN382 glioma cell that has a temperature-sensitive p53 mutation, Ne found that the activation of p53 prevents hyperploid formation after the prolonged nocodazole treatment. Furthermore, staurosporine, an inhibitor for a broad range of serine/threonine kinases including cdc2, was found to enhance hyperploid formation in U251MG cells by accelerating the induction of mitotic slippage. Interestingly, inhibitors specific for cdc2 kinase prevented the G2 to M transition but did not accelerate mitotic slippage, suggesting that staurosporine-sensitive kinases other than cdc2 are required for maintenance of spindle assembly checkpoint. Moreover, the enhancement of hyperploid formation by staurosporine was also blocked by p53-dependent G1 checkpoint. These results suggest that abrogation of G1 checkpoint is a critical factor for formation of hyperploid cells after the mitotic slippage.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8600811, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Nagoya, Aichi 4640021, Japan	Kumamoto University; Kumamoto University; Hokkaido University; Aichi Cancer Center	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Hongo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013; Inagaki, Masaki/B-9920-2016					ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BRUNO S, 1992, CANCER RES, V52, P470; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Hall LL, 1996, CANCER RES, V56, P3551; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Khan SH, 1998, CANCER RES, V58, P396; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; RIEDER CL, 1992, J CELL SCI, V102, P387; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tsuiki H, 2000, J CELL BIOCHEM, V76, P254, DOI 10.1002/(SICI)1097-4644(20000201)76:2<254::AID-JCB9>3.0.CO;2-G; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; Verdoodt B, 1999, MUTAGENESIS, V14, P513, DOI 10.1093/mutage/14.5.513; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	31	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					420	429		10.1038/sj.onc.1204126	http://dx.doi.org/10.1038/sj.onc.1204126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313973				2022-12-25	WOS:000166562500002
J	Persad, S; Attwell, S; Gray, V; Mawji, N; Deng, JT; Leung, D; Yan, J; Sanghera, J; Walsh, MP; Dedhar, S				Persad, S; Attwell, S; Gray, V; Mawji, N; Deng, JT; Leung, D; Yan, J; Sanghera, J; Walsh, MP; Dedhar, S			Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase - Critical roles for kinase activity and amino acids arginine 211 and serine 343	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PHOSPHOINOSITIDE-3-OH KINASE; EXTRACELLULAR-MATRIX; ILK; ACTIVATION; APOPTOSIS; ADHESION; PDK1; PATHWAYS; DOMAIN	Protein kinase B (PKB/Akt) is a regulator of cell survival and apoptosis. To become fully activated, PKB/Akt requires phosphorylation at two sites, threonine 308 and serine 473, in a phoshpatidylinositol (PI) 3-kinase-dependent manner. The kinase responsible for phosphorylation of threonine 308 is the PI 3-kinase-dependent kinase-1 (PDK-1), whereas phosphorylation of serine 473 has been suggested to be regulated by PKB/Akt autophosphorylation in a PDK-1-dependent manner. However, the integrin-linked kinase (ILK) has also been shown to regulate phosphorylation of serine 473 in a PI 3-kinase-dependent manner. Whether ILK phosphorylates this site directly or functions as an adapter molecule has been debated. We now show by in-gel kinase assay and matrix-assisted laser desorption-ionization time-of-flight mass spectrometry that biochemically purified ILK can phosphorylate PKB/Akt directly. Co-immunoprecipitation analysis of cell extracts demonstrates that ILK can complex with PKB/Akt as well as PDK-1 and that ILK can disrupt PDK-1/PKB association. The amino acid residue serine 343 of ILK within the activation loop is required for kinase activity as well as for its interaction with PKB/Akt. Mutational analysis of ILK further shows a crucial role for arginine 211 of ILK within the phosphoinositide phospholipid binding domain in the regulation of PKB- serine 473 phosphorylation. A highly selective small molecule inhibitor of ILK activity also inhibits the ability of ILK to phosphorylate PKB/Akt in vitro and in intact cells. These data demonstrate that ILK is an important upstream kinase for the regulation of PKB/Akt.	Vancouver Hosp, British Columbia Canc Agcy, Hlth Sci Ctr, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ Calgary, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Canadian Inst Hlth, Res Grp Regulat Vasc Contractil, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6P2, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Calgary; University of British Columbia	Dedhar, S (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.			Dedhar, Shoukat/0000-0003-4355-1657				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; KHAWJA A, 1997, EMBO J, V16, P2783; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	33	406	432	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27462	27469		10.1074/jbc.M102940200	http://dx.doi.org/10.1074/jbc.M102940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313365	hybrid			2022-12-25	WOS:000169966900097
J	Shen, YL; Musti, K; Hiramoto, M; Kikuchi, H; Kawarabayashi, Y; Matsui, I				Shen, YL; Musti, K; Hiramoto, M; Kikuchi, H; Kawarabayashi, Y; Matsui, I			Invariant Asp-1122 and Asp-1124 are essential residues for polymerization catalysis of family D DNA polymerase from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON; REPLICATION; COMPILATION; ALIGNMENT; FURIOSUS; ENZYMES; ALPHA	Family D DNA polymerase has recently been found in the Euryarchaeota subdomain of Archaea. Its genes are adjacent to several other genes related to DNA replication, repair, and recombination in the genome, suggesting that this enzyme may be the major DNA replicase in Euryarchaeota. Although it, possesses strong polymerization and proofreading activities, the motifs common to other DNA polymerase families are absent in its sequences. Here we report the mapping of the catalytic residues in a family D DNA polymerase from Pyrococcus horikoshii. Site-directed alanine mutants for 28 conserved aspartic acid or glutamic acid residues mere screened for polymerization and 3'-5' exonuclease activities. We identified the invariant aspartates Asp-1122 and Asp-1124 within the most conserved motif as the catalytic residues involved in DNA polymerization. Alanine mutation at either site caused a loss of polymerization activity, whereas the conserved mutants, D1122E, D1124N, and D1124E, had slightly reduced polymerization activity. We also found that the 3'-5' exonuclease activity remains in D1122A and D1124A, indicating that the catalytic residues of DNA polymerization are different from those of the 3'-5' exonuclease activity. Furthermore me determined the molecular mass of the recombinant enzyme by gel filtration and proposed a heterotetrameric structure for this enzyme.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Minist Int Trade & Ind, Natl Inst Technol & Evaluat, Shibuya Ku, Tokyo 150, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan.							Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Gangurde R, 2000, J BIOL CHEM, V275, P19685, DOI 10.1074/jbc.M002307200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Imamura M, 1995, BIOL PHARM BULL, V18, P1647; Ishino Y, 1998, J BACTERIOL, V180, P2232, DOI 10.1128/JB.180.8.2232-2236.1998; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	20	44	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27376	27383		10.1074/jbc.M011762200	http://dx.doi.org/10.1074/jbc.M011762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11319225	hybrid			2022-12-25	WOS:000169966900086
J	Sotomaru, Y; Kawase, Y; Ueda, T; Obata, Y; Suzuki, H; Domeki, I; Hatada, I; Kono, T				Sotomaru, Y; Kawase, Y; Ueda, T; Obata, Y; Suzuki, H; Domeki, I; Hatada, I; Kono, T			Disruption of imprinted expression of U2afbp-rs/U2af1-rs1 gene in mouse parthenogenetic fetuses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLELE-SPECIFIC METHYLATION; CHROMATIN STRUCTURE; SCANNING METHOD; H19 GENE; CHROMOSOME-11; PROTEIN; EMBRYOS; IDENTIFICATION; EMBRYOGENESIS; OSCILLATIONS	The present study shows that the U2afbp-rs gene, a paternally expressed imprinted gene, is activated and expressed in a biallelic manner from maternal alleles in parthenogenetic mouse fetuses on day 9.5 of gestation. The mean expression was detected to be 88% (31-134%) of that in control biparental fetuses, using real-time quantitative reverse transcription and polymerase chain reaction. This disrupted expression of the gene was associated with changes in the chromatin structure but not with the methylation pattern in the regulation region. The present results show that parental specific expression of imprinted genes is not always maintained in uniparental embryos. This suggests that both parental genomes are necessary to establish parental specific expression of the U2afbp-rs gene.	Tokyo Univ Agr, Dept Biosci, Setagaya Ku, Tokyo 1568502, Japan; Tokyo Univ Agr, Dept Anim Sci, Kanagawa 2430034, Japan; Niigata Univ, Mol Genet Res Lab, Niigata 9518510, Japan; Chugai Pharmaceut Co Ltd, Pharmaceut Technol Lab, Shizuoka 4128513, Japan; Gunma Univ, Ctr Gene Res, Maebashi, Gumma 3718511, Japan	Tokyo University of Agriculture; Tokyo University of Agriculture; Niigata University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Gunma University	Kono, T (corresponding author), Tokyo Univ Agr, Dept Biosci, Setagaya Ku, 1-1-1,Sakauragaoka, Tokyo 1568502, Japan.	tomohiro@nodai.ac.jp						BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; BosMikich A, 1997, DEV BIOL, V182, P172, DOI 10.1006/dbio.1996.8468; BOSMIKICH A, 1995, MOL REPROD DEV, V41, P84, DOI 10.1002/mrd.1080410113; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FERI R, 1997, J BIOL CHEM, V271, P14390; HATADA I, 1993, NUCLEIC ACIDS RES, V21, P5577, DOI 10.1093/nar/21.24.5577; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kono T, 1996, J CELL BIOL, V132, P915, DOI 10.1083/jcb.132.5.915; KONO T, 1993, MOL REPROD DEV, V34, P43, DOI 10.1002/mrd.1080340107; Kono T, 1996, NAT GENET, V13, P91, DOI 10.1038/ng0596-91; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MOORE T, 1995, REV REPROD, V2, P73; Obata Y, 1998, DEVELOPMENT, V125, P1553; Sasaki H, 1995, DEVELOPMENT, V121, P4195; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Shibata H, 1996, GENOMICS, V35, P248, DOI 10.1006/geno.1996.0348; Shibata H, 1997, GENOMICS, V44, P171, DOI 10.1006/geno.1997.4877; Sotomaru Yusuke, 2001, Journal of Reproduction and Development, V47, P139, DOI 10.1262/jrd.47.139; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SURANI MA, 1990, DEVELOPMENT, P89; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WALSH C, 1994, MECH DEVELOP, V46, P55, DOI 10.1016/0925-4773(94)90037-X; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WU C, 1979, CELL, V16, P797, DOI 10.1016/0092-8674(79)90095-3	39	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26694	26698		10.1074/jbc.M101367200	http://dx.doi.org/10.1074/jbc.M101367200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11306578	hybrid			2022-12-25	WOS:000169823300136
J	Tedford, HW; Fletcher, JI; King, GF				Tedford, HW; Fletcher, JI; King, GF			Functional significance of the beta-hairpin in the insecticidal neurotoxin omega-atracotoxin-Hv1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; IMPROVED BACULOVIRUS INSECTICIDE; ESCHERICHIA-COLI CYTOPLASM; PROGRAM; RESISTANCE; CONOTOXINS; EXPRESSION; MUTATIONS; PATHWAYS; PROTEINS	omega -Atracotoxin-Hv1a is an insect-specific neurotoxin whose phylogenetic specificity derives from its ability to antagonize insect, but not vertebrate, voltage-gated calcium channels. In order to help understand its mechanism of action and to enhance its utility as a lead compound for insecticide development, we used a combination of protein engineering and site-directed mutagenesis to probe the toxin for key functional regions. First, we constructed a Hairpinless mutant in which the C-terminal beta -hairpin, which is highly conserved in this family of neurotoxins, was excised without affecting the fold of the residual disulfide-rich core of the toxin. The Hairpinless mutant was devoid of insecticidal activity, indicating the functional importance of the hairpin. We subsequently developed a highly efficient system for production of recombinant toxin and then probed the hairpin for key functional residues using alanine-scanning mutagenesis followed by a second round of mutagenesis based on initial "hits" from the alanine scan. This revealed that two spatially proximal residues, Asn(27) and Arg(35), form a contiguous molecular surface that is essential for toxin activity. We propose that this surface of the beta -hairpin is a key site for interaction of the toxin with insect calcium channels.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Melbourne, Sch Biochem & Mol Biol, Melbourne, Vic 3010, Australia	University of Connecticut; University of Melbourne	King, GF (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, MC3305,263 Farmington Ave, Farmington, CT 06032 USA.		Fletcher, Jamie/V-4667-2019; King, Glenn F/J-5059-2012	King, Glenn F/0000-0002-2308-2200; Fletcher, Jamie/0000-0003-2949-9469				ATKINSON RK, 1993, Patent No. 9300039; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Billeter M, 1995, J BIOMOL NMR, V5, P1; Bonning BC, 1996, ANNU REV ENTOMOL, V41, P191, DOI 10.1146/annurev.en.41.010196.001203; BRUNGER AT, 1992, XPLOR VERSION 3 1; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; CORY JS, 1994, NATURE, V370, P138, DOI 10.1038/370138a0; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; Feyereisen R, 1995, TOXICOL LETT, V82-3, P83, DOI 10.1016/0378-4274(95)03470-6; ffrench-Constant RH, 1998, PHILOS T R SOC B, V353, P1685, DOI 10.1098/rstb.1998.0319; Fletcher JI, 1997, NAT STRUCT BIOL, V4, P559, DOI 10.1038/nsb0797-559; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Miller MK, 2000, TOXICON, V38, P409, DOI 10.1016/S0041-0101(99)00171-3; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; OERKE EC, 1994, CROP PRODUCTION CROP, P72; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; RILEY LG, 1994, EUR J BIOCHEM, V219, P877, DOI 10.1111/j.1432-1033.1994.tb18569.x; Shelton AM, 2000, NAT BIOTECHNOL, V18, P339, DOI 10.1038/73804; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STEWART LMD, 1991, NATURE, V352, P85, DOI 10.1038/352085a0; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TREACY MF, 1999, BIOPESTICIDES USES D, P321; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wang XH, 1999, EUR J BIOCHEM, V264, P488, DOI 10.1046/j.1432-1327.1999.00646.x; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2; Wuthrich K., 1986, NMR PROTEIN NUCL ACI; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	41	61	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26568	26576		10.1074/jbc.M102199200	http://dx.doi.org/10.1074/jbc.M102199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313356	hybrid			2022-12-25	WOS:000169823300121
J	Yoo, JY; Wang, WL; Desiderio, S; Nathans, D				Yoo, JY; Wang, WL; Desiderio, S; Nathans, D			Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha(2)-macroglobulin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-2-MACROGLOBULIN GENE; INTERLEUKIN-6 RESPONSIVE ELEMENT; INTERFERON-BETA ENHANCEOSOME; SIGNAL-TRANSDUCTION PATHWAY; EPIDERMAL GROWTH-FACTOR; ACUTE-PHASE RESPONSE; TRANSCRIPTIONAL ACTIVATION; REACTIVE PROTEIN; TYROSINE PHOSPHORYLATION; RECEPTOR	The transcriptional activity of natural promoters is sensitive to the precise spatial arrangement of DNA elements and their incorporation into higher order DNA-protein complexes. STAT3 and c-Jun form a specific ternary complex in vitro with a synthetic DNA element containing AP1 and SIE sites. These associations are critical for synergistic activation of transcription from a synthetic promoter by STAT3 and c-Jun. Expression of the acute phase protein alpha (2)-macroglobulin is induced in vivo by interleukin-6 (IL-6)-related cytokines; we demonstrate that coordinate interactions among STAT3, c-Jun, and a specific array of DNA elements contribute to activation of the alpha (2)-macroglobulin promoter in response to IL-6 family members. At least five promoter elements are involved in activation: two AP1 sites at -113 to -107 and -152 to -140, an acute phase response element (APRE (SIE)) at -171 to -163, and two AT-rich regions at -143 to -138 and -128 to -123. Synergism between STAT3 or STAT3-C and c-Jun is impaired by mutation of the APRE (SIE) or either AP1 site, as well as by mutations that alter the AT-rich regions or their phasing. Mutations of STAT3 previously shown to disrupt physical and functional interactions with c-Jun do not impair synergy between STAT3-C and c-Jun at the alpha2-macroglobulin promoter in HepG2 cells, suggesting that STAT3-C and STAT3 differ with respect to their precise contacts with c-Jun.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Desiderio, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CARRERA P, 1994, NUCLEIC ACIDS RES, V22, P3671, DOI 10.1093/nar/22.18.3671; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; Kasutani K, 1998, TOXICOL APPL PHARM, V151, P143, DOI 10.1006/taap.1998.8452; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Kophengnavong T, 1999, MOL CELL BIOL, V19, P3039; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; TSUCHIYA Y, 1987, GENE, V57, P73; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG DX, 1995, BIOCHEM J, V310, P143, DOI 10.1042/bj3100143; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26421	26429		10.1074/jbc.M009935200	http://dx.doi.org/10.1074/jbc.M009935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319221	hybrid			2022-12-25	WOS:000169823300103
J	Ii, M; Mihara, K				Ii, M; Mihara, K			Insertion of mitochondrial DNA-encoded F1F0-ATPase subunit 8 across the mitochondrial inner membrane in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PF3 COAT PROTEIN; SACCHAROMYCES-CEREVISIAE; THYLAKOID MEMBRANE; ESCHERICHIA-COLI; PLASMA-MEMBRANE; ATP SYNTHASE; MESSENGER-RNAS; NUCLEAR GENE; M13 PROCOAT; C-TERMINI	Cytochrome oxidase subunits I, II, and III, the mitochondrial DNA-encoded proteins, are inserted across the inner membrane by the Oxa1p-containing translocator in a membrane potential-dependent manner. Oxa1p is also involved in the insertion of the cytoplasmically synthesized precursor of Oxa1p itself into the inner membrane from the matrix via the conservative sorting pathway. The mechanism of insertion of the other mitochondrially synthesized proteins, however, is unexplored, The insertion of the mitochondrial DNA-encoded subunit 8 of F1F0-ATPase (Su8) across the inner membrane was analyzed in vitro using the inverted inner membrane vesicles and the Escherichia coli lysate-synthesized substrate. This assay revealed that the N-terminal segment of Su8 inserted across the membrane to the intermembrane space and assumed the correct trans-cia topology depending on the mitochondrial matrix fraction. This translocation reaction was similar to those of Sec-independent, direct insertion pathways of E, coli and chloroplast thylakoid membranes. (i) It required neither nucleotide triphosphates nor membrane potential, and hydrophobic forces drove the process. (ii) It did not require protease-sensitive membrane components facing the matrix space. (iii) It could be inserted across liposomes in the correct topology in a matrix fraction-dependent manner. Thus, a novel mechanism conserved in bacteria and chloroplasts also functions in the insertion of Su8 across the mitochondrial inner membrane.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan	Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan.	mihara@cell.med.kyushu-u.ac.jp						Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GELLER BL, 1985, J BIOL CHEM, V260, P3281; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; Ishihara N, 1998, J BIOCHEM-TOKYO, V123, P722; JASCUR T, 1991, METHOD CELL BIOL, V34, P359; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1987, SCIENCE, V238, P1413, DOI 10.1126/science.3317833; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; ODA T, 1989, BIOCHEM BIOPH RES CO, V165, P449, DOI 10.1016/0006-291X(89)91091-7; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WELTER C, 1989, GENE, V83, P169, DOI 10.1016/0378-1119(89)90415-0; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YAMANE K, 1987, J BIOL CHEM, V262, P2358	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24704	24712		10.1074/jbc.M102584200	http://dx.doi.org/10.1074/jbc.M102584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320097	hybrid			2022-12-25	WOS:000169800700040
J	Ishmael, FT; Alley, SC; Benkovic, SJ				Ishmael, FT; Alley, SC; Benkovic, SJ			Identification and mapping of protein-protein interactions between gp32 and gp59 by cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPLICATION FORK; BINDING-PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENE-41 PROTEIN; BACTERIOPHAGE-T4; HELICASE; PARAMETERS	The bacteriophage T4 59 protein (gp59) plays a vital role in recombination and replication by promoting the assembly of the gene 41 helicase (gp41) onto DNA, thus enabling replication as well as strand exchange in recombination, Loading of the helicase onto gp32 (the T4 single strand binding protein)-coated single-stranded DNA requires gp59 to remove gp32 and replace it with gp41. Cross-linking studies between gp32 and gp59 reveal an interaction between Cys-166 of gp32 and Cys-42 of gp59, Since Cys-166 lies in the DNA binding core domain of gp32, this interaction may affect the association of gp32 with DNA. In the presence of gp32 or DNA, gp59 is capable of forming a multimer consisting of at least five gp59 subunits, Kinetics studies suggest that gp59 and gp41 exist in a one-to-one ratio, predicting that gp59 is capable of forming a hexamer (Raney, K, D,, Carver, T, E,, and Benkovic, S. J. (1996) J. Biol. Chem. 271, 14074-14081), The C-terminal A-domain of gp32 is needed for gp59 oligomer formation. Cross-linking has established that gp59 can interact with gp32-A (a truncated form of gp32 lacking the A-domain) but cannot form higher species. The results support a model in which gp59 binds to gp32 on a replication fork, destabilizing the gp32-single-stranded DNA interaction concomitant with the oligomerization of gp59 that results in a switching of gp41 for gp32 at the replication fork.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, 414 Wart Lab, University Pk, PA 16802 USA.							Alley SC, 2000, J AM CHEM SOC, V122, P6126, DOI 10.1021/ja000591t; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kreuzer Kenneth N., 1994, P89; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1997, VIROLOGY, V230, P72, DOI 10.1006/viro.1997.8464; MOSIG G, 1994, MOL BIOL BACTERIOP T, V4, P54; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; San Martin C, 1998, STRUCTURE, V6, P501; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; Shier VK, 2001, J BIOL CHEM, V276, P14744, DOI 10.1074/jbc.M010688200; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	23	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25236	25242		10.1074/jbc.M100783200	http://dx.doi.org/10.1074/jbc.M100783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309384	hybrid			2022-12-25	WOS:000169800700108
J	Ramulu, P; Nathans, J				Ramulu, P; Nathans, J			Cellular and subcellular localization, N-terminal acylation, and calcium binding of Caenorhabditis elegans protein phosphatase with EF-hands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-MODULATED PALMITOYLATION; NUCLEOTIDE-GATED CHANNEL; BETA-ADRENERGIC-RECEPTOR; FATTY-ACID ACYLATION; RETINAL-DEGENERATION; BETA-2-ADRENERGIC RECEPTOR; PHOTOEXCITED RHODOPSIN; SENSORY NEURONS; 48-KDA PROTEIN; AMINO-TERMINUS	The RdgC/PPEF family of serine/threonine protein phosphatases is distinguished by the presence of C-terminal EF-hands and neuron-specific expression, including frequent expression in primary sensory neurons. Here we report that the sole Caenorhabditis elegans PPEF (CePPEF) homolog is also highly expressed in primary sensory neurons and is not found outside the nervous system. Neurons expressing CePPEF include the ciliary chemosensory neurons AWE and AWC; and within these neurons, CePPEF is highly enriched in the sensory cilia. In transgenic C, elegans and in transfected 293 cells, CePPEF is membrane-associated, and the N terminus of CePPEF is necessary and sufficient for this membrane association. [H-3]Myristate and [H-3]palmitate labeling studies in 293 cells demonstrated that this association was mediated by myristoylation at Gly(2) and palmitoylation at Cys(3). Introducing the G2A or C3S mutation into CePPEF greatly reduced membrane association in 293 cells and in transgenic nematodes. A recombinant C-terminal fragment of CePPEF containing two putative EF-hands bound between one and two Ca2+ ions/protein, and mutation of residues presumed to ligand calcium in the two putative EF-hands led to diminished calcium binding. These results establish the first direct evidence for fatty acylation and calcium binding of a PPEF family member and demonstrate a remarkable conservation of sensory neuron expression among the members of this distinctive family of protein phosphatases.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CARON MG, 1976, J BIOL CHEM, V251, P2374; CELIO MR, 1996, GUIDEBOOK CALCIUMBIN; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, J NEUROSCI, V17, P8259; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GREENLEE DV, 1979, BIOCHEM BIOPH RES CO, V88, P380, DOI 10.1016/0006-291X(79)92059-X; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; L'Etoile ND, 2000, NEURON, V25, P575, DOI 10.1016/S0896-6273(00)81061-2; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Sherman PM, 1997, P NATL ACAD SCI USA, V94, P11639, DOI 10.1073/pnas.94.21.11639; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YANG SD, 1988, J BIOL CHEM, V263, P8856; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	63	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25127	25135		10.1074/jbc.M011712200	http://dx.doi.org/10.1074/jbc.M011712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312268	hybrid			2022-12-25	WOS:000169800700094
J	Zhang, Y; Guan, R; Jiang, J; Kopchick, JJ; Black, RA; Baumann, G; Frank, SJ				Zhang, Y; Guan, R; Jiang, J; Kopchick, JJ; Black, RA; Baumann, G; Frank, SJ			Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BINDING PROTEIN GENERATION; JAK2 TYROSINE KINASE; EXTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; GROUP INACTIVATION; DISULFIDE LINKAGE; INSULIN-RECEPTOR; IM-9 LYMPHOCYTES; HUMAN-SERUM	Growth hormone (GH) initiates its cellular action by properly dimerizing GH receptor (GHR). A substantial fraction of circulating GH is complexed with a high-affinity GH-binding protein (GHBP) that in many species can be generated by GHR proteolysis and shedding of the receptor's ligand-binding extracellular domain. We previously showed that this proteolysis 1) can be acutely promoted by the phorbol ester phorbol 12-myristate 13-acetate (PMA), 2) requires a metalloprotease activity, 3) generates both shed GHBP and a membrane-associated GHR transmembrane/cytoplasmic domain remnant, and 4) results in down-regulation of GHR abundance and GH signaling. Using cell culture model systems, we now explore the effects of GH treatment on inducible GHR proteolysis and GHBP shedding. In human IM-9 lymphocytes, which endogenously express GHRs, and in Chinese hamster ovary cells heterologously expressing wild-type or cytoplasmic domain internal deletion mutant rabbit GHRs, brief exposure to GH inhibited PIMA-induced GHR proteolysis (receptor loss and remnant accumulation) by 60-93%. PMA-induced shedding of GHBP from Chinese hamster ovary transfectants was also inhibited by 70% in the presence of GH. The capacity of GH to inhibit inducible GHR cleavage did not rely on JAK2-dependent GH signaling, as evidenced by its continued protection in JAK2-deficient gamma 2A rabbit GHR cells. The GH concentration dependence for inhibition of PMA-induced GHR proteolysis paralleled that for its promotion of receptor dimerization las monitored by formation of GHR disulfide linkage. Unlike GH, the GH antagonist, G120K, which binds to but fails to properly dimerize GHRs, alone did not protect against PMA-induced GHR proteolysis; G120K did, however, antagonize the protective effect of GH. Our data suggest that GH inhibits PMA-induced GHR proteolysis and GHBP shedding by inducing GHR dimerization and that this effect does not appear to be related to GH site 1 binding, GHR internalization, or GHR signaling. The implications of these findings with regard to GH signaling and GHR down-regulation are discussed.	Univ Alabama, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL 35294 USA; Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA; Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA; Northwestern Univ, Sch Med, Dept Med, Ctr Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Vet Adm Chicago Hlth Syst, Lakeside Div, Chicago, IL 60611 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; Ohio University; University System of Ohio; Ohio University; Northwestern University	Frank, SJ (corresponding author), Univ Alabama, Dept Med, Div Endocrinol & Metab, 1530 3rd Ave,S,BDB 861, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R29DK046395, R01DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46395] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Amit T, 1996, ENDOCRINOLOGY, V137, P3986, DOI 10.1210/en.137.9.3986; AMIT T, 1992, HORM RES, V37, P205, DOI 10.1159/000182313; Amit T, 2000, J CLIN ENDOCR METAB, V85, P927, DOI 10.1210/jc.85.3.927; Amit T, 1999, ENDOCRINOLOGY, V140, P266, DOI 10.1210/en.140.1.266; Barnard R, 1997, J ENDOCRINOL, V153, P1, DOI 10.1677/joe.0.1530001; BAUMANN G, 1994, J ENDOCRINOL, V141, P1, DOI 10.1677/joe.0.1410001; BAUMANN G, 1989, METABOLISM, V38, P683, DOI 10.1016/0026-0495(89)90108-X; BAUMANN G, 1987, J CLIN ENDOCR METAB, V64, P657, DOI 10.1210/jcem-64-4-657; BAUMANN G, 1988, ENDOCRINOLOGY, V122, P976, DOI 10.1210/endo-122-3-976; Baumann G., 1999, GROWTH HORMONE, P37; BAUMANN G, 1989, ADV GROWTH HORMONE G, P69; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; Bick T, 1996, ENDOCRINOLOGY, V137, P3977, DOI 10.1210/en.137.9.3977; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Clark RG, 1996, ENDOCRINOLOGY, V137, P4308, DOI 10.1210/en.137.10.4308; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Flyvbjerg A, 1999, DIABETES, V48, P377, DOI 10.2337/diabetes.48.2.377; Frank SJ, 1999, ADV MOL CELL ENDOCR, V3, P1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HARRISON SM, 1995, ENDOCRINOLOGY, V136, P651, DOI 10.1210/en.136.2.651; HERINGTON AC, 1986, BIOCHEM BIOPH RES CO, V139, P150, DOI 10.1016/S0006-291X(86)80092-4; Hermansson M, 1997, J CLIN ENDOCR METAB, V82, P421, DOI 10.1210/jc.82.2.421; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KNUTSON VP, 1995, J BIOL CHEM, V270, P24972, DOI 10.1074/jbc.270.42.24972; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; KRATZSCH J, 1995, EUR J ENDOCRINOL, V132, P306, DOI 10.1530/eje.0.1320306; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; LIM L, 1990, ENDOCRINOLOGY, V127, P1287, DOI 10.1210/endo-127-3-1287; MANNOR DA, 1991, J CLIN ENDOCR METAB, V73, P30, DOI 10.1210/jcem-73-1-30; MARTHA PM, 1991, J CLIN ENDOCR METAB, V73, P175, DOI 10.1210/jcem-73-1-175; MASSA G, 1993, ACTA ENDOCRINOL-COP, V129, P559, DOI 10.1530/acta.0.1290559; MCGUFFIN W L JR, 1976, Endocrinology, V98, P1401; MERCADO M, 1993, J CLIN ENDOCR METAB, V76, P1291, DOI 10.1210/jc.76.5.1291; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLIS PE, 1995, MOL CELL ENDOCRINOL, V111, P181, DOI 10.1016/0303-7207(95)03567-Q; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SAITO Y, 1995, J BIOCHEM, V118, P521, DOI 10.1093/oxfordjournals.jbchem.a124939; Singh R, 1997, J CLIN INVEST, V100, P419, DOI 10.1172/JCI119549; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	63	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24565	24573		10.1074/jbc.M101281200	http://dx.doi.org/10.1074/jbc.M101281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309389	hybrid			2022-12-25	WOS:000169800700021
J	Andersen, JP; Sorensen, TLM; Povlsen, K; Vilsen, B				Andersen, JP; Sorensen, TLM; Povlsen, K; Vilsen, B			Importance of transmembrane segment M3 of the sarcoplasmic reticulum Ca2+-ATPase for control of the gateway to the Ca2+ sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; ADENOSINE-TRIPHOSPHATASE; STALK SEGMENT; CALCIUM-PUMP; AMINO-ACIDS; ATPASE; THAPSIGARGIN; TRANSPORT; DISSOCIATION; MECHANISM	The specific functional roles of various parts of the third transmembrane segment (M3) of the sarcoplasmic reticulum Ca2+-ATPase were examined by functionally characterizing a series of mutants with multiple or single substitutions of M3 residues. Steady-state and transient kinetic measurements, assisted by computer simulation of the time and Ca2+ dependences of the phosphorylation level, were used to study the partial reaction steps of the enzyme cycle, including the binding and dissociation of Ca2+ at the high affinity cytoplasmically facing sites. The mutation Lys-Leu-Asp-Glu(255) --> Glu-ne-Glu-Ris resulted in a conspicuous increase in the rate of Ca2+ dissociation as well as a displacement of the major conformational equilibria of the phosphoenzyme and dephosphoenzyme forms. The point mutant Phe(256) --> Ala also showed an increased rate of Ca2+ dissociation, whereas a conspicuous decrease both in the rate of Ca2+ dissociation and in the rate of Ca2+ binding was found for the mutant Gly-Glu-Gln-Leu(260) --> Ile-His-Leu-Ile. These findings suggest that the NH2-terminal half of M3 is involved in control of the gateway to the Ca2+ sites. The main effect of two mutations to the COOH-terminal half of M3, Ser-Lys-Val-Ile-Ser(265) --> Thr-Gly-Val-Ala-Val and Leu-Ile-Cys-Val-Ala-Val-Trp-Leu-Ile(274) --> Phe-Leu-Gly-Val-Ser-Phe-Phe-Ile-Leu, was a block of the dephosphorylation.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk	Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300; Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FORGE V, 1993, J BIOL CHEM, V268, P10953; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1988, METHOD ENZYMOL, V157, P154; INESI G, 1994, J MEMBRANE BIOL, V141, P1; LUND S, 1988, J BIOL CHEM, V263, P1654; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1991, J BIOL CHEM, V266, P16157; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	28	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23312	23321		10.1074/jbc.M102384200	http://dx.doi.org/10.1074/jbc.M102384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319233	hybrid			2022-12-25	WOS:000169531100015
J	Gong, XS; Chung, S; Fernandez-Velasco, JG				Gong, XS; Chung, S; Fernandez-Velasco, JG			Electron transfer and stability of the cytochrome b(6)f complex in a small domain deletion mutant of cytochrome f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASTOCYANIN IN-VITRO; CHLAMYDOMONAS-REINHARDTII; BC(1) COMPLEX; CRYSTAL-STRUCTURE; REDOX REACTIONS; GREEN-ALGA; BF COMPLEX; VIVO; MITOCHONDRIA; CHLOROPLASTS	The lumen segment of cytochrome f consists of a small and a large domain. The role of the small domain in the biogenesis and stability of the cytochrome b(6)f complex and electron transfer through the cytochrome b(6)f complex was studied with a small domain deletion mutant in Chlamydomonas reinhardtii. The mutant is able to grow photoautotrophically but with a slower rate than the wild type strain. The heme group is covalently attached to the polypeptide, and the visible absorption spectrum of the mutant protein is identical to that of the native protein. The kinetics of electron transfer in the mutant were measured by flash kinetic spectroscopy, Our results show that the rate for the oxidation of cytochrome f was unchanged (t(1/2) = similar to 100 mus), but the half-time for the reduction of cytochrome fis increased (t(1/2) = 32 ms; for wild type, t(1/2) = 2.1 ms). Cytochrome b(6) reduction was slower than that of the wild type by a factor of approximately 2 (t(1/2) = 8.6 ms; for wild type, t(1/2) = 4.7 ms); the slow phase of the electrochromic band shift also displayed a slower kinetics (t(1/2) = 5.5 ms; for wild type, t(1/2) = 2.7 ms). The stability of the cytochrome b(6)f complex in the mutant was examined by following the kinetics of the degradation of the individual subunits after inhibiting protein synthesis in the chloroplast. The results indicate that the cytochrome b(6)f complex in the small domain deletion mutant is less stable than in the wild type. We conclude that the small domain is not essential for the biogenesis of cytochrome f and the cytochrome b(6f) complex. However, it does have a role in electron transfer through the cytochrome b(6)f complex and contributes to the stability of the complex.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Gong, XS (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 111 Koshland Hall, Berkeley, CA 94720 USA.	xsg20@nature.berkeley.edu		Chung, Susana/0000-0003-2729-1808	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020571] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20571] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baymann F, 1999, J BIOL CHEM, V274, P22957, DOI 10.1074/jbc.274.33.22957; Berthold D. A., 1993, Plant Molecular Biology Reporter, V11, P338, DOI 10.1007/BF02905336; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BERTSCH J, 1991, PLANT MOL BIOL, V17, P131, DOI 10.1007/BF00036814; Bron P, 1999, J MOL BIOL, V287, P117, DOI 10.1006/jmbi.1999.2604; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Chain RK, 1995, PHOTOSYNTH RES, V46, P419, DOI 10.1007/BF00032296; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; Ejdeback M, 2000, BIOCHEMISTRY-US, V39, P5022, DOI 10.1021/bi992757c; Gong XS, 2000, EUR J BIOCHEM, V267, P1732, DOI 10.1046/j.1432-1327.2000.01168.x; Gong XS, 2000, EUR J BIOCHEM, V267, P3461, DOI 10.1046/j.1432-1327.2000.01366.x; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jamshidi A, 2000, BIOPHYS J, V78, p133A; JOLIOT P, 1986, BIOCHIM BIOPHYS ACTA, V849, P211, DOI 10.1016/0005-2728(86)90027-7; Joliot P, 1998, BIOCHEMISTRY-US, V37, P10404, DOI 10.1021/bi980546m; JONES RW, 1985, PHOTOBIOCH PHOTOBIOP, V9, P119; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURAS R, 1995, BIOCHEMISTRY-US, V34, P7468, DOI 10.1021/bi00022a021; KURAS R, 1995, J BIOL CHEM, V270, P27797, DOI 10.1074/jbc.270.46.27797; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; Majeran W, 2000, PLANT CELL, V12, P137; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MATSUMOTO T, 1991, PLANT CELL PHYSIOL, V32, P863; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pearson DC, 1996, BIOPHYS J, V71, P64, DOI 10.1016/S0006-3495(96)79236-6; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SELAK MA, 1982, FEBS LETT, V150, P286, DOI 10.1016/0014-5793(82)80753-9; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Soriano GM, 1997, BIOPHYS J, V73, P3265, DOI 10.1016/S0006-3495(97)78351-6; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhou JH, 1996, J BIOL CHEM, V271, P6225, DOI 10.1074/jbc.271.11.6225	52	14	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24365	24371		10.1074/jbc.M010721200	http://dx.doi.org/10.1074/jbc.M010721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320082	hybrid			2022-12-25	WOS:000169531100150
J	Kuge, O; Yamakawa, Y; Nishijima, M				Kuge, O; Yamakawa, Y; Nishijima, M			Enhancement of transport-dependent decarboxylation of phosphatidylserine by S100B protein in permeabilized Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; MITOCHONDRIA-ASSOCIATED MEMBRANES; AMINO-ACID-SEQUENCE; BIOSYNTHETIC DEFECT; GENE-PRODUCT; CHO-K1 CELLS; ANIMAL-CELLS; SYNTHASE-I; TRANSLOCATION; MUTANT	Phosphatidylethanolamine synthesis through the phosphatidylserine (PtdSer) decarboxylation pathway requires PtdSer transport from the endoplasmic reticulum or mitochondrial-associated membrane to the mitochondrial inner membrane in mammalian cells. The transport-dependent PtdSer decarboxylation in permeabilized Chinese hamster ovary (CHO) cells was enhanced by cytosolic factors from bovine brain. A cytosolic protein factor exhibiting this enhancing activity was purified, and its amino acid sequence was partially determined. The sequence was identical to part of the amino acid sequence of an EF-hand type calcium-binding protein, S100B. A His(6)-tagged recombinant CHO S100B protein was able to remarkably enhance the transport-dependent PtdSer decarboxylation in permeabilized CHO cells. Under the standard assay conditions for PtdSer decarboxylase, the recombinant S100B protein did not stimulate PtdSer decarboxylase activity and exhibited no PtdSer decarboxylase activity. These results implicated the S100B protein in the transport of PtdSer to the mitochondrial inner membrane.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Kuge, O (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.			Kuge, Osamu/0000-0003-4962-3519				BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P811; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; KUGE O, 1986, J BIOL CHEM, V261, P5790; Kuge O, 1996, BIOCHEM J, V319, P33, DOI 10.1042/bj3190033; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KUGE O, 1991, J BIOL CHEM, V266, P6370; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHGGER H, 1987, ANAL BIOCHEM, V166, P368; Shiao YJ, 1998, BIOCHEM J, V331, P217, DOI 10.1042/bj3310217; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1991, J BIOL CHEM, V266, P12185; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	28	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23700	23706		10.1074/jbc.M101911200	http://dx.doi.org/10.1074/jbc.M101911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320095	hybrid			2022-12-25	WOS:000169531100064
J	Panda, K; Ghosh, S; Stuehr, DJ				Panda, K; Ghosh, S; Stuehr, DJ			Calmodulin activates intersubunit electron transfer in the neuronal nitric-oxide synthase dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; L-ARGININE; SUBUNIT DIMERIZATION; BINDING; HEME; DOMAIN; TETRAHYDROBIOPTERIN; REVEALS; SITE; OXYGENASE	Neuronal nitric oxide synthase (nNOS) is composed of an oxygenase domain that binds heme, (6R)-tetrahydrobiopterin, and Arg, coupled to a reductase domain that binds FAD, FMN, and NADPH. Activity requires dimeric interaction between two oxygenase domains and calmodulin binding between the reductase and oxygenase domains, which triggers electron transfer between flavin and heme groups. We constructed four different nNOS heterodimers to determine the path of calmodulin-induced electron transfer in a nNOS dimer, A predominantly monomeric mutant of rat nNOS (G671A) and its Arg binding mutant (G671A/E592A) were used as full-length subunits, along with oxygenase domain partners that either did or did not contain the E592A mutation. The E592A mutation prevented Arg binding to the oxygenase domain in which it was present. It also prevented NO synthesis when it was located in the oxygenase domain adjacent to the full-length subunit, However, it had no effect when present in the full-length subunit (i.e. the subunit containing the reductase domain). The active heterodimer (G671A/E592A full-length subunit plus wild type oxygenase domain subunit) showed remarkable similarity with wild type homodimeric nNOS in its catalytic responses to five different forms and chimeras of calmodulin, This reveals an active involvement of calmodulin in supporting transelectron transfer between flavin and heme groups on adjacent subunits in nNOS, In summary, we propose that calmodulin functions to properly align adjacent reductase and the oxygenase domains in a nNOS dimer for electron transfer between them, leading to NO synthesis by the heme.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,Immunol NB-3, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Panda, Koustubh/E-5273-2017	Panda, Koustubh/0000-0002-4783-2221; Ghosh, Sanjay/0000-0001-8624-1494	NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P7160; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	54	108	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23349	23356		10.1074/jbc.M100687200	http://dx.doi.org/10.1074/jbc.M100687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11325964	hybrid			2022-12-25	WOS:000169531100019
J	Smith, KM; Van Etten, RA				Smith, KM; Van Etten, RA			Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; BINDING DOMAIN; GENE-PRODUCT; IN-VITRO; PROTEIN; MUTATION; BCR	c-Abl is a non-receptor tyrosine kinase that is activated in human leukemias by the fusion of Bcr or Tel sequences to the Abl NH, terminus. Although Bcr and Tel have little in common, both contain oligomerization domains. To determine whether oligomerization alone is sufficient to activate c-Abl, we have generated and characterized an Abl protein that can be activated selectively with the chemical inducer of dimerization, AP1510. Mutant Abl proteins with one (c4F1) or two (c4F2) copies of the AP1510 binding motif (FKBP) transformed NIH 3T3 cells in a ligand-dependent manner with the c4F2 protein 60-fold more potent than c4F1, Both chimeric proteins exhibited ligand-dependent dimerization in vivo, suggesting that the increased transformation efficiency of the c4F2 mutant reflects more effective dimerization rather than formation of higher order oligomers. In the absence of ligand, c4F2-expresssing fibroblasts morphologically reverted and arrested in G(1) In Ba/F3 cells, the c4F2 chimera exhibited Ligand-dependent kinase activation, transformation to interleukin S-independent growth, and relocalization of the fusion protein from nucleus to cytoplasm. These results demonstrate that dimerization alone is sufficient to activate the Abl kinase and provide a method to regulate conditionally c-Abl activity that will be useful for studying the normal physiological role of c-Abl and the mechanism of transformation and leukemogenesis.	Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Smith, KM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.	vanetten@cbr.med.harvard.edu		Smith, Kristen/0000-0003-0960-0937	NATIONAL CANCER INSTITUTE [R01CA072465] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623] Funding Source: NIH RePORTER; NCI NIH HHS [CA72465] Funding Source: Medline; NHLBI NIH HHS [T32-HL07623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; BRASHER BB, 2001, IN PRESS ONCOGENE; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gong JG, 1999, NATURE, V399, P806; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LI WJ, 1988, ONCOGENE, V2, P559; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Okuda K, 1997, J CLIN INVEST, V100, P1708, DOI 10.1172/JCI119695; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VANETTEN RA, 1995, ONCOGENE, V10, P1977; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	53	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24372	24379		10.1074/jbc.M100786200	http://dx.doi.org/10.1074/jbc.M100786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320088	Green Published, hybrid			2022-12-25	WOS:000169531100151
J	Friedrich, U; Nicolaes, GAF; Villoutreix, BO; Dahlback, B				Friedrich, U; Nicolaes, GAF; Villoutreix, BO; Dahlback, B			Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND CLEAVAGES; BLOOD-COAGULATION; FACTOR VA(R506Q); FACTOR XA; INACTIVATION; INHIBITION; THROMBIN; COMPLEX; SITES; LOOP	Proteolytic inactivation of activated factor V (FVa) by activated protein C (APC) is a key reaction in the regulation of hemostasis. We now demonstrate the importance of a positive cluster in loop 37 of the serine protease (SP) domain of APC for the degradation of FVa. Lysine residues in APC at positions 37, 38, and 39 form a secondary binding site for FVa, which is important for cleavage of FVa at Arg-506 while having no effect on Arg-306 cleavage, In contrast, topological neighbors Lys-62, Lys-63, and Arg-74 in APC appear of minor importance in FVa degradation. This demonstrates that secondary binding exosites of APC specifically guide the proteolytic action of APC, resulting in a more favorable degradation of the 506-507 peptide bond as compared with the 306-307 bond.	Univ Lund, Wallenberg Lab, MAS, Dept Clin Chem, SE-20502 Malmo, Sweden; Univ Paris 05, INSERM, U428, F-75006 Paris, France	Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Univ Lund, Wallenberg Lab, MAS, Dept Clin Chem, SE-20502 Malmo, Sweden.		Villoutreix, Bruno/I-4565-2015; Nicolaes, Gerry A.F./A-8421-2016	Villoutreix, Bruno/0000-0002-6456-7730; Nicolaes, Gerry A.F./0000-0002-2482-0412; Dahlback, Bjorn/0000-0003-1546-0328				Cleland W W, 1979, Methods Enzymol, V63, P103; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; Esmon CT, 1997, THROMB HAEMOSTASIS, V78, P70; FRIEDRICH U, 2001, IN PRESS J BIOL CHEM; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gale AJ, 2000, BLOOD, V96, P585; Gerlitz B, 1996, J BIOL CHEM, V271, P22285, DOI 10.1074/jbc.271.37.22285; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MESTERS RM, 1993, PROTEIN SCI, V2, P1482, DOI 10.1002/pro.5560020912; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Shen L, 1999, THROMB HAEMOSTASIS, V82, P72, DOI 10.1055/s-0037-1614632; Shen L, 2000, BIOCHEMISTRY-US, V39, P2853, DOI 10.1021/bi992357p; Shen L, 1999, THROMB HAEMOSTASIS, V82, P1078, DOI 10.1055/s-0037-1614332; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607; Villoutreix BO, 2001, J COMPUT AID MOL DES, V15, P13, DOI 10.1023/A:1011158717139; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	24	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23105	23108		10.1074/jbc.M103138200	http://dx.doi.org/10.1074/jbc.M103138200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309403	hybrid			2022-12-25	WOS:000169412700149
J	Matsuoka, T; Zhao, L; Stein, R				Matsuoka, T; Zhao, L; Stein, R			The DNA binding activity of the RIPE3b1 transcription factor of insulin appears to be influenced by tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; TYPE-2 DIABETES-MELLITUS; GENE-TRANSCRIPTION; PROTEIN PHOSPHATASE; HOMEODOMAIN PROTEIN; ACID-PHOSPHATASE; PHOSPHOTYROSYL-PROTEIN; ALKALINE-PHOSPHATASE; ISLET DEVELOPMENT; GROWTH-HORMONE	The RIPE3b1 DNA binding factor plays a critical role in pancreatic islet beta cell-specific and glucose-regulated transcription of the insulin gene, Recently it was shown that RIPE3b1 binding activity in beta cell nuclear extracts is reduced by treatment with either calf intestinal alkaline phosphatase (CIAP) or a brain-enriched phosphatase preparation (BPP) (Zhao, L., Cissell, M. A., Henderson, E., Colbran, R., and Stein, R, (2000) J. Biol. Chem. 275, 10532-10537). Evidence is presented here suggesting that a tyrosine phosphatase(s) influences the ability of RIPE3b1 to bind to the insulin C1 element in beta cells. We found that RIPE3b1 binding was inhibited upon incubating beta cell nuclear extracts at 30 degreesC, In contrast, PDX-1 and MLTF-1 transcription factor binding activity was unaffected under these conditions. The loss in RIPE3b1 binding activity was prevented by inhibitors of tyrosine phosphatases (sodium orthovanadate and sodium molybdate) but not by inhibitors of serine/threonine phosphatases (sodium fluoride, okadaic acid, and microcystin LR). CIAP- and BPP-catalyzed inhibition of RIPE3b1 binding was also blocked by these tyrosine phosphatase inhibitors. Collectively, the data suggested that removal of a tyrosine(s) within RIPE3b1 prevented activator binding to insulin C1 control element sequences. The presence of a key phosphorylated tyrosine(s) within this transcription factor was further supported by the ability of the 4G10 anti-phosphotyrosine monoclonal antibody to immunoprecipitate RIPE3b1 DNA binding activity. We discuss how tyrosine phosphorylation, a very rare and highly significant regulatory modification, may control RIPE3b1 activator function.	Vanderbilt Univ, Ctr Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Ctr Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.	Roland.Stein@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042505, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42505, P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Bramblett DE, 2000, ADV PHARMACOL, V47, P255; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; Cousin SP, 1999, BIOCHEM J, V344, P649, DOI 10.1042/0264-6021:3440649; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FOULKES JG, 1983, J BIOL CHEM, V258, P431; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; HALLBERG E, 1994, CELL BIOL LAB HDB, V1, P613; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; HATCH GM, 1990, BIOCHIM BIOPHYS ACTA, V1042, P374, DOI 10.1016/0005-2760(90)90167-V; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KREMERSKOTHEN J, 1993, MOL CELL BIOCHEM, V125, P1, DOI 10.1007/BF00926828; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LAU KHW, 1985, J BIOL CHEM, V260, P4653; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Li H, 1999, NAT GENET, V23, P67; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OKADA M, 1986, BIOCHEM J, V239, P155, DOI 10.1042/bj2390155; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHACTERNOIMAN E, 1983, J BIOL CHEM, V258, P4214; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SHINOZAKI T, 1995, EUR J BIOCHEM, V227, P367, DOI 10.1111/j.1432-1033.1995.tb20398.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; STEIN R, 1993, TRENDS ENDOCRIN MET, V122, P1409; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	64	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22071	22076		10.1074/jbc.M010321200	http://dx.doi.org/10.1074/jbc.M010321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309378	hybrid			2022-12-25	WOS:000169412700013
J	Mehta, D; Rahman, A; Malik, AB				Mehta, D; Rahman, A; Malik, AB			Protein kinase C-alpha signals Rho-guanine nucleotide dissociation inhibitor phosphorylation and Rho activation and regulates the endothelial cell barrier function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; THROMBIN RECEPTOR; FAMILY GTPASES; PERMEABILITY; DYSFUNCTION; ADHESION; CYTOSKELETON; INCREASE; PEPTIDE; CDC42HS	The Rho-GDP guanine nucleotide dissociation inhibitor (GDI) complexes with the GDP-bound form of Rho and inhibits its activation. We investigated the role of protein kinase C (PKC) isozymes in the mechanism of Rho activation and in signaling the loss of endothelial barrier function. Thrombin and phorbol la-myristate 13-acetate induced rapid phosphorylation of GDI and the activation of Rho-A in human umbilical venular endothelial cells. Inhibition of PKC by chelerythrine chloride abrogated the thrombin-induced GDI phosphorylation and Rho activation. Depletion of PKC prevented the thrombin-induced GDI phosphorylation and Rho activation, thereby indicating that these events occurred downstream of phorbol ester-sensitive PKC isozyme activation. The depletion of PKC or inhibition of Rho by C3 toxin also prevented the thrombin-induced decrease in transendothelial electrical resistance (a measure of increased transendothelial permeability), thus indicating that PKC-induced barrier dysfunction was mediated through Rho-dependent pathway. Using inhibitors and dominant-negative mutants, we found that Rho activation was regulated by PKC-alpha. Moreover, the stimulation of human umbilical venular endothelial cells with thrombin induced rapid association of PKC-alpha with Rho, Activated PKC-alpha but not PKC-epsilon induced marked phosphorylation of GDI in vitro. Taken together, these results indicate that PKC-alpha is critical in regulating GDI phosphorylation, Rho activation, and in signaling Rho-dependent endothelial barrier dysfunction.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	dmehta@uic.edu		Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL46350, HL45638, HL27016] Funding Source: Medline; NIGMS NIH HHS [R01 GM058531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046350, R01HL045638, R01HL027016, R37HL027016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Aschner JL, 1997, J CELL PHYSIOL, V173, P387, DOI 10.1002/(SICI)1097-4652(199712)173:3<387::AID-JCP11>3.0.CO;2-9; Bourmeyster N, 1996, BIOCHEM BIOPH RES CO, V218, P54, DOI 10.1006/bbrc.1996.0011; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Gao BC, 2000, J CELL SCI, V113, P247; GARCIA JGN, 1995, BLOOD COAGUL FIBRIN, V6, P609, DOI 10.1097/00001721-199510000-00001; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; Meacci E, 2000, FEBS LETT, V482, P97, DOI 10.1016/S0014-5793(00)02039-1; MORII N, 1995, METHOD ENZYMOL, V256, P196; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PATTERSON CE, 1994, MICROVASC RES, V48, P212, DOI 10.1006/mvre.1994.1050; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; QIAO RL, 1995, AM J PHYSIOL-CELL PH, V269, pC110, DOI 10.1152/ajpcell.1995.269.1.C110; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vuong PT, 1998, J CELL PHYSIOL, V175, P379, DOI 10.1002/(SICI)1097-4652(199806)175:3<379::AID-JCP16>3.3.CO;2-T; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116	50	215	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22614	22620		10.1074/jbc.M101927200	http://dx.doi.org/10.1074/jbc.M101927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309397	hybrid			2022-12-25	WOS:000169412700087
J	Rudolph, B; Hueber, AO; Evan, GI				Rudolph, B; Hueber, AO; Evan, GI			Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation	ONCOGENE			English	Article						Myc; Mad; oncogene; cell cycle; lymphocyte; tumor suppressor	MYC-MEDIATED APOPTOSIS; WILD-TYPE P53; C-MYC; CYCLE PROGRESSION; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSORS; MAX; ACTIVATION; MICE; DIFFERENTIATION	To investigate Mad1 function in vivo, transgenic mice were:generated that express a Mad1 transgene in T lineage cells under the control of the proximal lck promoter. Thymus size in lck-Mad1 transgenic mice is drastically reduced although representation of the various thymocyte sub populations appears normal. To investigate more closely any effects of Mad1 expression on thymocytes, we examined thymic selection using MHC class I-restricted H-Y-TCR transgenic mice. Mad1 expression in vivo reduces the efficiency of positive selection. Furthermore, thymocytes and splenic T cells from lck-Mad1 transgenic mice display a profound proliferative defect in response to activation with either PMA/lonomycin or immobilized anti-CD3/CD28 antibody. This proliferative defect is not reversed by addition of exogenous IL-2 and is p53-independent. The growth inhibition caused by Mad1 is overcome by expression of active c-Myc.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Evan, GI (corresponding author), Univ Calif San Francisco, Ctr Canc, 2340 Sutter St, San Francisco, CA 94143 USA.		Anne-Odile, Hueber/P-9860-2019; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BACKWOOD EM, 1992, GENE DEV, V6, P71; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BroussardDiehl C, 1996, J IMMUNOL, V156, P3141; CARDING S, 1987, THYMUS, V10, P219; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EDELHOFF S, 1994, ONCOGENE, V9, P665; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELSON A, 1995, ONCOGENE, V11, P181; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; Kiermaier A, 1997, CURR BIOL, V7, pR505, DOI 10.1016/S0960-9822(06)00249-1; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MOORE JP, 1987, ONCOGENE RES, V2, P65; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Rudolph B, 2000, ONCOGENE, V19, P1891, DOI 10.1038/sj.onc.1203508; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STEWART M, 1993, INT J CANCER, V53, P1023; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	56	17	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1164	1175		10.1038/sj.onc.1204196	http://dx.doi.org/10.1038/sj.onc.1204196			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313860				2022-12-25	WOS:000167570100003
J	Yuen, PH; Ryan, EA; Devroe, E; Wong, PKY				Yuen, PH; Ryan, EA; Devroe, E; Wong, PKY			A single Glu(62)-to-Lys(62) mutation in the Mos residues of the R7 Delta 447Gag-tMos protein causes the mutant virus to induce brain lesions	ONCOGENE			English	Article						Mos mutation; MEK; ERK; brain lesions	MURINE LEUKEMIA-VIRUS; MYELOPROLIFERATIVE SARCOMA-VIRUS; TEMPERATURE-SENSITIVE MUTANTS; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; TRANSFORMING GENE; OOCYTE MATURATION; CYTOSTATIC FACTOR; KINASE CASCADE; C-MOS	We previously reported that R7 Delta 447, a 2954-base-pair (bp) laboratory-generated Moloney murine sarcoma virus, induced subcutaneous tumors in about 14% of infected mice but did not induce brain lesions. We now report that R7 Delta 447K, a spontaneous mutant of R7 Delta 447, induced brain lesions as well as subcutaneous tumors in all injected mice. The genomes of the two viruses differ in a single base pair: the deduced Glu(62) of the Mos residue of the R7 Delta 447 Gag-tMos protein is changed to Lys(62), More R7 Delta 447 than R7 Delta 447K focus-forming units were detected in both NIH3T3 and mouse cerebral vascular endothelial (MCVE) cells. However, R7 Delta 447K transformed NIH3T3 and MCVE: cells more acutely than did R7 Delta 447. A distinctive feature that distinguished the morphologic transformation of R7 Delta 447- and R7 Delta 447K-infected MCVE cells is the markedly prolonged spindle-shaped phase exhibited by R7 Delta 447-infected MCVE cells. In addition, R7 Delta 447K was more efficient in inducting the phosphorylation of ERK1/2 than R7 Delta 447 in both MCVE and NIH3T3 cells. Moreover morphologic transformation was inhibited, and levels of phosphorylated ERK1/2 were reduced when R7 Delta 447- or R7 Delta 447K-infected NIH3T3 or MCVE cells were grown in the presence of the MEK1/2-specific inhibitor PD98095. Thus, ne have identified a key residue in the Gag-tMos protein that profoundly affects activation of the Mos/MEK/ERK pathway, virus and cell replication, morphologic transformation in vitro and pathogenicity in vivo.	Univ Texas, MD Anderson Canc Ctr, Div Res, Dept Carcinogenesis, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Yuen, PH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Res, Dept Carcinogenesis, Sci Pk, Smithville, TX 78957 USA.				NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALROY J, 1987, HISTOCHEMISTRY, V86, P603, DOI 10.1007/BF00489554; BERMAN LD, 1969, INT J CANCER, V4, P820, DOI 10.1002/ijc.2910040611; BOUSSEKERDILES MCL, 1980, EUR J CANCER, V16, P43, DOI 10.1016/0014-2964(80)90106-1; BROW MAD, 1984, J VIROL, V49, P579, DOI 10.1128/JVI.49.2.579-582.1984; CHIRIGOS MA, 1968, INT J CANCER, V3, P223, DOI 10.1002/ijc.2910030207; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; GAZDAR AF, 1972, INT J CANCER, V9, P219; GONZALEZSCARANO F, 1995, RETROVIRIDAE, V4, P409; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HAYASHI Y, 1988, PATHOL RES PRACT, V183, P314, DOI 10.1016/S0344-0338(88)80128-6; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Lim KY, 2000, J NEUROVIROL, V6, P106, DOI 10.3109/13550280009013154; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; OKAZAKI K, 1995, ONCOGENE, V10, P1149; OSTERTAG W, 1980, J VIROL, V33, P573, DOI 10.1128/JVI.33.2.573-582.1980; PERK K, 1966, J NATL CANCER I, V37, P581; PHAM CD, 1995, ONCOGENE, V10, P1683; PROPST F, 1990, P NATL ACAD SCI USA, V87, P9703, DOI 10.1073/pnas.87.24.9703; PROPST F, 1992, J NEUROPATH EXP NEUR, V51, P499, DOI 10.1097/00005072-199209000-00004; PULS A, 1995, ONCOGENE, V10, P623; RIBACCHI RODOLFO, 1966, LAV IST ANAT ISTOL PATOL UNTV STUDI PERUGIA, V26, P149; Robertson SC, 1996, MOL CELL BIOL, V16, P3472; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SIMONS PJ, 1970, J NATL CANCER I, V44, P1289; STACEY A, 1984, J VIROL, V50, P725, DOI 10.1128/JVI.50.3.725-732.1984; STANTON MF, 1968, J NATL CANCER I, V40, P1113; STOICA G, 1990, AM J PATHOL, V136, P933; TOPOL LZ, 1995, CELL GROWTH DIFFER, V6, P1119; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WONG PKY, 1990, CURR TOP MICROBIOL, V160, P29; WONG PKY, 1981, VIROLOGY, V109, P366, DOI 10.1016/0042-6822(81)90507-9; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; Yuen PH, 1998, AM J PATHOL, V152, P1509; YUEN PH, 1989, J VIROL, V63, P471, DOI 10.1128/JVI.63.2.471-480.1989; YUEN PH, 1991, MOL CARCINOGEN, V4, P72, DOI 10.1002/mc.2940040111; Yuen PH, 1997, VIROLOGY, V236, P213, DOI 10.1006/viro.1997.8729; YUEN PH, 1985, J VIROL, V54, P178, DOI 10.1128/JVI.54.1.178-185.1985; Yuen PH, 2000, J NEUROVIROL, V6, P329, DOI 10.3109/13550280009030759	46	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					692	703		10.1038/sj.onc.1204150	http://dx.doi.org/10.1038/sj.onc.1204150			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314003				2022-12-25	WOS:000166806000005
J	Strang, C; Cushman, SJ; DeRubeis, D; Peterson, D; Pfaffinger, PJ				Strang, C; Cushman, SJ; DeRubeis, D; Peterson, D; Pfaffinger, PJ			A central role for the T1 domain in voltage-gated potassium channel formation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; TETRAMERIZATION DOMAIN; CRYSTAL-STRUCTURE; MEMBRANE-PROTEIN; SUBUNIT; EXPRESSION; INTERFACE; COMPLEX; BRAIN	To interpret the recent atomic structures of the Kv (voltage-dependent potassium) channel T1 domain in a functional context, we must understand both how the T1 domain is integrated into the full-length functional channel protein and what functional roles the T1 domain governs. The T1 domain clearly plays a role in restricting Kv channel subunit heteromultimerization. However, the importance of T1 tetramerization for the assembly and retention of quarternary structure within full-length channels has remained controversial. Here we describe a set of mutations that disrupt both T1 assembly and the formation of functional channels and show that these mutations produce elevated levels of the subunit monomer that becomes subject to degradation within the cell. In addition, our experiments reveal that the T1 domain lends stability to the full-length channel structure, because channels lacking the T1 containing N terminus are more easily denatured to monomers. The integration of the T1 domain ultrastructure into the full-length channel was probed by proteolytic mapping with immobilized trypsin. Trypsin cleavage yields an N-terminal fragment that is further digested to a tetrameric domain, which remains reactive with antisera to T1, and that is similar in size to the T1 domain used for crystallographic studies. The trypsin-sensitive linkages retaining the T1 domain are cleaved somewhat slowly over hours. Therefore, they seem to be intermediate in trypsin resistance between the rapidly cleaved extracellular linker between the first and second transmembrane domains, and the highly resistant T1 core, and are likely to be partially structured or contain dynamic structure. Our experiments suggest that tetrameric atomic models obtained for the T1 domain do reflect a structure that the T1 domain sequence forms early in channel assembly to drive subunit protein tetramerization and that this structure is retained as an integrated stabilizing structural element within the full-length functional channel.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Pfaffinger, PJ (corresponding author), Baylor Coll Med, Div Neurosci, S613,1 Baylor Plaza, Houston, TX 77030 USA.	ppfaff@cns.neusc.bcm.tmc.edu						AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Biggin PC, 2000, CURR OPIN STRUC BIOL, V10, P456, DOI 10.1016/S0959-440X(00)00114-7; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Choe S, 1999, TRENDS BIOCHEM SCI, V24, P345, DOI 10.1016/S0968-0004(99)01440-1; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; TU L, 2000, BIOCHEMISTRY-US, V398, P24; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797	40	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28493	28502		10.1074/jbc.M010540200	http://dx.doi.org/10.1074/jbc.M010540200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11312262	hybrid			2022-12-25	WOS:000170093400100
J	Ahmed, Z; Ravandi, A; Maguire, GF; Emili, A; Draganov, D; La Du, BN; Kuksis, A; Connelly, PW				Ahmed, Z; Ravandi, A; Maguire, GF; Emili, A; Draganov, D; La Du, BN; Kuksis, A; Connelly, PW			Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; LIPID-PEROXIDATION; LDL OXIDATION; NITRIC-OXIDE; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; ALPHA-TOCOPHEROL; HUMAN-PLASMA; HYDROPEROXIDES; SUPEROXIDE	High density lipoprotein (HDL) is rich in polyunsaturated phospholipids that are sensitive to oxidation, However, the effect of apolipoprotein A-I and paraoxonase-l (PON-1) on phosphatidylcholine oxidation products has not been identified. We subjected native HDL, trypsinized HDL, and HDL lipid suspensions to oxidation by the peroxynitrite donor, 3-morpholinosydnonimine. HDL had a basal level of phosphatidylcholine mono- and di-hydroperoxides that increased to a greater extent in HDL, compared with either trypsinized HDL or HDL lipid alone. Phosphatidylcholine core aldehydes, which were present in small amounts, increased 10-fold during oxidation of native HDL, compared with trypsinized HDL (p = 0,004), and I-fold compared with HDL lipid suspensions (p = 0,0021), In addition, the content of lysophosphatidylcholine increased 300% during oxidation of native HDL, but only 80 and 25%, respectively, during oxidation of trypsinized HDL and HDL lipid suspensions. Phosphatidylcholine isoprostanes accumulated in comparable amounts during the oxidation of all three preparations. Incubation of apolipoprotein A-I with 1 -palmitoyl-2-linoleoyl glycerophosphocholine proteoliposomes in the presence of S-morpholinosyd-nonimine or apoAI with phosphatidylcholine hydroperoxides resulted in a significant increase in phosphatidyicholine core aldehydes with no formation of lysophosphatidylcholine. We propose that apolipoprotein A-I catalyzes a one-electron oxidation of alkoxyl radicals. Purified PON-1 hydrolyzed phosphatidylcholine core aldehydes to lysophosphatidylcholine. We conclude that, upon HDL oxidation with peroxynitrite, apolipoprotein AI increases the formation of phosphatidylcholine core aldehydes that are subsequently hydrolyzed by PON1.	Univ Toronto, St Michaels Hosp, J Alick Little Lipid Res Lab, Toronto, ON M5B 1A6, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5B 1A6, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5B 1A6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5B 1A6, Canada; Univ Toronto, Dept Med, Toronto, ON M5B 1A6, Canada; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Michigan System; University of Michigan	Connelly, PW (corresponding author), Univ Toronto, St Michaels Hosp, J Alick Little Lipid Res Lab, 38 Shuter St,Rm 1004 WA, Toronto, ON M5B 1A6, Canada.		Ravandi, Amir/O-7552-2019; Connelly, Philip W/B-7583-2012	Connelly, Philip W/0000-0001-7244-6843				[Anonymous], LIPID OXIDATION; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Bonnefont-Rousselot D, 1999, CLIN CHEM LAB MED, V37, P939, DOI 10.1515/CCLM.1999.139; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; CHEN CH, 1982, J LIPID RES, V23, P680; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Christen S, 1997, P NATL ACAD SCI USA, V94, P3217, DOI 10.1073/pnas.94.7.3217; Connelly PW, 1996, METHOD ENZYMOL, V263, P188; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; ECKERSON HW, 1983, AM J HUM GENET, V35, P1126; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Gardner HW, 1996, LIPIDS, V31, P1023, DOI 10.1007/BF02522458; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786; Hall LM, 1998, ANAL BIOCHEM, V258, P184, DOI 10.1006/abio.1998.2602; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; KAMIDO H, 1995, J LIPID RES, V36, P1876; Kanazawa K, 1998, BBA-LIPID LIPID MET, V1393, P336, DOI 10.1016/S0005-2760(98)00088-5; Khovidhunkit W, 2000, J INFECT DIS, V181, pS462, DOI 10.1086/315611; KUO CL, 1995, DRUG METAB DISPOS, V23, P935; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P379, DOI 10.1016/S0009-2797(99)00049-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laplaud PM, 1998, CLIN CHEM LAB MED, V36, P431, DOI 10.1515/CCLM.1998.073; Lee C, 1999, ARTERIOSCL THROM VAS, V19, P1437, DOI 10.1161/01.ATV.19.6.1437; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Mackness MI, 2000, CURR OPIN LIPIDOL, V11, P383, DOI 10.1097/00041433-200008000-00007; Macphee CH, 1999, BIOCHEM J, V338, P479, DOI 10.1042/0264-6021:3380479; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mashima R, 1998, J LIPID RES, V39, P1133; Pannala AS, 1998, FEBS LETT, V423, P297, DOI 10.1016/S0014-5793(98)00108-2; Patel RP, 1997, BIOCHEM J, V322, P425, DOI 10.1042/bj3220425; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RAVANDI A, 1995, J BIOCHEM BIOPH METH, V30, P271, DOI 10.1016/0165-022X(95)00015-7; Ravandi A, 1997, LIPIDS, V32, P989, DOI 10.1007/s11745-997-0129-6; Ravandi A, 1996, FEBS LETT, V381, P77, DOI 10.1016/0014-5793(96)00064-6; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Ronson RS, 1999, CARDIOVASC RES, V44, P47, DOI 10.1016/S0008-6363(99)00184-4; SHAIKH NA, 1994, ANAL BIOCHEM, V216, P313, DOI 10.1006/abio.1994.1047; SorciThomas MG, 1996, J LIPID RES, V37, P673; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Thomas SR, 2000, FREE RADICAL BIO MED, V28, P1795, DOI 10.1016/S0891-5849(00)00236-7; Thomas SR, 1998, CHEM RES TOXICOL, V11, P484, DOI 10.1021/tx970173a; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; VERDERY RB, 1974, BIOCHEM BIOPH RES CO, V57, P1271, DOI 10.1016/0006-291X(74)90833-X; Whitman SC, 1998, J LIPID RES, V39, P1008	58	101	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24473	24481		10.1074/jbc.M010459200	http://dx.doi.org/10.1074/jbc.M010459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320081	hybrid			2022-12-25	WOS:000169800700009
J	Kingan, TG; Cardullo, RA; Adams, ME				Kingan, TG; Cardullo, RA; Adams, ME			Signal transduction in eclosion hormone-induced secretion of ecdysis-triggering hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MANDUCA-SEXTA; NERVOUS-SYSTEM; NITRIC-OXIDE; CALYCULIN-A; BEHAVIORAL SEQUENCE; ENDOCRINE SYSTEM; CHROMAFFIN CELLS; INSECT ECDYSIS; CA2+ STORES	Inks cells of insect epitracheal glands (EGs) secrete preecdysis and ecdysis-triggering hormones (PETH and ETH) at the end of each developmental stage. Both peptides act in the central nervous system to evoke the ecdysis behavioral sequence, a stereotype behavior during which old cuticle is shed. Secretion of ETH is stimulated by a brain neuropeptide, eclosion hormone (EH), EH evokes accumulation of cGMP followed by release of ETH from Inks cells, and exogenous cGMP evokes secretion of ETH, The secretory responses to EH and cGMP are inhibited by the broad-spectrum kinase inhibitor staurosporine, and the response to EH is potentiated by the phosphatase inhibitor calyculin A Staurosporine did not inhibit EH-evoked accumulation of cGMP, Changes in cytoplasmic Ca2+ in Inks cells during EH signaling were monitored via fluorescence ratioing with fura-2-loaded EGs. Cytoplasmic Ca2+ increases within 30-120 s after addition of EH to EGs, and it remains elevated for at least 10 min, corresponding with the time course of secretion. Secretion is increased in dose-dependent manner by the Ca2+-ATPase inhibitor thapsigargin, a treatment that does not elevate glandular cGMP above basal levels. The secretory response to EH is partially inhibited in glands loaded with EGTA, while cGMP levels are unaffected. These findings suggest that EH activates second messenger cascades leading to cGMP accumulation and Ca2+ mobilization and/or influx and that both pathways are required for a full secretory response, cGMP activates a staurosporine-inhibitable protein kinase, We propose that Ca2+ acts vis a parallel cascade with a time course that is similar to that for cGMP activation of a cGMP-dependent protein kinase.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside	Kingan, TG (corresponding author), Univ Calif Riverside, Dept Entomol, 5419 Boyce Hall, Riverside, CA 92521 USA.		Adams, Michael/ABF-6728-2020; Cardullo, Richard/GVT-2950-2022	Adams, Michael/0000-0003-0519-6113; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040555, R01AI040555] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40555] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Ewer J, 1997, J EXP BIOL, V200, P869; Gammie SC, 1999, J EXP BIOL, V202, P343; GUTIERREZ LM, 1995, EUR J CELL BIOL, V68, P88; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; HEWES RS, 1991, J COMP PHYSIOL A, V168, P697; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; Kingan TG, 1997, J EXP BIOL, V200, P3245; Klein C, 1999, J INSECT PHYSIOL, V45, P65, DOI 10.1016/S0022-1910(98)00085-7; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Morgan A, 1997, SEMIN CELL DEV BIOL, V8, P141, DOI 10.1006/scdb.1996.0133; MORTON DB, 1985, J COMP PHYSIOL A, V157, P423, DOI 10.1007/BF00615142; MORTON DB, 1986, NATURE, V323, P264, DOI 10.1038/323264a0; Morton DB, 1995, J COMP PHYSIOL B, V165, P417, DOI 10.1007/BF00261295; Morton DB, 1997, ANN NY ACAD SCI, V814, P40, DOI 10.1111/j.1749-6632.1997.tb46143.x; NAKAZAWA M, 1994, EUR J PHARMACOL, V253, P179; Nighorn A, 1999, J BIOL CHEM, V274, P2525, DOI 10.1074/jbc.274.4.2525; Novicki A, 1996, J EXP BIOL, V199, P1757; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; SHIBANAKA Y, 1993, EUR J BIOCHEM, V211, P427, DOI 10.1111/j.1432-1033.1993.tb17567.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIFARO JM, 1992, EUR J PHARM-MOLEC PH, V225, P83, DOI 10.1016/0922-4106(92)90088-D; TRUMAN JW, 1981, NATURE, V291, P70, DOI 10.1038/291070a0; TRUMAN JW, 1980, J EXP BIOL, V88, P327; TRUMAN JW, 1989, J EXP BIOL, V147, P457; TRUMAN JW, 1979, J EXP BIOL, V84, P201; VITALE ML, 1992, NEUROSCIENCE, V51, P463, DOI 10.1016/0306-4522(92)90330-5; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WEEKS JC, 1984, J COMP PHYSIOL, V155, P407, DOI 10.1007/BF00610594; XU X, 1994, J BIOL CHEM, V269, P12645; Zitnan D, 2000, J EXP BIOL, V203, P1329; Zitnan D, 1999, NEURON, V23, P523, DOI 10.1016/S0896-6273(00)80805-3; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	44	24	24	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25136	25142		10.1074/jbc.M102421200	http://dx.doi.org/10.1074/jbc.M102421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313360	hybrid			2022-12-25	WOS:000169800700095
J	Schwartz, SH; Qin, XQ; Zeevaart, JAD				Schwartz, SH; Qin, XQ; Zeevaart, JAD			Characterization of a novel carotenoid cleavage dioxygenase from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; PSEUDOMONAS-PAUCIMOBILIS TMY1009; BETA-CAROTENE; ARABIDOPSIS-THALIANA; PHASEOLUS-VULGARIS; OXIDATIVE CLEAVAGE; GROWTH INHIBITOR; PROVITAMIN-A; VITAMIN-A; IDENTIFICATION	The plant hormone abscisic acid is derived from the oxidative cleavage of a carotenoid precursor. Enzymes that catalyze this carotenoid cleavage reaction, nine-cis epoxy-carotenoid dioxygenases, have been identified in several plant species. Similar proteins, whose functions are not yet known, are present in diverse organisms, A putative cleavage enzyme from Arabidopsis thaliana contains several highly conserved motifs found in other carotenoid cleavage enzymes. However, the overall homology with known abscisic acid biosynthetic enzymes is low. To determine the biochemical function of this protein, it was expressed in Escherichia coli and used for in vitro assays. The recombinant protein was able to cleave a variety of carotenoids at the 9-10 and 9'-10' positions. In most instances, the enzyme cleaves the substrate symmetrically to produce a C-14 dialdehyde and two C-13 products, which vary depending on the carotenoid substrate. Based upon sequence similarity, orthologs of this gene are present throughout the plant kingdom. A similar protein in beans catalyzes the same reaction in vitro. The characterization of these activities offers the potential to synthesize a variety of interesting, natural products and is the first step in determining the function of this gene family in plants.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Zeevaart, JAD (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.	zeevaart@msu.edu		Schwartz, Steve/0000-0002-5982-8553				Burbidge A, 1999, PLANT J, V17, P427, DOI 10.1046/j.1365-313X.1999.00386.x; BURDEN RS, 1972, PHYTOCHEMISTRY, V11, P2295, DOI 10.1016/S0031-9422(00)88393-4; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; DONALDSON JMI, 1990, J ECON ENTOMOL, V83, P1298, DOI 10.1093/jee/83.4.1298; EISNER T, 1966, SCIENCE, V153, P1341, DOI 10.1126/science.153.3742.1341; EUGSTER CH, 1991, ANGEW CHEM INT EDIT, V30, P654, DOI 10.1002/anie.199106541; Iuchi S, 2000, PLANT PHYSIOL, V123, P553, DOI 10.1104/pp.123.2.553; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P931, DOI 10.1271/bbb.57.931; KATONOGUCHI H, 1992, PHYSIOL PLANTARUM, V86, P583, DOI 10.1111/j.1399-3054.1992.tb02173.x; KATONOGUCHI H, 1993, PHYTOCHEMISTRY, V33, P553, DOI 10.1016/0031-9422(93)85447-Y; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; MARKIFISCHER E, 1988, HELV CHIM ACTA, V71, P1491, DOI 10.1002/hlca.19880710613; MEINWALD J, 1968, TETRAHEDRON LETT, P2959; MOLNAR P, 1979, ACTA CHIM HUNG, V99, P155; Neill SJ, 1998, J EXP BOT, V49, P1893, DOI 10.1093/jexbot/49.328.1893; Olson JA, 1995, FASEB J, V9, P1547, DOI 10.1096/fasebj.9.15.8529833; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Sun ZR, 1996, J BIOL CHEM, V271, P24349, DOI 10.1074/jbc.271.40.24349; Tan BC, 1997, P NATL ACAD SCI USA, V94, P12235, DOI 10.1073/pnas.94.22.12235; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; WALHBERG I, 1998, CAROTENOIDS, V3, P195; Walter MH, 2000, PLANT J, V21, P571, DOI 10.1046/j.1365-313x.2000.00708.x; Williams RN, 2000, J ECON ENTOMOL, V93, P1480, DOI 10.1603/0022-0493-93.5.1480; Winterhalter P, 2000, FOOD REV INT, V16, P39, DOI 10.1081/FRI-100100281; WINTERHALTER P, 1992, ACS SYM SER, V490, P98; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	31	258	285	1	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25208	25211		10.1074/jbc.M102146200	http://dx.doi.org/10.1074/jbc.M102146200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316814	hybrid			2022-12-25	WOS:000169800700104
J	Albert, CJ; Crowley, JR; Hsu, FF; Thukkani, AK; Ford, DA				Albert, CJ; Crowley, JR; Hsu, FF; Thukkani, AK; Ford, DA			Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens - Identification of 8-chlorohexadecanal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; OXIDANT MEMBRANE INJURY; HYPOCHLOROUS ACID; HYDROGEN-PEROXIDE; HUMAN-NEUTROPHILS; PANCREATIC-ISLETS; ARACHIDONIC-ACID; ANIMAL-CELLS; PLASMENYLCHOLINE; PHAGOCYTES	Plasmalogens contain a vinyl ether bond linking the sn-l aliphatic chain to the glycerol backbone of this predominant phospholipid molecular subclass, which is found in many mammalian tissues. The present study demonstrates that the vinyl ether bond of plasmalogens is a molecular target of the reactive chlorinating species produced by myeloperoxidase, Analysis by thin layer chromatography revealed that reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of the plasmalogen, lysoplasmenylcholine (1-O-hexadec-1 ''-enyl-sn-glycero3-phosphorylcholine), resulting in the production of a neutral lipid. Capillary gas chromatographic analyses demonstrated that the neutral lipid generated from lysoplasmenylcholine was neither hexadecanal nor did it contain masked hexadecanal (Le. the vinyl ether) because the dimethyl acetal of hexadecanal produced by acid methanolysis derivatization was no longer present. Electrospray ionization mass spectrometry of the myeloperoxidase-generated neutral Lipid product was consistent with the production of a 16-carbon fatty aldehyde containing one chlorine atom. Furthermore, proton NMR analysis indicated that this neutral lipid product was a 8-chloro-fatty aldehyde. Additional structural analysis of this neutral lipid by gas chromatography-mass spectrometry of the underivatized product as well as its pentafluorobenzyl oxime-derivative product was consistent with the neutral lipid being 2-chlorohexadecanal. The reactive chlorinating species, hypochlorous acid and chlorine gas, both attacked the vinyl ether bond of lysoplasmenylcholine resulting in the production of 2-chlorohexadecanal, The production of 2-chlorohexadecanal was dependent on the presence of the plasmalogen masked aldehyde (ae. the vinyl ether) in the substrate because the free fatty aldehyde, hexadecanal, was not converted to 2-chlorohexadecanal by the reactive chlorinating species generated by myeloperoxidase. Taken together, the present studies demonstrate for the first time the targeting of the vinyl ether bond of plasmalogens by the reactive chlorinating species produced by myeloperoxidase resulting in the production of novel chlorinated fatty aldehydes.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Washington Univ, Med Ctr, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL)	Ford, DA (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560; Hsu, Fong-Fu/0000-0001-5368-0183	NCRR NIH HHS [RR00954] Funding Source: Medline; NHLBI NIH HHS [K04 HL 03316-05, HL 42665-11] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL042665, K04HL003316, R01HL042665] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ARTHUR G, 1986, BIOCHEM J, V236, P475, DOI 10.1042/bj2360475; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARKSON CW, 1983, CIRC RES, V52, P543, DOI 10.1161/01.RES.52.5.543; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FORD DA, 1991, J CLIN INVEST, V88, P331, DOI 10.1172/JCI115296; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Ford DA, 1996, FEBS LETT, V394, P99, DOI 10.1016/0014-5793(96)00930-1; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; IGARASHI Y, 1990, BIOCHEM BIOPH RES CO, V172, P77, DOI 10.1016/S0006-291X(05)80175-5; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; LAMPERT MB, 1983, BLOOD, V62, P645; MCMASTER CR, 1992, LIPIDS, V27, P945, DOI 10.1007/BF02535569; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; POST JA, 1988, FEBS LETT, V240, P78, DOI 10.1016/0014-5793(88)80343-0; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; SASAKI Y, 1993, FEBS LETT, V320, P47, DOI 10.1016/0014-5793(93)81655-J; SEDLIS SP, 1983, AM J PHYSIOL, V244, pH32, DOI 10.1152/ajpheart.1983.244.1.H32; SEPE SM, 1985, J IMMUNOL, V134, P1888; SEPE SM, 1985, J IMMUNOL, V134, P1896; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Zeng YC, 1998, BIOCHEMISTRY-US, V37, P2346, DOI 10.1021/bi9725172; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	41	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23733	23741		10.1074/jbc.M101447200	http://dx.doi.org/10.1074/jbc.M101447200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11301330	hybrid			2022-12-25	WOS:000169531100069
J	Falls, LA; Furie, BC; Jacobs, M; Furie, B; Rigby, AC				Falls, LA; Furie, BC; Jacobs, M; Furie, B; Rigby, AC			The omega-loop region of the human prothrombin gamma-carboxyglutamic acid domain penetrates anionic phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FACTOR-VIII; VITAMIN-K; COAGULATION-FACTOR; BINDING-PROPERTIES; GLA DOMAIN; C2 DOMAIN; PARALLAX ANALYSIS; RICH DOMAIN; PROTEIN-C; FACTOR-VA	The hydrophobic omega -loop within the prothrombin gamma -carboxyglutamic acid-rich (Gla) domain is important in membrane binding. The role of this region in membrane binding was investigated using a synthetic peptide, PT-(1-46)F4W, which includes the N-terminal 46 residues of human prothrombin with Phe-4 replaced by Trp providing a fluorescent probe. PT-(1-46)F4W and PT-(1-46) bind calcium ions and phospholipid membranes, and inhibit the prothrombinase complex. PT-(1-46)F4W, but not PT-(1-46), exhibits a blue shift (5 nm) and red-edge excitation shift (28 nm) in the presence of phosphatidylserine (PS)-containing vesicles, suggesting Trp ii is located within the motionally restricted membrane interfacial region, PS-containing vesicles protect PT-(1-46)F4W, but not PT-(1-46), fluorescence from potassium iodide-induced quenching. Stern-Volmer analysis of the quenching of PT-(1-46)F4W in the presence and absence of 80% phosphatidylcholine/20% PS vesicles suggested that Trp-4 is positioned within the membrane and protected from aqueous quenching agents whereas Trp-41 remains solvent-accessible in the presence of PS-containing vesicles, Fluorescence quenching of membrane-bound PT-(1-46)F4W is optimal with 7- and 10-doxyl-labeled lipids, indicating that Trp-4 is inserted 5 to 7 Angstrom into the bilayer, This report demonstrates that the omega -loop region of prothrombin specifically interacts with PS-containing membranes within the interfacial membrane region.	Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Rigby, AC (corresponding author), Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis Res, POB 15732, Boston, MA 02215 USA.	arigby@caregroup.harvard.edu			NHLBI NIH HHS [HL42443, HL10328, HL18834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018834, R01HL018834, P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5322, DOI 10.1021/bi00138a011; ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; ASHCROFT RG, 1981, BIOCHIM BIOPHYS ACTA, V643, P191, DOI 10.1016/0005-2736(81)90232-7; ASUNCIONPUNZALAN E, 1995, BIOCHEMISTRY-US, V34, P11460, DOI 10.1021/bi00036a019; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; CHATTOPADHYAY A, 1991, BIOCHEMISTRY-US, V30, P7159, DOI 10.1021/bi00243a017; Chattopadhyay A, 1997, BIOPHYS J, V73, P839, DOI 10.1016/S0006-3495(97)78116-5; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Cheng CH, 2000, FASEB J, V14, pA110; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEMCHENKO AP, 1986, ESSAYS BIOCHEM, V22, P120; Falls LA, 2000, BIOCHEMISTRY-US, V39, P13216, DOI 10.1021/bi0009789; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Ghosh AK, 1997, BIOCHEMISTRY-US, V36, P14291, DOI 10.1021/bi971933j; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; JACOBS M, 1994, J BIOL CHEM, V269, P25494; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LENTZ BR, 1985, BIOCHEMISTRY-US, V24, P6997, DOI 10.1021/bi00345a037; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MacPhee CE, 1999, BIOCHEMISTRY-US, V38, P10878, DOI 10.1021/bi990726b; MANN KG, 1990, BLOOD, V76, P1; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; McGee MP, 1999, BBA-MOL BASIS DIS, V1453, P239, DOI 10.1016/S0925-4439(98)00108-2; McGee MP, 1998, BIOCHEM J, V330, P533; MORRIS SJ, 1985, BIOCHIM BIOPHYS ACTA, V818, P365, DOI 10.1016/0005-2736(85)90011-2; MUKHERJEE S, 1994, BIOCHEMISTRY-US, V33, P5089, DOI 10.1021/bi00183a012; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; Nicolaes GAF, 2000, BLOOD COAGUL FIBRIN, V11, P89, DOI 10.1097/00001721-200011010-00010; PEROCHON E, 1992, BIOCHEMISTRY-US, V31, P7672, DOI 10.1021/bi00148a031; PETERSEN TE, 1980, FEBS LETT, V114, P278, DOI 10.1016/0014-5793(80)81133-1; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; Smeets EF, 1996, THROMB RES, V81, P419, DOI 10.1016/0049-3848(96)00014-X; Smirnov MD, 1999, BIOCHEMISTRY-US, V38, P3591, DOI 10.1021/bi982538b; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; Wang SX, 1999, BIOCHEMISTRY-US, V38, P9477, DOI 10.1021/bi990084s; WEBER DJ, 1992, J BIOL CHEM, V267, P4564; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; ZHANG L, 1994, J BIOL CHEM, V269, P3590	64	52	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23895	23902		10.1074/jbc.M008332200	http://dx.doi.org/10.1074/jbc.M008332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312259	hybrid			2022-12-25	WOS:000169531100090
J	Lee, K; Cohen, SN				Lee, K; Cohen, SN			Effects of 3 ' terminus modifications on mRNA functional decay during in vitro protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RIBONUCLEASE-E; POLYNUCLEOTIDE PHOSPHORYLASE; ANTISENSE RNAI; CELL-DIVISION; DEGRADATION; TRANSCRIPTION; TRANSLATION; POLYMERASE; INITIATION	The pcnB gene, which encodes the principal poly(A) polymerase of Escherichia coli, promotes 3'-polyadenylation and chemical decay of mRNA. However, there is no evidence that pcnB-mediated mRNA destabilization decreases protein synthesis, suggesting that polyadenylation may enhance translational efficiency. Using in vitro translation by E, coli cell extracts and toeprinting analysis of transcripts encoded by the chloramphenicol acetyltransferase (CAT) and p-galactosidase genes to investigate this notion, we found no effect of poly(A) tails on protein synthesis. However, we observed that 3'-polyguanylation delayed the chemical decay of CAT mRNA and, even more dramatically, increased the ability of CAT mRNA to produce enzymatically active full-length protein in 30 S E. coli cell fractions, This resulted from interference with the primary mechanism for inactivation of CAT transcript function in cell extracts, which occurred by 3'-exonucleolytic degradation rather than endonucleolytic fragmentation by RNase E, Using bacteriophage T7 RNA polymerase to install poly(G) tails on mRNAs transcribed from polymerase chain reaction-generated DNA templates, we observed sharply increased synthesis of active proteins in vitro in coupled transcription/translation reactions. The ability of poly(G) tails to functionally stabilize transcripts from polymerase chain reaction-generated templates allows proteins encoded by translational open reading frames on genomic DNA or cDNA to be synthesized directly and efficiently in vitro.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Ctr Med, Dept Genet, Room M322, Stanford, CA 94305 USA.	sncohen@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Coburn GA, 1996, J BIOL CHEM, V271, P15776, DOI 10.1074/jbc.271.26.15776; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DREYFUS M, 1988, J MOL BIOL, V204, P79, DOI 10.1016/0022-2836(88)90601-8; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; Hagege JM, 1997, MOL MICROBIOL, V25, P1077, DOI 10.1046/j.1365-2958.1997.5311904.x; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; IOST I, 1992, J BACTERIOL, V174, P619, DOI 10.1128/jb.174.2.619-622.1992; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; Jones GH, 1996, J BACTERIOL, V178, P4281, DOI 10.1128/jb.178.14.4281-4288.1996; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Kim DM, 2000, BIOTECHNOL PROGR, V16, P385, DOI 10.1021/bp000031y; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Lisitsky I, 1999, EUR J BIOCHEM, V261, P468, DOI 10.1046/j.1432-1327.1999.00285.x; MCCARTHY JEG, 1994, TRENDS GENET, V10, P402, DOI 10.1016/0168-9525(94)90057-4; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MEACOCK PA, 1980, CELL, V20, P529, DOI 10.1016/0092-8674(80)90639-X; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Moll I, 1998, FEBS LETT, V436, P213, DOI 10.1016/S0014-5793(98)01131-4; NEVIN DE, 1991, FEBS LETT, V291, P259, DOI 10.1016/0014-5793(91)81297-L; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; RINGQUIST S, 1993, BIOCHEMISTRY-US, V32, P10254, DOI 10.1021/bi00089a048; Sarkar N, 1997, ANNU REV BIOCHEM, V66, P173, DOI 10.1146/annurev.biochem.66.1.173; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; STENT GS, 1966, PROC R SOC SER B-BIO, V164, P181, DOI 10.1098/rspb.1966.0022; Szalewska-Palasz A, 1998, FEBS LETT, V432, P70, DOI 10.1016/S0014-5793(98)00834-5; TAL M, 1972, BIOCHIM BIOPHYS ACTA, V281, P381, DOI 10.1016/0005-2787(72)90452-2; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	48	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23268	23274		10.1074/jbc.M102408200	http://dx.doi.org/10.1074/jbc.M102408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309400	hybrid			2022-12-25	WOS:000169531100009
J	Soref, CM; Di, YP; Hayden, L; Zhao, YH; Satre, MA; Wu, R				Soref, CM; Di, YP; Hayden, L; Zhao, YH; Satre, MA; Wu, R			Characterization of a novel airway epithelial cell specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALL-TRANS-RETINOL; CDNA CLONING; 13-CIS-RETINOIC ACID; ESCHERICHIA-COLI; MESSENGER-RNA; VITAMIN-A; IDENTIFICATION; RECEPTORS; TISSUE; MOUSE	Multiple retinoic acid responsive cDNAs were isolated from a high density cDNA microarray membrane, which was developed from a cDNA Library of human tracheobronchial epithelial cells. Five selected cDNA clones encoded the sequence of the same novel gene. The predicted open reading frame of the novel gene encoded a protein of 319 amino acids. The deduced amino acid sequence contains four motifs that are conserved in the short-chain alcohol dehydrogenase/reductase (SDR) family of proteins. The novel gene shows the greatest homology to a group of dehydrogenases that can oxidize retinol (retinol dehydrogenases), The mRNA of the novel gene was found in trachea, colon, tongue, and esophagus. In situ hybridization of airway tissue sections demonstrated epithelial cell-specific gene expression, especially in the ciliated cell type. Both all-trans-retinoic acid and g-cis-retinoic acid were able to elevate the expression of the novel gene in primary human tracheobronchial epithelial cells in vitro. This elevation coincided with an enhanced retinol metabolism in these cultures. COS cells transfected with an expression construct of the novel gene were also elevated in the metabolism of retinol. The results suggested that the novel gene represents a new member of the SDR family that may play a critical role in retinol metabolism in airway epithelia as well as in other epithelia of colon, tongue, and esophagus.	Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Wu, R (corresponding author), Univ Calif Davis, Ctr Comparat Resp Biol & Med, Surge 1 Bldg,Rm 1121,1 Shields Ave, Davis, CA 95616 USA.		Di, Yuanpu Peter/H-4191-2016	Di, Yuanpu Peter/0000-0003-2028-2087	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009573, R37HL035635, F32HL010324, R01HL035635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006230, R01ES009701] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL10324, F32 HL009573, HL35635, F32 HL09573] Funding Source: Medline; NIEHS NIH HHS [ES09701, ES06230, ES00628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Bhat PV, 1998, BIOCHEM CELL BIOL, V76, P59, DOI 10.1139/bcb-76-1-59; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; Booth SL, 1997, J NUTR, V127, P587, DOI 10.1093/jn/127.4.587; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOR MJ, 1987, BIOCHEM PHARMACOL, V36, P919, DOI 10.1016/0006-2952(87)90185-7; De Luca L M, 1985, Acta Vitaminol Enzymol, V7 Suppl, P13; DELEENHEER AP, 1982, J LIPID RES, V23, P1362; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; ECKHOFF C, 1990, J LIPID RES, V31, P1445; FELL HB, 1953, J PHYSIOL-LONDON, V119, P470, DOI 10.1113/jphysiol.1953.sp004860; Furr Harold C., 1994, P179; Gamble MV, 1999, J LIPID RES, V40, P2279; Gamble MV, 2000, BBA-PROTEIN STRUCT M, V1476, P3, DOI 10.1016/S0167-4838(99)00232-0; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; Haselbeck RJ, 1999, DEV GENET, V25, P353, DOI 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G; HUANG TH, 1989, DIFFERENTIATION, V41, P78, DOI 10.1111/j.1432-0436.1989.tb00735.x; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1986, BIOCHEM SOC T, V14, P930, DOI 10.1042/bst0140930; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; Koo JS, 1999, BIOCHEM J, V338, P351, DOI 10.1042/0264-6021:3380351; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; PERSSON B, 1995, ADV EXP MED BIOL, V372, P383; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Ribaya-Mercado JD, 1999, AM J CLIN NUTR, V69, P278; ROBINSON CB, 1991, J TISSUE CULTURE MET, V13, P95; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487; Simon A, 1999, J CELL SCI, V112, P549; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; Su J, 1999, ENDOCRINOLOGY, V140, P5275, DOI 10.1210/endo.140.11.7137; Ulven SM, 2000, DEV BIOL, V220, P379, DOI 10.1006/dbio.2000.9634; Vogel S, 2000, J LIPID RES, V41, P882; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WU R, 1986, J CELL PHYSIOL, V127, P73, DOI 10.1002/jcp.1041270110; WU R, 1997, GROWTH DEV LUNG, P211; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	58	42	43	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24194	24202		10.1074/jbc.M100332200	http://dx.doi.org/10.1074/jbc.M100332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11304534	hybrid			2022-12-25	WOS:000169531100128
J	Honey, K; Duff, M; Beers, C; Brissette, WH; Elliott, EA; Peters, C; Maric, M; Cresswell, P; Rudensky, A				Honey, K; Duff, M; Beers, C; Brissette, WH; Elliott, EA; Peters, C; Maric, M; Cresswell, P; Rudensky, A			Cathepsin S regulates the expression of cathepsin L and the turnover of gamma-interferon-inducible lysosomal thiol reductase in B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; INVARIANT-CHAIN; ANTIGEN PRESENTATION; DENDRITIC CELLS; SURFACE EXPRESSION; DISULFIDE BONDS; COMPLEX; MOLECULES; INHIBITION; PROTEINASES	Loading of antigenic peptide fragments on major histocompatibility complex class II molecules is essential for generation of CD4(+) T cell responses and occurs after cathepsin mediated degradation of the invariant chain chaperone molecule. Cathepsins are expressed differentially in antigen presenting cells, and mice deficient in cathepsin S or cathepsin L exhibit severely impaired antigen presentation in peripheral lymphoid organs and the thymus, respectively. To determine whether these defects are due solely to the block in invariant chain cleavage, we used cathepsin-deficient B cells to examine the role of cathepsins S and E in the degradation of other molecules important in the class II presentation pathway. Our data indicate that neither cathepsin S nor B is critical for H-2M degradation or processing of precursor gamma -interferon inducible lysosomal thiol reductase (GILT) to a mature thiol reductase, but suggest a role for cathepsin S in the turnover of mature GILT and in regulating levels of mature cathepsin L protein in E cells. Despite the presence of mature cathepsin L protein, no enzyme activity could be detected in B cells or dendritic cells. These experiments suggest a novel mechanism by which these functionally important enzymes may be regulated.	Univ Washington, Dept Immunol, Seattle, WA 98115 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98115 USA; Pfizer Inc, Dept Immunol, Groton, CT 06340 USA; Univ Freiburg, Inst Mol Med & Zellforsch, D-76106 Freiburg, Germany; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Pfizer; University of Freiburg; Howard Hughes Medical Institute; Yale University	Rudensky, A (corresponding author), Univ Washington, Dept Immunol, Seattle, WA 98115 USA.							ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; Arunachalam B, 1998, J IMMUNOL, V160, P5797; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Cimerman N, 1999, J ENZYM INHIB, V14, P167, DOI 10.3109/14756369909036552; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Guay J, 2000, EUR J BIOCHEM, V267, P6311, DOI 10.1046/j.1432-1327.2000.01730.x; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; Jensen P E, 1995, Semin Immunol, V7, P347, DOI 10.1006/smim.1995.0039; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; Leonardi A, 1996, BIOL CHEM H-S, V377, P319; Liuzzo JP, 1999, MOL MED, V5, P320, DOI 10.1007/BF03402068; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; Mach N, 2000, CANCER RES, V60, P3239; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MASON RW, 1989, BIOCHEM J, V263, P945, DOI 10.1042/bj2630945; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; MERKEL BJ, 1995, J IMMUNOL, V154, P128; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; Nakagawa TY, 1999, IMMUNOL REV, V172, P121, DOI 10.1111/j.1600-065X.1999.tb01361.x; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Phan UT, 2000, J BIOL CHEM, V275, P25907, DOI 10.1074/jbc.M003459200; Pierre P, 2000, J EXP MED, V191, P1057, DOI 10.1084/jem.191.6.1057; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; Riese RJ, 1998, J CLIN INVEST, V101, P2351, DOI 10.1172/JCI1158; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SALMINEN A, 1990, BIOCHEM J, V272, P39, DOI 10.1042/bj2720039; Shachar I, 1996, SCIENCE, V274, P106, DOI 10.1126/science.274.5284.106; Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	52	44	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22573	22578		10.1074/jbc.M101851200	http://dx.doi.org/10.1074/jbc.M101851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306582	hybrid			2022-12-25	WOS:000169412700081
J	Ritz, H; Schramek, N; Bracher, A; Herz, S; Eisenreich, W; Richter, G; Bacher, A				Ritz, H; Schramek, N; Bracher, A; Herz, S; Eisenreich, W; Richter, G; Bacher, A			Biosynthesis of riboflavin - Studies on the mechanism of GTP cyclohydrolase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REDUCTASE; SYNTHASE; GENE	GTP cyclohydrolase II catalyzes the first committed reaction in the biosynthesis of the vitamin riboflavin, The recombinant enzyme from Escherichia coli is shown to pro duce 2,5 diamino-6-beta -ribosylamino 4(3H)-pyrimidinone 5'-phosphate and GMP at an approximate molar ratio of 10:1. The main product is subject to spontaneous isomerization affording the alpha -anomer. O-18 from solvent water is incorporated by the enzyme into the phosphate group of the 5-aminopyrimidine derivative as well as GMP. These data are consistent with the transient formation of a covalent phosphoguanosyl derivative of the enzyme. Subsequent ring opening of the covalently bound nucleotide followed by hydrolysis of the phosphodiester bond could then afford the pyrimidine type product. The hydrolysis of the phosphodiester bond without prior ring opening could afford GMP. The enzyme reaction is cooperative with a Hill coefficient of 1.3, Inhibition by pyrophosphate is competitive. Inhibition by orthophosphate is partially uncompetitive at low concentration and competitive at concentrations above 6 mM.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Bacher, A (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Eisenreich, Wolfgang/A-1258-2013; Richter, Gerald/F-3642-2011	Eisenreich, Wolfgang/0000-0002-9832-8279; 				Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Bacher A, 1997, METHOD ENZYMOL, V280, P382; Bacher A., 1993, BIOORGANIC CHEM FRON, P147, DOI [10.1007/978-3-642-78110-0, DOI 10.1007/978-3-642-78110-0]; BLAU N, 1982, BIOCH CLIN ASPECTS P, V1, P103; Bracher A, 1998, J BIOL CHEM, V273, P28132, DOI 10.1074/jbc.273.43.28132; Bracher A, 1999, J BIOL CHEM, V274, P16727, DOI 10.1074/jbc.274.24.16727; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; BURG AW, 1968, J BIOL CHEM, V243, P2349; DIETRICH R, 1979, J AM CHEM SOC, V101, P6144, DOI 10.1021/ja00514a059; FOOR F, 1975, J BIOL CHEM, V250, P3545; Foor F, 1980, Methods Enzymol, V66, P303; Herz S, 2000, PHYTOCHEMISTRY, V53, P723, DOI 10.1016/S0031-9422(00)00013-3; Kobayashi M, 1998, J BIOL CHEM, V273, P26394, DOI 10.1074/jbc.273.41.26394; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NAR H, 1996, BIOCH SOC T S, V24, P37; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Schramek N, 2001, J BIOL CHEM, V276, P2622, DOI 10.1074/jbc.M004912200; SHIOTA T, 1965, J BIOL CHEM, V240, P4449	19	37	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22273	22277		10.1074/jbc.M100752200	http://dx.doi.org/10.1074/jbc.M100752200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301327	hybrid			2022-12-25	WOS:000169412700042
J	Suenaga, H; Goto, M; Furukawa, K				Suenaga, H; Goto, M; Furukawa, K			Emergence of multifunctional oxygenase activities by random priming recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCHLORINATED BIPHENYL DEGRADATION; PSEUDOMONAS-PSEUDOALCALIGENES KF707; SITE-DIRECTED MUTAGENESIS; SP STRAIN LB400; NAPHTHALENE DIOXYGENASE; CHLORINE SUBSTITUTION; SUBSTRATE-SPECIFICITY; TOLUENE DIOXYGENASE; ALPHA-SUBUNIT; AMINO-ACIDS	Biphenyl dioxygenase (Bph Dox) is responsible for the initial dioxygenation of biphenyl, The large subunit (BphA1) of Bph Dox plays a crucial role in determination of substrate specificity of biphenyl-related compounds including polychlorinated biphenyls (PCBs), Functional evolution of Bph Dox of Pseudomonas pseudoalcaligenes KF707 was accomplished by random priming recombination of the bphA1 gene, involving two rounds of in vitro recombination and mutation followed by selection for increased activity in vivo. Evolved Bph Dox acquired novel and multifunctional degradation capabilities not only for PCBs but also for dibenzofuran, dibenzo-p-dioxin, dibenzothiophene, and fluorene, the compounds scarcely attacked by the original KF707 Bph Dox. The modes of oxygenation were angular and lateral dioxygenation for dibenzofuran and dibenzo-p-dioxin, sulfoxidation for dibenzothiophene, and mono-oxygenation for fluorene, These enzymes also exhibited enhanced degradation abilities for PCB congeners, retaining 2,3-dioxygenase activity and gaining 3,4-dioxygenase activity, depending on the chlorine substitution of PCB congeners. Further mutation analysis revealed that the amino acid at position 376 in BphA1 is significantly involved in the acquisition of multifunctional oxygenase activities and mode of oxygenation.	Kyushu Univ, Appl Microbiol Lab, Grad Sch Bioresource & Bioenvironm Sci, Fukuoka 8128581, Japan	Kyushu University	Furukawa, K (corresponding author), Kyushu Univ, Appl Microbiol Lab, Grad Sch Bioresource & Bioenvironm Sci, Hakozaki 6-10-1, Fukuoka 8128581, Japan.		KENSUKE, FURUKAWA/R-3105-2019					BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; BEDARD DL, 1986, APPL ENVIRON MICROB, V51, P761, DOI 10.1128/AEM.51.4.761-768.1986; Beil S, 1997, EUR J BIOCHEM, V247, P190, DOI 10.1111/j.1432-1033.1997.00190.x; BUNZ PV, 1993, J BACTERIOL, V175, P6467; CERNIGLIA CE, 1979, BIOCHEM J, V180, P175, DOI 10.1042/bj1800175; CHUNG SY, 1994, BIOSCI BIOTECH BIOCH, V58, P2111, DOI 10.1271/bbb.58.2111; ERICKSON BD, 1993, APPL ENVIRON MICROB, V59, P3858, DOI 10.1128/AEM.59.11.3858-3862.1993; FURUKAWA K, 1986, J BACTERIOL, V166, P392, DOI 10.1128/jb.166.2.392-398.1986; FURUKAWA K, 1993, J BACTERIOL, V175, P5224, DOI 10.1128/JB.175.16.5224-5232.1993; FURUKAWA K, 1979, APPL ENVIRON MICROB, V38, P301, DOI 10.1128/AEM.38.2.301-310.1979; FURUKAWA K, 1982, BIODEGRADATION DETOX, P33; Furukawa Kensuke, 1994, Biodegradation, V5, P289, DOI 10.1007/BF00696466; GIBSON DT, 1995, J BACTERIOL, V177, P2615, DOI 10.1128/jb.177.10.2615-2621.1995; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; HIROSE J, 1994, GENE, V138, P27; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; MASAI E, 1995, APPL ENVIRON MICROB, V61, P2079, DOI 10.1128/AEM.61.6.2079-2085.1995; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; MONDELLO FJ, 1989, J BACTERIOL, V171, P1725, DOI 10.1128/jb.171.3.1725-1732.1989; Nojiri H, 1999, J BACTERIOL, V181, P3105, DOI 10.1128/JB.181.10.3105-3113.1999; Parales RE, 2000, J BACTERIOL, V182, P5495, DOI 10.1128/JB.182.19.5495-5504.2000; Parales RE, 2000, J BACTERIOL, V182, P1641, DOI 10.1128/JB.182.6.1641-1649.2000; Resnick SM, 1996, APPL ENVIRON MICROB, V62, P4073, DOI 10.1128/AEM.62.11.4073-4080.1996; SATO S, 1997, J BACTERIOL, V179, P1850; SHAO Z, 1998, NUCLEIC ACIDS RES, V26, P381; SIMON MJ, 1993, GENE, V127, P31, DOI 10.1016/0378-1119(93)90613-8; Suenaga H, 1999, J BIOSCI BIOENG, V87, P430, DOI 10.1016/S1389-1723(99)80090-5; Sylvestre Michel, 1994, P47; TAIRA K, 1992, J BIOL CHEM, V267, P4844; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; WACKETT LP, 1988, BIOCHEMISTRY-US, V27, P1360, DOI 10.1021/bi00404a041; WITTICH RM, 1992, APPL ENVIRON MICROB, V58, P1005, DOI 10.1128/AEM.58.3.1005-1010.1992	37	42	47	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22500	22506		10.1074/jbc.M101323200	http://dx.doi.org/10.1074/jbc.M101323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312272	hybrid			2022-12-25	WOS:000169412700071
J	Yamaguchi, N; Xin, CL; Meissner, G				Yamaguchi, N; Xin, CL; Meissner, G			Identification of apocalmodulin and Ca2+-calmodulin regulatory domain in skeletal muscle Ca2+ release channel, ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING SITES; SARCOPLASMIC-RETICULUM; CALCIUM RELEASE; PROTEIN; SENSITIVITY; MODULATION; EXPRESSION; CLONING; CA-2+; RYR1	Fusion proteins and full-length mutants were generated to identify the Ca2(+)-free (apoCaM) and Ca2(+)bound (CaCaM) calmodulin binding sites of the skeletal muscle Ca2+ release channel/ryanodine receptor (RyR1). [S-35]Calmodulin (CaM) overlays of fusion proteins revealed one potential Ca2+-dependent (aa 3553-3662) and one Ca2+-independent (aa 4302-4430) CaM binding domain. W3620A or L3624D substitutions almost abolished completely, whereas V3619A or L3624A substitutions reduced [S-35]CaM binding to fusion protein (aa 3553-3662). Three full-length RyR1 single-site mutants (V3619A, W3620A,L3624D) and one deletion mutant (Delta 4274-4535) were generated and expressed in human embryonic kidney 293 cells. L3624D exhibited greatly reduced [35S]CaM binding affinity as indicated by a lack of noticeabIe binding of apoCaM and CaCaM (nanomolar) and the requirement of CaCaM (micromolar) for the inhibition of RyR1 activity. W3620A bound CaM (nanomolar) only in the absence of Ca2+ and did not show inhibition of RyR1 activity by 3 muM CaCaM. V3619A and the deletion mutant bound apoCaM and CaCaM at levels compared with wild type. V3619A activity was inhibited by CaM with IC50 similar to 200 nM, as compared with IC50 similar to 50 nM for wild type and the deletion mutant. [S-35]CaM binding experiments with sarcoplasmic reticulum vesicles suggested that apoCaM and CaCaM bind to the same region of the native RyR1 channel complex. These results indicate that the intact RyR1 has a single CaM binding domain that is shared by apoCaM and CaCaM.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Yamaguchi, N (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	meissner@med.unc.edu			NIAMS NIH HHS [AR18687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018687, R37AR018687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALSHAW DM, 2001, IN PRESS J BIOL CHEM; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fruen BR, 2000, AM J PHYSIOL-CELL PH, V279, pC724, DOI 10.1152/ajpcell.2000.279.3.C724; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; GUERRINI R, 1995, BIOCHEMISTRY-US, V34, P5120, DOI 10.1021/bi00015a024; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Samso M, 2000, BIOPHYS J, V78, p149A; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Yamaguchi N, 2001, BIOPHYS J, V80, p385A; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	88	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22579	22585		10.1074/jbc.M102729200	http://dx.doi.org/10.1074/jbc.M102729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306590	hybrid, Green Published			2022-12-25	WOS:000169412700082
J	Graves, PR; Lovly, CM; Uy, GL; Piwnica-Worms, H				Graves, PR; Lovly, CM; Uy, GL; Piwnica-Worms, H			Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding	ONCOGENE			English	Article						cell cycle; Cdc25C; 14-3-3; nuclear import; nuclear export	CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; TYROSINE KINASE; DNA-DAMAGE; HUMAN WEE1; 7-HYDROXYSTAUROSPORINE UCN-01; PHOSPHORYLATION SITES; MOLECULAR-CLONING; DEPENDENT KINASES; G(2) CHECKPOINT	Entry into mitosis requires activation of the Cdc2 protein kinase by the Cdc25C protein phosphatase, The interactions between Cdc2 and Cdc25C are negatively regulated throughout interphase and in response to G2 checkpoint activation. This is accomplished in part by maintaining the Cdc25 phosphatase in a phosphorylated form that binds 14-3-3 proteins. Here we report that 14-3-3 binding regulates the intracellular trafficking of Cdc25C, Although primarily cytoplasmic, Cdc25C accumulated in the nuclei of leptomycin B (LMB)-treated cells, indicating that Cdc25C is actively exported out of the nucleus. A mutant of Cdc25C that is unable to bind 14-3-3 was partially nuclear in the absence of LMB and its nuclear accumulation was greatly enhanced by LMB-treatment, A nuclear export signal (NES) was identified within the amino terminus of Cdc25C, Although mutation of the NES did not effect 14-3-3 binding, it did cause nuclear accumulation of Cdc25C, These results demonstrate that 14-3-3 binding is dispensable for the nuclear export of Cdc25C, However, complete nuclear accumulation of Cdc25C required loss of both NES function and 14-3-3 binding and this was accomplished both pharmacologically and by mutation. These findings suggest that the nuclear export of Cdc25C is mediated by an intrinsic NES and that 14-3-3 binding negatively regulates nuclear import.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Piwnica-Worms, Helen/C-5214-2012; Uy, Geoffrey/A-2058-2010; Uy, Geoffrey/AAD-9815-2021	Uy, Geoffrey/0000-0002-7809-0996; Lovly, Christine/0000-0002-3641-6361				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Busby EC, 2000, CANCER RES, V60, P2108; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NISHI K, 1994, J BIOL CHEM, V269, P6320; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OGG S, 1994, J BIOL CHEM, V269, P30461; OUYANG B, 1997, J BIOL CHEM, P28646; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	71	168	175	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1839	1851		10.1038/sj.onc.1204259	http://dx.doi.org/10.1038/sj.onc.1204259			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313932				2022-12-25	WOS:000167908400005
J	Beadling, C; Cereseto, A; Fan, W; Naramura, M; Smith, KA				Beadling, C; Cereseto, A; Fan, W; Naramura, M; Smith, KA			Cytokine response gene 8 (CR8) regulates the cell cycle G1-S phase transition and promotes cellular survival	ONCOGENE			English	Article						basic helix-loop-helix; G1 progression; survival	LOOP-HELIX PROTEINS; ID PROTEINS; EXPRESSION; GROWTH; TRANSCRIPTION; PROGRESSION; APOPTOSIS; DIFFERENTIATION; ENHANCER; ARREST	Cellular proliferation and survival are modulated by the expression of specific genes. Cytokine response gene 8 (CR8), which was originally cloned as an IL-2-induced gene in human T lymphocytes, encodes a basic helix-loop-helix (bHLH) transcription factor, The CR8 gene product is highly conserved among human, mouse and rat, and contains sequence motifs that distinguish it from other bHLH families, The CR8 gene is ubiquitously expressed, and CR8 gene expression is induced by both growth-promoting as well as growth-inhibitory stimuli. As bHLH proteins have been found to regulate both the G1-S phase cell cycle transition, as well as cellular survival, the effects of CR8 on these processes were investigated. Ectopic CR8 expression in asynchronous U2OS cell cultures reduces the percentage of cells in the cell cycle S phase, and also slows the entry of G1-synchronized cells into S phase. The prolonged G1 interval correlates with impaired elevation of cyclin E protein and prolonged p21 protein expression in G1, CR8 expression also protects U2OS cells from serum-withdrawal induced apoptosis, These results indicate that CR8 is an important modulator of both the G1-S phase cell cycle transition, and cellular survival.	New York Presbyterian Cornell Med Ctr, Div Immunol, Dept Med, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Weill Med Coll, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Grad Sch Med Sci, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), New York Presbyterian Cornell Med Ctr, Div Immunol, Dept Med, 1300 York Ave, New York, NY 10021 USA.			Cereseto, Anna/0000-0003-4453-2597; Naramura, Mayumi/0000-0003-3658-0767	NIAID NIH HHS [1RO1 AI44207-O1A1, R01 AI 32031-24] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032031, R01AI044207] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; GONG J, 1994, CELL PROLIFERAT, V27, P357, DOI 10.1111/j.1365-2184.1994.tb01469.x; GONG JP, 1993, INT J ONCOL, V3, P1037; GULLBERG M, 1986, J EXP MED, V163, P270, DOI 10.1084/jem.163.2.270; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297	34	6	6	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1771	1783		10.1038/sj.onc.1204212	http://dx.doi.org/10.1038/sj.onc.1204212			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313924				2022-12-25	WOS:000167750900010
J	Kobrinsky, EM; Kirchberger, MA				Kobrinsky, EM; Kirchberger, MA			Evidence for a role of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in thapsigargin and Bcl-2 induced changes in Xenopus laevis oocyte maturation	ONCOGENE			English	Article						SERCA; Xenopus laevis; meiotic maturation; Bcl-2 thapsigargin; capacitative Ca2+ entry	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CA2+ STORES; ENDOPLASMIC-RETICULUM; CELL-LINE; CALCIUM-PUMP; PROTEIN; APOPTOSIS; ATPASE; PHOSPHOLAMBAN; INHIBITION	Thapsigargin (Tg), a selective inhibitor of sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (SERCA), causes depiction of intracellular Ca2+ stores, hence activation of capacitative Ca2+ entry (CCE). Incubation of Xenopus laevis oocytes with Tg resulted in an increased rate of progesterone-induced meiotic maturation. Non-mitochondrial Ca-45(2+) uptake by SERCA-containing microsomes prepared from control wild-type oocytes microinjected with sterile water was inhibited essentially 100% by Tg. However, overexpression of Bcl-2, an oncogene known to protect against Tg-induced apoptosis in certain cell types, resulted in only 40% inhibition of microsomal Ca-45(2+) uptake by Tg while non-inhibited Ca-45(2+) uptake remained unchanged, Moreover Bcl-2 overexpression also protected against inhibition of CCE. I-Cl(Ca) was similar in Bcl-2-overexpressing and control oocytes when intracellular Ca2+ store depletion was induced by microinjection of inositol 1,4,5-trisphosphate (InsP(3)) and other means and when CCE was induced by means independent of SERCA inhibition. Our data indicate that Bcl-2 affects neither the InsP(3) receptor nor Ca2+ entry itself. At the end of a 24-h period after progesterone addition to the medium, only 25% of Bcl-2-overexpressing oocytes had matured compared to 85% of control oocytes. Our data suggest that SERCA participates in Xenopus oocyte maturation by controlling cytosolic Ca2+ and/or intracellular Ca2+ stores, hence CCE. An observed progesterone-dependent protein kinase-catalysed phosphorylation of SERCA is further indication of its role in oocyte maturation.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Kirchberger, MA (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.				NHLBI NIH HHS [HL15764] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015764] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; Antipenko AY, 1997, CARDIOVASC RES, V36, P67, DOI 10.1016/S0008-6363(97)00183-1; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BOYER J, 1983, BIOCHIMIE, V65, P15, DOI 10.1016/S0300-9084(83)80024-8; CHOI OH, 1993, J IMMUNOL, V151, P5586; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; ENOUF J, 1987, J BIOL CHEM, V262, P9293; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Han JK, 1995, BIOCHEM BIOPH RES CO, V217, P931, DOI 10.1006/bbrc.1995.2860; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; Kobrinsky E, 1995, DEV BIOL, V172, P531, DOI 10.1006/dbio.1995.8058; Kobrinsky E, 1999, AM J PHYSIOL-CELL PH, V277, pC665, DOI 10.1152/ajpcell.1999.277.4.C665; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAMB M, 1994, P NATL ACAD SCI USA, V91, P6569; Lechleiter JD, 1998, BIOPHYS CHEM, V72, P123, DOI 10.1016/S0301-4622(98)00128-8; Mahaney J, 1999, ARCH BIOCHEM BIOPHYS, V372, P408, DOI 10.1006/abbi.1999.1524; Matten Wayne T., 1994, Seminars in Developmental Biology, V5, P173, DOI 10.1006/sedb.1994.1023; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Vairo G, 1996, ONCOGENE, V13, P1511; VILAIN JP, 1989, J EXP ZOOL, V250, P100, DOI 10.1002/jez.1402500114; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Wei HF, 1998, J NEUROCHEM, V70, P2305; Xu AD, 2000, J BIOL CHEM, V275, P4407, DOI 10.1074/jbc.275.6.4407; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T	44	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					933	941		10.1038/sj.onc.1204153	http://dx.doi.org/10.1038/sj.onc.1204153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314028				2022-12-25	WOS:000167097000004
J	Bradley, G; Irish, J; MacMillan, C; Mancer, K; Witterick, I; Hartwick, W; Gullane, P; Kamel-Reid, S; Benchimol, S				Bradley, G; Irish, J; MacMillan, C; Mancer, K; Witterick, I; Hartwick, W; Gullane, P; Kamel-Reid, S; Benchimol, S			Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma	ONCOGENE			English	Article						p53; mutation; immunohistochemistry; p14ARF; homozygous deletion; oral squamous carcinoma	NECK-CANCER; TUMOR-SUPPRESSOR; P53 ALTERATIONS; HEAD; MUTATIONS; SMOKING; GENE; OVEREXPRESSION; INACTIVATION; PROGRESSION	Oral squamous cell carcinoma (OSCC) is associated with heavy smoking and drinking, but the molecular pathway of tumorigenesis is not understood. Inactivation of the p53 tumor suppressor gene is likely to play an important role since p53 mutation is frequently found. The p14ARF tumor suppressor gene is functionally linked to p53, because it is activated by oncogenes and causes p53-dependent growth arrest and apoptosis, The relationship between p14ARF and p53 inactivation has not been described for OSCC, We studied 25 cases of OSCC to determine if there is an inverse correlation between p53 mutation and p14ARF inactivation by homozygous deletion or mutation. p53 mutation was found in 16 of 25 cases (64%), including nine missense and seven truncating mutations, While all cases with missense mutations showed abnormal accumulation of p53 protein, there were also five carcinomas which showed increased p53 staining in the absence of mutation. p14ARF deletion or mutation was found in eight cases (32%), six of which also demonstrated p53 mutation. Our findings indicate that OSCC often involves loss of both p14ARF and p53 function and suggest that inactivation of these two tumor suppressor genes are not functionally equivalent during tumorigenesis.	Univ Toronto, Fac Dent, Toronto, ON M5G 1G6, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Dept Otolaryngol Surg Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Toronto Gen Hosp, Dept Pathol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Mt Sinai Hosp, Dept Otolaryngol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Bradley, G (corresponding author), Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G6, Canada.			Kamel-Reid, Suzanne/0000-0002-4386-0292; Benchimol, Samuel/0000-0003-3433-890X				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BLOT WJ, 1988, CANCER RES, V48, P3282; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; Califano J, 1996, CANCER RES, V56, P2488; Casey G, 1996, ONCOGENE, V13, P1971; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Ichimura K, 2000, CANCER RES, V60, P417; Koch WM, 1999, LARYNGOSCOPE, V109, P1544, DOI 10.1097/00005537-199910000-00002; Liloglou T, 1997, CANCER RES, V57, P4070; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Markl IDC, 1998, CANCER RES, V58, P5348; MASHBERG A, 1993, CANCER-AM CANCER SOC, V72, P1369, DOI 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L; Prives C, 1999, J PATHOL, V187, P112; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Shahnavaz SA, 2000, J PATHOL, V190, P417; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; XU L, 1994, DIAGN MOL PATHOL, V3, P83, DOI 10.1097/00019606-199406000-00004; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	29	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					654	658		10.1038/sj.onc.1204131	http://dx.doi.org/10.1038/sj.onc.1204131			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313998				2022-12-25	WOS:000166755000013
J	Melillo, RM; Carlomagno, F; De Vita, G; Formisano, P; Vecchio, G; Fusco, A; Billaud, M; Santoro, M				Melillo, RM; Carlomagno, F; De Vita, G; Formisano, P; Vecchio, G; Fusco, A; Billaud, M; Santoro, M			The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret	ONCOGENE			English	Article						Ret; tyrosine kinase; IRS-1; P13-K	PROTEIN-KINASE B; TYROSINE PHOSPHORYLATION; NEUROTROPHIC FACTOR; DOCKING SITE; PTB DOMAINS; ACTIVATION; MUTATIONS; SURVIVAL; INTERLEUKIN-4; PROLIFERATION	Tyrosine 1062 of Ret, which represents an intracytoplasmic docking site for multiple signaling molecules, is essential for Ret-mediated activation of phosphatidylinositol 3-Kinase (PI3-K), PI3-K, in turn, has been implicated in inducing cell survival and neoplastic transformation mediated by Ret, We have examined the mechanisms by which Ret stimulates PD-K. Here me show that the Insulin Receptor Substrate-1 (IRS-1) is tyrosine phosphorylated and associated with the p85 regulatory subunit of PI3-K in response to Ret activation. IRS-1 coimmunoprecipitates with Ret and co-expression of IRS-1 results in the potentiation of Ret-mediated activation of Akt(PKB), a bona fide effector of PI3-K, The association with the PTB domain of IRS-1 depends on the phosphorylation of tyrosine 1062 of Ret, The deletion of asparagine 1059 (delN1059) and the substitution of leucine 1061 (L1061P), two Ret mutations identified in families affected by congenital megacolon (Hirscbsprungs disease), impair the binding of IRS-1 to Ret as well as Ret-mediated Akt(PKB) stimulation. Finally, me show that Shc, which was previously identified as another ligand of Y1062 of Ret, competes with IRS-1 for the binding to Ret pY1062. All together, these findings suggest that IRS-1 is a component of the signaling pathway which leads to Ret-mediated PI3-K activation, a pathway which can be targeted by Hirschsprung-associated Ret mutations. The alternative binding of Shc and IRS-1 to Ret pY1062 can be a system to modulate the activation of different intracellular signaling pathways and to elicit different biological responses following net activation.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; CNRS, UMR5641, Genet Lab, F-69373 Lyon 08, France	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Centre National de la Recherche Scientifique (CNRS)	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		melillo, rosa marina/O-5255-2015; De Vita, Gabriella/H-4422-2011; Billaud, Marc N/M-6954-2013; Formisano, Pietro/J-4237-2018	De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197; Formisano, Pietro/0000-0001-7020-6870; MELILLO, Rosa Marina/0000-0002-9233-5275				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BESSET V, 2000, IN PRESS J BIOL CHEM; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Vita G, 2000, CANCER RES, V60, P3916; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Melillo RM, 1999, CANCER RES, V59, P1120; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Siegal G, 1999, NAT STRUCT BIOL, V6, P7, DOI 10.1038/4873; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; van der Geer P, 1999, ONCOGENE, V18, P3071, DOI 10.1038/sj.onc.1202879; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, RECENT PROG HORM RES, V53, P119; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	55	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					209	218		10.1038/sj.onc.1204049	http://dx.doi.org/10.1038/sj.onc.1204049			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313948				2022-12-25	WOS:000166410900008
J	Biagini, GA; Knodler, LA; Saliba, KJ; Kirk, K; Edwards, MR				Biagini, GA; Knodler, LA; Saliba, KJ; Kirk, K; Edwards, MR			Na+-dependent pH regulation by the amitochondriate protozoan parasite Giardia intestinalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; H+-ATPASE; INTRACELLULAR PH; PLASMA-MEMBRANE; CYTOPLASMIC PH; GASTROINTESTINAL PH; LEISHMANIA-DONOVANI; CRITHIDIA-LUCILIAE; TRYPANOSOMA-CRUZI; TRANSIT TIMES	Giardia intestinalis is a pathogenic fermentative parasite, which inhabits the gastrointestinal tract of animals and humans. G. intestinalis trophozoites are exposed to acidic fluctuations in vivo and must also cope with acidic metabolic endproducts. In this study, a combination of independent techniques (UP NMR spectroscopy, distribution of the weak acid pH marker 5,5-dimethyl-2,4-oxazolidinedione (DMO) and the fluorescent pH indicator 2 ' ,7 ' -bis (carboxyethyl)-5,6-carboxyfluorescein (BCECF)) were used to show that G. intestinalis trophozoites exposed to an extracellular pH range of 6.0-7.5 maintain their cytosolic pH (pH(i)) within the range 6.7-7.1. Maintenance of the resting pH(i) was Na+-dependent but unaffected by amiloride (or analogs thereof). Recovery of pH, from an intracellular acidosis was also Na+-dependent, with the rate of recovery varying with the extracellular Na+ concentration in a saturable manner (K-m = 18 mm; V-max = 10 mM H+ min(-1)). The recovery of pH. from an acid load was inhibited by amiloride but unaffected by a number of its analogs. The postulated involvement of one or more Na+/H+ exchanger(s) in the regulation of pH(i) in G. intestinalis is discussed.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	University of New South Wales Sydney; Australian National University	Biagini, GA (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.		Saliba, Kevin J/C-9166-2009; Biagini, Giancarlo A/F-3449-2011; Kirk, Kiaran/C-8299-2009	Saliba, Kevin J/0000-0003-3345-8440; Biagini, Giancarlo A/0000-0001-6356-6595; Kirk, Kiaran/0000-0002-5613-2622; Knodler, Leigh/0000-0002-3028-2198				ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Benchimol M, 1998, BIOCHEM J, V332, P695, DOI 10.1042/bj3320695; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; Brown DM, 1998, INT J PARASITOL, V28, P149, DOI 10.1016/S0020-7519(97)00172-0; DuBose TD, 1999, CURR OPIN NEPHROL HY, V8, P597, DOI 10.1097/00041552-199909000-00011; EDWARDS MR, 1989, MOL BIOCHEM PARASIT, V37, P19, DOI 10.1016/0166-6851(89)90098-4; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; FALLINGBORG J, 1990, J PEDIATR GASTR NUTR, V11, P211, DOI 10.1097/00005176-199008000-00010; FALLINGBORG J, 1990, ALIMENT PHARM THERAP, V4, P247, DOI 10.1111/j.1365-2036.1990.tb00469.x; FARTHING MJG, 1994, GIARDIA: FROM MOLECULES TO DISEASE, P15; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; GLASER TA, 1988, P NATL ACAD SCI USA, V85, P7602, DOI 10.1073/pnas.85.20.7602; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GROTE R, 1990, MOL BIOCHEM PARASIT, V42, P109, DOI 10.1016/0166-6851(90)90118-6; IGARASHI P, 1987, J BIOL CHEM, V262, P860; JIANG SP, 1994, J CELL PHYSIOL, V159, P60, DOI 10.1002/jcp.1041590109; KINSELLA JL, 1987, J BIOL CHEM, V262, P7092; KIRK K, 1986, J MAGN RESON, V70, P484, DOI 10.1016/0022-2364(86)90141-1; KNODLER LA, 1994, EXP PARASITOL, V79, P117, DOI 10.1006/expr.1994.1071; Lanfredi-Rangel A, 1999, PARASITOL RES, V85, P951, DOI 10.1007/s004360050665; Moreno SNJ, 1998, BIOCHEM J, V330, P853; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; ORLOWSKI J, 1996, NAPLUS HPLUS EXCHANG; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; RINDLER MJ, 1981, J BIOL CHEM, V256, P820; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; SCHOFIELD PJ, 1991, MOL BIOCHEM PARASIT, V45, P39, DOI 10.1016/0166-6851(91)90025-2; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; TERKUILE BH, 1992, MOL BIOCHEM PARASIT, V55, P21, DOI 10.1016/0166-6851(92)90123-2; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THOMAS JA, 1982, INTRACELLULAR PH ITS; Vanderheyden N, 1996, BIOCHEM J, V318, P103, DOI 10.1042/bj3180103; VIEIRA L, 1994, J BIOL CHEM, V269, P16254; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Warren K. S., 1989, New strategies in parasitology. Proceedings of an international symposium sponsored by Glaxo Research, Brocket Hall, Hertfordshire, UK, 22-25 April 1989, P217; WEINMAN SA, 1982, J GEN PHYSIOL, V80, P299, DOI 10.1085/jgp.80.2.299; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	39	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29157	29162		10.1074/jbc.M102728200	http://dx.doi.org/10.1074/jbc.M102728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11297564	hybrid			2022-12-25	WOS:000170346000071
J	Stuible, HP; Kombrink, E				Stuible, HP; Kombrink, E			Identification of the substrate specificity-conferring amino acid residues of 4-coumarate : coenzyme A ligase allows the rational design of mutant enzymes with new catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-FORMING ENZYMES; CELL-SUSPENSION CULTURES; COA LIGASE; PEPTIDE SYNTHETASES; PARA-COUMARATE; ISOENZYMES; BIOSYNTHESIS; EXPRESSION; BINDING; DOMAINS	4-Coumarate:coenzyme A ligases (4CLs) generally use, in addition to coumarate, caffeate and ferulate as their main substrates, However, the recently cloned Arabidopsis thaliana isoform At4CL2 is exceptional because it has no appreciable activity with ferulate, On the basis of information obtained from the crystal structure of the phenylalanine-activating domain of gramicidin S-synthetase, 10 amino acid residues were identified that may form the substrate binding pocket of 4CL, Among these amino acids, representing the putative "substrate specificity motif," only one residue, Met(293), was not con served in At4CL2, compared with At4CL1 and At4CL3, two isoforms using ferulate, Substitution of Met(293) or Lys(320), another residue of the putative substrate specificity motif, which in the predicted three-dimensional structure is located in close proximity to Met(293), by smaller amino acids converted At4CL2 to an enzyme capable of using ferulate. The activity with caffeate was not or only moderately affected. Conversely, substitution of Met(293) by bulky aromatic amino acids increased the apparent affinity (K-m) for caffeate up to 10-fold, whereas single substitutions of Val(294) did not affect substrate use, The results support our structural assumptions and suggest that the amino acid residues 293 and 320 of At4CL2 directly interact with the 3-methoxy group of the phenolic substrate and therefore allow a first insight into the structural principles determining substrate specificity of 4CL.	Max Planck Inst Zuchtungsforsch, Biochem Abt, D-50829 Cologne, Germany	Max Planck Society	Kombrink, E (corresponding author), Max Planck Inst Zuchtungsforsch, Biochem Abt, Carl von Linne Weg 10, D-50829 Cologne, Germany.							BECKERANDRE M, 1991, J BIOL CHEM, V266, P8551; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; Ehlting J, 1999, PLANT J, V19, P9, DOI 10.1046/j.1365-313X.1999.00491.x; FULDA M, 1994, MOL GEN GENET, V242, P241, DOI 10.1007/BF00280412; GRAND C, 1983, PLANTA, V158, P225, DOI 10.1007/BF01075258; Hu WJ, 1998, P NATL ACAD SCI USA, V95, P5407, DOI 10.1073/pnas.95.9.5407; Kajita S, 1997, PLANT PHYSIOL, V114, P871, DOI 10.1104/pp.114.3.871; KNOBLOCH KH, 1977, ARCH BIOCHEM BIOPHYS, V184, P237, DOI 10.1016/0003-9861(77)90347-2; KNOBLOCH KH, 1975, EUR J BIOCHEM, V52, P311, DOI 10.1111/j.1432-1033.1975.tb03999.x; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; Lee D, 1997, PLANT CELL, V9, P1985, DOI 10.1105/tpc.9.11.1985; RANJEVA R, 1976, BIOCHIMIE, V58, P1255, DOI 10.1016/S0300-9084(76)80125-3; Sambrook J., 2002, MOL CLONING LAB MANU; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; Stuible HP, 2000, FEBS LETT, V467, P117, DOI 10.1016/S0014-5793(00)01133-9; von Dohren H, 1999, CHEM BIOL, V6, pR273, DOI 10.1016/S1074-5521(00)80014-9; WALLIS PJ, 1977, PHYTOCHEMISTRY, V16, P1891, DOI 10.1016/0031-9422(77)80090-3; Weisshaar B, 1998, CURR OPIN PLANT BIOL, V1, P251, DOI 10.1016/S1369-5266(98)80113-1	25	59	81	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26893	26897		10.1074/jbc.M100355200	http://dx.doi.org/10.1074/jbc.M100355200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11323416	hybrid			2022-12-25	WOS:000169966900023
J	Zhong, Q; Kolls, JK; Schwarzenberger, P				Zhong, Q; Kolls, JK; Schwarzenberger, P			Retrovirus molecular conjugates - A novel, high transduction efficiency, potentially safety-improved, gene transfer system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; GEL-ELECTROPHORESIS; TERMINAL FRAGMENTS; TARGET-CELLS; DNA LENGTH; VECTORS; THERAPY; RECEPTOR; FIBRONECTIN; PROGENITOR	Two significant barriers limit the use of amphotropic retrovirus for human gene transfer protocols: 1) low transduction efficiency in cells with low receptor expression and 2) safety concerns originating from the risk of formation and propagation of replication competent virus in vivo. In principle, if ecotropic retrovirus, which is incapable of infecting human cells, could be transiently modified to effectively transduce human cells, this safety risk could be alleviated. Here we demonstrate that formation of amphotropic retrovirus polylysine molecular conjugates (aMMLV-PL) enhanced gene transfer up to 10-fold in a variety of human cell lines over the equivalent of unconjugated vector (aMMLV). The polylysine modification and formation of ecotropic retrovirus molecular conjugates (eMMLV-PL) permitted effective and stable transduction of different human cell lines as well as primary human bone marrow stroma cells at frequencies of greater than 80%. It is conceivable that this novel ecotropic-based conjugate retrovirus vector could also potentially provide enhanced safety characteristics not only over amphotropic retrovirus vectors but also over genetically tropism-modified recombinant ecotropic vectors. In contrast to genetic modifications, physical or chemical modifications are not propagated. Thus, formation of replication competent eMMLV from conjugates would be self-limited and would not result in virus propagation in humans.	Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, New Orleans, LA 70122 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70122 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70122 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Schwarzenberger, P (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, 533 Bolivar St,Rm 611, New Orleans, LA 70122 USA.	pschwa1@lsuhsc.edu	Kolls, Jay/AAH-1829-2019; Schwarzenberger, Paul/AAZ-2174-2021	Kolls, Jay/0000-0001-5151-6304; 	NCI NIH HHS [R01 CA81125-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKATSUKA Y, 1994, INT J HEMATOL, V60, P251; Asada K, 1998, J BIOCHEM-TOKYO, V123, P1041; Avalosse Bernard, 1995, Current Opinion in Oncology, V7, P94; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chen L, 1996, J CLIN INVEST, V98, P2539, DOI 10.1172/JCI119072; CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; CORNETTA K, 1989, J VIROL METHODS, V23, P187, DOI 10.1016/0166-0934(89)90132-8; CROOKS GM, 1993, BLOOD, V82, P3290; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; ELDER JK, 1983, ANAL BIOCHEM, V128, P227, DOI 10.1016/0003-2697(83)90369-X; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fielding AK, 1998, BLOOD, V91, P1802, DOI 10.1182/blood.V91.5.1802.1802_1802_1809; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HADDADA H, 1995, CURR TOP MICROBIOL, V199, P297; HANANIA EG, 1995, AM J MED, V99, P537, DOI 10.1016/S0002-9343(99)80232-0; Jenks S, 1997, J NATL CANCER I, V89, P1182; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KIERNEY PC, 1987, BLOOD, V70, P1418; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; MacNeill EC, 1999, J VIROL, V73, P3960, DOI 10.1128/JVI.73.5.3960-3967.1999; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1990, BLOOD, V76, P271; Moritz T, 1996, BLOOD, V88, P855, DOI 10.1182/blood.V88.3.855.bloodjournal883855; NEDA H, 1991, J BIOL CHEM, V266, P14143; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; Sambrook J, 1989, MOL CLONING; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; Schwarzenberger P, 1997, J VIROL, V71, P8563, DOI 10.1128/JVI.71.11.8563-8571.1997; Schwarzenberger P, 1996, BLOOD, V87, P472, DOI 10.1182/blood.V87.2.472.bloodjournal872472; SKUTELSKY E, 1976, J CELL BIOL, V71, P232, DOI 10.1083/jcb.71.1.232; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; THOMA SJ, 1994, BLOOD, V83, P2103; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; YEE JK, 1994, METHOD CELL BIOL, V43, P99	41	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24601	24607		10.1074/jbc.M010318200	http://dx.doi.org/10.1074/jbc.M010318200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313337	hybrid			2022-12-25	WOS:000169800700026
J	Coon, SL; Weller, JL; Korf, HW; Namboodiri, MAA; Rollag, M; Klein, DC				Coon, SL; Weller, JL; Korf, HW; Namboodiri, MAA; Rollag, M; Klein, DC			cAMP regulation of arylalkylamine N-acetyltransferase (AANAT, EC 2.3.1.87) - A new cell line (1E7) provides evidence of intracellular AANAT activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELATONIN RHYTHM ENZYME; PINEAL-GLAND; PROTEASOMAL PROTEOLYSIS; ANGSTROM RESOLUTION; DISULFIDE EXCHANGE; NOCTURNAL INCREASE; PROTEIN THIOL; CYCLIC-AMP; EXPRESSION; INHIBITION	Arylalkylamine N-acetyltransferase (serotonin N-acetyltransferase, AANAT, EC 2.3.1.87) is the penultimate enzyme in melatonin synthesis. As described here, a cell line (1E7) expressing human AANAT (hAANAT) has been developed to study the human enzyme. 1E7 hAANAT is detectable in immunoblots as a 23-kDa band and is immunocytochemically visualized in the cytoplasm. The specific concentration of hAANAT in homogenates is comparable to that of the night rat pineal gland. Kinetics of AANAT extracted from 1E7 cells are the same as those of bacterially expressed hAANAT; both preparations of hAANAT are equally sensitive to the inhibitor CoA-S-N-acetyltryptamine. Studies of cAMP regulation indicate that treatment with forskolin, dibutyryl cAMP, isobutylmethylxanthine, or isoproterenol activate cellular hAANAT within intact 1E7 cells similar to8-fold without markedly increasing the abundance of AANAT protein or the activity of AANAT in broken cell preparations; and, that forskolin, isobutylmethylxanthine and isoproterenol elevate cyclic AMP production. These observations extend our understanding of cAMP regulation of AANAT activity, because it is currently thought that this only involves changes in the steady-state levels of AANAT protein. This previously unrecognized switching mechanism could function physiologically to control melatonin production without changing AANAT protein levels.	NICHD, Dev Neurobiol Lab, Sect Neuroendocrinol, NIH, Bethesda, MD 20892 USA; Univ Frankfurt, Inst Anat 2, D-60590 Frankfurt, Germany; Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Goethe University Frankfurt; Uniformed Services University of the Health Sciences - USA	Klein, DC (corresponding author), NICHD, Dev Neurobiol Lab, Sect Neuroendocrinol, NIH, Bldg 49,Rm 6A-80, Bethesda, MD 20892 USA.		Korf, Horst/ACX-9860-2022	Korf, Horst/0000-0002-5051-0303; Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000095, ZIAHD000095] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arent J., 1995, MELATONIN MAMMALIAN; Bernard M, 1997, J NEUROCHEM, V68, P213; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 1996, GENOMICS, V34, P76, DOI 10.1006/geno.1996.0243; Coon SL, 1999, J BIOL CHEM, V274, P9076, DOI 10.1074/jbc.274.13.9076; DAVIS S E, 1980, Journal of Immunoassay, V1, P15, DOI 10.1080/01971528008055773; Dixon M, 1964, ENZYMES, P54; Falcon J, 2001, ENDOCRINOLOGY, V142, P1804, DOI 10.1210/en.142.5.1804; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P161; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Iuvone P. Michael, 1995, P25; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1969, ANAL BIOCHEM, V31, P480, DOI 10.1016/0003-2697(69)90290-5; KLEIN DC, 1982, TRENDS BIOCHEM SCI, V7, P98, DOI 10.1016/0968-0004(82)90156-6; KLEIN DC, 1972, THYROID BIOGENIC AMI, P550; KLEIN DC, 1998, HDB BEHAV STATE CONT, V4, P45; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAMBOODIRI MAA, 1985, J NEUROCHEM, V45, P832, DOI 10.1111/j.1471-4159.1985.tb04069.x; NAMBOODIRI MAA, 1981, SCIENCE, V213, P571, DOI 10.1126/science.7017937; NAMBOODIRI MAA, 1980, J BIOL CHEM, V255, P6032; NAMBOODIRI MAA, 1984, J COMP BIOCH B, V80, P731; PERLOW MJ, 1980, BRAIN RES, V182, P211, DOI 10.1016/0006-8993(80)90848-3; PIERCE ME, 1989, J NEUROCHEM, V53, P307, DOI 10.1111/j.1471-4159.1989.tb07330.x; REPPERT SM, 1979, ENDOCRINOLOGY, V104, P295, DOI 10.1210/endo-104-2-295; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Schomerus C, 2000, J NEUROCHEM, V75, P2123, DOI 10.1046/j.1471-4159.2000.0752123.x; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; THIBAULT C, 1993, J NEUROCHEM, V61, P332, DOI 10.1111/j.1471-4159.1993.tb03572.x; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; Yanez J, 1996, GEN COMP ENDOCR, V101, P165, DOI 10.1006/gcen.1996.0018; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zatz M, 2000, J NEUROCHEM, V74, P2315, DOI 10.1046/j.1471-4159.2000.0742315.x; Zhan-Poe XY, 1999, J PINEAL RES, V27, P49, DOI 10.1111/j.1600-079X.1999.tb00596.x	40	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24097	24107		10.1074/jbc.M011298200	http://dx.doi.org/10.1074/jbc.M011298200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313340	hybrid			2022-12-25	WOS:000169531100116
J	Mukherjee, K; Parashuraman, S; Raje, M; Mukhopadhyay, A				Mukherjee, K; Parashuraman, S; Raje, M; Mukhopadhyay, A			SopE acts as an Rab5-specific nucleotide exchange factor and recruits non-prenylated Rab5 on Salmonella-containing phagosomes to promote fusion with early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; MEMBRANE ASSOCIATION; PROTEINS; TRANSPORT; GTPASES; TRAFFICKING; CYSTEINES; UNIQUE; DOMAIN	Rab-GTPase regulates the fusion between two specific vesicles. It is well documented that, for their biological function, Rab proteins need to be prenylated for attachment to the vesicle membrane. In contrast, we showed in the present investigation that SopE, a type III secretory protein of Salmonella, translocates onto Salmonella-containing phagosomes (LSP) and mediates the recruitment of non-prenylated RabB (Rab5:Delta C4) on LSP in GTP form. Simultaneously, SopE present in infected cell cytosol acts as an RabB specific exchange factor and converts the inactive Rab-GDP to the G;TP form. The non-prenylated Rab5 subsequently promoted efficient fusion of LSP with early endosomes. This is the first demonstration that a prenylation-deficient Rab protein retains biological activity and can promote vesicle fusion, if it is recruited on the membrane by some other method.	Natl Inst Immunol, Cell Biol Lab, New Delhi 110067, India; Inst Microbial Technol, Chandigarh 160036, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Mukhopadhyay, A (corresponding author), Natl Inst Immunol, Cell Biol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	amitabha@nii.res.in	Mukhopadhyay, Asok/C-4051-2009; Parashuraman, Seetharaman/P-3389-2014; parashuraman, seetharaman/ABE-2639-2020	Parashuraman, Seetharaman/0000-0001-5113-4592; parashuraman, seetharaman/0000-0001-5113-4592				Alory C, 2000, J CELL BIOL, V150, P89, DOI 10.1083/jcb.150.1.89; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Funato K, 1997, J BIOL CHEM, V272, P16147, DOI 10.1074/jbc.272.26.16147; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Garcia-del Portillo F, 1999, TRENDS MICROBIOL, V7, P467, DOI 10.1016/S0966-842X(99)01618-2; GARCIADELPORTILLO F, 1995, TRENDS MICROBIOL, V3, P373, DOI 10.1016/S0966-842X(00)88982-9; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gromov P, 1998, ELECTROPHORESIS, V19, P1803, DOI 10.1002/elps.1150191043; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hashim S, 2000, J BIOL CHEM, V275, P16281, DOI 10.1074/jbc.275.21.16281; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; Lobell RB, 1998, ADV IMMUNOL, V68, P145, DOI 10.1016/S0065-2776(08)60559-3; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Mukherjee K, 2000, J CELL BIOL, V148, P741, DOI 10.1083/jcb.148.4.741; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; Robinson LJ, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P248; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092; ZIEGLER K, 1981, J IMMUNOL, V127, P1869	40	60	60	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23607	23615		10.1074/jbc.M101034200	http://dx.doi.org/10.1074/jbc.M101034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316807	hybrid			2022-12-25	WOS:000169531100052
J	Papineni, RVL; Sanchez, JU; Baksi, K; Willcockson, IU; Pedersen, SE				Papineni, RVL; Sanchez, JU; Baksi, K; Willcockson, IU; Pedersen, SE			Site-specific charge interactions of alpha-conotoxin MI with the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; SUBUNIT INTERFACES; ESCHERICHIA-COLI; LIGAND-BINDING; MOLECULAR DISSECTION; HIGH-AFFINITY; GI; DETERMINANTS; FUSION; IDENTIFICATION	We have tested the importance of charge interactions for cy-conotoxin MI binding to the nicotinic acetylcholine receptor (AChR). Ionic residues on alpha -conotoxin MI were altered by site-directed mutagenesis or by chemical modification. In physiological buffer, removal of charges at the N terminus, His-5, and Lys-10 had small (2-4-fold) effects on binding affinity to the mouse muscle AChR and the Torpedo AChR, It was also demonstrated that conotoxin had no effect on the conformational equilibrium of either receptor, as assessed by the effects of the noncompetitive antagonist proadifen on conotoxin binding and, conversely, the effect of conotoxin on the affinity of phencyclidine, proadifen, and ethidium. Conotoxin displayed higher binding affinity in low ionic strength buffer; neutralization of Lys-10 and the N terminus by acetylation blocked this affinity shift at the alpha delta site but not at the alpha gamma site, It is concluded that Ctx residues Lys-10 and the N terminal interact with oppositely charged receptor residues only at the alpha delta site, and the two sites have distinct arrangements of charged residues. Ethidium fluorescence experiments demonstrated that conotoxin is formally competitive with a small cholinergic ligand, tetramethylammonium, Thus, alpha -conotoxin MI appears to interact with the portion of the binding site responsible for stabilizing agonist cations but does not do so with a cationic residue and is, consequently, incapable of inducing a conformational change.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Cent Caribe, Dept Anat & Cell Biol, Bayamon, PR 00960 USA	Baylor College of Medicine	Pedersen, SE (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.	pedersen@bcm.tmc.edu		Pedersen, Steen E./0000-0001-8755-8899	NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003035] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035212] Funding Source: NIH RePORTER; NCRR NIH HHS [2G12RR3035] Funding Source: Medline; NHLBI NIH HHS [T32-HL07676] Funding Source: Medline; NINDS NIH HHS [NS35212] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARRANTES FJ, 1998, NICOTINIC ACETYLCHOL, P1; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Bren N, 2000, J BIOL CHEM, V275, P12692, DOI 10.1074/jbc.275.17.12692; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; GRAY WR, 1983, J BIOL CHEM, V258, P2247; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; GUND TM, 1991, METHOD ENZYMOL, V203, P677; Hann RM, 1997, BIOCHEMISTRY-US, V36, P9051, DOI 10.1021/bi970807c; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; HASHIMOTO K, 1985, EUR J PHARMACOL, V118, P351, DOI 10.1016/0014-2999(85)90147-5; HERZ JM, 1987, J BIOL CHEM, V262, P7238; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; Lurtz MM, 1999, MOL PHARMACOL, V55, P159, DOI 10.1124/mol.55.1.159; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Means G.E., 1971, CHEM MODIFICATION PR, P214; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MYERS RA, 1989, THESIS U UTAH; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NISHIUCHI Y, 1982, FEBS LETT, V148, P260, DOI 10.1016/0014-5793(82)80820-X; Papineni RVL, 1997, J BIOL CHEM, V272, P24891, DOI 10.1074/jbc.272.40.24891; Pedersen S, 1995, Telemed J, V1, P47, DOI 10.1089/tmj.1.1995.1.47; Pedersen S E, 1999, Methods Enzymol, V294, P117; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1999, J BIOL CHEM, V274, P19623, DOI 10.1074/jbc.274.28.19623; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Song XZ, 2000, BIOPHYS J, V78, P1324, DOI 10.1016/S0006-3495(00)76687-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Sugiyama N, 1996, J BIOL CHEM, V271, P26575, DOI 10.1074/jbc.271.43.26575; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; WEBER M, 1974, MOL PHARMACOL, V10, P1; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23589	23598		10.1074/jbc.M102350200	http://dx.doi.org/10.1074/jbc.M102350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323431	hybrid			2022-12-25	WOS:000169531100050
J	Nagano, Y; Inaba, T; Furuhashi, H; Sasaki, Y				Nagano, Y; Inaba, T; Furuhashi, H; Sasaki, Y			Trihelix DNA-binding protein with specificities for two distinct cis-elements - Both important for light down-regulated and dark-inducible gene expression in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DOMAIN; MOTIF; GT-1	The DE1 sequence is a cis-regulatory element necessary and sufficient for light down-regulated and dark-inducible expression of the pea GTPase pra2 gene. This sequence does not show any sequence similarity to the previously reported ones involved in light regulated gene expression. A one-hybrid screen isolated a cDNA encoding a DNA-binding protein, named DF1, with specificity for the DE1 sequence 5'-TACAGT. DF1 has domains similar to the trihelix DNA-binding domain found in the GT-1 and GT-2 proteins, which are plant transcription factors. The DE1-binding domain of DF1 is most similar to the carboxyl-terminal trihelix domain of the rice GT-2 protein with specificity for the GT2 sequence 5'-GGTAATT, which is also necessary for dark-inducible expression of the rice phyA gene. An electrophoretic mobility shift assay showed that this DNA-binding domain specifically binds to two types of DNA sequences, DE1 and GT2. Additionally, using DF1/GT-1 chimeras, we show that the second and third helices of the trihelix DNA-binding domain of DF1 are responsible for this dual DNA binding specificity. Our results show that DF1 has specificity for the two distinct cis-regulatory elements, both important for light down-regulated and dark-inducible gene expression in higher plants.	Nagoya Univ, Grad Sch Agr Sci, Nagoya, Aichi 4648601, Japan	Nagoya University	Nagano, Y (corresponding author), Nagoya Univ, Grad Sch Agr Sci, Nagoya, Aichi 4648601, Japan.	nagano@agr.nagoya-u.ac.jp	Nagano, Yukio/H-8734-2019	Nagano, Yukio/0000-0001-5030-676X; Inaba, Takehito/0000-0003-1750-454X				DEHESH K, 1990, SCIENCE, V250, P1397, DOI 10.1126/science.2255908; DEHESH K, 1992, EMBO J, V11, P4131, DOI 10.1002/j.1460-2075.1992.tb05506.x; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; HIRATSUKA K, 1994, PLANT CELL, V6, P1805, DOI 10.1105/tpc.6.12.1805; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Inaba T, 1999, PLANT PHYSIOL, V120, P491, DOI 10.1104/pp.120.2.491; Inaba T, 2000, J BIOL CHEM, V275, P19723, DOI 10.1074/jbc.M001337200; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Nagano Y, 2000, PLANT PHYSIOL, V124, P491, DOI 10.1104/pp.124.2.491; NAGANO Y, 1995, P NATL ACAD SCI USA, V92, P6314, DOI 10.1073/pnas.92.14.6314; NAGANO Y, 1993, PLANT CELL PHYSIOL, V34, P447; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PERISIC O, 1992, PLANT CELL, V4, P831, DOI 10.1105/tpc.4.7.831; Smalle J, 1998, P NATL ACAD SCI USA, V95, P3318, DOI 10.1073/pnas.95.6.3318; Solano R, 1997, J BIOL CHEM, V272, P2889, DOI 10.1074/jbc.272.5.2889; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; YOSHIDA K, 1993, P NATL ACAD SCI USA, V90, P6636, DOI 10.1073/pnas.90.14.6636; Zhou DX, 1999, TRENDS PLANT SCI, V4, P210, DOI 10.1016/S1360-1385(99)01418-1	19	33	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22238	22243		10.1074/jbc.M102474200	http://dx.doi.org/10.1074/jbc.M102474200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301338	hybrid			2022-12-25	WOS:000169412700037
J	Roux, PP; Bhakar, AL; Kennedy, TE; Barker, PA				Roux, PP; Bhakar, AL; Kennedy, TE; Barker, PA			The p75 neurotrophin receptor activates Akt (protein kinase B) through a phosphatidylinositol 3-kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NF-KAPPA-B; ZINC-FINGER PROTEIN; CELL-DEATH; SIGNAL-TRANSDUCTION; NEURONAL APOPTOSIS; FACTOR-BINDING; SPHINGOMYELIN HYDROLYSIS; INTRACELLULAR DOMAIN; SURVIVAL SIGNALS	The Akt kinase plays a crucial role in supporting Trk-dependent cell survival, whereas the p75 neurotrophin receptor (p75NTR) facilitates cellular apoptosis. The precise mechanism that p75NTR uses to promote cell death is not certain, but one possibility is that p75NTR-dependent ceramide accumulation inhibits phosphatidylinositol 3-kinase mediated Akt activation. To test this hypothesis, we developed a system for examining p75NTR-dependent apoptosis and determined the effect of p75NTR on Akt activation. Surprisingly, p75NTR increased, rather than decreased, Akt phosphorylation in a variety of cell types, including human Niemann-Pick fibroblasts, which lack acidic sphingomyelinase activity. The p75NTR expression level required to elicit Akt phosphorylation was much lower than that required to activate the JNK pathway or to mediate apoptosis. Fire show that p75NTR dependent Akt phosphorylation was independent of TrkA signaling, required active phosphatidylinositol 3-kinase, and was associated with increased tyrosine phosphorylation of p85 and She and with reduced cytosolic tyrosine phosphatase activity. Finally, we show that p75NTR expression increased sur vival in cells exposed to staurosporine or subjected to serum withdrawal. These findings indicate that p75NTR facilitates cell survival through novel signaling cascades that result in Akt activation.	McGill Univ, Ctr Neuronal Survival, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Barker, PA (corresponding author), McGill Univ, Ctr Neuronal Survival, Montreal Neurol Inst, 3801 Univ Ave, Montreal, PQ H3A 2B4, Canada.		Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250				Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Blochl A, 1996, J BIOL CHEM, V271, P21100; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Brann AB, 1999, J NEUROSCI, V19, P8199; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Cochran B H, 1993, NIDA Res Monogr, V125, P3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Frade JM, 2000, J CELL SCI, V113, P1139; Frade JM, 1999, DEVELOPMENT, V126, P683; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1996, NATURE, V383, P166; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GROB PM, 1985, J BIOL CHEM, V260, P8044; Gu CH, 1999, J NEUROSCI, V19, P3043; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Majdan M, 1997, J NEUROSCI, V17, P6988; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Ozes ON, 1999, NATURE, V401, P82; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Verheij M, 1998, ACTA ONCOL, V37, P575, DOI 10.1080/028418698430287; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	67	122	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23097	23104		10.1074/jbc.M011520200	http://dx.doi.org/10.1074/jbc.M011520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312266	hybrid			2022-12-25	WOS:000169412700148
J	Karthikeyan, S; Leung, T; Ladias, JAA				Karthikeyan, S; Leung, T; Ladias, JAA			Structural basis of the Na+/H+ exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; LIGAND INTERACTIONS; CRYSTAL-STRUCTURE; CHLORIDE CHANNEL; DOMAIN; IDENTIFICATION; RECOGNITION; ASSOCIATION; MEMBRANE; PEPTIDE	The PDZ1 domain of the Na+/H+ exchanger regulatory factor (NHERF) binds with nanomolar affinity to the carboxyl-terminal sequence QDTRL of the cystic fibrosis transmembrane conductance regulator (CFTR) and plays a central role in the cellular localization and physiological regulation of this chloride channel. The crystal structure of human NHERF PDZ1 bound to the carboxyl-terminal peptide QDTRL has been determined at 1.7-(A) over circle resolution. The structure reveals the specificity and affinity determinants of the PDZ1-CFTR interaction and provides insights into carboxyl-terminal leucine recognition by class I PDZ domains. The peptide ligand inserts into the PDZ1 binding pocket forming an additional antiparallel beta -strand to the PDZ1 beta -sheet, and an extensive network of hydrogen bonds and hydrophobic interactions stabilize the complex. Remarkably, the guanido group of arginine at position -1 of the CFTR peptide forms two salt bridges and two hydrogen bonds with PDZ1 residues Glu(43) and Asn(22), respectively, providing the structural basis for the contribution of the penultimate amino acid of the peptide ligand to the affinity of the interaction.	Harvard Univ, Sch Med, Inst Med, Div Expt Med,Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Med, Div Expt Med,Macromol Crystallog Unit, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Leung, T (corresponding author), Harvard Univ, Sch Med, Inst Med, Div Expt Med,Mol Med Lab, Rm 354,4 Blackfan Circle, Boston, MA 02115 USA.		Karthikeyan, Subramanian/F-8808-2010					Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kocher O, 1998, LAB INVEST, V78, P117; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Milewski MI, 2001, J CELL SCI, V114, P719; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903	40	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19683	19686		10.1074/jbc.C100154200	http://dx.doi.org/10.1074/jbc.C100154200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11304524	hybrid			2022-12-25	WOS:000169135100002
J	Ruediger, R; Pham, HT; Walter, G				Ruediger, R; Pham, HT; Walter, G			Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene	ONCOGENE			English	Article						PP2A; A beta subunit; mutation; lung and colon cancer; tumor suppressor	ADENOVIRUS E4ORF4 PROTEIN; SERINE THREONINE PHOSPHATASES; REGULATORY B-SUBUNITS; PP2A CORE ENZYME; CATALYTIC SUBUNIT; MOLECULAR-CLONING; TUMOR-ANTIGENS; PPP2R1B GENE; SEQUENCE-ANALYSIS; DNA-REPLICATION	Protein phosphatase 2A (PP2A) consists of three subunits, A, B and C, The A and B subunits have regulatory functions while C is the catalytic subunit, PP2A core enzyme is composed of subunits A and C, and the holoenzyme of subunits A, B and C, All subunits exist as multiple isoforms or splice variants. The A subunit exists as two isoforms, A alpha and A beta. Here we report about the properties of eight A beta mutants, which were found in human lung and colon cancer. These mutants were reconstructed by site-directed mutagenesis and assayed for their ability to bind B and C subunits, Two mutants showed decreased binding of PR72, a member of the B " family of B subunits, but normal C subunit binding; two mutants exhibited decreased binding of the C subunit and of B " /PR72; and one mutant showed increased binding of both the C subunit and B " /PR72, Of three mutants that behaved like the wildtype A beta subunit, one is a polymorphic variant and another one is altered outside the binding region for B and C subunits, Importantly, we also found that the wildtype A alpha and A beta isoforms, although 85% identical, are remarkably different in their ability to bind B and C subunits, Our findings may have important implications in regard to the role of PP2A as a tumor suppressor.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Walter, G (corresponding author), Univ Calif San Diego, Dept Pathol, 0612,9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [CA-36111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOSCH M, 1995, EUR J BIOCHEM, V230, P1037, DOI 10.1111/j.1432-1033.1995.tb20653.x; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, J BIOL CHEM, V264, P21435; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hong YL, 2000, BIOCHEM BIOPH RES CO, V272, P84, DOI 10.1006/bbrc.2000.2733; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagase T, 1997, J BIOCHEM, V122, P178; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	65	108	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1892	1899		10.1038/sj.onc.1204279	http://dx.doi.org/10.1038/sj.onc.1204279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313937				2022-12-25	WOS:000167908400010
J	Galy, B; Creancier, L; Zanibellato, C; Prats, AC; Prats, H				Galy, B; Creancier, L; Zanibellato, C; Prats, AC; Prats, H			Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism	ONCOGENE			English	Article						FGF; p53; p73; post-transcriptional control; growth factor; tumour suppressor	INTERNAL RIBOSOME ENTRY; FACTOR MESSENGER-RNA; ALTERNATIVE TRANSLATION; HUMAN CANCERS; FIBROBLAST-GROWTH-FACTOR-2; INITIATION; PROTEIN; CELLS; GROWTH-FACTOR-2; LOCALIZATION	Fibroblast growth factor-2 (FGF-2) is a powerful mitogen and angiogenic factor whose expression is strongly regulated at the translational level. The constitutive upregulation of FGF-2 isoforms in transformed cells prompted us to investigate the posttranscriptional effects of a tumour suppressor, p53, on FGF-2 expression. We show here in human primary skin fibroblasts that the cell density-dependent variation of FGF-2 mRNA translatability was inversely correlated with endogenous p53 expression. Transient cell transfection revealed an inhibitory effect of wild-type p53 on the expression of chimeric FGF-CAT proteins. RNAse mapping experiments ruled out any effect of p53 on FGF-CAT mRNA accumulation, suggesting a translational inhibition. This inhibition was mediated by the FGF-2 mRNA leader, but not by vascular endothelial growth factor or platelet derived growth factor mRNA leaders. Neither p53-like protein p73, nor p21/waf had any inhibitory activity. Furthermore a set of hot spot mutants of p53 bearing mutations in the DNA binding domain had no post-transcriptional inhibitory effect. In contrast a p53 mutant of the transactivating domain was still able to block FGF - CAT expression, indicating that the post-transcriptional activity of p53 described here was independent of the trans-activation of target genes. Such data reveal a novel mechanism by which p53 efficiently blocks the expression of a major proliferating, anti-apoptotic and angiogenic gene.	CHU Rangueil, Inst Federat Rech Louis Bugnard, INSERM U397, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, H (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Prats, Herve/0000-0002-4861-2167; Galy, Bruno/0000-0002-0501-6357				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FUKS Z, 1994, CANCER RES, V54, P2582; Galy B, 1999, CANCER RES, V59, P165; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696	33	45	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1669	1677		10.1038/sj.onc.1204271	http://dx.doi.org/10.1038/sj.onc.1204271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313915				2022-12-25	WOS:000167750900001
J	Pianetti, S; Arsura, M; Romieu-Mourez, R; Coffey, RJ; Sonenshein, GE				Pianetti, S; Arsura, M; Romieu-Mourez, R; Coffey, RJ; Sonenshein, GE			Her-2/neu overexpression induces NF-kappa B via a PI3-kinase/Akt pathway involving calpain-mediated degradation of I kappa-B-alpha that can be inhibited by the tumor suppressor PTEN	ONCOGENE			English	Article						breast cancer; EGF receptor; transgenic mice; NF-kappa B; I kappa B-alpha; calpain	GROWTH-FACTOR-ALPHA; BREAST-CANCER; TRANSCRIPTION FACTOR; C-MYC; CONSTITUTIVE ACTIVATION; NECROSIS-FACTOR; PHOSPHOINOSITIDE 3-KINASE; MAMMARY EPITHELIUM; NEU PROTOONCOGENE; INDUCED APOPTOSIS	The Nuclear Factor (NF)-kappaB family of transcription factors controls expression of genes which promote cell growth, survival, and neoplastic transformation, Recently we demonstrated aberrant constitutive activation of NF-kappaB in primary human and rat breast cancer specimens and in cell lines. Overexpression of the epidermal growth factor receptor (EGFR) family member Her-2/neu, seen in approximately 30% of breast cancers, is associated with poor prognosis. Previously, Her-2/neu has been shown to signal via a phosphatidylinositol 3 (PI3)-kinase to Akt/protein kinase B (PKB) pathway. Since this signaling pathway was recently shown to activate NF-kappaB, here we have tested the hypothesis that Her-2/neu can activate TF-kappaB in breast cancer, Overexpression of Her-2/neu and EGFR-4 in Ba/F3 cells led to constitutive PI3- and Akt kinase activities, and induction of classical NF-kappaB (p50/p65). Similarly, a tumor cell line and tumors derived from MMTV-Her-2/neu transgenic mice displayed elevated levels of classical NF-kappaB, Engagement of Her-2/neu receptor downregulated the level of NF-kappaB. NF-kappaB binding and activity in the cultured cells was reduced upon inhibition of the PI3- to Akt kinase signaling pathway via ectopic expression of kinase inactive mutants, incubation with wortmannin, or expression of the tumor suppressor phosphatase PTEN, Inhibitors of calpain, but not the proteasome, blocked I kappaB-alpha degradation. Inhibition of Akt did not affect IKK activity, These results indicate that Her-2/neu activates NF-kappaB via a P13- to Akt kinase signaling pathway that can be inhibited via the tumor suppressor PTEN, and is mediated by calpain rather than the I kappaB kinase complex.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Program Res Womens Hlth, Boston, MA 02118 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA	Boston University; Boston University; Vanderbilt University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.				NCI NIH HHS [CA 82742, CA78616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078616, R01CA082742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BROWN K, 1995, CELL, V84, P853; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; CHEN ZJ, 1996, MOL CELL BIOL, V16, P1295; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Duffey DC, 1999, CANCER RES, V59, P3468; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Fields ER, 2000, J IMMUNOL, V164, P4762, DOI 10.4049/jimmunol.164.9.4762; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hortobagyi GN, 1999, SEMIN ONCOL, V26, P11; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Jeay S, 2000, MOL ENDOCRINOL, V14, P650, DOI 10.1210/me.14.5.650; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Miyajima A, 1999, INT J HEMATOL, V69, P137; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Mori N, 1999, BLOOD, V93, P2360; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ozes ON, 1999, NATURE, V401, P82; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Rawadi G, 1999, J BIOL CHEM, V274, P30794, DOI 10.1074/jbc.274.43.30794; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REGNIER CH, 1997, SCIENCE, V278, P866; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Ross, 1998, Oncologist, V3, P237; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Tam S. W., 1997, Leukemia (Basingstoke), V11, P363; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	70	232	243	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1287	1299		10.1038/sj.onc.1204257	http://dx.doi.org/10.1038/sj.onc.1204257			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313873				2022-12-25	WOS:000167495000003
J	Bilanges, B; Varrault, A; Mazumdar, A; Pantaloni, C; Hoffmann, A; Bockaert, J; Spengler, D; Journot, L				Bilanges, B; Varrault, A; Mazumdar, A; Pantaloni, C; Hoffmann, A; Bockaert, J; Spengler, D; Journot, L			Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities	ONCOGENE			English	Article						ZAC; cell cycle; apoptosis; breast cancer; transient neonatal diabetes; imprinting	ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR-I; BREAST-CANCER; CHROMOSOME 6Q; CELLS; HETEROZYGOSITY; IDENTIFICATION; SPECIFICITY; EXPRESSION; CARCINOMAS	ZAC encodes a zinc finger protein with antiproliferative activity, is maternally imprinted and is a candidate for the tumor suppressor gene on 6q24, ZAC expression is frequently lost in breast and ovary tumor-derived cell lines and down-regulated in breast primary tumors. In this report, we describe ZAC Delta2, an alternatively spliced variant of ZAC lacking the sequence encoding the two IV-terminal zinc fingers. Messenger RNAs encoding ZAC or ZAC Delta2 mere equally abundant and both proteins were nuclear. ZAC Delta2 displayed an improved transactivation activity and an enhanced affinity for a ZAC binding site, suggesting that the two N-terminal zinc fingers negatively regulated ZAC binding to its target DNA sequences. Both proteins were equally efficient in preventing colony formation, indicating similar overall antiproliferative activities. However, these activities resulted from a differential regulation of apoptosis vs cell cycle progression since ZAC Delta2 was more efficient at induction of cell cycle arrest than ZAC, whereas it was the reverse for apoptosis induction. Hence, these data further underline that ZAC gene is critically controlled, both at the transcriptional level through imprinting and at the functional level through alternative splicing.	CNRS, UPR 9023, F-34094 Montpellier 05, France; Max Planck Inst Psychiat, D-80804 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Journot, L (corresponding author), CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Journot, Laurent/T-9652-2018; Bilanges, Benoit/AAP-6078-2020	Journot, Laurent/0000-0003-3499-8887; Bilanges, Benoit/0000-0003-4400-3716				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Cabanillas AM, 1996, DNA CELL BIOL, V15, P643, DOI 10.1089/dna.1996.15.643; Cave H, 2000, DIABETES, V49, P108, DOI 10.2337/diabetes.49.1.108; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVILEE P, 1991, ONCOGENE, V6, P1705; FERGUSON AW, 1970, ARCH DIS CHILD, V45, P80, DOI 10.1136/adc.45.239.80; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NEGRINI M, 1994, CANCER RES, V54, P1331; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Noviello C, 1996, CLIN CANCER RES, V2, P1601; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Queimado L, 1999, LAB INVEST, V79, P583; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Theile M, 1996, ONCOGENE, V13, P677; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835	39	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1246	1253		10.1038/sj.onc.1204237	http://dx.doi.org/10.1038/sj.onc.1204237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313869				2022-12-25	WOS:000167570100012
J	Jaks, V; Joers, A; Kristjuhan, A; Maimets, T				Jaks, V; Joers, A; Kristjuhan, A; Maimets, T			p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin	ONCOGENE			English	Article						p53; DNA damage; cell cycle; apoptosis	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; UV-LIGHT; TRANSCRIPTIONAL ACTIVITY; DEPENDENT KINASES; HUMAN FIBROBLASTS; GENE-EXPRESSION; STRAND BREAKS; APOPTOSIS; RADIATION	In this studyw we characterize the connections between p53-dependent G1 cell cycle arrest, transcriptional activation of the protein and the increase of its intracellular steady-state concentration, Several cell lines expressing wild-type p53 protein were treated with increasing concentrations of DNA-damaging drug camptothecin, Lower doses of the drug caused transcriptional activation of p53, but no accumulation of the protein was detected. Only after a certain threshold dose of camptothecin does the amount of the protein rapidly increase and reach its plateau levels. The threshold dose was different for different cell lines, but the general non-linear profile was similar, Increase of p53 level was accompanied by additional transcriptional activation of some p53 target genes (i,e, waf1), but not the others (mdm2), We demonstrate here that transcriptional activation of p53 after the treatment of camptothecin is not sufficient to cause p53-dependent G1 cell cycle arrest. The latter is observable only after the inrease of steady-state level of p53, Low drug concentrations, although accompanied by transcriptional activation of p53, do not cause either p53 protein accumulation nor cell cycle arrest at G1, We propose a model for p53 acting as a part of cellular sensor system detecting the severity of DNA damage.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia	University of Tartu	Maimets, T (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-51010 Tartu, Estonia.		Jaks, Viljar/H-2467-2012; Maimets, Toivo/E-9268-2017	Jaks, Viljar/0000-0002-2221-6262; Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952; Joers, Arvi/0000-0003-2083-3977				AVEMANN K, 1998, MOL CELL BIOL, V8, P3206; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN C, 1995, GENE DEV, V12, P600; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DEIRY WS, 1993, CELL, V75, P817; Deptala A, 1999, INT J ONCOL, V15, P861; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Ewen ME, 1996, J LAB CLIN MED, V128, P355, DOI 10.1016/S0022-2143(96)80006-0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P291; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P295; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; Kristjuhan A, 1998, ONCOGENE, V16, P2413, DOI 10.1038/sj.onc.1201749; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li G, 1998, BRIT J DERMATOL, V139, P3; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Selkirk JK, 1996, ELECTROPHORESIS, V17, P1764, DOI 10.1002/elps.1150171114; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shieh SY, 2000, GENE DEV, V14, P289; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P704; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	55	15	15	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1212	1219		10.1038/sj.onc.1204232	http://dx.doi.org/10.1038/sj.onc.1204232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313865				2022-12-25	WOS:000167570100008
J	Labuhn, M; Jones, G; Speel, EJM; Maier, D; Zweifel, C; Gratzl, O; Van Meir, EG; Hegi, ME; Merlo, A				Labuhn, M; Jones, G; Speel, EJM; Maier, D; Zweifel, C; Gratzl, O; Van Meir, EG; Hegi, ME; Merlo, A			Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas	ONCOGENE			English	Article						INK4A locus; P16(INK4A); p14(ARF); co-deletions; quantitative real-time PCR	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; HOMOZYGOUS DELETION; INK4A LOCUS; P15(INK4B) GENE; HUMAN CANCERS; BRAIN-TUMORS; CPG ISLAND; LOW-GRADE; P53	In many human cancers, the INK4A locus is frequently mutated by homozygous deletions, By alternative splicing this locus encodes two non-related tumor suppressor genes, p16(INK4A) and p14(ARF) (p19(ARF) in mice), which regulate cell cycle and cell survival in the retinoblastoma protein (pRb) and p53 pathways, respectively, In mice, the role of p16(INK4A) as th, critical tumor suppressor gene at the INK4A locus was challenged when it was found that p19(ARF) only knock-out mice developed tumors, including gliomas, We have analysed the genetic status of the INK4A locus in 105 primary gliomas using both microsatellite mapping (MSM) and quantitative realtime PCR (QRT-PCR). Comparison of the results of the two methods revealed agreement in 67% of the tumors examined, In discordant cases, fluorescence in situ hybridization (FISH) analysis was always found to support QRT-PCR classification, Direct assessment of p14(ARF) exon 1 beta, p16(INK4A) exon 1 alpha and exon 2 by QRT-PCR revealed 43 (41%) homozygous and eight (7%) hemizygous deletions at the INK4A locus. In 49 (47%) gliomas, both alleles were retained, In addition, QRT-PCR, but not MSM, detected hyperploidy in five (5%) tumors, Deletion of p14(ARF) was always associated with co-deletion of p16(INK4A) and increased in frequency upon progression from low to high grade gliomas, Shorter survival was associated with homozygous deletions of INK4A in the subgroup of glioblastoma patients older than 50 years of age (P = 0.025, Anova test single factor, alpha =0.05).	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; CHU Vaudois, Lab Tumor Biol & Genet, CH-1101 Lausanne, Switzerland; Emory Univ, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Univ Maastricht, Dept Mol Cell Biol & Genet, NL-6200 MD Maastricht, Netherlands	University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Maastricht University	Merlo, A (corresponding author), Univ Basel Hosp, Dept Res, Schanzenstr 46, CH-4031 Basel, Switzerland.		Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DURO D, 1995, ONCOGENE, V11, P21; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; GLENDENING JM, 1995, CANCER RES, V55, P5531; Gortz B, 1999, INT J CANCER, V80, P373, DOI 10.1002/(SICI)1097-0215(19990129)80:3<373::AID-IJC7>3.0.CO;2-B; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; LI YJ, 1995, ONCOGENE, V11, P597; Lloyd AC, 2000, NAT CELL BIOL, V2, pE48, DOI 10.1038/35004078; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; Newcomb EW, 1998, BRAIN PATHOL, V8, P655, DOI 10.1111/j.1750-3639.1998.tb00191.x; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; ROCCHI M, 1991, GENOMICS, V9, P517, DOI 10.1016/0888-7543(91)90419-F; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Speel EJM, 1997, J HISTOCHEM CYTOCHEM, V45, P1439, DOI 10.1177/002215549704501013; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wang YW, 1997, ELECTROPHORESIS, V18, P1742, DOI 10.1002/elps.1150181007; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhuang ZP, 1997, CANCER RES, V57, P4682	42	54	58	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1103	1109		10.1038/sj.onc.1204197	http://dx.doi.org/10.1038/sj.onc.1204197			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314047				2022-12-25	WOS:000167232100010
J	Ozbek, S; Peters, M; Breuhahn, K; Mann, A; Blessing, M; Fischer, M; Schirmacher, P; Mackiewicz, A; Rose-John, S				Ozbek, S; Peters, M; Breuhahn, K; Mann, A; Blessing, M; Fischer, M; Schirmacher, P; Mackiewicz, A; Rose-John, S			The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells	ONCOGENE			English	Article						designer cytokine; GM-CSF; interleukin-6; melanoma; soluble receptor; tumor rejection	SOLUBLE IL-6 RECEPTOR; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; HEMATOPOIETIC PROGENITOR CELLS; DOUBLE-TRANSGENIC MICE; TUMOR-CELLS; IN-VIVO; INTERLEUKIN-6 RECEPTOR; ANTITUMOR-ACTIVITY; GENE-TRANSFER	The low immunogenic B16 melanoma cell line was transfected with a mammalian expression vector containing the complementary DNA for a sIL-6R/IL-6 fusion protein, termed Hyper-IL-6 (H-IL-6), which was shown to have biological activities at 100-1000-fold lower concentrations than IL-6 in combination with sIL-6R. The secreted p84 glycoprotein was detected in the supernatant of transfected cells and was fully active on BAF3/gp130 cells, which respond to IL-6/sIL-6R but not to IL-6 alone. Administration of recombinant H-IL-6 to C57BL/6 mice resulted in a prolonged acute phase protein gene expression indicating long systemic persistence of the fusion protein. Transfected B16 cells (B16/ H-IL6 cells) showed morphological alterations in combination with a dramatic growth inhibition in vitro. Subcutaneous injection in C57BL/6 mice resulted in an almost complete rejection of B16/H-IL6 cells. This effect was partially abolished in FVB/BL/6 mice transgenic for a GM-CSF receptor antagonist, indicating a GM-CSF-deependent rejection of H-IL-6 transfected B16 cells. These results demonstrate that the anti-tumor effect of cytokines like IL-6 which are secreted by transfected melanoma cells at least in part depends on GM-CSF activity.	Univ Kiel, Inst Biochem, Dept Biochem, D-24098 Kiel, Germany; Univ Mainz, Dept Med, Sect Pathophysiol, D-55101 Mainz, Germany; Univ Cologne, Inst Pathol, D-5000 Cologne, Germany; Great Poland Canc Ctr, Dept Canc Immunol, Poznan, Poland	University of Kiel; Johannes Gutenberg University of Mainz; University of Cologne; Wielkopolskie Centrum Onkologii	Rose-John, S (corresponding author), Univ Kiel, Inst Biochem, Dept Biochem, Olshausenstr 40, D-24098 Kiel, Germany.		Rose-John, Stefan/A-7998-2010; Özbek, Suat/D-3701-2014	Rose-John, Stefan/0000-0002-7519-3279; Breuhahn, Kai/0000-0002-2462-1229; Ozbek, Suat/0000-0003-2569-3942				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; Bernhard H, 2000, EXP HEMATOL, V28, P365, DOI 10.1016/S0301-472X(00)00126-0; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Englaro W, 1999, ONCOGENE, V18, P1553, DOI 10.1038/sj.onc.1202446; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; Greene AL, 1997, J INTERF CYTOK RES, V17, P727, DOI 10.1089/jir.1997.17.727; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HERMANN E, 1989, CLIN EXP RHEUMATOL, V7, P411; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HOGAN BF, 1986, MANIPULATING MOUSE M; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; Klouche M, 1999, J IMMUNOL, V163, P4583; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; MACKIEWICZ A, 1995, HUM GENE THER, V6, P805, DOI 10.1089/hum.1995.6.6-805; MACKIEWICZ A, 1995, CYTOKINE, V7, P142, DOI 10.1006/cyto.1995.1019; MCINTOSH JK, 1989, J IMMUNOL, V143, P162; MULE JJ, 1990, J EXP MED, V171, P629, DOI 10.1084/jem.171.3.629; MULE JJ, 1992, J IMMUNOL, V148, P2622; MULE JJ, 1992, RES IMMUNOL, V143, P777, DOI 10.1016/0923-2494(92)80023-E; MULLEN CA, 1992, CANCER RES, V52, P6020; Nawrocki S, 2000, IMMUNOL LETT, V74, P81, DOI 10.1016/S0165-2478(00)00253-4; NOVICK D, 1992, CYTOKINE, V4, P6, DOI 10.1016/1043-4666(92)90029-Q; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; Peters M, 1996, IMMUNOL LETT, V54, P177, DOI 10.1016/S0165-2478(96)02669-7; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Peters M, 1998, J IMMUNOL, V161, P3575; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; PORGADOR A, 1992, CANCER RES, V52, P3679; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUN WH, 1992, CANCER RES, V52, P5412; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; Wu TY, 1998, J INTERF CYTOK RES, V18, P829, DOI 10.1089/jir.1998.18.829	47	25	32	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					972	979		10.1038/sj.onc.1204180	http://dx.doi.org/10.1038/sj.onc.1204180			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314032				2022-12-25	WOS:000167097000008
J	Baross-Francis, A; Makhani, N; Liskay, RM; Jirik, FR				Baross-Francis, A; Makhani, N; Liskay, RM; Jirik, FR			Elevated mutant frequencies and increased C : G -> T : A transitions in Mlh1(-/-) versus Pms2(-/-) murine small intestinal epithelial cells	ONCOGENE			English	Article						DNA mismatch repair; Mlh1; Pms2; transgenic; lacI	DNA MISMATCH REPAIR; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PROMOTER METHYLATION; TRANSGENIC MICE; GENE PMS2; LACI GENE; MUTATIONS; MLH1; HMLH1	Mutations in DNA mismatch repair (MMR) genes are associated with increased genomic instability and susceptibility to cancer. Mice rendered deficient in either Mlh1 or Pms2 as a result of gene targeting are prone to tumorigenesis, particularly, lymphomas, In addition, although Mlh1(-/-) mice also develop small intestinal adenomas and adenocarcinomas, Pms2(-/-) animals remain free of such tumors. To establish whether this phenotypic dichotomy might he associated with quantitative and/or qualitative difference in genomic instability in these mice, we determined small intestinal epithelial cell DNA mutant frequency and mutation using a transgenic lambda -phage lacI reporter Mutant frequencies obtained from both Mlh1(-/-) and Pms2(-/-) mice revealed elevations of 18 and 13-fold, respectively, as compared to their wild-type littermates. interestingly, we found that C:G-->T:A transitions, were significantly elevated in MlH1 (/-) mice, accounting in large measure for the 1.5-fold lacI mutant frequency increase seen in these animals, We hypothesize that the increased level of C:G-->T:A mutations may explain, in part, why Mlh1(-/) mice, but not Pms2(-/-) mice, develop small intestinal tumors, Furthermore, the difference in the lacI mutational spectrum of Mlh1 and Pms2(-/-) mice suggests that other MutL-like heterodimers may play important roles in the repair of G : T mispairs arising within murine small intestinal epithelial cells.	Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 4H4, Canada; Oregon Hlth Sci Univ, Dept Med & Mol Genet, Portland, OR 97201 USA	University of British Columbia; University of British Columbia; Oregon Health & Science University	Jirik, FR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032741] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM32741] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; de Boer JG, 1998, GENETICS, V148, P1441; DEBOER J, 1999, BIG BLUE WEBSITE; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dogliotti E, 1996, CARCINOGENESIS, V17, P2113, DOI 10.1093/carcin/17.10.2113; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, GENET ANAL-BIOMOL E, V7, P212, DOI 10.1016/0735-0651(90)90003-X; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; Leung SY, 1999, CANCER RES, V59, P159; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Ricciardone MD, 1999, CANCER RES, V59, P290; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Toft NJ, 1998, J PATHOL, V185, P123; Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067; Wang Q, 1999, CANCER RES, V59, P294; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yang Y, 1999, MOL GEN GENET, V261, P777, DOI 10.1007/s004380050021; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	41	32	32	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					619	625		10.1038/sj.onc.1204138	http://dx.doi.org/10.1038/sj.onc.1204138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313994				2022-12-25	WOS:000166755000009
J	Zwerner, JP; May, WA				Zwerner, JP; May, WA			PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors	ONCOGENE			English	Article						Ewing's sarcoma; Ewing family tumors; PDGF-C; EWS/FLI	FUSION GENE; SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR; EXPRESSION CLONING; EWS GENE; CELLS; ONCOGENE; RECEPTOR; PROTEIN; BINDING	The aberrant transcription factors associated with many human malignancies function by deregulation of tumorigenic pathways, However, identification of these pathways has come slowly . Virtually all cases of Ewing's Sa;coma and peripheral Primitive, Neuroectodermal Tumor (PNET) are associated with aberrant transcription factors which fuse amino-terminal EWS with the DNA binding moiety of an ETS transcription factor (FLI-1 in 90% of cases), Attempts to identify the downstream targets of these chimeras in the Ewing Family Tumors (EFT) on the basis of differential gene regulation have produced little association with tumor biology, As an alternative approach, we have used highly efficient retroviral systems to biologically screen cDNA derived from cells transformed by EWS/FLI-1. We have identified the recently described PDGF-C as target of EWS/ETS transcriptional deregulation, This transcriptional deregulation is specific to EWS/FLI, PDGF-C possesses substantial biologic activity in vitro and in vivo. It is expressed in EFT cell lines and in primary tumors, Within these EFT cell lines, PDGF-C expression is dependent upon EWS/FLI activity. These results suggest that PDGF-C may be a significant mediator of EWS/FLI driven oncogenesis.	Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	May, WA (corresponding author), Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ding H, 2000, MECH DEVELOP, V96, P209, DOI 10.1016/S0925-4773(00)00425-1; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HELDIN CH, 1992, KIDNEY INT, V41, P571, DOI 10.1038/ki.1992.84; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Im YH, 2000, CANCER RES, V60, P1536; JEON IS, 1995, ONCOGENE, V10, P1229; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; Lawlor ER, 1998, CANCER RES, V58, P2469; LESSNICK SL, 1995, ONCOGENE, V10, P423; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thompson AD, 1996, ONCOGENE, V13, P2649; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vukmirovic OG, 2000, NATURE, V405, P820, DOI 10.1038/35015690; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	40	97	105	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					626	633		10.1038/sj.onc.1204133	http://dx.doi.org/10.1038/sj.onc.1204133			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313995	Green Accepted			2022-12-25	WOS:000166755000010
J	Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Montalvo, EA; Gao, SJ				Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Montalvo, EA; Gao, SJ			Characterization of the promoter region of the viral interferon regulatory factor encoded by Kaposi's sarcoma-associated herpesvirus	ONCOGENE			English	Article						Kaposi's sarcoma-associated herpesvirus; viral interferon regulatory factor; oncogene; promoter; TPA induction	MULTICENTRIC CASTLEMANS DISEASE; CAVITY-BASED LYMPHOMA; DNA-SEQUENCES; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION; GENES; KSHV; IRF-1; IDENTIFICATION; PATHWAY	Viral interferon regulatory factor (vIRF) encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) inhibits the expression of interferon-responsive genes, causes cellular transformation and transactivates KSHV genes. In the present study, we characterized the mRNA expression pattern of the vIRF gene and its promoter, A vIRF transcript of 1.7 kb in size was detected in low level in uninduced KSHV-infected cells and its expression was inducible by 12-O-tetradecanoylphorbol-13-acetate (TPA), sensitive to cycloheximide and resistant to phosphonoacetic acid. The transcription start site was mapped to 79 nt upstream of the ATG initiation site by 5'-RACE. Mutagenesis analysis identified a region between -56 and the transcription start site (+1) as the minimal promoter region that contains a functional TATA box at -27. A region between -337 and -125 contains a repressor domain negated by sequence from -991 to -499 in BCBL-1 cells, a region which was also identified to be responsive to TPA induction. These results demonstrate vIRF as st KSHV early gene, identify its promoter and define the promoter regions that contain regulatory elements controlling vIRF transcription.	Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Gao, SJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA.		Gao, Shou-Jiang/B-8641-2012	Gao, Shou-Jiang/0000-0001-6194-1742	NHLBI NIH HHS [HL60604-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060604] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASUBEL FM, 1995, CURRENT PROTOCOLS MO; BOSHOFF C, 1995, LANCET, V345, P1043; Burysek L, 1999, J VIROL, V73, P7334; Carbone A, 1996, BRIT J HAEMATOL, V94, P533, DOI 10.1046/j.1365-2141.1996.d01-1826.x; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHADBURN A, 1996, LAB INVEST, V74, pA109; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chen JG, 2000, J VIROL, V74, P8623, DOI 10.1128/JVI.74.18.8623-8634.2000; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gessain A, 1996, BLOOD, V87, P414; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; Inagi R, 1999, J HUMAN VIROL, V2, P63; KARCHER DS, 1995, NEW ENGL J MED, V333, P797; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; PASTORE C, 1995, BRIT J HAEMATOL, V91, P918, DOI 10.1111/j.1365-2141.1995.tb05410.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Roan F, 1999, J GEN VIROL, V80, P2205, DOI 10.1099/0022-1317-80-8-2205; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	35	17	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					523	530		10.1038/sj.onc.1204115	http://dx.doi.org/10.1038/sj.onc.1204115			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313983				2022-12-25	WOS:000166562500012
J	Wright, MM; Henneberry, AL; Lagace, TA; Ridgway, ND; McMaster, CR				Wright, MM; Henneberry, AL; Lagace, TA; Ridgway, ND; McMaster, CR			Uncoupling farnesol-induced apoptosis from its inhibition of phosphatidylcholine synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINEPHOSPHOTRANSFERASE ACTIVITY; CELL-DEATH; BIOSYNTHESIS; INDUCTION; CANCER; FARNESYLTRANSFERASE; TOXICITY; CLONING; CHOLINE	Genetic inactivation of the synthesis of phosphatidylcholine, the most abundant membrane lipid in eukaryotic cells, induces apoptosis, Administration of farnesol, a catabolite within the isoprenoid/cholesterol pathway, also induces apoptosis, The mechanism by which farnesol induces apoptosis is currently believed to be by direct competitive inhibition with diacylglycerol for cholinephosphotransferase, the final step in the phosphatidylcholine biosynthetic pathway. Our recent isolation of the first mammalian cholinephosphotransferase cDNA has enabled us to more precisely assess how farnesol affects phosphatidylcholine synthesis and the induction of apoptosis, Induced over-expression of cholinephosphotransferase in Chinese hamster ovary cells prevented the block in phosphatidylcholine biosynthesis associated with exposure to farnesol, However, induced over-expression of cholinephosphotransferase was not sufficient for the prevention of farnesol-induced apoptosis, In addition, exogenous administration of diacylglycerol prevented farnesol-induced apoptosis but did not relieve the farnesol-induced block in phosphatidylcholine synthesis. We also developed an in vitro lipid mixed micelle cholinephosphotransferase enzyme assay, as opposed to the delivery of the diacylglycerol substrate in a detergent emulsion, and demonstrated that there was no direct inhibition of cholinephosphotransferase by farnesol or its phosphorylated metabolites. The execution of apoptosis by farnesol appears to be a separate and distinct event from farnesol-induced inhibition of phosphatidylcholine biosynthesis and instead likely occurs through a diacylglycerol-mediated process that is downstream of phosphatidylcholine synthesis.	Dalhousie Univ, Atlantic Res Ctr, IWK Hlth Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, IWK Hlth Ctr, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, Atlantic Res Ctr, IWK Hlth Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada.			McMaster, Christopher/0000-0003-0822-5776; Ridgway, Neale/0000-0002-0441-6228				ADANY I, 1994, CANCER LETT, V79, P175, DOI 10.1016/0304-3835(94)90257-7; AMES BN, 1960, J BIOL CHEM, V235, P769; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Henneberry AL, 2000, J BIOL CHEM, V275, P29808, DOI 10.1074/jbc.M005786200; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOLESNICK RN, 1990, BIOCHEM J, V267, P17, DOI 10.1042/bj2670017; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mangues R, 1998, CANCER RES, V58, P1253; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MELNYKOVYCH G, 1992, BIOCHEM BIOPH RES CO, V186, P543, DOI 10.1016/S0006-291X(05)80842-3; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; O KM, 1993, BIOCHEM J, V289, P727, DOI 10.1042/bj2890727; Park HW, 1997, CURR OPIN STRUC BIOL, V7, P873; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Rioja A, 2000, FEBS LETT, V467, P291, DOI 10.1016/S0014-5793(00)01168-6; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; TANIGUCHI S, 1986, J BIOCHEM-TOKYO, V100, P485, DOI 10.1093/oxfordjournals.jbchem.a121737; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; VOZIYAN PA, 1995, BIOCHEM BIOPH RES CO, V212, P479, DOI 10.1006/bbrc.1995.1995; VOZIYAN PA, 1993, BIOCHEM J, V295, P757, DOI 10.1042/bj2950757; Williams SNO, 1998, MAGNET RESON MED, V40, P411, DOI 10.1002/mrm.1910400311; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; YAZLOVITSKAYA EM, 1995, CANCER LETT, V88, P179, DOI 10.1016/0304-3835(94)03635-V	37	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25254	25261		10.1074/jbc.M011552200	http://dx.doi.org/10.1074/jbc.M011552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11306571	hybrid			2022-12-25	WOS:000169800700110
J	Battaglia, E; Gollan, J				Battaglia, E; Gollan, J			A unique multifunctional transporter translocates estradiol-17 beta-glucuronide in rat liver microsomal vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONIC ACID; MULTIDRUG-RESISTANCE PROTEIN; ENDOPLASMIC-RETICULUM; GLUCURONOSYLTRANSFERASE ACTIVITY; GLUCOSE-TRANSPORT; SUBSTRATE; MEMBRANE; LOCALIZATION; GLUTATHIONE; CARRIER	A wide array of drugs, xenobiotics, and endogenous compounds undergo detoxification by conjugation with glucuronic acid in the Liver via the action of UDP-glucuronosyl-transferases. The mechanism whereby glucuronides, generated by this enzyme system in the lumen of the endoplasmic reticulum (ER), are exported to the cytosol prior to excretion is unknown. We examined this process in purified rat liver microsomes using a rapid filtration technique and [H-3]estradiol-17 beta -D-glucuronide ([H-3]E(2)17 betaG) as model substrate. Time-dependent uptake of intact [H-3]E(2)17 betaG was observed and shrinkage of ER vesicles by raffinose lowered the steady-state level of [H-3]E(2)17 betaG accumulation. In addition, rapid efflux of [H-3]E(21)7 betaG fi om rat liver microsomal vesicles suggested that the transport process is bidirectional. Microsomal uptake was saturable with an apparent K-m and V-max of 3.29 +/- 0.58 muM and 0.19 +/- 0.02 nmol(.)min(-1) mg protein(-1), respectively. Transport of [H-3]E(2)17 betaG was inhibited by the anion transport inhibitors 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid and probenecid. Specificity of the transport process was investigated by studying the cis-inhibitory effect of anionic metabolites, as well as substrates of the plasma membrane multidrug resistance-associated proteins on the uptake of [H-3]E(2)17 betaG. Collectively, these data are indicative of a novel multifunctional and bidirectional protein carrier for E(2)17 betaG and other anionic compounds in the hepatic ER This intracellular membrane transporter may contribute to the phenomenon of multidrug resistance.	UFR Sci Fondamentales & Appl, Lab Ingn Mol & Biochim Pharmacol, F-57070 Metz, France; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; Univ Adelaide, Royal Adelaide Hosp, Dept Med, Adelaide, SA 5000, Australia	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Royal Adelaide Hospital; University of Adelaide	Battaglia, E (corresponding author), UFR Sci Fondamentales & Appl, Lab Ingn Mol & Biochim Pharmacol, Campus Bridoux P7,Rue Claude Bernard, F-57070 Metz, France.	battaglia@sciences.univ-metz.fr			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036887] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-36887] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; ARION WJ, 1989, METHOD ENZYMOL, V174, P58; Banhegyi G, 1998, ARCH BIOCHEM BIOPHYS, V359, P133, DOI 10.1006/abbi.1998.0888; Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BANHEGYI G, 1993, FEBS LETT, V328, P149, DOI 10.1016/0014-5793(93)80983-2; Banhegyi G, 1996, BIOCHEM J, V315, P171, DOI 10.1042/bj3150171; BATTAGLIA E, 1994, ARCH BIOCHEM BIOPHYS, V309, P266, DOI 10.1006/abbi.1994.1112; Battaglia E, 1997, DRUG METAB DISPOS, V25, P406; Battaglia E, 1996, BBA-BIOMEMBRANES, V1283, P223, DOI 10.1016/0005-2736(96)00098-3; Battaglia E, 1998, BIOCHEMISTRY-US, V37, P258, DOI 10.1021/bi9716332; BATTAGLIA E, 1999, HEPATOLOGY, V30; BERG CL, 1995, GASTROENTEROLOGY, V108, P183, DOI 10.1016/0016-5085(95)90023-3; BLAIR JNR, 1988, BIOCHIM BIOPHYS ACTA, V964, P161, DOI 10.1016/0304-4165(88)90162-6; BOSSUYT X, 1994, BIOCHEM J, V302, P261, DOI 10.1042/bj3020261; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; CRAWFORD JM, 1992, J BIOL CHEM, V267, P16943; Cui YH, 1999, MOL PHARMACOL, V55, P929; DUTTON GJ, 1966, GLUCURONIC ACID FREE, P464; Eckhardt U, 1999, AM J PHYSIOL-GASTR L, V276, pG1037, DOI 10.1152/ajpgi.1999.276.4.G1037; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; HAUSER SC, 1988, BIOCHIM BIOPHYS ACTA, V967, P149, DOI 10.1016/0304-4165(88)90004-9; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Huang LY, 2000, HEPATOLOGY, V32, P66, DOI 10.1053/jhep.2000.8263; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF326, DOI 10.1152/ajprenal.1996.270.2.F326; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; Keppler D, 1997, BIOL CHEM, V378, P787; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; LILLY LB, 1995, AM J PHYSIOL-GASTR L, V268, pG1017, DOI 10.1152/ajpgi.1995.268.6.G1017; Little JM, 1997, DRUG METAB DISPOS, V25, P5; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; Morikawa A, 2000, PHARM RES-DORDR, V17, P546, DOI 10.1023/A:1026412915168; Nardai G, 2001, J BIOL CHEM, V276, P8825, DOI 10.1074/jbc.M010563200; RADOMINSKA A, 1993, J BIOL CHEM, V268, P15127; RADOMINSKA A, 1994, BBA-BIOMEMBRANES, V1195, P63, DOI 10.1016/0005-2736(94)90010-8; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; STDENIS JF, 1995, J BIOL CHEM, V270, P21092, DOI 10.1074/jbc.270.36.21092; SUGAWARA I, 1995, INT J CANCER, V64, P322, DOI 10.1002/ijc.2910640507; VORE M, 1983, LIFE SCI, V32, P2989, DOI 10.1016/0024-3205(83)90650-1; WADDELL ID, 1995, MOL MEMBR BIOL, V12, P283, DOI 10.3109/09687689509072429; WHITING JF, 1993, J BIOL CHEM, V268, P23197; Zucker SD, 1999, J BIOL CHEM, V274, P10852, DOI 10.1074/jbc.274.16.10852	52	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23492	23498		10.1074/jbc.M102494200	http://dx.doi.org/10.1074/jbc.M102494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313362	hybrid			2022-12-25	WOS:000169531100037
J	Ehses, JA; Lee, SST; Pederson, RA; McIntosh, CHS				Ehses, JA; Lee, SST; Pederson, RA; McIntosh, CHS			A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling - Evidence for the involvement of phospholipase A, in GIP-stimulated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; RAT PANCREATIC-ISLETS; BETA-GAMMA-SUBUNITS; ARACHIDONIC-ACID; PROTEIN-KINASE; CYCLIC-AMP; FUNCTIONAL EXPRESSION; LIGAND-BINDING; A(2); CELLS	The hormone glucose-dependent insulinotropic polypeptide (GIP) is an important regulator of insulin secretion. GIP has been shown to increase adenylyl cyclase activity, elevate intracellular Ca2+ levels, and stimulate a mitogen-activated protein kinase pathway in the pancreatic beta -cell. In the current study we demon strate a role for arachidonic acid in GIP-mediated signal transduction. Static incubations revealed that both GIP (100 nM) and ATP (5 muM) significantly increased [H-3] arachidonic acid ([H-3]AA) efflux from transfected Chinese hamster ovary K1 cells expressing the GIP receptor (basal, 128 +/- 11 cpm/well; GIP, 212 +/- 32 cpm/well; ATP, 263 +/- 35 cpm/well; n = 4; p < 0.05). In addition, GIP receptors were shown for the first time to be capable of functionally coupling to AA production through G beta gamma dimers in Chinese hamster ovary K1 cells. In a beta -cell model (beta TC-3), GIP was found to elicit [H-3]AA release, independent of glucose, in a concentration-dependent manner (EC50 value of 1.4 +/- 0.62 nM; n = 3). Although GIP did not potentiate insulin release under extracellular Ca2+-free conditions, it was still capable of elevating intracellular cAMP and stimulating [H-3]AA release. Our data suggest that cAMP is the proximal signaling intermediate responsible for GIP-stimulated AA release. Finally, stimulation of GIP-mediated AA production was shown to be mediated via a Ca2+-independent phospholipase A(2). Arachidonic acid is therefore a new component of GIP-mediated signal transduction in the beta -cell.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	McIntosh, CHS (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca	Ehses, Jan/AAK-1635-2020	Ehses, Jan/0000-0001-9066-7607				AMIRANOFF B, 1984, BIOCHEM BIOPH RES CO, V123, P671, DOI 10.1016/0006-291X(84)90281-X; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bymaster FP, 1999, CELL SIGNAL, V11, P405, DOI 10.1016/S0898-6568(99)00006-6; CATALAND S, 1974, J CLIN ENDOCR METAB, V39, P223, DOI 10.1210/jcem-39-2-223; Chen M, 1996, ENDOCRINOLOGY, V137, P2901, DOI 10.1210/en.137.7.2901; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DICKERSON CD, 1995, EXP CELL RES, V216, P46, DOI 10.1006/excr.1995.1006; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FALKO JM, 1975, J CLIN ENDOCR METAB, V41, P260, DOI 10.1210/jcem-41-2-260; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; Hinke SA, 2000, J ENDOCRINOL, V165, P281, DOI 10.1677/joe.0.1650281; Holst JJ, 1997, DIABETOLOGIA, V40, P984, DOI 10.1007/s001250050779; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kubota A, 1997, BIOCHEM BIOPH RES CO, V235, P171, DOI 10.1006/bbrc.1997.6743; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; LOWETH AC, 1995, MOL CELL ENDOCRINOL, V112, P177, DOI 10.1016/0303-7207(95)03595-X; LU M, 1993, ENDOCRINOLOGY, V132, P94, DOI 10.1210/en.132.1.94; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; McIntosh CHS, 1996, ACTA PHYSIOL SCAND, V157, P361, DOI 10.1046/j.1365-201X.1996.44267000.x; MCINTOSH CHS, 1981, CAN J PHYSIOL PHARM, V59, P468, DOI 10.1139/y81-069; McIntosh CHS, 1999, ENDOCRINOLOGY, V140, P398, DOI 10.1210/en.140.1.398; METZ SA, 1988, DIABETES, V37, P1453, DOI 10.2337/diabetes.37.11.1453; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; NAUCK M, 1986, DIABETOLOGIA, V29, P46, DOI 10.1007/BF02427280; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Owada S, 1999, J BIOL CHEM, V274, P2000, DOI 10.1074/jbc.274.4.2000; PEDERSON RA, 1975, DIABETES, V24, P1050, DOI 10.2337/diabetes.24.12.1050; PEDERSON RA, 1978, ENDOCRINOLOGY, V103, P610, DOI 10.1210/endo-103-2-610; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; Ramanadham S, 1997, BBA-LIPID LIPID MET, V1344, P153, DOI 10.1016/S0005-2760(96)00139-7; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Sauvadet A, 1997, J BIOL CHEM, V272, P12437, DOI 10.1074/jbc.272.19.12437; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; SIEGEL EG, 1985, DIABETOLOGIA, V28, P857, DOI 10.1007/BF00291078; Simonsson E, 2000, BIOCHEM BIOPH RES CO, V269, P242, DOI 10.1006/bbrc.2000.2248; Simonsson E, 2000, INT J PANCREATOL, V27, P1, DOI 10.1385/IJGC:27:1:01; Simonsson E, 1998, DIABETES, V47, P1436, DOI 10.2337/diabetes.47.9.1436; Straub SG, 1996, BIOCHEM BIOPH RES CO, V224, P369, DOI 10.1006/bbrc.1996.1035; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; TURK J, 1993, DIABETES, V42, P367, DOI 10.2337/diabetes.42.3.367; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WAHL MA, 1992, MOL CELL ENDOCRINOL, V90, P117, DOI 10.1016/0303-7207(92)90109-J; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Zhang H, 1998, FEBS LETT, V424, P202, DOI 10.1016/S0014-5793(98)00176-8	57	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23667	23673		10.1074/jbc.M103023200	http://dx.doi.org/10.1074/jbc.M103023200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323439	hybrid			2022-12-25	WOS:000169531100060
J	Romeo, AM; Christen, L; Niles, EG; Kosman, DJ				Romeo, AM; Christen, L; Niles, EG; Kosman, DJ			Intracellular chelation of iron by bipyridyl inhibits DNA virus replication - Ribonucleotide reductase maturation as a probe of intracellular iron pools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; VACCINIA VIRUS; SMALL-SUBUNIT; FERRITIN; PROTEIN; ACQUISITION; BINDING; YEAST; GENE; SIDEROPHORES	The efficient replication of large DNA viruses requires dNTPs supplied by a viral ribonucleotide reductase, Viral ribonucleotide reductase is an early gene product of both vaccinia and herpes simplex virus. For productive infection, the apoprotein must scavenge iron from the endogenous, labile iron pool(s), The membrane-permeant, intracellular Fe2+ chelator, 2,2'-bipyridine (bipyridyl, BIP), is known to sequester iron from this pool. We show here that BIP strongly inhibits the replication of both vaccinia and herpes simplex virus, type 1, In a standard plaque assay, 50 muM BIP caused a 50% reduction in plaque-forming units with either virus, Strong inhibition was observed only when BIP was added within 3 h post-infection. This time dependence was observed also in regards to inhibition of viral late protein and DNA synthesis by BIP, BIP did not inhibit the activity of vaccinia ribonucleotide reductase (RR), its synthesis, nor its stability indicating that BIP blocked the activation of the apoprotein, In parallel with its inhibition of vaccinia RR activation, BIP treatment increased the RNA binding activity of the endogenous iron-response protein, IRP1, by 1.9-fold. The data indicate that the diiron prosthetic group in vaccinia RR is assembled from iron taken from the BIP-accessible, labile iron pool that is sampled also by ferritin and the iron-regulated protein found in the cytosol of mammalian cells.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kosman, DJ (corresponding author), SUNY Buffalo, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@acsu.buffalo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053820] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43933] Funding Source: Medline; NIDDK NIH HHS [DK53820] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; Britigan BE, 2000, INFECT IMMUN, V68, P1271, DOI 10.1128/IAI.68.3.1271-1275.2000; Cabantchik ZI, 1999, FEMS IMMUNOL MED MIC, V26, P289, DOI 10.1111/j.1574-695X.1999.tb01401.x; CAMERON JM, 1988, J GEN VIROL, V69, P2607, DOI 10.1099/0022-1317-69-10-2607; Chabes A, 2000, P NATL ACAD SCI USA, V97, P2474, DOI 10.1073/pnas.97.6.2474; Cinatl J, 1996, ANTIVIR RES, V31, P23, DOI 10.1016/0166-3542(95)00833-0; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Cooper CE, 1996, J BIOL CHEM, V271, P20291, DOI 10.1074/jbc.271.34.20291; CORNELISSEN CN, 1994, MOL MICROBIOL, V14, P843, DOI 10.1111/j.1365-2958.1994.tb01320.x; Darnell G, 1999, BLOOD, V94, P781, DOI 10.1182/blood.V94.2.781.414k32_781_792; Eisenstein RS, 1997, CH MICROBIOL SER, P157; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; Harrison MD, 1999, J BIOL INORG CHEM, V4, P145, DOI 10.1007/s007750050297; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; HILL HAO, 1983, BIOL ASPECTS METALS, P15; Howard DH, 1999, CLIN MICROBIOL REV, V12, P394, DOI 10.1128/CMR.12.3.394; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; HOWELL ML, 1993, J BIOL CHEM, V268, P7155; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; IDOWU AD, 1992, ANTIVIR RES, V17, P145, DOI 10.1016/0166-3542(92)90048-A; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; Konijn AM, 1999, BLOOD, V94, P2128, DOI 10.1182/blood.V94.6.2128.418k20_2128_2134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, BIOCHEM J, V320, P129, DOI 10.1042/bj3200129; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Mabeza GF, 1999, PHARMACOL THERAPEUT, V81, P53, DOI 10.1016/S0163-7258(98)00037-0; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Nguyen HHT, 1999, P NATL ACAD SCI USA, V96, P12339, DOI 10.1073/pnas.96.22.12339; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Polla BS, 1999, BIOCHEM PHARMACOL, V57, P1345, DOI 10.1016/S0006-2952(99)00017-9; PRICHARD MN, 1995, CHEMOTHERAPY, V41, P384, DOI 10.1159/000239371; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Richardson DR, 1997, CAN J PHYSIOL PHARM, V75, P1164, DOI 10.1139/cjpp-75-10-11-1164; SLABAUGH MB, 1986, J VIROL, V60, P506, DOI 10.1128/JVI.60.2.506-514.1986; SLABAUGH MB, 1993, J BIOL CHEM, V268, P17803; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; SWENSON GR, 1991, BIOL MET, V4, P48, DOI 10.1007/BF01135557; Taramelli D, 2000, INFECT IMMUN, V68, P1724, DOI 10.1128/IAI.68.3.1724-1726.2000; Thomas F, 1999, J BIOL CHEM, V274, P13375, DOI 10.1074/jbc.274.19.13375; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; WEINBERG ED, 1995, CURR OPIN INFECT DIS, V8, P164, DOI 10.1097/00001432-199506000-00004; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x	51	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24301	24308		10.1074/jbc.M010806200	http://dx.doi.org/10.1074/jbc.M010806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11301321	hybrid			2022-12-25	WOS:000169531100141
J	Ginsberg, MH; Yaspan, B; Forsyth, J; Ulmer, TS; Campbell, ID; Slepak, M				Ginsberg, MH; Yaspan, B; Forsyth, J; Ulmer, TS; Campbell, ID; Slepak, M			A membrane-distal segment of the integrin alpha(IIb) cytoplasmic domain regulates integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUT SIGNAL-TRANSDUCTION; PLATELET GPIIB-IIIA; BETA-SUBUNIT; PROXIMAL REGION; CELL-ADHESION; TALIN-BINDING; TAIL; MODULATION; RECEPTOR; AFFINITY	Previous evidence suggests that interactions between integrin cytoplasmic domains regulate integrin activation. We have constructed and validated recombinant structural mimics of the heterodimeric alpha (IIb)beta (3) cytoplasmic domain. The mimics elicited polyclonal antibodies that recognize a combinatorial epitope(s) formed in mixtures of the alpha (.)(IIb) and beta (3) cytoplasmic domains but not present in either isolated tail. This epitope(s) is present within intact alpha (IIb)beta (3), indicating that interaction between the tails can occur in the native integrin. Furthermore, the combinatorial epitope(s) is also formed by introducing the activation-blocking beta (3)(Y747A) mutation into the beta (3) tail. A membrane-distal heptapeptide sequence in the alpha (IIb) tail ((RPPLEED)-R-997) is responsible for this effect on beta (3). Membrane-permeant palmitoylated peptides, containing this alpha (IIb) sequence, specifically blocked alpha (IIb)beta (3) activation in platelets. Thus, this region of the alpha (IIb) tail causes the beta (3) tail to resemble that of beta (3)(Y747A) and suppresses activation of the integrin.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Scripps Research Institute; University of Oxford	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Yaspan, Brian/0000-0002-3787-2510				BOYD J, 1992, J MAGN RESON, V98, P660, DOI 10.1016/0022-2364(92)90021-X; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CROWE DT, 1994, J BIOL CHEM, V269, P14411; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHN M, 1994, J BIOL CHEM, V269, P16247; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; Laplantine E, 2000, J CELL SCI, V113, P1167; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; LEONG L, 1995, J CELL SCI, V108, P3817; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; OTOOLE TE, 1991, SCIENCE, V254, P854; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; PLOW EF, 1984, J BIOL CHEM, V259, P5388; RABB H, 1993, J IMMUNOL, V151, P990; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Wang RG, 1997, J CLIN INVEST, V100, P2393, DOI 10.1172/JCI119780; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	42	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22514	22521		10.1074/jbc.M101915200	http://dx.doi.org/10.1074/jbc.M101915200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304543	hybrid			2022-12-25	WOS:000169412700073
J	Knudsen, C; Wieden, HJ; Rodnina, MV				Knudsen, C; Wieden, HJ; Rodnina, MV			The importance of structural transitions of the switch II region for the functions of elongation factor Tu on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR-EF-TU; ESCHERICHIA-COLI RIBOSOME; GTPASE-ACTIVATING-PROTEIN; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; RAS P21; ANGSTROM-RESOLUTION; BINDING DOMAIN; COMPLEX	Elongation factor Tu (EF-Tu) undergoes a large con formational transition when switching from the GTP to GDP forms. Structural changes in the switch I and II regions in the G domain are particularly important for this rearrangement. In the snitch II region, helix alpha2 is flanked by two glycine residues: Gly(83) in the consensus element DXXG at the N terminus and Gly(94) the C terminus. The role of helix alpha2 was studied by pre-steady state kinetic experiments using Escherichia coli EF-Tu mutants where either Gly(83), Gly(94), Or both were replaced with alanine. The G83A mutation slows down the association of the ternary complex EF-Tu.GTP.aminoacyl-tRNA with the ribosome and abolishes the ribosome-induced GTPase activity of EF-Tu. The G94A mutation strongly impairs the conformational change of EF-Tu from the GTP- to the GDP-bound form and decelerates the dissociation of EF-Tu GDP from the ribosome. The behavior of the double mutant is dominated by the G83A mutation. The results directly relate structural transitions in the switch II region to specific functions of EF-Tu on the ribosome.	Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany; Aarhus Univ, Inst Mol & Struct Biol, DK-8000 Aarhus C, Denmark	Witten Herdecke University; Aarhus University	Rodnina, MV (corresponding author), Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany.		Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Wieden, Hans-Joachim/0000-0001-5181-6059; Knudsen, Charlotte/0000-0003-2356-4821				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Berghuis AM, 1996, STRUCTURE, V4, P1277, DOI 10.1016/S0969-2126(96)00136-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; KJAERSGARD IVH, 1995, EUR J BIOCHEM, V228, P184; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; LEE E, 1992, J BIOL CHEM, V267, P1212; Ma JP, 1997, P NATL ACAD SCI USA, V94, P11905, DOI 10.1073/pnas.94.22.11905; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; Pape T, 2000, NAT STRUCT BIOL, V7, P104; Piepenburg O, 2000, BIOCHEMISTRY-US, V39, P1734, DOI 10.1021/bi992331y; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Song HW, 1999, J MOL BIOL, V285, P1245, DOI 10.1006/jmbi.1998.2387; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Vorstenbosch E, 1996, EMBO J, V15, P6766, DOI 10.1002/j.1460-2075.1996.tb01066.x	39	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22183	22190		10.1074/jbc.M102186200	http://dx.doi.org/10.1074/jbc.M102186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304547	hybrid			2022-12-25	WOS:000169412700030
J	Lechner, PS; Croniger, CM; Hakimi, P; Millward, C; Fekter, C; Yun, JS; Hanson, RW				Lechner, PS; Croniger, CM; Hakimi, P; Millward, C; Fekter, C; Yun, JS; Hanson, RW			The use of transgenic mice to analyze the role of accessory factor two in the regulation of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE UNIT; TISSUE-SPECIFIC EXPRESSION; GROWTH-HORMONE GENE; BINDING PROTEIN-1; PEPCK GENE; INSULIN; INDUCTION; PROMOTER; IDENTIFICATION; METABOLISM	The regulation of transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C) (4.1.1.32) during diabetes is a complex process that involves a number of regulatory elements in the PEPCK-C gene promoter. The accessory factor 2 (AF2)-binding region that is contained within the glucocorticoid regulatory unit of the PEPCK C gene promoter (-451 to -353) has been implicated in the action of both insulin and glucocorticoids on PEPCK-C gene transcription. To determine the role of AF2 in these processes, we have generated a mouse model bearing a transgene that contains the PEPCK-C gene promoter with a mutation in the AF2-binding region. This promoter is linked to the structural gene for human growth hormone that is biologically inactive (AF2-2000/hGx). In the absence of the AF2 regulatory element, the transcription of the transgene in the liver is not induced by diabetes but is inhibited by the administration of insulin. There is also a marked reduction in the response of the AF2-2000/hGx gene in the kidney to the administration of glucocorticoids. The AF2-2000/hGx gene in the liver responds normally to a high carbohydrate diet with a marked decrease in gene transcription. This suggests that insulin is not exerting its usual negative effect on the PEPCK-C gene promoter through the AF2 site. In contrast, the response of this transgene to a high fat/ carbohydrate free diet is severely blunted. Our results support a role for the AF2 site in the PEPCK-C gene promoter in the effect of glucocorticoids, but not insulin, on PEPCK C gene transcription in the liver.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Ohio Univ, Edison Anim Biotechnol Ctr, Athens, OH 45107 USA	Case Western Reserve University; Ohio University	Hanson, RW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	rwh@po.cwru.edu	Hakimi, Parvin/AAB-1643-2021		NIDDK NIH HHS [DK-07319, DK-22451] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER DK, 1992, DIABETES CARE, V15, P369, DOI 10.2337/diacare.15.3.369; GUNN JM, 1975, BIOCHEM J, V150, P195, DOI 10.1042/bj1500195; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HANSON RW, 1993, ADV ENZYMOL RAMB, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; OBERBAUMER I, 1992, NUCLEIC ACIDS RES, V20, P671; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PATEL YM, 1994, J BIOL CHEM, V269, P5619; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880	37	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22675	22679		10.1074/jbc.M102422200	http://dx.doi.org/10.1074/jbc.M102422200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309401	hybrid			2022-12-25	WOS:000169412700094
J	Usacheva, A; Smith, R; Minshall, R; Baida, G; Seng, SH; Croze, E; Colamonici, O				Usacheva, A; Smith, R; Minshall, R; Baida, G; Seng, SH; Croze, E; Colamonici, O			The WD motif-containing protein receptor for activated protein kinase C (RACK1) is required for recruitment and activation of signal transducer and activator of transcription 1 through the type I interferon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; STAT-PATHWAY; ALPHA; INTERACTS; COMMON; CHAIN	An obligatory step in the activation of Signal Transducers and Activators of Transcription (STATs) by cytokines is their docking to specific receptors via phosphotyrosines. However, this model does not address whether STATs pre-associate with their corresponding receptor or exist free in the cytoplasm before receptor activation. In this report, we demonstrate that pre-association of STAT1 with the receptor is required for type I interferon (IFN) signaling. Interestingly, the interaction between the human type I IFN receptor and STAT1 is not direct but mediated by the adapter protein receptor for activated protein kinase C (RACK1). Disruption of the IFN alpha receptor-RACK1 interaction abolishes not only IFN alpha -induced tyrosine phosphorylation of STAT1 but also activation of STATE, indicating that RACK1 plays a central role in early signaling through the Jak-STAT pathway. These findings demonstrate the involvement of RACK1 in STAT1 activation and raise the possibility that other STATs may pre-associate with cytokine receptors through similar adapter-STAT-mediated interactions.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, O (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott Ave,M-C868 Rm E403, Chicago, IL 60612 USA.		Usacheva, Anna/J-7543-2018	Usacheva, Anna/0000-0001-7508-6513	NIGMS NIH HHS [GM54709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHEUNG SC, 1991, J IMMUNOL, V146, P121; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; Collum RG, 2000, P NATL ACAD SCI USA, V97, P10120, DOI 10.1073/pnas.170192197; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; GHISLAIN J, 1995, J BIOL CHEM, V270, P21785, DOI 10.1074/jbc.270.37.21785; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SCHINDLER S, 1995, ANNU REV BIOCHEM, V64, P621; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	36	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22948	22953		10.1074/jbc.M100087200	http://dx.doi.org/10.1074/jbc.M100087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301323	hybrid			2022-12-25	WOS:000169412700129
J	White, PW; Pelletier, A; Brault, K; Titolo, S; Welchner, E; Thauvette, L; Fazekas, M; Cordingley, MG; Archambault, J				White, PW; Pelletier, A; Brault, K; Titolo, S; Welchner, E; Thauvette, L; Fazekas, M; Cordingley, MG; Archambault, J			Characterization of recombinant HPV6 and 11 E1 helicases - Effect of ATP on the interaction of E1 with E2 and mapping of a minimal helicase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS TYPE-1 E1; LARGE T-ANTIGEN; DNA-POLYMERASE-ALPHA; NUCLEAR-LOCALIZATION SIGNAL; SEDIMENTATION-VELOCITY DATA; REPLICATION PROTEIN-A; LARGE TUMOR-ANTIGEN; BOVINE PAPILLOMAVIRUS; BINDING DOMAIN; VIRAL E1	To better characterize the enzymatic activities required for human papillomavirus (HPV) DNA replication, the El helicases of HPV types 6 and 11 were produced using a baculovirus expression system. The purified wild type proteins and a version of HPV11 El lacking the N-terminal 71 amino acids, which was better expressed, were found to be hexameric over a wide range of concentrations and to have helicase and ATPase activities with relatively low values for K-m(ATP) of 12 muM for HPV6 El and 6 muM for HPV11 El. Interestingly, the value of K-m(ATP) was increased 7-fold in the presence of the E2 transactivation domain. In turn, ATP was found to perturb the co-operative binding of El and E2 to DNA. Mutant and truncated versions of in vitro translated El were used to identify a minimal ATPase domain composed of the C-terminal 297 amino acids. This fragment was expressed, purified, and found to be fully active in ATP hydrolysis, single-stranded DNA binding, and unwinding assays, despite lacking the minimal origin-binding domain.	Boehringer Ingelheim Canada Ltd, Dept Sci Biol, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim	White, PW (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Sci Biol, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	pwhite@lav.boehringer-ingelheim.com		Archambault, Jacques/0000-0001-8107-3428				Amin AA, 2000, VIROLOGY, V272, P137, DOI 10.1006/viro.2000.0328; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; BISHOP EO, 1981, BIOCHIM BIOPHYS ACTA, V635, P63, DOI 10.1016/0005-2728(81)90007-4; Biswas EE, 1999, BIOCHEMISTRY-US, V38, P10919, DOI 10.1021/bi990048t; BISWAS SB, 1994, BIOCHEMISTRY-US, V33, P11307, DOI 10.1021/bi00203a028; BLITZ IL, 1991, J VIROL, V65, P649, DOI 10.1128/JVI.65.2.649-656.1991; BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; Chen G, 1998, J VIROL, V72, P2567, DOI 10.1128/JVI.72.4.2567-2576.1998; CLARK R, 1981, J BIOL CHEM, V256, P1854; CLERTANT P, 1984, NATURE, V311, P276, DOI 10.1038/311276a0; Conger KL, 1999, J BIOL CHEM, V274, P2696, DOI 10.1074/jbc.274.5.2696; Cooper CS, 1998, VIROLOGY, V241, P312, DOI 10.1006/viro.1997.8941; Cueille N, 1998, J VIROL, V72, P7255, DOI 10.1128/JVI.72.9.7255-7262.1998; DEAN FB, 1992, J BIOL CHEM, V267, P14129; FERSHT A, 1999, STRUCTURE MECH PROTE, P126; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; FRATTINI MG, 1994, P NATL ACAD SCI USA, V91, P12398, DOI 10.1073/pnas.91.26.12398; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GORBALENYA AE, 1990, FEBS LETT, V262, P145, DOI 10.1016/0014-5793(90)80175-I; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15336, DOI 10.1021/bi981094g; HUGHES FJ, 1998, NUCLEIC ACIDS RES, V21, P5817; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Jenkins O, 1996, J GEN VIROL, V77, P1805, DOI 10.1099/0022-1317-77-8-1805; KUO SR, 1994, J BIOL CHEM, V269, P24058; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Leng X, 1997, J VIROL, V71, P848, DOI 10.1128/JVI.71.1.848-852.1997; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; LUSKY M, 1993, J BIOL CHEM, V268, P15795; Ma TL, 1999, P NATL ACAD SCI USA, V96, P382, DOI 10.1073/pnas.96.2.382; MACPHERSON P, 1994, VIROLOGY, V204, P403, DOI 10.1006/viro.1994.1544; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; McShan GD, 1997, J GEN VIROL, V78, P171, DOI 10.1099/0022-1317-78-1-171; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Muller F, 1996, VIROLOGY, V219, P247, DOI 10.1006/viro.1996.0242; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Phelps WC, 1998, ANTIVIR CHEM CHEMOTH, V9, P359, DOI 10.1177/095632029800900501; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; RAJ K, 1995, J GEN VIROL, V76, P2949, DOI 10.1099/0022-1317-76-12-2949; Rocque WJ, 2000, PROTEIN EXPRES PURIF, V18, P148, DOI 10.1006/prep.1999.1182; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SANTUCCI S, 1995, J GEN VIROL, V76, P1129, DOI 10.1099/0022-1317-76-5-1129; SARAFI TR, 1995, VIROLOGY, V211, P385, DOI 10.1006/viro.1995.1421; Scherzinger E, 1997, J BIOL CHEM, V272, P30228, DOI 10.1074/jbc.272.48.30228; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SHAH KV, 1996, FIELDS VIROLOGY, P2077; Singer VL, 1997, ANAL BIOCHEM, V249, P228, DOI 10.1006/abio.1997.2177; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; Sun YN, 1998, J GEN VIROL, V79, P1651, DOI 10.1099/0022-1317-79-7-1651; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; Titolo S, 2000, J VIROL, V74, P7349, DOI 10.1128/JVI.74.16.7349-7361.2000; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Walker SL, 1997, J VIROL, V71, P6996, DOI 10.1128/JVI.71.9.6996-7004.1997; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WINOKUR PL, 1992, EMBO J, V11, P4111, DOI 10.1002/j.1460-2075.1992.tb05504.x; Wu CX, 1998, J VIROL, V72, P10256, DOI 10.1128/JVI.72.12.10256-10259.1998; XIAO XL, 1994, J GEN VIROL, V75, P2463, DOI 10.1099/0022-1317-75-9-2463; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	85	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22426	22438		10.1074/jbc.M101932200	http://dx.doi.org/10.1074/jbc.M101932200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304544	hybrid			2022-12-25	WOS:000169412700062
J	Rashid, SF; Moore, JS; Walker, E; Driver, PM; Engel, J; Edwards, CE; Brown, G; Uskokovic, MR; Campbell, MJ				Rashid, SF; Moore, JS; Walker, E; Driver, PM; Engel, J; Edwards, CE; Brown, G; Uskokovic, MR; Campbell, MJ			Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D-3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A	ONCOGENE			English	Article; Proceedings Paper	91st Annual Meeting of the American-Association-for-Cancer-Research	APR 01-05, 2000	SAN FRANCISCO, CALIFORNIA	Amer Assoc Canc Res		histone deacetylation inhibitors; 1 alpha,25 Dihydroxyvitamin D-3; prostate cancer; growth inhibition; apoptosis	VITAMIN-D-RECEPTOR; D-RESPONSIVE ELEMENTS; HISTONE DEACETYLASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; INDUCED-DIFFERENTIATION; 24-HYDROXYLASE ACTIVITY; PROMYELOCYTIC LEUKEMIA; PROMOTER SELECTIVITY; GENE POLYMORPHISM	Prostate cancer is a major cause of male cancer death. In vitro and in vivo data support a role for 1 alpha ,25 Dihydroxyvitamin D-3 (1 alpha ,25(OH)(2)D-3) in regulating the growth and differentiation of the normal prostate gland yet prostate cancer cells appear significantly less sensitive to this action. Vitamin D-3 receptor (VDR) content or mutational status do not correlate clearly with the antiproliferative effects of 1 alpha ,25(OH)(2)D-3 and therefore it is unclear why prostate cancer cell lines are significantly less sensitive to this action. We hypothesized that the antiproliferative responses of prostate cancer cells to 1 alpha ,25(OH)(2)D-3 are suppressed by a process involving histone deacetylation, Sodium butyrate (NaB) and trichostatin A (TSA) are inhibitors of histone deacetylase (HDAC) activity. Low doses of NaB or TSA (300 muM and 15 nM respectively), which alone were relatively inactive, synergized with 1 alpha ,25(OH)(2)D-3 in liquid and semi-solid agar to inhibit the growth of LNCaP, PC-3 and DU-145 prostate cancer cells. Still greater synergy was observed between vitamin D-3 hexafluoride analogs and either NaB or TSA, The mechanism appeared to involve neither the cyclin-dependent kinase inhibitor, p21((waf1/cip1)) nor cell cycle arrest, but rather induction of apoptosis, These data suggest that cells dysregulate the normal pro-apoptotic signals of 1 alpha ,25(OH)(2)D-3 during prostate cancer development by a mechanism involving histone deacetylation, Combination therapy with potent vitamin D-3 analogs and clinically approved HDAC inhibitors may overcome this lesion and improve the treatment of both androgen-dependent and independent prostate cancer.	Univ Birmingham, Sch Med, Div Med Sci, Dept Med, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TH, W Midlands, England; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	University of Birmingham; University of Birmingham; Roche Holding	Campbell, MJ (corresponding author), Univ Birmingham, Sch Med, Div Med Sci, Dept Med, Birmingham B15 2TH, W Midlands, England.		FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Campbell, Moray/ABF-1264-2021; Campbell, Moray J/A-1311-2013	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Campbell, Moray/0000-0002-3355-0928; Brown, Geoffrey/0000-0003-0821-0275				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; ANZANO MA, 1994, CANCER RES, V54, P1653; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Campbell MJ, 1999, BRIT J CANCER, V79, P101, DOI 10.1038/sj.bjc.6690018; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 1999, MOL CELL ENDOCRINOL, V149, P169, DOI 10.1016/S0303-7207(98)00245-7; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; deVos S, 1997, PROSTATE, V32, P115; Ellerhorst J, 1999, INT J ONCOL, V14, P225; Evans SRT, 1999, INT J ONCOL, V14, P979; EWING CM, 1995, CANCER RES, V55, P4813; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Habuchi T, 2000, CANCER RES, V60, P305; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Hedlund TE, 1996, J STEROID BIOCHEM, V58, P277, DOI 10.1016/0960-0760(96)00030-1; Hedlund TE, 1997, CLIN CANCER RES, V3, P1331; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; IOWA Y, 1999, CANCER RES, V59, P4266; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Koike M, 1997, CANCER RES, V57, P4545; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krill D, 1999, UROLOGY, V54, P171, DOI 10.1016/S0090-4295(99)00103-X; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lea MA, 1998, ANTICANCER RES, V18, P2717; Li X, 1995, CELL PROLIFERAT, V28, P571, DOI 10.1111/j.1365-2184.1995.tb00045.x; Liang JY, 1999, PROSTATE, V38, P228; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; MAIYAR AC, 1992, MOL CELL ENDOCRINOL, V84, P99, DOI 10.1016/0303-7207(92)90076-I; Medina V, 1997, CANCER RES, V57, P3697; Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; Nayeri S, 1997, BIOCHEM J, V327, P561, DOI 10.1042/bj3270561; Pace BS, 2000, EXP HEMATOL, V28, P283, DOI 10.1016/S0301-472X(99)00153-8; PEEHL DM, 1994, CANCER RES, V54, P805; PEEHL DM, 1993, ENDOC J, V132, P1952; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rashid SF, 2001, STEROIDS, V66, P433, DOI 10.1016/S0039-128X(00)00203-8; Rosenthal DS, 1998, CA-CANCER J CLIN, V48, P3, DOI 10.3322/canjclin.48.1.3; Schwartz GG, 1998, CANCER EPIDEM BIOMAR, V7, P391; SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; TANAKA Y, 1989, BIOCHEM PHARMACOL, V38, P3859, DOI 10.1016/0006-2952(89)90596-0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Watanabe M, 1999, ANTICANCER RES, V19, P4511; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YONEDA T, 1984, BIOCHEM BIOPH RES CO, V121, P796, DOI 10.1016/0006-291X(84)90748-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1992, ANTICANCER RES, V12, P1947; ZHANG SH, 1997, MOL CELL ENDOCRINOL, V126, P83; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	66	107	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1860	1872		10.1038/sj.onc.1204269	http://dx.doi.org/10.1038/sj.onc.1204269			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313934				2022-12-25	WOS:000167908400007
J	Olsen, RJ; Hinrichs, SH				Olsen, RJ; Hinrichs, SH			Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins	ONCOGENE			English	Article						sarcoma; fusion protein; phosphorylation; IQ domain; EWS/ATF1; EWS/FLI1	CLEAR-CELL-SARCOMA; DNA-BINDING; CHIMERIC TRANSCRIPTS; MALIGNANT-MELANOMA; KINASE-C; TRANSLOCATION; INHIBITION; REQUIRES; TRANSACTIVATION; EWS-FLI-1	Specific chromosomal translocations are commonly present in mesenchymal tumors and frequently involve genes encoding transcription factors, The combination of different domains from unrelated genes results in chimeric proteins belie, ed to play a key role in the neoplastic process. The EWS/ATF1 and EWS/FLI1 fusion proteins associated with Clear Cell Sarcoma and Ewing's Sarcoma, respectively, were utilized to study the comparative effect of the EWS component on two different DNA binding partners. A potential regulatory site within the EWS IQ domain at serine266 was identified, and studies were performed to demonstrate that EWS is phosphorylated in cells and phosphorylation of serine266 regulates transcriptional activity. Mutational analysis showed that elimination of phosphorylation significantly reduced DNA binding activity by EMSA and reporter activation in luciferase assays, whereas phosphorylation mimicry resulted in a partial restoration to wild-type levels. Phosphorylation was also observed to mediate cellular compartmentalization. These studies confirm that IQ domain phosphorylation regulates the transcriptional activity of exogenous EWS/ATF1 and EWS/FLI1 and suggests that post-translational modifications may potentiate the neoplastic behavior of fusion proteins in general. Since the IQ domain is incorporated into only a subset of fusion transcripts, these findings may provide insight into the molecular mechanism underlying clinical heterogeneity observed in Ewing's sarcoma.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 69198 USA	University of Nebraska System; University of Nebraska Medical Center	Hinrichs, SH (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 69198 USA.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bosilevac JM, 1998, J BIOL CHEM, V273, P16874, DOI 10.1074/jbc.273.27.16874; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; BRIDGE JA, 1991, CANCER GENET CYTOGEN, V52, P101, DOI 10.1016/0165-4608(91)90059-4; BRIDGE JA, 1990, AM J CLIN PATHOL, V93, P26, DOI 10.1093/ajcp/93.1.26; Bridge Julia A., 1996, Current Opinion in Oncology, V8, P284; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Dohjima T, 2000, BRIT J CANCER, V82, P16, DOI 10.1054/bjoc.1998.0870; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Fujimura Y, 1996, ONCOGENE, V12, P159; GILCHRIST C, 1995, J BIOCH SCI, V3, P96; Gilchrist CA, 1995, ANTIBODY IMMUNOCONJ, V8, P281; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Li KKC, 1998, ONCOGENE, V16, P1325, DOI 10.1038/sj.onc.1201649; Lin PP, 1999, CANCER RES, V59, P1428; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419	32	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1756	1764		10.1038/sj.onc.1204268	http://dx.doi.org/10.1038/sj.onc.1204268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313922				2022-12-25	WOS:000167750900008
J	Nishimoto, A; Miura, N; Horikawa, I; Kugoh, H; Murakami, Y; Hirohashi, S; Kawasaki, H; Gazdar, AF; Shay, JW; Barrett, JC; Oshimura, M				Nishimoto, A; Miura, N; Horikawa, I; Kugoh, H; Murakami, Y; Hirohashi, S; Kawasaki, H; Gazdar, AF; Shay, JW; Barrett, JC; Oshimura, M			Functional evidence for a telomerase repressor gene on human chromosome 10p15.1	ONCOGENE			English	Article						microcell-mediated chromosome transfer; telomerase; chromosome 10p; telomerase repressor gene; hTERT	HUMAN PROSTATE-CANCER; CATALYTIC SUBUNIT HTERT; TUMOR-SUPPRESSOR GENES; CELLULAR SENESCENCE; EFFICIENT MODIFICATION; INSITU HYBRIDIZATION; MAMMALIAN TELOMERASE; IMMORTAL CELLS; HUMAN GLIOMAS; ALLELIC LOSS	Based on the sites of frequent allelic loss in hepatocellular carcinoma, five normal human chromosomes (2, 4, 5, 10 and 16) were transferred individually into a telomerase-positive human hepatocellular carcinoma cell line, Li7HM, by microcell-mediated chromosome transfer (MMCT). Chromosome 10, but not the others, repressed telomerase activity immediately and stopped cell growth after 50 population doublings (PDs), Loss of the transferred 10p loci resulted in the emergence of revertant cells that continued to proliferate and expressed telomerase activity, suggesting the presence of a telomerase repressor gene on this chromosomal arm. Transfer of a series of defined fragments from chromosome 10p successfully narrowed down the responsible region: a 28.9-cM region on 10p15 (between WI-4752 and D10S249), but not a 26.2-cM region (between D10S1728 and D10S249), caused repression of telomerase activity and progressive telomere shortening. A strong correlation between the expression level of telomerase catalytic subunit gene (hTERT) and telomerase activity was observed. These findings suggest that a novel telomerase repressor gene which controls the expression of hTERT is located on the 2.7-cM region (between WI-4752 and D10S1728) on chromosome 10p15.1.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Tottori 6838503, Japan; NCI, Lab Biosyst & Canc, Canc & Aging Sect, Bethesda, MD 20892 USA; Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Tottori Univ, Dept Internal Med 2, Tottori 6838503, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Tottori University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan; National Cancer Center - Japan; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Tottori 6838503, Japan.		Shay, Jerry W/F-7878-2011					CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIROHASHI S, 1979, CANCER RES, V39, P1819; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; Ittmann M, 1996, CANCER RES, V56, P2143; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Kuroiwa Y, 1998, NUCLEIC ACIDS RES, V26, P3447, DOI 10.1093/nar/26.14.3447; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; Murakami Y, 2000, J HUM GENET, V45, P370, DOI 10.1007/s100380070011; Murakami YS, 1996, CANCER RES, V56, P2157; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Robertson GP, 1999, CANCER RES, V59, P3596; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; TAHARA H, 1995, CANCER RES, V55, P2734; Takakura M, 1999, CANCER RES, V59, P551; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Trybus TM, 1996, CANCER RES, V56, P2263; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Voesten AMJ, 1997, GENE CHROMOSOME CANC, V20, P167, DOI 10.1002/(SICI)1098-2264(199710)20:2<167::AID-GCC7>3.0.CO;2-1; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	41	44	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					828	835		10.1038/sj.onc.1204165	http://dx.doi.org/10.1038/sj.onc.1204165			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314017				2022-12-25	WOS:000166924400006
J	Li, Y; DeFatta, R; Anthony, C; Sunavala, G; De Benedetti, A				Li, Y; DeFatta, R; Anthony, C; Sunavala, G; De Benedetti, A			A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed	ONCOGENE			English	Article						eIF4E; translational regulation; histone H3 kinase; Tousled-like kinase; radioresistance	INITIATION-FACTOR 4E; PROTEIN-KINASE; MESSENGER-RNA; DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; GROWTH; GENE; FIBROBLASTS; EXPRESSION	The gene Tousled of Arabidopsis Thaliana encodes a protein kinase which, when mutated, results in abnormal flower development, From a library of mRNAs that are translationally upregulated by overexpression of the translation initiation factor 4E, we identified a mammalian Tousled Like kinase (TLK1B), The human TLK1B mRNA contains a 5'UTR 1088-nt-long with two upstream AUG codons, and was found to be very inhibitory for translation, The TLK1B protein localizes almost exclusively mammalian cells rendered them more resistant to ionizing radiation OR). Purified TLK1S phosphorylated histone H3 at S-10 with high specificity both in a mis of core histones and in isolated chromatin, suggesting that histone H3 is a physiological substrate for TLK1B, Moreover, overexpression of TLK1B in transfected cells resulted in a higher degree of H3 phosphorylation. Expression of TLK1B in a yeast strain that harbors a temperature-sensitive mutation of the major H3 kinase, IpI1, complemented the growth defect; restored normal levels of histone H3 phosphorylation; and increased their resistance to IR. Phosphorylation of H3 has been linked to the activation of the immediate-early gems upon mitogenic stimulation, and to chromatin condensation during mitotic/meiotic events, A possible role for TLK1B in radioprotection is discussed.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	De Benedetti, A (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.				NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHAN CSM, 1993, GENETICS, V135, P677; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; DEBENEDETTI A, 1991, NUCLEIC ACIDS RES, V19, P1925, DOI 10.1093/nar/19.8.1925; GEBALLE AP, 1994, TIBS, V19, P150; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; GROSS DS, 1985, J MOL BIOL, V183, P251, DOI 10.1016/0022-2836(85)90218-9; Howard EL, 1999, MOL CELL BIOL, V19, P1990; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MOORE SA, 1988, J BIOL CHEM, V263, P9674; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Newton GL, 1996, RADIAT RES, V145, P776, DOI 10.2307/3579370; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Shalom S, 1999, MOL REPROD DEV, V52, P392, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;392::AID-MRD8&gt;3.0.CO;2-Y; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yamakawa A, 1997, GENE, V202, P193, DOI 10.1016/S0378-1119(97)00495-2	36	71	72	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					726	738		10.1038/sj.onc.1204147	http://dx.doi.org/10.1038/sj.onc.1204147			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314006				2022-12-25	WOS:000166806000008
J	van Kempen, LCLT; Nelissen, JMDT; Degen, WGJ; Torensma, R; Weidle, UH; Bloemers, HPJ; Figdor, CG; Swart, GWM				van Kempen, LCLT; Nelissen, JMDT; Degen, WGJ; Torensma, R; Weidle, UH; Bloemers, HPJ; Figdor, CG; Swart, GWM			Molecular basis for the hemophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; HUMAN-MELANOMA; TUMOR PROGRESSION; LIGAND-BINDING; CD6 LIGAND; DM-GRASP; DOMAIN; EXPRESSION; CLONING; ANTIGEN	Activated leukocyte cell adhesion molecule (ALCAM/ CD166), a member of the immunoglobulin superfamily with five extracellular immunoglobulin-like domains, facilitates heterophilic (ALCAM-CD6) and hemophilic (ALCAM-ALCAM) cell-cell interactions, While expressed in a wide variety of tissues and cells, ALCAM is restricted to subsets of cells usually involved in dynamic growth and/or migration processes. A structure-function analysis, using two monoclonal anti-ALCAM antibodies and a series of amino-terminally deleted ALCAM constructs, revealed that hemophilic cell adhesion depended on ligand binding mediated by the membrane-distal amino-terminal immunoglobulin domain and on avidity controlled by ALCAM clustering at the cell surface involving membrane-proximal immunoglobulin domains. Go-expression of a transmembrane ALCAM. deletion mutant, which lacks the ligand binding domain, and endogenous wild-type ALCAM inhibited hemophilic cell-cell interactions by interference with ALCAM avidity, while hemophilic, soluble ligand binding remained unaltered. The extracellular structures of ALCAM thus provide two structurally and functionally distinguishable modules, one involved in ligand binding and the other in avidity. Functionality of both modules is required for stable hemophilic ALCAM-ALCAM cell-cell adhesion.	Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr St Radboud, Dept Tumor Immunol, Nijmegen, Netherlands; Roche Diagnost GmbH, D-82372 Penzberg, Germany	Radboud University Nijmegen; Radboud University Nijmegen; Roche Holding	Swart, GWM (corresponding author), Univ Nijmegen, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Figdor, Carl G/A-4232-2010; van Kempen, Léon/AAX-5866-2021; van Kempen, Leon/ABG-6815-2020; Torensma, Ruurd/C-2853-2009; van kempen, leon/A-8598-2012	Figdor, Carl G/0000-0002-2366-9212; van Kempen, Léon/0000-0003-0646-0705; Torensma, Ruurd/0000-0002-0555-7903; 				Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Bodian DL, 1997, BIOCHEMISTRY-US, V36, P2637, DOI 10.1021/bi962560+; Bowen MA, 1997, EUR J IMMUNOL, V27, P1469, DOI 10.1002/eji.1830270625; Bowen MA, 1996, J BIOL CHEM, V271, P17390, DOI 10.1074/jbc.271.29.17390; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; Bowen MA, 2000, PROTEINS, V40, P420; Bruder SP, 1998, J BONE MINER RES, V13, P655, DOI 10.1359/jbmr.1998.13.4.655; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Cortes F, 1999, BLOOD, V93, P826, DOI 10.1182/blood.V93.3.826.403k28_826_837; Degen WGJ, 1998, AM J PATHOL, V152, P805; ETZIONI A, 1994, CELL ADHES COMMUN, V2, P257, DOI 10.3109/15419069409004445; FEIZI T, 1994, TRENDS BIOCHEM SCI, V19, P233, DOI 10.1016/0968-0004(94)90144-9; Heffron DS, 2000, J NEUROSCI, V20, P2287; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Levesque MC, 1998, ARTHRITIS RHEUM, V41, P2221, DOI 10.1002/1529-0131(199812)41:12<2221::AID-ART18>3.0.CO;2-I; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Matsumoto A, 1997, J BIOL CHEM, V272, P16778, DOI 10.1074/jbc.272.27.16778; Nelissen JMDT, 2000, MOL BIOL CELL, V11, P2057, DOI 10.1091/mbc.11.6.2057; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; POURQUIE O, 1992, P NATL ACAD SCI USA, V89, P5261, DOI 10.1073/pnas.89.12.5261; Sekine-Aizawa Y, 1998, EUR J NEUROSCI, V10, P2810, DOI 10.1111/j.1460-9568.1998.00288.x; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Skonier JE, 1997, PROTEIN ENG, V10, P943, DOI 10.1093/protein/10.8.943; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; Uchida N, 1997, BLOOD, V89, P2706, DOI 10.1182/blood.V89.8.2706; van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729	28	123	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25783	25790		10.1074/jbc.M011272200	http://dx.doi.org/10.1074/jbc.M011272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11306570	Green Published, hybrid			2022-12-25	WOS:000169823300021
J	Abdel-Ghany, M; Cheng, HC; Elble, RC; Pauli, BU				Abdel-Ghany, M; Cheng, HC; Elble, RC; Pauli, BU			The breast cancer beta(4) integrin and endothelial human CLCA2 mediate lung metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DIPEPTIDYL PEPTIDASE IV; CARCINOMA CELL-LINES; MATRIX METALLOPROTEINASES; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; MAMMALIAN HEPARANASE; CYSTIC-FIBROSIS; TUMOR INVASION; E-CADHERIN	Adhesion of blood-borne cancer cells to the endothelium is a critical determinant of organ-specific metastasis. Here we show that colonization of the lungs by human breast cancer cells is correlated with cell surface expression of the alpha (6)beta (4) integrin and adhesion to human CLCA2 (hCLCA2), a Ca2+-sensitive chloride channel protein that is expressed on the endothelial cell luminal surface of pulmonary arteries, arterioles, and venules, Tumor cell adhesion to endothelial hCLCA2 is mediated by the beta (4) integrin, establishing for the first time a cell-cell adhesion property for this integrin that involves an entirely new adhesion partner. This adhesion is augmented by an increased surface expression of the alpha (6)beta (4) integrin in breast cancer cells selected in vivo for enhanced lung colonization but abolished by the specific cleavage of the beta (4) integrin with matrilysin. beta (4) integrin/hCLCA2 adhesion-blocking antibodies directed against either of the two interacting adhesion molecules inhibit lung colonization, while overexpression of the beta (4) integrin in a model murine tumor cell line of modest lung colonization potential significantly increases the lung metastatic performance. Our data clearly show that the beta (4)/hCLCA2 adhesion is critical for lung metastasis, yet expression of the beta (4) integrin in many benign breast tumors shows that this integrin is insufficient to bestow metastatic competence on cells that lack invasiveness and other established properties of metastatic cells.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Pauli, BU (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.	bup1@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA047668, R01CA071626] Funding Source: NIH RePORTER; NCI NIH HHS [CA71626, CA47668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 1998, INVAS METAST, V18, P35, DOI 10.1159/000024497; ABDELGHANY M, 1987, P NATL ACAD SCI USA, V84, P8888, DOI 10.1073/pnas.84.24.8888; AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bohm JP, 2000, J PATHOL, V192, P321; Cheng HC, 1998, J BIOL CHEM, V273, P24207, DOI 10.1074/jbc.273.37.24207; Cimino L, 1997, CANCER DETECT PREV, V21, P158; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; Donovan D, 1997, ANN SURG ONCOL, V4, P621, DOI 10.1007/BF02303745; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; FALCIONI R, 1986, CANCER RES, V46, P5772; Fidler IJ, 2000, CANCER J, V6, pS134; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Goetz DJ, 1996, INT J CANCER, V65, P192, DOI 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jones JL, 1997, EXP CELL RES, V235, P325, DOI 10.1006/excr.1997.3662; Kebers F, 1998, EXP CELL RES, V240, P197, DOI 10.1006/excr.1998.3935; KEMPERMAN H, 1993, CANCER RES, V53, P3611; Lee-Huang S, 2000, ANTICANCER RES, V20, P653; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Maguire PD, 2000, ONCOLOGY-BASEL, V59, P139, DOI 10.1159/000012151; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Martin DK, 1996, MICROVASC RES, V52, P200, DOI 10.1006/mvre.1996.0058; Mbalaviele G, 1996, CANCER RES, V56, P4063; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PAULI BU, 1988, LAB INVEST, V58, P379; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; PAULI BU, 1997, ENCY CANC, V1, P464; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PERROTTI D, 1990, ANTICANCER RES, V10, P1587; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Pulyaeva H, 1997, CLIN EXP METASTAS, V15, P111, DOI 10.1023/A:1018444609098; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Roetger A, 1998, AM J PATHOL, V153, P1797, DOI 10.1016/S0002-9440(10)65694-5; ROSSEN K, 1994, ACTA DERM-VENEREOL, V74, P101; Russell RL, 1997, CANCER, V79, P1158, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1158::AID-CNCR14>3.0.CO;2-Z; Shain KH, 2000, CURR OPIN ONCOL, V12, P557, DOI 10.1097/00001622-200011000-00008; Shaw LM, 1996, CANCER RES, V56, P959; SOULE HD, 1990, CANCER RES, V50, P6075; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Taverna D, 1998, CANCER RES, V58, P848; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Walsh MD, 1999, BREAST CANCER RES TR, V58, P255; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; Yip D, 1999, INVEST NEW DRUG, V17, P387, DOI 10.1023/A:1006386406584; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZHU DZ, 1993, INT J CANCER, V53, P628; ZHU DZ, 1991, J HISTOCHEM CYTOCHEM, V39, P1137, DOI 10.1177/39.8.1856462; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	76	107	117	4	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25438	25446		10.1074/jbc.M100478200	http://dx.doi.org/10.1074/jbc.M100478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320086	hybrid			2022-12-25	WOS:000169800700134
J	Basran, J; Sutcliffe, MJ; Scrutton, NS				Basran, J; Sutcliffe, MJ; Scrutton, NS			Deuterium isotope effects during carbon-hydrogen bond cleavage by trimethylamine dehydrogenase - Implications for mechanism and vibrationally assisted hydrogen tunneling in wild-type and mutant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON TRANSFERRING FLAVOPROTEIN; ALCOHOL-DEHYDROGENASE; PROTON-TRANSFER; COUPLED MOTION; CATALYSIS; SUBSTRATE; OXIDASE; OXIDATION; DYNAMICS; KINETICS	His-172 and Tyr-169 are components of a triad in the active site of trimethylamine dehydrogenase (TMADH) comprising Asp-267, His-172, and Tyr-169, Stopped-flow kinetic studies with trimethylamine as substrate have indicated that mutation of His-172 to Gin reduces the limiting rate constant for flavin reduction similar to 10-fold (Basran, J,, Sutcliffe, M. J,, Hille, R,, and Scrutton, N, S, (1999) Biochem, J, 341, 397-314), A kinetic isotope effect (KIE = k(H)/K-D) accompanies flavin reduction by H172Q TIMADH, the magnitude of which varies significantly with solution pH, With trimethylamine, flavin reduction by H172Q TMADH is controlled by a single macroscopic ionization (pK(a) = 6.8 +/- 0.1), This ionization is perturbed (pK(a) = 7.4 +/- 0.1) in reactions with perdeuterated trimethylamine and is responsible for the apparent variation in the KIE with solution pH, At pH 9.5, where the functional group controlling flavin reduction is fully ionized, the KIE is independent of temperature in the range 277-297 K, consistent with vibrationally assisted hydrogen tunneling during breakage of the substrate C-H bond. Y169F TMADH is similar to4-fold more compromised than H172Q TMADH for hydrogen transfer, which occurs non-classically. Studies with Y169F TMADH suggest partial thermal excitation of substrate prior to hydrogen tunneling by a vibrationally assisted mechanism. Our studies illustrate the varied effects of compromising mutations on tunneling regimes in enzyme molecules.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Sutcliffe, Mike/0000-0003-0414-1700				Abad JL, 2000, ANGEW CHEM INT EDIT, V39, P3279, DOI 10.1002/1521-3773(20000915)39:18<3279::AID-ANIE3279>3.0.CO;2-G; Alhambra C, 2000, J AM CHEM SOC, V122, P8197, DOI 10.1021/ja001476l; Alston WC, 1996, BIOCHEMISTRY-US, V35, P12873, DOI 10.1021/bi960831a; Antoniou D, 1997, P NATL ACAD SCI USA, V94, P12360, DOI 10.1073/pnas.94.23.12360; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; Basran J, 1999, J BIOL CHEM, V274, P13155, DOI 10.1074/jbc.274.19.13155; Basran J, 2000, BIOCHEMISTRY-US, V39, P9188, DOI 10.1021/bi0006868; Basran J, 1999, BIOCHEM J, V341, P307, DOI 10.1042/0264-6021:3410307; Basran J, 1997, BIOCHEMISTRY-US, V36, P1989, DOI 10.1021/bi962623o; Basran J, 2001, J BIOL CHEM, V276, P6234, DOI 10.1074/jbc.M008141200; Basran J, 1999, BIOCHEMISTRY-US, V38, P3218, DOI 10.1021/bi982719d; Bell R. P., 1980, TUNNEL EFFECT CHEM, P51; BORGIS D, 1991, J CHEM PHYS, V94, P3619, DOI 10.1063/1.459733; BRUNO WJ, 1992, BIOPHYS J, V63, P689, DOI 10.1016/S0006-3495(92)81654-5; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; Colby TD, 1998, BIOCHEMISTRY-US, V37, P9295, DOI 10.1021/bi973184b; Harris RJ, 2000, BIOCHEMISTRY-US, V39, P1189, DOI 10.1021/bi991941v; HUANG LX, 1995, J BIOL CHEM, V270, P23958, DOI 10.1074/jbc.270.41.23958; Jang MH, 1999, J BIOL CHEM, V274, P13147, DOI 10.1074/jbc.274.19.13147; Jonsson T, 1996, J AM CHEM SOC, V118, P10319, DOI 10.1021/ja961827p; JONSSON T, 1994, BIOCHEMISTRY-US, V33, P14871, DOI 10.1021/bi00253a026; Karsten WE, 1999, BIOCHEMISTRY-US, V38, P4398, DOI 10.1021/bi982439y; Kohen A, 2000, J AM CHEM SOC, V122, P10738, DOI 10.1021/ja002229k; Kohen A, 1999, CHEM BIOL, V6, pR191, DOI 10.1016/S1074-5521(99)80058-1; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Kohen A, 1997, BIOCHEMISTRY-US, V36, P2603, DOI 10.1021/bi962492r; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; Kuznetsov AM, 1999, CAN J CHEM, V77, P1085, DOI 10.1139/cjc-77-5-6-1085; LIM LW, 1986, J BIOL CHEM, V261, P5140; Miller JR, 1999, BIOCHEMISTRY-US, V38, P13670, DOI 10.1021/bi990920y; NAGY J, 1979, J BIOL CHEM, V254, P2684; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; Northrop DB, 2000, BIOCHEMISTRY-US, V39, P2406, DOI 10.1021/bi992537z; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; Scrutton NS, 1999, EUR J BIOCHEM, V264, P666, DOI 10.1046/j.1432-1327.1999.00645.x; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Sutcliffe MJ, 2000, TRENDS BIOCHEM SCI, V25, P405, DOI 10.1016/S0968-0004(00)01642-X; Sutcliffe MJ, 2000, PHILOS T ROY SOC A, V358, P367, DOI 10.1098/rsta.2000.0536; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; Whittaker MM, 1998, BIOCHEMISTRY-US, V37, P8426, DOI 10.1021/bi980328t; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024	46	73	73	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24581	24587		10.1074/jbc.M101178200	http://dx.doi.org/10.1074/jbc.M101178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11304539	hybrid			2022-12-25	WOS:000169800700023
J	Yang, QH; Zhu, Z; Dong, MQ; Ling, S; Wu, CL; Li, L				Yang, QH; Zhu, Z; Dong, MQ; Ling, S; Wu, CL; Li, L			Binding of ATP to the fructose-2,6-bisphosphatase domain of chicken liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase leads to activation of its 6-phosphofructo-2-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-LIVER; BIFUNCTIONAL ENZYME; 2-KINASE DOMAIN; CRYSTAL-STRUCTURE; FRUCTOSE 6-PHOSPHATE,2-KINASE; ESCHERICHIA-COLI; BASIC RESIDUES; MECHANISM; 2,6-BISPHOSPHATASE	To understand the mechanism by which the activity of the 6-phosphofructo-2-kinase (6PF-2K) of chicken liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is stimulated by its substrate ATP, we studied two mutants of the enzyme. Mutation of either Arg-279, the penultimate basic residue within the Walker A nucleotide-binding fold in the bisphosphatase domain, or Arg-359 to Ala eliminated the activation of the chicken 6PF-2K by ATP, Binding analysis by fluorescence spectroscopy using 2 ' (3 ')-O-(N-methylanthraniloyl)-ATP revealed that the kinase domains of these two mutants, unlike that of the wild type enzyme, showed no cooperativity in ATP binding and that the mutant enzymes possess only the high affinity ATP binding site, suggesting that the ATP binding site on the bisphosphatase domain represents the low affinity site. This conclusion was supported by the result that the affinity of ATP for the isolated bisphosphatase domain is similar to that for the low affinity site in the wild type enzyme. In addition, we found that the 6PP-2K of a chimeric enzyme, in which the last 25 residues of chicken enzyme were replaced with those of the rat enzyme, could not be activated by ATP, despite the fact that the ATP-binding properties of this chimeric enzyme were not different from those of the wild type chicken enzyme, These results demonstrate that activation of the chicken 6PF-2K by ATP may result from allosteric binding of ATP to the bisphosphatase domain where residues Arg-279 and Arg-359 are critically involved and require specific C-terminal sequences.	Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, L (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.							ABE Y, 1995, BIOCHEMISTRY-US, V34, P2553, DOI 10.1021/bi00008a020; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; Bertrand L, 1997, BIOCHEM J, V321, P623, DOI 10.1042/bj3210623; Bertrand L, 1997, BIOCHEM J, V321, P615, DOI 10.1042/bj3210615; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; KURLAND IJ, 1995, PROTEIN SCI, V4, P1023, DOI 10.1002/pro.5560040601; Kurland IJ, 2000, BIOCHEM J, V347, P459, DOI 10.1042/0264-6021:3470459; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; LEE YH, 1994, J BIOL CHEM, V269, P11002; Li L, 1997, BIOCHEM J, V328, P751, DOI 10.1042/bj3280751; LI L, 1992, J BIOL CHEM, V267, P4386; LI L, 1991, SCI CHINA SER B, V34, P916; LI L, 1995, BIOCHEM BIOPH RES CO, V209, P883, DOI 10.1006/bbrc.1995.1581; LI L, 1993, BIOCHEM BIOPH RES CO, V190, P397, DOI 10.1006/bbrc.1993.1061; LI L, 1992, J BIOL CHEM, V267, P21588; LIN K, 1994, J BIOL CHEM, V269, P16953; MAPES JP, 1978, ARCH BIOCHEM BIOPHYS, V190, P193; Mizuguchi H, 1997, BIOCHEMISTRY-US, V36, P8775, DOI 10.1021/bi970639o; Okar DA, 2000, BIOCHEMISTRY-US, V39, P9754, DOI 10.1021/bi000815k; PEARCE J, 1977, INT J BIOCHEM, V8, P260; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; RIDER MH, 1994, BIOCHEM J, V300, P111, DOI 10.1042/bj3000111; ROUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99, DOI 10.1016/S0079-6603(08)60868-5; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Uyeda K, 1997, J BIOL CHEM, V272, P7867, DOI 10.1074/jbc.272.12.7867; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; Vertommen D, 1996, J BIOL CHEM, V271, P17875, DOI 10.1074/jbc.271.30.17875; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang ZX, 1996, FEBS LETT, V388, P73, DOI 10.1016/0014-5793(96)00498-X; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Wu RF, 1999, ARCH BIOCHEM BIOPHYS, V371, P15, DOI 10.1006/abbi.1999.1430; Yang QH, 1997, PROTEIN EXPRES PURIF, V10, P320, DOI 10.1006/prep.1997.0749; Yuen MH, 1999, J BIOL CHEM, V274, P2176, DOI 10.1074/jbc.274.4.2176; Zhu Z, 2000, BIOL CHEM, V381, P1195, DOI 10.1515/BC.2000.147	36	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24608	24613		10.1074/jbc.M102366200	http://dx.doi.org/10.1074/jbc.M102366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325970	hybrid			2022-12-25	WOS:000169800700027
J	Fan, GF; Shumay, E; Wang, HY; Malbon, CC				Fan, GF; Shumay, E; Wang, HY; Malbon, CC			The scaffold protein gravin (cAMP-dependent protein kinase-anchoring protein 250) binds the beta(2)-adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 domain and provides a mobile scaffold during desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; BETA-ADRENERGIC-RECEPTOR; PHOSPHORYLATION; COMPLEXES; ROLES	The cyclic AMP-dependent kinase-anchoring proteins (AKAPs) function as scaffolds for a wide-range of protein-protein interactions. The 250-kDa AKAP known as gravin plays a central role in organizing G-protein-coupled receptors to the protein kinases and phosphatases that regulate receptor function in desensitization, resensitization, and sequestration. Although gravin is critical for G-protein-linked receptor biology, the molecular features of the receptor necessary for interaction with this scaffold are not known. Herein, we map the regions of the beta (2)-adrenergic receptor that are required for binding to gravin, Intracellular loops 1, 2, and 3 appear not to participate in the binding of the receptor to the scaffold. In contrast, the C-terminal cytoplasmic region of the receptor (Arg-329 to Leu-413) competes readily for the binding of the beta (2)-adrenergic receptor by gravin, both using in vitro and in vivo assays. C-terminally truncated peptides with sequences ranging from Arg-329 to Leu-342 (13 aminoacyl residues), to Asn-352 (23 residues), to Tyr-366 (37 residues), to Asp-380 (51 residues), or to His-390 (61 residues), as well as N-terminally truncated peptides from Gln-391 to Leu-413 (23 residues) or Leu-381 to Leu-413 (33 residues) displayed no ability to block binding of receptor to gravin, The combination of Arg-329 to His-390 peptide and Gln-391 to Leu-413 peptide, however, reconstitutes a fragmented but full-length C-terminal region and also potently blocks the ability of gravin to bind the beta (2)-adrenergic receptor. The gravin-receptor interaction was examined in response to agonist by confocal microscopy, Remarkably, the association of the receptor with gravin was not disrupted during agonist-induced sequestration. The receptor-scaffold complex was maintained during agonist-induced sequestration. These data, in agreement with the biochemical data, reveal that gravin binds the receptor through the beta2-adrenergic receptor C-terminal cytoplasmic domain and that this interaction is maintained as the receptor is internalized. This is the first report of an AKAP scaffold protein translocating with its receptor, in this case a G-protein-coupled receptor.	SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Diabet & Metab Dis Res Program,Med Ctr, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Med Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Diabet & Metab Dis Res Program,Med Ctr, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020					Bahouth SW, 1996, RECEPT SIGNAL TRANS, V6, P141; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Doronin S, 2000, PROTEIN EXPRES PURIF, V20, P451, DOI 10.1006/prep.2000.1322; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; WANG HY, 1989, J BIOL CHEM, V264, P14424	14	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24005	24014		10.1074/jbc.M011199200	http://dx.doi.org/10.1074/jbc.M011199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309381	hybrid			2022-12-25	WOS:000169531100104
J	Lim, SE; Copeland, WC				Lim, SE; Copeland, WC			Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTI-HIV DEOXYNUCLEOTIDES; MITOCHONDRIAL-DNA; REVERSE-TRANSCRIPTASE; EXONUCLEASE ACTIVITY; NUCLEOSIDE ANALOGS; (-)-2'-DEOXY-3'-THIACYTIDINE 3TC; INTRACELLULAR PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; INSERTION FIDELITY	Mitochondrial toxicity can result hom antiviral nucleotide analog therapy used to control human immunodeficiency virus type 1 infection. We evaluated the ability of such analogs to inhibit DNA synthesis by the human mitochondrial DNA polymerase (pol gamma) by comparing the insertion and exonucleolytic removal of six antiviral nucleotide analogs. Apparent steady-state K-m and k(cat) values for insertion of 2 ' ,3 ' -dideoxy-TTP (ddTTP), 3 ' -azido-TTP (AZT-TP), 2 ' ,3 ' -dideoxy-TTP (dd-TTP), 2 ' ,3 ' -didehydro-TTP (D4T-TP), (-)-2 ' ,3 ' -dideoxy-3 ' -thiacytidine (3TC-TP), and carbocyclic 2 ' ,3 ' -didehydro-ddGTP (CBV-TP) indicated incorporation of all six analogs, albeit with varying efficiencies. Dideoxynucleotides and D4T-TP were utilized by pol gamma in vitro as efficiently as natural deoxynucleotides, whereas AZT-TP, 3TC-TP, and CBV-TP were only moderate inhibitors of DNA chain elongation. Inefficient excision of dideoxynucleotides, D4T, AZT, and CBV from DNA predicts persistence in vivo following successful incorporation. In contrast, removal of 3'-terminal 3TC residues was 50% as efficient as natural 3 ' termini. Finally, me observed inhibition of exonuclease activity by concentrations of AZT-monophosphate known to occur in cells. Thus, although their greatest inhibitory effects are through incorporation and chain termination, persistence of these analogs in DNA and inhibition of exonucleolytic proofreading may also contribute to mitochondrial toxicity.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065080, ZIAES065080, ZIAES065078, Z01ES065078] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal RP, 1997, MUTAT RES-GEN TOX EN, V390, P223, DOI 10.1016/S1383-5718(97)00014-4; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; Ayers KM, 1996, FUND APPL TOXICOL, V32, P148, DOI 10.1006/faat.1996.0118; BEBENEK K, 1993, MOL PHARMACOL, V43, P57; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bialkowska A, 2000, CARCINOGENESIS, V21, P1059, DOI 10.1093/carcin/21.5.1059; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Bridges EG, 1996, BIOCHEM PHARMACOL, V51, P731, DOI 10.1016/0006-2952(96)00056-1; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; BRIDGES EG, 1993, BIOCHEM PHARMACOL, V45, P1571, DOI 10.1016/0006-2952(93)90296-9; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CID MG, 1994, MUTAT RES, V321, P113, DOI 10.1016/0165-1218(94)90127-9; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; GRAY NM, 1995, BIOCHEM PHARMACOL, V50, P1043, DOI 10.1016/0006-2952(95)96620-A; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1990, J BIOL CHEM, V265, P11914; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; KAGUNI LS, 1988, CANCER CELL, V6, P425; Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288; LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; MEDINA DJ, 1994, ANTIMICROB AGENTS CH, V38, P1824, DOI 10.1128/AAC.38.8.1824; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Meng QX, 2000, MUTAGENESIS, V15, P405, DOI 10.1093/mutage/15.5.405; Meng QX, 2000, TOXICOL SCI, V54, P322, DOI 10.1093/toxsci/54.2.322; NICKEL W, 1992, J BIOL CHEM, V267, P848; Olivero OA, 1999, AIDS, V13, P919, DOI 10.1097/00002030-199905280-00007; OLSON MW, 1992, J BIOL CHEM, V267, P23136; *PAN CLIN PRACT TR, 2001, GUID US ANT AG HIV I; Parker WB, 1997, ANTIVIR RES, V34, P131, DOI 10.1016/S0166-3542(97)01033-4; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PETERS BS, 1993, Q J MED, V86, P5; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Sussman HE, 1999, MUTAT RES-FUND MOL M, V429, P249, DOI 10.1016/S0027-5107(99)00111-6; Szabados E, 1999, FREE RADICAL BIO MED, V26, P309, DOI 10.1016/S0891-5849(98)00199-3; UNAIDS/World Health Organization, 2000, AIDS EP UPD, P1; WALLACE DC, 1992, J INHERIT METAB DIS, V15, P472, DOI 10.1007/BF01799605; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Wang HY, 1996, BBA-MOL BASIS DIS, V1316, P51, DOI 10.1016/0925-4439(96)00015-4; YARCHOAN R, 1988, LANCET, V1, P76; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333; Zhu CY, 2000, J BIOL CHEM, V275, P26727	61	186	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23616	23623		10.1074/jbc.M101114200	http://dx.doi.org/10.1074/jbc.M101114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319228	hybrid			2022-12-25	WOS:000169531100053
J	Moreno, CS; Lane, WS; Pallas, DC				Moreno, CS; Lane, WS; Pallas, DC			A mammalian homolog of yeast MOB1 is both a member and a putative substrate of striatin family-protein phosphatase 2A complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; DUPLICATION GENE MPS1; RHO-ASSOCIATED KINASE; OKADAIC ACID; NUCLEAR AUTOANTIGEN; CATALYTIC SUBUNIT; CDC2 KINASE; PHOSPHORYLATION; MITOSIS; VIMENTIN	Striatin and S/G(2) nuclear autoantigen (SG2NA) are related proteins that contain membrane binding domains and associate with protein phosphatase 2A (PP2A) and many additional proteins that may be PP2A regulatory targets. Here we identify a major member of these complexes as class II mMOB1, a mammalian homolog of the yeast protein MOB1, and show that its phosphorylation appears to be regulated by PP2A. Yeast MOB1 is critical for cytoskeletal reorganization during cytokinesis and exit from mitosis. We show that mMOB1 associated with PP2A is not detectably phosphorylated in asynchronous murine fibroblasts. However, treatment with the PP2A inhibitor okadaic acid induces phosphorylation of PP2A-associated mMOB1 on serine. Moreover, specific inhibition of PP2A also results in hyperphosphorylation of striatin, SG2NA, and three unidentified proteins, suggesting that these proteins may also be regulated by PP2A. Indirect immunofluorescence produced highly similar staining patterns for striatin, SG2NA, and mMOB1, with the highest concentrations for each protein adjacent to the nuclear membrane. We also present evidence that these complexes may interact with each other. These data are consistent with a model in which PP2A may regulate mMOB1, striatin, and SG2NA to modulate changes in the cytoskeleton or interactions between the cytoskeleton and membrane structures.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	Emory University; Emory University; Harvard University	Pallas, DC (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	dpallas@emory.edu	Moreno, Carlos S/B-3863-2009	Moreno, Carlos S/0000-0002-5582-0028	NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 1997, J BIOCHEM, V122, P409; Baillat G, 2001, MOL BIOL CELL, V12, P663, DOI 10.1091/mbc.12.3.663; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Castets F, 2000, J BIOL CHEM, V275, P19970, DOI 10.1074/jbc.M909782199; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Cheng S, 2000, CELL MOTIL CYTOSKEL, V47, P337, DOI 10.1002/1097-0169(200012)47:4<337::AID-CM7>3.3.CO;2-2; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Frenz LM, 2000, J CELL SCI, V113, P3399; Giasson BI, 1997, J NEUROBIOL, V32, P193, DOI 10.1002/(SICI)1097-4695(199702)32:2<193::AID-NEU4>3.0.CO;2-3; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Gowdy PM, 1998, J CELL SCI, V111, P3401; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; Hoyt MA, 2000, CELL, V102, P267, DOI 10.1016/S0092-8674(00)00031-3; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MURO Y, 1995, BIOCHEM BIOPH RES CO, V207, P1029, DOI 10.1006/bbrc.1995.1288; Nakamura Y, 2000, GENES CELLS, V5, P823, DOI 10.1046/j.1365-2443.2000.00372.x; Nakayama T, 1999, J NEUROBIOL, V41, P326, DOI 10.1002/(SICI)1097-4695(19991115)41:3<326::AID-NEU2>3.0.CO;2-W; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Salimova E, 2000, J CELL SCI, V113, P1695; Salin P, 1998, J COMP NEUROL, V397, P41; Schutz AR, 1998, MOL BIOL CELL, V9, P759, DOI 10.1091/mbc.9.4.759; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; TEMELES GL, 1994, MOL REPROD DEV, V37, P121, DOI 10.1002/mrd.1080370202; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; VANDRE DD, 1992, J CELL SCI, V101, P79; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185	43	73	77	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24253	24260		10.1074/jbc.M102398200	http://dx.doi.org/10.1074/jbc.M102398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319234	Green Accepted, hybrid			2022-12-25	WOS:000169531100134
J	Lu, CX; Schwartzbauer, G; Sperling, MA; Devaskar, SU; Thamotharan, S; Robbins, PD; McTiernan, CF; Liu, JL; Jiang, J; Frank, SJ; Menon, RK				Lu, CX; Schwartzbauer, G; Sperling, MA; Devaskar, SU; Thamotharan, S; Robbins, PD; McTiernan, CF; Liu, JL; Jiang, J; Frank, SJ; Menon, RK			Demonstration of direct effects of growth hormone on neonatal cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPROVES CARDIAC-FUNCTION; FACTOR-I; TYROSINE PHOSPHORYLATION; GLUCOSE TRANSPORTERS; DISULFIDE LINKAGE; GENE-EXPRESSION; ACID-TRANSPORT; RECEPTOR; INSULIN; RAT	The cellular and molecular basis of growth hormone (GH) actions on the heart remain poorly defined, and it is unclear whether GH effects on the myocardium are direct or mediated at least in part via insulin-like growth factor (IGF-1). Here, we demonstrate that the cultured neonatal cardiomyocyte is not an appropriate model to study the effects of GH because of artifactual loss of GH receptors (GHRs). To circumvent this problem, rat neonatal cardiomyocytes were infected with a recombinant adenovirus expressing the murine GHR, Functional integrity of GHR was suggested by GH-induced activation of the cognate JAK2/STAT5, MAPK, and Akt intracellular pathways in the cells expressing GHR. Although exposure to GH resulted in a significant increase in the size of the cardiomyocyte and increased expression of c fos, myosin light chain 2, and skeletal a-actin mRNAs, there were no significant changes in IGF-1 or atrial natriuretic factor mRNA levels in response to GH stimulation. In this model, GH increased incorporation of leucine, uptake of palmitic acid, and abundance of fatty acid transport protein mRNA. In contrast, GH decreased uptake of a-deoxy-D-glucose and levels of Glut1 protein. Thus, in isolated rat neonatal cardiomyocytes expressing GHR, GH induces hypertrophy and causes alterations in cellular metabolic profile in the absence of demonstrable changes in IGF-1 mRNA, suggesting that these effects may be independent of IGF-1.	Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cardiol, Pittsburgh, PA 15213 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; McGill University	Menon, RK (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Div Endocrinol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	menonr@chplink.chp.edu	Liu, Jun-Li/A-1501-2008; liu, jun-li/O-2115-2019	Liu, Jun-Li/0000-0001-6251-6406; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD025024, R01HD025024, R01HD033997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046395, R01DK049845, R56DK046395, T32DK007729, R29DK046395, R56DK049845, R29DK049845] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25024, HD33997] Funding Source: Medline; NIDDK NIH HHS [DK49845, DK46395, T32DK07729] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Camarillo IG, 1998, ENDOCRINOLOGY, V139, P3585, DOI 10.1210/en.139.8.3585; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Cittadini A, 1997, ENDOCRINOLOGY, V138, P5161, DOI 10.1210/en.138.12.5161; Cittadini A, 1997, J AM COLL CARDIOL, V29, P1109, DOI 10.1016/S0735-1097(97)00010-7; CLAYCOMB WC, 1983, ADV EXP MED BIOL, V161, P249; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Das UG, 1999, AM J PHYSIOL-REG I, V276, pR809, DOI 10.1152/ajpregu.1999.276.3.R809; DONATH MY, 1994, P NATL ACAD SCI USA, V91, P1686, DOI 10.1073/pnas.91.5.1686; Duerr RL, 1996, CIRCULATION, V93, P2188, DOI 10.1161/01.CIR.93.12.2188; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Frank SJ, 1999, ADV MOL CELL ENDOCR, V3, P1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRUSTACI A, 1992, AM J CLIN PATHOL, V97, P503, DOI 10.1093/ajcp/97.4.503; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GLATZ JFC, 1982, BIOCHIM BIOPHYS ACTA, V711, P327, DOI 10.1016/0005-2760(82)90042-X; GLENNON PE, 1995, BRIT HEART J, V73, P496; HAMLIN G, 1999, DIABETES, V48, P2255; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harvey S., 1995, GROWTH HORMONE; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HJALMARSON A, 1969, AM J PHYSIOL, V217, P1795, DOI 10.1152/ajplegacy.1969.217.6.1795; Isgaard J, 1997, EUR J CLIN INVEST, V27, P517, DOI 10.1046/j.1365-2362.1997.1430692.x; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KILGOUR E, 1995, J ENDOCRINOL, V145, P27, DOI 10.1677/joe.0.1450027; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kirshenbaum LA, 1997, MOL CELL BIOCHEM, V172, P13, DOI 10.1023/A:1006853824044; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; MORVAN D, 1991, EUR HEART J, V12, P666; Napoli R, 1996, BIOCHEM J, V315, P959, DOI 10.1042/bj3150959; NIEUWENHOVEN FA, 1999, INT J BIOCHEM CELL B, V31, P489; ODriscoll JG, 1997, LANCET, V349, P1068, DOI 10.1016/S0140-6736(05)62290-8; Osterziel KJ, 1998, LANCET, V351, P1233, DOI 10.1016/S0140-6736(97)11329-0; *PERK APPL BIOS, 1997, US B, V2; *PERK APPL BIOS, 1998, US B, V5; Ross J, 1999, CIRCULATION, V99, P15, DOI 10.1161/01.CIR.99.1.15; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555; Schaap FG, 1997, BBA-GENE STRUCT EXPR, V1354, P29, DOI 10.1016/S0167-4781(97)00121-8; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Shen YT, 1996, AM J PHYSIOL-HEART C, V271, pH1721, DOI 10.1152/ajpheart.1996.271.5.H1721; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; TAI PKK, 1990, J BIOL CHEM, V265, P21828; Tanaka N, 1998, AM J PHYSIOL-HEART C, V275, pH393, DOI 10.1152/ajpheart.1998.275.2.H393; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VICK GW, 1998, SCI PRACTICE PEDIAT, P155; Wang J, 1999, ENDOCRINOLOGY, V140, P3391, DOI 10.1210/en.140.7.3391; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; YANG RH, 1995, CIRCULATION, V92, P262, DOI 10.1161/01.CIR.92.2.262; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072	67	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22892	22900		10.1074/jbc.M011647200	http://dx.doi.org/10.1074/jbc.M011647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303022	hybrid			2022-12-25	WOS:000169412700122
J	Wong, AST; Pelech, SL; Woo, MMM; Yim, G; Rosen, B; Ehlen, T; Leung, PCK; Auersperg, N				Wong, AST; Pelech, SL; Woo, MMM; Yim, G; Rosen, B; Ehlen, T; Leung, PCK; Auersperg, N			Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?	ONCOGENE			English	Article						hepatocyte growth factor; Met; ovarian surface epithelial cells; cell signaling; familial ovarian cancer; ovarian cancer	FACTOR SCATTER FACTOR; SURFACE EPITHELIAL-CELLS; C-MET; EXTRACELLULAR-MATRIX; CARCINOMA CELLS; FAMILY HISTORY; HGF RECEPTOR; CANCER; EXPRESSION; KINASE	Since autocrine regulation of HGF-Met is implicated in many forms of human cancer, we investigated whether the predisposition to develop ovarian cancer in women with hereditary ovarian cancer syndromes involves changes in the expression of HGF-Met by the tissue of origin of epithelial ovarian cancers, the ovarian surface epithelium (OSE), We compared cultures of normal OSE from women with (FH-OSE) (n = 20) and with no (NFH-OSE) (n = 48) family histories of ovarian cancer, SV40 Tag immortalized OSE lines (IOSE, n = 5) and ovarian cancer cell lines (n = 3), Cultures derived from 21/22 women with NFH-OSE and 13/13 women with FH-OSE expressed Met mRNA initially. After two to three passages, Met was downregulated in 37% of NFH-OSE cultures but persisted in 100% of FH-OSE cultures and ovarian cancer lines, like other epithelial differentiation markers that are stabilized in FH-OSE and neoplasia, HGF and Met mRNA were concomitantly expressed by NFH-OSE from only three of 32 women but in FH-OSE from eight of 13 women, and also in five of five IOSE and two of three ovarian cancer lines. Conditioned media from FH-OSE, but not NFH-OSE, contained immunoreactive HGF and induced cohort migration which was inhibited by neutralizing HGF antibody. Several signaling molecules of the PI3K pathway, including Akt2 and p70 S6K, were constitutively activated in FH-OSE from six of six women but in NFH-OSE from only four of eight women. Exogenous HGF was mitogenic in OSE, and that effect was regulated through the MAP kinase (ERK1/ERK2) and FRAP/p70 S6K pathways. The proliferative response to HGF was greater in NFH-OSE than in FH-OSE cultures. The results show that FH-OSE cultures differ from NFH-OSE by increased stability of Met expression and by HGF secretion. Constitutive phosphorylation of kinases and a diminished growth response to HGF suggest the presence of autocrine regulation in FH-OSE. In analogy with other cell types where an autocrine HGF-R let loop has been implicated in tumorigenic transformation, this change in FH-OSE may play a role in the enhanced susceptibility to ovarian carcinogenesis in women with hereditary ovarian cancer syndromes.	Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V6H 3V5, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6H 3V5, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada	University of British Columbia; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Auersperg, N (corresponding author), Univ British Columbia, British Columbia Childrens Hosp, Dept Obstet & Gynecol, 2H30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.		Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475; Leung, Peter/0000-0003-3152-3800				AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 1998, SEMIN ONCOL, V25, P281; AUERSPERG N, 1995, AM J OBSTET GYNECOL, V173, P558, DOI 10.1016/0002-9378(95)90282-1; Aunoble B, 2000, INT J ONCOL, V16, P567; Balkovetz DF, 1999, LIFE SCI, V64, P1393, DOI 10.1016/S0024-3205(99)00073-9; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; ELLIOTT WM, 1993, BIOTECH HISTOCHEM, V68, P29, DOI 10.3109/10520299309105573; Gulati R, 1997, ENDOCRINOLOGY, V138, P1847, DOI 10.1210/en.138.5.1847; Hess S, 1999, ENDOCRINOLOGY, V140, P2908, DOI 10.1210/en.140.6.2908; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; Huntsman D, 1999, AM J PATHOL, V155, P343, DOI 10.1016/S0002-9440(10)65130-9; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim SO, 1998, J CELL BIOCHEM, V71, P328, DOI 10.1002/(SICI)1097-4644(19981201)71:3<328::AID-JCB2>3.0.CO;2-U; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Nabeshima K, 1998, INT J CANCER, V78, P750, DOI 10.1002/(SICI)1097-0215(19981209)78:6<750::AID-IJC13>3.0.CO;2-#; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; Parrott JA, 2000, BIOL REPROD, V62, P491, DOI 10.1095/biolreprod62.3.491; PARROTT JA, 1994, ENDOCRINOLOGY, V135, P569, DOI 10.1210/en.135.2.569; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Sato N, 1997, Respirology, V2, P185, DOI 10.1111/j.1440-1843.1997.tb00077.x; Scully RE, 1995, J CELL BIOCHEM, P208; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; STOKER M, 1985, J CELL SCI, V77, P209; To CTT, 1998, ONCOL REP, V5, P1013; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wong AST, 1999, INT J CANCER, V81, P180; Wong AST, 2000, GYNECOL ONCOL, V78, P158, DOI 10.1006/gyno.2000.5877; ZILTENER HJ, 1993, BIOL REPROD, V49, P635, DOI 10.1095/biolreprod49.3.635	44	65	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1318	1328		10.1038/sj.onc.1204253	http://dx.doi.org/10.1038/sj.onc.1204253			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313876				2022-12-25	WOS:000167495000006
J	Berry, DM; Benn, SJ; Cheng, AM; McGlade, CJ				Berry, DM; Benn, SJ; Cheng, AM; McGlade, CJ			Caspase-dependent cleavage of the hematopoietic specific adaptor protein Gads alters signalling from the T cell receptor	ONCOGENE			English	Article						Gads; caspase; T cell receptor; SH2 domain; SH3 domain	PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHOPROTEIN; MAMMALIAN CASPASES; MOLECULAR-CLONING; ACTIVATION; SLP-76; LAT; APOPTOSIS; GRB2; DEATH	Gads is a SH2 and SH3 domain-containing, hematopoietic-specific adaptor protein that functions in signalling from the T cell receptor. Gads acts by linking SLP-76, bound by the carboxy-terminal Gads SH3 domain, to tyrosine phosphorylated LAT which contains binding sites for the Gads SH2 domain. Gads is distinguished from Grb2 and the closely related Grap protein by the presence of a 120 amino acid unique region between the SH2 domain and the carboxy terminal SH3 domain. Here we demonstrate that the unique region of Gads contains a capase cleavage site. Induction of apoptosis in lymphocytes results in detectable Gads cleavage by 60 min. Gads cleavage is blocked in vivo by treating cells with a caspase 3 inhibitor. A putative caspase 3 cleavage site was identified within the unique region and mutation of this site prevented Gads cleavage in vitro, and in vivo. The Gads cleavage products retained the predicted binding specificity for SLP-76 and LAT, Expression of the Gads cleavage products in Jurkat T cells inhibited NFAT activation following TCR cross linking. These findings indicate that cleavage of Gads in vivo could function to alter signalling downstream of the T cell receptor by disrupting cross talk between SLP-76 and LAT.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Washington University (WUSTL)	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	39	23	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1203	1211		10.1038/sj.onc.1204218	http://dx.doi.org/10.1038/sj.onc.1204218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313864				2022-12-25	WOS:000167570100007
J	Imamura, O; Fujita, K; Shimamoto, A; Tanabe, H; Takeda, S; Furuichi, Y; Matsumoto, T				Imamura, O; Fujita, K; Shimamoto, A; Tanabe, H; Takeda, S; Furuichi, Y; Matsumoto, T			Bloom helicase is involved in DNA surveillance in early S phase in vertebrate cells	ONCOGENE			English	Article						Bloom helicase; Bloom syndrome; DT40; chromosomal instability	SISTER-CHROMATID EXCHANGE; SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SYNDROME FIBROBLASTS; ULTRAVIOLET-LIGHT; MOLECULAR-CLONING; MAMMALIAN-CELLS	Bloom syndrome (BS) is a recessive human genetic disorder characterized by short stature, immunodeficiency and an elevated risk of malignancy. The gene mutated in BS, BLM, encodes a RecQ-type DNA helicase. BS cells have mutator phenotypes such as hyper-recombination, chromosome instability and an increased frequency of sister chromatid exchange (SCE). To define the primary role of BLM, we generated BLM-/- mutants of the chicken B-cell line DT40. In addition to characteristics of BLM-/- cells reported previously by the other group, they are hypersensitive to genotoxic agents such as etoposide, bleomycin and 4-nitroquinoline-1-oxide and irradiation with the short wave length of UV (UVC) light, whereas they exhibit normal sensitivity to X-ray irradiation and hydroxyurea. UVC irradiation to BLM-/- cells during G(1) to early S phase caused chromosomal instability such as chromatid breaks and chromosomal quadriradials, leading to eventual cell death. These results suggest that BLM is involved in surveillance of base abnormalities in genomic DNA that may be encountered by replication forks in early S phase. Such surveillance would maintain genomic stability in vertebrate cells, resulting in the prevention of cellular tumorigenesis.	AGENE REs Inst, Kanagawa 2470063, Japan; Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, Tokyo 1588501, Japan; Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan	National Institute of Health Sciences - Japan; Kyoto University	Matsumoto, T (corresponding author), AGENE REs Inst, 200 Kajiwara, Kanagawa 2470063, Japan.			Takeda, Shunichi/0000-0002-7924-7991				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Dedon PC, 1998, P NATL ACAD SCI USA, V95, P11113, DOI 10.1073/pnas.95.19.11113; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GALIEGUEZOUITINA S, 1984, ANAL BIOCHEM, V138, P454, DOI 10.1016/0003-2697(84)90839-X; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; HENSON P, 1981, CANCER RES, V41, P760; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; KADYK LC, 1993, GENETICS, V133, P469; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; Kusano K, 1999, GENETICS, V151, P1027; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Matsumoto L, 1999, MUTAT RES-FUND MOL M, V426, P79, DOI 10.1016/S0027-5107(99)00042-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; RAY JH, 1984, CHROMOSOMA, V90, P383, DOI 10.1007/BF00294165; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; SHIRAISHI Y, 1985, EMBO J, V4, P2553, DOI 10.1002/j.1460-2075.1985.tb03970.x; SMITH GJ, 1983, MUTAT RES, V111, P405, DOI 10.1016/0027-5107(83)90036-2; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WERNERFAVRE C, 1984, AM J MED GENET, V18, P215, DOI 10.1002/ajmg.1320180205; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	34	35	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1143	1151		10.1038/sj.onc.1204195	http://dx.doi.org/10.1038/sj.onc.1204195			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313858				2022-12-25	WOS:000167570100001
J	McGarvey, TW; Nguyen, T; Tomaszewski, JE; Monson, FC; Malkowicz, SB				McGarvey, TW; Nguyen, T; Tomaszewski, JE; Monson, FC; Malkowicz, SB			Isolation and characterization of the TERE1 gene, a gene down-regulated in transitional cell carcinoma of the bladder	ONCOGENE			English	Article						tumor related gene; bladder neoplasms; TERE1 gene	TUMOR-SUPPRESSOR REGION; CHROMOSOME 1P; GENOMIC INSTABILITY; DELETION; LOCALIZATION; ABERRATIONS; FREQUENT; DNA; HETEROZYGOSITY; METHYLATION	We have identified a novel cDNA product designated transitional epithelial response gene (TERE1), which was localized to chromosome 1p36. The TERE1 transcript (1.5 and 3.5 kb) is present in most normal human tissues including urothelium, but was reduced or absent in the majority of muscle invasive TCC tumors (22 out of 29 cases). The open reading frame encodes a protein of 338 amino acids (MW 36.8 KD). This protein is 57% homologous to a Drosophila protein called heir. We have shown by Western blotting and immuno-histochemistry with a polyclonal antibody to a specific TERE1 peptide, reduced or absent staining in muscle invasive tumors. Transfection of a sense TERE1 construct resulted in an 80-90% inhibition of cellular proliferation in two TCC cell lines and a lack of aneuploidy in the TERE1-transduced J82 cell line, These data suggest a potential role for this gene product in the progression of bladder cancer.	Dept Surg, Div Urol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania	Malkowicz, SB (corresponding author), Dept Surg, Div Urol, 1 Rhoads,3400 Spruce St, Philadelphia, PA 19104 USA.							*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; Ashburner M, 1999, GENETICS, V153, P179; Bieche I, 1998, ONCOL REP, V5, P267; Boni R, 1998, J INVEST DERMATOL, V110, P215, DOI 10.1046/j.1523-1747.1998.00109.x; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; CAIRNS P, 1991, ONCOGENE, V6, P2305; CHANG WYH, 1995, CANCER RES, V55, P3246; Chen HL, 1996, CANCER GENET CYTOGEN, V86, P102, DOI 10.1016/0165-4608(95)00186-7; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Ebrahimi SA, 1999, CANCER RES, V59, P311; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gasparian AV, 1998, BRIT J CANCER, V77, P1604, DOI 10.1038/bjc.1998.263; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hayashi K, 1991, PCR Methods Appl, V1, P34; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HONG L, 1998, A DROS RES C, V39, pB373; KNOWLES MA, 1994, CANCER RES, V54, P531; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Malkowicz S B, 1997, Semin Urol Oncol, V15, P169; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Monteiro ANA, 2000, HISTOL HISTOPATHOL, V15, P299, DOI 10.14670/HH-15.299; NAGAI H, 1995, CANCER RES, V55, P1752; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PRAML C, 1995, ONCOGENE, V11, P1357; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; ROSIN MP, 1995, CANCER RES, V55, P5213; Salem C, 2000, CANCER RES, V60, P2473; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Sattler HP, 1999, PROSTATE, V39, P79; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Simon R, 1998, J PATHOL, V185, P345; SPRUCK CH, 1994, CANCER RES, V54, P784; Steenman M, 1997, CYTOGENET CELL GENET, V77, P296, DOI 10.1159/000134602; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Wagner U, 1997, AM J PATHOL, V151, P753; White RWD, 1998, ONCOLOGY-NY, V12, P1717; Williamson C, 1997, J MED GENET, V34, P617, DOI 10.1136/jmg.34.8.617; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206	43	35	42	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1042	1051		10.1038/sj.onc.1204143	http://dx.doi.org/10.1038/sj.onc.1204143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314041				2022-12-25	WOS:000167232100004
J	Lallemand, F; Mazars, A; Prunier, C; Bertrand, F; Kornprost, M; Gallea, S; Roman-Roman, S; Cherqui, G; Atfi, A				Lallemand, F; Mazars, A; Prunier, C; Bertrand, F; Kornprost, M; Gallea, S; Roman-Roman, S; Cherqui, G; Atfi, A			Smad7 inhibits the survival nuclear factor kappa B and potentiates apoptosis in epithelial cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; Smad7	PROTEIN-KINASE B/AKT; ACTIVATION; RAS; INSULIN; PATHWAY; GENES; DEATH	In this study, we examined the effect of the stable expression of Smad7 in two different cell lines on apoptosis induced by various stimuli including TGF-beta, serum withdrawal, loss of cell adhesion (anoikis) and TNF-alpha. Smad7 increased TGF-beta -mediated apoptosis in Mv1Lu cells as well as anoikis and/or serum withdrawal-induced apoptosis in Mv1Lu and MDCK cells. Smad7 markedly decreased the activity of the survival NF-kappaB transcription factor in MDCK cells, Interestingly, the stable expression of oncogenic Ras in MDCK cells which suppressed Smad7 inhibition of NF-kappaB also suppressed Smad7 potentiation of serum withdrawal-induced apoptosis and anoikis, In addition, Smad7 inhibited TNF-alpha stimulation of NF-kappaB and increased TNF-alpha -mediated apoptosis in MDCK cells. Our results provide the first evidence that Smad7 induces sensitization of cells to different forms of cell death. They moreover demonstrate that Smad7 inhibits the survival NF-kappaB factor, providing a potential mechanism whereby Smad7 potentiates cell death.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U402, F-75571 Paris, France; Hoechst Marion Roussel, Romainville, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis; Sanofi France	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Roman-Roman, Sergio/K-9993-2014; Frottier, Celine Prunier/G-8259-2017	Roman-Roman, Sergio/0000-0001-6459-2613; Frottier, Celine Prunier/0000-0002-7784-0273				Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Bitzer M, 2000, GENE DEV, V14, P187; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200	25	92	99	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					879	884		10.1038/sj.onc.1204167	http://dx.doi.org/10.1038/sj.onc.1204167			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314022				2022-12-25	WOS:000166924400012
J	Katich, SC; Zerfass-Thome, K; Hoffmann, I				Katich, SC; Zerfass-Thome, K; Hoffmann, I			Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene	ONCOGENE			English	Article						Cdc25; cell cycle; human papillomavirus type 16; E7 oncoprotein	CELL-CYCLE REGULATION; S-PHASE; G(1)/S TRANSITION; EXPRESSION; ACTIVATION; E2F; PHOSPHATASE; PHOSPHORYLATION; ONCOPROTEIN; REPRESSION	Cdc25A is a tyrosine phosphatase that is involved in the regulation of the G1/S phase transition by activating cyclin E/Cdk2 and cyclin A/Cdk2 complexes through removal of inhibitory phosphorylations. The E6 and E7 oncoproteins of the high-risk human papillomaviruses (HPV) interact with and functionally abrogate the p53 and pRB proteins, respectively. In the present study we have investigated the regulation of the Cdc25A promoter during G1 and S-phases of the cell cycle and by the HPV-16 E7 oncoprotein. Serum induction leads to a derepression of the Cdc25A promoter and can be mediated through two E2F binding sites, E2F-A and E2F-C, While E2F-A is by both E2F1 and E2F4, E2F-C is regulated only by E2F1, The Cdc25A promoter is transactivated by the E7 oncogene of HPV-16. Furthermore, Cdc25A levels art highly increased in E7-expressing cell lines, Inducible expression of E7 leads to an immediate increase in Cdc25A protein levels. These data suggest that Cdc25A may be a critical target of HPV-16 E7 in the disruption of the G1/S phase transition.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoffmann, I (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; Chen X, 1999, MOL CELL BIOL, V19, P4695; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; Iavarone A, 1999, MOL CELL BIOL, V19, P916; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Lammer C, 1998, J CELL SCI, V111, P2445; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Spitkovsky D, 1996, ONCOGENE, V12, P2549; Vigo E, 1999, MOL CELL BIOL, V19, P6379; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	32	33	38	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					543	550		10.1038/sj.onc.1204130	http://dx.doi.org/10.1038/sj.onc.1204130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313986				2022-12-25	WOS:000166755000001
J	Han, DC; Rodriguez, LG; Guan, JL				Han, DC; Rodriguez, LG; Guan, JL			Identification of a novel interaction between integrin beta 1 and 14-3-3 beta	ONCOGENE			English	Article						integrins; 14-3-3 proteins; cell migration; protein-protein interaction	FOCAL ADHESION KINASE; PROTEIN-KINASE; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; CELL-MIGRATION; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; FIBRONECTIN RECEPTOR; 14-3-3-PROTEINS	Integrins are cell surface receptors for extracellular matrix, which play important roles ina a variety of biological processes. 14-3-3 proteins are a highly conserved family of cytoplasmic proteins that associate with several intracellular signaling molecules in regulation of various cellular functions. Here, we report identification of an interaction between the integrin beta1 cytoplasmic domain and 14-3-3 beta by using the yeast two-hybrid screen, Like several other proteins, the integrin beta1 cytoplasmic domain associated with 14-3-3 beta by a non-phosphoserine mechanism. The 14-3-3 beta /integrin beta1 interaction was confirmed by iir vitro binding assays as well as to-precipitation in vivo. Furthermore, we found that 14-3-3 beta co-localized with integrin beta1 during the early stage of cell spreading on fibronectin, suggesting a potential role of the 14-3-3 beta /integrin beta1 interaction in the regulation of cell adhesion. Using tetracycline-regulated expression system, we showed that overexpression of 14-3-3 beta stimulated cell spreading and migration on fibronectin but not on poly-L-lysine. However, the induced expression of 14-3-3 beta did not affect tyrosine phosphorylation of FAK or its substrates, p130(cas) and paxillin, suggesting that 14-3-3 beta regulated integrin-mediated cell spreading and migration by FAK-independent mechanisms. Taken together, these results identify an interaction between integrin and 14-3-3 proteins and suggest a potentially novel cellular function for 14-3-3 proteins in the regulation of integrin-mediated cell adhesion and signaling events.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Aplin AE, 1998, PHARMACOL REV, V50, P197; Autieri MV, 1996, CELL GROWTH DIFFER, V7, P1453; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHUN JS, 1993, MOL BIOL CELL, V4, P271; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Loftus JC, 1997, J CLIN INVEST, V100, pS77; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Meller N, 1996, MOL CELL BIOL, V16, P5782; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORGAN A, 1992, BIOCHEM J, V286, P807, DOI 10.1042/bj2860807; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	75	79	83	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					346	357		10.1038/sj.onc.1204068	http://dx.doi.org/10.1038/sj.onc.1204068			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313964				2022-12-25	WOS:000166411000009
J	Jee, SH; Shen, SC; Chiu, HC; Tsai, WL; Kuo, ML				Jee, SH; Shen, SC; Chiu, HC; Tsai, WL; Kuo, ML			Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency	ONCOGENE			English	Article						interleukin-6; anti-apoptosis; basal cell carcinoma cells; Mcl-1; cyclooxygenase; vascular endothelial growth factor	GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; HUMAN KERATINOCYTES; TNF-ALPHA; IN-VITRO; BCL-2; IL-6; EXPRESSION; TRANSCRIPTION; ANGIOGENESIS	Interleukin-6 (IL-6) is a pleiotropic cytokine that is capable of modulating the diverse functions of cells such as acute phase responses and inflammation. Excessive or insufficient production of IL-6 may contribute to certain diseases of the skin. The aim of this study was to investigate the possible role of IL-6 in the tumorigenesis of basal cell carcinoma (BCC), Initially, ffe transfected IL-6 expression vector, under the control of a CMV promoter, into human BCC cells and successfully obtained IL-6-overespressing clones (BCC/IL-6-c1 and BCC/IL-6-c2) and a mixture (BCC/IL-6). DNA synthesis assay determined using H-3-thymidine pulse incorporation revealed that IL-6-expressing BCC cells exhibited a much higher DNA synthesis rate than the neo control or parental BCC cells. Ne also detected a greater abundance of IL-6-expressing cell colonies formed in soft agar than in the vector control cells. Furthermore, BCC/IL-6 cells, but not vector control cells, were resistant to UV and photodynamic therapy (PDT)-induced apoptosis, as confirmed using DNA fragmentation and morphologic change analyses. Immunoblot analysis showed that Mcl-1, an anti-apoptotic protein, was specifically up-regulated IL-6 transfectants but not in the control cells, Transient transfection of IL-6 transfectants with antisense mcl-1 greatly enhanced their apoptosis frequency by UV treatment, In tumorigenesis assay, IL-6 transfected clones formed tumors in nude mice more rapidly than the control cells. These tumors appeared to be highly vascularized using pathological examination, Supportive of this finding, ffe found that IL-6 transfected cells expressed elevated levels of two angiogenic factors, cycloosygenase (Cos)-2 and vascular endothelial growth factor (VEGF). These results suggest that overexpression of IL-6 enhances the tumorigenic activity of BCC cells by both suppressing apoptosis and actively promoting angiogenesis.	Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol,Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan; Taipei Med Univ, Sch Med, Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; National Taiwan University	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol,Dept Dermatol, 1 Sec,1 Jen Ai Rd, Taipei, Taiwan.		Kuo, Min-Liang/C-4872-2009	CHIU, HSIEN-CHING/0000-0002-1409-8470; KUO, MIN-LIANG/0000-0002-7139-0144; JEE, SHIOU-HWA/0000-0001-6737-6297				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akira S, 1992, Semin Cancer Biol, V3, P17; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Ando T, 1998, ENDOCR RES, V24, P955, DOI 10.3109/07435809809032715; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoyagi T, 1996, Int J Urol, V3, P392, DOI 10.1111/j.1442-2042.1996.tb00560.x; Avalos-Diaz E, 1999, REV RHUM, V66, P13; Barton BE, 1997, CLIN IMMUNOL IMMUNOP, V85, P16, DOI 10.1006/clin.1997.4420; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; CALLERY MP, 1990, J SURG RES, V48, P523, DOI 10.1016/0022-4804(90)90224-P; Cassell GH, 1998, EMERG INFECT DIS, V4, P475, DOI 10.3201/eid0403.980339; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Dietrich JB, 1997, ARCH PHYSIOL BIOCHEM, V105, P125, DOI 10.1076/apab.105.2.125.12927; Eberlein-Konig B, 1998, BRIT J DERMATOL, V139, P415; Elder DJE, 1996, CANCER RES, V56, P2273; Gniadecki R, 1998, ARCH DERMATOL RES, V290, P528, DOI 10.1007/s004030050347; HANADA N, 1995, NUCL ACID ENZYME, V40, P1713; HORII Y, 1993, KIDNEY INT, V43, pS71; HOUSSIAU F, 1992, RES IMMUNOL, V143, P740, DOI 10.1016/0923-2494(92)80014-C; Kinoshita T, 1999, CANCER, V85, P2526, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3; Kondo S, 1998, J CELL PHYSIOL, V177, P493, DOI 10.1002/(SICI)1097-4652(199812)177:3<493::AID-JCP12>3.0.CO;2-B; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Kuo ML, 1998, ONCOGENE, V17, P2225, DOI 10.1038/sj.onc.1202133; Lear JT, 1998, J ROY SOC MED, V91, P585, DOI 10.1177/014107689809101110; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; Lu C, 1996, CLIN CANCER RES, V2, P1417; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Okamoto M, 1997, INT J CANCER, V72, P149, DOI 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D; OTAKE S, 1996, J BONE MINER RES, V11, P88; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; REZAI AR, 1994, J NEURO-ONCOL, V19, P131, DOI 10.1007/BF01306454; Rifas L, 1999, J BONE MINER RES, V14, P1096, DOI 10.1359/jbmr.1999.14.7.1096; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; SCHLAG P, 1984, CANCER TREAT REV, V11, P131, DOI 10.1016/0305-7372(84)90052-5; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Seymour J F, 1996, Cancer Treat Res, V84, P167; SKELLY SM, 1994, J BIOTECHNOL, V34, P79, DOI 10.1016/0168-1656(94)90168-6; Soriani M, 1999, CARCINOGENESIS, V20, P727, DOI 10.1093/carcin/20.4.727; Swiergiel AH, 1999, BRAIN BEHAV IMMUN, V13, P252, DOI 10.1006/brbi.1999.0565; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Tseng JF, 1996, J CLIN ENDOCR METAB, V81, P1118, DOI 10.1210/jc.81.3.1118; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Wang JM, 1999, MOL CELL BIOL, V19, P6195; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yen HT, 1996, ARCH DERMATOL RES, V288, P157, DOI 10.1007/BF02505826	54	109	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					198	208		10.1038/sj.onc.1204076	http://dx.doi.org/10.1038/sj.onc.1204076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313947				2022-12-25	WOS:000166410900007
J	Giampuzzi, M; Botti, G; Cilli, M; Gusmano, R; Borel, A; Sommer, P; Di Donato, A				Giampuzzi, M; Botti, G; Cilli, M; Gusmano, R; Borel, A; Sommer, P; Di Donato, A			Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of Ras proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; RECEPTOR EXPRESSION; BETA-SUBUNITS; MESSENGER-RNA; UP-REGULATION; I RECEPTOR; H-RAS; GENE; INSULIN	Several investigations have suggested a putative tumor suppressor role for lysyl oxidase because it is downregulated in many human and oncogene-induced tumors. To address this issue we down-regulated the enzyme in normal rat kidney fibroblasts by stable transfection of its cDNA in an antisense orientation. The selected clones revealed an absence of lysyl oxidase and dramatic phenotypic changes, interpretable as signs of transformation. The antisense lysyl oxidase clones showed, indeed, loose attachment to the plate and anchorage-independent growth and were highly tumorigenic in nude mice. Moreover, we found an impaired response of the PDGF and IGF-1 receptors to their ligands. In particular, the transformed cells showed a down-regulation of both PDGF receptors and expressed the 105-kDa isoform of the IGF-1 beta receptor, which was not present in the normal control cells. The lack of response to PDGF-BB has been described as a feature of many ras-transformed phenotypes. Therefore, we looked at the status of the p21(ras). Indeed, we found a significantly higher level of active p21(ras) both during steady-state growth and prolonged starvation. Our data reveal new evidence for a tumor suppressor activity of lysyl oxidase, highlighting its particular role in controlling Ras activation and growth factor dependence.	Ist Giannina Gaslini, Dept Nephrol, I-16147 Genoa, Italy; Ist Nazl Ric Canc, I-16136 Genoa, Italy; CNRS, UPR 412, Inst Biol & Chim Prot, F-69367 Lyon, France	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; Centre National de la Recherche Scientifique (CNRS)	Di Donato, A (corresponding author), Ist Giannina Gaslini, Dept Nephrol, Largo G Gaslini 5, I-16147 Genoa, Italy.			Cilli, Michele/0000-0003-4083-8986				BARENTON B, 1993, ENDOCRINOLOGY, V133, P651, DOI 10.1210/en.133.2.651; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; CARNERO A, 1994, ONCOGENE, V9, P1387; CHANOKI M, 1995, BRIT J DERMATOL, V133, P710; CONTENTE S, 1993, GENOMICS, V16, P395, DOI 10.1006/geno.1993.1202; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Decitre M, 1998, LAB INVEST, V78, P143; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; DiDonato A, 1997, NEPHRON, V76, P192, DOI 10.1159/000190168; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; Garrouste FL, 1997, ENDOCRINOLOGY, V138, P2021, DOI 10.1210/en.138.5.2021; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; HAINAUT P, 1991, BIOCHEM J, V273, P673, DOI 10.1042/bj2730673; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; KAGAN HM, 1991, AM J RESP CELL MOL B, V5, P296; KELLERER M, 1990, J BIOL CHEM, V265, P9340; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; MOSS AM, 1993, BIOCHEM J, V294, P685, DOI 10.1042/bj2940685; MURAWAKI Y, 1991, HEPATOLOGY, V14, P1167, DOI 10.1002/hep.1840140635; Nellaiappan K, 2000, J CELL BIOCHEM, V79, P576, DOI 10.1002/1097-4644(20001215)79:4<576::AID-JCB60>3.0.CO;2-A; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; Perez-Juste G, 1999, ONCOGENE, V18, P5393, DOI 10.1038/sj.onc.1202906; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; RAKE JB, 1991, J BIOL CHEM, V266, P5348; Rice PL, 1999, MOL CARCINOGEN, V25, P285, DOI 10.1002/(SICI)1098-2744(199908)25:4<285::AID-MC7>3.0.CO;2-F; RILEY DJ, 1982, AM REV RESPIR DIS, V125, P67; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Scotlandi K, 1996, CANCER RES, V56, P4570; SIEGEL RC, 1978, P NATL ACAD SCI USA, V75, P2945, DOI 10.1073/pnas.75.6.2945; SOMMER P, 1993, LAB INVEST, V69, P460; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626	40	64	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29226	29232		10.1074/jbc.M101695200	http://dx.doi.org/10.1074/jbc.M101695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11323426	hybrid			2022-12-25	WOS:000170346000080
J	Asami, T; Mizutani, M; Fujioka, S; Goda, H; Min, YK; Shimada, Y; Nakano, T; Takatsuto, S; Matsuyama, T; Nagata, N; Sakata, K; Yoshida, S				Asami, T; Mizutani, M; Fujioka, S; Goda, H; Min, YK; Shimada, Y; Nakano, T; Takatsuto, S; Matsuyama, T; Nagata, N; Sakata, K; Yoshida, S			Selective interaction of triazole derivatives with DWF4, a cytochrome P450 monooxygenase of the brassinosteroid biosynthetic pathway, correlates with brassinosteroid deficiency in Planta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; EXPRESSION; GENE; INHIBITORS; ELONGATION; REDUCTASE; MUTANTS; GROWTH; FACKEL	Brassinazole, a synthetic chemical developed in our laboratory, is a triazole-type brassinosteroid biosynthesis inhibitor that induces dwarfism in various plant species. The target sites of brassinazole were investigated by chemical analyses of endogenous brassinosteroids (BRs) in brassinazole-treated Catharanthus roseus cells. The levels of castasterone and brassinolide in brassinazole-treated plant cells were less than 6% of the levels in untreated cells. In contrast, campestanol and 6-oxocampestanol levels were increased, and levels of BR intermediates with hydroxy groups on the side chains were reduced, suggesting that brassinazole treatment reduced BR levels by inhibiting the hydroxylation of the C-22 position. DWF4, which is an Arabidopsis thaliana cytochrome P450 isolated as a putative steroid 22-hydroxylase, was expressed in Escherichia coli, and the binding affinity of brassinazole and its derivatives to the recombinant DWF4 were analyzed. Among several triazole derivatives, brassinazole had both the highest binding affinity to DWF4 and the highest growth inhibitory activity. The binding affinity and the activity for inhibiting hypocotyl growth were well correlated among the derivatives. In brassinazole-treated A. thaliana, the CPD gene involved in BR biosynthesis was induced within 3 h, most likely because of feedback activation caused by the reduced levels of active BRs, These results indicate that brassinazole inhibits the hydroxylation of the C-22 position of the side chain in BRs by direct binding to DWF4 and that DWF4 catalyzes this hydroxylation reaction.	RIKEN, Wako, Saitama 3510198, Japan; Kyoto Univ, Chem Res Inst, Uji, Kyoto 6110011, Japan; Joetsu Univ Educ, Dept Chem, Niigata 9438512, Japan; RIKEN, Plant Sci Ctr, Wako, Saitama 3510198, Japan	RIKEN; Kyoto University; Joetsu University Education; RIKEN	Asami, T (corresponding author), RIKEN, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Shimada, Yukihisa/D-8879-2016; Nakano, Takeshi/E-9171-2013	Shimada, Yukihisa/0000-0001-7497-9408; Nakano, Takeshi/0000-0002-3188-7770; Matsuyama, Tomoki/0000-0002-4473-7720				Asami T, 1999, TRENDS PLANT SCI, V4, P348, DOI 10.1016/S1360-1385(99)01456-9; Asami T, 2000, PLANT PHYSIOL, V123, P93, DOI 10.1104/pp.123.1.93; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Bishop GJ, 1999, P NATL ACAD SCI USA, V96, P1761, DOI 10.1073/pnas.96.4.1761; Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; Choe SW, 1999, PLANT CELL, V11, P207, DOI 10.1105/tpc.11.2.207; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; Jang JC, 2000, GENE DEV, V14, P1485; KAWAKAMI N, 1988, PLANT CELL PHYSIOL, V29, P33; Mathur J, 1998, PLANT J, V14, P593, DOI 10.1046/j.1365-313X.1998.00158.x; Min YK, 1999, BIOORG MED CHEM LETT, V9, P425, DOI 10.1016/S0960-894X(99)00008-6; Mizutani M, 1998, PLANT PHYSIOL, V116, P357, DOI 10.1104/pp.116.1.357; Mizutani M, 1997, PLANT PHYSIOL, V113, P755, DOI 10.1104/pp.113.3.755; Noguchi T, 2000, PLANT PHYSIOL, V124, P201, DOI 10.1104/pp.124.1.201; Noguchi T, 1999, PLANT PHYSIOL, V121, P743, DOI 10.1104/pp.121.3.743; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Sambrook J., 2002, MOL CLONING LAB MANU; Schrick K, 2000, GENE DEV, V14, P1471; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Yamamuro C, 2000, PLANT CELL, V12, P1591, DOI 10.1105/tpc.12.9.1591; YOKOTA T, 1991, GIBBERELLINS, P339; Yokota T, 1997, TRENDS PLANT SCI, V2, P137, DOI 10.1016/S1360-1385(97)01017-0	26	131	139	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25687	25691		10.1074/jbc.M103524200	http://dx.doi.org/10.1074/jbc.M103524200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319239	hybrid			2022-12-25	WOS:000169823300009
J	Quan, TH; He, TY; Voorhees, JJ; Fisher, GJ				Quan, TH; He, TY; Voorhees, JJ; Fisher, GJ			Ultraviolet irradiation blocks cellular responses to transforming growth factor-beta by down-regulating its Type-II receptor and inducing Smad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; HUMAN SKIN; COMPLEX-FORMATION; TYROSINE KINASES; BINDING-PROTEINS; RETINOIC ACID; PROMOTER; ACTIVATION; CELLS	Transforming growth factor-beta (TGF-beta) is a multi-functional cytokine that regulates cell growth and differentiation. Cellular responses to TGF-beta are mediated through its cell surface receptor complex, which activates transcription factors Smad2 and Smad3. Here we report that UV irradiation of mink lung epithelial cells causes near complete inhibition of TFG-beta -induced Smad2/3-mediated gene expression. UV irradiation inhibited TGF-P-induced phosphorylation of Smad2 and subsequent nuclear translocation and DNA binding of Smad2/3. Specific cell surface binding of TGF-beta was substantially reduced after UV irradiation. This loss of TGF-beta binding resulted from W-induced down-regulation of TGF-beta type II receptor (T beta RII) mRNA and protein. UV irradiation significantly inhibited T beta RII promoter reporter constructs, indicating that UV reduction of T beta RII expression involved transcriptional repression. In contrast to its effects on T beta RII, W irradiation rapidly induced Smad7 mRNA and protein. Smad7 is known to antagonize activation of Smad2/3 and thereby block TGF-beta -dependent gene expression. UV irradiation stimulated Smad7 promoter reporter constructs, indicating that increased Smad7 expression resulted, at least in part, from increased transcription. Overexpression of Smad7 protein to the level induced by W irradiation inhibited TGF-beta -induced gene expression 30%, Maintaining T beta RII levels by overexpression of T beta RII prevented UV inhibition of TGF-beta responsiveness. Taken together, these data indicate that UV irradiation blocks cellular responsiveness to TGF-beta through two mechanisms that impair TGF-beta receptor function. The primary mechanism is down-regulation of T beta RII, and the secondary mechanism is induction of Smad7.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, 1150 W Med Ctr Dr,Med Sci 1,Rm 6447, Ann Arbor, MI 48109 USA.		Voorhees, John/AAM-9966-2020	Voorhees, John/0000-0003-1856-785X; Quan, Taihao/0000-0002-0954-5109				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Barr RM, 1999, J INVEST DERMATOL, V112, P692, DOI 10.1046/j.1523-1747.1999.00570.x; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bitzer M, 2000, GENE DEV, V14, P187; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COFFER PJ, 1995, ONCOGENE, V11, P561; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVOS S, 1994, J INVEST DERMATOL, V103, P92, DOI 10.1111/1523-1747.ep12391818; DUMONT N, 1995, MOL CELL ENDOCRINOL, V111, P57, DOI 10.1016/0303-7207(95)03548-L; Fisher G J, 1998, J Investig Dermatol Symp Proc, V3, P61; Fisher GJ, 2000, J CLIN INVEST, V106, P663, DOI 10.1172/JCI9362; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kondo Seijo, 1995, Journal of Dermatology (Tokyo), V22, P888; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; MARKOWITZ S, 2000, BIOCHIM BIOPHYS ACTA, V1470, P13; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MILLER JH, 1972, EXPRESSION MOL GENET; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Quan TH, 1999, J BIOL CHEM, V274, P28566, DOI 10.1074/jbc.274.40.28566; Riggins GJ, 1997, CANCER RES, V57, P2578; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHWARTZ E, 1989, J INVEST DERMATOL, V93, P142, DOI 10.1111/1523-1747.ep12277386; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; Takashima Akira, 1995, Journal of Dermatology (Tokyo), V22, P876; Tam BYY, 1998, J CELL PHYSIOL, V176, P553, DOI 10.1002/(SICI)1097-4652(199809)176:3<553::AID-JCP12>3.3.CO;2-A; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wells RG, 1997, J BIOL CHEM, V272, P11444; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yu YS, 1996, BIOCHEM BIOPH RES CO, V225, P302, DOI 10.1006/bbrc.1996.1170; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHAO J, 1995, CANCER RES, V55, P6181; Zhao Y, 1999, MOL CELL ENDOCRINOL, V150, P91, DOI 10.1016/S0303-7207(99)00021-0	72	130	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26349	26356		10.1074/jbc.M010835200	http://dx.doi.org/10.1074/jbc.M010835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11320083	hybrid			2022-12-25	WOS:000169823300094
J	Ghanouni, P; Gryczynski, Z; Steenhuis, JJ; Lee, TW; Farrens, DL; Lakowicz, JR; Kobilka, BK				Ghanouni, P; Gryczynski, Z; Steenhuis, JJ; Lee, TW; Farrens, DL; Lakowicz, JR; Kobilka, BK			Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta(2) adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; PROTON TRANSLOCATION; CYTOPLASMIC DOMAINS; REQUIREMENT; ACTIVATION; RHODOPSIN; BINDING; STATE	G protein-coupled receptors represent the largest class of drug discovery targets, Drugs that activate G protein-coupled receptors are classified as either agonists or partial agonists, To study the mechanism whereby these different classes of activating ligands modulate receptor function, we directly monitored ligand-induced conformational changes in the G protein-coupling domain of the P, adrenergic receptor. Fluorescence lifetime analysis of a reporter fluorophore covalently attached to this domain revealed that, in the absence of ligands, this domain oscillates around a single detectable conformation. Binding to an antagonist does not change this conformation but does reduce the flexibility of the domain. However, when the P, adrenergic receptor is bound to a full agonist, the G protein coupling domain exists in two distinct conformations. Moreover, the conformations induced by a full agonist can be distinguished from those induced by partial agonists. These results provide new insight into the structural consequence of antagonist binding and the basis of agonism and partial agonism.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, Baltimore, MD 21201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University System of Maryland; University of Maryland Baltimore; Oregon Health & Science University	Kobilka, BK (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu		Kobilka, Brian/0000-0001-5958-3990				ARNIS S, 1994, J BIOL CHEM, V269, P23879; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Freire E, 2000, P NATL ACAD SCI USA, V97, P11680, DOI 10.1073/pnas.97.22.11680; GETHER U, 1995, J BIOL CHEM, V270, P28268; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; GRATTON E, 1989, FLUORESCENT BIOMOLEC, P17; HOSHI T, 1994, J GEN PHYSIOL, V103, P249, DOI 10.1085/jgp.103.2.249; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; LACZKO G, 1990, REV SCI INSTRUM, V61, P2331, DOI 10.1063/1.1141360; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perez DM, 1996, MOL PHARMACOL, V49, P112; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; TOTA MR, 1990, MOL PHARMACOL, V37, P996; Tucek S, 1997, TRENDS PHARMACOL SCI, V18, P414	26	314	333	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24433	24436		10.1074/jbc.C100162200	http://dx.doi.org/10.1074/jbc.C100162200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320077	hybrid			2022-12-25	WOS:000169800700001
J	Craggs, G; Kellie, S				Craggs, G; Kellie, S			A functional nuclear localization sequence in the C-terminal domain of SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; HEMATOPOIETIC-CELL PHOSPHATASE; SIGNAL-TRANSDUCTION; SH2 DOMAIN; CRYSTAL-STRUCTURE; ANTIGEN RECEPTOR; ASSOCIATION; KINASE; INACTIVATION; PTP1C	The Src homology 2 domain-containing protein tyrosine phosphatases SHP-1 and SHP-2 play an important role in many intracellular signaling pathways. Both SHP-1 and SHP-2 have been shown to interact with a diverse range of cytosolic and membrane-bound signaling proteins. Generally, SHP-1 and SHP-2 perform opposing roles in signaling processes; SHP-1 acts as a negative regulator of transduction in hemopoietic cells, whereas SHP-2 acts as a positive regulator. Intriguingly, SHP-1 has been proposed to play a positive regulating role in non-hemopoietic cells, although the mechanisms for this are not understood. Here we show that green fluorescent protein-tagged SHP-1 is unexpectedly localized within the nucleus of transfected HEK293 cells. In contrast, the highly related SHP-2 protein is more abundant within the cytoplasm of transfected cells. In accordance with this, endogenous SHP-1 is localized within the nucleus of several other nonhemopoietic cell types, whereas SHP-2 is distributed throughout the cytoplasm. In contrast, SHP-1 is confined to the cytoplasm of hemopoietic cells, with very little nuclear SHP-1 evident. Using chimeric SHP proteins and mutagenesis studies, the nuclear localization signal of SHP-1 was identified within the C-terminal domain of SHP-1 and found to consist of a short cluster of basic amino acids (KRK), Although the KRK motif resembles half of a bipartite nuclear localization signal, it appears to function independently and is absolutely required for nuclear import. Our findings show that SHP-1 and SHP-2 are distinctly localized within nonhemopoietic cells, with the localization of SHP-1 differing dramatically between nonhemopoietic and hemopoietic cell lineages. This implies that SHP-1 nuclear import is a tightly regulated process and indicates that SHP-1 may possess novel nuclear targets.	Yamanouchi Res Inst, Oxford OX4 4SX, England		Craggs, G (corresponding author), Yamanouchi Res Inst, Littlemore Pk, Oxford OX4 4SX, England.		Kellie, Stuart/A-6036-2010	Kellie, Stuart/0000-0002-8163-1474				Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Erlich H.A., 1989, PCR TECHNOLOGY; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Jin YJ, 1999, J BIOL CHEM, V274, P28301, DOI 10.1074/jbc.274.40.28301; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	34	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23719	23725		10.1074/jbc.M102846200	http://dx.doi.org/10.1074/jbc.M102846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323437	hybrid			2022-12-25	WOS:000169531100067
J	Friedrich, U; Blom, AM; Dahlback, B; Villoutreix, BO				Friedrich, U; Blom, AM; Dahlback, B; Villoutreix, BO			Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR-V; BLOOD-COAGULATION; MAST-CELLS; DOMAIN; IDENTIFICATION; INHIBITOR; THROMBIN; ALPHA-1-ANTITRYPSIN; STIMULATION	Human activated protein C (APC) is a key component of a natural anticoagulant system that regulates blood coagulation, rn vivo, the catalytic activity of APC is regulated by two serpins, alpha1-antitrypsin and the protein C inhibitor (PCI), the inhibition by the latter being stimulated by heparin, We have identified a heparin-binding site in the serine protease domain of APC and characterized the energetic basis of the interaction with heparin. According to the counter-ion condensation theory, the binding of heparin to APC is 66% ionic in nature and comprises four to six net; ionic interactions. To localize the heparin-binding site, five recombinant APC variants containing amino acid exchanges in loops 37, 60, and 70 (chymotrypsinogen numbering) were created. As demonstrated by surface plasmon resonance, reduction of the electropositive character of loops 37 and 60 resulted in complete loss of heparin binding. The functional consequence was loss in heparin-induced stimulation of APC inhibition by PCI, whereas the PCI-induced APC inhibition in the absence of heparin was enhanced. Presumably, the former observations were due to the inability of heparin to bridge some APC mutants to PCI, whereas the increased inhibition of certain APC variants by PCI in the absence of heparin was due to reduced repulsion between the enzymes and the serpin. The heparin-binding site of APC was also shown to interact with heparan sulfate, albeit with lower affinity. In conclusion, we have characterized and spatially localized the functionally important heparin/heparan sulfate-binding site of APC.	Univ Lund, MAS, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Paris 05, INSERM U428, F-75006 Paris, France	Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Univ Lund, MAS, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden.		Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009; Villoutreix, Bruno/I-4565-2015	Blom, Anna/0000-0002-1348-1734; Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				Aznar J, 1996, THROMB HAEMOSTASIS, V76, P983; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Cleland W W, 1979, Methods Enzymol, V63, P103; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; Esmon CT, 1997, THROMB HAEMOSTASIS, V78, P70; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FISHER CL, 1994, PROTEIN SCI, V3, P588; FRIEDRICH U, 1994, THROMB HAEMOSTASIS, V72, P567; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Hari SP, 2000, BIOCHEMISTRY-US, V39, P3763, DOI 10.1021/bi9926734; HEEB MJ, 1988, J BIOL CHEM, V263, P11613; HERMANS JM, 1993, BIOCHEM J, V295, P239, DOI 10.1042/bj2950239; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; Montserret R, 1999, BIOCHEMISTRY-US, V38, P6479, DOI 10.1021/bi9900222; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Neese LL, 1998, ARCH BIOCHEM BIOPHYS, V355, P101, DOI 10.1006/abbi.1998.0716; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Rosing J, 1997, THROMB HAEMOSTASIS, V78, P427; SALI A, 1993, J BIOL CHEM, V268, P9023; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Shen L, 1999, THROMB HAEMOSTASIS, V82, P72, DOI 10.1055/s-0037-1614632; Shen L, 2000, BIOCHEMISTRY-US, V39, P2853, DOI 10.1021/bi992357p; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; WACEY AI, 1993, BRIT J HAEMATOL, V84, P290, DOI 10.1111/j.1365-2141.1993.tb03067.x; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641; [No title captured]	37	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24122	24128		10.1074/jbc.M011567200	http://dx.doi.org/10.1074/jbc.M011567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316800	hybrid			2022-12-25	WOS:000169531100119
J	Glading, A; Uberall, F; Keyse, SM; Lauffenburger, DA; Wells, A				Glading, A; Uberall, F; Keyse, SM; Lauffenburger, DA; Wells, A			Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; PROTEIN-KINASE; SELECTIVE LOCALIZATION; CELL-MIGRATION; CLEAVAGE; MOTILITY; CALCIUM; PATHWAY; TALIN; INTERNALIZATION	Localization of signaling is critical in directing cellular outcomes, especially in pleiotropic signaling pathways. The extracellular signal-regulated kinase (ERK)/ microtubule-associated protein kinase, which promotes cell migration, proliferation, and differentiation is found in the nucleus and throughout the cytoplasm. Recently, it has been shown that nuclear translocation of ERK is required for transcriptional changes and cell proliferation. However, the cellular consequences, of cytoplasmic signaling have not been defined. We explored whether cytoplasmic, specifically membrane-proximal, ERK signaling is involved in growth factor-induced cell motility, We previously have demonstrated that increased M-calpain activity downstream of epidermal growth factor receptor (EGFR)-mediated ERK activation is necessary for epidermal growth factor (EGF)induced motility. Calpain isoforms also have been found in nuclear, cytosolic, and plasma membrane-associated compartments in a variety of cell types. We now employ cell engineering approaches to control localization of the upstream EGFR and ERK activities to examine the spatial effect of upstream signal locale on downstream calpain activity. With differential ligand-induced internalization and trafficking-restricted receptor variants, we find that calpain activity is triggered only by plasma membrane-restricted activated EGFR, not by internalized (although still active) EGFR. Cells transfected with membrane-targeted ERK1 and ERK2, which sequester endogenous ERKs, exhibited normal EGF-induced calpain activity. Transfection of an inactive ERK phosphatase (MKP-3/Pyst1) that sequesters ERK in the cytoplasm prevented calpain activation as well as deadhesion. These data strongly suggest that EGF-induced calpain activity can be enhanced near sites of membrane-proximal EGFR-mediated ERK signaling, providing insights about how calpain activity might be regu lated and targeted to enhance its effects on adhesion-related substrates.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Ninewells Hosp, Biomed Res Ctr, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Innsbruck; University of Dundee; Massachusetts Institute of Technology (MIT)	Wells, A (corresponding author), Univ Pittsburgh, Dept Pathol, 713 Scaife Hall, Pittsburgh, PA 15261 USA.	wellsa@msx.upmc.edu	Keyse, Stephen M./B-9575-2009; Glading, Angela/AAI-3455-2020	Keyse, Stephen M./0000-0002-5150-8221; Wells, Alan/0000-0002-1637-8150; Glading, Angela/0000-0002-1830-6601	NCI NIH HHS [CA69213] Funding Source: Medline; NIGMS NIH HHS [GM54739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIYOSHI H, 1993, BIOCHEM MOL BIOL INT, V30, P63; Ariyoshi H, 1998, ARTERIOSCL THROM VAS, V18, P493, DOI 10.1161/01.ATV.18.3.493; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; KITAHARA A, 1985, FEBS LETT, V184, P120, DOI 10.1016/0014-5793(85)80666-9; KITAHARA A, 1986, J CLIN ENDOCR METAB, V63, P343, DOI 10.1210/jcem-63-2-343; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V128, P331, DOI 10.1016/0006-291X(85)91683-3; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; Santella L, 1998, CELL CALCIUM, V23, P123, DOI 10.1016/S0143-4160(98)90110-5; Shiraha H, 1999, J CELL BIOL, V146, P243; TOMPA P, 1995, ANAL BIOCHEM, V228, P287, DOI 10.1006/abio.1995.1352; TRANQUI L, 1995, EXP CELL RES, V217, P149, DOI 10.1006/excr.1995.1074; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Xie H, 1998, J CELL SCI, V111, P615; YOSHIMURA N, 1984, J BIOL CHEM, V259, P9847; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	43	177	183	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23341	23348		10.1074/jbc.M008847200	http://dx.doi.org/10.1074/jbc.M008847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319218				2022-12-25	WOS:000169531100018
J	Sun, CT; Lo, WY; Wang, IH; Lo, YH; Shiou, SR; Lai, CK; Ting, LP				Sun, CT; Lo, WY; Wang, IH; Lo, YH; Shiou, SR; Lai, CK; Ting, LP			Transcription repression of human hepatitis B virus genes by negative regulatory element-binding protein/SON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL PLATELET DISORDER; DNA-BINDING; CORE PROMOTER; 2ND ENHANCER; NUCLEOCAPSID PROMOTER; ACTIVE REPRESSION; CELL SPECIFICITY; THYROID-HORMONE; DOWN-SYNDROME; MECHANISM	A negative regulatory element (NRE) is located immediately upstream of the upstream regulatory sequence of core promoter and second enhancer of human hepatitis B virus (HBV), NRE represses the transcription activation function of the upstream regulatory sequence of core promoter and the second enhancer. In this study, we described the cloning and characterization of an NRE-binding protein (NREBP) through expression cloning. NREBP cDNA is 8266 nucleotides in size and encodes a protein of 2386 amino acids with a predicted molecular mass of 262 kDa, Three previously described cDNAs, DBP-5, SONB, and SONA, are partial sequence and/or alternatively spliced forms of NREBP, The genomic locus of the NREBP/SON gene is composed of 13 exons and 12 introns, The endogenous NREBP protein is localized in the nucleus of human hepatoma HuH-7 cells. Antibody against NREBP protein can specifically block the NRE binding activity present in fractionated nuclear extracts in gel shifting assays, indicating that NREBP is the endogenous nuclear protein that binds to NRE sequence. By polymerase chain reaction-assisted binding site selection assay, we determined that the consensus sequence for NREBP binding is GA(GPT)AN(C/G)(A/G)CC, Overexpression of NREBP enhances the repression of the HBV core promoter activity via NRE. Overexpression of NREBP can also repress the transcription of HBV genes and the production of HBV virions in a transient transfection system that mimics the viral infection in vivo.	Natl Yang Ming Univ, Sch Life Sci, Inst Microbiol & Immunol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Ting, LP (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Microbiol & Immunol, Taipei 112, Taiwan.							Arepally G, 1998, BLOOD, V92, P2600, DOI 10.1182/blood.V92.7.2600; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARSOUM J, 1992, J VIROL, V66, P3941, DOI 10.1128/JVI.66.6.3941-3945.1992; BERDICHEVSKII F B, 1988, Molekulyarnaya Biologiya (Moscow), V22, P794; Bliskovskii V. V., 1992, Molekulyarnaya Biologiya (Moscow), V26, P793; Bliskovskii V. V., 1992, Molekulyarnaya Biologiya (Moscow), V26, P807; Buckwold VE, 1997, VIROLOGY, V227, P515, DOI 10.1006/viro.1996.8360; CHEN M, 1995, VIROLOGY, V214, P198, DOI 10.1006/viro.1995.9940; CHUMAKOV I M, 1991, Molekulyarnaya Biologiya (Moscow), V25, P731; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Delabar Jean-Maurice, 1993, European Journal of Human Genetics, V1, P114; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOWTON SB, 1985, BLOOD, V65, P557; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Gilbert S, 2000, J VIROL, V74, P5032, DOI 10.1128/JVI.74.11.5032-5039.2000; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GUO WT, 1993, MOL CELL BIOL, V13, P443, DOI 10.1128/MCB.13.1.443; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; Ho CY, 1996, BLOOD, V87, P5218, DOI 10.1182/blood.V87.12.5218.bloodjournal87125218; Huang CJ, 2000, J BIOMED SCI, V7, P160, DOI 10.1159/000025442; Ikeda K, 1998, MOL CELL BIOL, V18, P10, DOI 10.1128/MCB.18.1.10; Ishida H, 2000, J VIROL, V74, P1241, DOI 10.1128/JVI.74.3.1241-1251.2000; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON JL, 1995, VIROLOGY, V208, P147, DOI 10.1006/viro.1995.1138; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KHAN IM, 1994, ANN HUM GENET, V58, P25, DOI 10.1111/j.1469-1809.1994.tb00723.x; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lai CK, 1999, J VIROL, V73, P3197, DOI 10.1128/JVI.73.4.3197-3209.1999; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Li M, 1995, VIROLOGY, V214, P371, DOI 10.1006/viro.1995.0046; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; LO WY, 1994, J VIROL, V68, P1758, DOI 10.1128/JVI.68.3.1758-1764.1994; LO WY, 1997, THESIS NATL YANG MIN; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; MATTIONI T, 1992, CHROMOSOMA, V101, P618, DOI 10.1007/BF00360539; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCCORMICK MK, 1989, GENOMICS, V5, P325, DOI 10.1016/0888-7543(89)90065-7; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Raney AK, 1997, J VIROL, V71, P1058, DOI 10.1128/JVI.71.2.1058-1071.1997; RANEY AK, 1991, J VIROL, V65, P5774, DOI 10.1128/JVI.65.11.5774-5781.1991; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang WX, 1998, RES VIROLOGY, V149, P99, DOI 10.1016/S0923-2516(98)80085-X; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YUH CH, 1991, MOL CELL BIOL, V11, P5044, DOI 10.1128/MCB.11.10.5044; YUH CH, 1993, J VIROL, V67, P142, DOI 10.1128/JVI.67.1.142-149.1993; YUH CH, 1992, J VIROL, V66, P4073, DOI 10.1128/JVI.66.7.4073-4084.1992; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990	69	46	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24059	24067		10.1074/jbc.M101330200	http://dx.doi.org/10.1074/jbc.M101330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306577	hybrid			2022-12-25	WOS:000169531100111
J	Qian, ZJ; Lin, C; Espinosa, R; LeBeau, M; Rosner, MR				Qian, ZJ; Lin, C; Espinosa, R; LeBeau, M; Rosner, MR			Cloning and characterization of MST4, a novel Ste20-like kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; SAPK/JNK PATHWAY; APOPTOSIS; IDENTIFICATION; CASCADE; DOMAIN; DICTYOSTELIUM	MST4, a novel member of the germinal center kinase subfamily of human Ste20-like kinases, was cloned and characterized. Composed of a C-terminal regulatory domain and an N-terminal kinase domain, MST4 is most closely related to mammalian Ste20 kinase family member MST3. Both the kinase and C-terminal regulatory domains of MST4 are required for full activation of the kinase. Northern blot analysis indicates that MST4 is ubiquitously distributed, and the MST4 gene is localized to chromosome Xq26, a disease-rich region, by fluorescence in situ hybridization. Although some members of the MST4 family function as upstream regulators of mitogen-activated protein kinase cascades, expression of MST4 in 293 cells was not sufficient to activate or potentiate extracellular signal-regulated kinase, c-Jun N-terminal kinase, or p38 kinase. An alternatively spliced isoform of MST4 (MST4a) was isolated by yeast two-hybrid interaction with the catalytic domain of Raf from a human fetal brain cDNA library and also found in a variety of human fetal and adult tissues. MST4a lacks an exon encoding kinase subdomains M-XI that stabilizes substrate binding. The existence of both MST4 isoforms suggests that the MST4 kinase activity is highly regulated, and MST4a may function as a dominant-negative regulator of the MST4 kinase.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Rosner, MR (corresponding author), Univ Chicago, Ben May Inst Canc Res, 5841 S Maryland Ave,MC 6027, Chicago, IL 60637 USA.	mrosner@ben-may.bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033858] Funding Source: NIH RePORTER; NCI NIH HHS [CA40046] Funding Source: Medline; NIGMS NIH HHS [T32 GM07151] Funding Source: Medline; NINDS NIH HHS [NS 33858] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Chung CY, 1998, GENE DEV, V12, P3564, DOI 10.1101/gad.12.22.3564; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Ling P, 1999, MOL CELL BIOL, V19, P1359; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WISHART MJ, 1995, J BIOL CHEM, V270, P26782, DOI 10.1074/jbc.270.45.26782; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	45	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22439	22445		10.1074/jbc.M009323200	http://dx.doi.org/10.1074/jbc.M009323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306563	hybrid			2022-12-25	WOS:000169412700063
J	Sawada, M; Nakashima, S; Kiyono, T; Nakagawa, M; Yamada, J; Yamakawa, H; Banno, Y; Shinoda, J; Nishimura, Y; Nozawa, Y; Sakai, N				Sawada, M; Nakashima, S; Kiyono, T; Nakagawa, M; Yamada, J; Yamakawa, H; Banno, Y; Shinoda, J; Nishimura, Y; Nozawa, Y; Sakai, N			p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells	ONCOGENE			English	Article						ceramide; glioma; neutral sphingomyelinase; p53; reactive oxygen species	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; INDUCED APOPTOSIS; HYDROGEN-PEROXIDE; P53-INDUCED APOPTOSIS; CASPASE ACTIVATION; GROWTH ARREST; DEATH; INHIBITION	The present study was designed to elucidate the relationship between p53 and ceramide, both of which are involved in apoptotic signaling, Treatment of human glioma cells with etoposide caused apoptosis only in cells expressing functional p53. p53 activation was followed by the formation of reactive oxygen species (ROS), superoxide anion (O-2(-.)) measured by hydroethidium oxidation into ethidium and hydrogen peroxide (H2O2) measured by oxidation of 2',7'-dichlorofluorescin (DCFH) into 2',7'-dichlorofluorescein (DCF), which was accompanied with ceramide generation through the activation of neutral, but not acid, sphingomyelinase. Superoxide dismutase (SOD), a selective antioxidant for O-2(-.) had no effects on p53 expression but inhibited ceramide generation and apoptotic cell death caused by etoposide, However, catalase, a specific antioxidant for H2O2, only weakly inhibited and sodium formate, a hydroxyl radical ((OH)-O-.) scavenger, unaffected etoposide-induced apoptosis, Like etoposide-induced cell death, treatment of glioma cells with the O-2(-.)-releasing agent, pyrogallol, induced typical apoptosis and ceramide generation even in the presence of catalase, In contrast, human glioma cells lacking functional p53, either due to mutation or the expression of E6 protein of human papillomavirus, were highly resistant to etoposide and exhibited no significant change in the ceramide level. Moreover, expression of functional p53 protein in glioma cells expressing mutant p53 using a temperature-sensitive human p53(Val138) induced ceramide accumulation by the activation of neutral sphingomyelinase which was dependent on the generation of O-2(-.), Taken together, these results suggest that p53 may modulate ceramide generation by activation of neutral sphingomyelinase through the formation of O-2(-.), but not its downstream compounds H2O2 or (OH)-O-..	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Aichi Canc Ctr, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Int Inst Biotechnol, Mitake, Gifu 5050116, Japan	Gifu University; Gifu University; Aichi Cancer Center	Sawada, M (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, Tsukasamachi 40, Gifu 5008705, Japan.		Kiyono, Tohru/H-5834-2011					BOREK C, 1987, British Journal of Cancer, V55, P74; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKEL RH, 1992, CANCER RES, V52, P1427; GomezManzano C, 1996, CANCER RES, V56, P694; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Jacobs S, 1996, IN SESSION-PSYCHOTH, V2, P21; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Narayanan PK, 1997, CANCER RES, V57, P3963; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAMAKRISHNAN N, 1992, J IMMUNOL, V148, P1817; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; VAVSSIARE JL, 1994, P NATL ACAD SCI USA, V91, P11752; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WALKER PR, 1991, CANCER RES, V51, P1078; Xie YW, 1998, CIRC RES, V82, P891; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zhang P, 1997, J BIOL CHEM, V272, P9609	53	89	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1368	1378		10.1038/sj.onc.1204207	http://dx.doi.org/10.1038/sj.onc.1204207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313880				2022-12-25	WOS:000167495000010
J	Yan, W; Kero, J; Suominen, J; Toppari, J				Yan, W; Kero, J; Suominen, J; Toppari, J			Differential expression and regulation of the retinoblastoma family of proteins during testicular development and spermatogenesis: roles in the control of germ cell proliferation, differentiation and apoptosis	ONCOGENE			English	Article						retinoblastoma protein family; spermatogenesis; cell cycle; apoptosis; differentiation	MESSENGER-RIBONUCLEIC-ACID; STAGE-SPECIFIC EXPRESSION; KIT RECEPTOR; ANDROGEN RECEPTOR; MOLECULAR-CLONING; SURVIVAL FACTOR; LEYDIG-CELLS; MICE LACKING; GENE FAMILY; C-KIT	Normal spermatogenesis is highly dependent on well-balanced germ cell proliferation, differentiation, and apoptosis, However, the molecular mechanisms that govern these processes are largely unknown. Retinoblastoma family proteins (pRb, p107 and p130) are potentially important regulators of cell growth, differentiation and apoptosis, pRb has been shown to be expressed in the rat testis and involved in the regulation of spermatogenesis, In the present study, the expression and localization of the other two pRb family members, p107 and p130, were analysed at both mRNA and protein levels during testicular development and spermatogenesis using Northern, Western blotting, immunohistochemistry, and in situ hybridization, Furthermore, changes of levels and phosphorylation status of pRb family proteins in response to growth suppression and/or apoptosis induction were investigated using a seminiferous tubule culture system and three animal models, Our data suggest that: (1) pRb family proteins are differentially expressed in the rat testis and they function in a cell-type-specific manner during testicular development and spermatogenesis; (2) they participate in the control of germ cell cycle and act in a cell cycle-phase-specific fashion during germ cell proliferation, and (3) they are also involved in the regulation of apoptosis of germ cells and Leydig cells.	Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland	University of Turku; University of Turku	Toppari, J (corresponding author), Univ Turku, Dept Physiol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.		Yan, Wei/G-1618-2011; kero, jukka/G-3448-2014	kero, jukka/0000-0001-8767-7222				Beumer TL, 1999, ENDOCRINOLOGY, V140, P1834, DOI 10.1210/en.140.4.1834; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hakovirta H, 1999, ENDOCRINOLOGY, V140, P1492, DOI 10.1210/en.140.3.1492; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARDY MP, 1989, ENDOCRINOLOGY, V124, P762, DOI 10.1210/endo-124-2-762; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; Huppi K, 1996, MAMM GENOME, V7, P353, DOI 10.1007/s003359900102; JACKSON CM, 1984, J REPROD FERTIL, V71, P393; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Krishnamurthy H, 1998, J ANDROL, V19, P710; LeCouter JE, 1996, ONCOGENE, V12, P1433; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; McKinnell C, 1997, INT J ANDROL, V20, P171; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PARVINEN M, 1986, INT REV CYTOL, V104, P115, DOI 10.1016/S0074-7696(08)61925-7; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Stiegler P, 1998, J CELL BIOCHEM, P30; Suter L, 1998, ARCH TOXICOL, V72, P791, DOI 10.1007/s002040050575; TAJIMA Y, 1994, J REPROD FERTIL, V102, P117, DOI 10.1530/jrf.0.1020117; Teerds K. J., 1996, LEYDIG CELL, P203; TENASEMPERE M, 1994, ENDOCRINOLOGY, V135, P1018, DOI 10.1210/en.135.3.1018; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Vincent S, 1998, DEVELOPMENT, V125, P4585; Yan W, 2000, DEV BIOL, V227, P169, DOI 10.1006/dbio.2000.9885; Yan W, 1997, MOL CELL ENDOCRINOL, V132, P137, DOI 10.1016/S0303-7207(97)00129-9; Yan W, 2000, MOL ENDOCRINOL, V14, P682, DOI 10.1210/me.14.5.682; Yan W, 2000, J CELL SCI, V113, P161; Yan W, 1999, ENDOCRINOLOGY, V140, P1499, DOI 10.1210/en.140.3.1499; Yan W, 2000, MOL CELL ENDOCRINOL, V165, P115, DOI 10.1016/S0303-7207(00)00257-4; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	48	36	37	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1343	1356		10.1038/sj.onc.1204254	http://dx.doi.org/10.1038/sj.onc.1204254			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313878				2022-12-25	WOS:000167495000008
J	Chen, XB; Zheng, YM; Zhu, JH; Jiang, JY; Wang, J				Chen, XB; Zheng, YM; Zhu, JH; Jiang, JY; Wang, J			p73 is transcriptionally regulated by DNA damage, p53, and p73	ONCOGENE			English	Article						p53; p73; DNA damage; transcriptional regulation	KINASE C-ABL; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; IDENTIFICATION; PROTEIN; DOMAIN; CELLS; GENES	p73 is a member of the p53 family, Recent studies have shown that DNA damage can stabilize p73 protein and enhance p73-mediated apoptosis in a c-Abl dependent manner. To determine what regulates p73 transcriptionally, we analysed the expression of p73 in several cell lines following genotoxic stresses. We found that p73 is induced in certain cell lines when treated with therapeutic DNA damaging agents. We also found that p53 and p73, but not mutant p53(R249S) and p73 beta 292, directly induce the expression of the p73 gene. In addition, we found one potential p53-binding site in the promoter of the p73 gene. This binding site is responsive to p53, p73, and DIVA damage. Taken together, these data suggest that p73 is transcriptionally regulated by DNA damage and p53, and is autoregulated.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [R01 CA81237, CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069, R01CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	23	84	86	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					769	774		10.1038/sj.onc.1204149	http://dx.doi.org/10.1038/sj.onc.1204149			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314010				2022-12-25	WOS:000166806000012
J	Pucci, S; Mazzarelli, P; Rabitti, C; Giai, M; Gallucci, M; Flammia, G; Alcini, A; Altomare, V; Fazio, VM				Pucci, S; Mazzarelli, P; Rabitti, C; Giai, M; Gallucci, M; Flammia, G; Alcini, A; Altomare, V; Fazio, VM			Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies	ONCOGENE			English	Article						Ku70/80 heterodimer; DNA repair; DNA double-strand breaks; DNA-PK; human tumors	DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; KU-PROTEIN; V(D)J RECOMBINATION; PROGNOSTIC MARKERS; CELL-SURFACE; ANTIGEN-KU; CANCER; AUTOANTIGEN; REPAIR	The Ku70/80 heterodimer is the regulatory subunit of the DNA-dependent protein kinase (DNA-PK) and its DNA-binding activity mediates DNA double-strand breaks repair. Although Ku80 was recently proposed as a caretaker gene involved in the control of genome integrity, no data are available on Ku70/80 DNA-binding activity in human tumors. Heterodimer DNA-binding activity and protein expression were assayed by electrophoretic-mobility-shift-assay (EMSA) and Western blot analysis, in nuclear and cytoplasmic extracts from eight breast, seven bladder primary tumors and three metastatic nodes from breast cancers. Corresponding normal tissues of the same patients were used as controls. Ten out of 15 tumors showed nuclear Ku-binding activity 3-10 times higher than in the normal tissues, irrespective of bladder or breast origin. Conversely, in 5/15 primary tumors and in all the metastatic nodes analysed, nuclear Ku-activity was 1.5-4.5-fold lower than in the corresponding normal tissues. Cytoplasmic heterodimer activity significantly differed between tumor and normal tissues, displaying a 2-10-fold increase in neoplastic tissues. Three different patterns combining both Ku expression and activity with tumor characteristics were identified. In low aggressive breast tumors p70/p80 proteins were expressed in tumor but not in normal tissues. The heterodimer binding-activity matched the protein levels. In non-invasive bladder carcinomas no significant differences in protein expression between tumor and the corresponding normal tissues were found, however heterodimer binding-activity was increased in tumor samples. In breast and bladder tumors, at the advanced stage and in node metastases, the binding activity was strongly reduced in tumor biopsies, however no differences mere demonstrated between normal and tumor protein levels, Our results suggest a different modulation of Ku70/80 DNA-binding activity in human neoplastic tissues, possibly related to tumor progression. Findings provide further data on tissue-specific protein expression and post-translational regulation of heterodimer activity.	CNR, Inst Expt Med, I-00133 Rome, Italy; Lab Mol Med & Biotechnol, I-00155 Rome, Italy; Lab Histopathol, I-00155 Rome, Italy; Dept Urol, I-00155 Rome, Italy; Dept Gen Surg, I-00155 Rome, Italy; IRCCS H Casa Sollievo Sofferenza, Lab Mol Pathol, I-71013 San Giovanni Rotondo, FG, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Casa Sollievo Della Sofferenza	Fazio, VM (corresponding author), CNR, Inst Expt Med, Via Fosso Cavaliere 100, I-00133 Rome, Italy.		Pucci, Sabina/J-2542-2012; Fazio, Vito Michele VMF/H-3007-2016; Gallucci, Michele/K-9600-2016	Fazio, Vito Michele VMF/0000-0002-7751-1867; Altomare, Vittorio/0000-0002-9839-4129; Gallucci, Michele/0000-0002-3637-6531; Pucci, Sabina/0000-0002-2418-6482				Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; Dahiya R, 1998, BREAST CANCER RES TR, V52, P185, DOI 10.1023/A:1006101729631; DALZIEL RG, 1992, AUTOIMMUNITY, V13, P265, DOI 10.3109/08916939209112334; DEVITA R, 1991, EUR UROL, V19, P65; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frasca D, 1998, MECH AGEING DEV, V100, P197, DOI 10.1016/S0047-6374(97)00137-1; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hwang BJ, 1999, METH MOL B, V113, P103; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Kessel David, 1994, In Vivo (Attiki), V8, P829; Kinsella AR, 1997, BRIT J CANCER, V75, P935, DOI 10.1038/bjc.1997.164; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Koike M, 1999, J CELL SCI, V112, P4031; Korkolopoulou P, 1997, PATHOL RES PRACT, V193, P767, DOI 10.1016/S0344-0338(97)80055-6; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Moll U, 1999, ONCOGENE, V18, P3114, DOI 10.1038/sj.onc.1202640; MORGAN WF, 1995, CANCER METAST REV, V14, P49, DOI 10.1007/BF00690211; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; ONEILL KL, 1992, MED LAB SCI, V49, P244; POWELL SN, 1993, CYTOTECHNOLOGY, V12, P325, DOI 10.1007/BF00744671; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; SATO T, 1991, CANCER RES, V51, P5794; Sekowski JW, 1998, CANCER RES, V58, P3259; Teoh G, 1998, J CLIN INVEST, V101, P1379; Tovari J, 1998, CELL SIGNAL, V10, P277, DOI 10.1016/S0898-6568(97)00128-9; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Wong SWJ, 1999, PATHOLOGY, V31, P90, DOI 10.1080/003130299105241; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yoo S, 1998, BIOCHEMISTRY-US, V37, P1336, DOI 10.1021/bi972100w; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	43	83	84	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					739	747		10.1038/sj.onc.1204148	http://dx.doi.org/10.1038/sj.onc.1204148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314007				2022-12-25	WOS:000166806000009
J	Komatsu, M; Jepson, S; Arango, ME; Carraway, CAC; Carraway, KL				Komatsu, M; Jepson, S; Arango, ME; Carraway, CAC; Carraway, KL			Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor	ONCOGENE			English	Article						Muc4; apoptosis; ErbB2; xenotransplanted tumor; tumor growth; sialomucin complex	SURFACE GLYCOPROTEIN COMPLEX; MAMMARY ADENOCARCINOMA CELLS; SIALOMUCIN COMPLEX; EXTRACELLULAR-MATRIX; RAT MUC4; MOLECULAR-CLONING; EPITHELIAL-CELLS; FACTOR-BETA; EXPRESSION; MEMBRANE	Overexpression of the membrane mucin MUC4/Sialo-mucin complex (SMC) has been observed during malignant progression of mammary tumors in both humans and rats, suggesting that deregulation of MUC4/SMC expression might facilitate development of these malignancies, As previously reported, overexpression of SMC results in suppression of both cell adhesion and immune killing of tumor cells, SMC also acts as a ligand for ErbB2/Neu, modulating phosphorylation of the receptor tyrosine kinase in the presence and absence of heregulin. The present studies investigated the effect of Muc4/SMC up-regulation on primary tumor growth using a tetracycline-inducible SMC expression system in a xenotransplanted tumor model. SMC upregulation provoked rapid growth of transfected A375 melanoma in nude mice. Up-regulation of SMC, however, did not significantly increase proliferation of A375 cells in vitro, Instead, a strong suppression of apoptosis was observed in situ in SMC-overexpressing tumors, These data suggest that Muc4/SMC expression promotes tumor growth in vivo at least in part via suppression of tumor cell apoptosis, Importantly, reduction of apoptosis was also observed in vitro, indicating that anti-apoptotic effect of SMC is independent of tumor-host interactions, These findings strongly suggest that SMC up-regulation alters intracellular signaling to favor cell survival, providing for the first time evidence for the regulation of programmed cell death by a gene of the MUC family.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA.			Komatsu, Masanobu/0000-0001-7548-137X	NCI NIH HHS [CA52498, CA74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498, R01CA074072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 1996, BREAST CANCER RES TR, V38, P49, DOI 10.1007/BF01803783; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CARRAWAY KL, 1992, J CELL SCI, V103, P299; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; DHAWAN J, 1995, SOMAT CELL MOLEC GEN, V21, P233, DOI 10.1007/BF02255778; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; HUGGINS JW, 1980, CANCER RES, V40, P1873; Idris N, 2000, J CELL PHYSIOL, V185, P310, DOI 10.1002/1097-4652(200011)185:2<310::AID-JCP16>3.0.CO;2-W; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; PANDEY P, 1995, CANCER RES, V55, P4000; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WU K, 1994, J BIOL CHEM, V269, P11950; WU K, 1994, ONCOGENE, V9, P3139; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	39	106	115	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					461	470		10.1038/sj.onc.1204106	http://dx.doi.org/10.1038/sj.onc.1204106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313977				2022-12-25	WOS:000166562500006
J	Kawada, N; Kristensen, DB; Asahina, K; Nakatani, K; Minamiyama, Y; Seki, S; Yoshizato, K				Kawada, N; Kristensen, DB; Asahina, K; Nakatani, K; Minamiyama, Y; Seki, S; Yoshizato, K			Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMOBILIZED PH GRADIENTS; IN-VIVO; 2-DIMENSIONAL ELECTROPHORESIS; SAMPLE APPLICATION; MASS-SPECTROMETRY; TISSUE INHIBITOR; OXIDATIVE STRESS; UP-REGULATION; EXPRESSION; LIVER	A proteome approach for the molecular analysis of the activation of rat stellate cell, a liver-specific pericyte, led to the discovery of a novel protein named STAP (stellate cell activation-associated protein). We cloned STAP cDNA, STAP is a cytoplasmic protein with molecular weight of 21,496 and shows about 40% amino acid sequence homology with myoglobin, STAP was dramatically induced in in vivo activated stellate cells isolated from fibrotic liver and in stellate cells undergoing in vitro activation during primary culture. This induction was seen together with that of other activation-associated molecules, such as smooth muscle alpha -actin, PDGF receptor-beta, and neural cell adhesion molecule. The expression of STAP protein and mRNA was augmented time dependently in thioacetamide-induced fibrotic liver. Immunoelectron microscopy and proteome analysis detected STAP in stellate cells but not in other hepatic constituent cells. Biochemical characterization of recombinant rat STAP revealed that STAP is a heme protein exhibiting peroxidase activity toward hydrogen peroxide and linoleic acid hydroperoxide. These results indicate that STAP is a novel endogenous peroxidase catabolizing hydrogen peroxide and lipid hydroperoxides, both of which have been reported to trigger stellate cell activation and consequently promote progression of liver fibrosis, STAP could thus play a role as an antifibrotic scavenger of peroxides in the liver.	Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Dev Biol Lab, Higashihiroshima 7398526, Japan; Japan Sci & Technol Corp, Hiroshima Tissue Regenerat Project, Hiroshima Prefecture Collaborat Reg Ent Advancemen, Hiroshima 7390046, Japan; Hiroshima Technol Org, Reg Sci Program, Hiroshima Proteome Lab, Hiroshima 7390046, Japan; Osaka City Univ, Sch Med, Grad Sch Med, Dept Hepatol, Osaka 5458585, Japan	Hiroshima University; Japan Science & Technology Agency (JST); Osaka Metropolitan University	Yoshizato, K (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Dev Biol Lab, 1-3-1 Kagamiyama, Higashihiroshima 7398526, Japan.		kawada, norifumi/AAS-1367-2020; Asahina, Kinji/X-8794-2019	Asahina, Kinji/0000-0003-0398-8395				Asahina K, 1999, MATRIX BIOL, V18, P89, DOI 10.1016/S0945-053X(99)00005-0; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; Eaton W A, 1981, Methods Enzymol, V76, P175; Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7, DOI 10.1152/ajpgi.2000.279.1.G7; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118; Gressner AM, 1998, CELL TISSUE RES, V292, P447, DOI 10.1007/s004410051073; Hellerbrand C, 1996, HEPATOLOGY, V24, P670; Ikeda K, 1998, AM J PATHOL, V153, P1695, DOI 10.1016/S0002-9440(10)65683-0; Kawada N, 1997, HISTOL HISTOPATHOL, V12, P1069; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; KAWAMOTO S, 1977, ARCH MICROBIOL, V112, P1, DOI 10.1007/BF00446647; KHARASCH ED, 1985, J BIOL CHEM, V260, P645; Knittel T, 1996, AM J PATHOL, V149, P449; Kristensen DB, 2000, ELECTROPHORESIS, V21, P430, DOI 10.1002/(SICI)1522-2683(20000101)21:2<430::AID-ELPS430>3.3.CO;2-S; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Lang A, 2000, AM J PHYSIOL-GASTR L, V279, pG1333, DOI 10.1152/ajpgi.2000.279.6.G1333; Maher JJ, 1997, BIOCHEM PHARMACOL, V53, P637, DOI 10.1016/S0006-2952(96)00865-9; Marra F, 1998, AM J PATHOL, V152, P423; Nagy NE, 1997, J LIPID RES, V38, P645; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Pinzani M, 1999, SEMIN LIVER DIS, V19, P397, DOI 10.1055/s-2007-1007128; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PINZANI M, 1995, HEPATOLOGY, V22, P997; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; RAMADORI G, 1990, CELL PATHOL INCL MOL, V59, P349; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Reichard JF, 2000, BBA-MOL CELL BIOL L, V1487, P222, DOI 10.1016/S1388-1981(00)00095-0; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Roepstorff P, 1997, CURR OPIN BIOTECH, V8, P6, DOI 10.1016/S0958-1669(97)80151-6; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Shao R, 1999, J BIOL CHEM, V274, P3228, DOI 10.1074/jbc.274.5.3228; SHEA SM, 1968, AM J PATHOL, V52, P55; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; TAKAICHI S, 1981, J BIOCHEM-TOKYO, V89, P1513, DOI 10.1093/oxfordjournals.jbchem.a133344; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; Wang SC, 1998, J BIOL CHEM, V273, P302, DOI 10.1074/jbc.273.1.302; Whalen R, 1999, HEPATOLOGY, V30, P927, DOI 10.1002/hep.510300404; Yates JR, 1998, J MASS SPECTROM, V33, P1	42	281	309	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25318	25323		10.1074/jbc.M102630200	http://dx.doi.org/10.1074/jbc.M102630200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320098	hybrid			2022-12-25	WOS:000169800700118
J	Yoo, MH; Woo, CH; You, HJ; Cho, SH; Kim, BC; Choi, JE; Chun, JS; Jhun, BH; Kim, TS; Kim, JH				Yoo, MH; Woo, CH; You, HJ; Cho, SH; Kim, BC; Choi, JE; Chun, JS; Jhun, BH; Kim, TS; Kim, JH			Role of the cytosolic phospholipase A(2)-linked cascade in signaling by an oncogenic, constitutively active Ha-Ras isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; TERNARY COMPLEX-FORMATION; ARACHIDONIC-ACID RELEASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; ANNEXIN-I; ACTIVATION; A(2); PHOSPHORYLATION; GROWTH	Activation of Res signaling by growth factors has been associated with gene regulation and cell proliferation. Here we characterize the contributory role of cytosolic phospholipase A(2) in the oncogenic Ha-Ras(V12) signaling pathway leading to activation of c-fos serum response element (SRE) and transformation in Rat-a fibroblasts. Using a c-fos SRE-luciferase reporter gene, we showed that the transactivation of SRE by Ha-Ras(V12) is mainly via a Rac-linked cascade, although the Raf-mitogen-activated protein kinase cascade is required for full activation. In addition, Ha-Ras(V12)-induced DNA synthesis was significantly attenuated by microinjection of recombinant Rac(N17), a dominant negative mutant of Rad. To identify the mediators downstream of Rac in the Ha-Ras(V12) signaling, we investigated the involvement of cytosolic phospholipase A(2). Oncogenic Ha-Ras(V12)-induced SRE activation was significantly inhibited by either pretreatment with mepacrine, a phospholipase A(2) inhibitor, or cotransfection with the antisense oligonucleotide of cytosolic phospholipase A(2). We also found cytosolic phospholipase A(2) to be situated downstream of Ha-Ras(V12) in a signal pathway leading to transformation. Together, these results are indicative of mediatory roles of Rac and cytosolic phospholipase A(2) in the signaling pathway by which Ha-Ras(V12) transactivates c-fos SRE and transformation. Our findings point to cytosolic phospholipase A(2) as a novel potential target for suppressing oncogenic Ha-Ras(V12) signaling in the cell.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwang Ju 500712, South Korea; Chonnam Natl Univ, Coll Pharm, Kwang Ju 500757, South Korea; Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Gwangju Institute of Science & Technology (GIST); Chonnam National University; Pusan National University	Kim, JH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwang Ju 500712, South Korea.	jkim@eunhasu.kjist.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1997, FEBS LETT, V407, P7, DOI 10.1016/S0014-5793(97)00289-5; Kim BC, 1998, BIOCHEM J, V330, P1009, DOI 10.1042/bj3301009; Kim JH, 1997, FEBS LETT, V406, P93, DOI 10.1016/S0014-5793(97)00249-4; KIM JH, 1994, J BIOL CHEM, V269, P13740; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUMAR CC, 1992, CANCER RES, V52, P6877; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVERS SL, 1996, SIGNAL TRANSDUCTION, P143; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Oh J, 2000, FEBS LETT, V477, P244, DOI 10.1016/S0014-5793(00)01812-3; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WARNER LC, 1993, ONCOGENE, V8, P3249; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Woo CH, 2000, BIOCHEM BIOPH RES CO, V268, P231, DOI 10.1006/bbrc.2000.2102; Woo CH, 2000, BIOCHEM J, V348, P525, DOI 10.1042/0264-6021:3480525; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	49	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24645	24653		10.1074/jbc.M101975200	http://dx.doi.org/10.1074/jbc.M101975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323430	hybrid			2022-12-25	WOS:000169800700032
J	Bungert, S; Molday, LL; Molday, RS				Bungert, S; Molday, LL; Molday, RS			Membrane topology of the ATP binding cassette transporter ABCR and its relationship to ABC1 and related ABCA transporters - Identification of N-linked glycosylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STARGARDT MACULAR DYSTROPHY; DISEASE GENE ABCR; HUMAN P-GLYCOPROTEIN; ROD OUTER SEGMENTS; RETINITIS-PIGMENTOSA; RIM PROTEIN; TANGIER-DISEASE; DISK MEMBRANES; MUTATIONS; DEGENERATION	ABCR is a member of the ABCA subclass of ATP binding cassette transporters that is responsible for Stargardt macular disease and implicated in retinal transport across photoreceptor disc membranes. It consists of a single polypeptide chain arranged in two tandem halves, each having a multi-spanning membrane domain followed by a nucleotide binding domain. To delineate between several proposed membrane topological models, we have identified the exocytoplasmic (extracellular/lumen) N-linked glycosylation sites on ABCR, Using trypsin digestion, site-directed mutagenesis, concanavalin A binding, and endoglycosidase digestion, we show that ABCR contains eight glycosylation sites. Four sites reside in a 600-amino acid exocytoplasmic domain of the N-terminal half between the first transmembrane segment H1 and the first multi-spanning membrane domain, and four sites are in a 275-amino acid domain of the C half between transmembrane segment H7 and the second multi-spanning membrane domain. This leads to a model in which each half has a transmembrane segment followed by a large exocytoplasmic domain, a multi-spanning membrane domain, and a nucleotide binding domain. Other ABCA transporters, including ABC1 linked to Tangier disease, are proposed to have a similar membrane topology based on sequence similarity to ABCR. Studies also suggest that the N and C halves of ABCR are linked through disulfide bonds.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.				NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Klevering BJ, 1999, BRIT J OPHTHALMOL, V83, P914, DOI 10.1136/bjo.83.8.914; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 1999, BIOCHEMISTRY-US, V38, P5124, DOI 10.1021/bi982525y; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; MOLDAY RS, 1979, J BIOL CHEM, V254, P4653; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; Pullinger CR, 2000, BIOCHEM BIOPH RES CO, V271, P451, DOI 10.1006/bbrc.2000.2652; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Souied EH, 1999, INVEST OPHTH VIS SCI, V40, P2740; Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Zhao LX, 2000, BIOCHEM J, V350, P865, DOI 10.1042/0264-6021:3500865	41	115	125	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23539	23546		10.1074/jbc.M101902200	http://dx.doi.org/10.1074/jbc.M101902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320094	hybrid			2022-12-25	WOS:000169531100044
J	Lee, SH; Hannink, M				Lee, SH; Hannink, M			The N-terminal nuclear export sequence of I kappa B alpha is required for RanGTP-dependent binding to CRM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REL PROTEINS; SIGNAL; TRANSPORT; LOCALIZATION; ACTIVATION; RANGAP1; PATHWAY; COMPLEX; IMPORT	Nuclear export of I kappaB alpha is mediated by the CRM1 nuclear export receptor. However, the identity of the nuclear export sequences NES(s) in I kappaB alpha that are responsible for binding of I kappaB alpha to CRM1 is controversial. Both a N-terminal NES-like region (amino acids 45-54) and a C-terminal NES-like region (amino acids 265-280) have, in a number of reports from different laboratories, been implicated in CRM1-dependent nuclear export of I kappaB alpha. We now demonstrate that the N-terminal NES-like region, but not the C-terminal NES-like region, is required for RanGTP-dependent binding of I kappaB alpha to CRM1. I kappaB alpha is a relatively weak substrate for CRM1, with an affinity for CRM1 that is 100 fold less than the minute virus of mice NS2 protein, a high affinity cargo protein for CRM1, We also demonstrate that I kappaB alpha functions as a physical adaptor between CRM1 and NF kappaB/Rel proteins. Both free I kappaB alpha and Rel-associated I kappaB alpha have comparable affinities for CRM1, suggesting that CRM1 does not discriminate between free I kappaB alpha and Rel-associated I kappaB alpha. Nuclear export of c-Rel by I kappaB alpha requires the N-terminal NES-like sequence of I kappaB alpha but is not affected by alanine substitutions within the C-terminal NES-like sequence of I kappaB alpha. In contrast, nuclear export of the v-Rel oncoprotein by I kappaB alpha is disrupted by alanine substitutions within either the N-terminal or the C-terminal NES-like sequences. However, alanine substitutions within the C-terminal NES-like sequence significantly reduce the affinity of I kappaB alpha for v-Rel, suggesting that loss of export function for this mutant is secondary to reduced association between I kappaB alpha and v-Rel, Taken together, our results demonstrate that the N-terminal NES-like sequence in I kappaB alpha is required for RanGTP-dependent binding of both free I kappaB alpha and NF kappaB/Rel-associated I kappaB alpha proteins to CRM1.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Hannink, M (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65212 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059213] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM59213] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREZANASEISDEDO.F, 1997, J CELL SCI, V110, P369; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J, 1989, MOL CLOINING LAB MAN; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000	25	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23599	23606		10.1074/jbc.M011197200	http://dx.doi.org/10.1074/jbc.M011197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319224	hybrid			2022-12-25	WOS:000169531100051
J	Smaili, SS; Stellato, KA; Burnett, P; Thomas, AP; Gaspers, LD				Smaili, SS; Stellato, KA; Burnett, P; Thomas, AP; Gaspers, LD			Cyclosporin A inhibits inositol 1,4,5-trisphosphate-dependent Ca2+ signals by enhancing Ca2+ uptake into the endoplasmic reticulum and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; RAT-LIVER MITOCHONDRIA; ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOSOLIC CALCIUM OSCILLATIONS; CELL-DEATH; DIFFERENTIAL MODULATION; BINDING-PROTEIN; GENE-EXPRESSION; CYCLOPHILIN-D; RECEPTOR	Cytosolic Ca2+ ([Ca2+](i)) oscillations may be generated by the inositol 1,4,5-trisphosphate receptor (IP3R) driven through cycles of activation/inactivation by local Ca2+. feedback. Consequently, modulation of the local Ca2+ gradients influences IP3R excitability as well as the duration and amplitude of the [Ca2+](i) oscillations. In the present work, we demonstrate that the immunosuppressant cyclosporin A (CSA) reduces the frequency of IP3-dependent [Ca2+](i) oscillations in intact hepatocytes, apparently by altering the local Ca2+ gradients. Permeabilized cell experiments demonstrated that CSA lowers the apparent IF, sensitivity for Ca2+ release from intracellular stores. These effects on IP3-dependent [Ca2+](i) signals could not be attributed to changes in calcineurin activity, altered ryanodine receptor function, or impaired Ca2+ fluxes across the plasma membrane. However, CSA enhanced the removal of cytosolic Ca2+ by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), lowering basal and interspike [Ca2+](i). In addition, CSA stimulated a stable rise in the mitochondrial membrane potential (Delta psi (m)), presumably by inhibiting the mitochondrial permeability transition pore, and this was associated with increased Ca2+ uptake and retention by the mitochondria during a rise in [Ca2+](i). We suggest that CSA suppresses local Ca2+ feedback by enhancing mitochondrial and endoplasmic reticulum Ca2+ uptake, these actions of CSA underlie the lower IP3 sensitivity found in permeabilized cells and the impaired IP3-dependent [Ca2+](i) signals in intact cells. Thus, CSA binding proteins (cyclophilins) appear to fine tune agonist-induced [Ca2+](i) signals, which, in turn, may adjust the output of downstream Ca2+-sensitive pathways.	New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA; Univ Fed Sao Paulo, Dept Farmacol, UNIFESP EPM, BR-04044 Sao Paulo, Brazil	Rutgers State University New Brunswick; Rutgers State University Medical Center; Universidade Federal de Sao Paulo (UNIFESP)	Gaspers, LD (corresponding author), New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.		Smaili, Soraya/AAH-2129-2019; Gaspers, Lawrence/W-8766-2019; Thomas, Andrew/C-6755-2013	Smaili, Soraya/0000-0001-5844-1368; Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Budd SL, 1996, J NEUROCHEM, V67, P2282; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Fall CP, 1999, BBA-BIOENERGETICS, V1410, P77, DOI 10.1016/S0005-2728(98)00177-7; FLIRI H, 1993, ANN NY ACAD SCI, V696, P47; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1098, P61; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUNTER KK, 1991, J BIOL CHEM, V266, P21640; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HOEK JB, 1995, BBA-MOL BASIS DIS, V1271, P93, DOI 10.1016/0925-4439(95)00015-V; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; JUNG DW, 1995, J BIOL CHEM, V270, P672, DOI 10.1074/jbc.270.2.672; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; KRONER H, 1986, BIOL CHEM H-S, V367, P483, DOI 10.1515/bchm3.1986.367.1.483; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Morgan AJ, 1999, METH MOL B, V114, P93; NATHANSON MH, 1994, GASTROENTEROLOGY, V106, P1349, DOI 10.1016/0016-5085(94)90030-2; NICCHITTA CV, 1985, J BIOL CHEM, V260, P3613; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Ramesh V, 1998, ANN NY ACAD SCI, V853, P341, DOI 10.1111/j.1749-6632.1998.tb08295.x; Reddy PA, 1999, INT J BIOL MACROMOL, V25, P345, DOI 10.1016/S0141-8130(99)00053-7; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Robb-Gaspers LD, 1998, BBA-BIOENERGETICS, V1366, P17, DOI 10.1016/S0005-2728(98)00118-2; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SCHREIER MH, 1993, TRANSPLANT P, V25, P502; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Smaili SS, 1999, CELL CALCIUM, V26, P121, DOI 10.1054/ceca.1999.0061; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	71	51	52	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23329	23340		10.1074/jbc.M100989200	http://dx.doi.org/10.1074/jbc.M100989200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323421	hybrid			2022-12-25	WOS:000169531100017
J	Bigger, BW; Tolmachov, O; Collombet, JM; Fragkos, M; Palaszewski, I; Coutelle, C				Bigger, BW; Tolmachov, O; Collombet, JM; Fragkos, M; Palaszewski, I; Coutelle, C			An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; MUTANT LOX SITES; ESCHERICHIA-COLI; INFLAMMATORY RESPONSE; PLASMID DNA; CPG MOTIFS; GENOME; INTEGRATION; DELIVERY; PROMOTER	The presence of CpG motifs and their associated sequences in bacterial DNA causes an immunotoxic response following the delivery of these plasmid vectors into mammalian hosts. We describe a biotechnological approach to the elimination of this problem by the creation of a bacterial ore recombinase expression system, tightly controlled by the arabinose regulon, This permits the Cre-mediated and -directed excision of the entire bacterial vector sequences from plasmid constructs to create supercoiled gene expression minicircles for gene therapy. Minicircle yields using standard culture volumes are sufficient for most in vitro and in vivo ap plications whereas minicircle expression in vitro is significantly increased over standard plasmid transfection. By the simple expedient of removing the bacterial DNA complement, we significantly reduce the size and CpG content of these expression vectors, which should also reduce DNA-induced inflammatory responses in a dose dependent manner. We further describe the generation of minicircle expression vectors for mammalian mitochondrial gene therapy, for which no other vector systems currently exist. The removal of bacterial vector sequences should permit appropriate transcription and correct transcriptional cleavage from the mitochondrial minicircle constructs in a mitochondrial environment and brings the realization of mitochondrial gene therapy a step closer.	Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Cyst Fibrosis Gene Therapy Grp, London SW7 2AZ, England	Imperial College London	Bigger, BW (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Cyst Fibrosis Gene Therapy Grp, SAF Bldg,Exhibit Rd, London SW7 2AZ, England.	b.bigger@ic.ac.uk	Fragkos, Michalis/GQQ-1030-2022; Bigger, Brian/I-3553-2012	Fragkos, Michalis/0000-0003-2721-4327; Tolmachov, Oleg/0000-0002-6926-4229; Bigger, Brian/0000-0002-9708-1112				ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ALBERT H, 1995, PLANT J, V7, P649, DOI 10.1046/j.1365-313X.1995.7040649.x; Araki K, 1997, NUCLEIC ACIDS RES, V25, P868, DOI 10.1093/nar/25.4.868; Aristidou AA, 1999, BIOTECHNOL PROGR, V15, P140, DOI 10.1021/bp980115v; Bigger B, 2000, ANAL BIOCHEM, V277, P236, DOI 10.1006/abio.1999.4382; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P3118, DOI 10.1093/nar/24.15.3118; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; Collombet JM, 1997, J BIOL CHEM, V272, P5342, DOI 10.1074/jbc.272.8.5342; Darquet AM, 1997, GENE THER, V4, P1341, DOI 10.1038/sj.gt.3300540; Darquet AM, 1999, GENE THER, V6, P209, DOI 10.1038/sj.gt.3300816; Gschaedler A, 1999, BIOTECHNOL BIOENG, V63, P712, DOI 10.1002/(SICI)1097-0290(19990620)63:6<712::AID-BIT9>3.0.CO;2-R; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAHN S, 1984, J MOL BIOL, V180, P61, DOI 10.1016/0022-2836(84)90430-3; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HIRSH J, 1973, J MOL BIOL, V80, P433, DOI 10.1016/0022-2836(73)90414-2; KAZAKOVA TB, 1983, GENETIKA+, V19, P381; KOSIBA BE, 1982, J MOL BIOL, V156, P53, DOI 10.1016/0022-2836(82)90458-2; Kreiss P, 1998, APPL MICROBIOL BIOT, V49, P560, DOI 10.1007/s002530051213; Krieg AM, 2000, MOL THER, V1, P209, DOI 10.1006/mthe.2000.0041; Krieg AM, 1999, J GENE MED, V1, P56, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<56::AID-JGM5>3.3.CO;2-Y; Krieg AM, 1996, J LAB CLIN MED, V128, P128, DOI 10.1016/S0022-2143(96)90004-9; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Leahy P, 1997, NUCLEIC ACIDS RES, V25, P449, DOI 10.1093/nar/25.2.449; McLachlan G, 2000, GENE THER, V7, P384, DOI 10.1038/sj.gt.3301097; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V2; Norman J, 2000, GENE THER, V7, P1425, DOI 10.1038/sj.gt.3301240; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; OJALA D, 1980, CELL, V22, P393, DOI 10.1016/0092-8674(80)90350-5; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; Sambrook J., 2002, MOL CLONING LAB MANU; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; SWARTZ MN, 1962, J BIOL CHEM, V237, P1961; TOLMACHOV OE, 1990, BIOTEKHNOLOGIYA, V1, P25; Wheeler VC, 1996, GENE, V169, P251, DOI 10.1016/0378-1119(95)00812-8; Wheeler VC, 1997, GENE, V198, P203, DOI 10.1016/S0378-1119(97)00315-6; Yew NS, 2000, MOL THER, V1, P255, DOI 10.1006/mthe.2000.0036; Yew NS, 1999, HUM GENE THER, V10, P223, DOI 10.1089/10430349950019011	38	116	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23018	23027		10.1074/jbc.M010873200	http://dx.doi.org/10.1074/jbc.M010873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304530	hybrid			2022-12-25	WOS:000169412700138
J	Shao, RG; Cao, CX; Nieves-Neira, W; Dimanche-Boitrel, MT; Solary, E; Pommier, Y				Shao, RG; Cao, CX; Nieves-Neira, W; Dimanche-Boitrel, MT; Solary, E; Pommier, Y			Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells	ONCOGENE			English	Article						Bar; caspase; FADD; z-VAD; nuclease; programmed cell death	DRUG-INDUCED APOPTOSIS; CANCER-CELLS; TOPOISOMERASE-I; CUTTING EDGE; DNA-DAMAGE; WILD-TYPE; DEATH; CD95; CYTOTOXICITY; EXPRESSION	The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line. CPT-induced apoptosis was associated with high molecular weight DNA fragmentation as measured by filter elution, This fragmentation was inhibited by the caspase inhibitor, z-VAD-fmk and by cycloheximide, which also prevented proteolytic activation of caspase-3 and poly(ADP-ribose)polymerase cleavage. Under such conditions, Fas, Fas ligand, Bar, and p21 expression were increased and Fas recruited the FADD adaptor. Fas expression increase was blocked by cycloheximide but not by z-VAD-fmk, consistent with caspase activation downstream from Fas, Treatment of HT29 cells with Fast or with the CH-11 agonistic anti-Fas antibody potentiated the apoptotic response of cells treated with CPT, The anti-Fas blocking antibody ZB4 and the Fas-ligand inhibitor failed to protect HT29 cells from CPT-induced apoptosis, Such a protection was obtained by transient expression of constructs encoding a dominant-negative mutant of FADD, FADD in an antisense orientation and E8 or MC159 viral proteins that inhibit Fas-induced apoptosis at the level of FADD and procaspase-8, respectively. Together, these data show that topoisomerase I-mediated DNA damage-induced apoptosis involves activation of the Fas pathway without detectable Fas-ligand requirement in CPT-treated cells.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Fac Med & Pharm Dijon, INSERM U517, Dept Biol & Therapy Canc, Dijon, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 4E28, Bethesda, MD 20892 USA.		Dimanche-Boitrel, Marie-Therese M/I-4642-2015	Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Favre-Felix N, 2000, J IMMUNOL, V164, P5023, DOI 10.4049/jimmunol.164.10.5023; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Goldwasser F, 1996, CANCER RES, V56, P4430; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Khodarev NN, 1998, INT J RADIAT BIOL, V73, P455; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Memon SA, 1998, J IMMUNOL, V160, P2046; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MIYASHITA T, 1995, CELL, V80, P293; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OConnor PM, 1997, CANCER RES, V57, P4285; OCONNOR PM, 1991, CANCER COMMUN, V3, P233, DOI 10.3727/095535491820873083; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Rusnak JM, 1996, MOL PHARMACOL, V49, P244; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SHIMIZU T, 1995, CANCER RES, V55, P228; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Villunger A, 1997, CANCER RES, V57, P3331; ZHAN QM, 1995, INT J ONCOL, V6, P937	44	70	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1852	1859		10.1038/sj.onc.1204264	http://dx.doi.org/10.1038/sj.onc.1204264			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313933				2022-12-25	WOS:000167908400006
J	Cures, A; House, C; Kanei-Ishii, C; Kemp, B; Ramsay, RG				Cures, A; House, C; Kanei-Ishii, C; Kemp, B; Ramsay, RG			Constitutive c-Myb amino-terminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle	ONCOGENE			English	Article						c-Myb; casein kinase 2; DNA binding; phosphorylation	PROTO-ONCOGENE; LEUCINE-ZIPPER; MESSENGER-RNA; EXPRESSION; PROLIFERATION; ACTIVATION; PROTEINS; GENE; DIFFERENTIATION; INHIBITION	The c-myb gene encodes a transcription factor that is central to hematopoietic cell growth, Phosphorylation of c-Myb by casein kinase 2 (CK2) at serines 11 and 12 has been variously implicated in the regulation of DNA binding. However, it is unclear when c-Myb phosphorylation at serines II and 12 occurs during the cell cycle and how this is regulated, We generated specific antisera that recognize phosphoserines II and 12 of c-Myb, C-Myb protein levels, extent of CK2 phosphorylation and DNA binding were then monitored following mitogenic stimulus and passage through the cell cycle in normal peripheral T-cells and the T leukemia cell line CCRF-CEM, We found that endogenous c-Myb is constitutively phosphorylated at serines 11 and 12, The amount of phosphorylated c-Myb correlates with DNA binding activity in cycling CEM cells but not upon entry of T-cells into the cell cycle, Exogenous expression of c-Myb with substitutions of serines 11 and 12 with glutamic acid or alanine had no effect on the transactivation of a c-Myb responsive reporter. These data strongly suggest that c-Myb is constitutively phosphorylated on serines 11 and 12 by CK2 or like activity and is not regulated during the cell cycle.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3000, Australia; RIKEN, Tsukuba Inst, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan	Peter Maccallum Cancer Center; RIKEN	Ramsay, RG (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, 481 Little Lonsdale St, Melbourne, Vic 3000, Australia.		Ramsay, Robert G/C-3291-2015; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Ramsay, Robert G/0000-0001-5003-0433; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1991, BLOOD, V77, P149; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCARTHY RE, 1965, EXP CELL RES, V40, P197, DOI 10.1016/0014-4827(65)90316-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NORMAN MR, 1977, CANCER RES, V37, P3785; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; Ramsay R G, 1995, Methods Mol Biol, V37, P369; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1995, ONCOGENE, V11, P2113; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sala A, 1996, CANCER RES, V56, P1991; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TIGANIS T, 1993, BIOCHIM BIOPHYS ACTA, V1203, P282, DOI 10.1016/0167-4838(93)90095-9; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Zorbas M, 1999, ONCOGENE, V18, P5821, DOI 10.1038/sj.onc.1202971	38	14	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1784	1792		10.1038/sj.onc.1204345	http://dx.doi.org/10.1038/sj.onc.1204345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313925				2022-12-25	WOS:000167750900011
J	Turton, NJ; Judah, DJ; Riley, J; Davies, R; Lipson, D; Styles, JA; Smith, AG; Gant, TW				Turton, NJ; Judah, DJ; Riley, J; Davies, R; Lipson, D; Styles, JA; Smith, AG; Gant, TW			Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance	ONCOGENE			English	Article						multidrug resistance; cDNA microarrays; differential gene expression; genomic amplification; doxorubicin resistance; breast cancer	CANCER-CELLS; P-GLYCOPROTEIN; PATTERNS; OVEREXPRESSION; METASTASIS; INVASION; ANTIGEN; DISPLAY; LINES	The multidrug resistance (MDR) phenotype is a major cause of cancer treatment failure. Here the expressions of 4224 genes were analysed for association with intrinsic or acquired doxorubicin (DOX) resistance. A cluster of overexpressed genes related to DOX resistance was observed. Included in this cluster was ABCB1 the P-glycoprotein transporter protein gene and MMPI (Matrix Metalloproteinase 1), indicative of the invasive nature of resistant cells, and the oxytocin receptor (OXTR), a potential new therapeutic target. Overexpression of genes associated with xenobiotic transformation, cell transformation, cell signalling and lymphocyte activation was also associated with DOX resistance as was estrogen receptor negativity, In all carcinoma cells, compared with HBL100 a putatively normal breast epithelial cell line, a cluster of overexpressed genes was identified which included several keratins, in particular keratins 8 and 18 which are regulated through the ras signalling pathway. Analysis of genomic amplifications and deletions revealed specific genetic alterations common to both intrinsic and acquired DOX resistance including ABCB1, PGY3 (ABCB4) and BAK, The findings shown here indicate new possibilities for the diagnosis of DOX resistance using gene expression, and potential novel therapeutic targets for pharmacological intervention.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Technion Israel Inst Technol, IL-32000 Haifa, Israel	University of Leicester; Technion Israel Institute of Technology	Gant, TW (corresponding author), Univ Leicester, MRC, Toxicol Unit, Lancaster Rd, Leicester LE1 9HN, Leics, England.			Gant, Timothy/0000-0001-9057-4937				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BATIST G, 1986, J BIOL CHEM, V261, P5544; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Blatchford DR, 1999, J CELL PHYSIOL, V181, P304, DOI 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 2000, J PATHOL, V190, P470, DOI 10.1002/(SICI)1096-9896(200003)190:4<470::AID-PATH550>3.0.CO;2-G; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHEN G, 1994, CANCER RES, V54, P4980; Davies R, 1996, BRIT J CANCER, V73, P307, DOI 10.1038/bjc.1996.54; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EISEN MB, 1999, DNA ARRAYS ANAL GENE, P179; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones JL, 1997, INT J ONCOL, V11, P609; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Martin K, 2000, CANCER RES, V60, P2232; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Stephen R, 1998, J MOL ENDOCRINOL, V20, P375, DOI 10.1677/jme.0.0200375; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; Vasudevan S, 1998, J BIOL CHEM, V273, P25413, DOI 10.1074/jbc.273.39.25413; WEINSTEIN RS, 1991, CANCER RES, V51, P2720	31	95	106	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1300	1306		10.1038/sj.onc.1204235	http://dx.doi.org/10.1038/sj.onc.1204235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313874				2022-12-25	WOS:000167495000004
J	Sugibayashi, R; Shimizu, T; Suzuki, T; Yamamoto, N; Hamada, H; Takeda, K				Sugibayashi, R; Shimizu, T; Suzuki, T; Yamamoto, N; Hamada, H; Takeda, K			Upregulation of p21(WAF1/CIP1) leads to morphologic changes and esterase activity in TPA-mediated differentiation of human prostate cancer cell line TSU-Pr1	ONCOGENE			English	Article						prostate cancer; TSU-Prl; differentiation; TPA; p21(WAF1/CIF1)	PROTEIN-KINASE-C; LEUKEMIA-CELLS; DOWN-REGULATION; PHORBOL ESTERS; CYCLE ARREST; MAP KINASE; EXPRESSION; GROWTH; P21; INHIBITOR	We reported previously that human prostate cancer cell line TSU-Pr1 can differentiate into microglia-like cells by 12-O-tetra-decanoylphorbol-13-acetate (TPA) treatment. In this study, we identified a signal transduction pathway involved in TPA-induced TSU-Pr1 cell differentiation and investigated the mechanism of growth arrest that accompanies this differentiation. TPA-induced differentiation and growth arrest of TSU-Pr1 cells were inhibited by treatment with Protein kinase C (PKC) inhibitor GF109203X and mitogen-activated protein (MAP) kinase inhibitor PD98059, Treatment of TSU-Pr1 cells with TPA for 15 min or longer resulted in translocation of PKC alpha, PKC gamma, and PKC epsilon from cytosolic to membrane fraction. Our results suggest that TPA-induced TSU-Pr1 cell differentiation is associated with activation of MAP kinase and PKC alpha, PKC gamma, and PKC epsilon, The mechanism of growth arrest in TSU-Pr1 cells that underwent TPA-induced differentiation were examined for factors in the signaling pathway downstream of MAP kinase that control the cell cycle. Upregulation of p21(WAF1/CIP1) cyclin-dependent kinase inhibitor protein was observed in a manner dependent on PKC or MAP kinase, Moreover, adenovirus-mediated overexpression of recombinant p21(WAF1/CP1) in TSU-Pr1 cells result in growth arrest, morphological change to microglia-like cells, and increased alpha -naphthyl acetate esterase activity, all of which are associated with cellular differentiation. Thus, our results indicate that p21(WAF1/CIP1) mediates TPA-induced growth arrest and differentiation of TSU-Pr1 cells.	Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, Tokyo 1620826, Japan; Sapporo Med Univ, Dept Mol Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Tokyo University of Science; Sapporo Medical University	Takeda, K (corresponding author), Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, 12 Ichigaya Funagawara Machi, Tokyo 1620826, Japan.							Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Barboule N, 1999, FEBS LETT, V444, P32, DOI 10.1016/S0014-5793(99)00022-8; BARENDSEN N, 1990, LEUKEMIA RES, V14, P467, DOI 10.1016/0145-2126(90)90034-7; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen J, 1996, ONCOGENE, V13, P1395; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Frey MR, 1997, J BIOL CHEM, V272, P9424; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; HEIKKILA J, 1993, BIOCHEM BIOPH RES CO, V197, P1185, DOI 10.1006/bbrc.1993.2602; HEIKKILA JE, 1989, J CELL PHYSIOL, V140, P593, DOI 10.1002/jcp.1041400326; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUPPI K, 1994, ONCOGENE, V9, P3017; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Itayasu T, 1998, ANTICANCER RES, V18, P113; JIANG HP, 1994, ONCOGENE, V9, P3397; Joshi US, 1998, PANCREAS, V16, P107, DOI 10.1097/00006676-199803000-00001; Joshi US, 1998, CANCER GENE THER, V5, P183; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Kiley S C, 1994, Trends Cell Biol, V4, P223, DOI 10.1016/0962-8924(94)90146-5; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Liu J, 2000, J BIOL CHEM, V275, P11846, DOI 10.1074/jbc.275.16.11846; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V264, P457, DOI 10.1006/bbrc.1999.1516; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIKAWA M, 1986, LIFE SCI, V39, P1101, DOI 10.1016/0024-3205(86)90202-X; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Takahashi N, 2000, PROSTATE, V44, P328, DOI 10.1002/1097-0045(20000901)44:4<328::AID-PROS10>3.0.CO;2-8; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; YAMAUCHI Y, 1989, BRIT J CANCER, V60, P15, DOI 10.1038/bjc.1989.211; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	59	13	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1220	1228		10.1038/sj.onc.1204206	http://dx.doi.org/10.1038/sj.onc.1204206			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313866				2022-12-25	WOS:000167570100009
J	Daniel, L; Durbec, P; Gautherot, E; Rouvier, E; Rougon, G; Figarella-Branger, D				Daniel, L; Durbec, P; Gautherot, E; Rouvier, E; Rougon, G; Figarella-Branger, D			A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process	ONCOGENE			English	Article						PSA; adhesion; metastasis; nude mice; carcinogenesis	CELL-ADHESION MOLECULE; N-CAM; NEUROECTODERMAL TUMORS; MONOCLONAL-ANTIBODY; NEURONAL MIGRATION; OLFACTORY-BULB; NCAM; EXPRESSION; PROGRESSION; MOUSE	PSA is an oncodevelopmental antigen usually expressed in human tumors with high metastatic potential. Here we set up a metastatic model in nude mice by using TE671 cells, which strongly express PSA-NCAM. We observed the formation of lung metastases when TE671 cells were injected intravenously, intramuscularly, and intraperitoneously, hut not subcutaneously. Intraperitoneous injections also induced peritoneal carcinosis, ascites, and liver metastases. To evaluate the putative role of PSA in the metastatic process we used a specific cleavage of PSA on NCAM by endoneuraminidase-N on intraperitoneous primary tumors. Mice with primary intramuscular tumors were taken as control. Repeated injections of endoneuraminidase-N led to a decrease in PSA expression in primary intraperitoneous nodules and ascites but not in intramuscular primary tumors. Endoneuraminidase-N also increased the delay in ascitic formation and decreased the number of lung or liver metastases in the case of intraperitoneous tumors but not in the case of intramuscular tumors. When metastases occurred in endoneuraminidase-N injected animals, they strongly expressed PSA-NCAM. Therefore, we established a relationship between PSA expression on the surface of primary tumor cells and the metastatic process.	Fac Med, Inst Biol Dev Marseille, Lab Biopathol Nerveuse & Musculaire, F-13385 Marseille 05, France; CNRS, Lab Genet & Physiol Dev, F-13288 Marseille 09, France; Immunotech SA, Dept Imagerie & Therapeut, F-13009 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Figarella-Branger, D (corresponding author), Fac Med, Inst Biol Dev Marseille, Lab Biopathol Nerveuse & Musculaire, JE2053,27 Bd Jean Moulin, F-13385 Marseille 05, France.		ROUGON, Genevieve/G-2578-2013; daniel, laurent/R-2826-2016	ROUGON, Genevieve/0000-0003-1316-8200; daniel, laurent/0000-0002-7539-0109				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; Barr FG, 1997, J PEDIAT HEMATOL ONC, V19, P483, DOI 10.1097/00043426-199711000-00001; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Daniel L, 2000, CANCER RES, V60, P80; DUBOIS C, 1995, J IMMUNOL METHODS, V181, P125, DOI 10.1016/0022-1759(94)00336-U; FigarellaBranger D, 1996, J CLIN ONCOL, V14, P2066, DOI 10.1200/JCO.1996.14.7.2066; FIGARELLABRANGER D, 1992, J NEUROPATH EXP NEUR, V51, P12, DOI 10.1097/00005072-199201000-00003; FIGARELLABRANGER DF, 1990, CANCER RES, V50, P6364; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; GAFFNEY EF, 1993, AM J SURG PATHOL, V17, P601, DOI 10.1097/00000478-199306000-00008; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; Gluer S, 1998, PEDIATR RES, V43, P145, DOI 10.1203/00006450-199801000-00022; GOKAL R, 1992, OXFORD TXB CLIN NEPH, P1477; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; HUSMANN M, 1989, EUR J IMMUNOL, V19, P1761, DOI 10.1002/eji.1830190935; KUBOTA T, 1994, J CELL BIOCHEM, V56, P4, DOI 10.1002/jcb.240560103; LACKIE PM, 1990, DEVELOPMENT, V110, P933; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; MCALLISTER RM, 1977, INT J CANCER, V20, P206, DOI 10.1002/ijc.2910200207; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; OUSMENAR BN, 1995, EUR J NEUROSCI, V7, P480; PARISH RW, 1987, J CELL SCI, P181; Rapoport J, 1999, NEPHRON, V81, P375, DOI 10.1159/000045319; ROUGON G, 1986, J BIOL CHEM, V261, P3396; ROUGON G, 1993, EUR J CELL BIOL, V61, P197; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; ROUGON G, 1993, POLYSIALIC ACID MICR, P323; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SILOBRCIC V, 1990, INT J CANCER, V45, P325, DOI 10.1002/ijc.2910450220; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; STRATTON MR, 1989, NATURE, V337, P311, DOI 10.1038/337311c0; Theodosis DT, 1999, J NEUROSCI, V19, P10228; TOGO S, 1995, CANCER RES, V55, P681; WANG C, 1994, J NEUROSCI, V14, P4446; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	42	61	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					997	1004		10.1038/sj.onc.1204176	http://dx.doi.org/10.1038/sj.onc.1204176			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314035				2022-12-25	WOS:000167097000011
J	Rozovskaia, T; Feinstein, E; Mor, O; Foa, R; Blechman, J; Nakamura, T; Croce, CM; Cimino, G; Canaani, E				Rozovskaia, T; Feinstein, E; Mor, O; Foa, R; Blechman, J; Nakamura, T; Croce, CM; Cimino, G; Canaani, E			Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality	ONCOGENE			English	Article						Meis1; HoxA9; acute lymphocytic leukemias	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; ALL-1 GENE; EXPRESSION; FUSION; CELLS; HRX; T(7-11)(P15-P15)	Rearrangements of the human ALL-1 gene are frequently encountered in acute lymphocytic leukemias (ALL) and acute myeloid leukemias (AML), These rearrangements are mostly due to chromosome translocations and result in production of chimeric proteins composed of the N-terminal fragment of ALL-1 and the C-terminal segments of the partner proteins. The most common chromosome translocation involving ALL-I is the t(4:11) associated with ALL. ALL-1 is the human homologue of Drosophila trithorax and directly activates transcription of multiple Hox genes. A preliminary DNA microarray screen indicated that the Meis1, HoxA9 and AC133 genes were overexpressed in ALLs with t(4:11), compared to ALLs with very similar phenotype but without the chromosomal abnormality. These genes, as well as additional five Hox genes, were subjected to comprehensive semi-quantitative or quantitative RT-PCR analysis in 57 primary ALL and AML tumors. Meis1 and HoxA9 were found expressed in 13/14 of ALLs with the t(4:11) and in 8/8 of AMLs with ALL-1 rearrangements. The two genes were not consistently transcribed in other types of ALL, AC133 was transcribed in 13/14 of ALLs with t(4:11), but in only 4/8 of AMLs with ALL-1 rearrangements. HoxA10 was expressed in most leukemias with ALL-1 alterations, but was also transcribed in PrePreB CD10(-) ALLs lacking the t(4 : 11). Expression of HoxA5, HoxA7, HoxC8 and HoxC10 did not correlate with ALL-1 rearrangements. Coexpression of Meis1 and HoxA9, overexpression of HoxA10, and overexpression or fusion of HoxA9 were previously implicated in certain acute myeloid leukemias in mice and humans. The present work suggests that upregulation of Meis1, HoxA9, and possibly HoxA10 might also play a role in pathogenesis of acute lymphocytic and acute myeloid leukemias associated with ALL-1 fusions.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, BLSB, Philadelphia, PA 19107 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ouark Biotech Inc, Pleasanton, CA USA; Univ La Sapienza, Dept Human Biopathol, I-00161 Rome, Italy	Jefferson University; Weizmann Institute of Science; Sapienza University Rome	Canaani, E (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, BLSB, Room 608,233 S 10th St, Philadelphia, PA 19107 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; CIMINO, Giuseppe/0000-0002-7781-0816	NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O., 1997, Blood, V90, p67A; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Buhring HJ, 1999, BLOOD, V94, P832, DOI 10.1182/blood.V94.2.832.414a50_832_833; CHEN CS, 1993, BLOOD, V81, P2386; CIMINO G, 1995, LEUKEMIA, V9, P391; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRIESINGER F, 1994, LEUKEMIA, V8, P542; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HOFFMAN R, 2000, HEMATOLOGY BASIC PRI; HUNGER SP, 1993, BLOOD, V81, P3197; Johansson B, 1998, LEUKEMIA, V12, P779, DOI 10.1038/sj.leu.2401012; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lee G, 1999, WINTROBES CLIN HEMAT; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MOSCOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Tillib S, 1999, MOL CELL BIOL, V19, P5189; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	39	131	138	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					874	878		10.1038/sj.onc.1204174	http://dx.doi.org/10.1038/sj.onc.1204174			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314021				2022-12-25	WOS:000166924400011
J	Fleisher, AS; Esteller, M; Tamura, G; Rashid, A; Stine, OC; Yin, J; Zou, TT; Abraham, JM; Kong, DH; Nishizuka, S; James, SP; Wilson, KT; Herman, JG; Meltzer, SJ				Fleisher, AS; Esteller, M; Tamura, G; Rashid, A; Stine, OC; Yin, J; Zou, TT; Abraham, JM; Kong, DH; Nishizuka, S; James, SP; Wilson, KT; Herman, JG; Meltzer, SJ			Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia	ONCOGENE			English	Article						hypermethylation; hMLH1; microsatellite instability; mismatch repair; gastric cancer; gastric neoplasia	HELICOBACTER-PYLORI INFECTION; REPLICATION ERROR PHENOTYPE; DIFFERENTIATED TYPE; CANCER; METHYLATION; EXPRESSION; CARCINOMA; DNA; TUMORS; INACTIVATION	A significant portion of gastric cancers exhibit defective DNA mismatch repair, manifested as microsatellite instability (MSI). High-frequency MSI (MSI-H) is associated with hypermethylation of the human mut-L homologue 1 (hMLH1) mismatch repair gene promoter and diminished hMLH1 expression in advanced gastric cancers, However, the relationship between MSI and hMLH1 hypermethylation has not been studied in early gastric neoplasms, We therefore investigated hMLH1 hypermethylation, hMLH1 expression and MSI in a group of early gastric cancers and gastric adenomas, Sixty-four early gastric neoplasms mere evaluated, comprising 28 adenomas, 18 mucosal carcinomas, and 18 carcinomas with superficial submucosal invasion but clear margins, MSI was evaluated using multiplex fluorescent PCR to amplify loci D2S123, D5S346, D17S250, BAT 25 and BAT 26, Methylation-specific PCR was performed to determine the methylation status of hMLH1. In two hypermethylated MSI-H cancers, hMLH1 protein expression was also evaluated by immunohistochemistry. Six of sixty-four early gastric lesions were MSI-H, comprising 1 adenoma, 4 mucosal carcinomas, and 1 carcinoma with superficial submucosal invasion, Two lesions tone adenoma and one mucosal carcinoma) demonstrated low-frequency MSI (MSI-L), The remaining 56 neoplasms were MSI-stable (MSI-S), Six of six MSI-H, one of two MSI-L, and none of thirty MSI-S lesions showed hMLH1 hypermethylation (P < 0.001), Diminished hMLH1 protein expression was demonstrated by immunohistochemistry in two of two MSI-H hypermethylated lesions, hMLH1 promoter hypermethylation is significantly associated with MSI and diminished hMLH1 expression in early gastric neoplasms, MSI and hypermethylation-associated inactivation of hMLH1 are more prevalent in early gastric cancers than in gastric adenomas, Thus, hypermethylation-associated inactivation of the hMLH1 gene can occur early in gastric carcinogenesis.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Genet Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Yamagata Univ, Sch Med, Dept Pathol, Yamagata 990, Japan; Univ Calif Irvine, Dept Mol Genet & Microbiol, Irvine, CA USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Yamagata University; University of California System; University of California Irvine	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Wilson, Keith/0000-0003-4421-1830	NATIONAL CANCER INSTITUTE [R01CA078843, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA85069, CA78843] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Boland CR, 1998, CANCER RES, V58, P5248; Claij N, 1999, EXP CELL RES, V246, P1, DOI 10.1006/excr.1998.4299; CORREA P, 1994, CANCER RES, V54, pS1941; CRAANEN ME, 1992, AM J GASTROENTEROL, V87, P572; Cunningham JM, 1998, CANCER RES, V58, P3455; DosSantos NR, 1996, GASTROENTEROLOGY, V110, P38, DOI 10.1053/gast.1996.v110.pm8536886; Driessen A, 1999, GASTROEN CLIN BIOL, V23, P747; ECKARDT VF, 1990, GASTROENTEROLOGY, V98, P708, DOI 10.1016/0016-5085(90)90292-9; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fleisher AS, 1999, CANCER RES, V59, P1090; FUKUTOMI H, 1984, JPN J CLIN ONCOL, V14, P169; Halling KC, 1999, AM J PATHOL, V155, P205, DOI 10.1016/S0002-9440(10)65114-0; HAN HJ, 1993, CANCER RES, V53, P5087; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoang JM, 1997, CANCER RES, V57, P300; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Isogaki J, 1999, CANCER DETECT PREV, V23, P204, DOI 10.1046/j.1525-1500.1999.99020.x; Kane MF, 1997, CANCER RES, V57, P808; Kang GH, 1999, LAB INVEST, V79, P903; Karran P, 1996, CANCER SURV, V28, P69; Keller G, 1998, AM J PATHOL, V152, P1281; Kuipers EJ, 1998, ALIMENT PHARM THER, V12, P25, DOI 10.1111/j.1365-2036.1998.00009.x; Leach FS, 1996, CANCER RES, V56, P235; Leung SY, 1999, CANCER RES, V59, P159; ORLOW I, 1994, CANCER RES, V54, P2848; Ottini L, 1997, CANCER RES, V57, P4523; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; RHYU MG, 1994, ONCOGENE, V9, P29; Sasaki I, 1999, CANCER, V85, P1719, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1719::AID-CNCR11>3.3.CO;2-M; SAVIDES C, 1999, TUMORS STOMACH, V1, P1500; Semba S, 1996, CANCER, V77, P1620, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1620::AID-CNCR30>3.3.CO;2-P; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; SUZUKI H, 1994, CANCER RES, V54, P4841; Tamura G, 1996, PATHOL INT, V46, P834, DOI 10.1111/j.1440-1827.1996.tb03556.x; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; TOMASULO J, 1971, CANCER-AM CANCER SOC, V27, P1346, DOI 10.1002/1097-0142(197106)27:6<1346::AID-CNCR2820270612>3.0.CO;2-V; Wu MS, 1997, J GASTROEN HEPATOL, V12, P425, DOI 10.1111/j.1440-1746.1997.tb00460.x; Yin J, 1997, HUM MUTAT, V10, P474, DOI 10.1002/(SICI)1098-1004(1997)10:6<474::AID-HUMU9>3.0.CO;2-D; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	50	97	104	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					329	335		10.1038/sj.onc.1204104	http://dx.doi.org/10.1038/sj.onc.1204104			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313962				2022-12-25	WOS:000166411000007
J	Schlichter, U; Burk, O; Worpenberg, S; Klempnauer, KH				Schlichter, U; Burk, O; Worpenberg, S; Klempnauer, KH			The chicken Pdcd4 gene is regulated by v-Myb	ONCOGENE			English	Article						v-myb oncogene; target gene; differential display; Pdcd4	RECEPTOR FUSION PROTEIN; 2 DIFFERENT MECHANISMS; C-MYB; MIM-1 GENE; CELL-LINES; TOPOISOMERASE INHIBITORS; SYNERGISTIC ACTIVATION; MYELOMONOCYTIC CELLS; TRANS-ACTIVATION; MYELOID CELLS	The retroviral oncogene v-myb encodes a transcription factor (v-Myb) which is responsible for the ability of avian myeloblastosis virus (AMV) to transform mlyelomonocytic cells. v-Myb is thought to disrupt the differentiation of myelomonocytic cells by affecting the expression of specific target genes. To identify such genes we have analysed the gene expression in a myelomonocytic chicken cell Line that carries an estrogen inducible version of v-Myb by differential display, Here me describe the identification of the chicken homolog of the mouse Pdcd4 gene as a novel v-Myb target gene. Pdcd4 is also known as MA-3, TIS and H731 and has recently been shown to suppress the transformation of epidermal cells by tumor promoters. Our results provide the first evidence that v-Myb directly regulates the expression of a potential tumor suppressor gene.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							AKIYAMA Y, 1974, BIKEN J, V17, P105; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; PLAZA S, 1995, ONCOGENE, V10, P329; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Sitzmann J, 1995, ONCOGENE, V11, P2273; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wagner C, 1998, MAR BIOL, V131, P411, DOI 10.1007/s002270050334; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179	52	49	55	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					231	239		10.1038/sj.onc.1204071	http://dx.doi.org/10.1038/sj.onc.1204071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313950				2022-12-25	WOS:000166410900010
J	Mouchantaf, R; Kumar, U; Sulea, T; Patel, YC				Mouchantaf, R; Kumar, U; Sulea, T; Patel, YC			A conserved alpha-helix at the amino terminus of prosomatostatin serves as a sorting signal for the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROHORMONE CONVERTASE PC2; CARBOXYPEPTIDASE-E; CHROMOGRANIN-B; CPE(FAT)/CPE(FAT) MICE; VESICLE BIOGENESIS; HORMONE STORAGE; DISULFIDE BOND; GROWTH-HORMONE; CPE(FAT) MICE	Mammalian prosomatostatin (PSST) contains the bioactive peptides SST-14 and SST-28 at the COOH-terminal end of the molecule and a putative sorting signal in the propeptide segment for targeting the precursor to the regulated secretory pathway. The NH2-terminal segment of PSST consists of an amphipathic cu-helix, which has been totally conserved throughout vertebrate evolution. We have analyzed the PSST-(3-15) region for sorting function by alanine scanning and deletional mutagenesis, Mutants created were stably expressed in AtT-SO cells. Regulated secretion was studied by analyzing basal and stimulated release of SST-14 LI and by immunocytochemistry for staining of SST-14 LI in punctate granules. Deletion of the PSST-(3-15) segment blocked regulated secretion and rerouted PSST for constitutive secretion as unprocessed precursor. Alanine scanning mutagenesis identified the region Pro(5)-Gln(12) as being important in precursor targeting, with Leu(7) and Leu(11) being critical. Molecular modeling demonstrated that these two residues are located in close proximity on a hydrophobic surface of the alpha -helix. Disruption of the alpha -helix did not impair the ability of PSST to be processed at the COOH terminus to SST-14 and SST-28. Processing, however, was shifted to the early compartments of the secretory pathway rather than storage granules and was relatively inefficient.	McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Neurol & Neurosurg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Pharmacol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Therapeut, Montreal, PQ H3A 1A1, Canada; Montreal Neurol Inst, Montreal, PQ H3A 1A1, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; National Research Council Canada	Patel, YC (corresponding author), McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada.							Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BENOIT R, 1990, METABOLISM, V39, P22, DOI 10.1016/0026-0495(90)90202-N; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CASTLE AM, 1995, J CELL SCI, V108, P3827; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; GALANOPOULOU AS, 1995, BIOCHEM J, V309, P33, DOI 10.1042/bj3090033; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HALBAN PA, 1994, BIOCHEM J, V299, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; Lee MS, 2001, J BIOL CHEM, V276, P715, DOI 10.1074/jbc.M008530200; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOUCHANTAF R, 2000, P ANN M SOC NEUR NEW, P27; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PATEL YC, 1988, J BIOL CHEM, V263, P745; Patel YC, 1997, MOL CELL ENDOCRINOL, V131, P183, DOI 10.1016/S0303-7207(97)00107-X; RAVAZZOLA M, 1989, J CLIN INVEST, V83, P362, DOI 10.1172/JCI113892; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHMIDT WK, 1994, J BIOL CHEM, V269, P27115; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SEVARINO KA, 1991, J BIOL CHEM, V266, P18507; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Zhang CF, 1999, MOL ENDOCRINOL, V13, P527, DOI 10.1210/me.13.4.527	52	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26308	26316		10.1074/jbc.M102514200	http://dx.doi.org/10.1074/jbc.M102514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11309402	hybrid			2022-12-25	WOS:000169823300089
J	Aramli, LA; Teschke, CM				Aramli, LA; Teschke, CM			Alleviation of a defect in protein folding by increasing the rate of subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; PHAGE-P22 COAT PROTEIN; INCLUSION-BODY FORMATION; P22 TAILSPIKE PROTEIN; TEMPERATURE-SENSITIVE MUTATIONS; TAIL SPIKE PROTEIN; IN-VITRO; SCAFFOLDING PROTEIN; POLYPEPTIDE-CHAINS; ESCHERICHIA-COLI	Understanding the nature of protein grammar is critical because amino acid substitutions in some proteins cause misfolding and aggregation of the mutant protein resulting in a disease state. Amino acid substitutions in phage P22 coat protein, known as tsf (temperature-sensitive folding) mutations, cause folding defects that result in aggregation at high temperatures. We have isolated global su (suppressor) amino acid substitutions that alleviate the tsf phenotype in coat protein (Aramli, L. A. and Teschke, C. M. (1999) J. Biol. Chem. 274, 22217-22224). Unexpectedly, we found that a global su amino acid substitution in tsf coat proteins made aggregation worse and that the tsf phenotype was suppressed by increasing the rate of subunit assembly, thereby decreasing the concentration of aggregation-prone folding intermediates.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Teschke, CM (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, U-3125,75 N Eagleville Rd, Storrs, CT 06269 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053567, R29GM053567] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS AT, 1986, ELECTROPHORESIS THEO, P5; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Aramli LA, 1999, J BIOL CHEM, V274, P22217, DOI 10.1074/jbc.274.32.22217; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; Betts SD, 1998, PROTEIN SCI, V7, P1516, DOI 10.1002/pro.5560070704; BREMS DN, 1988, BIOCHEMISTRY-US, V27, P4541, DOI 10.1021/bi00412a048; Capen CM, 2000, BIOCHEMISTRY-US, V39, P1142, DOI 10.1021/bi991956t; CHRUNYK BA, 1993, J BIOL CHEM, V268, P18053; EARNSHAW W, 1980, J MOL BIOL, V134, P575; FANE B, 1991, GENETICS, V127, P263; FANE B, 1991, J BIOL CHEM, V266, P11640; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; FULLER MT, 1981, VIROLOGY, V112, P529, DOI 10.1016/0042-6822(81)90300-7; FULLER MT, 1980, BIOPHYS J, V32, P381, DOI 10.1016/S0006-3495(80)84963-0; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; Greene B, 1999, J BIOL CHEM, V274, P16135, DOI 10.1074/jbc.274.23.16135; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; Huang WZ, 1997, P NATL ACAD SCI USA, V94, P8801, DOI 10.1073/pnas.94.16.8801; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lanman J, 1999, BIOCHEMISTRY-US, V38, P14614, DOI 10.1021/bi9915420; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; McGee WA, 1998, PROTEIN SCI, V7, P1071, DOI 10.1002/pro.5560070501; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; Nakonechny WS, 1998, J BIOL CHEM, V273, P27236, DOI 10.1074/jbc.273.42.27236; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; PREVELIGE PE, 1993, PROG MED VIROL, V40, P206; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; Schuler B, 1998, J MOL BIOL, V281, P227, DOI 10.1006/jmbi.1998.1944; Sideraki V, 2001, P NATL ACAD SCI USA, V98, P283, DOI 10.1073/pnas.011454198; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SPEED MA, 1995, PROTEIN SCI, V4, P900; Teschke Carolyn M., 1992, Current Opinion in Biotechnology, V3, P468, DOI 10.1016/0958-1669(92)90073-R; Teschke CM, 1999, BIOCHEMISTRY-US, V38, P2873, DOI 10.1021/bi982739f; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; Teschke CM, 1996, BIOCHEMISTRY-US, V35, P14831, DOI 10.1021/bi960860l; THATCHER DR, 1992, MECH PROTEIN FOLDING, P229; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; Van der Schueren J, 1998, PROTEIN ENG, V11, P1211, DOI 10.1093/protein/11.12.1211; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979	57	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25372	25377		10.1074/jbc.M101759200	http://dx.doi.org/10.1074/jbc.M101759200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11304542	hybrid			2022-12-25	WOS:000169800700125
J	Lee, SH; Eom, M; Lee, SD; Kim, S; Park, HJ; Park, D				Lee, SH; Eom, M; Lee, SD; Kim, S; Park, HJ; Park, D			beta Pix-enhanced p38 activation by Cdc42/Rac/PAK/MKK3/6-mediated pathway - Implication in the regulation of membrane ruffling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; RHO-FAMILY PROTEINS; ACTIN REORGANIZATION; KINASE ACTIVATION; SIGNALING PATHWAY; BINDING PROTEINS; CELL-MIGRATION; LIM-KINASE; PAK; RAC	beta Pix (PAK-interacting exchange factor) is a recently identified guanine nucleotide exchange factor for Rho family small G protein Cdc42/Rac, The protein interacts with p21-activated protein kinase (PAK) through its SH3 domain. We examined the effect of beta Pix on MAP kinase signaling and cytoskeletal rearrangement in NIH3T3 fibroblast cells. Overexpression of beta Pix enhanced the activation of p38 in the absence of other stimuli and also induced translocation of p38 to the nucleus. This beta Pix-induced p38 activation was blocked by coexpression of dominant-negative Cdc42/Rac or kinase-inactive PAK, indicating that the effect of beta Pix on p38 is exerted through the Cdc42/Rac-PAK pathway and requires PAK kinase activity. The essential role of beta Pix in growth factor-stimulated p38 activation was evidenced by the blocking of platelet-derived growth factor-induced p38 activation in the cells expressing beta Pix SH3m (W43K) and beta Pix DHm (L238R,L239R). In addition, SB203580, a p38 inhibitor, and kinase-inactive p38 (T180A;Y182F) blocked membrane ruffling induced by beta Pix, suggesting that p38 might be involved in mediating beta Pix-induced membrane ruffling. The results in this study suggest that beta Pix might have a role in nuclear signaling, as well as in actin cytoskeleton regulation, and that some part of these cellular functions is possibly mediated by p38 MAP kinase.	Seoul Natl Univ, Sch Biol Sci, Kwanak Gu, Seoul 151742, South Korea	Seoul National University (SNU)	Park, D (corresponding author), Seoul Natl Univ, Sch Biol Sci, Kwanak Gu, Seoul 151742, South Korea.		Kim, Seyun/B-3387-2012	Lee, Seung Joon/0000-0001-6690-2830				Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hout J, 1998, J CELL BIOL, V143, P1361; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Leung T, 1996, MOL CELL BIOL, V16, P5313; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Philip A, 2000, J BIOL CHEM, V275, P5911, DOI 10.1074/jbc.275.8.5911; Salojin KV, 1999, J IMMUNOL, V163, P844; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	33	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25066	25072		10.1074/jbc.M010892200	http://dx.doi.org/10.1074/jbc.M010892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309380	hybrid			2022-12-25	WOS:000169800700085
J	Marc, F; Weigel, P; Legrain, C; Glansdorff, N; Sakanyan, V				Marc, F; Weigel, P; Legrain, C; Glansdorff, N; Sakanyan, V			An invariant threonine is involved in self-catalyzed cleavage of the precursor protein for ornithine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; SITE-DIRECTED MUTAGENESIS; BACILLUS-STEAROTHERMOPHILUS; SACCHAROMYCES-CEREVISIAE; ARGININE-BIOSYNTHESIS; INTRAMOLECULAR PROTEOLYSIS; CRYSTAL-STRUCTURE; ACETYL CYCLE; MECHANISM; ENZYME	In Bacillus stearothermophilus ornithine acetyltransferase is a bifunctional enzyme, catalyzing the first and the fifth steps of arginine biosynthesis; it follows a ping-pong kinetic mechanism. A single chain precursor protein is cleaved between the alanine and threonine residues in a highly conserved ATML sequence leading to the formation of alpha and beta subunits that assemble into a heterotetrameric 2 alpha2 beta molecule. The beta subunit has been shown to form an acetylated intermediate in the course of the transacetylation reaction. The present data show that the precursor protein synthesized in vitro or in vivo undergoes a self-catalyzed cleavage involving an invariant threonine (Thr-197). Using site-directed mutagenesis T197G, T197S, and T197C derivatives have been generated. The T197G substitution abolishes both precursor protein cleavage and catalytic activity, whereas T197S and T197C substitutions reduce precursor cleavage and catalytic activity in the order Thr-197 (wild type) --> Ser-197 --> Cys-197. A mechanism is proposed in which Thr-197 plays a crucial role in the autoproteolytic cleavage of ornithine acetyltransferase.	Univ Nantes, Fac Sci & Tech, FRE CNRS 2230 Biocatalyse, Biotechnol Lab, F-44322 Nantes 3, France; Jean Marie Wiame Inst Microbiol Res, B-1070 Brussels, Belgium; Free Univ Brussels, Lab Genet & Microbiol, B-1070 Brussels, Belgium; Flanders Interuniv Inst Biotechnol, Dept Microbiol, B-1070 Brussels, Belgium	Nantes Universite; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Sakanyan, V (corresponding author), Univ Nantes, Fac Sci & Tech, FRE CNRS 2230 Biocatalyse, Biotechnol Lab, F-44322 Nantes 3, France.			Sakanyan, Vehary/0000-0002-0513-8434				Abadjieva A, 2000, J BIOL CHEM, V275, P11361, DOI 10.1074/jbc.275.15.11361; ARONSON NN, 1996, GLYCOBIOLOGY, P699; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HZ, 1983, METHOD ENZYMOL, V101, P674; Crabeel M, 1997, EUR J BIOCHEM, V250, P232, DOI 10.1111/j.1432-1033.1997.0232a.x; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Grahame DA, 1996, J BIOL CHEM, V271, P8352, DOI 10.1074/jbc.271.14.8352; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Guo HC, 1998, J BIOL CHEM, V273, P20205, DOI 10.1074/jbc.273.32.20205; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Karaivanova IM, 1999, J MOL BIOL, V291, P843, DOI 10.1006/jmbi.1999.3016; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LIU YS, 1995, EUR J BIOCHEM, V228, P291, DOI 10.1111/j.1432-1033.1995.tb20262.x; Marc F, 2000, EUR J BIOCHEM, V267, P5217, DOI 10.1046/j.1432-1327.2000.01593.x; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; SAKANYAN V, 1992, J GEN MICROBIOL, V138, P125, DOI 10.1099/00221287-138-1-125; SAKANYAN V, 1993, J GEN MICROBIOL, V139, P393, DOI 10.1099/00221287-139-3-393; Sakanyan V, 1996, MICROBIOL-SGM, V142, P99, DOI 10.1099/13500872-142-1-99; SAKANYAN VA, 1990, GENETIKA+, V26, P1915; Savchenko A, 1998, GENE, V212, P167, DOI 10.1016/S0378-1119(98)00174-7; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	30	19	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25404	25410		10.1074/jbc.M100392200	http://dx.doi.org/10.1074/jbc.M100392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320085	hybrid			2022-12-25	WOS:000169800700130
J	Wang, X; Li, MX; Spyracopoulos, L; Beier, N; Chandra, M; Solaro, RJ; Sykes, BD				Wang, X; Li, MX; Spyracopoulos, L; Beier, N; Chandra, M; Solaro, RJ; Sykes, BD			Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I INHIBITORY PEPTIDE; N-TERMINAL DOMAIN; PULSED-FIELD GRADIENT; REGULATORY DOMAIN; SKELETAL-MUSCLE; CALCIUM SENSITIZATION; RESONANCE ASSIGNMENTS; IMPROVED SENSITIVITY; STUNNED MYOCARDIUM; CRYSTAL-STRUCTURE	Ca2+ binding to cardiac troponin C (cTnC) triggers contraction in heart muscle. In heart failure, myofilaments response to Ca2+ are often altered and compounds that sensitize the myofilaments to Ca2+ possess therapeutic value in this syndrome. One of the most potent and selective Ca2+ sensitizers is the thiadiazinone derivative EMD 57033, which increases myocardial contractile function both in vivo and in vitro and interacts with cTnC in vitro. We have determined the NMR structure of the 1:1 complex between Ca2+-saturated C-domain of human cTnC (cCTnC) and EMD 57033. Favorable hydrophobic interactions between the drug and the protein position EMD 57033 in the hydrophobic cleft of the protein. The drug molecule is orientated such that the chiral group of EMD 57033 fits deep in the hydrophobic pocket and makes several key contacts with the protein. This stereospecific interaction explains why the (-)-enantiomer of EMD 57033 is inactive. Titrations of the cCTnC EMD 57033 complex with two regions of cardiac troponin I (CTnI(34-71) and cTnI(128-147)) reveal that the drug does not share a common binding epitope with cTnI(128-147) but is completely displaced by cTnI(34-71). These results have important implications for elucidating the mechanism of the Ca2+ sensitizing effect of EMD 57033 in cardiac muscle contraction.	Univ Alberta, Dept Biochem, Grp Prot Struct & Funct, CIHR, Edmonton, AB T6G 2H7, Canada; Merck KGaA, Pharmaceut Res Dept, D-64271 Darmstadt, Germany; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Alberta; Merck KGaA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Sykes, BD (corresponding author), Univ Alberta, Dept Biochem, Grp Prot Struct & Funct, CIHR, Edmonton, AB T6G 2H7, Canada.							ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CAMPBELL AP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P35, DOI 10.1016/0167-4838(92)90036-D; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; de Zeeuw S, 2000, EUR J PHARMACOL, V403, P99, DOI 10.1016/S0014-2999(00)00513-6; de Zeeuw S, 2000, BRIT J PHARMACOL, V129, P1413, DOI 10.1038/sj.bjp.0703231; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; GROSS T, 1993, J MOL CELL CARDIOL, V25, P239, DOI 10.1006/jmcc.1993.1030; Haeusler G, 1997, J CARDIOVASC PHARM, V29, P647, DOI 10.1097/00005344-199705000-00013; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOWARTH JW, 1995, PROTEIN SCI, V4, P671; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kleerekoper Q, 1999, J BIOL CHEM, V274, P23932, DOI 10.1074/jbc.274.34.23932; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LAN JQ, 1989, BIOCHEMISTRY-US, V28, P7380, DOI 10.1021/bi00444a035; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MX, 2000, BIOCHEMISTRY-US, V39, P8782, DOI 10.1021/bi000473i; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; Li Y, 2000, P NATL ACAD SCI USA, V97, P5140, DOI 10.1073/pnas.090098997; LUES I, 1993, J CARDIOVASC PHARM, V21, P883, DOI 10.1097/00005344-199306000-00006; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; McKay RT, 2000, BIOCHEMISTRY-US, V39, P12731, DOI 10.1021/bi001240u; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; Mercier P, 2000, BIOCHEMISTRY-US, V39, P2902, DOI 10.1021/bi992579n; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NGAI SM, 1994, J BIOL CHEM, V269, P2165; NGAI SM, 1992, J BIOL CHEM, V267, P15715; Nicholls A., 1992, GRASP GRAPHICAL REPR; NielsenKudsk JE, 1995, J CARDIOVASC PHARM, V26, pS77; Ogura K, 1996, J BIOMOL NMR, V8, P492, DOI 10.1007/BF00228150; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Senzaki H, 2000, CIRCULATION, V101, P1040, DOI 10.1161/01.CIR.101.9.1040; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SOLARO RJ, 1993, CIRC RES, V73, P981, DOI 10.1161/01.RES.73.6.981; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; SORSA T, 2000, J BIOL CHEM, V11, P11; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tsutsui H, 2001, J CARDIOVASC PHARM, V37, P16, DOI 10.1097/00005344-200101000-00003; Tung CS, 2000, PROTEIN SCI, V9, P1312; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Varro A, 1995, J CARDIOVASC PHARM, V26, pS32; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; VENTURA C, 1992, CIRC RES, V70, P1081, DOI 10.1161/01.RES.70.6.1081; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	65	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25456	25466		10.1074/jbc.M102418200	http://dx.doi.org/10.1074/jbc.M102418200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320096	hybrid			2022-12-25	WOS:000169800700136
J	Ammendola, A; Geiselhoringer, A; Hofmann, F; Schlossmann, J				Ammendola, A; Geiselhoringer, A; Hofmann, F; Schlossmann, J			Molecular determinants of the interaction between the inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate (IRAG) and cGMP kinase I beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; PHOSPHORYLATION SITES; VIVO PHOSPHORYLATION; MYOSIN PHOSPHATASE; NITRIC-OXIDE; CA2+ RELEASE; CELLS; CAMP; INHIBITION	Cyclic GMP-dependent protein kinase I (cGKI) affects the inositol 1,4,5-trisphosphate (InsP(3))-dependent release of intracellular calcium by phosphorylation of IRAG (inositol 1,4,5-trisphophate receptor-associated cGMP kinase substrate). IRAG is present in a macromolecular complex with the InsP(3) receptor type I (InsP(3)RI) and cGKI beta. The specificity of the interaction between these three proteins was investigated by using the yeast two-hybrid system and by co-precipitation of expressed proteins. The amino terminal region containing the leucine zipper (amino acids 1-53) of cGKI beta but not that of cGKI alpha or cGKZII interacted with the sequence between amino acids 152 and 184 of IRAG in vitro and in vivo most likely through electrostatic interaction. cGKT beta did not interact with the InsP(3)RI, but co-precipitated the InsP(3)RI in the presence of IRAG indicating that IRAG bound to the InsP(3)RI and to cGKI beta. cGKI beta phosphorylated up to four serines in IRAG. Mutation of these four serines to alanine showed that cGKI beta -dependent phosphorylation of Ser(696) is necessary to decrease calcium release from InsP(3)-sensitive stores. These results show that cGMP induced reduction of cytosolic calcium concentrations requires cGKI beta and phosphorylation of Ser(696) of IRAG.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Schlossmann, J (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.		Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839				Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; BUTT E, 1994, J BIOL CHEM, V269, P14509; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Endo S, 1999, P NATL ACAD SCI USA, V96, P2467, DOI 10.1073/pnas.96.5.2467; FELBEL J, 1988, J BIOL CHEM, V263, P16764; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hall KU, 1999, J BIOL CHEM, V274, P3485, DOI 10.1074/jbc.274.6.3485; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann F, 2000, J CELL SCI, V113, P1671; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LINCOLN TM, 1990, AM J PHYSIOL, V258, P399; MacDonald JA, 2000, FEBS LETT, V479, P83, DOI 10.1016/S0014-5793(00)01884-6; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Moore DD, 1995, GLOB MOB SURV; Murthy KS, 1998, J BIOL CHEM, V273, P34519, DOI 10.1074/jbc.273.51.34519; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; Tertyshnikova X, 1998, J PHYSIOL-LONDON, V512, P89, DOI 10.1111/j.1469-7793.1998.089bf.x; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Wyatt TA, 1998, AM J PHYSIOL-HEART C, V274, pH448, DOI 10.1152/ajpheart.1998.274.2.H448; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897	45	107	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24153	24159		10.1074/jbc.M101530200	http://dx.doi.org/10.1074/jbc.M101530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309393	hybrid			2022-12-25	WOS:000169531100123
J	Kasahara, J; Fukunaga, K; Miyamoto, E				Kasahara, J; Fukunaga, K; Miyamoto, E			Activation of calcium/calmodulin-dependent protein kinase IV in long term potentiation in the rat hippocampal CA1 region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SYNAPTIC PLASTICITY; BINDING PROTEIN; PHOSPHATASE 2A; LATE-PHASE; NEURONS; LTP; PHOSPHORYLATION; IDENTIFICATION; INDUCTION	The importance of well characterized calcium/calmodulin-dependent protein kinase (CaMK) II in hippocampal long term potentiation (LTP) is widely well established; however, several CaMKs other than CaMKII are not yet clearly characterized and understood, Here we report the activation of CaMKIV, which is phosphorylated by CaMK kinase and localized predominantly in neuronal nuclei, and its functional role as a cyclic AMP-responsive element-binding protein (CREB) kinase in high frequency stimulation (HFS)-induced LTP in the rat hippocampal CA1 region, CaMKIV was transiently activated in neuronal nuclei after HFS, and the activation returned to the basal level within 30 min. Phosphorylation of CREB, which is a CaMKIV substrate, and expression of c-Fos protein, which is regulated by CREE, increased during LTP. This increase was inhibited mainly by CaMK inhibitors and also by an inhibitor for mitogen-activated protein kinase cascade, although to a lesser extent. Our results suggest that CaMKIV functions as a CREB kinase and controls CREB-regulated gene expression during HFS-induced LTP in the rat hippocampal CA1 region.	Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan	Kumamoto University	Miyamoto, E (corresponding author), Kumamoto Univ, Sch Med, Dept Pharmacol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Fukunaga, Kohji/AAI-8811-2021	Fukunaga, Kohji/0000-0001-8526-2824				Ahn S, 1999, NEURON, V23, P559, DOI 10.1016/S0896-6273(00)80808-9; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Fukunaga K, 2000, NEUROSCI RES, V38, P3, DOI 10.1016/S0168-0102(00)00139-5; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kasahara J, 1999, J BIOL CHEM, V274, P9061, DOI 10.1074/jbc.274.13.9061; Kasahara J, 2000, J NEUROSCI RES, V59, P594, DOI 10.1002/(SICI)1097-4547(20000301)59:5<594::AID-JNR2>3.3.CO;2-H; Liu J, 1999, J NEUROSCI, V19, P8292; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MIYANO O, 1992, J BIOL CHEM, V267, P1198; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; RIBER TJ, 2000, J NERUOSCI, V20, P1; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; Sanes JR, 1999, NAT NEUROSCI, V2, P597, DOI 10.1038/10154; SERBERT MA, 1995, J BIOL CHEM, V270, P17616; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Tokuda M, 1997, BRAIN RES, V755, P162, DOI 10.1016/S0006-8993(97)00189-3; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Wang Y, 1996, MOL CELL BIOL, V16, P5915; Watabe AM, 2000, J NEUROSCI, V20, P5924, DOI 10.1523/JNEUROSCI.20-16-05924.2000; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	47	98	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24044	24050		10.1074/jbc.M100247200	http://dx.doi.org/10.1074/jbc.M100247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306573	hybrid			2022-12-25	WOS:000169531100109
J	Bennett, TA; Key, TA; Gurevich, VV; Neubig, R; Prossnitz, ER; Sklar, LA				Bennett, TA; Key, TA; Gurevich, VV; Neubig, R; Prossnitz, ER; Sklar, LA			Real-time analysis of G protein-coupled receptor reconstitution in a solubilized system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTOR; CHEMOATTRACTANT RECEPTORS; PHOSPHOLIPID-VESICLES; HUMAN NEUTROPHIL; TERNARY COMPLEX; ARRESTIN; BINDING; CELLS; FLUORESCENCE; ASSOCIATION	Receptor based signaling mechanisms are the primary source of cellular regulation. The superfamily of G protein-coupled receptors is the largest and most ubiquitous of the receptor mediated processes. We describe here the analysis in real-time of the assembly and disassembly of soluble G protein-coupled receptor a protein complexes. A fluorometric method was utilized to determine the dissociation of a fluorescent ligand from the receptor solubilized in detergent. The ligand dissociation rate differs between a receptor coupled to a G protein and the receptor alone. By observing the sensitivity of the dissociation of a fluorescent ligand to the presence of guanine nucleotide, we have shown a time- and concentration-dependent reconstitution of the N-formyl peptide receptor with endogenous G proteins. Furthermore, after the clearing of endogenous G proteins, purified G alpha subunits premixed with bovine brain G beta gamma subunits were also able to reconstitute with the solubilized receptors. The solubilized N-formyl peptide receptor and G(alpha i3) protein interacted with an affinity of similar to 10(-6) M with other alpha subunits exhibiting lower affinities (G(alpha i3) > G(alpha i2) > G(alpha i1) much greater than G(alphao)). The N-formyl peptide receptor-G protein interactions were inhibited by peptides corresponding to the G(alphai) C-terminal regions, by G(alphai) mAbs, and by a truncated form of arrestin-3. This system should prove useful for the analysis of the specificity of receptor a protein interactions, as well as for the elucidation and characterization of receptor molecular assemblies and signal transduction complexes.	Univ New Mexico, Ctr Canc, Ctr Hlth Sci, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Ctr Canc, Ctr Hlth Sci, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85351 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico; Banner Research; Banner Health; Banner Sun Health Research Institute; University of Michigan System; University of Michigan	Sklar, LA (corresponding author), Univ New Mexico, Ctr Canc, Ctr Hlth Sci, Dept Pathol, 2325 Camino de Salud,CRF219A, Albuquerque, NM 87131 USA.		Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008; Gurevich, Vsevolod/A-3236-2008	Prossnitz, Eric/0000-0001-9190-8302; Gurevich, Vsevolod/0000-0002-3950-5351; Neubig, Richard/0000-0003-0501-0008	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036357, R29AI036357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM060799] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01315] Funding Source: Medline; NEI NIH HHS [EY11500] Funding Source: Medline; NIAID NIH HHS [AI36357] Funding Source: Medline; NIGMS NIH HHS [GM60799] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOMMAKANTI RK, 1994, BBA-PROTEIN STRUCT M, V1209, P69, DOI 10.1016/0167-4838(94)90138-4; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; DE LA, 1980, J BIOL CHEM, V255, P7108; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; KLOTZ KN, 1994, J IMMUNOL, V152, P801; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; MCEWEN DP, 2001, IN PRESS METHODS ENZ; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; NEUBIG RR, 1994, FEBS LETT, V355, P251, DOI 10.1016/0014-5793(94)01212-1; Nolan John P., 1998, P19; POSNER RG, 1994, MOL PHARMACOL, V45, P65; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; Sklar LA, 2000, BIOTECHNIQUES, V28, P976, DOI 10.2144/00285rr03; SKLAR LA, 1989, J BIOL CHEM, V264, P8483; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3	32	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22453	22460		10.1074/jbc.M009679200	http://dx.doi.org/10.1074/jbc.M009679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309376	hybrid			2022-12-25	WOS:000169412700065
J	Heritage, D; Wonderlin, WF				Heritage, D; Wonderlin, WF			Translocon pores in the endoplasmic reticulum are permeable to a neutral, polar molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE MAMMARY-GLAND; GLUCOSIDASE-II; PROTEIN TRANSLOCATION; ER MEMBRANE; GLYCOPROTEIN; PURIFICATION; SUBUNIT; MICROSOMES; CHANNEL; CHAIN	The pore of the translocon complex in the endoplasmic reticulum (ER) is large enough to be permeated by small molecules, but it is generally believed that permeation is prevented by a barrier at the luminal end of the pore. We tested the hypothesis that 4-methylumbel-liferyl alpha -D-glucopyranoside (4M alphaG), a small, neutral dye molecule, cannot permeate an empty translocon pore by measuring its activation by an ER resident alpha -glucosidase, which is dependent on entry into the ER, The basal entry of dye into the ER of broken Chinese hamster ovary-S cells was remarkably high, and it was increased by the addition of puromycin, which purges translocon pores of nascent polypeptides, creating additional empty pores. The basal and puromycin-dependent entries of 4M alphaG were mediated by a common, salt-sensitive pathway that was partially blocked by spermine. A similar activation of 4M alphaG was observed in nystatin-perforated cells, indicating that the entry of 4MaG into the ER did not result simply from the loss of cytosolic factors in broken cells. We reject the hypothesis and conclude that a small, neutral molecule can permeate the empty pore of a translocon complex, and we propose that translationally inactive, ribosome-bound translocons could provide a pathway for small molecules to cross the ER membrane.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA	West Virginia University	Wonderlin, WF (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA.	wonder@wvu.edu						ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BURNS DM, 1982, J BIOL CHEM, V257, P9991; COHEN BE, 1975, J MEMBRANE BIOL, V20, P235, DOI 10.1007/BF01870638; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Gillece P, 2000, P NATL ACAD SCI USA, V97, P4609, DOI 10.1073/pnas.090083497; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HINO Y, 1985, BIOCHEMISTRY-US, V24, P800, DOI 10.1021/bi00324a040; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MEISSNER G, 1981, J BIOL CHEM, V256, P6413; Morgan DG, 2000, J MOL BIOL, V301, P301, DOI 10.1006/jmbi.2000.3947; Pestka S, 1974, Methods Enzymol, V30, P261; Potter MD, 2001, TRENDS CELL BIOL, V11, P112, DOI 10.1016/S0962-8924(00)01905-X; Romisch K, 1999, J CELL SCI, V112, P4185; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; SHAILUBHAI K, 1991, J BIOL CHEM, V266, P16587; SHAILUBHAI K, 1987, BIOCHEM J, V247, P555, DOI 10.1042/bj2470555; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; SOLOMON AK, 1972, BIOCHIM BIOPHYS ACTA, V255, P1019, DOI 10.1016/0005-2736(72)90416-6; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65	27	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22655	22662		10.1074/jbc.M102409200	http://dx.doi.org/10.1074/jbc.M102409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303028	Green Published, hybrid			2022-12-25	WOS:000169412700092
J	Liberati, NT; Moniwa, M; Borton, AJ; Davie, JR; Wang, XF				Liberati, NT; Moniwa, M; Borton, AJ; Davie, JR; Wang, XF			An essential role for Mad homology domain 1 in the association of Smad3 with histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; N-COR; INDUCED PHOSPHORYLATION; INDUCED TRANSCRIPTION; TUMOR-SUPPRESSOR; DIRECT BINDING; DNA-BINDING; SKI ACTS; COMPLEX; PROTEINS	The Smads are a family of sequence-specific DNA-binding proteins that modulate transcription in response to transforming growth factor beta (TGF beta) by recruiting transcriptional activators like the histone acetyltransferase, p300/CBP, or repressors like the his tone deacetylase, HDAC1, to TGF beta target genes. The association of Smads and HDAC1 is mediated in part by direct binding of Smads to the HDAC1-associated proteins, TG-interacting factor, c-ski, and SnoN. Although ectopic expression of these proteins inhibits Smad-activated transcription, the contribution of histone deacetylase enzymatic activity to transcriptional repression by TGF beta is unknown. Here, the biological requirements for the interaction between Smads and endogenous histone deacetylase activity are investigated. We identify residues in Mad homology domain I of Smad3 that are required for association with histone deacetylase activity. An amino acid change at one of these critical residues does not disrupt the association of Smad3 with c-ski, SnoN, and transforming growth-interacting factor but does abrogate the ability of Smad3 to repress transcription, These findings indicate that the association of Smad3 and histone deacetylase activity relies on additional protein mediators that make contact with Smad3 at its amino terminus. Moreover, these data suggest that the suppressive effect of Smad3 on transcription is dependent upon its association with histone deacetylase enzymatic activity.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada	Duke University; University of Manitoba; University of Manitoba	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27708 USA.	wang0011@mc.duke.edu		Davie, James/0000-0002-0420-6888	NATIONAL CANCER INSTITUTE [R01CA075368] Funding Source: NIH RePORTER; NCI NIH HHS [CA75368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; KERR LD, 1988, J BIOL CHEM, V263, P16999; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PIRSKANEN A, 1994, J BONE MINER RES, V9, P1635; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	66	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22595	22603		10.1074/jbc.M010778200	http://dx.doi.org/10.1074/jbc.M010778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306568	hybrid			2022-12-25	WOS:000169412700084
J	Rozenvayn, N; Flaumenhaft, R				Rozenvayn, N; Flaumenhaft, R			Phosphatidylinositol 4,5-bisphosphate mediates Ca2+-induced platelet alpha-granule secretion - Evidence for type II phosphatidylinositol 5-phosphate 4-kinase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PERMEABILIZED HUMAN PLATELETS; GTP-GAMMA-S; PHOSPHOLIPASE-C; MEMBRANE-FUSION; PHOSPHOINOSITIDE 3-KINASE; CA2+-ACTIVATED SECRETION; INOSITOL PHOSPHOLIPIDS; MOLECULAR MECHANISMS; THROMBIN STIMULATION	To understand the molecular basis of granule release from platelets, we examined the role of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) in alpha -granule secretion. Streptolysin O-permeabilized platelets synthesized PtdIns(4,5)P-2 when incubated in the presence of ATP. Incubation of streptolysin O permeabilized platelets with phosphatidylinositol-specific phospholipase C reduced PtdIns(4,5)P-2 levels and resulted in a dose and time-dependent inhibition of Ca2+-induced alpha -granule secretion. Exogenously added PtdIns(4,5)P-2 inhibited alpha -granule secretion, with 80% inhibition at 50 muM PtdIns(4,5)P-2. Nanomolar concentrations of wortmannin, 33.3 muM LY294002, and antibodies directed against PtdIns 3-kinase did not inhibit Ca2+-induced alpha -granule secretion, suggesting that PtdIns 3-kinase is not involved in alpha -granule secretion. However, micromolar concentrations of wortmannin inhibited both PtdIns(4,5)P-2 synthesis and alpha -granule secretion by similar to 50%. Antibodies directed against type II phosphatidylinositol-phosphate kinase (phosphatidylinositol 5-phosphate 4-kinase) also inhibited both PtdIns(4,5)P-2 synthesis and Ca2+-induced alpha -granule secretion by similar to 50%. These antibodies inhibited alpha -granule secretion only when added prior to ATP exposure and not when added following ATP exposure, prior to Ca2+-mediated triggering. The inhibitory effects of micromolar wortmannin and anti-type II phosphatidylinositol-phosphate kinase antibodies were additive, These results show that PtdIns(4,5)P-2 mediates platelet alpha -granule secretion and that PtdIns(4,5)P-2 synthesis required for Ca2+-induced alpha -granule secretion involves the type II phosphatidylinositol 5-phosphate 4-kinase-dependent pathway.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis Res, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Flaumenhaft, R (corresponding author), RE 319,Res East,POB 15732, Boston, MA 02215 USA.				NHLBI NIH HHS [HL63250] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063250] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Avery J, 1999, ANNU REV PHYSIOL, V61, P777, DOI 10.1146/annurev.physiol.61.1.777; BENISTANT C, 1990, BIOCHEM J, V269, P489, DOI 10.1042/bj2690489; Bernstein AM, 1999, BLOOD, V93, P571, DOI 10.1182/blood.V93.2.571.402k05_571_579; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; BRASS LF, 1920, HEMATOLOGY BASIC PRI; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Coorssen JR, 1996, AM J PHYSIOL-CELL PH, V270, pC1153, DOI 10.1152/ajpcell.1996.270.4.C1153; COORSSEN JR, 1993, FEBS LETT, V316, P170, DOI 10.1016/0014-5793(93)81209-I; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Flaumenhaft R, 1999, J CELL PHYSIOL, V179, P1; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; GINSBERG MH, 1980, BLOOD, V55, P661; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HASLAM RJ, 1993, ADV EXP MED BIOL, V344, P149; HASLAM RJ, 1984, BIOCHEM J, V222, P351, DOI 10.1042/bj2220351; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Hinchliffe KA, 1999, BIOCHEM SOC T, V27, P657, DOI 10.1042/bst0270657; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; LAPETINA EG, 1985, J BIOL CHEM, V260, P7078; LASSING I, 1990, FEBS LETT, V262, P231, DOI 10.1016/0014-5793(90)80197-Q; LEFEBVRE P, 1993, EUR J CELL BIOL, V62, P194; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Martin TFJ, 1997, BIOCHEM SOC T, V25, P1137, DOI 10.1042/bst0251137; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Padfield PJ, 1996, BIOCHEM J, V314, P123, DOI 10.1042/bj3140123; PATEL S, 1991, BIOCHEM J, V273, P561, DOI 10.1042/bj2730561; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; PLOW EF, 2000, HEMATOLOGY BASIC PRI; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; RACAUDSULTAN C, 1993, FEBS LETT, V330, P347, DOI 10.1016/0014-5793(93)80902-7; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; SANCHEZ A, 1985, FEBS LETT, V191, P283, DOI 10.1016/0014-5793(85)80025-9; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Sloan DC, 1997, BIOCHEM J, V328, P13; SueAQuan AK, 1997, J CELL PHYSIOL, V172, P94, DOI 10.1002/(SICI)1097-4652(199707)172:1<94::AID-JCP11>3.0.CO;2-O; Way G, 2000, BIOCHEM J, V346, P63, DOI 10.1042/0264-6021:3460063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WHITE JG, 1983, AM J PATHOL, V112, P207; WHITE JG, 1982, BLOOD, V60, P474; White JG, 1999, BLOOD, V93, P2422, DOI 10.1182/blood.V93.7.2422.407a36c_2422_2425; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; YANO H, 1993, J BIOL CHEM, V268, P25846	63	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22410	22419		10.1074/jbc.M008184200	http://dx.doi.org/10.1074/jbc.M008184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304526	hybrid			2022-12-25	WOS:000169412700060
J	Baskakov, IV; Legname, G; Prusiner, SB; Cohen, FE				Baskakov, IV; Legname, G; Prusiner, SB; Cohen, FE			Folding of prion protein to its native alpha-helical conformation is under kinetic control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; 106 RESIDUES; DOMAIN; STABILITY; DISEASES; PH	The recombinant mouse prion protein (MoPrP) can be folded either to a monomeric alpha -helical or oligomeric beta -sheet-rich isoform. By using circular dichroism spectroscopy and size-exclusion chromatography, we show that the beta -rich isoform of MoPrP is thermodynamically more stable than the native alpha -helical isoform. The conformational transition from the alpha -helical to beta -rich isoform is separated by a large energetic barrier that is associated with unfolding and with a higher order kinetic process related to oligomerization. Under partially denaturing acidic conditions, MoPrP avoids the kinetic trap posed by the alpha -helical isoform and folds directly to the thermodynamically more stable beta -rich isoform. Our data demonstrate that the folding of the prion protein to its native alpha -helical monomeric conformation is under kinetic control.	Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol Pharmaceut Chem & M, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cohen, FE (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Box 0450, San Francisco, CA 94143 USA.		Legname, Giuseppe/C-1723-2012	Legname, Giuseppe/0000-0003-0716-4393	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010770] Funding Source: NIH RePORTER; NIA NIH HHS [AG10770, AG0Z132] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Broome BM, 2000, J MOL BIOL, V296, P961, DOI 10.1006/jmbi.2000.3514; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; GROB M, 1999, PROTEIN SCI, V8, P1350; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Yutani K, 2000, BIOCHEMISTRY-US, V39, P2769, DOI 10.1021/bi991406v; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	23	194	196	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19687	19690		10.1074/jbc.C100180200	http://dx.doi.org/10.1074/jbc.C100180200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11306559	hybrid			2022-12-25	WOS:000169135100003
J	Sengupta, SM; VanKanegan, M; Persinger, J; Logie, C; Cairns, BR; Peterson, CL; Bartholomew, B				Sengupta, SM; VanKanegan, M; Persinger, J; Logie, C; Cairns, BR; Peterson, CL; Bartholomew, B			The interactions of yeast SWI/SNF and RSC with the nucleosome before and after chromatin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE OCTAMER; TRANSCRIPTION COMPLEX; NUCLEAR-PROTEIN; DNA; GENE; BINDING; SUBUNITS; ENCODES; ATPASE	Interactions of the yeast chromatin-remodeling complexes SWI/SNF and RSC with nucleosomes were probed using site-specific DNA photoaffinity labeling. 5 S rDNA was engineered with photoreactive nucleotides incorporated at different sites in DNA to scan for the subunits of SWI/SNF in close proximity to DNA when SWI/SNF is bound to the 5 S nucleosome or to the free 5 S rDNA The Swi2/Snf2 and Snf6 subunits of SWI/SNF were efficiently cross-linked at several positions in the nucleosome, whereas only Snf6 was efficiently cross-linked when SWI/SNF was bound to free DNA DNA photoaffinity labeling of RSC showed that the Reel subunit is in close proximity to nucleosomal DNA and not when RSC is bound to free DNA After remodeling, the Swi2/Snf2 and Rsc4 subunits are no longer detected near the nucleosomal DNA and are evidently displaced from the surface of the nucleosome, indicating significant changes in SWI/SNF and RSC contacts with DNA after remodeling.	So Illinois Univ, Sch Med, Program Mol Biol Microbiol & Mol Biol, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Bartholomew, B (corresponding author), So Illinois Univ, Sch Med, Program Mol Biol Microbiol & Mol Biol, Carbondale, IL 62901 USA.		Logie, Colin/A-1528-2010; Logie, Colin/L-9833-2019	Logie, Colin/0000-0002-8534-6582; Logie, Colin/0000-0002-8534-6582	NIGMS NIH HHS [GM48413, R01 GM049650, R37 GM049650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048413, R29GM048413, R01GM049650, R37GM049650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Du J, 1998, GENETICS, V150, P987; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HENRY NR, COMMUNICATION; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lannutti BJ, 1996, BIOCHEMISTRY-US, V35, P9821, DOI 10.1021/bi960525x; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; Logie C, 1999, METHOD ENZYMOL, V304, P726; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; RENART J, 1984, METHOD ENZYMOL, V104, P455; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Sengupta SM, 1999, METHODS, V19, P434, DOI 10.1006/meth.1999.0880; SZERLONG H, UNPUB; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TSUCHIYA E, 1992, EMBO J, V11, P4017, DOI 10.1002/j.1460-2075.1992.tb05495.x; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	51	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12636	12644		10.1074/jbc.M010470200	http://dx.doi.org/10.1074/jbc.M010470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11304548	Green Published, hybrid			2022-12-25	WOS:000168198600024
J	Kasten, M; Giordano, A				Kasten, M; Giordano, A			Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity	ONCOGENE			English	Article						Cdk; Ets2; transcription; cell cycle	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; PROSTATE-CANCER; PROTEIN-KINASE; FAMILY; ACTIVATION; EXPRESSION; PISSLRE; GROWTH; DOMAIN	Cdk10 is a Cdc2-related kinase that may play a role in regulating the G2/M phase of the cell cycle. However little is known about the proteins that interact with this putative kinase and contribute to its function in the cell. We report in this study that Cdk10 interacts with the N-terminus of the Ets2 transcription factor, which contains the highly conserved Pointed domain and transactivation domain. The Pointed domain has been implicated in protein-protein interactions and we find that Ets2 requires an intact Pointed domain to bind Cdk10, The Pointed domain of Ets1 is highly similar to Ets2, however Cdk10 does not recognize Ets1 in a two-hybrid assay thereby demonstrating significant binding specificity on the part of Cdk10, We find that Cdk10 binds full length Ets2 in vitro and in vivo and inhibits Ets2 transactivation in mammalian cells.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Anat, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Giordano, A (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [T32CA009137] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA 09137] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; GOLEMIS EA, 1997, CURRENT PROTOCOLS MO; GRANA X, 1994, ONCOGENE, V9, P2097; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; LI S, 1995, CANCER RES, V55, P3992; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Puri PL, 2000, GENE DEV, V14, P574; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Watson MA, 1996, BIOTECHNIQUES, V21, P255; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Yang BS, 1996, MOL CELL BIOL, V16, P538	31	85	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1832	1838		10.1038/sj.onc.1204295	http://dx.doi.org/10.1038/sj.onc.1204295			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313931				2022-12-25	WOS:000167908400004
J	Kalma, Y; Marash, L; Lamed, Y; Ginsberg, D				Kalma, Y; Marash, L; Lamed, Y; Ginsberg, D			Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2	ONCOGENE			English	Article						E2F; cell cycle; DNA chips; RPA	NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; CELL-CYCLE; TOPOISOMERASE-II; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; DEREGULATED EXPRESSION; MAMMALIAN CDC6	The transcription factor E2F-1 plays a pivotal role in the regulation of G1/S transition in higher eukaryotes cell cycle. We used a cell line containing an inducible E2F-1 and oligonucleotide microarray analysis to identify novel E2F target genes. We show that E2F-1 up-regulates the expression of a number of genes coding for components of the DNA replication machinery. Among them is the gene coding for the 32 Kd subunit of replication protein A (RPA2). Replication protein A is the most abundant single strand DNA binding complex and it is essential for DNA replication. We demonstrate that RPA2 is a novel E2F target gene whose expression can be directly regulated by E2F-1 via E2F binding sites in its promoter. In addition, expression of Topoisomerase II alpha and subunit IV of DNA polymerase alpha is also up-regulated upon E2F-1 induction. Taken together, these results provide novel links between components of the DNA replication machinery and the cell growth regulatory pathway involving the Rb tumor suppressor and E2F.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			ginsberg, doron/0000-0002-1257-4920				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HASEGAWA T, 1993, BIOCHEM BIOPH RES CO, V195, P409, DOI 10.1006/bbrc.1993.2058; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KENNY MK, 1990, J BIOL CHEM, V265, P769; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LI L, 1995, MOL CELL BIOL, V15, P5396; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nishikawa NS, 2000, NUCLEIC ACIDS RES, V28, P1525, DOI 10.1093/nar/28.7.1525; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	51	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1379	1387		10.1038/sj.onc.1204230	http://dx.doi.org/10.1038/sj.onc.1204230			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313881				2022-12-25	WOS:000167495000011
J	Law, W; Linial, ML				Law, W; Linial, ML			Transforming ability of Gag-Myc fusion proteins correlates with Gag-Myc protein stability and transcriptional repression	ONCOGENE			English	Article						myc; repression; avian retrovirus; Gag-Myc	ROUS-SARCOMA VIRUS; ORNITHINE DECARBOXYLASE GENE; UBIQUITIN-PROTEASOME PATHWAY; NUCLEOTIDE-SEQUENCE ANALYSIS; DNA-DAMAGING AGENTS; C-MYC; V-MYC; NEOPLASTIC TRANSFORMATION; NUCLEOCAPSID PROTEIN; CELL-TRANSFORMATION	Avian retroviruses that have transduced c-myc are useful tools to study the conditions necessary for cellular transformation. FH3, one such retrovirus which encodes a Gag-Myc fusion protein, is not transforming in quail embryonic fibroblasts, but a late variant of FH3 that arose after passaging FH3-infected cells is transforming. Mutational analysis of FH3 revealed that the presence of a portion of the retroviral protease in FH3 inhibited transformation and that this inhibition was transferable to more highly transforming retrovirus, MC29. Transforming and non-transforming FH3-derived and MC29-derived Gag-Myc proteins were used to further explore characteristics of Myc necessary for transformation. Gag-Myc proteins which were transforming were found to be the most stable in the cell, To distinguish whether transactivation and/or repression is correlated to transformation, the various Gag-Myc fusion proteins were tested for their ability to activate or repress c-Myc targets. Results indicated that a correlation exists between transforming Gag-Myc proteins and their ability to repress, whereas all Gag-Myc proteins could transactivate, regardless of their ability to transform, Taken together, these results suggest that protein stabilization of Myc and repression of target genes by Myc are important for cellular transformation.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Linial, ML (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Mail Stop A3-015,1100 Fairview Ave N, Seattle, WA 98109 USA.				NATIONAL CANCER INSTITUTE [R01CA018282, T32CA009657, R01CA058809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-18282, CA-58809, 5 T32 CA-09657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIEGALKE BJ, 1990, VIROLOGY, V177, P657, DOI 10.1016/0042-6822(90)90531-U; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRASIER AR, 1995, CURRENT PROTOCOLS MO; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CHEN CA, 1996, CURRENT PROTOCOLS MO; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Coffin JM, 1996, VIROLOGY, P1767; COHN SL, 1990, ONCOGENE, V5, P1821; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; DUPRAZ P, 1992, J VIROL, V66, P4662, DOI 10.1128/JVI.66.8.4662-4670.1992; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRYKBERG L, 1987, ONCOGENE, V1, P415; FU XD, 1988, J BIOL CHEM, V263, P2140; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; GELFAND CA, 1993, J BIOL CHEM, V268, P18450; GRINDE B, 1992, J BIOL CHEM, V267, P9481; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee CM, 1999, ONCOGENE, V18, P2997, DOI 10.1038/sj.onc.1202786; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MAO Y, 1993, BIOCHEM J, V295, P641, DOI 10.1042/bj2950641; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIN SY, 1992, ONCOGENE, V7, P1531; MLADENOV Z, 1967, JNCI-J NATL CANCER I, V38, P251; MOSHIER JA, 1993, CANCER RES, V53, P2618; OERTLE S, 1992, J VIROL, V66, P3873, DOI 10.1128/JVI.66.6.3873-3878.1992; PENA A, 1993, J BIOL CHEM, V268, P27277; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1993, J VIROL, V67, P3635, DOI 10.1128/JVI.67.6.3635-3638.1993; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	74	4	5	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1118	1127		10.1038/sj.onc.1204226	http://dx.doi.org/10.1038/sj.onc.1204226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314049				2022-12-25	WOS:000167232100012
J	Lin, RT; Genin, P; Mamane, Y; Sgarbanti, M; Battistini, A; Harrington, WJ; Barber, GN; Hiscott, J				Lin, RT; Genin, P; Mamane, Y; Sgarbanti, M; Battistini, A; Harrington, WJ; Barber, GN; Hiscott, J			HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators	ONCOGENE			English	Article						interferon; chemokines; herpes; vIRF-1; IRF-3; CBP/P300; transcription	SARCOMA-ASSOCIATED HERPESVIRUS; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; FUNCTIONAL-ANALYSIS; POSITIVE FEEDBACK; VIRUS-INFECTION; DNA-SEQUENCES; KAPPA-B; ACTIVATION; PROTEIN	Human herpes virus 8 (HHV-8) has developed unique mechanisms for altering cellular proliferative and apoptotic control pathways by incorporating viral homologs to several cellular regulatory genes into its genome. One of the, important pirated genes encoded by the ORF K9 reading frame is a viral homolog of the interferon regulatory factors (TRF), a family of cellular transcription proteins that regulates expression of genes involved in pathogen response, immune modulation and cell proliferation, vIRF-1 has been shown to downregulate the interferon- and IRF-mediated transcriptional activation of ISG and murine IFNA4 gene promoters. In this study we demonstrate that vIRF-1 efficiently inhibited virus-induced expression of endogenous interferon B, CC chemokine RANTES and CXC chemokine IP-10 genes, Go-expression analysis revealed that vIRF-1 selectively blocked IRF-3 but not IRF-7-mediated transactivation. vIRF-1 was able to bind to both IRF-3 and IRF-7 in vivo as detected by coimmunoprecipitation analysis, but did not affect IRF-3 dimerization, nuclear translocation and DNA binding activity, Rather, vIRF-1 interacted with the CBP/p300 coactivators and efficiently inhibited the formation of transcriptionally competent IRF-3-CBP/p300 complexes, These results illustrate that vIRF-1 is able to block the early stages of the IFN response to virus infection by interfering with the activation of IRF-3 responsive, immediate early IFN genes.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol & Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Ist Super Sanita, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; University of Miami; Istituto Superiore di Sanita (ISS)	Lin, RT (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada.		BATTISTINI, ANGELA/C-2944-2016; SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503; Genin, Pierre/0000-0002-7502-3851				Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Burysek L, 1999, J VIROL, V73, P7334; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kung AL, 2000, GENE DEV, V14, P272; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; LIN RT, 1994, J BIOL CHEM, V269, P17542; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; NGUYEN H, 1995, ONCOGENE, V11, P537; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Oike Y, 1999, BLOOD, V93, P2771; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Vescio RA, 1999, CURR TOP MICROBIOL, V246, P403; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	38	167	177	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					800	811		10.1038/sj.onc.1204163	http://dx.doi.org/10.1038/sj.onc.1204163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314014				2022-12-25	WOS:000166924400003
J	Niitsu, N; Hayashi, Y; Honma, Y				Niitsu, N; Hayashi, Y; Honma, Y			Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23;p13)	ONCOGENE			English	Article						differentiation; MLL-CBP; t(11;16)(q23;p13); RXR agonist, butyrate	RETINOID-X-RECEPTOR; ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; NUCLEAR-PROTEIN CBP; HISTONE ACETYLTRANSFERASE; BUTYRIC-ACID; SODIUM-BUTYRATE; TRANSCRIPTIONAL ACTIVATION; MYELOMONOCYTIC LEUKEMIA	The translocation t(11;16)(q23;p13) has only been documented in patients with acute leukemia or myelodysplasia secondary to therapy with drugs targeting DNA topoisomerase II. We have established a myeloid cell line (SN-1) with the MLL-CBP fusion gene from an acute leukemia patient with t(11;16)(q23;p13), Although SN-1 cells were not induced to differentiate by all-tr mw retinoic acid (ATRA) and 1 alpha ,25-dihydroxyvitamin D-3 (VD3), retinoid Ii receptor (RXR) agonists, such as 9-cis retinoic acid and Ro48-2250, effectively induced differentiation of the cells. Downregulation of the expression of the MLL-CBP fusion gene occurred during the differentiation of SN-1 cells, When SN-1 cells were treated with MLL-CBP antisense oligonucleotide, the cells were induced to differentiate by ATRA or VD3, suggesting that the MLL-CBP fusion gene dominant-negatively suppresses ATRA- or VD3-induced differentiation. Moreover, suboptimal concentrations of sodium butyrate, a histone deacetylase inhibitor, had a cooperative effect with ATRA or VD3 in inducing the differentiation of SN-1 cells, The downregulation of the expression of MLL-CBP mRNA was accompanied by the induction of differentiation. These findings suggest that RXR agonists or a clinically applicable combination of ATRA and butyrate derivatives might be useful for differentiation therapy in leukemia patients with the MLL-CBP fusion gene.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan; Toho Univ, Sch Med, Dept Internal Med 1, Tokyo 153, Japan; Univ Tokyo, Fac Med, Dept Pediat, Tokyo 113, Japan	Toho University; University of Tokyo	Honma, Y (corresponding author), Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan.							Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; AVIRAM A, 1994, INT J CANCER, V56, P906, DOI 10.1002/ijc.2910560625; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayashi Y, 2000, CANCER RES, V60, P1139; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONMA Y, 1983, EUR J CANCER CLIN ON, V19, P251, DOI 10.1016/0277-5379(83)90424-8; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iijima T, 1999, CHEM PHARM BULL, V47, P398; Joh T, 1999, ONCOGENE, V18, P1125, DOI 10.1038/sj.onc.1202400; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kasukabe T, 1997, BRIT J CANCER, V75, P850, DOI 10.1038/bjc.1997.151; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Makishima M, 1996, BLOOD, V87, P3384, DOI 10.1182/blood.V87.8.3384.bloodjournal8783384; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Niitsu N, 1997, CELL GROWTH DIFFER, V8, P319; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; NUDELMAN A, 1992, J MED CHEM, V35, P687, DOI 10.1021/jm00082a009; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRASAD KN, 1980, LIFE SCI, V27, P1351, DOI 10.1016/0024-3205(80)90397-5; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; Rowley JD, 1997, BLOOD, V90, P535; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1997, PEDIATRICS, V100, P101, DOI 10.1542/peds.100.1.101; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yokoyama A, 1996, BLOOD, V88, P3555, DOI 10.1182/blood.V88.9.3555.bloodjournal8893555; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4	54	12	15	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					375	384		10.1038/sj.onc.1204081	http://dx.doi.org/10.1038/sj.onc.1204081			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313967				2022-12-25	WOS:000166411000012
J	Ehrhardt, GRA; Korherr, C; Wieler, JS; Knaus, M; Schrader, JW				Ehrhardt, GRA; Korherr, C; Wieler, JS; Knaus, M; Schrader, JW			A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth	ONCOGENE			English	Article						Ras; exchange factor; negative regulation; Elk-1	NUCLEOTIDE DISSOCIATION STIMULATOR; GTPASE-ACTIVATING PROTEIN; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; KINASE; IDENTIFICATION; PATHWAY; FAMILY; PHOSPHORYLATION	Here, we report the identification and characterization of a new member of the RaIGDS-family, which is widely expressed and interacts strongly and selectively with the GTP-bound forms of M-Ras and p21 Ras, This Ras pathway modulator (RPM), also termed RGL3, exhibited Ras-binding and catalytic domains typical of the RalGDS-family of guanine nucleotide exchange factors, and nas most similar to Rlf (RalGDS-like factor), but ras distinguished by a unique proline-rich region with multiple candidate SH3-domain binding sites. RPM/ RGL3 resembled AF-6 and Nore1 in interacting strongly with constitutively active M-Ras and p21 Ras. In contrast to Rlf, transiently expressed RPM/RGL3 did not activate an Elk-1-indueible reporter gene alone or in combination with activated p21 Ras, but strongly inhibited induction of this reporter gene by co-expression of activated H-Ras or MEKK-1. This inhibitory effect was independent of the Ras binding domain and required a second signal provided by p21 Ras or MEKK-1, but not Raf-1 or M-Ras. Expression of RPM/RGL3 also strongly inhibited cell growth of fibroblasts transformed by an activated Src Y527F. Thus, RPM/RGL3 is a novel potential effector of both p21 Ras and M-Ras with the novel function of negatively regulating Elk-1-dependent gene induction downstream of p21 Ras or MEKK-1.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Orchansky PL, 1999, J BIOL CHEM, V274, P20818, DOI 10.1074/jbc.274.30.20818; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353	41	29	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					188	197		10.1038/sj.onc.1204053	http://dx.doi.org/10.1038/sj.onc.1204053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313946				2022-12-25	WOS:000166410900006
J	Butscher, WG; Haggerty, CM; Chaudhry, S; Gardner, K				Butscher, WG; Haggerty, CM; Chaudhry, S; Gardner, K			Targeting of p300 to the interleukin-2 promoter via CREB-Rel cross-talk during mitogen and oncogenic molecular signaling in activated T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITOUS TRANSCRIPTION FACTORS; CYTOKINE GENE-EXPRESSION; DNA-BINDING ACTIVITY; LEUKEMIA-VIRUS; I TAX; COACTIVATOR CBP; IL-2 GENE; PROTEIN; RECEPTOR	In this report, we explore the mechanisms of targeting of p300 to the interleukin-2 (IL-2) promoter in response to mitogenic and oncogenic molecular signals. Recruitment of p300 by cAMP-responsive element-binding protein-Rel cross-talk at the composite CD28 response element (CD28RE)-TRE element of the IL-2 promoter is essential for promoter inducibility during T-cell activation, and CD28RE-TRE is the exclusive target of the human T-cell lymphotropic virus type I oncoprotein Tax. The intrinsic histone acetyltransferase activity of p300 is dispensable for activation of the IL-2 promoter, and the N-terminal 743 residues contain the minimal structural requirements for synergistic transactivation of the CD28RE-TRE, the IL-2 promoter, and endogenous IL-2 gene expression. Mutational analysis of p300 reveals differential structural requirements for the N-terminal p300 module by individual cis-elements within the IL-2 promoter. These findings provide evidence that p300 assembles at the IL-2 promoter to form an enhanceosome-like signal transduction target that is centrally integrated at the CD28RE-TRE element of the IL-2 promoter through specific protein module-targeted associations in activated T-cells.	NCI, Ctr Adv Technol, Pathol Lab, NIH, Bethesda, MD 20892 USA; Howard Univ, Coll Med, Dept Microbiol, Washington, DC 20059 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard University	Gardner, K (corresponding author), NCI, Ctr Adv Technol, Pathol Lab, NIH, Rm 134C,8717 Grovemont Circle, Bethesda, MD 20892 USA.			Haggerty, Cynthia/0000-0002-6019-2724				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; AVOTS A, 1995, IMMUNOBIOLOGY, V193, P254, DOI 10.1016/S0171-2985(11)80551-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Eckner R, 1996, BIOL CHEM, V377, P685; GARDNER K, 1994, J BIOL CHEM, V269, P32963; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Glass CK, 2000, GENE DEV, V14, P121; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KANNO T, 1995, J BIOL CHEM, V270, P11745, DOI 10.1074/jbc.270.20.11745; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; MANGER B, 1987, J IMMUNOL, V139, P2755; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MUNOZ E, 1995, IMMUNOBIOLOGY, V193, P128, DOI 10.1016/S0171-2985(11)80535-8; PETRAK D, 1994, J IMMUNOL, V153, P2046; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RISSE G, 1990, ENVIRON HEALTH PERSP, V88, P133; Semmes OJ, 1996, J BIOL CHEM, V271, P9730, DOI 10.1074/jbc.271.16.9730; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; Yasui H, 1997, J BIOL CHEM, V272, P28762, DOI 10.1074/jbc.272.45.28762; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	49	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27647	27656		10.1074/jbc.M009614200	http://dx.doi.org/10.1074/jbc.M009614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313336	hybrid			2022-12-25	WOS:000169966900120
J	Oelmann, S; Stanley, P; Gerardy-Schahn, R				Oelmann, S; Stanley, P; Gerardy-Schahn, R			Point mutations identified in Lec8 Chinese hamster ovary glycosylation mutants that inactivate both the UDP-galactose and CMP-sialic acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-MANNOSE TRANSPORTER; NUCLEOTIDE SUGAR TRANSPORTERS; CELL-ADHESION MOLECULE; EXPRESSION CLONING; GOLGI; DEFICIENT; BIOSYNTHESIS; PROTEIN; TRANSLOCATION; PURIFICATION	Nucleotide-sugar transporters (NSTs) are critical components of glycosylation pathways in eukaryotes, The identification of structural elements that are involved in NST functions provides an important task. Chinese hamster ovary glycosylation mutants defective in nucleotide-sugar transport provide access to inactive transporters that can define such structure/function relationships. In this study, we have cloned the hamster UDP-galactose transporter (UGT) and identified defects in UGT gene transcripts from nine independent Chinese hamster ovary mutants that belong to the Lec8 complementation group. Reverse transcription polymerase chain reaction with primers that span the UGT open reading frame showed that three Lec8 mutants express a full-length open reading frame, while six Lec8 mutants predominantly express truncated UGT gene transcripts. Sequencing identified different single or triplet nucleotide changes in full-length UGT transcripts from three of the mutants. These mutations translate into three different amino acid changes at positions that are highly conserved in all the known mammalian NSTs. Transfection of a cDNA encoding either of the mutations Delta serine 213 or G281D failed to correct the UDP-galactose transport defect in Lec8 transfectants. Most importantly, introducing these same mutations into the homologous region of the murine CMP-sialic acid transporter caused inactivation of this transporter. Thus, identifying point mutations that inactivate UGT in Lec8 mutants resulted in the discovery of amino acids that are critical to the activity of both UGT and CST, the two most divergent mammalian NSTs.	Hannover Med Sch, Inst Physiol Chem, D-30625 Hannover, Germany; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Hannover Medical School; Yeshiva University; Albert Einstein College of Medicine	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Physiol Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy-schahn.rita@mh-hannover.de		Stanley, Pamela/0000-0001-5704-3747	NATIONAL CANCER INSTITUTE [R01CA036434] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 36434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe M, 1999, FEBS LETT, V458, P309, DOI 10.1016/S0014-5793(99)01177-1; Aoki K, 1999, J BIOCHEM, V126, P940, DOI 10.1093/oxfordjournals.jbchem.a022538; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; Cacan R, 1998, BIOCHIMIE, V80, P59, DOI 10.1016/S0300-9084(98)80057-6; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gao XD, 2001, J BIOL CHEM, V276, P4424, DOI 10.1074/jbc.M009114200; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GERARDYSCHAHN R, 1994, INT J CANCER, P38; GERARDYSCHAHN R, 2000, OLIGOSACCHARIDES CHE, V2, P19; HARA T, 1989, J BIOCHEM-TOKYO, V106, P236, DOI 10.1093/oxfordjournals.jbchem.a122838; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 1999, J BIOCHEM, V126, P1107, DOI 10.1093/oxfordjournals.jbchem.a022556; Kawakita M, 1998, J BIOCHEM, V123, P777; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; PELS RW, 1995, BIOCHEM J, V305, P865; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; ROTH J, 1997, GOLGI APPARATUS, P131; Segawa H, 1999, FEBS LETT, V451, P295, DOI 10.1016/S0014-5793(99)00596-7; STANLEY P, 1991, Glycobiology, V1, P307, DOI 10.1093/glycob/1.3.307; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; Takegawa K, 1996, BIOSCI BIOTECH BIOCH, V60, P1156; Toma L, 1996, J BIOL CHEM, V271, P3897; Yoshioka S, 1997, J BIOCHEM, V122, P691	49	76	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26291	26300		10.1074/jbc.M011124200	http://dx.doi.org/10.1074/jbc.M011124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319223	hybrid			2022-12-25	WOS:000169823300087
J	Berry, FB; Miura, Y; Mihara, K; Kaspar, P; Sakata, N; Hashimoto-Tamaoki, T; Tamaoki, T				Berry, FB; Miura, Y; Mihara, K; Kaspar, P; Sakata, N; Hashimoto-Tamaoki, T; Tamaoki, T			Positive and negative regulation of myogenic differentiation of C2C12 cells by isoforms of the multiple homeodomain zinc finger transcription factor ATBF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; ENHANCER-BINDING PROTEIN; LOOP-HELIX PROTEINS; MUSCLE DIFFERENTIATION; GENE-EXPRESSION; DNA-BINDING; NEURONAL DIFFERENTIATION; DROSOPHILA ZFH-1; SKELETAL-MUSCLE; MRF4 PROMOTER	The ATBF1 gene encodes two protein isoforms, the 404-kDa ATBF1-A, possessing four homeodomains and 23 zinc fingers, and the 306-kDa ATBF1-B, lacking a 920-amino acid N-terminal region of ATBF1-A which contains 5 zinc fingers. ln vitro, ATBF1-A was expressed in proliferating C2C12 myoblasts, but its expression levels decreased upon induction of myogenic differentiation in low serum medium. Forced expression of ATBF1-A in C2C12 cells resulted in repression of MyoD and myogenin expression and elevation of Id3 and cyclin D1 expression, leading to inhibition of myogenic differentiation in low serum. In contrast, transfection of C2C12 cells with the ATBF1-B isoform led to an acceleration of myogenic differentiation, as indicated by an earlier onset of myosin heavy chain expression and formation of a higher percentage of multinucleated myotubes. The fourth homeodomain of ATBF1-A bound to an AT-rich element adjacent to the El E-box of the muscle regulatory factor 4 promoter mediating transcriptional repression. The ATBF1-A-specific N-terminal region possesses general transcription repressor activity. These results suggest that ATBF1-A plays a role in the maintenance of the undifferentiated myoblast state, and its down-regulation is a prerequisite to initiate terminal differentiation of C2C12 cells.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Nagoya City Univ, Fac Med, Dept Bioregulat Res, Nagoya, Aichi 4678601, Japan; Showa Pharmaceut Univ, Dept Biochem, Tokyo 1948543, Japan; Hyogo Coll Med, Dept Genet, Nishinomiya, Hyogo 6638501, Japan	University of Calgary; Nagoya City University; Showa Pharmaceutical University; Hyogo College of Medicine	Berry, FB (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.		Kaspar, Petr/G-5864-2014; Sakata, Nobuo/L-9753-2015; Kaspar, Petr/J-1705-2014	Sakata, Nobuo/0000-0001-9967-8409; 				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JCJ, 1999, CELL TISSUE RES, V296, P213, DOI 10.1007/s004410051282; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HASHIMOTO T, 1992, MECH DEVELOP, V39, P125, DOI 10.1016/0925-4773(92)90031-E; IDO A, 1994, DEV BIOL, V163, P184, DOI 10.1006/dbio.1994.1134; IKEDA K, 1995, EUR J BIOCHEM, V233, P73, DOI 10.1111/j.1432-1033.1995.073_1.x; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; Kataoka H, 2000, BIOCHEM BIOPH RES CO, V267, P91, DOI 10.1006/bbrc.1999.1911; KOSTICH WA, 1995, DEV DYNAM, V202, P145, DOI 10.1002/aja.1002020206; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lemercier C, 1997, DEV BIOL, V182, P101, DOI 10.1006/dbio.1996.8454; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; MADDEN SL, 1993, ONCOGENE, V8, P1713; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P515, DOI 10.1007/BF02255842; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; Olson EN, 1998, DEV BIOL, V202, P153, DOI 10.1006/dbio.1998.9020; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; Postigo AA, 1999, MOL CELL BIOL, V19, P7255; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walsh K, 1997, Prog Cell Cycle Res, V3, P53; Watanabe M, 1996, MOL BRAIN RES, V42, P344, DOI 10.1016/S0169-328X(96)00204-5; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395; Yoshida S, 1996, J CELL BIOL, V132, P181, DOI 10.1083/jcb.132.1.181; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	64	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25057	25065		10.1074/jbc.M010378200	http://dx.doi.org/10.1074/jbc.M010378200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312261	hybrid			2022-12-25	WOS:000169800700084
J	Choi, KS; Fitzpatrick, SL; Filipenko, NR; Fogg, DK; Kassam, G; Magliocco, AM; Waisman, DM				Choi, KS; Fitzpatrick, SL; Filipenko, NR; Fogg, DK; Kassam, G; Magliocco, AM; Waisman, DM			Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RECEPTOR; EXTRACELLULAR-MATRIX; T-PA; TETRAMER; ACTIVATOR; BINDING; SYSTEM; SURFACE; ENHANCEMENT; MECHANISMS	In a previous report we showed that plasmin-dependent lysis of a fibrin polymer, produced from purified components, was totally blocked if annexin II heterotetramer (AIIt) was present during fibrin polymer formation. Here, we show that AIIt inhibits fibrin clot lysis by stimulation of plasmin autodegradation, which results in a loss of plasmin activity. Furthermore, the C-terminal lysine residues of its pll subunit play an essential role in the inhibition of fibrin clot lysis by AIIt, We also found that AIIt binds to fibrin with a K-d of 436 nM and a stoichiometry of about 0.28 mol of AIIt/mol of fibrin monomer. The binding of AIIt to fibrin was not dependent on the C-terminal lysines of the p11 subunit, Furthermore, in the presence of plasminogen, the binding of AIIt to fibrin was increased to about 1.3 mol of AIIt/mol of fibrin monomer, suggesting that AIIt and plasminogen do not compete for identical sites on fibrin. Immunohistochemical identification of p36 and p11 subunits of AIIt in a pathological clot provides important evidence for its role as a physiological fibrinolytic regulator. These results suggest that AIIt may play a key role in the regulation of plasmin activity on the fibrin clot surface.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pathol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@acs.ucalgary.ca	Magliocco, Anthony M/E-5723-2010	Waisman, David/0000-0002-5097-9662				Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Choi KS, 1998, BIOCHEMISTRY-US, V37, P648, DOI 10.1021/bi971005k; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; Filipenko NR, 2001, J BIOL CHEM, V276, P3718; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Hajjar K A, 1995, Curr Opin Hematol, V2, P345; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; HUSAIN SS, 1991, ARCH BIOCHEM BIOPHYS, V285, P373, DOI 10.1016/0003-9861(91)90375-S; JESPERSEN J, 1986, THROMB RES, V41, P395, DOI 10.1016/0049-3848(86)90250-1; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P387; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MAGNUSSON S, 1996, PROTEOLYSIS PHYSIOLO, P203; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MOSER TL, 1993, J BIOL CHEM, V268, P18917; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; MUSIAL J, 1986, PROSTAGLANDINS, V31, P61, DOI 10.1016/0090-6980(86)90225-X; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Olman MA, 1999, BLOOD, V94, P2029, DOI 10.1182/blood.V94.6.2029.418k25_2029_2038; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; STUMP DC, 1988, ANN EMERG MED, V17, P1138, DOI 10.1016/S0196-0644(88)80059-3; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TAKADA A, 1988, Haemostasis, V18, P25; TRACY PB, 1988, SEMIN THROMB HEMOST, V14, P227, DOI 10.1055/s-2007-1002782; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	47	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25212	25221		10.1074/jbc.M101426200	http://dx.doi.org/10.1074/jbc.M101426200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319229	hybrid			2022-12-25	WOS:000169800700105
J	Lively, TN; Ferguson, HA; Galasinski, SK; Seto, AC; Goodrich, JK				Lively, TN; Ferguson, HA; Galasinski, SK; Seto, AC; Goodrich, JK			c-Jun binds the N terminus of human TAF(II)250 to derepress RNA polymerase II transcription in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BOX-BINDING; DNA-BINDING; MEDIATED TRANSCRIPTION; PROMOTER SELECTIVITY; ACTIVATION DOMAIN; LACKING TAF(II)S; COMPLEX; PROTEIN; TFIIA; YEAST	c-Jun is an oncoprotein that activates transcription of many genes involved in cell growth and proliferation. We studied the mechanism of transcriptional activation by human c-Jun in a human RNA polymerase II transcription system composed of highly purified recombinant and native transcription factors. Transcriptional activation by c-Jun depends on the TATA-binding protein (TBP)-associated factor (TAF) subunits of transcription factor IID (TFIID), Protein-protein interaction assays revealed that c-Jun binds with high specificity to the largest subunit of human TFIID, TAF(II)250, The region of TAF(II)250 bound by c-Jun lies in the N-terminal 163 amino acids. This same region of TAF(II)250 binds to TBP and represses its interaction with TATA boxes, thereby decreasing DNA binding by TFIID. We hypothesized that c-Jun is capable of derepressing the effect of the TAF(II)250 N terminus on TFIID-driven transcription. In support of this hypothesis, we found that c-Jun increased levels of TFIID-driven transcription in vitro when added at high concentrations to a DNA template lacking activator protein 1 (AP-1) sites. Moreover, c-Jun blocked the repression of TBP DNA binding caused by the N terminus of TAF(II)250. In addition to revealing a mechanism by which c-Jun activates transcription, our studies provide the first evidence that an activator can bind directly to the N terminus of TAF(II)250 to derepress RNA polymerase II transcription in vitro.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Goodrich, JK (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135, R01GM055235] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55235, T32 GM07135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478	46	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25582	25588		10.1074/jbc.M100278200	http://dx.doi.org/10.1074/jbc.M100278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316804	hybrid			2022-12-25	WOS:000169800700149
J	Barnes, BJ; Moore, PA; Pitha, PM				Barnes, BJ; Moore, PA; Pitha, PM			Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I INTERFERON; TRANSCRIPTION FACTORS; FUNCTIONAL-ANALYSIS; MEDIATED INDUCTION; POSITIVE FEEDBACK; PROMOTER REGION; PROTEIN; CELLS; IDENTIFICATION; EXPRESSION	Interferon regulatory factor (IRF) genes encode DNA-binding proteins that are involved in the innate immune response to infection. Two of these proteins, IRF-3 and IRF-7, serve as direct transducers of virus-mediated signaling and play critical roles in the induction of type I interferon genes. We have now shown that another factor, IRF-5, participates in the induction of interferon A (IFNA) and IFNB genes and can replace the requirement for IRF-7 in the induction of IFNA genes, We demonstrate that, despite the functional similarity, IRF-5 possesses unique characteristics and does not have a redundant role. Thus, 1) activation of IRF-5 by phosphorylation is virus-specific, and its in vivo association with the IFNA promoter can be detected only in cells infected with NDV, not Sendai virus, while both viruses activate IRF-3 and IRF-7, and 2) NDV infection of IFNA8 overexpressing cells preferentially induced the IFNA8 subtype, while IFNA1 was primarily induced in IRF-7 expressing cells. These data indicate that multiple signaling pathways induced by infection may be differentially recognized by members of the IRF family and modulate transcription of individual IFNA genes in a virus and cell type-specific manner.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; GlaxoSmithKline; Human Genome Sciences Inc	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 1650 Orleans St, Baltimore, MD 21231 USA.				NIAID NIH HHS [AII937] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Burysek L, 1999, J VIROL, V73, P7334; DEMAEYER E, 1988, INTERFERONS OTHER RE, P364; Dent CL, 1996, J INTERF CYTOK RES, V16, P99, DOI 10.1089/jir.1996.16.99; DIAZ MO, 1995, SEMIN VIROL, V6, P143, DOI 10.1006/smvy.1995.0019; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; FITZGERALDBOCAR.PA, 2000, EUR CYTOKINE NETW, V11, P33; Foster GR, 1996, J INTERF CYTOK RES, V16, P1027, DOI 10.1089/jir.1996.16.1027; Hayashida S, 2000, GENOMICS, V66, P221, DOI 10.1006/geno.2000.6206; Hibbert L, 1999, J INTERF CYTOK RES, V19, P309, DOI 10.1089/107999099314009; HO M, 1973, INTERFERONS INTERFER, P29; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Juang YT, 1999, J BIOL CHEM, V274, P18060, DOI 10.1074/jbc.274.25.18060; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lopez SB, 2000, MOL CELL BIOL, V20, P7527, DOI 10.1128/MCB.20.20.7527-7540.2000; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Slifka MK, 2000, IMMUNITY, V12, P451, DOI 10.1016/S1074-7613(00)80197-1; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Touchman JW, 1997, GENOME RES, V7, P281, DOI 10.1101/gr.7.3.281; WATHELET MG, 1998, MOL CELL, V1, P1359; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	54	300	307	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23382	23390		10.1074/jbc.M101216200	http://dx.doi.org/10.1074/jbc.M101216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11303025	hybrid			2022-12-25	WOS:000169531100023
J	Goda, M; Hashimoto, Y; Shimizu, S; Kobayashi, M				Goda, M; Hashimoto, Y; Shimizu, S; Kobayashi, M			Discovery of a novel enzyme, isonitrile hydratase, involved in nitrogen-carbon triple bond cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOCOCCUS-RHODOCHROUS J1; MASS NITRILE HYDRATASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; PSEUDOMONAS-CHLORORAPHIS B23; DNA-BASE COMPOSITION; REACTION-PRODUCT; GENE-CLUSTER; PURIFICATION; IDENTIFICATION; AMIDASE	Isonitrile containing an N equivalent toC triple bond was degraded by microorganism sp N19-2, which was isolated from soil through a 2-month acclimatization culture in the presence of this compound. The isonitrile-degrading microorganism was identified as Pseudomonas putida The microbial degradation was found to proceed through an enzymatic reaction, the isonitrile being hydrated to the corresponding N-substituted formamide. The enzyme, named isonitrile hydratase, was purified and characterized. The native enzyme had a molecular mass of about 59 kDa and consisted of two identical subunits. The enzyme stoichiometrically catalyzed the hydration of cyclohexyl isocyanide tan isonitrile) to N-cyclohexylformamide, but no formation of other compounds was detected. The apparent K-m value for cyclohexyl isocyanide mas 16.2 mM. Although the enzyme acted on various isonitriles, no nitriles or amides were accepted as substrates.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	University of Tsukuba; Kyoto University	Kobayashi, M (corresponding author), Univ Tsukuba, Inst Appl Biochem, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.							ACHENBAC.H, 1972, CHEM BER-RECL, V105, P784, DOI 10.1002/cber.19721050307; ACHENBACH H, 1965, Z NATURFORSCH PT B, VB 20, P137, DOI 10.1515/znb-1965-0209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRESON BJ, 1975, J AM CHEM SOC, V97, P4763, DOI 10.1021/ja00849a053; CAFIERI F, 1973, TETRAHEDRON, V29, P4259, DOI 10.1016/0040-4020(73)80267-4; EDENBOROUGH MS, 1988, NAT PROD REP, V5, P229, DOI 10.1039/np9880500229; HAGADONE MR, 1984, J AM CHEM SOC, V106, P2447, DOI 10.1021/ja00320a044; HAGEDORN J, 1957, PHARMAZIE, V12, P567; KATAYAMAFUJIMURA Y, 1984, AGR BIOL CHEM TOKYO, V48, P3169, DOI 10.1080/00021369.1984.10866660; KATOH K, 1983, REPT NATL FOOD RES I, V43, P79; KELLY M, 1967, BIOCHEM J, V102, pC1, DOI 10.1042/bj1020001C; Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9; KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714; KOBAYASHI M, 1989, EUR J BIOCHEM, V182, P349, DOI 10.1111/j.1432-1033.1989.tb14837.x; Kobayashi M, 2000, CURR OPIN CHEM BIOL, V4, P95, DOI 10.1016/S1367-5931(99)00058-7; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042; KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746; Kobayashi M, 1998, NAT BIOTECHNOL, V16, P733, DOI 10.1038/nbt0898-733; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOBAYASHI M, 1994, FEMS MICROBIOL LETT, V120, P217, DOI 10.1016/0378-1097(94)90474-X; KOBAYASHI M, 1990, J BACTERIOL, V172, P4807, DOI 10.1128/jb.172.9.4807-4815.1990; Komeda H, 1996, P NATL ACAD SCI USA, V93, P4267, DOI 10.1073/pnas.93.9.4267; Komeda H, 1996, J BIOL CHEM, V271, P15796, DOI 10.1074/jbc.271.26.15796; Komeda H, 1996, P NATL ACAD SCI USA, V93, P10572, DOI 10.1073/pnas.93.20.10572; Komeda H, 1997, P NATL ACAD SCI USA, V94, P36, DOI 10.1073/pnas.94.1.36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAGASAWA T, 1987, EUR J BIOCHEM, V162, P691, DOI 10.1111/j.1432-1033.1987.tb10692.x; NAGASAWA T, 1986, BIOCHEM BIOPH RES CO, V139, P1305, DOI 10.1016/S0006-291X(86)80320-5; NISHIYAMA M, 1991, J BACTERIOL, V173, P2465, DOI 10.1128/jb.173.8.2465-2472.1991; PFEIFER S, 1972, PHARMAZIE, V27, P536; RUBINSON JF, 1983, BIOCHEMISTRY-US, V22, P6260, DOI 10.1021/bi00295a034; SCHEUER PJ, 1992, ACCOUNTS CHEM RES, V25, P433, DOI 10.1021/ar00022a001; SUGIURA Y, 1987, J AM CHEM SOC, V109, P5848, DOI 10.1021/ja00253a046; TAMAOKA J, 1984, FEMS MICROBIOL LETT, V25, P125, DOI 10.1016/0378-1097(84)90059-4; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391	39	37	45	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23480	23485		10.1074/jbc.M007856200	http://dx.doi.org/10.1074/jbc.M007856200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306561	hybrid			2022-12-25	WOS:000169531100035
J	Pincas, H; Laverriere, JN; Counis, R				Pincas, H; Laverriere, JN; Counis, R			Pituitary adenylate cyclase-activating polypeptide and cyclic adenosine 3 ',5 '-monophosphate stimulate the promoter activity of the rat gonadotropin-releasing hormone receptor gene via a bipartite response element in gonadotrope-derived cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; SIGNAL-TRANSDUCTION PATHWAYS; MESSENGER RIBONUCLEIC-ACIDS; PROTEIN-KINASE-C; TRANSCRIPTIONAL ACTIVATION; 5'-FLANKING REGION; ALPHA-T3-1 CELLS; RNA LEVELS; EXPRESSION; GNRH	Specific type I receptors for pituitary adenylate cyclase-activating polypeptide (PACAP) are present in gonadotrope cells of the anterior pituitary gland. By transient transfection of mouse gonadotrope-derived alpha T3-1 cells, which are direct targets for PACAP and express gonadotropin-releasing hormone receptor (GnRH-R), a marker of the gonadotrope lineage, we provide the first evidence that PACAP stimulates rat GnRH-R gene promoter activity. The EC50 of this stimulation is compatible with a mediation via activation of the cyclic AMP-dependent signaling pathway and, consistently, co-transfection of an expression vector expressing the protein kinase A inhibitor causes reduction in PACAP as well as cholera toxin-stimulated promoter activity. Deletion and mutational analyses indicate that PACAP activation necessitates a bipartite response element that consists of a first region (-272/-237) termed PACAP response element (PARE) I that includes a steroidogenic factor-1 (SF-1)-binding site and a second region (-136/-101) referred to as PARE II that contains an imperfect cyclic AMP response element. Gel shift experiments indicate the specific binding of the SF-1 and a potential SF-1-interacting factor to PARE I while a protein inununologically related to the cyclic AMP response element-binding protein interacts with PARE II. These findings suggest that PACAP might regulate the GnRH-R gene at the transcriptional level, providing novel insights into the regulation of pituitary-specific genes by hypothalamic hypophysiotropic signals.	Univ Paris 06, CNRS, ESA 7080, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Counis, R (corresponding author), Univ Paris 06, CNRS, ESA 7080, Case 244, F-75252 Paris 05, France.	Raymond.Counis@snv.jussieu.fr	Laverriere, Jean-Noel/L-3286-2017	Laverriere, Jean-Noel/0000-0003-0442-1358				Alarid ET, 1996, DEVELOPMENT, V122, P3319; ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attardi B, 1998, MOL CELL ENDOCRINOL, V137, P97, DOI 10.1016/S0303-7207(98)00006-9; BAUERDANTOIN AC, 1993, ENDOCRINOLOGY, V133, P1911, DOI 10.1210/en.133.4.1911; Burrin JM, 1998, ENDOCRINOLOGY, V139, P1731, DOI 10.1210/en.139.4.1731; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Cheng KW, 2000, ENDOCRINOLOGY, V141, P3611, DOI 10.1210/en.141.10.3611; CLAY CM, 1995, ENDOCRINE, V3, P615, DOI 10.1007/BF02953028; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; Duval DL, 1999, ENDOCRINOLOGY, V140, P1949, DOI 10.1210/en.140.4.1949; Duval DL, 1997, MOL ENDOCRINOL, V11, P1814, DOI 10.1210/me.11.12.1814; FAN NC, 1995, MOL CELL ENDOCRINOL, V107, pR1, DOI 10.1016/0303-7207(94)03460-B; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HART GR, 1992, J ENDOCRINOL, V134, P33, DOI 10.1677/joe.0.1340033; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; ISHIZAKA K, 1993, ENDOCRINOLOGY, V133, P2040, DOI 10.1210/en.133.5.2040; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; KAISER UB, 1993, ENDOCRINOLOGY, V133, P931, DOI 10.1210/en.133.2.931; LERRANT Y, 1995, ENDOCRINOLOGY, V136, P2803, DOI 10.1210/en.136.7.2803; Lin XW, 1998, ENDOCRINOLOGY, V139, P3896, DOI 10.1210/en.139.9.3896; Lin XW, 1999, ENDOCRINOLOGY, V140, P358, DOI 10.1210/en.140.1.358; Lopez D, 1999, ENDOCRINOLOGY, V140, P3034, DOI 10.1210/en.140.7.3034; Maya-Nunez G, 1999, ENDOCRINOLOGY, V140, P3452, DOI 10.1210/en.140.8.3452; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Naville D, 1999, BIOCHEM BIOPH RES CO, V255, P28, DOI 10.1006/bbrc.1998.9891; Ngan ESW, 1999, ENDOCRINOLOGY, V140, P2452, DOI 10.1210/endo.140.6.6759; Norwitz ER, 1999, J BIOL CHEM, V274, P867, DOI 10.1074/jbc.274.2.867; OSUGA Y, 1992, ENDOCRINOL JAPON, V39, P153; Pincas H, 2001, MOL ENDOCRINOL, V15, P319, DOI 10.1210/me.15.2.319; Pincas H, 1998, MOL CELL ENDOCRINOL, V144, P95, DOI 10.1016/S0303-7207(98)00149-X; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; Reinhart J, 1997, MOL CELL ENDOCRINOL, V130, P1, DOI 10.1016/S0303-7207(97)00064-6; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; TSUJII T, 1994, ENDOCRINOLOGY, V135, P826, DOI 10.1210/en.135.3.826; TSUJII T, 1995, MOL CELL ENDOCRINOL, V113, P123, DOI 10.1016/0303-7207(95)03613-C; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VAUDRY D, 2000, PHARMACOL REV, V52, P296; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Winters SJ, 1997, ENDOCRINOLOGY, V138, P4324, DOI 10.1210/en.138.10.4324; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	44	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23562	23571		10.1074/jbc.M100563200	http://dx.doi.org/10.1074/jbc.M100563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320087	hybrid			2022-12-25	WOS:000169531100047
J	Tsuji, S; Uehori, J; Matsumoto, M; Suzuki, Y; Matsuhisa, A; Toyoshima, K; Seya, T				Tsuji, S; Uehori, J; Matsumoto, M; Suzuki, Y; Matsuhisa, A; Toyoshima, K; Seya, T			Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEREGRINA HUMORAL LECTIN; MANNOSE-BINDING PROTEIN; C-TYPE LECTIN; XENOPUS-LAEVIS; SERINE-PROTEASE; ASIALOGLYCOPROTEIN RECEPTOR; LEISHMANIA-MAJOR; CLONING; CDNA; EXPRESSION	Galactofuranosyl residues are present in various microorganisms but not in mammals, In this study, we identified a human lectin binding to galactofuranosyl residues and named this protein human intelectin (hIntL). The mature hIntL was a secretory glycoprotein consisting of 295 amino acids and N-linked oligosaccharides, and its basic structural unit was a 120-kDa homotrimer in which 40-kDa polypeptides mere bridged by disulfide bonds. The hIntL gene was spilt into 8 exons on chromosome 1q21.3, and hIntL mRNA was expressed in the heart, small intestine, colon, and thymus, hIntL showed high levels of homology with mouse intelectin, Xenopus laevis cortical granule lectin/oocyte lectin, lamprey serum lectin, and ascidian galactose-specific lectin, These homologues commonly contained no carbohydrate recognition domain, which is a characteristic of C-type lectins, although some of them have been reported as Ca2+-dependent lectins. Recombinant hIntL revealed affinities to D-pentoses and a D-galactofuranosyl residue in the presence of Ca2+, and recognized the bacterial arabinogalactan of Nocardia containing D-galactofuranosyl residues. These results suggested that hIntL is a new type lectin recognizing galactofuranose, and that hIntL plays a role in the recognition of bacteria-specific components in the host.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan; Osaka Prefectural Inst Publ Hlth, Higashinari Ku, Osaka 5370025, Japan; Fuso Pharmaceut Ind Ltd, Ctr Res & Dev, Joto Ku, Osaka 5368523, Japan; Org Pharmaceut Safety & Res, Tokyo 1000013, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Prefectural Institute of Public Health; Fuso Pharmaceutical Industries, Ltd.	Seya, T (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan.		Suzuki, Yasuhiko/F-6890-2012; Seya, Tsukasa/A-4336-2012					Abe Y, 1999, EUR J BIOCHEM, V261, P33, DOI 10.1046/j.1432-1327.1999.00238.x; ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P8568, DOI 10.1021/bi00099a012; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DELEDERKREMER RM, 1995, GLYCOBIOLOGY, V5, P547, DOI 10.1093/glycob/5.6.547; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GERTON GL, 1986, DEV BIOL, V116, P1, DOI 10.1016/0012-1606(86)90036-9; Inoue N, 2001, J IMMUNOL, V166, P424, DOI 10.4049/jimmunol.166.1.424; IZUMI S, 1987, CANCER RES, V47, P1785; IZUMI S, 1986, CANCER RES, V46, P1960; KOMANO H, 1985, DEV COMP IMMUNOL, V9, P31, DOI 10.1016/0145-305X(85)90057-6; Komiya T, 1998, BIOCHEM BIOPH RES CO, V251, P759, DOI 10.1006/bbrc.1998.9513; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; Lee JK, 1997, GLYCOBIOLOGY, V7, P367, DOI 10.1093/glycob/7.3.367; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; Naik UP, 2001, J CELL SCI, V114, P539; NISHIHARA T, 1986, BIOCHEMISTRY-US, V25, P6013, DOI 10.1021/bi00368a027; NOTERMANS S, 1988, MOL IMMUNOL, V25, P975, DOI 10.1016/0161-5890(88)90003-X; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; OZAKI K, 1992, J BIOL CHEM, V267, P9229; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Quill TA, 1996, ARCH BIOCHEM BIOPHYS, V333, P326, DOI 10.1006/abbi.1996.0398; ROBERSON MM, 1983, J CELL BIOL, V97, P1875, DOI 10.1083/jcb.97.6.1875; ROBERSON MM, 1982, J BIOL CHEM, V257, P7520; Sandrin MS, 1996, IMMUNOGENETICS, V43, P13; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STAUNTON DE, 1989, J EXP MED, V169, P1087, DOI 10.1084/jem.169.3.1087; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; SUPER M, 1989, LANCET, V2, P1236; Suzuki E, 1997, GLYCOBIOLOGY, V7, P463, DOI 10.1093/glycob/7.4.463; Suzuki N, 1996, J IMMUNOL, V156, P128; TAKAHASHI H, 1985, J BIOL CHEM, V260, P2228; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; WARR GA, 1980, BIOCHEM BIOPH RES CO, V93, P737, DOI 10.1016/0006-291X(80)91139-0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G	41	276	299	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23456	23463		10.1074/jbc.M103162200	http://dx.doi.org/10.1074/jbc.M103162200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313366	hybrid			2022-12-25	WOS:000169531100032
J	Lambert, C; Prange, R				Lambert, C; Prange, R			Dual topology of the hepatitis B virus large envelope protein - Determinants influencing post-translational pre-S translocatton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE SURFACE PROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE TOPOLOGY; PARTICLE MORPHOGENESIS; MEMBRANE-PROTEIN; ANTIGEN; GLYCOPROTEIN; SEQUENCE; DOMAIN; INSERTION	The large (L) envelope protein of the hepatitis B virus (HBV) has the peculiar capacity to form two transmembrane topologies via an as yet uncharacterized process of partial post-translational translocation of its pre-S domain across membranes. In view of a current model that predicts an HBV-specific channel generated during virion envelope assembly to enable pre-S translocation, we have examined parameters influencing L topogenesis by using protease protection analysis of wild-type and mutant L proteins synthesized in transfected cells. We demonstrate that contrary to expectation, all determinants, thought to be responsible for channel formation, are dispensable for pre-S reorientation. In particular, we observed that this process does not require (i) the helper function of the HBV S (small) and M (middle) envelope proteins, (ii) covalent dimer formation of envelope chains, or (iii) either of the three amphipathic transmembrane segments of L. Rather, the most hydro phobic transmembrane segment 2 of L was identified as a vital topogenic determinant, essential and sufficient for post-translational pre-S translocation. Cell fractionation studies revealed that pre-S refolding and thus the dual topology of L is established at the endoplasmic reticulum (ER) membrane rather than at a post-ER compartment as originally supposed. Together our data pro vide evidence to suggest that the topological reorientation of L is facilitated by a host cell transmembrane transport machinery such as the ER translocon.	Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Prange, R (corresponding author), Univ Mainz, Inst Med Microbiol & Hyg, Augustuspl, D-55101 Mainz, Germany.							Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; Berting A, 1995, INTERVIROLOGY, V38, P8, DOI 10.1159/000150409; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x; BRUSS V, 1995, J VIROL, V69, P6652, DOI 10.1128/JVI.69.11.6652-6657.1995; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1990, J VIROL, V64, P1414, DOI 10.1128/JVI.64.3.1414-1419.1990; Foster W, 2000, J BIOL CHEM, V275, P34157, DOI 10.1074/jbc.M000165200; GERHARDT E, 1995, J VIROL, V69, P1201, DOI 10.1128/JVI.69.2.1201-1208.1995; Grgacic EVL, 2000, J VIROL, V74, P2455, DOI 10.1128/JVI.74.5.2455-2458.2000; Guo JT, 1997, J VIROL, V71, P1107, DOI 10.1128/JVI.71.2.1107-1114.1997; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEDGE RS, 1999, TRENDS CELL BIOL, V9, P132; HEDGE RS, 1998, MOL CELL, V2, P85; Hildt E, 1996, VIROLOGY, V225, P235, DOI 10.1006/viro.1996.0594; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; KRIJNSELOCKER J, 1992, J BIOL CHEM, V267, P21911; Le Seyec J, 1998, J VIROL, V72, P5573, DOI 10.1128/JVI.72.7.5573-5578.1998; Le Seyec J, 1999, J VIROL, V73, P2052, DOI 10.1128/JVI.73.3.2052-2057.1999; Levy D, 1996, Essays Biochem, V31, P49; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Loffler-Mary H, 2000, VIROLOGY, V270, P358, DOI 10.1006/viro.2000.0268; LofflerMary H, 1997, VIROLOGY, V235, P144, DOI 10.1006/viro.1997.8689; Lu XY, 1996, J VIROL, V70, P2277, DOI 10.1128/JVI.70.4.2277-2285.1996; Lu Y, 2000, MOL BIOL CELL, V11, P2973, DOI 10.1091/mbc.11.9.2973; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Nassal M, 1996, CURR TOP MICROBIOL, V214, P297; Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154; OSTAPCHUK P, 1994, EMBO J, V13, P1048, DOI 10.1002/j.1460-2075.1994.tb06353.x; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PRANGE R, 1992, J VIROL, V66, P5832, DOI 10.1128/JVI.66.10.5832-5841.1992; PRANGE R, 1995, EMBO J, V14, P247, DOI 10.1002/j.1460-2075.1995.tb06998.x; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Sansom MSP, 1998, BIOESSAYS, V20, P992, DOI 10.1002/(SICI)1521-1878(199812)20:12<992::AID-BIES5>3.0.CO;2-7; Satoh O, 2000, J BIOCHEM-TOKYO, V127, P543, DOI 10.1093/oxfordjournals.jbchem.a022639; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; STIRK HJ, 1992, INTERVIROLOGY, V33, P148, DOI 10.1159/000150244; Swameye I, 1997, J VIROL, V71, P9434, DOI 10.1128/JVI.71.12.9434-9441.1997; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	44	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22265	22272		10.1074/jbc.M100956200	http://dx.doi.org/10.1074/jbc.M100956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301328	hybrid			2022-12-25	WOS:000169412700041
J	Wang, Q; Ko, KS; Kapus, A; McCulloch, CAG; Ellen, RP				Wang, Q; Ko, KS; Kapus, A; McCulloch, CAG; Ellen, RP			A spirochete surface protein uncouples store-operated calcium channels in fibroblasts - A novel cytotoxic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; TREPONEMA-DENTICOLA; GINGIVAL FIBROBLASTS; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; HUMAN PLATELETS; ACTIN CYTOSKELETON; ESCHERICHIA-COLI; OUTER SHEATH; ION CHANNELS	The cytotoxicity of infectious agents can be mediated by disruption of calcium signaling in target cells. Outer membrane proteins of the spirochete Treponema denticola, a periodontal pathogen, inhibit agonist induced Ca2+ release from internal stores in gingival fibroblasts, but the mechanism is not defined. We determined here that the major surface protein (Msp) of T. denticola perturbs calcium signaling in human fibroblasts by uncoupling store-operated channels. Msp localized in complexes on the cell surface. Ratio fluorimetry showed that in cells loaded with fura-2 or fura-C18, Msp induced cytoplasmic and near-plasma membrane Ca2+ transients, respectively. Increased conductance was confirmed by fluorescence quenching of fura-2-loaded cells with Mn2+ after Msp treatment. Calcium entry was blocked with anti-Msp antibodies and inhibited by chelating external Ca2+ with EGTA. Msp pretreatment reduced the amplitude of [Ca2+](i) transients upon challenge with ATP or thapsigargin. In experiments using cells loaded with mag-fura-a to report endoplasmic reticulum Ca2+, Msp reduced Ca2+ efflux from endoplasmic reticulum stores when ATP was used as an agonist. Msp alone did not induce Ca2+ release from these stores. Msp inhibited store-operated influx of extracellular calcium following intracellular Ca2+ depletion by thapsigargin and also promoted the assembly of subcortical actin filaments. This actin assembly was blocked by chelating intracellular Ca2+ with 1,2 bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester. The reduced amplitude of agonist-induced transients and inhibition of store-operated Ca2+ entry due to Msp were reversed by latrunculin B, an inhibitor of actin filament assembly. Thus, Msp retards Ca2+ release from endoplasmic reticulum stores, and it inhibits subsequent Ca2+ influx by uncoupling store-operated channels. Actin filament rearrangement coincident with conformational uncoupling of store operated calcium fluxes is a novel mechanism by which surface proteins and toxins of pathogenic microorganisms may damage host cells.	Univ Toronto, Fac Dent, Dent Res Inst, Toronto, ON M5G 1G6, Canada; Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Periodontal Physiol, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1G6, Canada; Toronto Gen Hosp, Div Surg, Toronto, ON M5G 1G6, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Ellen, RP (corresponding author), Univ Toronto, Fac Dent, Dent Res Inst, 124 Edward St, Toronto, ON M5G 1G6, Canada.							Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; BAEHNI PC, 1992, INFECT IMMUN, V60, P3360, DOI 10.1128/IAI.60.8.3360-3368.1992; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; Battikhi T, 1999, INFECT IMMUN, V67, P1220, DOI 10.1128/IAI.67.3.1220-1226.1999; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; BIBBY KJ, 1994, AM J PHYSIOL, V266, pC1639, DOI 10.1152/ajpcell.1994.266.6.C1639; Buommino E, 1999, INFECT IMMUN, V67, P4794, DOI 10.1128/IAI.67.9.4794-4800.1999; DAWSON JR, 1990, INFECT IMMUN, V58, P3924, DOI 10.1128/IAI.58.12.3924-3928.1990; DEFILIPPO AB, 1995, ARCH ORAL BIOL, V40, P199, DOI 10.1016/0003-9969(95)98809-D; DYTOC M, 1994, GASTROENTEROLOGY, V106, P1150, DOI 10.1016/0016-5085(94)90004-3; EGLI C, 1993, INFECT IMMUN, V61, P1694, DOI 10.1128/IAI.61.5.1694-1699.1993; Ellen RP, 1999, MICROBES INFECT, V1, P621, DOI 10.1016/S1286-4579(99)80062-8; Ellen RP, 2000, J MOL MICROB BIOTECH, V2, P581; ELLEN RP, 1994, INFECT IMMUN, V62, P3033, DOI 10.1128/IAI.62.7.3033-3037.1994; ETTER EF, 1994, J BIOL CHEM, V269, P10141; Fenno JC, 1996, J BACTERIOL, V178, P2489, DOI 10.1128/jb.178.9.2489-2497.1996; Fenno JC, 1997, J BACTERIOL, V179, P1082, DOI 10.1128/jb.179.4.1082-1089.1997; Fenno JC, 1998, INFECT IMMUN, V66, P1869, DOI 10.1128/IAI.66.5.1869-1877.1998; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAAPASALO M, 1992, INFECT IMMUN, V60, P2058, DOI 10.1128/IAI.60.5.2058-2065.1992; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Izutsu KT, 1996, FEMS MICROBIOL LETT, V144, P145, DOI 10.1111/j.1574-6968.1996.tb08521.x; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kallstrom H, 1998, J BIOL CHEM, V273, P21777, DOI 10.1074/jbc.273.34.21777; Ko KSC, 1998, INFECT IMMUN, V66, P703, DOI 10.1128/IAI.66.2.703-709.1998; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; KULKARNI GV, 1994, J CELL SCI, V107, P1169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mathers DA, 1996, INFECT IMMUN, V64, P2904, DOI 10.1128/IAI.64.8.2904-2910.1996; McCloskey MA, 2000, J CELL BIOL, V148, P137, DOI 10.1083/jcb.148.1.137; Muller A, 1999, EMBO J, V18, P339, DOI 10.1093/emboj/18.2.339; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PENDER N, 1991, J CELL SCI, V100, P187; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCOPES RK, 1997, CURRENT PROTOCOLS MO, V2; Seidl J, 1999, CYTOMETRY, V36, P102, DOI 10.1002/(SICI)1097-0320(19990601)36:2<102::AID-CYTO3>3.0.CO;2-D; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; UITTO VJ, 1995, INFECT IMMUN, V63, P3401, DOI 10.1128/IAI.63.9.3401-3410.1995; Yang PF, 1998, INFECT IMMUN, V66, P696, DOI 10.1128/IAI.66.2.696-702.1998	51	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23056	23064		10.1074/jbc.M011735200	http://dx.doi.org/10.1074/jbc.M011735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312269	hybrid			2022-12-25	WOS:000169412700143
J	Seno, K; Kishimoto, M; Abe, M; Higuchi, Y; Mieda, M; Owada, Y; Yoshiyama, W; Liu, H; Hayashi, F				Seno, K; Kishimoto, M; Abe, M; Higuchi, Y; Mieda, M; Owada, Y; Yoshiyama, W; Liu, H; Hayashi, F			Light- and guanosine 5 '-3-O-(thio)triphosphate-sensitive localization of a G protein and its effector on detergent-resistant membrane rafts in rod photoreceptor outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP PHOSPHODIESTERASE; GAMMA-SUBUNIT; ALPHA-SUBUNIT; TRANSDUCIN; DOMAIN; CYSTEINE; BINDING	Detergent-resistant membrane microdomains in the plasma membrane, known as lipid rafts, have been implicated in various cellular processes. We report here that a low-density Triton X-100-insoluble membrane (detergent-resistant membrane; DRM) fraction is present in bovine rod photoreceptor outer segments (ROS), In dark-adapted ROS, transducin and most of cGMP-phosphodiesterase (PDE) were detergent-soluble. When ROS membranes were exposed to light, however, a large portion of transducin localized in the DRM fraction. Furthermore, on addition of guanosine 5'-3-O-(thio)triphosphate (GTP gammaS) to light-bleached ROS, transducin became detergent-soluble again. PDE was not recruited to the DRM fraction after light stimulus alone, but simultaneous stimulation by light and GTP gammaS induced a massive translocation of all PDE subunits to the DRM, A cholesterol-removing reagent, methyl-beta -cyclodextrin, selectively but partially solubilized PDE from the DRM, suggesting that cholesterol contributes, at least in part, to the association of PDE with the DRM, By contrast, transducin was not extracted by the depletion of cholesterol, These data suggest that transducin and PDE are likely to perform their functions in phototransduction by changing their localization between two distinct lipid phases, rafts and surrounding fluid membrane, on disc membranes in an activation-dependent manner.	Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Grad Sch Sci & Technol, Nada Ku, Kobe, Hyogo 657, Japan	Kobe University; Kobe University	Hayashi, F (corresponding author), Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe, Hyogo 657, Japan.	fhayashi@kobe-u.ac.jp						ANANT JS, 1992, J BIOL CHEM, V267, P687; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Liu W, 1998, J BIOL CHEM, V273, P34284, DOI 10.1074/jbc.273.51.34284; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Maekawa S, 1999, J BIOL CHEM, V274, P21369, DOI 10.1074/jbc.274.30.21369; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690	23	94	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20813	20816		10.1074/jbc.C100032200	http://dx.doi.org/10.1074/jbc.C100032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11319214	hybrid			2022-12-25	WOS:000169297900003
J	Weterman, MAJ; van Groningen, JJM; den Hartog, A; van Kessel, AG				Weterman, MAJ; van Groningen, JJM; den Hartog, A; van Kessel, AG			Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes	ONCOGENE			English	Article						renal cell carcinoma; TFE3; PRCC; malignant transformation; t(X;1)	HELIX-LOOP-HELIX; TRANSLOCATION X-1; TUMORS; SUBTYPE; ADENOCARCINOMA; CLASSIFICATION; ZIPPER; CHILD	A recurrent chromosomal abnormality associated with a subset of papillary renal cell carcinomas is t(X;1)(p11;q21). This translocation leads to the formation of two fusion genes, TFE3PRCC and the reciprocal product PRCCTFE3. Both fusion genes are expressed in t(X;1)-positive renal cell carcinomas and contain major parts of the coding regions of the parental transcription factor PRCC and TFE3 genes, respectively. To find out whether these fusion genes possess transforming capacity, we transfected NIH3T3 and rat-1 cells with the fusion products, either separately or combined, When using soft agar assays, we observed colony formation in all cases. NIH3T3 cells transfected with PRCCTFE3 or PRCCTFE3 together with TFE3PRCC yielded the highest colony forming capacities. Examination of other characteristics associated with malignant transformation, i.e., growth under low-serum conditions and formation of tumors in athymic nude mice, revealed that cells transfected nith PRCCTFE3 exhibited all these transformation-associated characteristics. Upon transfection of the fusion products into conditionally immortalized kidney cells, derived from the proximal tubules of an H-2Kb-tsA58 transgenic mouse, and consecutive incubation under non-permissive conditions, growth arrest was observed, followed by differentiation except for those cells transfected with PRCCTFE3, Therefore, we conclude that PRCCTFE3 may be the t(X;1)-associated fusion product that is most critical for the development of papillary renal cell carcinomas.	Univ Nijmegen, Med Ctr, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Weterman, MAJ (corresponding author), Univ Nijmegen, Med Ctr, Dept Human Genet 417, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; Carcao MD, 1998, MED PEDIATR ONCOL, V31, P153, DOI 10.1002/(SICI)1096-911X(199809)31:3<153::AID-MPO5>3.0.CO;2-A; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; Desangles F, 1999, CANCER GENET CYTOGEN, V113, P141, DOI 10.1016/S0165-4608(98)00261-1; DIJKHUIZEN T, 1995, GENE CHROMOSOME CANC, V14, P43, DOI 10.1002/gcc.2870140108; HERNANDEZMARTI MJ, 1995, CANCER GENET CYTOGEN, V83, P82, DOI 10.1016/0165-4608(94)00184-7; KOVACS G, 1988, CYTOGENET CELL GENET, V48, P242, DOI 10.1159/000132637; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Perot C, 1999, CANCER GENET CYTOGEN, V110, P54, DOI 10.1016/S0165-4608(98)00181-2; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; VANDENBERG E, 1993, INT J CANCER, V55, P223, DOI 10.1002/ijc.2910550210; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 1996, HUM GENET, V98, P16, DOI 10.1007/s004390050153; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044	22	25	27	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1414	1424		10.1038/sj.onc.1204213	http://dx.doi.org/10.1038/sj.onc.1204213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313885				2022-12-25	WOS:000167595200002
J	Guiducci, C; Cerone, MA; Bacchetti, S				Guiducci, C; Cerone, MA; Bacchetti, S			Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability	ONCOGENE			English	Article						telomerase; hTR mutants; telomere malfunction	IN-VITRO; RNA COMPONENT; DNA-DAMAGE; PROTEIN; TRF2; RECONSTITUTION; LENGTH; YEAST; END; INSTABILITY	We have reconstituted wild type or mutant telomerase activity in two human cell lines that lack constitutive expression of both core subunits of the enzyme and maintain telomeres by a telomerase-independent mechanism (ALT cells). Wild type telomerase RNA and four telomerase RNAs with single point mutations in their template domain were used to express enzymes specifying different telomeric DNA sequences, Expression of wild type telomerase for up to 32 days had no detectable effect on cell growth or viability, In contrast, cells expressing mutant telomerases had slower growth rate, abnormal cell cycle and reduced viability. Dramatically aberrant nuclei, typical of cells undergoing mitotic catastrophe, and large numbers of fused chromosomes were also characteristic of these populations, Notably, all phenotypes were apparent within the first few cell divisions after expression of the enzymes. Unlike wild type, mutant telomerase activity was progressively selected against with cell culturing, and this correlated with the disappearance of cells with aberrant phenotypes. Our results suggest that even very limited synthesis of mutated sequences can affect telomere structure in human cells, and that the toxicity of mutant telomerases is due to telomere malfunction.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	McMaster University	Bacchetti, S (corresponding author), McMaster Med Ctr, Room 4H30,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1196; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Evans SK, 2000, J CELL SCI, V113, P3357; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Iijima M, 1996, INT J CANCER, V66, P698; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRK KE, 1997, SCIENCE, V275, P1748; Kurenova EV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1242; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; MCEACHERN M, 1995, NATURE, V376, P404; McEachern MJ, 2000, P NATL ACAD SCI USA, V97, P11409, DOI 10.1073/pnas.210388397; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Namba M, 1981, GANN MONOGR CANCER R, V27, P221; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	56	78	85	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					714	725		10.1038/sj.onc.1204145	http://dx.doi.org/10.1038/sj.onc.1204145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314005				2022-12-25	WOS:000166806000007
J	Bartke, T; Siegmund, D; Peters, N; Reichwein, M; Henkler, F; Scheurich, P; Wajant, H				Bartke, T; Siegmund, D; Peters, N; Reichwein, M; Henkler, F; Scheurich, P; Wajant, H			p53 upregulates cFLIP, inhibits transcription of NF-kappa B-regulated genes and induces caspase-8-independent cell death in DLD-1 cells	ONCOGENE			English	Article						apoptosis; FLIP; NF-kappa B; p53; caspase; death receptors	DOMAIN-CONTAINING PROTEIN; P53-DEPENDENT APOPTOSIS; CASPASE HOMOLOG; IN-VIVO; ACTIVATION; FLICE; FAS; EXPRESSION; INTERACTS; INDUCTION	One of the main functions of the tumor suppressor p53 is the induction of programmed cell death, Here we investigated in detail the molecular mechanisms that underlay p53 transactivation-dependent apoptosis in the human colon cancer cell line DLD-1, Although p53 upregulated the death receptors Fas, TRAIL-R1 and TRAIL-R2 in this cell line, p53-induced cell death occurred without detectable caspase-8 activation whereas, activation of caspase-9 and caspase-3 was readily observed. In addition to the upregulation of death receptors, p53 induced the pro-apoptotic Bcl-2 family members Bik and Bak and downregulated the anti-apoptotic Bcl-xL protein. Moreover, in RNase protection assay analyses as well as in reporter gene analyses we found a p53-dependent upregulation of the death receptor-inhibitory protein cFLIP. Together, these data argue for a p53-mediated activation of the mitochondrial pathway of apoptosis, In contrast to recently published data obtained in different cellular systems, there was no evidence for an essential role of NF-kappaB in p53-induced cell death. Moreover, induction of p53 interfered,with TNF-induced NF-kappaB activation independently from apoptosis-induction.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; EL DW, 1993, CELL, V75, P817; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Uberti D, 2000, AMINO ACIDS, V19, P253, DOI 10.1007/s007260070056; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	41	91	94	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					571	580		10.1038/sj.onc.1204124	http://dx.doi.org/10.1038/sj.onc.1204124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313989				2022-12-25	WOS:000166755000004
J	Sonneveld, E; Vrieling, H; Mullenders, LHF; van Hoffen, A				Sonneveld, E; Vrieling, H; Mullenders, LHF; van Hoffen, A			Mouse mismatch repair gene Msh2 is not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers	ONCOGENE			English	Article						mismatch repair; transcription-coupled repair; UV-damage; mouse fibroblasts	NUCLEOTIDE-EXCISION-REPAIR; INDUCED DNA-DAMAGE; CANCER; PREDISPOSITION; FIBROBLASTS; DEFICIENCY; CELLS	The human mutS homolog gene MSH2 is essential for DNA mismatch repair (MMR) and defects in this gene can result in increased mutagenesis, genomic instability and hereditary nonpolyposis colorectal cancer (HNPCC). Besides correcting mismatch errors arising from DNA replication, it mas shown that deficiencies in bacterial and human MMR genes including MSH2 resulted in defective transcription-coupled repair (TCR) of UV-induced photolesions. Here we show that MMR-deficient fibroblasts derived from two independent isogenic mouse strains,vith defined Msh2 deficiencies are as proficient in TCR of UV-induced cyclobutane pyrimidine dimers (CPD) as wildtype fibroblasts. Our results indicate that in mouse cells Msh2 is not essential for TCR of UV-induced CPD in contrast to bacteria and human cells and suggest that the biological effects of UV in mouse Msh2(-/-) cells and mice are not due to defective TCR.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis MGC, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Cell Biol & Genet MGC, NL-3000 DR Rotterdam, Netherlands; Interuniv Res Inst Radiopathol & Radiat Protect, JA Cohen Inst, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam	Mullenders, LHF (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis MGC, POB 9503, NL-2300 RA Leiden, Netherlands.		Vrieling, Harry/ABC-8068-2020	Vrieling, Harry/0000-0002-3034-2664				Berg RJW, 2000, CANCER RES, V60, P2858; Berry SE, 2000, CANCER RES, V60, P5773; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHEO DL, 1997, MUTAT RES, V4, P1; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Wind N, 1998, CANCER RES, V58, P248; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P99, DOI 10.1016/S0921-8777(99)00068-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Leadon SA, 1998, MUTAT RES-DNA REPAIR, V407, P177, DOI 10.1016/S0921-8777(98)00007-X; Leadon SA, 1997, CANCER RES, V57, P3784; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Reitmair AH, 1997, CANCER RES, V57, P3765; Rey O, 1999, ONCOGENE, V18, P6997, DOI 10.1038/sj.onc.1203180; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Sweder KS, 1996, GENETICS, V143, P1127; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; Van Sloun PPH, 1999, NUCLEIC ACIDS RES, V27, P3276, DOI 10.1093/nar/27.16.3276; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Wu JX, 1999, MOL CELL BIOL, V19, P8292	28	17	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					538	541		10.1038/sj.onc.1204125	http://dx.doi.org/10.1038/sj.onc.1204125			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313985				2022-12-25	WOS:000166562500014
J	Gatei, M; Shkedy, D; Khanna, KK; Uziel, T; Shiloh, Y; Pandita, TK; Lavin, MF; Rotman, G				Gatei, M; Shkedy, D; Khanna, KK; Uziel, T; Shiloh, Y; Pandita, TK; Lavin, MF; Rotman, G			Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; p53; p21(WAF1/CIP1); cdc2; alpha-lipoic acid; oxidative stress	DOUBLE-STRAND BREAKS; CELL-CYCLE CHECKPOINTS; ATM-DEFICIENT MICE; DNA-DAMAGE; OXIDATIVE DAMAGE; INDUCED PHOSPHORYLATION; GENOTOXIC STRESS; GENE-PRODUCT; P53; REPAIR	Cells from patients with the genetic disorder ataxia-telangiectasia (A-T) are hypersensitive to ionizing radiation and radiomimetic agents, both of which generate reactive oxygen species capable of causing oxidative damage to DNA and other macromolecules. We describe in A-T cells constitutive activation of pathways that normally respond to genotoxic stress, Basal levels of p53 and p21(WAF1/CIP1), phosphorylation on serine 15 of p53, and the Tyr15-phosphorylated form of cdc2 are chronically elevated in these cells. Treatment of A-T cells with the antioxidant alpha -lipoic acid significantly reduced the levels of these proteins, pointing to the involvement of reactive oxygen species in their chronic activation. These findings suggest that the absence of functional ATM results in a mild but continuous state of oxidative stress, which could account for several features of the pleiotropic phenotype of A-T.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; PO Royal Melbourne Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Labs, Brisbane, Qld 4029, Australia; Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Univ Queensland, PO Royal Melbourne Hosp, Dept Surg, Brisbane, Qld 4029, Australia	Tel Aviv University; Sackler Faculty of Medicine; QIMR Berghofer Medical Research Institute; Royal Melbourne Hospital; Columbia University; Royal Melbourne Hospital; University of Queensland	Rotman, G (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel.		Lavin, Martin F/F-5961-2014; Khanna, Kum Kum/I-1747-2013; Pandita, Tej K/AAM-9188-2020	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381	NINDS NIH HHS [NS31763, NS34746] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746, R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Appella E, 2000, PATHOL BIOL, V48, P227; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CANMAN CE, 1994, CANCER RES, V54, P5054; CONFORTH MN, 1985, SCIENCE, V227, P1589; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Pagano G, 1998, MED HYPOTHESES, V51, P253, DOI 10.1016/S0306-9877(98)90084-6; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PAULES RS, 1995, CANCER RES, V55, P1763; Reichenbach J, 1999, CLIN EXP IMMUNOL, V117, P535; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; SHILOH Y, 1985, ATAXIA TELANGIECTASI, P111; SiddooAtwal C, 1996, CANCER RES, V56, P443; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; TAYLOR AMR, 1989, INT J RADIAT BIOL, V56, P677, DOI 10.1080/09553008914551901; TEALE B, 1993, J BIOL CHEM, V268, P22450; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Varghese S, 1998, ARCH PHARM RES, V21, P640, DOI 10.1007/BF02976750; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Westphal CH, 1997, CANCER RES, V57, P1664; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	50	56	56	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					289	294		10.1038/sj.onc.1204111	http://dx.doi.org/10.1038/sj.onc.1204111			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313957				2022-12-25	WOS:000166411000002
J	Mukhopadhyay, D; Sundereshan, S; Rao, C; Karande, AA				Mukhopadhyay, D; Sundereshan, S; Rao, C; Karande, AA			Placental protein 14 induces apoptosis in T cells but not in monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTAGEN-ASSOCIATED PROTEIN; BETA-LACTOGLOBULIN HOMOLOG; ENDOMETRIAL PROTEIN; MENSTRUAL-CYCLE; CASPASE FAMILY; LUTEAL-PHASE; SERUM LEVELS; SEQUENCE; PP14; IDENTIFICATION	Substantial evidence exists in literature to suggest that placental protein 14 (PP14) (recently renamed glycodelin A), exhibits immunosuppressive properties and is an indispensable macromolecule in the maternal system for the establishment, maintenance, and progression of pregnancy. Though there are several reports substantiating the above, the mechanism of its action at the molecular level has not been elucidated as yet. In this paper we provide data that suggest that amniotic fluid PP14 and recombinant PP14 expressed in Pichia pastoris induce apoptosis in human peripheral blood lymphocytes upon activation, independent of monocytes. That PP14 has a direct apoptotic action on T cells but not on monocytes was also demonstrated by utilizing human cell lines. PP14 was shown to induce apoptosis in the human T cell lines, Jurkat and MOLT-4 cells, but not in the human monocytic cell line, U937.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; Raos Matern Hosp, Bangalore 560044, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Karande, AA (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009					Bohn H, 1982, Placenta Suppl, V4, P67; BOLTON AE, 1987, LANCET, V1, P593; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Bulmer J, 1987, IMMUNOREGULATION FET, P111; CHECK JH, 1993, INT J FERTIL, V38, P34; Dutta B, 1998, PROTEIN EXPRES PURIF, V14, P327, DOI 10.1006/prep.1998.0961; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HUHTALA ML, 1987, ENDOCRINOLOGY, V120, P2620, DOI 10.1210/endo-120-6-2620; JOSHI SG, 1983, J STEROID BIOCHEM, V19, P751, DOI 10.1016/0022-4731(83)90007-9; JOSHI SG, 1981, J CLIN ENDOCR METAB, V52, P1185, DOI 10.1210/jcem-52-6-1185; JULKUNEN M, 1986, FERTIL STERIL, V45, P47; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; JULKUNEN M, 1990, MOL ENDOCRINOL, V4, P700, DOI 10.1210/mend-4-5-700; JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x; Karri T, 2000, HISTOCHEM J, V32, P711, DOI 10.1023/A:1004144909714; KROEMER G, 1997, IMMUNOLOGY METHODS M, P1121; Lalitkumar PGL, 1998, HUM REPROD, V13, P3478, DOI 10.1093/humrep/13.12.3478; MACKENNA A, 1993, FERTIL STERIL, V59, P577; Miller RE, 1998, FEBS LETT, V436, P455, DOI 10.1016/S0014-5793(98)01184-3; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OKAMOTO N, 1991, AM J REPROD IMMUNOL, V26, P137, DOI 10.1111/j.1600-0897.1991.tb00713.x; POCKLEY AG, 1990, IMMUNOLOGY, V69, P277; Rachmilewitz J, 1999, CELL IMMUNOL, V191, P26, DOI 10.1006/cimm.1998.1408; REDDY BMMMK, 1992, MOL IMMUNOL, V29, P511, DOI 10.1016/0161-5890(92)90008-L; Seppala M, 1997, CLIN ENDOCRINOL, V46, P381, DOI 10.1046/j.1365-2265.1997.1510943.x; SEPPALA M, 1991, BAILLIERE CLIN OB GY, V5, P61, DOI 10.1016/S0950-3552(05)80070-7; SEPPO A, 1998, CELLS LAB MANUAL, V1, P335; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomczak S, 1996, ARCH GYNECOL OBSTET, V258, P165, DOI 10.1007/s004040050120; TULPPALA M, 1995, FERTIL STERIL, V63, P792, DOI 10.1016/S0015-0282(16)57483-4; VAISSE C, 1990, DNA CELL BIOL, V9, P401, DOI 10.1089/dna.1990.9.401; WAITES GT, 1990, HUM REPROD, V5, P487, DOI 10.1093/oxfordjournals.humrep.a137130; Westergaard LG, 1998, HUM REPROD, V13, P2612, DOI 10.1093/humrep/13.9.2612	35	62	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28268	28273		10.1074/jbc.M010487200	http://dx.doi.org/10.1074/jbc.M010487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11325960	hybrid			2022-12-25	WOS:000170093400071
J	Huang, WH; Yung, BYM; Syu, WJ; Lee, YHW				Huang, WH; Yung, BYM; Syu, WJ; Lee, YHW			The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX PROTEIN; LYMPHOTOXIN-BETA RECEPTOR; BINDING-ACTIVITY; CORE PROTEIN; LOCALIZATION SIGNALS; TRANSCRIPTION FACTOR; GENOME REPLICATION; TARGETING SIGNAL; GENE-EXPRESSION; POLYMERASE-II	Hepatitis delta virus (HDV) encodes two isoforms of delta antigens (HDAgs), The small form of HDAg is required for HDV RNA replication, while the large form of HDAg inhibits the viral replication and is required for virion assembly. In this study, we found that the expression of B23, a nucleolar phosphoprotein involved in disparate functions including nuclear transport, cellular proliferation, and ribosome biogenesis, is up-regulated by these two HDAgs, Using in vivo and in vitro experimental approaches, we have demonstrated that both isoforms of HDAg can interact with B23 and their interaction domains were identified as the NH2-terminal fragment of each molecule encompassing the nuclear localization signal but not the coiled-coil region of HDAg, Sucrose gradient centrifugation analysis indicated that the majority of small HDAg, but a lesser amount of the large HDAg, co-sedimented with B23 and nucleolin in the large nuclear complex. Transient transfection experiments also indicated that introducing exogenous full-length B23, but not a mutated B23 defective in HDAg binding, enhanced HDV RNA replication. All together, our results reveal that HDAg has two distinct effects on nucleolar B23, up-regulation of its gene expression and the complex formation, which in turn regulates HDV RNA replication. Therefore, this work demonstrates the important role of nucleolar protein in regulating the HDV RNA replication through the complex formation with the key positive regulator being small HDAg.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Chang Gung Univ, Coll Med, Dept Pharmacol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Chang Gung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.			Yung, Benjamin Yat Ming/0000-0003-0093-3196; Lee Wu, Yan-Hwa/0000-0001-7299-7354				ADACHI Y, 1993, J BIOL CHEM, V268, P13930; Bell P, 2000, J VIROL, V74, P5329, DOI 10.1128/JVI.74.11.5329-5336.2000; Bichko VV, 1996, J VIROL, V70, P8064, DOI 10.1128/JVI.70.11.8064-8070.1996; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; CHAN PK, 1989, CANCER RES, V49, P3271; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHANG FL, 1991, P NATL ACAD SCI USA, V88, P8490, DOI 10.1073/pnas.88.19.8490; CHANG MF, 1988, J VIROL, V62, P2403, DOI 10.1128/JVI.62.7.2403-2410.1988; CHANG MF, 1993, J VIROL, V67, P2529, DOI 10.1128/JVI.67.5.2529-2536.1993; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; CHEN CM, 1991, J BIOL CHEM, V266, P7754; CHEN PJ, 1990, P NATL ACAD SCI USA, V87, P5253, DOI 10.1073/pnas.87.14.5253; Chou HC, 1998, J VIROL, V72, P3684, DOI 10.1128/JVI.72.5.3684-3690.1998; Cunha C, 1998, RNA, V4, P680, DOI 10.1017/S135583829898013X; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dingle K, 1998, J VIROL METHODS, V75, P199, DOI 10.1016/S0166-0934(98)00117-7; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; Filipovska J, 2000, RNA, V6, P41, DOI 10.1017/S1355838200991167; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GLENN JS, 1991, J VIROL, V65, P2357, DOI 10.1128/JVI.65.5.2357-2361.1991; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GOWANS EJ, 1988, VIROLOGY, V167, P274, DOI 10.1016/0042-6822(88)90078-5; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; HOFFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321; Hu HM, 1996, J VIROL METHODS, V60, P39; Huang ZS, 1998, J BIOL CHEM, V273, P26455, DOI 10.1074/jbc.273.41.26455; HWANG SB, 1993, J VIROL, V67, P7659, DOI 10.1128/JVI.67.12.7659-7662.1993; HWANG SB, 1992, VIROLOGY, V190, P413, DOI 10.1016/0042-6822(92)91227-L; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LAZINSKI DW, 1993, J VIROL, V67, P2672, DOI 10.1128/JVI.67.5.2672-2680.1993; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Lo K, 1998, VIROLOGY, V247, P178, DOI 10.1006/viro.1998.9253; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MACNAUGHTON TB, 1991, VIROLOGY, V184, P387, DOI 10.1016/0042-6822(91)90855-6; MACNAUGHTON TB, 1990, J GEN VIROL, V71, P1339, DOI 10.1099/0022-1317-71-6-1339; MACNAUGHTON TB, 1990, VIROLOGY, V177, P692, DOI 10.1016/0042-6822(90)90535-Y; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Modahl LE, 2000, MOL CELL BIOL, V20, P6030, DOI 10.1128/MCB.20.16.6030-6039.2000; Mu JJ, 1999, J VIROL, V73, P10540, DOI 10.1128/JVI.73.12.10540-10545.1999; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; TAYLOR J, 1987, J VIROL, V61, P2891, DOI 10.1128/JVI.61.9.2891-2895.1987; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WANG DR, 1994, J BIOL CHEM, V269, P30994; WANG JG, 1993, J VIROL, V67, P446, DOI 10.1128/JVI.67.1.446-454.1993; Wei Y, 1998, J VIROL, V72, P2089, DOI 10.1128/JVI.72.3.2089-2096.1998; WEINER AJ, 1988, J VIROL, V62, P594, DOI 10.1128/JVI.62.2.594-599.1988; WU JC, 1992, HEPATOLOGY, V16, P1120; XIA YP, 1992, J VIROL, V66, P6641, DOI 10.1128/JVI.66.11.6641-6648.1992; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yeh TS, 1998, VIROLOGY, V249, P12, DOI 10.1006/viro.1998.9310; Yeh TS, 1996, J VIROL, V70, P6190, DOI 10.1128/JVI.70.9.6190-6198.1996; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; ZHANG XT, 1989, BIOCHEM BIOPH RES CO, V164, P176, DOI 10.1016/0006-291X(89)91699-9; Zuccola HJ, 1998, STRUCTURE, V6, P821, DOI 10.1016/S0969-2126(98)00084-7	97	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25166	25175		10.1074/jbc.M010087200	http://dx.doi.org/10.1074/jbc.M010087200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309377	hybrid			2022-12-25	WOS:000169800700099
J	Zaar, A; Eisenreich, W; Bacher, A; Fuchs, G				Zaar, A; Eisenreich, W; Bacher, A; Fuchs, G			A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENITRIFYING PSEUDOMONAS SP; PHENYLACETYL-COA CATABOLON; COENZYME-A LIGASE; 4-CHLOROBENZOATE DEHALOGENASE; MOLECULAR CHARACTERIZATION; ANAEROBIC DEGRADATION; SP CBS3; ACID; PURIFICATION; OXIDATION	The aerobic catabolism of benzoate was studied in the Gram-negative proteobacterium Azoarcus evansii and in the Gram-positive bacterium Bacillus stearothermophilus, In contrast to earlier proposals, benzoate was not converted into hydroxybenzoate or gentisate, Rather, benzoyl-CoA was a product of benzoate catabolism in both microbial species under aerobic conditions in vivo. Benzoyl-CoA was converted into various CoA thioesters by cell extracts of both species in oxygen- and NADPH-dependent reactions. Using [ring-C-13(6)]benzoyl-CoA as substrate, cis-3,4-[2,3,4,5,6-C-13(5)]dehydroadipyl-CoA, trans-2,3-[2,3,4,5,6-C-13(5)]dehydroadipyl-CoA, the 3,6-lactone of 3-[2,3,4,5,6-C-13(5)]hydroxyadipyl-CoA, and 3-[2,3, 4,5,6-C-13(5)]hydroxyadipyl-CoA were identified as products by MMR spectroscopy. A protein mixture of A. evansii transformed [ring-C-13(6)]benzoyl-CoA in an NADPH- and oxygen-dependent reaction into 6-[2,3,4,5,6-C-13(5)]hydroxy-3-hexenoyl-CoA. The data suggest a novel aerobic pathway of benzoate catabolism via CoA intermediates leading to beta -ketoadipyl-CoA, an intermediate of the known beta -ketoadipate pathway.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Technical University of Munich; University of Freiburg	Eisenreich, W (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ALTENSCHMIDT U, 1991, J BACTERIOL, V173, P5494, DOI 10.1128/jb.173.17.5494-5501.1991; ALTENSCHMIDT U, 1993, J BACTERIOL, V175, P4851, DOI 10.1128/JB.175.15.4851-4858.1993; ANDERS HJ, 1995, INT J SYST BACTERIOL, V45, P327, DOI 10.1099/00207713-45-2-327; BRAUN K, 1984, APPL ENVIRON MICROB, V48, P102, DOI 10.1128/AEM.48.1.102-107.1984; BUDER R, 1989, EUR J BIOCHEM, V191, P365; BUSWELL JA, 1976, J GEN MICROBIOL, V96, P209, DOI 10.1099/00221287-96-1-209; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P5605, DOI 10.1021/bi00139a025; Clark D. P., 1996, ESCHERICHIA COLI SAL, P343; CLARK JS, 1979, J GEN MICROBIOL, V112, P191, DOI 10.1099/00221287-112-1-191; COLIGAN JE, 1995, CURRENT PROTOCOLS SC; CRAWFORD RL, 1976, J BACTERIOL, V127, P204, DOI 10.1128/JB.127.1.204-210.1976; CROOKS GP, 1994, BIOCHEMISTRY-US, V33, P11645, DOI 10.1021/bi00204a028; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; Fu WJ, 1999, EXTREMOPHILES, V3, P45, DOI 10.1007/s007920050098; Garcia B, 1999, J BIOL CHEM, V274, P29228, DOI 10.1074/jbc.274.41.29228; GROSS GG, 1966, Z NATURFORSCH PT B, VB 21, P683; Hartmann S, 1999, P NATL ACAD SCI USA, V96, P7831, DOI 10.1073/pnas.96.14.7831; Harwood CS, 1996, ANNU REV MICROBIOL, V50, P553, DOI 10.1146/annurev.micro.50.1.553; Kiemer P, 1996, BIOL FERT SOILS, V23, P307, DOI 10.1007/BF00335959; LOFFLER F, 1995, BIODEGRADATION, V6, P203, DOI 10.1007/BF00700458; LOFFLER F, 1991, FEBS LETT, V290, P224, DOI 10.1016/0014-5793(91)81265-A; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; Mohamed ME, 2000, J BACTERIOL, V182, P286, DOI 10.1128/JB.182.2.286-294.2000; NIEMETZ R, 1995, EUR J BIOCHEM, V227, P161, DOI 10.1111/j.1432-1033.1995.tb20372.x; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; SCHACHTER D, 1976, J BIOL CHEM, V203, P925; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; Takami H, 1999, EXTREMOPHILES, V3, P29, DOI 10.1007/s007920050096; Torres RA, 1999, P NATL ACAD SCI USA, V96, P14748, DOI 10.1073/pnas.96.26.14748; TSCHECH A, 1987, ARCH MICROBIOL, V148, P213, DOI 10.1007/BF00414814; VITOVSKI S, 1993, FEMS MICROBIOL LETT, V108, P1; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; ZIEGLER K, 1989, ARCH MICROBIOL, V151, P171, DOI 10.1007/BF00414434	33	48	50	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24997	25004		10.1074/jbc.M100291200	http://dx.doi.org/10.1074/jbc.M100291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11306574	hybrid			2022-12-25	WOS:000169800700076
J	Wu, XY; Li, H; Park, EJ; Chen, JD				Wu, XY; Li, H; Park, EJ; Chen, JD			SMRTe inhibits MEF2C transcriptional activation by targeting HDAC4 and 5 to nuclear domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTORS; II HISTONE DEACETYLASES; N-COR; COREPRESSOR COMPLEX; MEDIATED REPRESSION; PROTEIN; INTERACTS; PATHWAY; DIFFERENTIATION; COACTIVATOR	The silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) mediates transcriptional repression by recruiting histone deacetylases (HDACs) to the DNA-bound nuclear receptor complex, The full-length SMRT (SMRTe) contains an N-terminal sequence that is highly conserved to the nuclear receptor corepressor N-CoR To date, Little is known about the activity and function of the full-length SMRTe protein, despite extensive studies on separated receptor interaction and transcriptional repression domains. Here we show that SMRTe inhibits MEF2C transcriptional activation by targeting selective HDACs to unique subnuclear domains. Indirect immunofluorescence studies with anti-SMRTe antibody reveal discrete cytoplasmic and nuclear speckles, which contain RAR alpha in an RA-sensitive manner. Formation of the SMRTe nuclear speckles results in recruitment of several class I and class II HDACs to these subnuclear domains in a process depending on HDAC enzymatic activity. Intriguingly, although HDAC4 is located primarily in the cytoplasm, coexpression of SMRTe dramatically translocates HDAC4 from the cytoplasm into the nucleus, where HDAC4 prevents MEF2C from activating muscle differentiation, SMRTe also translocates HDAC5 from diffusive nucleoplasm into discrete nuclear domains, Accordingly, SMRTe synergizes with HDAC4 and 5 to inhibit MEF2C transactivation of target promoter, suggesting that nuclear domain targeting of HDAC4/5 may be important in preventing muscle cell differentiation. These results highlight an unexpected new function of the nuclear receptor corepressor SMRTe for its role in regulating cellular trafficking of nuclear receptor and selective HDACs that may play an important role in regulation of cell growth and differentiation.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Li, H (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, 55 Lake Ave N, Worcester, MA 01655 USA.				NIDDK NIH HHS [DK52542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052542] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang EY, 2000, GENE DEV, V14, P45; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kao HY, 2000, GENE DEV, V14, P55; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	38	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24177	24185		10.1074/jbc.M100412200	http://dx.doi.org/10.1074/jbc.M100412200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11304536	hybrid			2022-12-25	WOS:000169531100126
J	Keenan, SM; Bellone, C; Baldassare, JJ				Keenan, SM; Bellone, C; Baldassare, JJ			Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; FUNCTIONAL INACTIVATION; NUCLEAR TRANSLOCATION; G(1)/S TRANSITION; D1 EXPRESSION; E GENE; PHOSPHORYLATION	Activation of cyclin-dependent kinase 2 (CDK2)-cyclin E in the late G(1) phase of the cell cycle is important for transit into S phase. In Chinese hamster embryonic fibroblasts (IIC9) phosphatidylinositol 3-kinase and ERK regulate cu-thrombin-induced G, transit by their effects on cyclin D1 protein accumulation (Phillips-Mason, P. J., Raben, D. M., and Baldassare, J. J. (2000) J. Biol. Chem, 275, 18046-18053). Here, we show that ERK also affects CDK2-cyclin E activation by regulating the subcellular localization of CDK2, Ectopic expression of cyclin E rescues the inhibition of alpha -thrombin-induced activation of CDK2-cyclin E and transit into S phase brought about by treat ment of IIC9 cells with LY29004, a selective inhibitor of mitogen stimulation of phosphatidylinositol 3-kinase activity. However, cyclin E expression is ineffectual in rescuing these effects when ERK activation is blocked by treatment with PD98059, a selective inhibitor of MEK activation of ERR. Investigation into the mechanistic reasons for this difference found the following. 1) Although treatment with LY29004 inhibits alpha -thrombin-stimulated nuclear localization, ectopic expression of cyclin E rescues CDK2 translocation. 2) In contrast to treatment with LY29004, ectopic expression of cyclin E fails to restore alpha -thrombin-stimulated nuclear CDK2 translocation in IIC9 cells treated with PD98059. 3) CDK2-cyclin E complexes are not affected by treatment with either inhibitor. These data indicate that, in addition to its effects on cyclin D1 expression, ERK activity is an important controller of the translocation of CDK2 into the nucleus where it is activated.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Blanchard DA, 2000, ONCOGENE, V19, P4184, DOI 10.1038/sj.onc.1203761; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 1996, ONCOGENE, V12, P1173; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; KATO J, 1993, GENE DEV, V7, P331; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEW DJ, 1993, CELL, V72, P488, DOI 10.1016/0092-8674(93)90068-2; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320	37	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22404	22409		10.1074/jbc.M100409200	http://dx.doi.org/10.1074/jbc.M100409200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304535	hybrid			2022-12-25	WOS:000169412700059
J	Swift, LL; Farkas, MH; Major, AS; Valyi-Nagy, K; Linton, MF; Fazio, S				Swift, LL; Farkas, MH; Major, AS; Valyi-Nagy, K; Linton, MF; Fazio, S			A recycling pathway for resecretion of internalized apolipoprotein E in liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; CHOLESTEROL EFFLUX; RECEPTOR-BINDING; HEPATIC-UPTAKE; APOPROTEIN-E; E EXPRESSION; BETA-VLDL; SECRETION; MICE; LDL	We have investigated the recycling of apoE in livers of apoE(-/-) mice transplanted with wild type bone marrow (apoE(+/+) --> apoE(-/-)), a model in which circulating apoE is derived exclusively from macrophages. Nascent Gels lipoproteins were recovered from livers of apoE(+/+) --> apoE(-/-) mice 8 weeks after transplantation. ApoE was identified with nascent d < 1.006 and with d 1.006-1.210 g/ml lipoproteins at a level similar to6% that of nascent lipoproteins from C57BL/6 mice. Hepatocytes from apoE(+/+) --> apoE(-/-) mice were isolated and cultured in media free of exogenous apoE, ApoE was found in the media primarily on the d < 1.006 g/ml fraction, indicating a resecretion of internalized apoprotein. Secretion of apoE from C57BL/6 hepatocytes was consistent with constitutive production, whereas the majority of apoE secreted from apoE(+/+) --> apoE(-/-) hepatocytes was recovered in the last 24 h of culture, This suggests that release may be triggered by accumulation of an acceptor, such as very low density lipoproteins, in the media. In agreement with the in vivo data, total recovery of apoE from apoE(+/+) --> apoE(-/-) hepatocytes was similar to6% that of the apoE recovered from C57BL/6 hepatocytes. Since plasma apoE levels in the transplanted mice are similar to 10% of control levels, the findings indicate that up to 60% of the internalized apoE may be reutilized under physiologic conditions. These studies provide definitive evidence for the sparing of apoE and its routing through the secretory pathway and demonstrate that internalized apoE can be resecreted in a quantitatively significant fashion.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Swift, LL (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA.	macrae.linton@mcmail.vanderbilt.edu; sergio.fazio@mcmail.vanderbilt.edu		Valyi-Nagy, Klara/0000-0002-3035-6388	NHLBI NIH HHS [HL57984, 5T32 HL07751, HL57986] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057984, R01HL057986, T32HL007751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BERNSTEIN SE, 1975, BIOL LABORATORY MOUS, P337; DAWSON PA, 1989, J LIPID RES, V30, P403; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Heeren J, 1999, J CELL SCI, V112, P349; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JI ZS, 1994, J BIOL CHEM, V269, P2764; Jong MC, 1996, ARTERIOSCL THROM VAS, V16, P934, DOI 10.1161/01.ATV.16.8.934; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kinoshita M, 2000, J Atheroscler Thromb, V6, P22; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Langer C, 2000, J MOL MED, V78, P217, DOI 10.1007/s001090000096; Lin CY, 1999, J LIPID RES, V40, P1618; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Rensen PCN, 2000, J BIOL CHEM, V275, P8564, DOI 10.1074/jbc.275.12.8564; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; Swift LL, 1996, J BIOL CHEM, V271, P31491; Swift LL, 2001, J LIPID RES, V42, P218; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tsukamoto K, 2000, J LIPID RES, V41, P253; WONG L, 1989, J CELL PHYSIOL, V141, P441, DOI 10.1002/jcp.1041410227	32	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22965	22970		10.1074/jbc.M100172200	http://dx.doi.org/10.1074/jbc.M100172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304532	hybrid			2022-12-25	WOS:000169412700131
J	Zehnulova, J; Kasparkova, J; Farrell, N; Brabec, V				Zehnulova, J; Kasparkova, J; Farrell, N; Brabec, V			Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-I; DIETHYL PYROCARBONATE; CHEMICAL-REACTIVITY; MAJOR ADDUCT; CISPLATIN; SITE; BINDING; HMG1; TRANS-DIAMMINEDICHLOROPLATINUM(II); CIS-DIAMMINEDICHLOROPLATINUM(II)	`The new antitumor trinuclear platinum compound [[trans-PtCl(NH3)(2)}(2)mu -trans Pt(NH3)(2){H2N(CH2)(2)NH2}(2)](4+) (designated as BBR3464) is currently in phase II clinical trials. DNA is generally considered the major pharmacological target of platinum drugs. As such it is of considerable interest to understand the patterns of DNA damage. The bifunctional DNA binding of BBR3464 is characterized by the rapid formation of long range intra-and interstrand cross links. We examined how the structures of the various types of the intrastrand crosslinks of BBR3464 affect conformational properties of DNA, and how these adducts are recognized by high mobility group 1 protein and removed from DNA during in, vitro nucleotide excision repair reactions. The results have revealed that intrastrand cross-links of BBR3484 create a local conformational distortion, but none of these cross-links results in a stable curvature. In addition, we have observed no recognition of these crosslinks by high mobility group 1 proteins, but we have observed effective removal of these adducts from DNA by nucleotide excision repair. These results suggest that the processing of the intrastrand cross-links of BBR3464 in tumor cells sensitive to this drug may not be relevant to its antitumor effects. Hence, polynuclear platinum compounds apparently represent a novel class of platinum anticancer drugs acting by a different mechanism than cisplatin and its analogues.	Virginia Commonwealth Univ, Dept Chem, Richmond, VA 23284 USA; Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic	Virginia Commonwealth University; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Farrell, N (corresponding author), Virginia Commonwealth Univ, Dept Chem, Med Coll Virginia Campus, Richmond, VA 23284 USA.	nfarrell@maill.vcu.edu; brabec@ibp.cz	Brabec, Viktor/H-1946-2014	Brabec, Viktor/0000-0002-8233-1393	NCI NIH HHS [R01-CA78754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANIN MF, 1990, NUCLEIC ACIDS RES, V18, P4395, DOI 10.1093/nar/18.15.4395; BAILLY C, 1994, BIOCHEM J, V300, P165, DOI 10.1042/bj3000165; BAILLY C, 1997, DRUG DNA INTERACTION, P51; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BRABEC V, 1993, P NATL ACAD SCI USA, V90, P5345, DOI 10.1073/pnas.90.11.5345; BRABEC V, 1993, BIOCHEMISTRY-US, V32, P11676, DOI 10.1021/bi00094a025; Brabec V, 2000, CANC DRUG DISC DEV, V7, P37; Brabec V, 1999, BIOCHEMISTRY-US, V38, P6781, DOI 10.1021/bi990124s; BRABEC V, 1992, BIOCHEMISTRY-US, V31, P12397, DOI 10.1021/bi00164a014; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; Calvert PM, 1999, CLIN CANCER RES, V5, p3796S; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; COMESS KM, 1990, BIOCHEMISTRY-US, V29, P2102, DOI 10.1021/bi00460a020; Cox JW, 2001, J AM CHEM SOC, V123, P1316, DOI 10.1021/ja0012772; Farrell N, 2000, CANC DRUG DISC DEV, V7, P321; FARRELL N, 1999, CISPLATIN CHEM BIOCH, P479; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; He Q, 2000, BIOCHEMISTRY-US, V39, P14426, DOI 10.1021/bi001700j; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Johnson N.P., 1989, PROG CLIN BIOCH MED, V10, P1, DOI [DOI 10.1007/978-3-642-74760-1, 10.1007/978-3-642-74760-1_1, DOI 10.1007/978-3-642-74760-1_1]; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; JONES SL, 1994, INT J CANCER, V59, P388, DOI 10.1002/ijc.2910590317; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 1996, BIOCHEMISTRY-US, V35, P16705, DOI 10.1021/bi961160j; Kasparkova J, 2000, J BIOL CHEM, V275, P15789, DOI 10.1074/jbc.M000777200; Kloster MBG, 1999, BIOCHEMISTRY-US, V38, P14731, DOI 10.1021/bi991202e; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LEMAIRE M, 1990, BIOCHEM J, V267, P431, DOI 10.1042/bj2670431; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; LENG M, 1990, BIOPHYS CHEM, V35, P155, DOI 10.1016/0301-4622(90)80005-R; Li MJ, 1999, INT J ONCOL, V15, P1177; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Maxam A M, 1980, Methods Enzymol, V65, P499; MCANULTY MM, 1995, NUCLEIC ACIDS MOL BI, V9, P264; MCCARTHY JG, 1991, NUCLEIC ACIDS RES, V19, P3421, DOI 10.1093/nar/19.12.3421; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Naegeli H., 1997, MECH DNA DAMAGE RECO; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; O'Dwyer P. J., 1999, CISPLATIN CHEM BIOCH, P31; O'Dwyer PJ, 2000, DRUGS, V59, P19, DOI 10.2165/00003495-200059004-00003; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Perego P, 1999, MOL PHARMACOL, V55, P528; Perego P, 1999, J INORG BIOCHEM, V77, P59, DOI 10.1016/S0162-0134(99)00142-7; Pratesi G, 1999, BRIT J CANCER, V80, P1912, DOI 10.1038/sj.bjc.6690620; Qu Y, 2000, J MED CHEM, V43, P3189; Reardon JT, 1999, CANCER RES, V59, P3968; REARDON JT, 1998, ADV DNA DAMAGE REPAI, P377; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; Roberts JD, 1999, J INORG BIOCHEM, V77, P51, DOI 10.1016/S0162-0134(99)00147-6; Roberts JD, 1999, J INORG BIOCHEM, V77, P47, DOI 10.1016/S0162-0134(99)00137-3; Rosenberg B., 1999, CISPLATIN CHEM BIOCH, P1, DOI DOI 10.1002/9783906390420; Ross SA, 1996, NUCLEIC ACIDS RES, V24, P5062, DOI 10.1093/nar/24.24.5062; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHWARTZ A, 1989, BIOCHEMISTRY-US, V28, P7975, DOI 10.1021/bi00446a001; Sessa C, 2000, ANN ONCOL, V11, P977, DOI 10.1023/A:1008302309734; Stros M, 1998, J BIOL CHEM, V273, P10355; Teuben JM, 1999, BIOCHEMISTRY-US, V38, P12305, DOI 10.1021/bi9904757; Whitehead JP, 1996, MET IONS BIOL SYST, V32, P687; Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Zaludova R, 1997, EUR J BIOCHEM, V246, P508, DOI 10.1111/j.1432-1033.1997.00508.x; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	74	88	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22191	22199		10.1074/jbc.M103118200	http://dx.doi.org/10.1074/jbc.M103118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303029	hybrid			2022-12-25	WOS:000169412700031
J	Dohadwala, M; Luo, J; Zhu, L; Lin, Y; Dougherty, GJ; Sharma, S; Huang, M; Pold, N; Batra, RK; Dubinett, SM				Dohadwala, M; Luo, J; Zhu, L; Lin, Y; Dougherty, GJ; Sharma, S; Huang, M; Pold, N; Batra, RK; Dubinett, SM			Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASED EXPRESSION; CARCINOMA CELLS; TUMOR INVASION; HUMAN PROSTATE; UP-REGULATION; TGF-BETA; IN-VIVO; APOPTOSIS; INHIBITION; GROWTH	Elevated tumor cyclooxygenase (COX-2) expression is associated with increased angiogenesis, tumor invasion, and suppression of host immunity. We have previously shown that genetic inhibition of tumor COX-2 expression reverses the immunosuppression induced by nonsmall cell lung cancer (NSCLC). To assess the impact of COX-2 expression in lung cancer invasiveness, NSCLC cell lines were transduced with a retroviral vector expressing the human COX-2 cDNA in the sense (COX-2-S) and antisense (COX-2-AS) orientations. COX-2-S clones expressed significantly more COX-2 protein, produced 10-fold more prostaglandin E-2, and demonstrated an enhanced invasive capacity compared with control vector-transduced or parental cells. CD44, the cell surface receptor for hyaluronate, was overexpressed in COX-2-S cells, and specific blockade of CD44 significantly decreased tumor cell invasion. In contrast, COX-2-AS clones had a very limited capacity for invasion and showed diminished expression of CD44. These findings suggest that a COX-2-mediated, CD44-dependent pathway is operative in NSCLC invasion. Because tumor COX-2 expression appears to have a multifaceted role in conferring the malignant phenotype, COX-2 may be an important target for gene or pharmacologic therapy in NSCLC.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Radiat Oncol, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Dubinett, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Batra, Raj K./0000-0002-1126-543X	NATIONAL CANCER INSTITUTE [R01CA078654, P50CA090388] Funding Source: NIH RePORTER; NCI NIH HHS [1P50 CA90388, R01 CA78654, R01 CA71817, P50 CA090388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achiwa H, 1999, CLIN CANCER RES, V5, P1001; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; Beck C, 2001, MICROSC RES TECHNIQ, V52, P387, DOI 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W; Chan G, 1999, CANCER RES, V59, P991; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; Ding XZ, 2000, ANTICANCER RES, V20, P2625; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; ENDO T, 1995, AM J RESP CELL MOL, V12, P358, DOI 10.1165/ajrcmb.12.3.7873203; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 2000, CLIN CANCER RES, V6, P2006; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang M, 1998, CANCER RES, V58, P1208; Huang M, 1996, J IMMUNOL, V157, P5512; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; KOHN EC, 1995, CANCER RES, V55, P1856; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Leahy KM, 2000, CURR MED CHEM, V7, P1163, DOI 10.2174/0929867003374336; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Masferrer JL, 2000, CANCER RES, V60, P1306; Molina MA, 1999, CANCER RES, V59, P4356; Murata H, 1999, AM J GASTROENTEROL, V94, P451; Ochiai M, 1999, JPN J CANCER RES, V90, P1338, DOI 10.1111/j.1349-7006.1999.tb00717.x; PASS HI, 2000, LUNG CANC ETIOLOGY E, P367; Ramanathan RK, 1997, SEMIN ONCOL, V24, P440; Ryu HS, 2000, GYNECOL ONCOL, V76, P320, DOI 10.1006/gyno.1999.5690; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; Shah AH, 2000, PROSTATE, V45, P167, DOI 10.1002/1097-0045(20001001)45:2<167::AID-PROS11>3.0.CO;2-J; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Sun LK, 2001, KIDNEY INT, V59, P190, DOI 10.1046/j.1523-1755.2001.00479.x; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tanji N, 2000, ANTICANCER RES, V20, P2313; Tian B, 2000, EXP CELL RES, V257, P135, DOI 10.1006/excr.2000.4871; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Watkins DN, 1999, EUR RESPIR J, V14, P412, DOI 10.1034/j.1399-3003.1999.14b28.x; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wolff H, 1998, CANCER RES, V58, P4997; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163	50	195	211	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20809	20812		10.1074/jbc.C100140200	http://dx.doi.org/10.1074/jbc.C100140200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11320076	hybrid, Green Accepted			2022-12-25	WOS:000169297900002
J	Zhou, HQ; Lee, KAW				Zhou, HQ; Lee, KAW			An hsRPB4/7-dependent yeast assay for trans-activation by the EWS oncogene	ONCOGENE			English	Article						EWS oncogene; transcriptional activation; yeast; RPB4; RPB7	RNA-POLYMERASE-II; 2 DISSOCIABLE SUBUNITS; TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONAL ACTIVATION; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; CHIMERIC PROTEIN; STRESS SURVIVAL; CELL VIABILITY; FUSION	Chromosomal fusions of the N-terminal region of the Ewings Sarcoma Oncogene (EWS-Activation-Domain, EAD) to the DNA-binding domains of a variety of cellular transcription factors, produce oncogenic proteins (EWS-fusion proteins (EFPs)) that cause a variety of malignancies. The EAD can act as a potent transcriptional activation domain and is required for the oncogenic activity of EFPs. Previous studies demonstrating a physical interaction between the EAD and the human RNA Polymerase II subunit hsRPB7 suggest a crucial role for RPB7 and its partner, RPB4, in EAD function. Homologues of hsRPB4/7 exist in S. cerevisiae, and here we describe an RPB4/7-dependent yeast assay for EAD-mediated trans-activation. Conditional yeast strains lacking RPB4 are defective for transactivation by a Gal4/EAD fusion protein at the permissive temperature. Introduction of hsRPB4 alone is unable to rescue trans-activation, while a combination of hsRPB4 and hsRPB7 significantly rescues activity. These findings provide the first functional evidence for a direct role of the RPB4/7 complex in EAD-mediated trans-activation. In addition, the yeast assay provides a tractable system for further molecular analysis of EAD and RPB4/7 action.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.		Zhou, Huiqing/B-1721-2013	Zhou, Huiqing/0000-0002-2434-3986				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BROWN AD, 1995, ONCOGENE, V10, P1749; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fujimura Y, 1996, ONCOGENE, V12, P159; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Khazak V, 1998, MOL CELL BIOL, V18, P1935, DOI 10.1128/MCB.18.4.1935; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kovar Heinrich, 1999, Current Opinion in Oncology, V11, P275, DOI 10.1097/00001622-199907000-00007; Larkin RM, 1998, J BIOL CHEM, V273, P5631, DOI 10.1074/jbc.273.10.5631; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; OHNO T, 1993, CANCER RES, V53, P5859; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; Sakurai H, 1999, MOL CELL BIOL, V19, P7511; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Schaller S, 1999, FEBS LETT, V461, P253, DOI 10.1016/S0014-5793(99)01441-6; Shen XQ, 1999, ENDOCRINE, V10, P281, DOI 10.1007/BF02738627; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	29	19	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1519	1524		10.1038/sj.onc.1204135	http://dx.doi.org/10.1038/sj.onc.1204135			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313895				2022-12-25	WOS:000167595200012
J	Mitin, N; Kudla, AJ; Konieczny, SF; Taparowsky, EJ				Mitin, N; Kudla, AJ; Konieczny, SF; Taparowsky, EJ			Differential effects of Ras signaling through NF kappa B on skeletal myogenesis	ONCOGENE			English	Article						Ras; myogenesis; NF kappa B; signal transduction	ACTIVATED PROTEIN-KINASE; CELL-CYCLE PROGRESSION; ONCOGENIC RAS; TRANSCRIPTIONAL ACTIVITY; MUSCLE DIFFERENTIATION; MAP KINASE; 3T3 CELLS; INHIBITION; GROWTH; TRANSFORMATION	Oncogenic Ras (H-Ras G12V) inhibits skeletal myogenesis through multiple signaling pathways. Previously, we demonstrated that the major downstream effecters of Ras (i.e., MEK/MAPK, RalGDS and Rac/Rho) play a minor, if any, role in the differentiation-defective phenotype of Ras myoblasts, Recently, NF kappaB, another Ras signaling target, has been shown to inhibit myogenesis presumably by stimulating cyclin D1 accumulation and cell cycle progression. In this study, we address the involvement of NF kappaB activation in the Ras-induced inhibition of myogenesis, Using H-Ras G12V and three G12V effector-loop variants, we detect high levels of NF kappaB transcriptional activity in C3H10T1/2-MyoD cells treated with differentiation medium. Myogenesis is blocked by all Ras proteins tested, yet only in the case of H-Ras G12V are cyclin D1 levels increased and cell cycle progression maintained, Expression of I kappaB alpha SR, an inhibitor of NF kappaB, does not reverse the differentiation-defective phenotype of Ras expressing cultures, but does induce differentiation in cultures treated with tumor necrosis factor (TNF alpha) or in cultures expressing the RelA/p65 subunit of NF kappaB, These data confirm that NF kappaB is a target of Ras and suggest that the cellular actions of NF kappaB require additional signals that are discriminated by the Ras effector-loop variants. Results with I kappaB alpha SR convincingly demonstrate that H-Ras G12V does not rely on NF kappaB activity to block myogenesis, an observation that continues to implicate another unidentified signaling pathway(s) in the inhibition of skeletal myogenesis by Ras.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.		Mitin, Natalia/E-8043-2012		NCI NIH HHS [T32 CA09634] Funding Source: Medline; NIAMS NIH HHS [AR41115-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	60	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1276	1286		10.1038/sj.onc.1204223	http://dx.doi.org/10.1038/sj.onc.1204223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313872				2022-12-25	WOS:000167495000002
J	Wood, LD; Halvorsen, TL; Dhar, S; Baur, JA; Pandita, RK; Wright, WE; Hande, MP; Calaf, G; Hei, TK; Levine, F; Shay, JW; Wang, JJY; Pandita, TK				Wood, LD; Halvorsen, TL; Dhar, S; Baur, JA; Pandita, RK; Wright, WE; Hande, MP; Calaf, G; Hei, TK; Levine, F; Shay, JW; Wang, JJY; Pandita, TK			Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression	ONCOGENE			English	Article						ATM; hTERT; senescence; immortal; ionizing radiation	DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; HUMAN-CELLS; END ASSOCIATIONS; ATM KINASE; KAPPA-B; C-ABL; PROTEIN; CANCER; GENE	Ataxia-telangiectasia (A-T) is an autosomal recessive disease characterized by progressive cerebellar degeneration, immunodeficiencies, genomic instability and gonadal atrophy, A-T patients are hypersensitive to ionizing radiation and have an elevated cancer risk, Cells derived from A-T patients require higher levels of serum factors, exhibit cytoskeletal defects and undergo premature senescence in culture, We show here that expression of the catalytic subunit of telomerase (hTERT) in primary A-T patient fibroblasts can rescue the premature senescence phenotype, Ectopic expression of hTERT does not rescue the radiosensitivity or the telomere fusions in A-T fibroblasts. The hTERT+AT cells also retain the characteristic defects in cell-cycle checkpoints, and show increased chromosome damage before and after ionizing radiation, Although A-T patients have an increased susteptibility to cancer, the expression of hTERT in A-T fibroblasts does not stimulate malignant transformation. These immortalized A-T cells provide a more stable cell system to investigate the molecular mechanisms underlying the cellular phenotypes of Ataxia-telangiectasia.	Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Columbia University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine	Pandita, TK (corresponding author), Columbia Univ, Ctr Radiol Res, VC11-213,630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020; Baur, Joseph A/D-8163-2011; Levine, Fred/L-2693-2013; Wood, Laura/ABF-1531-2020; Shay, Jerry W/F-7878-2011; Hande, M. Prakash/B-1645-2008	Levine, Fred/0000-0002-7336-2526; Hande, M. Prakash/0000-0002-4511-6256; Baur, Joseph/0000-0001-8262-6549	NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, CA43054, R37 CA043054] Funding Source: Medline; NIDDK NIH HHS [DK55065] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner BP, 1999, CANCER RES, V59, P5456; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Harley CB, 1997, CANCER SURV, V29, P263; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sawant SG, 1999, FASEB J, V13, P1047, DOI 10.1096/fasebj.13.9.1047; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shay JW, 1996, LEUKEMIA, V10, P1255; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	65	78	81	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					278	288		10.1038/sj.onc.1204072	http://dx.doi.org/10.1038/sj.onc.1204072			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313956				2022-12-25	WOS:000166411000001
J	Fournes, B; Sadekova, S; Turbide, C; Letourneau, S; Beauchemin, N				Fournes, B; Sadekova, S; Turbide, C; Letourneau, S; Beauchemin, N			The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity	ONCOGENE			English	Article						CEACAM1; CEA; BGP; CD66a; C-CAM; tumor suppressor; colon cancer; Ser phosphorylation; PMA	HUMAN CARCINOEMBRYONIC ANTIGEN; BILIARY GLYCOPROTEIN CD66A; MOLECULE C-CAM; ADHESION MOLECULE; CYTOPLASMIC DOMAIN; ENDOGENOUS SUBSTRATE; ECTO-ATPASE; NEISSERIA-GONORRHOEAE; TYROSINE KINASE; GENE FAMILY	CEACAM1 (also known as biliary glycoprotein, C-CAM or CD66a) is a cell adhesion molecule of the immunoglobulin family behaving as a tumor inhibitory protein in colon, prostate, liver, endometrial and breast cancers. Inhibition of tumor development is dependent upon the presence of the long 71-73 amino acid cytoplasmic domain of the CEACAM1 protein (CEACAM1-L). We have recently defined a number of cis-acting motifs within the long cytoplasmic domain participating in tumor cell growth inhibition. These are Tyr488, corresponding to an Immunoreceptor Tyrosine-based Inhibition Motif, as web as the three terminal lysine residues of the protein. In this study, we provide evidence that treatment with phorbol esters leads to increased phosphorylation of in vivo P-32-labeled CEACAM1-L in mouse CT51 carcinoma cells, in the mouse 1MEA 7R.1 liver carcinoma cells and in 293 human embryonic kidney cells transfected with the Ceacam1-L cDNA. Basal level Ser phosphorylation was abrogated by treatment with the staurosporine inhibitor, but not by the protein kinase C-specific inhibitor calphostin C or other inhibitors such as H7 or sphingosine. Specific inhibitors of protein kinase A or calmodulin kinase had only minimal effects on the levels of basal or PMA-induced Ser phosphorylation, Furthermore, PMA treatment of the CT51 cells induced cell spreading and cellular relocalization of the CEACAM1-L protein. Since Ser503 has been described as a PMA-induced phosphorylation site in other cell systems, we investigated whether Ser503 was involved in these responses in mouse intestinal cells, No differences were noticed in the basal or the PMA-induced phosphorylation levels, kinase inhibitor sensitivity or the PMA-induced relocalization of the protein between the wild-type and the Ser503Ala mutant CEACAM1-L. However, we provide evidence that Ser503 participates in CEACAM1-L-mediated tumor inhibition as its mutation to an Ala led to in vivo tumor development, contrary to the tumor inhibitory phenotype observed with the wild-type CEACAM1-L protein.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osier, Montreal, PQ H3G 1Y6, Canada.							Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1999, EXP CELL RES, V252, P243; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BRUMMER J, 1995, ONCOGENE, V11, P1649; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; Danilov V, 1996, RUSS J MATH PHYS, V4, P272; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; FRANGSMYR L, 1995, CANCER RES, V55, P2963; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HANSSON M, 1989, EXP CELL RES, V181, P63, DOI 10.1016/0014-4827(89)90182-1; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ilantzis C, 1997, LAB INVEST, V76, P703; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kunath T, 1995, ONCOGENE, V11, P2375; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1998, ONCOGENE, V16, P1141, DOI 10.1038/sj.onc.1201619; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MCENTIRE KD, 1989, CANCER RES, V49, P6795; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nollau P, 1997, CANCER RES, V57, P2354; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P314; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Turbide C, 1997, CANCER RES, V57, P2781; VANDERGEER P, 1994, CELL BIOL LAB HDB, P422; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x	58	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					219	230		10.1038/sj.onc.1204058	http://dx.doi.org/10.1038/sj.onc.1204058			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313949				2022-12-25	WOS:000166410900009
J	Wu, YL; Mehew, JW; Heckman, CA; Arcinas, M; Boxer, LM				Wu, YL; Mehew, JW; Heckman, CA; Arcinas, M; Boxer, LM			Negative regulation of bcl-2 expression by p53 in hematopoietic cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; p53	WILD-TYPE P53; TATA-BINDING PROTEIN; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR P53; FOLLICULAR LYMPHOMA; HISTONE DEACETYLASES; FUNCTIONAL DOMAIN; CREB PROTEINS; MDR1 GENE; BAX GENE	The p53 protein activates promoters containing p53 binding sites, and it represses other promoters. We examined the effect of p53 on bcl-2 expression in both the DHL-4 B cell line and the K562 erythroleukemia line. Transient transfection analyses revealed that wild-type p53 repressed the bcl-2 full-length promoter, The region of the bcl-2 promoter that was responsive to p53 was mapped to the bcl-2 P2 minimal promoter region, and we showed that p53 and the TATA binding protein bound to the bcl-2 TATA sequence. The TATA binding protein, p53, histone deacetylase-1 and mSin3a could be co-immunoprecipitated from K562 cell nuclear extract, The TATA binding protein and mSin3a could be recovered in a complex at the bcl-2 promoter TATA. sequence, however, the formation of this complex was not dependent on the presence of p53. Treatment of K562 cells,vith the histone deacetylase inhibitor, trichostatin ii, resulted in an increase in bcl-2 promoter activity whether p53 was present or not. Therefore, we demonstrated that p53 and the histone deacetylases repress the bcl-2 promoter independently. Similar results were obtained when endogenous bcl-2 mRNA or protein levels were measured in response to either p53 or trichostatin A, and p53 expression resulted in enhanced apoptosis, RNase protection assays demonstrated that transcription from the endogenous 3' bcl-2 promoter was decreased by p53. The regions of p53 that were required for repression of the bcl-2 promoter were defined. We conclude that the TATA sequence in the bcl-2 P2 minimal promoter is the target far repression by p53, and that the interaction between p53 and TBP is most likely responsible for the repression. Mutation of p53 may play a role in the up-regulation of bcl-2 expression in some B cell lymphomas.	Palo Alto Vet Affairs Med Ctr, Ctr Mol Biol Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Boxer, LM (corresponding author), Palo Alto Vet Affairs Med Ctr, Ctr Mol Biol Med, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARRANS S, 1995, BRIT J HAEMATOL, V90, P830, DOI 10.1111/j.1365-2141.1995.tb05203.x; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gotlieb T. M., 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Ilyas M, 1996, J PATHOL, V180, P249; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kramer MHH, 1996, J CLIN ONCOL, V14, P2131, DOI 10.1200/JCO.1996.14.7.2131; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEVINE AJ, 1997, CELL, V88, P232; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Miyazaki N., 1994, HDB MARINE MAMMALS, V5, P1; Moller MB, 1999, MODERN PATHOL, V12, P1010; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nguyen PL, 1996, AM J CLIN PATHOL, V105, P538; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SAID JW, 1992, AM J PATHOL, V141, P1343; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; SOINI Y, 1992, J CLIN PATHOL, V45, P1011, DOI 10.1136/jcp.45.11.1011; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Takano Y, 1997, PATHOL INT, V47, P90, DOI 10.1111/j.1440-1827.1997.tb03726.x; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VILLUENDAS R, 1992, J PATHOL, V166, P235, DOI 10.1002/path.1711660305; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang TTY, 1997, CANCER LETT, V116, P61, DOI 10.1016/S0304-3835(97)00175-4; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; YOSHIDA M, 1990, J BIOL CHEM, V265, P13062; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	59	182	186	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					240	251		10.1038/sj.onc.1204067	http://dx.doi.org/10.1038/sj.onc.1204067			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313951				2022-12-25	WOS:000166410900011
J	Briknarova, K; Gehrmann, M; Banyai, L; Tordai, H; Patthy, L; Llinas, M				Briknarova, K; Gehrmann, M; Banyai, L; Tordai, H; Patthy, L; Llinas, M			Gelatin-binding region of human matrix metalloproteinase-2 - Solution structure, dynamics, and function of the COL-23 two-domain construct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-BINDING; N-15 NMR; DISTANCE GEOMETRY; IV COLLAGENASE; TYPE-2 MODULE; II MODULE; FIBRONECTIN; SPECTROSCOPY; DOMAIN; PLASMINOGEN	Human matrix metalloproteinase-2 (MMP-2) contains an array of three fibronectin type II (FII) modules postulated to interact with gelatin (denatured collagen). Here, we verify that the NMR solution structure of the third FII repeat (COL-3) is similar to that of the second FII repeat (COL-2); characterize its ligand-binding properties; and derive dynamics properties and relative orientation in solution for the two domains of the COL-23 fragment, a construct comprising COL-2 and COL-3 in tandem, with each domain possessing a putative collagen-binding site. Interaction of the synthetic gelatin-like octadecapeptide (Pro-Pro-Gly)(6) (PPG6) with COL-3 is weaker than with COL-2. We found that a synthetic peptide comprising segment 33-42 (peptide 33-42) from the MMP-2 prodomain interacts with COL-3 and, albeit with lower affinity, with COL-2 in a way that mimics PPG6 binding. COL-3 strongly prefers peptide 33-42 over PPG6, which suggests that intramolecular interactions with the prodomain could modulate binding of pro-MMP-2 to its gelatin substrate. In COL-23, the two modules retain their structural individuality and tumble independently. Overall, the NMR data indicate that the relative orientation of the modules in COL-23 is not fixed in solution, that the modules do not interact with one another, and that COL-23 is rather flexible. The binding sites face opposite each other, and their responses to, and normalized affinities for, the longer ligand PPG12 are virtually identical to those of the individual domains for PPG6, thus precluding cooperativity, although they may interact simultaneously with multiple sites of the extracellular matrix.	Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	Carnegie Mellon University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Llinas, M (corresponding author), Carnegie Mellon Univ, Dept Chem, 4400 5th Ave, Pittsburgh, PA 15213 USA.	Ilinas+@andrew.cmu.edu	Patthy, Laszlo/Q-6058-2019; Patthy, Laszlo/A-2353-2013	Tordai, Hedvig/0000-0002-0875-5569	NHLBI NIH HHS [HL29409] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; An SSA, 1998, PROTEIN SCI, V7, P1960, DOI 10.1002/pro.5560070911; An SSA, 1998, PROTEIN SCI, V7, P1947, DOI 10.1002/pro.5560070910; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Briknarova K, 1999, STRUCTURE, V7, P1235, DOI 10.1016/S0969-2126(00)80057-X; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; Copie V, 1998, J MOL BIOL, V277, P663; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; DEMARCO A, 1977, J MAGN RESON, V26, P527, DOI 10.1016/0022-2364(77)90104-4; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Dux P, 1997, J BIOMOL NMR, V10, P301, DOI 10.1023/A:1018393225804; FRIEDRICHS MS, 1995, J BIOMOL NMR, V5, P147, DOI 10.1007/BF00208805; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KOBAYASHI Y, 1970, BIOPOLYMERS, V9, P415, DOI 10.1002/bip.1970.360090404; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; LUKACSOVICH T, 1987, J BACTERIOL, V169, P272, DOI 10.1128/jb.169.1.272-277.1987; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Martinez MJF, 1997, HELICOBACTER, V2, P36, DOI 10.1111/j.1523-5378.1997.tb00055.x; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MULLER L, 1979, J AM CHEM SOC, V101, P4481; MURPHY G, 1994, J BIOL CHEM, V269, P6632; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Smith SP, 2000, BIOCHEMISTRY-US, V39, P8374, DOI 10.1021/bi000427i; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STERNLICHT MD, 1999, GUIDEBOOK EXTRACELLU, P545; Sticht H, 1998, J MOL BIOL, V276, P177, DOI 10.1006/jmbi.1997.1528; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; Tordai H, 1999, EUR J BIOCHEM, V259, P513, DOI 10.1046/j.1432-1327.1999.00070.x; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; VANZIJL PCM, 1995, J MAGN RESON SER A, V113, P265, DOI 10.1006/jmra.1995.1092; Yu AE, 1998, BIOL EXTRAC, P85; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	58	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27613	27621		10.1074/jbc.M101105200	http://dx.doi.org/10.1074/jbc.M101105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11320090	hybrid			2022-12-25	WOS:000169966900116
J	Quintas, A; Vaz, DC; Cardoso, I; Saraiva, MJM; Brito, RMM				Quintas, A; Vaz, DC; Cardoso, I; Saraiva, MJM; Brito, RMM			Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL PROTEIN; POLYNEUROPATHY; FIBRILLOGENESIS; THYROXINE; BINDING; MODEL	Amyloid fibril formation and deposition is a common feature of a wide range of fatal diseases including spongiform encephalopathies, Alzheimer's disease, and familial amyloidotic polyneuropathies (FAP), among many others. In certain forms of FAP, the amyloid fibrils are mostly constituted by variants of transthyretin (TTR), a homotetrameric plasma protein. Recently, we showed that transthyretin in solution may undergo dissociation to a non-native monomer, even under close to physiological conditions of temperature, pH, ionic strength, and protein concentration. We also showed that this non-native monomer is a compact structure, does not behave as a molten globule, and may lead to the formation of partially unfolded monomeric species and high molecular mass soluble aggregates (Quintas, A., Saraiva, M.J.M., and Brito, R.M.M. (1999) J. Biol. Chem. 274, 32943-32949), Here, based on aging experiments of tetrameric TTR and chemically induced protein unfolding experiments of the non-native monomeric forms, we show that tetramer dissociation and partial unfolding of the monomer precedes amyloid fibril formation. We also show that TTR variants with the least thermodynamically stable non-native monomer produce the largest amount of partially unfolded monomeric species and soluble aggregates under conditions that are close to physiological. Additionally, the soluble aggregates formed by the amyloidogenic TTR variants showed morphological and thioflavin-T fluorescence properties characteristic of amyloid. These results allowed us to conclude that amyloid fibril formation by some TTR variants might be triggered by tetramer dissociation to a compact non-native monomer with low conformational stability, which originates partially unfolded monomeric species with a high tendency for ordered aggregation into amyloid fibrils. Thus, partial unfolding and conformational fluctuations of molecular species with marginal thermodynamic stability may play a crucial role on amyloid formation in vivo.	Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal; Univ Coimbra, Ctr Neurociencias Coimbra, P-3004517 Coimbra, Portugal; Inst Super Ciencias Saude Sul, P-2825 Monte De Caparica, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4050 Porto, Portugal; Univ Porto, Inst Mol & Cellular Biol, P-4050 Porto, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade do Porto; Universidade do Porto	Brito, RMM (corresponding author), Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal.	brito@ci.uc.pt	Cardoso, Isabel/K-3903-2013; Quintas, Alexandre/J-6436-2012; de Moura Cipreste Vaz, Daniela Barroso/W-5725-2019; Vaz, Daniela C./E-2941-2015; Saraiva, Maria João/K-3907-2013	Cardoso, Isabel/0000-0003-2472-7055; Quintas, Alexandre/0000-0002-5188-0453; de Moura Cipreste Vaz, Daniela Barroso/0000-0001-7562-4676; Saraiva, Maria João/0000-0002-3360-6899; Brito, Rui/0000-0001-9128-2557				Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Connors LH, 2000, AMYLOID, V7, P54, DOI 10.3109/13506120009146826; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; FURUYA H, 1991, BIOCHEMISTRY-US, V30, P2415, DOI 10.1021/bi00223a017; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Inouye H, 1998, AMYLOID, V5, P163, DOI 10.3109/13506129809003842; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Pace C N, 1986, Methods Enzymol, V131, P266; Quintas A, 1999, J BIOL CHEM, V274, P32943, DOI 10.1074/jbc.274.46.32943; Quintas A, 1997, FEBS LETT, V418, P297, DOI 10.1016/S0014-5793(97)01398-7; Raffen R, 1999, PROTEIN SCI, V8, P509; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; RAZ A, 1969, J BIOL CHEM, V244, P3230; Redondo C, 2000, J MOL BIOL, V304, P461, DOI 10.1006/jmbi.2000.4220; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Saraiva M J, 1996, J Peripher Nerv Syst, V1, P179; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; Shnyrov VL, 2000, BIOPHYS CHEM, V88, P61, DOI 10.1016/S0301-4622(00)00199-X; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; STAUDER AJ, 1986, J HISTOCHEM CYTOCHEM, V34, P949, DOI 10.1177/34.7.3458812; TAWARA S, 1981, J LAB CLIN MED, V98, P811; Uversky VN, 1998, P NATL ACAD SCI USA, V95, P5480, DOI 10.1073/pnas.95.10.5480; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364	27	253	264	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27207	27213		10.1074/jbc.M101024200	http://dx.doi.org/10.1074/jbc.M101024200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11306576	hybrid, Green Published			2022-12-25	WOS:000169966900065
J	Ghosh, A; Sarkar, SN; Rowe, TM; Sen, GC				Ghosh, A; Sarkar, SN; Rowe, TM; Sen, GC			A specific isozyme of 2 '-5 ' oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA; 2-5A SYNTHETASE; CELL-DEATH; 2'-5'-OLIGOADENYLATE SYNTHETASES; CONSTITUTIVE EXPRESSION; APOPTOSIS; GROWTH; IDENTIFICATION; REGULATORS; SURVIVAL	2-5(A) synthetases are a family of interferon-induced enzymes that polymerize ATP into 2 ' -5 ' linked oligoadenylates that activate RNase L and cause mRNA degradation. Because they all can synthesize 2-5(A), the reason for the existence of so many synthetase isozymes is unclear. Here we report that the 9-2 isozyme of 2-5(A) synthetase has an additional activity: it promotes apoptosis in mammalian cells. The proapoptotic activity of 9-2 was isozyme-specific and enzyme activity-independent. The 9-2-expressing cells exhibited many properties of cells undergoing apoptosis, such as DNA fragmentation, caspase activation, and poly ADP-ribose polymerase and lamin B cleavage. The isozyme-specific carboxyl-terminal tail of the 9-2 protein was shown, by molecular modeling, to contain a Bcl-2 homology 3 (BH3) domain, suggesting that it may be able to interact with members of the Bcl-2 family that contain BH1 and BH2 domains. Co-immunoprecipitate assays and confocal microscopy showed that 9-2 can indeed interact with the anti-apoptotic proteins Bcl-2 and Bclx(L) in vivo and in vitro. Mutations in the BH3 domain that eliminated the 9-2-Bcl-2 amd 9-2-Bclx(L) interactions also eliminated the apoptotic activity of 9-2. Thus, we have identified an interferon-induced dual function protein of the Bcl-2 family that can synthesize 2-5(A) and promote cellular apoptosis independently. Moreover, the cellular abundance of this protein is regulated by alternative splicing; the other isozymes encoded by the same gene are not proapoptotic.	Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org	Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA062220, R01 CA068782, CA62220, CA68782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; ETIENNESMEKENS M, 1983, P NATL ACAD SCI-BIOL, V80, P4609, DOI 10.1073/pnas.80.15.4609; Ghosh A, 1997, J BIOL CHEM, V272, P15452, DOI 10.1074/jbc.272.24.15452; Ghosh A, 1997, J BIOL CHEM, V272, P33220, DOI 10.1074/jbc.272.52.33220; Ghosh A, 2000, VIROLOGY, V266, P319, DOI 10.1006/viro.1999.0085; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; Gibson L, 1996, ONCOGENE, V13, P665; ICHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117, DOI 10.1093/nar/14.24.10117; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KERR IM, 1987, J INTERFERON RES, V7, P505, DOI 10.1089/jir.1987.7.505; Luchetti F, 1998, HAEMATOLOGICA, V83, P974; MARIE I, 1992, J BIOL CHEM, V267, P9933; Otsuki T, 1998, BRIT J HAEMATOL, V103, P518, DOI 10.1046/j.1365-2141.1998.01000.x; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; REBOUILLAT D, 1999, J INTERFERON CYTOKIN, V19, P1917; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SILVERMAN RH, 1997, GENE REGULATION, P295; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; VILCEK J, 1996, FIELDS VIROLOGY, P375	29	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25447	25455		10.1074/jbc.M100496200	http://dx.doi.org/10.1074/jbc.M100496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323417	hybrid			2022-12-25	WOS:000169800700135
J	Li, HT; Samouilov, A; Liu, XP; Zweier, JL				Li, HT; Samouilov, A; Liu, XP; Zweier, JL			Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrite reduction - Evaluation of its role in nitric oxide generation in anoxic tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; D-GLUCAMINE DITHIOCARBAMATE; O-2-DEPENDENT TYPES; DEHYDROGENASE; HEART; PEROXYNITRITE; PURIFICATION; INHIBITION; MECHANISM; PATHWAY	Xanthine oxidase (XO)-catalyzed nitrite reduction with nitric oxide (NO) production has been reported to occur under anaerobic conditions, but questions remain regarding the magnitude, kinetics, and biological importance of this process, To characterize this mechanism and its quantitative importance in biological systems, electron paramagnetic resonance spectroscopy, chemiluminescence NO analyzer, and NO electrode studies were performed. The XO reducing substrates xanthine, NADH, and 2,3-dihydroxybenz-aldehyde triggered nitrite reduction to NO, and the molybdenum-binding XO inhibitor oxypurinol inhibited this NO formation, indicating that nitrite reduction occurs at the molybdenum site. However, at higher xanthine concentrations, partial inhibition was seen, suggesting the formation of a substrate-bound reduced enzyme complex with xanthine blocking the molybdenum site. Studies of the pH dependence of NO formation indicated that XO-mediated nitrite reduction occurred via an acid-catalyzed mechanism, Nitrite and reducing substrate concentrations were important regulators of XO-catalyzed NO generation. The substrate dependence of anaerobic XO-catalyzed nitrite reduction followed Michaelis-Menten kinetics, enabling prediction of the magnitude of NO formation and delineation of the quantitative importance of this process in biological systems. It was determined that under conditions occurring during no-flow ischemia, myocardial XO and nitrite levels are sufficient to generate NO levels comparable to those produced from nitric oxide synthase, Thus, XO-catalyzed nitrite reduction can be an important source of NO generation under ischemic conditions.	Johns Hopkins Univ, Sch Med, Mol & Cellular Biophys Labs, Dept Med,Div Cardiol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Elect Paramagnet Resonance Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, EPR Ctr, 5501 Hopkins Bayview Circle,Rm LA-14, Baltimore, MD 21224 USA.	jzweier@welch.jhu.edu	Liu, Xiaoping/A-4516-2008; Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011	Liu, Xiaoping/0000-0002-7516-382X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R29HL038324, P01HL065608, R01HL063744] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL63744, HL65608] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLISON RC, 1990, J APPL PHYSIOL, V69, P597, DOI 10.1152/jappl.1990.69.2.597; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; Giraldez RR, 1997, J BIOL CHEM, V272, P21420, DOI 10.1074/jbc.272.34.21420; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; HILLE R, 1984, J BIOL CHEM, V259, P1570; HUNT J, 1992, J BIOL CHEM, V267, P21479; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANGREHR JM, 1993, TRANSPLANTATION, V55, P1205, DOI 10.1097/00007890-199306000-00001; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; McCord J M, 1985, Adv Myocardiol, V5, P183; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Sarnesto A, 1996, LAB INVEST, V74, P48; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Trujillo M, 1998, J BIOL CHEM, V273, P7828, DOI 10.1074/jbc.273.14.7828; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Xia M, 1999, J BIOL CHEM, V274, P3323, DOI 10.1074/jbc.274.6.3323; Xia Y, 2000, FREE RADICAL BIO MED, V29, P793, DOI 10.1016/S0891-5849(00)00427-5; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	32	217	223	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24482	24489		10.1074/jbc.M011648200	http://dx.doi.org/10.1074/jbc.M011648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312267	hybrid			2022-12-25	WOS:000169800700010
J	Tachibana, M; Sugimoto, K; Fukushima, T; Shinkai, Y				Tachibana, M; Sugimoto, K; Fukushima, T; Shinkai, Y			SET domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY GENE INDUCTION; DNA-BINDING PROTEIN; C CENP-C; CHROMOSOME CONDENSATION; CHROMATIN STRUCTURE; FISSION YEAST; CELL-CYCLE; PHOSPHORYLATION; HETEROCHROMATIN; DROSOPHILA	The covalent modification of histone tails has regulatory roles in various nuclear processes, such as control of transcription and mitotic chromosome condensation. Among the different groups of enzymes known to catalyze the covalent modification, the most recent additions are the histone methyltransferases (HMTases), whose functions are now being characterized. Here we show that a SET domain-containing protein, G9a, is a novel mammalian lysine-preferring HMTase. Like Suv39 h1, the first identified lysine-preferring mammalian HMTase, G9a transfers methyl groups to the lysine residues of histone H3, but with a 10-20-fold higher activity, It was reported that lysines 4, 9, and 27 in H3 are methylated in mammalian cells. G9a was able to add methyl groups to lysine 27 as well as 9 in H3, compared with Suv39 hi, which was only able to methylate lysine 9, Our data clearly demonstrated that G9a has an enzymatic nature distinct from Suv39 h1 and its homologue h2, Finally, fluorescent protein-labeled G9a was shown to be localized in the nucleus but not in the repressive chromatin domains of centromeric loci, in which Suv39 h1 family proteins were localized. This finding indicates that G9a may contribute to the organization of the higher order chromatin structure of non-centromeric loci.	Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan; Osaka Prefecture Univ, Dept Appl Biochem, Lab Appl Mol Biol, Sakai, Osaka 5998501, Japan; Nippon Med Sch, Dept Microbiol & Immunol, Bunkyo Ku, Tokyo 1138602, Japan	Kyoto University; Osaka Metropolitan University; Nippon Medical School	Shinkai, Y (corresponding author), Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan.	yshinkai@virus.kyoto-u.ac.jp	Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484; Tachibana, Makoto/0000-0001-7977-1120				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Duerre John A., 1991, Critical Reviews in Oncogenesis, V2, P97; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Muro Y, 2000, CLIN EXP IMMUNOL, V120, P218, DOI 10.1046/j.1365-2249.2000.01189.x; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sugimoto K, 1996, J BIOCHEM, V120, P153; SUGIMOTO K, 1994, J BIOCHEM-TOKYO, V116, P877, DOI 10.1093/oxfordjournals.jbchem.a124610; SUGIMOTO K, 1992, J BIOCHEM, V111, P478, DOI 10.1093/oxfordjournals.jbchem.a123783; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Yamada T, 1999, J BIOCHEM, V125, P832, DOI 10.1093/oxfordjournals.jbchem.a022356; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592	43	606	628	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25309	25317		10.1074/jbc.M101914200	http://dx.doi.org/10.1074/jbc.M101914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316813	hybrid			2022-12-25	WOS:000169800700117
J	Deng, XM; Xiao, L; Lang, WH; Gao, FQ; Ruvolo, P; May, WS				Deng, XM; Xiao, L; Lang, WH; Gao, FQ; Ruvolo, P; May, WS			Novel role for JNK as a stress-activated Bcl2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; PROTEIN-KINASE; CELL-DEATH; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PHOSPHORYLATION; PATHWAY; MITOCHONDRIA; BCL-X(L); IDENTIFICATION	Interleukin (IL)-3-induced Bcl2 phosphorylation at Ser(70) may be required for its full and potent antiapoptotic activity. However, in the absence of IL-3, increased expression of Bcl2 can also prolong cell survival. To determine how Bcl2 may be functionally phosphorylated following IL-3 withdrawal, a stress-activated Bcl2 kinase (SAK) was sought. Results indicate that anisomycin, a potent activator of the stress kinase JNK/SAPK, can induce Bcl2 phosphorylation at Ser70 and that JNK1 can be latently activated following IL-3 withdrawal to mediate Bcl2 phosphorylation. JNK1 directly phosphorylates Bc12 in vitro, co-localizes with Bc12, and collaborates with Bcl-2 to mediate prolonged cell survival in the absence of IL-3 or following various stress applications. Dominant-negative (DN)-JNK1 can block both anisomycin and latent IL-3 withdrawal-induced Bc12 phosphorylation (> 90%) and potently enhances cell death. Furthermore, low dose okadaic acid (OA), a potent protein phosphatase 1 and 2A inhibitor, can activate the mito gen-activated protein kinases JNK1 and ERK1/2, but not p38 kinase, to induce Bcl2 phosphorylation and prolong cell survival in factor-deprived cells. Since PD98059, a specific MEK inhibitor, can only partially inhibit OA-induced Bc12 phosphorylation but completely blocks OA-induced Bc12 phosphorylation in cells expressing DN-JNK1, this supports the conclusion that OA may stimulate Bc12 phosphorylation via a mechanism involving both JNK1 and ERK1/2. Collectively, these findings indicate a novel role for JNK1 as a SAK, and may explain, at least in part, how functional phosphorylation of Bc12 can occur in the absence of growth factor.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	May, WS (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd,Med Sci Bldg,N505,POB 100232, Gainesville, FL 32610 USA.	smay@ufscc.ufl.edu			NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER; NCI NIH HHS [CA44649-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Andre N, 2000, CANCER RES, V60, P5349; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dixon SC, 1997, ANN PHARMACOTHER, V31, P76, DOI 10.1177/106002809703100113; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Krajewska M, 1997, CANCER RES, V57, P1605; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murata M, 1997, CELL MOL LIFE SCI, V53, P737, DOI 10.1007/s000180050093; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Shu JY, 1996, ONCOGENE, V13, P2421; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; TANG C, 1994, LEUKEMIA, V8, P1960; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yue TL, 1998, J MOL CELL CARDIOL, V30, P495, DOI 10.1006/jmcc.1997.0614; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	52	236	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23681	23688		10.1074/jbc.M100279200	http://dx.doi.org/10.1074/jbc.M100279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323415	hybrid			2022-12-25	WOS:000169531100062
J	Hallstrom, TC; Lambert, L; Schorling, S; Balzi, E; Goffeau, A; Moye-Rowley, WS				Hallstrom, TC; Lambert, L; Schorling, S; Balzi, E; Goffeau, A; Moye-Rowley, WS			Coordinate control of sphingolipid biosynthesis and multidrug resistance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; TRANSCRIPTIONAL CONTROL; OLIGOMYCIN RESISTANCE; STRESS-RESPONSE; YEAST; GENE; PROTEIN; PDR1; IDENTIFICATION; MUTANTS	Multiple or pleiotropic drug resistance often occurs in the yeast Saccharomyces cerevisiae through genetic activation of the Cys(6)-Zn(II) transcription factors Pdr1p and Pdr3p. Hyperactive alleles of these proteins cause overproduction of target genes that include drug efflux pumps, which in turn confer high level drug resistance. Here we provide evidence that both Pdr1p and Pdr3p act to regulate production of an enzyme involved in sphingolipid biosynthesis in S. cerevisiae. The last step in formation of the major sphingolipid in the yeast plasma membrane, mannosyldiinositol phosphorylceramide, is catalyzed by the product of the IPT1 gene, inositol phosphotransferase (Ipt1p), Transcription of the IPT1 gene is responsive to changes inactivity of Pdrlp and Pdr3p. A single Pdr1p/Pdr3p response element is present in the IPT1 promoter and is required for regulation by these factors. Loss of IPT1 has complex effects on drug resistance of the resulting strain, consistent with an important role for mannosyldiinositol phosphorylceramide in normal plasma membrane function. Direct assay for Lipid contents of cells demonstrates that changes in sphingolipid composition correlate with changes in the activity of Pdr3p. These data suggest that Pdr1p and Pdr3p may act to modulate the lipid composition of membranes in S. cerevisiae through activation of sphingolipid biosynthesis along with other target genes.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Max Planck Inst Biochem, Dept Membrane Biochem, D-82152 Martinsried, Germany; Univ Catholique Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	University of Iowa; Max Planck Society; Universite Catholique Louvain	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-612 Bowen Sci Bldg, Iowa City, IA 52242 USA.		Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BEELER T, 1994, J BIOL CHEM, V269, P7279; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4048; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUERINEAU M, 1974, BIOCHEM BIOPH RES CO, V61, P462, DOI 10.1016/0006-291X(74)90979-6; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; HANSON BA, 1980, J LIPID RES, V21, P309; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LEPPERT G, 1990, GENETICS, V125, P13; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; NASS G, 1976, MOL GEN GENET, V147, P39, DOI 10.1007/BF00337933; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stock SD, 2000, ANTIMICROB AGENTS CH, V44, P1174, DOI 10.1128/AAC.44.5.1174-1180.2000; TAGUCHI N, 1994, MICROBIOL-SGM, V140, P353, DOI 10.1099/13500872-140-2-353; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446; Yoshida S, 2000, MOL GEN GENET, V263, P877, DOI 10.1007/s004380000255; ZHAO C, 1994, J BIOL CHEM, V269, P21480	52	69	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23674	23680		10.1074/jbc.M101568200	http://dx.doi.org/10.1074/jbc.M101568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323424	hybrid			2022-12-25	WOS:000169531100061
J	Hussain, I; Christie, G; Schneider, K; Moore, S; Dingwall, C				Hussain, I; Christie, G; Schneider, K; Moore, S; Dingwall, C			Prodomain processing of Asp1 (BACE2) is autocatalytic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE CLEAVAGE; ALZHEIMERS-DISEASE; GOLGI-COMPLEX; CELL-SURFACE; IDENTIFICATION; TRANSPORT; ENZYME; SITE; PURIFICATION	Generation of the amyloid peptide through proteolytic processing of the amyloid precursor protein by beta -and gamma -secretases is central to the etiology of Alzheimer's disease. The highly elusive beta -secretase was recently identified as a transmembrane aspartic proteinase, Asp2 (BACE). The Asp2 homolog Asp1 (BACE2/DRAP) has also been reported to exhibit beta -secretase cleavage of amyloid precursor protein. Most aspartic proteinases are generated as inactive proenzymes, requiring removal of the prodomain to generate active proteinase, Here we show that prodomain processing of Asp1 occurs between Leu(62) and Ala(63) and is autocatalytic. Asp1 cleaved a maltose-binding protein-Asp1 prodomain fusion protein and a synthetic peptide at this site. Mutation of one of the conserved catalytic aspartic acid residues in the active site of Asp1 to asparagine (D110N) abolished this cleavage. Mutation of P-1' and P-2' residues in the substrate to phenylalanine reduced cleavage at this site. Asp1 expressed in cells was the mature form, and prodomain processing occurred intramolecularly within the endoplasmic reticulum/early Golgi. Interestingly, a proportion of mature Asp1 was expressed on the cell surface. When full-length Asp1(D110N) was expressed in COS-7 cells, it was not processed, suggesting that no other proteinase can activate Asp1 in these cells.	GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Computat & Struct Sci, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Dingwall, C (corresponding author), GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Colin_Dingwall@sbphrd.com	Schneider, Klaus/N-6604-2014	Schneider, Klaus/0000-0002-3068-8681				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Howlett DR, 2000, TRENDS NEUROSCI, V23, P565, DOI 10.1016/S0166-2236(00)01647-7; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROSA P, 1992, J BIOL CHEM, V267, P12227; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Saunders AJ, 1999, SCIENCE, V286; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 2000, SCIENCE, V289, P2296, DOI 10.1126/science.289.5488.2296; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	35	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23322	23328		10.1074/jbc.M101069200	http://dx.doi.org/10.1074/jbc.M101069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316808	hybrid			2022-12-25	WOS:000169531100016
J	Loewith, R; Smith, JS; Meijer, M; Williams, TJ; Bachman, N; Boeke, JD; Young, D				Loewith, R; Smith, JS; Meijer, M; Williams, TJ; Bachman, N; Boeke, JD; Young, D			Pho23 is associated with the Rpd3 histone deacetylase and is required for its normal function in regulation of gene expression and silencing in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; IN-VIVO; N-COR; NUCLEOSOMAL DNA; RIBOSOMAL DNA; YEAST; COMPLEX; ACETYLATION; CHROMATIN; SIN3	The Rpd8 histone deacetylase (HDAC) functions in a large complex containing many proteins including Sin3 and Sap30, Previous evidence indicates that the pho23, rpd3, sin3, and sap30 mutants exhibit similar defects in PHO5 regulation, We report that pho23 mutants like rpd3, sin3, and sap30 are hypersensitive to cycloheximide and heat shock and exhibit enhanced silencing of rDNA, telomeric, and HMR loci, suggesting that these genes are functionally related. Based on these observations, we explored whether Pho23 is a component of the Rpds HDAC complex. Our results demonstrate that Myc-Pho23 co-immunoprecipitates with HA-Rpd3 and HA-Sap30. Furthermore, similar levels of HDAC activity were detected in immunoprecipitates of HA-Pho23, HA-Rpd3, or HA-Sap30, In contrast, HDAC activity was not detected in immunoprecipitates of HA-Pho23 or HA-Sap30 from strains lacking Rpd3, suggesting that Rpd8 is the HDAC associated with these proteins. However, HDAC activity was detected in immunoprecipitates of HA-Sap30 or HA-Rpd3 from cells lacking Pho23, although levels were significantly lower than those detected in wild-type cells, indicating that Rpd3 activity is compromised in the absence of Pho23, Together, our genetic and biochemical studies provide strong evidence that Pho23 is a component of the Rpd3 HDAC complex, and. is required for the normal function of this complex.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Virginia; Johns Hopkins University	Young, D (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.		Loewith, Robbie J/S-6289-2016	Loewith, Robbie J/0000-0002-2482-603X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061692] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM61692-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; DeRubertis F, 1996, NATURE, V384, P589; Dorland S, 2000, GENETICS, V154, P573; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Gunduz M, 2000, CANCER RES, V60, P3143; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HONG L, 1993, J BIOL CHEM, V268, P305; Hubberstey A, 1996, J CELL BIOCHEM, V61, P459, DOI 10.1002/(SICI)1097-4644(19960601)61:3<459::AID-JCB13>3.0.CO;2-E; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lau WTW, 1998, GENETICS, V150, P1349; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun ZW, 1999, GENETICS, V152, P921; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TO EA, 1973, J BACTERIOL, V113, P727; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Vannier D, 1996, GENETICS, V144, P1343; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	66	59	60	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24068	24074		10.1074/jbc.M102176200	http://dx.doi.org/10.1074/jbc.M102176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306585	hybrid			2022-12-25	WOS:000169531100112
J	Dobransky, T; Davis, WL; Rylett, RJ				Dobransky, T; Davis, WL; Rylett, RJ			Functional characterization of phosphorylation of 69-kDa human choline acetyltransferase at serine 440 by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPAL TISSUE; CENTRAL-NERVOUS-SYSTEM; TYROSINE-HYDROXYLASE; O-ACETYLTRANSFERASE; ALZHEIMERS-DISEASE; LOCALIZATION; MEMBRANES; ISOZYMES; TORPEDO; ENZYME	Choline acetyltransferase, the enzyme that synthesizes the transmitter acetylcholine in cholinergic neurons, is a substrate for protein kinase C, In the present study, we used mass spectrometry to identify serine 440 in recombinant human 69-kDa choline acetyltransferase as a protein kinase C phosphorylation site, and site-directed mutagenesis to determine that phosphorylation of this residue is involved in regulation of the enzyme's catalytic activity and binding to subcellular membranes. Incubation of HEK293 cells stably expressing wild-type 69-kDa choline acetyltransferase with the protein kinase C activator phorbol la myristate 13-acetate showed time- and dose-related increases in specific activity of the enzyme; in control and phorbol ester-treated cells, the enzyme was distributed predominantly in cytoplasm (about 88%) with the remainder (about 12%) bound to cellular membranes. Mutation of serine 440 to alanine resulted in localization of the enzyme entirely in cytoplasm, and this was unchanged by phorbol ester treatment. Furthermore, activation of mutant enzyme in phorbol ester-treated HEK293 cells was about 50% that observed for wild-type enzyme, Incubation of immunoaffinity purified wild-type and mutant choline acetyltransferase with protein kinase C under phosphorylating conditions led to incorporation of [P-32]phosphate, with radiolabeling of mutant enzyme being about one-half that of wild-type, indicating that another residue is phosphorylated by protein kinase C, Acetylcholine synthesis in HEK293 cells expressing wild-type choline acetyltransferase, but not mutant enzyme, was increased by about 17% by phorbol ester treatment.	Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada; John P Robarts Res Inst, Neurodegenerat Dis Grp, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Rylett, RJ (corresponding author), Univ Western Ontario, Dept Physiol, Med Sci Bldg, London, ON N6A 5C1, Canada.		Rylett, Rebecca Jane/K-3597-2013	Rylett, Rebecca Jane/0000-0002-9158-9599				ATTERWILL CK, 1978, J NEUROCHEM, V31, P719, DOI 10.1111/j.1471-4159.1978.tb07846.x; BRUCE G, 1989, NEUROCHEM RES, V14, P613, DOI 10.1007/BF00964869; CARROLL PT, 1990, J NEUROCHEM, V54, P1047, DOI 10.1111/j.1471-4159.1990.tb02356.x; CLARK EA, 1991, LAB INVEST, V64, P35; COLE G, 1988, BRAIN RES, V452, P165, DOI 10.1016/0006-8993(88)90021-2; COOPER JR, 1994, J NEUROCHEM, V63, P395; Dobransky T, 2000, BIOCHEM J, V349, P141, DOI 10.1042/0264-6021:3490141; EDERCOLLI L, 1992, BRAIN RES, V573, P284, DOI 10.1016/0006-8993(92)90774-4; EDERCOLLI L, 1985, NEUROSCIENCE, V15, P577, DOI 10.1016/0306-4522(85)90235-0; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HABERT E, 1992, J NEUROCHEM, V58, P1447, DOI 10.1111/j.1471-4159.1992.tb11362.x; Haycock JW, 1998, J NEUROCHEM, V71, P1670; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; Keenan C, 1997, IMMUNOLOGY, V90, P557, DOI 10.1046/j.1365-2567.1997.00198.x; KEENAN C, 1995, EUR J IMMUNOL, V25, P13, DOI 10.1002/eji.1830250104; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASLIAH E, 1990, J NEUROSCI, V10, P2113; Misawa H, 1997, MOL BRAIN RES, V44, P323, DOI 10.1016/S0169-328X(96)00231-8; ODA Y, 1992, MOL BRAIN RES, V16, P287, DOI 10.1016/0169-328X(92)90237-6; Ohno K, 2001, P NATL ACAD SCI USA, V98, P2017, DOI 10.1073/pnas.98.4.2017; Pahud G, 1998, EUR J NEUROSCI, V10, P1644, DOI 10.1046/j.1460-9568.1998.00177.x; PISANO M R, 1991, Biomedical and Environmental Sciences, V4, P173; Resendes MC, 1999, J BIOL CHEM, V274, P19417, DOI 10.1074/jbc.274.27.19417; RYLETT RJ, 1993, J NEUROCHEM, V61, P1388, DOI 10.1111/j.1471-4159.1993.tb13632.x; RYLETT RJ, 1989, J NEUROCHEM, V52, P869, DOI 10.1111/j.1471-4159.1989.tb02535.x; SALEM N, 1993, BRAIN RES, V609, P223, DOI 10.1016/0006-8993(93)90876-O; SCHMIDT BM, 1993, J NEUROCHEM, V61, P1774, DOI 10.1111/j.1471-4159.1993.tb09815.x; SCHMIDT BM, 1993, NEUROSCIENCE, V54, P649, DOI 10.1016/0306-4522(93)90236-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SMITH LK, 1993, BRAIN RES, V605, P155, DOI 10.1016/0006-8993(93)91367-2	32	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22244	22250		10.1074/jbc.M011702200	http://dx.doi.org/10.1074/jbc.M011702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303024	hybrid			2022-12-25	WOS:000169412700038
J	Kanaoka, Y; Maekawa, A; Penrose, JF; Austen, KF; Lam, BK				Kanaoka, Y; Maekawa, A; Penrose, JF; Austen, KF; Lam, BK			Attenuated zymosan-induced peritoneal vascular permeability and IgE dependent passive cutaneous anaphylaxis in mice lacking leukotriene C-4 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE INFLAMMATORY RESPONSES; GLUTATHIONE S-TRANSFERASE; MAST-CELLS; MOLECULAR-CLONING; MEMBRANE-PROTEIN; DEFICIENT MICE; MOUSE EAR; PURIFICATION; METABOLISM; EXPRESSION	Leukotriene C-4 synthase (LTC4S), the terminal 5-lipoxygenase pathway enzyme that is responsible for the biosynthesis of cysteinyl leukotrienes, has been deleted by targeted gene disruption to define its tissue distribution and integrated pathway function in vitro and in vivo. The LTC4S (-/-) mice developed normally and were fertile. LTC4S activity, assessed by conjugation of leukotriene (LT) A(4) methyl ester with glutathione, was absent from tongue, spleen, and brain and greater than or equal to 90% reduced in lung, stomach, and colon of the LTC4S (-/-) mice. Bone marrow-derived mast cells (BMMC) from the LTC4S (-/-) mice provided no LTC, in response to IgE dependent activation. Exocytosis and the generation of prostaglandin D-2, LTB4, and 5-hydroxyeicosatetraenoic acid by BMMC from LTC4S (-/-) mice and LTC4S (+/+) mice were similar, whereas the degraded product of LTA(4), 6-trans-LTB4, was doubled in BMMC from LTC4S (-/-) mice because of lack of utilization. The zymosan elicited intraperitoneal extravasation of plasma protein and the IgE-mediated passive cutaneous anaphylaxis in the ear were significantly diminished in the LTC4S (-/-) mice. These observations indicate that LTC4S, but not microsomal or cytosolic glutathione S-transferases, is the major LTC4-producing enzyme in tissues and that its integrated function includes mediation of increased vascular permeability in either innate or adaptive immune host inflammatory responses.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Lam, BK (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 628,1 Jimmy Fund Way, Boston, MA 02115 USA.				NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI31599] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031599, U01AI031599] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byrum RS, 1999, J IMMUNOL, V163, P6810; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HSIEH FH, 2000, J EXP MED, V275, P30531; INAGAKI N, 1986, INT ARCH ALLER A IMM, V80, P285, DOI 10.1159/000234067; INAGAKI N, 1985, INT ARCH ALLER A IMM, V78, P113, DOI 10.1159/000233873; ISHIKAWA T, 1988, EUR J BIOCHEM, V176, P551, DOI 10.1111/j.1432-1033.1988.tb14313.x; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jakobsson PJ, 1997, J BIOL CHEM, V272, P22934, DOI 10.1074/jbc.272.36.22934; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; KOLLER M, 1985, BIOCHIM BIOPHYS ACTA, V833, P128, DOI 10.1016/0005-2760(85)90260-7; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; Lynch KR, 1999, NATURE, V399, P789; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MIURA T, 1992, EUR J PHARMACOL, V221, P333; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; Penrose JF, 1997, EUR J BIOCHEM, V248, P807, DOI 10.1111/j.1432-1033.1997.00807.x; RAO TS, 1994, J PHARMACOL EXP THER, V269, P917; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; Scoggan KA, 1997, J BIOL CHEM, V272, P10182; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TSUCHIDA S, 1987, EUR J BIOCHEM, V170, P159, DOI 10.1111/j.1432-1033.1987.tb13681.x; URADE Y, 1990, J BIOL CHEM, V265, P371; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745	49	124	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22608	22613		10.1074/jbc.M103562200	http://dx.doi.org/10.1074/jbc.M103562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11319240	hybrid			2022-12-25	WOS:000169412700086
J	Miranda, KC; Khromykh, T; Christy, P; Le, TL; Gottardi, CJ; Yap, AS; Stow, JL; Teasdale, RD				Miranda, KC; Khromykh, T; Christy, P; Le, TL; Gottardi, CJ; Yap, AS; Stow, JL; Teasdale, RD			A dileucine motif targets E-cadherin to the basolateral cell surface in Madin-Darby canine kidney and LLC-PK1 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; DI-LEUCINE MOTIF; MDCK CELLS; SORTING SIGNALS; ADHESION MOLECULE; STRUCTURAL REQUIREMENTS; CYTOPLASMIC DOMAIN; COMPLEX-FORMATION; CATENIN COMPLEX; PLASMA-MEMBRANE	E-cadherin is a major adherens junction protein of epithelial cells, with a central role in cell-cell adhesion and cell polarity. Newly synthesized E-cadherin is targeted to the basolateral cell surface, We analyzed targeting information in the cytoplasmic tail of E-cadherin by utilizing chimeras of E-cadherin fused to the ectodo- main of the interleukin-2 alpha (IL-2 alpha) receptor expressed in Madin-Darby canine kidney and LLC-PK1 epithelial cells, Chimeras containing the full-length or membrane-proximal half of the E-cadherin cytoplasmic tail were correctly targeted to the basolateral domain. Sequence analysis of the membrane-proximal tail region revealed the presence of a highly conserved dileucine motif, which was analyzed as a putative targeting signal by mutagenesis. Elimination of this motif resulted in the loss of Tac/E-cadherin basolateral localization, pinpointing this dileucine signal as being both necessary and sufficient for basolateral targeting of E-cadherin, Truncation mutants unable to bind beta -catenin were correctly targeted, showing, contrary to current understanding, that beta -catenin is not required for basolateral trafficking. Our results also provide evidence that dileucine mediated targeting is maintained in UC-PK, cells despite the altered polarity of basolateral proteins with tyrosine-based signals in this cell line, These results provide the first direct insights into how E-cadherin is targeted to the basolateral membrane.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Queensland; University of Queensland; University of Queensland; Memorial Sloan Kettering Cancer Center	Teasdale, RD (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Stow, Jennifer L/I-4723-2013; Khromykh, Tatiana/D-3952-2017; Yap, Alpha S./J-1554-2014; Teasdale, Rohan/AAD-6698-2019; Teasdale, Rohan D/B-2538-2009; Gottardi, Cara J./AAU-4691-2021	Stow, Jennifer L/0000-0002-5409-9101; Khromykh, Tatiana/0000-0001-6629-6885; Yap, Alpha S./0000-0002-1038-8956; Teasdale, Rohan/0000-0001-7455-5269; Teasdale, Rohan D/0000-0001-7455-5269; Gottardi, Cara J./0000-0003-0912-7617				Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; DEALMEIDA JB, 1991, AM J PHYSIOL, V260, pC691, DOI 10.1152/ajpcell.1991.260.4.C691; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Distel B, 1998, J BIOL CHEM, V273, P186, DOI 10.1074/jbc.273.1.186; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; El Nemer W, 1999, J BIOL CHEM, V274, P31903, DOI 10.1074/jbc.274.45.31903; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Huber O, 1999, J CELL SCI, V112, P4415; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lechner J, 1999, KIDNEY INT, V55, P2178, DOI 10.1046/j.1523-1755.1999.00487.x; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Polakis P, 2000, GENE DEV, V14, P1837; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V200, P1754, DOI 10.1006/bbrc.1994.1656; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sambrook J., 2002, MOL CLONING LAB MANU; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Simmen T, 1999, MOL CELL BIOL, V19, P3136; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	57	134	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22565	22572		10.1074/jbc.M101907200	http://dx.doi.org/10.1074/jbc.M101907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312273	hybrid			2022-12-25	WOS:000169412700080
J	El-Tanani, MK; Barraclough, R; Wilkinson, MC; Rudland, PS				El-Tanani, MK; Barraclough, R; Wilkinson, MC; Rudland, PS			Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4	ONCOGENE			English	Article						metastasis-inducing DNA; osteopontin promoter; Tcf-4; metastasis	BETA-CATENIN; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; HMG BOX; OSTEOPONTIN; CANCER; EXPRESSION; CARCINOMA; IDENTIFICATION; ACTIVATION	Small 1000 bp fragments of DNA derived from human malignant breast cancer cells have been isolated which, when transfected into a benign rat mammary cell line induce the production of osteopontin and thereby endow those cells with the capability to metastasize in syngeneic rats. Using transient transfections of an osteopontin promoter-reporter construct, we have now identified the active moiety in the metastasis-inducing DNA as the binding site for the T cell factor (Tcf) family of transcription factors and located Tcf-4, beta -catenin and E-cadherin in the relevant DNA complex in vitro. The regulatory effects of the metastasis-inducing DNAs are therefore exerted, at least in part, by a CAAAG sequence which can sequester Tcf-4, thereby promoting transcription of the direct effector for metastasis in this system, osteopontin.	Univ Liverpool, Canc & Polio Res Fund Labs, Mol Med Grp, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Rudland, PS (corresponding author), Univ Liverpool, Canc & Polio Res Fund Labs, Mol Med Grp, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England.		Barraclough, Roger/AAH-6516-2020	Wilkinson, Mark/0000-0003-3109-6888; Barraclough, Roger/0000-0002-7203-1194; El-Tanani, Mohamed/0000-0002-4735-5445				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen DS, 1997, J BIOL CHEM, V272, P20283, DOI 10.1074/jbc.272.32.20283; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DAVIES BR, 1994, CANCER RES, V54, P2785; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oates AJ, 1996, ONCOGENE, V13, P97; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; RUDLAND PS, 1997, Patent No. 9725443; Schilham MW, 1998, SEMIN IMMUNOL, V10, P127, DOI 10.1006/smim.1998.0114; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x	19	33	34	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1793	1797		10.1038/sj.onc.1204358	http://dx.doi.org/10.1038/sj.onc.1204358			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313926				2022-12-25	WOS:000167750900012
J	Wolff, A; Technau, A; Ihling, C; Technau-Ihling, K; Erber, R; Bosch, FX; Brandner, G				Wolff, A; Technau, A; Ihling, C; Technau-Ihling, K; Erber, R; Bosch, FX; Brandner, G			Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex	ONCOGENE			English	Article						p53-localization; neuroblastoma; PAb1801; p53-conformation; TPEN; Cd2+; leptomycin B	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CYTOPLASMIC SEQUESTRATION; MONOCLONAL-ANTIBODIES; NUCLEAR-LOCALIZATION; BINDING; PHOSPHORYLATION; CYCLE; MDM2; TRANSACTIVATION	Neuroblastoma (NB) cells reportedly accumulate wildtype p53 exclusively in the cytoplasm, However, immunofluorescence assays with five different antibodies showed that p53 accumulates in the nucleus of up to 10% of NB cells. PAb1801 detected cytoplasmic 'punctate structures' which were also found in p53-null cells, rendering this antibody unsuitable for p53 detection, A comparison of DO-1 and PAb1801 staining in NB tissue sections confirmed the results obtained with NB cells. Nuclear accumulation of p53 was induced in NB cells using substances which disturb p53's tertiary structure at its zinc finger motif, or by treatment with mitomycin C, Constitutive nuclear accumulation was observed in an SK-N-SH variant, AW-1, which has a point mutation in p53 at Cys176>Ser, disturbing the same motif, Even though p53 showed DNA-binding capability after mitomycin C treatment of NB cells, the target gene products MDM2 and p21(WAF1.CIP1.SDI1) were not synthesized and no p53 transactivating activity measured in a reporter gene assay. Therefore we suggest that p53 in NB cells might be predominantly in a conformation refractory to integration into the transcriptional complex, resulting in at Least partial transcriptional inactivity, hyperactive nuclear export and resistance to degradation by exogenously expressed MDM2.	Univ Freiburg, Inst Med Microbiol & Hyg, Dept Virol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany; Univ Heidelberg, ENT Univ Hosp, Mol Biol Lab, D-69120 Heidelberg, Germany	University of Freiburg; University of Freiburg; Ruprecht Karls University Heidelberg	Technau, A (corresponding author), Univ Freiburg, Inst Med Microbiol & Hyg, Dept Virol, Hermann Herder Str 11, D-79104 Freiburg, Germany.		Erber, Ralf/B-6790-2008; Erber, Ralf/AAF-3002-2020; Wolff, Antonio C./T-8796-2019	Wolff, Antonio C./0000-0003-3734-1063				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; BOSARI S, 1995, AM J PATHOL, V147, P790; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GOLDER H, 1996, ARION, V4, P1; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Komarova EA, 1997, CANCER RES, V57, P5217; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Merlin T, 1998, INT J ONCOL, V13, P1007; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Plaumann B, 1996, ONCOGENE, V13, P1605; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schwab M, 1999, NATURWISSENSCHAFTEN, V86, P71, DOI 10.1007/s001140050574; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SIEGEL J, 1995, ONCOGENE, V11, P1363; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TECHNAU A, 2001, IN PRESS INT J ONCOL, V18; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wolff A, 1997, INT J ONCOL, V11, P123; WOLFF A, 1999, J CANC RES CLIN ON S, V125, P24; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474	53	33	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1307	1317		10.1038/sj.onc.1204251	http://dx.doi.org/10.1038/sj.onc.1204251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313875				2022-12-25	WOS:000167495000005
J	Patterson, T; Vuong, H; Liaw, YS; Wu, R; Kalvakolanu, DV; Reddy, SPM				Patterson, T; Vuong, H; Liaw, YS; Wu, R; Kalvakolanu, DV; Reddy, SPM			Mechanism of repression of squamous differentiation marker, SPRR1B, in malignant bronchial epithelial cells: role of critical TRE-sites and its transacting factors	ONCOGENE			English	Article						SPRR1; squamous cell differentiation; AP-1 proteins; bronchial epithelial cells	KERATINOCYTE TERMINAL DIFFERENTIATION; PROLINE-RICH PROTEIN; C-FOS; IN-VITRO; EXPRESSION; TRANSCRIPTION; BINDING; FRA-2; AP-1; SPR1	The overexpression of SPRR1B in bronchial epithelium is a marker for early metaplastic changes and the loss of its expression is associated with an irreversible malignant transformation. In the present study, we have used a model system consisting of normal and malignant bronchial epithelial (BE) cells to elucidate the differential transcriptional control of SPRR1B, SPRR1B expression is either detectable or PMA (phorbol 13-myristate 12-acetate) including squamous, adeno, small and large cell carcinomas. Loss of SPRR1B expression is correlated well with the lack of strong in vivo protein-DNA interactions at the -152 bp promoter, which contains two functional TRE sites. Even though the basal level AP-1 protein DNA binding pattern is different between normal and malignant cells, PMA significantly enhances Jun and Fos binding to the consensus TRE site in both cell types. Intriguingly, the composition of AP-1 protein binding to the -152 to -86 bp SPRR1B promoter is quite different. In untreated cells, SPRR1B promoter is predominantly occupied by JunD and Fra2, PMA significantly induced binding of JunB and Fra1 in normal cells, while JunB and Fra2 bound to TREs in the malignant cells. Overexpression of fr nl in malignant cells significantly enhanced SPRRIB promoter activity. In contrast, overexpression of fra2, but not fra1, strongly reduced both basal and PMA-inducible promoter activities in normal cells. Together, these results indicate that either temporal expression and/or differential activation of AP-1 proteins, especially Fra1 and Fra2, might contribute to the dysregulation of terminal differentiation marker, SPRR1B, expression in various BE cells.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; University of California System; University of California Davis; University System of Maryland; University of Maryland Baltimore	Reddy, SPM (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.				NCI NIH HHS [CA-71401, CA-78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NIEHS NIH HHS [ES-06230, ES03819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, R01ES006230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; Anisowicz A, 1999, MOL MED, V5, P526, DOI 10.1007/BF03401980; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; CARRASCO D, 1995, ONCOGENE, V10, P1069; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P25, DOI 10.1165/ajrcmb.19.1.3078; Deng J, 2000, J BIOL CHEM, V275, P5739, DOI 10.1074/jbc.275.8.5739; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lau D, 2000, AM J RESP CELL MOL, V22, P92, DOI 10.1165/ajrcmb.22.1.3637; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147	39	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					634	644		10.1038/sj.onc.1204134	http://dx.doi.org/10.1038/sj.onc.1204134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313996				2022-12-25	WOS:000166755000011
J	Fortune, JM; Lavrukhin, OV; Gurnon, JR; Van Etten, JL; Lloyd, RS; Osheroff, N				Fortune, JM; Lavrukhin, OV; Gurnon, JR; Van Etten, JL; Lloyd, RS; Osheroff, N			Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWINE FEVER VIRUS; NUCLEAR-LOCALIZATION SIGNALS; HAIRPIN LOOP STRUCTURE; VACCINIA VIRUS; CIRCULAR PERMUTATION; ANTINEOPLASTIC DRUGS; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; TARGETED DRUGS; HYDRA-VIRIDIS	Chlorella virus PBCV-1 topoisomerase II is the only functional type II enzyme known to be encoded by a virus that infects eukaryotic cells. However, it has not been established whether the protein is expressed following viral infection or whether the enzyme has any catalytic features that distinguish it from cellular type II topoisomerases. Therefore, the present study characterized the physiological expression of PBCV-1 topoisomerase II and individual reaction steps catalyzed by the enzyme. Results indicate that the topoisomerase II gene is widely distributed among Chlorella viruses and that the protein is expressed 60-90 min after viral infection of algal cells. Furthermore, the enzyme has an extremely high DNA cleavage activity that sets it apart from all known eukaryotic type II topoisomerases. Levels of DNA scission generated by the viral enzyme are similar to 30 times greater than those observed with human topoisomerase II alpha, The high levels of cleavage are not due to inordinately tight enzyme-DNA binding or to impaired DNA religation, Thus, they most likely reflect an elevated forward rate of scission. The robust DNA cleavage activity of PBCV-1 topoisomerase II provides a unique tool for studying the catalytic functions of type II topoisomerases.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Nebraska System; University of Nebraska Lincoln	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Robinson Res Bldg, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu		Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944, R01GM032441] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05355] Funding Source: Medline; NIGMS NIH HHS [GM33944, GM32441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; BAUER WR, 1977, P NATL ACAD SCI USA, V74, P1841, DOI 10.1073/pnas.74.5.1841; BAYLIS SA, 1992, J MOL BIOL, V228, P1003, DOI 10.1016/0022-2836(92)90887-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; Cowell IG, 1998, EXP CELL RES, V243, P232, DOI 10.1006/excr.1998.4150; DELIUS H, 1984, J VIROL, V49, P609, DOI 10.1128/JVI.49.2.609-614.1984; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; GARCIABEATO R, 1992, VIROLOGY, V188, P938, DOI 10.1016/0042-6822(92)90558-7; GESHELIN P, 1974, J MOL BIOL, V88, P785, DOI 10.1016/0022-2836(74)90399-4; GONZALEZ A, 1986, NUCLEIC ACIDS RES, V14, P6835, DOI 10.1093/nar/14.17.6835; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Karakashian M. W, 1975, Symposia Soc exp Biol, VNo. 29, P145; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1999, BIOCHEMISTRY-US, V38, P3457, DOI 10.1021/bi982855i; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; KRAUZER KN, 1983, BACTERIOPHAGE T4, P90; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavrukhin OV, 2000, J BIOL CHEM, V275, P6915, DOI 10.1074/jbc.275.10.6915; Li Y, 1997, VIROLOGY, V237, P360, DOI 10.1006/viro.1997.8805; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; Mirski SEL, 1997, EXP CELL RES, V237, P452, DOI 10.1006/excr.1997.3805; MIRSKI SEL, 1995, CANCER RES, V55, P2129; Mirski SEL, 1999, EXP CELL RES, V251, P329, DOI 10.1006/excr.1999.4587; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Muller K, 1999, VIRUS GENES, V18, P243, DOI 10.1023/A:1008072319875; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; ORTIN J, 1979, J VIROL, V31, P579; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; REISSER W, 1992, ALGAE SYMBIOSIS; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROHOZINSKI J, 1989, VIROLOGY, V168, P363, DOI 10.1016/0042-6822(89)90277-8; ROSS PM, 1989, BIOTECHNIQUES, V7, P680; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNITZLER P, 1987, VIROLOGY, V160, P66, DOI 10.1016/0042-6822(87)90045-6; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; SOLTAU JB, 1987, J GEN VIROL, V68, P2717, DOI 10.1099/0022-1317-68-10-2717; STETLER GL, 1979, P NATL ACAD SCI USA, V76, P3737, DOI 10.1073/pnas.76.8.3737; Sun LW, 1999, VIROLOGY, V263, P376, DOI 10.1006/viro.1999.9958; UDVARDY A, 1986, J MOL BIOL, V191, P231, DOI 10.1016/0022-2836(86)90260-3; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; VANETTEN JL, 1982, P NATL ACAD SCI-BIOL, V79, P3867; VANETTEN JL, 1981, VIROLOGY, V113, P704, DOI 10.1016/0042-6822(81)90199-9; VANETTEN JL, 1991, MICROBIOL REV, V55, P586, DOI 10.1128/MMBR.55.4.586-620.1991; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; Wessel I, 1997, CANCER RES, V57, P4451; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; ZHANG YP, 1994, VIROLOGY, V202, P1079, DOI 10.1006/viro.1994.1444	78	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24401	24408		10.1074/jbc.M101693200	http://dx.doi.org/10.1074/jbc.M101693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323425	hybrid			2022-12-25	WOS:000169531100155
J	Marchbank, T; Cox, HM; Goodlad, RA; Giraud, AS; Moss, SF; Poulsom, R; Wright, NA; Jankowski, J; Playford, RJ				Marchbank, T; Cox, HM; Goodlad, RA; Giraud, AS; Moss, SF; Poulsom, R; Wright, NA; Jankowski, J; Playford, RJ			Effect of ectopic expression of rat trefoil factor family 3 (intestinal trefoil factor) in the jejunum of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PANCREATIC SPASMOLYTIC POLYPEPTIDE; EPITHELIAL-CELLS; FACTOR RECEPTOR; CELIAC-DISEASE; PEPTIDE; PROTEIN; PS2; SECRETION; STOMACH	To further examine the function of the trefoil factor family (TFF), the expression of which is up-regulated at sites of injury, we have produced transgenic mice that chronically express rat TFF3 within the jejunum (using a rat fatty acid-binding protein promoter). The expression of rat TFF3 was limited to the villi of the jejunum and had no effect on base-line morphology. Rat TFF3 expression did result, however, in a reduced sensitivity to indomethacin (85 mg/kg sulbcutaneously), which only caused a 29% reduction in villus height in transgenics versus 51% reduction in controls (p < 0.01). Indomethacin increased initial intestinal epithelial cell proliferation and migration, but the presence of rat TFF3 caused no additional change in proliferation (bromodeoxyuridine), cell migration ([H-3]thymidine and bromodeoxyuridine), apoptosis (terminal deoxyuridine nucleotidyl nick end labeling), or E-cadherin immunostaining, In vitro studies following changes in resistance of intestinal strips in Ussing chambers (voltage-clamp technique) showed increased base-line resistance in the rat TFF3-expressing region (326 +/- 60 versus 195 +/- 48 ohm.cm(2) in controls, p < 0.05) and reduced the fall in resistance following Hel exposure by about 40% (p < 0.01). Overexpression of TFF3 stabilizes the mucosa against noxious agents, supporting its role in mucosal protection/repair. It may therefore provide a novel approach to the prevention and/or treatment of intestinal ulceration.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Dept Gastroenterol, London W12 0NN, England; Kings Coll London, Ctr Neurosci, London SE1 9RT, England; Imperial Canc Res Fund, London WC2A 2PX, England; Univ Melbourne, Melbourne, Vic 3011, Australia; St Lukes Roosevelt Hosp, New York, NY 10025 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, London W12 0NN, England; Univ Hosp Birmingham, Birmingham B15 2TM, W Midlands, England	Imperial College London; University of London; King's College London; Cancer Research UK; University of Melbourne; Mount Sinai St. Luke's; Mount Sinai West; Imperial College London	Playford, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Dept Gastroenterol, Du Cane Rd, London W12 0NN, England.	r.playford@ic.ac.uk	Wright, Nicholas/HHY-7227-2022; Jankowski, Janusz/H-2706-2012; Cox, Helen M/F-2783-2015	Jankowski, Janusz/0000-0003-2130-9181; Goodlad, Robert/0000-0002-7660-4287; Playford, Raymond/0000-0003-1235-8504; Cox, Helen/0000-0001-9024-1497; Wright, Nicholas/0000-0002-5525-3457				ALISON MR, 1995, J PATHOL, V175, P405, DOI 10.1002/path.1711750408; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; Calnan DP, 1999, J PATHOL, V188, P312, DOI 10.1002/(SICI)1096-9896(199907)188:3<312::AID-PATH360>3.0.CO;2-P; CHINERY R, 1995, PEPTIDES, V16, P749, DOI 10.1016/0196-9781(95)00045-L; CHINERY R, 1995, CLIN SCI, V88, P401, DOI 10.1042/cs0880401; CHINERY R, 1995, BRIT J PHARMACOL, V115, P77, DOI 10.1111/j.1476-5381.1995.tb16322.x; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; GOODLAD RA, 1994, CELL BIOL LAB HDB, P205; Gott P, 1996, EUR J HUM GENET, V4, P308; GREGORY H, 1985, J CELL SCI, P11; HANBY AM, 1993, GASTROENTEROLOGY, V105, P1110, DOI 10.1016/0016-5085(93)90956-D; HOOSEIN NM, 1989, FEBS LETT, V247, P303, DOI 10.1016/0014-5793(89)81357-2; JORGENSEN KD, 1982, REGUL PEPTIDES, V3, P231, DOI 10.1016/0167-0115(82)90128-8; Kanai M, 1998, P NATL ACAD SCI USA, V95, P178, DOI 10.1073/pnas.95.1.178; KIDA N, 1989, CANCER RES, V49, P3494; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Konturek PC, 1997, REGUL PEPTIDES, V68, P71, DOI 10.1016/S0167-0115(96)02106-4; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; LEVI S, 1994, BRIT J RHEUMATOL, V33, P605; Liu D, 1997, LAB INVEST, V77, P557; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; McKenzie C, 1997, AM J PHYSIOL-GASTR L, V273, pG112, DOI 10.1152/ajpgi.1997.273.1.G112; Moss SF, 1996, GUT, V39, P811, DOI 10.1136/gut.39.6.811; Otto WR, 1996, EUR J BIOCHEM, V235, P64, DOI 10.1111/j.1432-1033.1996.00064.x; Perry I, 1999, LAB INVEST, V79, P1489; Playford RJ, 1997, GUT, V40, P286, DOI 10.1136/gut.40.2.286; Playford RJ, 1996, GUT, V39, P262, DOI 10.1136/gut.39.2.262; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P108, DOI 10.1016/0016-5085(95)90014-4; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Playford RJ, 1999, GUT, V44, P653, DOI 10.1136/gut.44.5.653; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; Poulsen SS, 1998, GUT, V43, P240, DOI 10.1136/gut.43.2.240; POULSOM R, 1992, SCAND J GASTROENTERO, V27, P17, DOI 10.3109/00365529209095975; RUTTEN MJ, 1984, MECH MUCOSAL PROTECT, P987; Sands BE, 1996, ANNU REV PHYSIOL, V58, P253, DOI 10.1146/annurev.ph.58.030196.001345; SILEN W, 1985, ANNU REV PHYSIOL, V47, P217; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; Taupin D, 2000, GASTROENTEROLOGY, V118, pA823, DOI 10.1016/S0016-5085(00)85436-0; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; TAUPIN DR, 1995, PEPTIDES, V16, P1001, DOI 10.1016/0196-9781(95)00070-Z; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6	45	46	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24088	24096		10.1074/jbc.M101363200	http://dx.doi.org/10.1074/jbc.M101363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11301329	hybrid			2022-12-25	WOS:000169531100115
J	Marcinkeviciene, J; Luo, Y; Graciani, NR; Combs, AP; Copeland, RA				Marcinkeviciene, J; Luo, Y; Graciani, NR; Combs, AP; Copeland, RA			Mechanism of inhibition of beta-site amyloid precursor protein-cleaving enzyme (BACE) by a statine-based peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 PROTEASE; SECRETASE; BINDING; BRAIN	Inhibition of beta -site amyloid precursor protein-cleaving enzyme by a statine-based inhibitor has been studied using steady state and stopped-sow methods. A slow onset rate of inhibition has been observed under steady state conditions, and a K-i of 22 nM has been derived using progress curves analysis. Simulation of stopped-flow protein fluorescence transients provided an estimate of the K-d for initial inhibitor binding of 660 nM. A two-step inhibition mechanism is proposed, wherein slower "tightening up" of the initial encounter complex occurs, Two hypotheses have been proposed in the literature to address the nature of the slow step in the inhibition of aspartic proteases by peptidomimetic inhibitors: a conformational change related to the "flap" movement and displacement of a catalytic water. We compared substrate and inhibitor binding rates under pre-steady-state conditions. Both ligands are likely to cause flap movement, whereas no catalytic mater replacement occurs during substrate binding. Our results suggest that both ligands bind to the enzyme at a rate significantly lower than the diffusion limit, but there are additional rate limitations involved in inhibitor binding, resulting in a k(on) of 3.5 x 10(4) M-1 s(-1) for the inhibitor compared with 3.5 x 10(5) M-1 s(-1) for the substrate. Even though specific intermediate formation steps might be different in the productive inhibitor and substrate binding to p-site amyloid precursor protein-cleaving enzyme, a similar final optimized conformation is achieved in both cases, as judged by the comparable free energy changes (Delta DeltaG of 2.01 versus 1.97 kcal/mol) going from the initial to the final enzyme-inhibitor or enzyme-substrate complexes.	Dupont Merck Pharmaceut Co, Dept Chem Enzymol, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Combinatorial Chem Grp, Wilmington, DE 19880 USA	DuPont; DuPont	Marcinkeviciene, J (corresponding author), Dupont Merck Pharmaceut Co, Dept Chem Enzymol, Wilmington, DE 19880 USA.	jovita.marcinkeviciene@dupontpharma.com						Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; CHO YK, 1994, BIOCHEMISTRY-US, V33, P9637, DOI 10.1021/bi00198a032; ERMOLIEFF J, 1908, BIOCHEMISTRY-US, V39, P12450; Ghosh AK, 2000, J AM CHEM SOC, V122, P3522, DOI 10.1021/ja000300g; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; JOHNSON KA, 1992, ENZYMES, V20, P2; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Mallender WD, 2001, MOL PHARMACOL, V59, P619, DOI 10.1124/mol.59.3.619; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; RICH DH, 1985, J MED CHEM, V28, P263, DOI 10.1021/jm00381a001; RODRIGUEZ EJ, 1993, BIOCHEMISTRY-US, V32, P3557, DOI 10.1021/bi00065a006; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	21	37	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23790	23794		10.1074/jbc.M101896200	http://dx.doi.org/10.1074/jbc.M101896200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306583	hybrid			2022-12-25	WOS:000169531100077
J	Miyake, JH; Doung, XDT; Strauss, W; Moore, GL; Castellani, LW; Curtiss, LK; Taylor, JM; Davis, RA				Miyake, JH; Doung, XDT; Strauss, W; Moore, GL; Castellani, LW; Curtiss, LK; Taylor, JM; Davis, RA			Increased production of apolipoprotein B-containing lipoproteins in the absence of hyperlipidemia in transgenic mice expressing cholesterol 7 alpha-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; TRIGLYCERIDE TRANSFER PROTEIN; BILE-ACID BIOSYNTHESIS; LOW-DENSITY LIPOPROTEINS; RECEPTOR LXR-ALPHA; NUCLEAR RECEPTOR; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; OXYSTEROL 7-ALPHA-HYDROXYLASE; BINDING PROTEIN-1	The finding that expression of a cholesterol 7 alpha -hydroxylase (CYP7A1) transgene in cultured rat hepatoma cells caused a coordinate increase in lipogenesis and secretion of apoB-containing lipoproteins led to the hypothesis that hepatic production of apoB-containing lipoproteins may be linked to the expression of CYP7A1 (Wang, S.-L., Du, E., Martin, T. D., and Davis, R. A (1997) J. Biol. Chem. 272, 19351-19358). To examine this hypothesis in vivo, a transgene encoding CYP7A1 driven by the constitutive liver-specific enhancer of the human apoE gene was expressed in C56BL/6 mice. The expression of CYP7A1 mRNA (20-fold), protein (similar to 10-fold), and enzyme activity (5-fold) was markedly increased in transgenic mice compared with non-transgenic littermates, The bile acid pool of CYP7A1 transgenic mice was doubled mainly due to increased hydrophobic dihydroxy bile acids. In CYP7A1 transgenic mice, livers contained similar to3-fold more sterol response element-binding protein-2 mRNA. Hepatic expression of mRNAs encoding lipogenic enzymes (i.e. fatty-acid synthase, acetyl-CoA carboxylase, stearoyl-CoA desaturase, squalene synthase, farnesyl-pyrophosphate synthase, 3-hydroxy-3-methylglutaryl-CoA reductase, and low density lipoprotein receptor) as well as microsomal triglyceride transfer protein mere elevated similar to3-5-fold in transgenic mice. CYP7A1 transgenic mice also displayed a >2-fold increase in hepatic production and secretion of triglyceride-rich apoB-containing lipoproteins. Despite the increased hepatic secretion of apoB-containing lipoproteins in CYP7A1 mice, plasma levels of triglycerides and cholesterol were not significantly increased. These data suggest that the 5-fold increased expression of the low density lipoprotein receptor displayed by the livers of CYP7A1 transgenic mice was sufficient to compensate for the 2-fold increase production of apoB-containing lipoproteins. These findings emphasize the important homeostatic role that CYP7A1 plays in balancing the anabolic lipoprotein assembly/secretion pathway with the cholesterol catabolic bile acid synthetic pathway.	San Diego State Univ, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Scripps Res Inst, La Jolla, CA 92037 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	California State University System; San Diego State University; University of California System; University of California Los Angeles; Scripps Research Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes	Davis, RA (corresponding author), San Diego State Univ, Mammalian Cell & Mol Biol Lab, Life Sci Bldg LS307,5500 Campanile Dr, San Diego, CA 92182 USA.	rdavis@sunstroke.sdsu.edu			NHLBI NIH HHS [HL57974, HL51648] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057974, R01HL051648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEIS D, 1992, SEMIN LIVER DIS, V12, P397, DOI 10.1055/s-2008-1040409; ANGELIN B, 1978, J LIPID RES, V19, P1004; ANGELIN B, 1987, P NATL ACAD SCI USA, V84, P5434, DOI 10.1073/pnas.84.15.5434; BEIL U, 1982, METABOLISM, V31, P438, DOI 10.1016/0026-0495(82)90231-1; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CAMARRI E, 1978, BIOMED EXPRESS, V29, P193; Cavallo D, 1998, J BIOL CHEM, V273, P33397, DOI 10.1074/jbc.273.50.33397; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DAVIS RA, 1989, J BIOL CHEM, V264, P8970; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; Duane WC, 1997, J LIPID RES, V38, P183; DUANE WC, 1995, J LIPID RES, V36, P96; Duane WC, 2000, J LIPID RES, V41, P1384; DUELAND S, 1993, J LIPID RES, V34, P923; EDWARDS PA, 1996, N COMP BIOC, V31, P341; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fleming JF, 1999, J BIOL CHEM, V274, P9509, DOI 10.1074/jbc.274.14.9509; FRIEDMAN M, 1965, ARCH INTERN MED, V116, P807, DOI 10.1001/archinte.116.6.807; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GOLDSTEIN JL, 1985, J CELL SCI, P131, DOI 10.1242/jcs.1985.Supplement_3.13; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; Havel RJ, 1997, P NUTR SOC, V56, P659, DOI 10.1079/PNS19970065; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Kim E, 1998, J LIPID RES, V39, P703; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Moore GL, 1997, BIOCHEM J, V324, P863, DOI 10.1042/bj3240863; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Qian XB, 1998, ARTERIOSCL THROM VAS, V18, P1013, DOI 10.1161/01.ATV.18.6.1013; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Sehayek E, 1996, Z Gastroenterol, V34 Suppl 3, P110; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; TENG BB, 1994, J BIOL CHEM, V269, P29395; Tietge UJF, 1999, J LIPID RES, V40, P2134; Trawick JD, 1996, J LIPID RES, V37, P588; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Vega GL, 1998, AM J CARDIOL, V81, p36B, DOI 10.1016/S0002-9149(98)00036-8; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; VLAHCEVIC ZR, 1992, SEMIN LIVER DIS, V12, P403, DOI 10.1055/s-2008-1040410; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; WETTERAU JR, 1992, SCIENCE, V258, P999; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	79	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23304	23311		10.1074/jbc.M101853200	http://dx.doi.org/10.1074/jbc.M101853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323427	hybrid			2022-12-25	WOS:000169531100014
J	Hoffman, MP; Engbring, JA; Nielsen, PK; Vargas, J; Steinberg, Z; Karmand, AJ; Nomizu, M; Yamada, Y; Kleinman, HK				Hoffman, MP; Engbring, JA; Nielsen, PK; Vargas, J; Steinberg, Z; Karmand, AJ; Nomizu, M; Yamada, Y; Kleinman, HK			Cell type-specific differences in glycosaminoglycans modulate the biological activity of a heparin-binding peptide (RKRLQVQLSIRT) from the G domain of the laminin alpha 1 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE PROTEOGLYCANS; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; IDENTIFICATION; DYSTROGLYCAN; SITE; SEQUENCES; SURFACE; MATRIX; FAMILY	AG73 (RKRLQVQLSIRT), a peptide from the G domain of the laminin alpha1 chain, has diverse biological activities with different cell types, The heparan sulfate side chains of syndecan-1 on human salivary gland cells were previously identified as the cell surface ligand for AG73. We used homologous peptides from the other laminin cu-chains (A2G73-A5G73) to determine whether the bioactivity of the AG73 sequence is conserved. Human salivary gland cells and a mouse melanoma cell line (B16F10) both bind to the peptides, but cell attachment was inhibited by glycosaminoglycans, modified heparin, and sized heparin fragments in a cell type-specific manner. In other assays, AG73, but not the homologous peptides, inhibited branching morphogenesis of salivary glands and B16F10 network formation on Matrigel. We identified residues critical for AG73 bioactivity using peptides with amino acid substitutions and truncations. Fewer residues were critical for inhibiting branching morphogenesis (XKXLXVXXXIRT) than those required to inhibit B16F10 network formation on Matrigel (N-terminal XxRLQVQLSIRT). In addition, surface plasmon resonance analysis identified the C-terminal IRT of the sequence to be important for heparin binding. Structure based sequence alignment predicts AG73 in a P-sheet with the N-terminaI K (Lys(2)) and the C-terminal R (Arg(10)) on the surface of the G domain. In conclusion, we have determined that differences in cell surface glycosaminoglycans and differences in the amino acids in AG73 recognized by cells modulate the biological activity of the peptide and provide a mechanism to explain its cell-specific activities.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 0600810, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Hokkaido University	Hoffman, MP (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, 30-430,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.	mhoffman@mail.nih.gov						Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Caldwell EEO, 1999, ARCH BIOCHEM BIOPHYS, V361, P215, DOI 10.1006/abbi.1998.0996; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DESAI UR, 1993, ANAL BIOCHEM, V213, P120, DOI 10.1006/abio.1993.1394; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; Goldfinger LE, 2000, J BIOL CHEM, V275, P34887, DOI 10.1074/jbc.M006652200; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; Kadoya Y, 1999, HISTOCHEM CELL BIOL, V112, P417, DOI 10.1007/s004180050423; Kadoya Y, 1998, DEV DYNAM, V212, P394; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; KATO M, 1994, J BIOL CHEM, V269, P18881; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kim WH, 1998, INT J CANCER, V77, P632, DOI 10.1002/(SICI)1097-0215(19980812)77:4<632::AID-IJC25>3.0.CO;2-6; KRAMER RH, 1986, CANCER RES, V46, P1980; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; TURNBULL JE, 1988, BIOCHEM J, V251, P597, DOI 10.1042/bj2510597; WALKER A, 1994, J BIOL CHEM, V269, P931; Weeks BS, 1998, EXP CELL RES, V243, P375, DOI 10.1006/excr.1998.4157; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; Yoshida I, 1999, J CELL PHYSIOL, V179, P18, DOI 10.1002/(SICI)1097-4652(199904)179:1<18::AID-JCP3>3.0.CO;2-K; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981	48	99	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22077	22085		10.1074/jbc.M100774200	http://dx.doi.org/10.1074/jbc.M100774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11304538	hybrid			2022-12-25	WOS:000169412700014
J	Lopez, GN; Turck, CW; Schaufele, F; Stallcup, MR; Kushner, PJ				Lopez, GN; Turck, CW; Schaufele, F; Stallcup, MR; Kushner, PJ			Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; THYROID-HORMONE RECEPTOR; ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTORS; CROSS-TALK; BINDING; CBP; PHOSPHORYLATION; TRANSCRIPTION	Promoter-bound steroid receptors activate gene expression by recruiting members of the p160 family of coactivators. Many steroid receptors, most notably the progesterone and estrogen receptors, are regulated both by cognate hormone and independently by growth factors, Here we show that epidermal growth factor regulates the activities of the p160 GRIP1 through the extracellular signal-regulated kinase (ERK) family of mitogen-activated protein kinases. ERKs phosphorylate GRIP1 at a specific site, Ser-736, the integrity of which is required for full growth factor induction of GRIP1 transcriptional activation and coactivator function. We propose that growth factors signal to nuclear receptors in part by targeting the p160 coactivators.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Southern California	Kushner, PJ (corresponding author), Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA080210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051083] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 80210] Funding Source: Medline; NIDDK NIH HHS [R01 DK51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai WL, 1997, J BIOL CHEM, V272, P10457; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; IGNARTROWBRIDGE DM, 1995, ENVIRON HEALTH PERSP, V103, P35, DOI 10.2307/3432505; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Ma H, 1999, MOL CELL BIOL, V19, P6164; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	42	118	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22177	22182		10.1074/jbc.M010718200	http://dx.doi.org/10.1074/jbc.M010718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301320	hybrid			2022-12-25	WOS:000169412700029
J	O'Regan, P; Wilson, C; Townsend, S; Thacker, J				O'Regan, P; Wilson, C; Townsend, S; Thacker, J			XRCC2 is a nuclear RAD51-like protein required for damage-dependent RAD51 focus formation without the need for ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-REPAIR GENE; HOMOLOGOUS RECOMBINATION; CELL-CYCLE; ESCHERICHIA-COLI; RECA PROTEIN; IN-VIVO; P-LOOP; BRCA1; EXPRESSION	The human XRCC2 gene was recently identified by its ability to complement a hamster cell line, irs1, which is sensitive to DNA-damaging agents and shows genetic instability. The XRCC2 protein is highly conserved in mammalian species and has structural features, including a putative ATP-binding domain (P-loop), consistent with membership of the RecA/RAD51 family of recombination-repair proteins. We show that a hybrid XRCC2-green fluorescent protein, which was found to be functional by complementation, localizes to the nucleus. We have established a functional link between XRCC-2 and RAD51 by looking at damage dependent RAD51 focus formation in the irs1 cell line. Little or no formation of RAD51 foci occurred in irs1. This effect was specific to the loss of XRCC2 because transfection of the gene into irs1 restored normal levels of focus formation. Surprisingly, XRCC2 genes carrying site-specific mutations in P-loop residues were found to be able to complement the XRCC2-deficient irs1 line for a number of different end points, We conclude that XRCC2 is important in the early stages of homologous recombination in mammalian cells to facilitate RAD51-dependent recombination repair but that it does not make use of ATP binding to promote this function.	MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England		Thacker, J (corresponding author), MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England.							Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Braybrooke JP, 2000, J BIOL CHEM, V275, P29100, DOI 10.1074/jbc.M002075200; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; Deans B, 2000, EMBO J, V19, P6675, DOI 10.1093/emboj/19.24.6675; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haijema BJ, 1996, MOL MICROBIOL, V21, P989, DOI 10.1046/j.1365-2958.1996.601424.x; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Li MJ, 1997, EXP CELL RES, V237, P93, DOI 10.1006/excr.1997.3761; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pittman DL, 2000, GENESIS, V26, P167, DOI 10.1002/(SICI)1526-968X(200003)26:3<167::AID-GENE1>3.0.CO;2-M; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shu ZG, 1999, MOL CELL BIOL, V19, P8686; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1994, MUTAGENESIS, V9, P163, DOI 10.1093/mutage/9.2.163; TUCKER JD, 1991, MUTAT RES, V254, P143, DOI 10.1016/0921-8777(91)90005-A; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yuan SSF, 1999, CANCER RES, V59, P3547	52	80	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22148	22153		10.1074/jbc.M102396200	http://dx.doi.org/10.1074/jbc.M102396200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301337	hybrid			2022-12-25	WOS:000169412700025
J	Liu, BL; Fang, M; Lu, Y; Mendelsohn, J; Fan, Z				Liu, BL; Fang, M; Lu, Y; Mendelsohn, J; Fan, Z			Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody	ONCOGENE			English	Article						EGF receptor; monoclonal antibody; apoptosis; cell cycle arrest; bFGF; IGF-1	PROTEIN-KINASE PATHWAY; EPITHELIAL-CELLS; G(1) ARREST; BAD PHOSPHORYLATION; CARCINOMA-CELLS; INHIBITION; ACTIVATION; SURVIVAL; ALPHA; AKT	DiFi human colon carcinoma cells are stimulated by the transforming growth factor-alpha (TGF-alpha)/epidermal growth factor (EGF) receptor autocrine loop. Exposure of DiFi cells to monoclonal antibody (mAb) 225, which blocks ligand-induced activation of the EGF receptor, induces G1 arrest and subsequent cell death via apoptosis, We investigated the signal pathways by which basic fibroblast growth factor (bFGF) and insulin-like growth factor-1 (IGF-1) modulate mAb 225-induced G1 arrest and apoptosis in DiFi cells. Both bFGF and IGF-1 activated the mitogen-activated protein kinase (MAPK) kinase (MEK) pathway in DiFi cells, Additionally, IGF-1 activated the phosphoinositide 3-kinase (PI-3K)/Akt pathway. Both bFGF and IGF-1 inhibited mAb 225-induced apoptosis; however, bFGF provided sustained protection against apoptosis, while the protection by IGF-1 was only temporary. Also, bFGF reversed the mAb 225-induced increase in the p27(Kip1) level, inhibition of cyclin-dependent kinase-2 (CDK-2) activity, dephosphorylation of the retinoblastoma (Rb) protein and the resultant G1 arrest of the cells. In contrast, IGF-1 did not reverse such effects by mAb 225, The prevention of mAb 225-induced G1 arrest and apoptosis in DiFi cells by bFGF was sensitive to the MEK/MAPK inhibitor PD98059 but not to the PI-3K inhibitor LY294002. In contrast, inhibition of apoptosis by IGF-1 in DiFi cells was sensitive only to LY294002 and not to PD98059, These results further our understanding of how mAb 225 induces apoptosis in DiFi cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 36,1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caraglia M, 1999, CELL DEATH DIFFER, V6, P773, DOI 10.1038/sj.cdd.4400550; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROSS ME, 1991, CANCER RES, V51, P1452; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Lan L, 1999, FEBS LETT, V444, P90, DOI 10.1016/S0014-5793(99)00032-0; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Liu B, 2000, BRIT J CANCER, V82, P1991; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Peng D, 1996, CANCER RES, V56, P3666; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; Sato J D, 1983, Mol Biol Med, V1, P511; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; ULLRICH A, 1990, CELL, V61, P303; UNTAWALE S, 1993, CANCER RES, V53, P1630; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu XP, 1996, ONCOGENE, V12, P1397; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	39	96	103	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1913	1922		10.1038/sj.onc.1204277	http://dx.doi.org/10.1038/sj.onc.1204277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313939				2022-12-25	WOS:000167908400012
J	Lucas, L; Hernandez-Alcoceba, R; Penalva, V; Lacal, JC				Lucas, L; Hernandez-Alcoceba, R; Penalva, V; Lacal, JC			Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity	ONCOGENE			English	Article						phospholipase D; antitumor drug; hexadecylphosphorylcholine; choline kinase	CHOLINE KINASE INHIBITORS; XENOPUS-LAEVIS OOCYTES; CANINE KIDNEY-CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ANALOG HEXADECYLPHOSPHOCHOLINE; GROWTH-FACTORS; SIGNAL-TRANSDUCTION; D ACTIVATION; PROTEIN; RAS	Hexadecylphosphorylcholine (HePC, D-18506, INN: Mitelfosine) belongs to the family of alkylphosphocholines with anticancer activity. Previous reports have related its antitumoral activity to their ability to interfere with phospholipid metabolism, However a clear mechanism of action has not been established yet, We have investigated the effect of HePC on two enzymes recently reported to play a role in cell growth proliferation, phospholipase D (PLD) and choline kinase (ChoK). Our results demonstrate that treatment with HePC induces a rapid stimulation of PLD, that may be achieved by PKC dependent or independent mechanisms, depending on the cell line investigated. Both PLD1 and PLD2 isoenzymes are sensitive to HePC activation. By contrast, no effect was observed by HePC on Cho, a new target for anticancer drug development. Furthermore, in all cell lines tested, a chronic exposure of the cells to HePC abrogates PLD activation by either phorbol esters or HePC itself with no effect on total cellular PLD levels. This is reflected in a strong inhibition of PLD activity. We suggest that the inhibitory effects on PLD by HePC may be related to its antitumoral action.	CSIC, Inst Invest Biomed, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid, Spain.		Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				BERKOVIC D, 1994, EUR J CANCER, V30A, P509, DOI 10.1016/0959-8049(94)90428-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bhakoo KK, 1996, CANCER RES, V56, P4630; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CUADRADO A, 1993, ONCOGENE, V8, P2959; DECHAVES EP, 1995, BIOCHEM J, V312, P411, DOI 10.1042/bj3120411; delPeso L, 1997, BIOCHEM J, V322, P519; DELPESO L, 1996, J CELL BIOCHEM, V60, P1; DETMAR M, 1994, J INVEST DERMATOL, V102, P490, DOI 10.1111/1523-1747.ep12373109; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; Han JS, 1998, BIOCHEM MOL BIOL INT, V45, P1089; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HOULIHAN WJ, 1995, MED RES REV, V15, P157, DOI 10.1002/med.2610150302; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1990, J BIOL CHEM, V265, P12232; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; Malcolm KC, 1996, BIOCHEM BIOPH RES CO, V225, P514, DOI 10.1006/bbrc.1996.1204; MALY K, 1995, ANTI-CANCER DRUG DES, V10, P411; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; PAZIT BA, 1989, FEBS LETT, V259, P64; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; POWIS G, 1995, MED RES REV, V15, P121, DOI 10.1002/med.2610150204; SEEWALD MJ, 1990, CANCER RES, V50, P4458; SINGER S, 1995, CANCER RES, V55, P5140; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; STORME G, 1983, P AM ASSOC CANC RES, V24, P31; UBERALL F, 1991, CANCER RES, V51, P807; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WIEDER T, 1993, BIOCHEM J, V291, P561, DOI 10.1042/bj2910561; Wieder T, 1996, CANCER LETT, V100, P71, DOI 10.1016/0304-3835(95)04072-2; Wieder T, 1999, PROG LIPID RES, V38, P249, DOI 10.1016/S0163-7827(99)00004-1; ZENG B, 1990, CANCER RES, V50, P3025	50	37	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1110	1117		10.1038/sj.onc.1204216	http://dx.doi.org/10.1038/sj.onc.1204216			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314048				2022-12-25	WOS:000167232100011
J	Monni, R; Santos, SCR; Mauchauffe, M; Berger, R; Ghysdael, J; Gouilleux, F; Gisselbrecht, S; Bernard, O; Penard-Lacronique, V				Monni, R; Santos, SCR; Mauchauffe, M; Berger, R; Ghysdael, J; Gouilleux, F; Gisselbrecht, S; Bernard, O; Penard-Lacronique, V			The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells	ONCOGENE			English	Article						leukemogenesis; TEL-Jak2; Socs1; Ba/F3; interferon-gamma	GENE-EXPRESSION; IFN-GAMMA; PROTEINS; STAT5; MICE; FAMILY; ALPHA; JAK2; TEL; CIS	The leukemia-associated TEL-Jak2 fusion protein possesses a constitutive tyrosine kinase activity and transforming properties in hematopoietic cell lines and animal models, In the murine pro-B Ba/F3 cell line, this fusion constitutively activates the Signal Transducer and Activator of Transcription 5 (Stat5) factors and, as a consequence, induces the sustained expression of various Stat5-target genes including the Cytokine Inducible SH2-containing protein (Cis) gene, which codes for a member of the Suppressor of Cytokine Signaling (Socs) protein family, In TEL-Jak2-transformed Ba/F3 cells, me also observed the upregulation of the Socs1 gene, whose product has been reported to negatively regulate the Jak kinase activity. In transient transfection experiments, Socs1 physically interacts with TEL-Jak2 and interferes with the TEL-Jak2-induced phosphorylation and activation of Stat5 factors, probably through the Socs1-induced proteasome-mediated degradation of the fusion protein. Interestingly, TEL-Jak2-expressing Ba/F3 cells were found to be resistant to the antiproliferative activities of gamma interferon (IFN-gamma) seemingly as a consequence of Socs1 constitutive expression. These results indicate that the Socs1-dependent cytokine feedback loop, although active, is bypassed by the TEL-Jak2 fusion, but may play a role in the leukemogenic process by altering the cytokine responses of the leukemic cells. Our results also suggest that Socs1 plays a role in shutting down the signaling from the normally activated Jak2 kinase by inducing its proteasome-dependent degradation.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Paris 05, Inst Cochin Genet Mol, INSERM, U363, F-75014 Paris, France; Ctr Univ, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Penard-Lacronique, V (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.		GHYSDAEL, Jacques/F-3377-2013; Santos, Susana/AAM-8902-2021; Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019; Bernard, Olivier A./E-5721-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747; Constantino Rosa Santos, Susana/0000-0002-5711-1292; Gouilleux, Fabrice/0000-0001-6047-1718				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Carron C, 2000, BLOOD, V95, P3891; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 1999, EMBO J, V18, P904; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	38	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					849	858		10.1038/sj.onc.1204201	http://dx.doi.org/10.1038/sj.onc.1204201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314018	Green Published			2022-12-25	WOS:000166924400008
J	Fabrizi, C; Silei, V; Menegazzi, M; Salmona, M; Bugiani, O; Tagliavini, F; Suzuki, H; Lauro, GM				Fabrizi, C; Silei, V; Menegazzi, M; Salmona, M; Bugiani, O; Tagliavini, F; Suzuki, H; Lauro, GM			The stimulation of inducible nitric-oxide synthase by the prion protein fragment 106-126 in human microglia is tumor necrosis factor-alpha-dependent and involves p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-INFECTED MICE; FACTOR-KAPPA-B; CREUTZFELDT-JAKOB-DISEASE; EXPRESSION; CELLS; LIPOPOLYSACCHARIDE; PRP; RESIDUES-106-126; NEUROTOXICITY; MACROPHAGES	A synthetic peptide consisting of amino acid residues 106-126 of the human prion protein (PrP-(106-126)) has been previously demonstrated to be neurotoxic and to induce microglial activation. The present study investigated the expression of the inducible form of the nitric-oxide synthase (NOS-II) in human microglial cells treated with PrP-(106-126). Using reverse transcriptase-polymerase chain reaction, we found that PrP-(106-126) induces NOS-II gene expression after 24 h of treatment and that this effect is accompanied by a peak of nuclear factor kappa B (NF-KB) binding at 30 min as evaluated by electrophoretic mobility shift assay. Since our previous data demonstrated tumor necrosis factor-alpha (TNF-alpha) to be a potent inducer of NOS-II in these cells, we analyzed the expression of this cytokine in PrP-(106-126)treated microglia, PrP-(106-126) caused the release of TNF-alpha as detected by enzyme-linked immunosorbent assay, and a blocking antibody, anti-TNF-alpha, abolished NOS-II induction elicited by this peptide. Moreover, PrP-(106-126) activates p38 mitogen-activated protein kinase, and the inhibition of this pathway determines the ablation of NF-kappaB binding induced by this fragment peptide.	Univ Roma Tre, Dipartimento Biol, I-00146 Rome, Italy; Univ Verona, Sez Chim Biol, Dipartimento Sci Neurol, I-37134 Verona, Italy; Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy; Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy	Roma Tre University; University of Verona; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Neurologico Besta	Lauro, GM (corresponding author), Univ Roma Tre, Dipartimento Biol, Viale Marconi 446, I-00146 Rome, Italy.	lauro@uniroma3.it	fabrizi, cinzia/G-2379-2012; salmona, mario/ABI-4066-2020; salmona, mario/AAA-7116-2020; Tagliavini, Fabrizio/AAO-7891-2021; Menegazzi, Marta/AAE-7079-2019	salmona, mario/0000-0002-9098-9873; Tagliavini, Fabrizio/0000-0003-1039-7315; Menegazzi, Marta/0000-0003-1310-9227				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chen CC, 1999, MOL PHARMACOL, V55, P481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; COLASANTI M, 1995, NEUROSCI LETT, V200, P144, DOI 10.1016/0304-3940(95)12101-9; Combs CK, 1999, J NEUROSCI, V19, P928; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; FORLONI G, 1994, EUR J NEUROSCI, V6, P1415, DOI 10.1111/j.1460-9568.1994.tb01003.x; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Hippenstiel S, 2000, BLOOD, V95, P3044; Jeon YJ, 2000, J PHARMACOL EXP THER, V294, P548; Ju WK, 1998, J NEUROVIROL, V4, P445; Keshet GI, 1999, J NEUROCHEM, V72, P1224, DOI 10.1046/j.1471-4159.1999.0721224.x; Kim JI, 1999, MOL BRAIN RES, V73, P17, DOI 10.1016/S0169-328X(99)00229-6; Lauro GM, 1995, INT J DEV NEUROSCI, V13, P739, DOI 10.1016/0736-5748(95)00059-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Muhleisen H, 1995, NEUROPATH APPL NEURO, V21, P505, DOI 10.1111/j.1365-2990.1995.tb01097.x; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ovadia H, 1996, J BIOL CHEM, V271, P16856, DOI 10.1074/jbc.271.28.16856; PRICHETT W, 1995, J INFLAMM, V45, P97; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; Sharief MK, 1999, NEUROLOGY, V52, P1289, DOI 10.1212/WNL.52.6.1289; Silei V, 1999, BRAIN RES, V818, P168, DOI 10.1016/S0006-8993(98)01272-4; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Williams A, 1997, EXP NEUROL, V144, P433, DOI 10.1006/exnr.1997.6424; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X; Zielasek J, 1996, ADV NEUROIMMUNOL, V6, P191, DOI 10.1016/0960-5428(96)00017-4	38	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25692	25696		10.1074/jbc.M100133200	http://dx.doi.org/10.1074/jbc.M100133200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316802	hybrid			2022-12-25	WOS:000169823300010
J	Taniyama, Y; Sato, K; Sugawara, A; Uruno, A; Ikeda, Y; Kudo, M; Ito, S; Takeuchi, K				Taniyama, Y; Sato, K; Sugawara, A; Uruno, A; Ikeda, Y; Kudo, M; Ito, S; Takeuchi, K			Renal tubule-specific transcription and chromosomal localization of rat thiazide-sensitive Na-Cl cotransporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL CONVOLUTED TUBULE; SODIUM-CHLORIDE COTRANSPORTER; CELL-SPECIFIC ACTIVITY; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; GITELMANS-SYNDROME; MOLECULAR-CLONING; RECEPTOR DENSITY; DNA-BINDING; KIDNEY; EXPRESSION	The molecular mechanism underlying the renal expression localization of the thiazide-sensitive Na-CI cotransporter (TSC) gene was studied, The TSC gene was localized to chromosome 19p12-14, In cultured cells, tissue-specific transcription activity of the 5 ' -flanking region of the rat rTSC gene (5 ' FL/rTSC) was demonstrated, and the major promoter region was located between position -580 and -141. To further examine the tissue-specific transcription, transgenic rats harboring the 5 ' FL/rTSC fused upstream of the LacZ gene were generated. Immunohistochemical analysis clearly showed that LacZ gene expression was co-localized to distal convoluted tubules (DCT) with TSC, indicating that the 5 ' FL/rTSC regulates the renal tubule-specific TSC expression. Because a transcription factor, HFH-3 (hepatocyte nuclear factor-3/folk head homologue-3), had also been localized to DCT, a possible role of the putative cia-acting element (HPH-3/rTSC, -400/-387 position) for HFH-3 binding in the tissue-specific transcription was examined. Deletion and mutation analyses suggested that transcription of the HFH-3/rTSC was actually responsive to HFH-3, and electrophoretic mobility shift assay showed a direct binding of in vitro synthesized HFH-3 to the HFH-3/rTSC. In conclusion, the rTSC gene is localized to rat chromosome 19p12-24. The transcription regulatory region of the TSC gene confers DCT-specific gene expression, DCT-specific transcription factor HFH-3 may be involved in the renal tubule-specific transcription of TSC gene.	Tohoku Univ, Grad Sch Med, Mol Biol Unit,Dept Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University	Takeuchi, K (corresponding author), Tohoku Univ, Grad Sch Med, Mol Biol Unit,Dept Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kazut2i@mail.cc.tohoku.ac.jp	Uruno, Akira/U-1812-2019; Uruno, Akira/ABF-3988-2020; Ito, Sadayoshi/A-3933-2015	Sugawara, Akira/0000-0003-4511-8101; Ito, Sadayoshi/0000-0002-5092-3626				ADACHI S, 1994, J BIOL CHEM, V269, P17677; BACHMANN S, 1995, J CLIN INVEST, V96, P2510, DOI 10.1172/JCI118311; Blakely P, 1996, J AM SOC NEPHROL, V7, P1052; Bostonjoglo M, 1998, J AM SOC NEPHROL, V9, P1347; CHEN ZF, 1994, J AM SOC NEPHROL, V5, P1361; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Hilfiker H, 1998, AM J PHYSIOL-RENAL, V274, pF197, DOI 10.1152/ajprenal.1998.274.1.F197; Igarashi P, 1996, J BIOL CHEM, V271, P9666, DOI 10.1074/jbc.271.16.9666; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kim GH, 1998, P NATL ACAD SCI USA, V95, P14552, DOI 10.1073/pnas.95.24.14552; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Levi M, 1996, J MEMBRANE BIOL, V154, P1, DOI 10.1007/s002329900127; Mastroianni N, 1996, GENOMICS, V35, P486, DOI 10.1006/geno.1996.0388; Obermuller N, 1995, AM J PHYSIOL-RENAL, V269, pF900, DOI 10.1152/ajprenal.1995.269.6.F900; Overdier DG, 1997, J BIOL CHEM, V272, P13725, DOI 10.1074/jbc.272.21.13725; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Pathak BG, 1996, GENOMICS, V33, P124, DOI 10.1006/geno.1996.0168; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Pollak MR, 1996, J AM SOC NEPHROL, V7, P2244; Sambrook J, 1989, MOL CLONING; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; SCHUNG J, 1997, CBILTR19971001V00 U; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Takahashi N, 1998, BIOCHEM BIOPH RES CO, V244, P489, DOI 10.1006/bbrc.1998.8283; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; Takeuchi K, 1996, J CLIN ENDOCR METAB, V81, P4496, DOI 10.1210/jc.81.12.4496; Takeuchi K, 1996, KIDNEY INT, pS183; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Uchida S, 1998, AM J PHYSIOL-RENAL, V274, pF602, DOI 10.1152/ajprenal.1998.274.3.F602; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Velazquez H, 1998, KIDNEY INT, V54, P464, DOI 10.1046/j.1523-1755.1998.00036.x; Velazquez H, 1996, AM J PHYSIOL-RENAL, V270, pF211, DOI 10.1152/ajprenal.1996.270.1.F211; Whyte DA, 1999, AM J PHYSIOL-RENAL, V277, pF587, DOI 10.1152/ajprenal.1999.277.4.F587	38	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26260	26268		10.1074/jbc.M101614200	http://dx.doi.org/10.1074/jbc.M101614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313351	hybrid			2022-12-25	WOS:000169823300083
J	Chen, BS; Sun, ZW; Hampsey, M				Chen, BS; Sun, ZW; Hampsey, M			A Ga14-sigma(54) hybrid protein that functions as a potent activator of RNA polymerase II transcription in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; ESCHERICHIA-COLI; SAGA COMPLEX; ADA COMPLEX; SIGMA 54; PROMOTER; RECRUITMENT; COMPONENTS; INITIATION; SUBUNIT	The bacterial sigma (54) protein associates with core RNA polymerase to form a holoenzyme complex that renders cognate promoters enhancer-dependent. Although unusual in bacteria, enhancer-dependent transcription is the paradigm in eukaryotes. Here we report that a fragment of Escherichia coli sigma (54) encompassing amino acid residues 29-177 functions as a potent transcriptional activator in yeast when fused to a Gal4 DNA binding domain. Activation by Gal4-sigma (54) is TATA-dependent and requires the SAGA coactivator complex, suggesting that Gal4-sigma (54) functions by a normal mechanism of transcriptional activation. Surprisingly, deletion of the AHC1 gene, which encodes a polypeptide unique to the ADA coactivator complex, stimulates Gal4-sigma (54)-mediated activation and enhances the toxicity of Gal4-sigma (54). Accordingly, the SAGA and ADA complexes, both of which include Gcn5 as their histone acetyltransferase subunit, exert opposite effects on transcriptional activation by Gal4-sigma (54). Gal4-sigma (54) activation and toxicity are also dependent upon specific sigma (54) residues that are required for activator-responsive promoter melting by sigma (54) in bacteria, implying that activation is a consequence of sigma (54)-specific features rather than a structurally fortuitous polypeptide fragment. As such, Gal4-sigma (54) represents a novel tool with the potential to provide insight into the mechanism by which natural activators function in eukaryotic cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acids, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Hampsey, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acids, 675 Hoes Lane, Piscataway, NJ 08854 USA.	hampsemi@umdnj.edu	Chen, Bo-Shiun/H-4633-2012; Chen, Bo-Shiun/E-2736-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039484, R29GM039484] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39484] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dudley AM, 1999, GENETICS, V151, P1365; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Gallegos MT, 1999, J MOL BIOL, V288, P539, DOI 10.1006/jmbi.1999.2704; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Guo YL, 1997, J BACTERIOL, V179, P1239, DOI 10.1128/jb.179.4.1239-1245.1997; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; JAEHNING JA, 1991, SCIENCE, V253, P859, DOI 10.1126/science.1876846; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pappas DL, 2000, MOL CELL BIOL, V20, P8343, DOI 10.1128/MCB.20.22.8343-8351.2000; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Roberts SM, 1997, GENETICS, V147, P451; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; TINTUT Y, 1995, J BACTERIOL, V177, P5818, DOI 10.1128/jb.177.20.5818-5825.1995; Todone F, 2000, P NATL ACAD SCI USA, V97, P6306, DOI 10.1073/pnas.97.12.6306; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wu WH, 1999, P NATL ACAD SCI USA, V96, P2764, DOI 10.1073/pnas.96.6.2764; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Yee A, 2000, P NATL ACAD SCI USA, V97, P6311, DOI 10.1073/pnas.97.12.6311; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	50	5	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23881	23887		10.1074/jbc.M102893200	http://dx.doi.org/10.1074/jbc.M102893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313364	hybrid			2022-12-25	WOS:000169531100088
J	Gautam, A; Mulugu, S; Alexander, K; Bastia, D				Gautam, A; Mulugu, S; Alexander, K; Bastia, D			A single domain of the replication termination protein of Bacillus subtilis is involved in arresting both DnaB helicase and RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; ESCHERICHIA-COLI; POLAR CONTRAHELICASE; TRANSCRIPTION; IDENTIFICATION; TRANSLOCATION; MECHANISM; COMPLEX	The current models that have been proposed to explain the mechanism of replication termination are (i) passive arrest of a replication fork by the terminus (Ter) DNA-terminator protein complex that impedes the replication fork and the replicative helicase in a polar fashion and (ii) an active barrier model in which the Ter-terminator protein complex arrests a fork not only by DNA-protein interaction but also by mechanistically significant terminator protein-helicase interaction. Despite the existence of some evidence supporting in vitro interaction between the replication terminator protein (RTP) and DnaB helicase, there has been continuing debate in the literature questioning the validity of the protein-protein interaction model. The objective of the present work was two-fold: (i) to reexamine the question of RTP-DnaB interaction by additional techniques and different mutant forms of RTP, and (ii) to investigate if a common domain of RTP is involved in the arrest of both helicase and RNA polymerase, The results validate and confirm the RTP-DnaB interaction in vitro and suggest a critical role for this interaction in replication fork arrest. The results also show that the Tyr(33) residue of RTP plays a critical role both in the arrest of helicase and RNA polymerase.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	Duke University; Duke University	Bastia, D (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.							Bastia D., 1996, DNA REPLICATION EUKA, P177; BUSSIERE DE, 1995, CELL, V80, P651; Bussiere DE, 1999, MOL MICROBIOL, V31, P1611, DOI 10.1046/j.1365-2958.1999.01287.x; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Duggin IG, 1999, J MOL BIOL, V286, P1325, DOI 10.1006/jmbi.1999.2553; Gautam A, 2001, J BIOL CHEM, V276, P8771, DOI 10.1074/jbc.M009538200; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; Mohanty BK, 2001, J BIOL CHEM, V276, P13160, DOI 10.1074/jbc.M010940200; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; Pai KS, 1996, EMBO J, V15, P3164, DOI 10.1002/j.1460-2075.1996.tb00679.x; Pai KS, 1996, P NATL ACAD SCI USA, V93, P10647, DOI 10.1073/pnas.93.20.10647; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Wake RG, 1997, STRUCTURE, V5, P1, DOI 10.1016/S0969-2126(97)00160-3; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	26	13	13	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23471	23479		10.1074/jbc.M009537200	http://dx.doi.org/10.1074/jbc.M009537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313334	hybrid			2022-12-25	WOS:000169531100034
J	Sanders, CM; Stenlund, A				Sanders, CM; Stenlund, A			Mechanism and requirements for bovine papillomavirus, type 1, E1 initiator complex assembly promoted by the E2 transcription factor bound to distal sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; REPLICATION PROTEIN; ORIGIN; HELICASE; TRANSACTIVATOR; ROLES; ACTIVATION; ENHANCER; REVEALS; ATPASE	DNA replication of papillomavirus requires the viral initiator E1 and the transcription factor E2. Bovine papillomavirus, type 1 (BPV-1), E1, and E2 bind cooperatively as dimers to proximal sites in the viral replicator generating a sequence-specific E1E2-ori complex. This complex is critical for replication and can be converted to a multimeric E1-ori initiator complex by displacement of E2 in the presence of hydrolyzable ATP. However, E2 can function over extended distances, and E2 at a distal position 33 base pairs upstream of the E1-binding site also loads an E1 dimer onto ori. Under these conditions, neither displacement of E2 nor ATP hydrolysis are required for E1-ori formation, consistent with a need for ATP hydrolysis in E2 displacement from E1E2-ori. However, ATP is required for stabilization of the resulting E1 ori complex. These results indicate that BPV (with a proximal E2-binding site) and human papillomaviruses (with distal E2-binding sites) utilize the same general mechanism for E1 loading but suggest that E1E2-ori, which forms preferentially on ori, may perform an additional role in BPV replication.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stenlund, A (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	Stenlund@cshl.org			NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Chen G, 2000, J VIROL, V74, P1506, DOI 10.1128/JVI.74.3.1506-1512.2000; Chen G, 1998, J VIROL, V72, P2567, DOI 10.1128/JVI.72.4.2567-2576.1998; Cleary MA, 1997, P NATL ACAD SCI USA, V94, P8450, DOI 10.1073/pnas.94.16.8450; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; Ferguson MK, 1996, J VIROL, V70, P4193, DOI 10.1128/JVI.70.7.4193-4199.1996; FRATTINI MG, 1994, P NATL ACAD SCI USA, V91, P12398, DOI 10.1073/pnas.91.26.12398; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; Gillette TG, 1998, J VIROL, V72, P5735, DOI 10.1128/JVI.72.7.5735-5744.1998; Gillitzer E, 2000, EMBO J, V19, P3069, DOI 10.1093/emboj/19.12.3069; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HOLT SE, 1994, J VIROL, V68, P1094, DOI 10.1128/JVI.68.2.1094-1102.1994; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; MACPHERSON P, 1994, VIROLOGY, V204, P403, DOI 10.1006/viro.1994.1544; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; McShan GD, 1997, VIROLOGY, V237, P198, DOI 10.1006/viro.1997.8793; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; Sanders CM, 2000, J BIOL CHEM, V275, P3522, DOI 10.1074/jbc.275.5.3522; SARAFI TR, 1995, VIROLOGY, V211, P385, DOI 10.1006/viro.1995.1421; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STENLUND A, 1996, DNA REPLICATION EUKA, P679; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; Sun YN, 1996, VIROLOGY, V216, P219, DOI 10.1006/viro.1996.0050; SVERDRUP F, 1995, J VIROL, V69, P1319, DOI 10.1128/JVI.69.2.1319-1323.1995; SYRJANEN K, 1987, PAPILLOMAVIRUSES HUM, P69; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; Winokur PL, 1996, VIROLOGY, V221, P44, DOI 10.1006/viro.1996.0351; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	42	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23689	23699		10.1074/jbc.M101861200	http://dx.doi.org/10.1074/jbc.M101861200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323428	hybrid			2022-12-25	WOS:000169531100063
J	Huang, AY; Castle, AM; Hinton, BT; Castle, JD				Huang, AY; Castle, AM; Hinton, BT; Castle, JD			Resting (basal) secretion of proteins is provided by the minor regulated and constitutive-like pathways and not granule exocytosis in parotid acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; MDCK CELLS; LYSOSOMAL-ENZYMES; AMYLASE RELEASE; CARBACHOL; DISTINCT; STORAGE; BIOGENESIS; TRANSPORT	Resting secretion of salivary proteins by the parotid gland is sustained in situ between periods of eating by parasympathetic stimulation and has been assumed to involve low level granule exocytosis. By using parotid lobules from ad libitum fed rats stimulated with low doses of carbachol as an in vitro analog of resting secretion, we deduce from the composition of discharged proteins that secretion does not involve granule exocytosis. Rather, it derives from two other acinar export routes, the constitutive-like (stimulus-independent) pathway and the minor regulated pathway, which responds to low doses of cholinergic or P-adrenergic agonists (Castle, J, D,, and Castle, A. M. (1996) J, Cell Sci, 109, 2591-2599). The protein composition collected in vitro mimics that collected from cannulated ducts of glands given low level stimulation in situ. Analysis of secretory trafficking along the two pathways of resting secretion has indicated that the constitutive-like pathway may pass through endosomes after diverging from the minor regulated pathway at a brefeldin A sensitive branch point. The branch point is deduced to be distal to a common vesicular budding event by which both pathways originate from immature granules. Detectable perturbation of neither pathway in lobules was observed by wortmannin addition, and neither serves as a significant export route for lysosomal procathepsin B. These findings show that parotid acinar cells use low capacity, high sensitivity secretory pathways for resting secretion and reserve granule exocytosis, a high capacity, low sensitivity pathway, for massive salivary protein export during meals, An analogous strategy may be employed in other secretory cell types.	Univ Virginia, Sch Med, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Castle, JD (corresponding author), Univ Virginia, Sch Med, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA.	jdc4r@virginia.edu	Hinton, Barry/AAT-5786-2021		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008941] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08941] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; ASKING B, 1980, ACTA PHYSIOL SCAND, V109, P415, DOI 10.1111/j.1748-1716.1980.tb06614.x; ASKING B, 1980, ACTA PHYSIOL SCAND, V109, P407, DOI 10.1111/j.1748-1716.1980.tb06613.x; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BAUM EJ, 1987, J DENT RES, V55, P628; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BREWER CB, 1995, J CELL SCI, V108, P789; BRIGNONI M, 1995, J CELL SCI, V108, P1931; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; Castle AM, 1997, J CELL BIOL, V138, P45, DOI 10.1083/jcb.138.1.45; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; Castle D, 1998, CRIT REV ORAL BIOL M, V9, P4, DOI 10.1177/10454411980090010301; Castle JD, 1996, J CELL SCI, V109, P2591; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; Christensen BM, 2000, AM J PHYSIOL-RENAL, V278, pF29, DOI 10.1152/ajprenal.2000.278.1.F29; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeLisle RC, 1996, EUR J CELL BIOL, V71, P62; DVORAK AM, 1991, AM J PATHOL, V138, P69; Eaton BA, 2000, J NEUROSCI, V20, P7334; EMMELIN N, 1987, J DENT RES, V66, P509, DOI 10.1177/00220345870660022101; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; GIRARD LR, 1993, J BIOL CHEM, V268, P26592; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HENDRICKS LC, 1992, P NATL ACAD SCI USA, V89, P7242, DOI 10.1073/pnas.89.15.7242; Hirono C, 1998, J MEMBRANE BIOL, V164, P197, DOI 10.1007/s002329900405; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KOMHOFF M, 1994, EUR J CELL BIOL, V63, P192; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; LARSSON O, 1989, ACTA PHYSIOL SCAND, V137, P231, DOI 10.1111/j.1748-1716.1989.tb08743.x; LEONG DA, 1991, J BIOL CHEM, V266, P9016; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; PHANEUF S, 1984, CELL TISSUE RES, V235, P699; PHANEUF S, 1985, CELL TISSUE RES, V239, P105, DOI 10.1007/BF00214909; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Salem N, 1998, NAT NEUROSCI, V1, P551, DOI 10.1038/2787; SESSO A, 1980, ACTA ANAT, V108, P521; SHARONI Y, 1976, J CELL BIOL, V71, P107, DOI 10.1083/jcb.71.1.107; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; TAKEMURA H, 1984, JPN J PHARMACOL, V36, P107, DOI 10.1254/jjp.36.107; TEMPLETON D, 1990, PFLUGERS ARCH, V384, P287; Turner MD, 2000, J BIOL CHEM, V275, P14025, DOI 10.1074/jbc.275.19.14025; VONZASTROW M, 1989, J BIOL CHEM, V264, P6566; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WALKER AM, 1980, ENDOCRINOLOGY, V107, P1095, DOI 10.1210/endo-107-4-1095; Wang EI, 2000, TRAFFIC, V1, P480, DOI 10.1034/j.1600-0854.2000.010606.x; YELDHUIS JD, 2000, NOVART FDN SYMP, V227, P1	56	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22296	22306		10.1074/jbc.M100211200	http://dx.doi.org/10.1074/jbc.M100211200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301325	hybrid			2022-12-25	WOS:000169412700045
J	Drane, P; Bravard, A; Bouvard, V; May, E				Drane, P; Bravard, A; Bouvard, V; May, E			Reciprocal down-regulation of p53 and SOD2 gene expression - implication in p53 mediated apoptosis	ONCOGENE			English	Article						p53; superoxide dismutase; apoptosis; gene regulation; NF-kappa B	MANGANESE SUPEROXIDE-DISMUTASE; WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; NF-KAPPA-B; TRANSCRIPTIONAL REPRESSION; DNA-BINDING; IN-VIVO; MALIGNANT PHENOTYPE; OXIDATIVE STRESS	p53 regulates the transcription of a number of genes among which are different redox-related genes. It has been proposed that these genes can induce a cellular oxidative stress leading to p53-dependent apoptosis (Polyak er al., 1997). MnSOD, the product of superoxide dismutase 2 (SOD2) gene, is one of the major cellular defences against oxidative stress. We demonstrate here that p53 is able to repress SOD2 gene expression and that this repression takes place at promoter level. We show the importance of this regulation for the p53 function, by demonstrating that an overexpression of MnSOD decreases p53-mediated induction of apoptosis. Moreover, we demonstrate that MnSOD overexpression decreases p53-gene expression at the promoter level. These findings raise the hypothesis that p53 and SOD2 genes are mutually regulated leading to the modulation of various cellular processes including apoptosis.	CEA, Lab Cancerogenese Mol, CNRS,UMR 217, DRR,DSV, F-92265 Fontenay Aux Roses, France; CEA, Lab Radiobiol Cellulaire, DRR, DSV, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); CEA	May, E (corresponding author), CEA, Lab Cancerogenese Mol, CNRS,UMR 217, DRR,DSV, BP6, F-92265 Fontenay Aux Roses, France.			BRAVARD, Anne/0000-0002-0314-9092				BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Borgstahl GEO, 1996, BIOCHEMISTRY-US, V35, P4287, DOI 10.1021/bi951892w; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cho G, 1997, BIOCHEM MOL BIOL INT, V42, P949; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Frei B, 1999, FASEB J, V13, P963, DOI 10.1096/fasebj.13.9.963; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6; Iotsova V, 1996, ONCOGENE, V13, P2331; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; Kaluzova M, 2000, BBA-GENE STRUCT EXPR, V1491, P20, DOI 10.1016/S0167-4781(00)00015-4; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kuo SY, 1999, J BIOL CHEM, V274, P3345, DOI 10.1074/jbc.274.6.3345; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; LI JJ, 1995, ONCOGENE, V10, P1989; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Pani G, 2000, CANCER RES, V60, P4654; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRICE BD, 1993, ONCOGENE, V8, P3055; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shatrov VA, 2000, INT J CANCER, V85, P93, DOI 10.1002/(SICI)1097-0215(20000101)85:1<93::AID-IJC17>3.0.CO;2-I; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sheng-Tanner X, 1998, RADIAT RES, V150, P636, DOI 10.2307/3579886; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Wang QJ, 1998, CANCER RES, V58, P5762; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WU HY, 1994, J BIOL CHEM, V269, P20067; YonishRouach E, 1995, ONCOGENE, V11, P2197; Zhao RB, 2000, GENE DEV, V14, P981; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	63	128	135	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					430	439		10.1038/sj.onc.1204101	http://dx.doi.org/10.1038/sj.onc.1204101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313974				2022-12-25	WOS:000166562500003
J	Fukuhara, H; Maruyama, T; Nomura, S; Oshimura, M; Kitamura, T; Sekiya, T; Murakami, Y				Fukuhara, H; Maruyama, T; Nomura, S; Oshimura, M; Kitamura, T; Sekiya, T; Murakami, Y			Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers	ONCOGENE			English	Article						prostate cancer; tumor suppressor gene; chromosome 10p15; microcell-mediated chromosome transfer	CELL-LINE; ALLELIC LOSS; SHORT ARM; MALIGNANT PHENOTYPE; METASTASIS; LOCI; FRAGMENTS; CARCINOMA; DELETION; HETEROZYGOSITY	Loss of heterozygosity on chromosome 10p was observed frequently in human prostate cancers. Studies have demonstrated that the introduction of the short arm of human chromosome 10 into a human prostate cancer cell line, PPC-I, by microcell-mediated chromosome transfer (MMCT), suppressed the malignant phenotype, suggesting the presence of a prostate tumor suppressor gene(s) within a region of 17 cM at distal 10p, To narrow down the candidate region harboring the tumor suppressor gene, a series of 10p fragments were transferred into PPC-1 cells by MMCT using a panel of hamster-human hybrid cells containing various portions of 10p, Pour of the six hybrid tells obtained showed decreased tumorigenicity when injected subcutaneously irate athymic nude mice. Tumors developed only at six of 40 injection sites for these four hybrid cells. In contrast, the other two hybrid cells, as well as parental PPC-1 cells, were judged to he fully tumorigenic because tumors appeared at a total 26 of 32 sites for the two hybrid cells and 15 of 16 sites for PPC-I, Allelotyping of 10p combined with fluorescence in situ hybridization in these hybrid cells suggested that a prostate tumor suppressor gene was located within a fragment of approximately 1.2 Mb flanked by D10S1172 and D10S226 on 10p15.1.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; BML, R&D Ctr, Kawagoe, Saitama 3501101, Japan; Tottori Univ, Fac Med, Sch Life Sci, Yonago, Tottori 6838503, Japan; Univ Tokyo, Sch Med, Dept Urol, Tokyo 1138655, Japan	National Cancer Center - Japan; Tottori University; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022; Kitamura, Toshio/AAA-2071-2021	Nomura, Sachio/0000-0001-9214-4041; 				ALBERTSEN H, 1994, AM J HUM GENET, V54, P516; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOVA GS, 1993, CANCER RES, V53, P3869; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; BROTHMAN AR, 1990, CANCER RES, V50, P3795; BROTHMAN AR, 1995, GENE CHROMOSOME CANC, V13, P278, DOI 10.1002/gcc.2870130408; BROTHMAN AR, 1992, CYTOGENET CELL GENET, V60, P8, DOI 10.1159/000133283; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EFFERT PJ, 1992, J UROLOGY, V147, P789, DOI 10.1016/S0022-5347(17)37387-1; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISAACS WB, 1991, CANCER RES, V51, P4716; Ittmann M, 1996, CANCER RES, V56, P2143; Kawana Y, 1997, PROSTATE, V32, P205; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1993, GENE CHROMOSOME CANC, V8, P88, DOI 10.1002/gcc.2870080205; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; MURAKAMI Y, 2000, IN PRESS J HUM GENET; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; Nihei N, 1996, GENE CHROMOSOME CANC, V17, P260, DOI 10.1002/(SICI)1098-2264(199612)17:4<260::AID-GCC8>3.0.CO;2-1; Nihei N, 1999, GENE CHROMOSOME CANC, V24, P1, DOI 10.1002/(SICI)1098-2264(199901)24:1<1::AID-GCC1>3.0.CO;2-A; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; Robertson GP, 1999, CANCER RES, V59, P3596; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Shimura M, 1999, CANCER RES, V59, P2259; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Trybus TM, 1996, CANCER RES, V56, P2263; VISAKORPI T, 1995, CANCER RES, V55, P342; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	48	21	21	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					314	319		10.1038/sj.onc.1204079	http://dx.doi.org/10.1038/sj.onc.1204079			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313960				2022-12-25	WOS:000166411000005
J	Lin, E; Graziano, JH; Freyer, GA				Lin, E; Graziano, JH; Freyer, GA			Regulation of the 75-kDa subunit of mitochondrial complex I by iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; RESPONSIVE ELEMENT; PARKINSONS-DISEASE; TRANSLATIONAL REGULATION; TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; BINDING PROTEIN; CYTOSOLIC PROTEIN; FREE-RADICALS	Iron homeostasis is tightly regulated, as cells work to conserve this essential but potentially toxic metal, The translation of many iron proteins is controlled by the binding of two cytoplasmic proteins, iron regulatory protein 1 and 2 (IRP1 and IRP2) to stem loop structures, known as iron-responsive elements (IREs), found in the untranslated regions of their mRNAs. In short, when iron is depleted, IRP1 or IRP2 bind IREs; this decreases the synthesis of proteins involved in iron storage and mitochondrial metabolism (e.g. ferritin and mitochondrial aconitase) and increases the synthesis of those involved in iron uptake (e.g. transferrin receptor). It is likely that more iron containing proteins have IREs and that other IRPs may exist. One obvious place to search is in Complex I of the mitochondrial respiratory chain, which contains at least 6 iron-sulfur (Fe-S) subunits, Interestingly, in idiopathic Parkinson's disease, iron homeostasis is altered, and Complex I activity is diminished. These findings led us to investigate whether iron status affects the Fe-S subunits of Complex I. We found that the protein levels of the 75-kDa subunit of Complex I were modulated by levels of iron in the cell, whereas mRNA levels were minimally changed. Isolation of a clone of the 75-kDa Fe-S subunit with a more complete 5'-untranslated region sequence revealed a novel IRE-like stem loop sequence. RNA protein gel shift assays demonstrated that a specific cytoplasmic protein bound the novel IRE and that the binding of the protein was affected by iron status. Western blot analysis and supershift assays showed that this cytosolic protein is neither IRP1 nor IRP2. In addition, ferritin IRE was able to compete for binding with this putative IRP, These results suggest that the 75-kDa Fe-S subunit of mitochondrial Complex I may be regulated by a novel IRE-IRP system.	Columbia Univ, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University	Freyer, GA (corresponding author), Columbia Univ, Div Environm Hlth Sci, 722 W 168th St,PI Annex,Rm 114, New York, NY 10032 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032527] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES09089] Funding Source: Medline; NINDS NIH HHS [NS32527] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKRELL BAC, 1984, J BIOL CHEM, V259, P53; Allerson CR, 1999, J BIOL CHEM, V274, P26439, DOI 10.1074/jbc.274.37.26439; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; COOPER JM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P198, DOI 10.1016/S0005-2728(05)80019-2; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DAVIES KJA, 1982, AM J PHYSIOL, V242, pE418, DOI 10.1152/ajpendo.1982.242.6.E418; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HIRSCH EC, 1993, EUR NEUROL, V33, P52, DOI 10.1159/000118538; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; Kohler SA, 1999, J BIOL CHEM, V274, P2401, DOI 10.1074/jbc.274.4.2401; LANGSTON JW, 1984, CAN J NEUROL SCI, V11, P160; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1983, NEW ENGL J MED, V309, P310; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; MAGUIRE JJ, 1982, BIOCHIM BIOPHYS ACTA, V679, P210, DOI 10.1016/0005-2728(82)90292-4; MANN VM, 1994, ANN NEUROL, V36, P876, DOI 10.1002/ana.410360612; McCord JM, 1998, SEMIN HEMATOL, V35, P5; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOCHIZUKI H, 1994, NEUROSCI LETT, V168, P251, DOI 10.1016/0304-3940(94)90462-6; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; PIETRANGELO A, 1991, HEPATOLOGY, V14, P1083, DOI 10.1002/hep.1840140623; PIETRANGELO A, 1990, HEPATOLOGY, V11, P798, DOI 10.1002/hep.1840110513; PILKINGTON SJ, 1993, BIOCHEM SOC T, V21, P26, DOI 10.1042/bst0210026; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SCHAPIRA AHV, 1993, ADV NEUROL, V60, P288; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Schapira AHV, 1996, CURR OPIN NEUROL, V9, P260, DOI 10.1097/00019052-199608000-00003; SCHAPIRA AHV, 1993, BIOCHEM SOC T, V21, P367, DOI 10.1042/bst0210367; SIERZPUTOWSKAGRACZ H, 1995, NUCLEIC ACIDS RES, V23, P146, DOI 10.1093/nar/23.1.146; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WHITE K, 1988, J BIOL CHEM, V263, P8938	51	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27685	27692		10.1074/jbc.M100941200	http://dx.doi.org/10.1074/jbc.M100941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313346	hybrid			2022-12-25	WOS:000169966900125
J	Settasatian, N; Duong, MN; Curtiss, LK; Ehnholm, C; Jauhiainen, M; Huuskonen, J; Rye, KA				Settasatian, N; Duong, MN; Curtiss, LK; Ehnholm, C; Jauhiainen, M; Huuskonen, J; Rye, KA			The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; ESTER TRANSFER PROTEIN; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; PARTICLE FUSION; CONVERSION; SIZE; HDL; PHOSPHATIDYLCHOLINE; PRECIPITATION	Phospholipid transfer protein (PLTP) remodels high density lipoproteins (HDL) into large and small particles. It also mediates the dissociation of lipid-poor or lipid-free apolipoprotein A-I (apoA-I) from HDL, Remodeling is enhanced markedly in triglyceride (TG)-enriched HDL (Rye, K.-A, Jauhiainen, M,, Barter, P, J,, and Ehnholm, C, (1998) J; Lipid. Res. 39, 613-622), This study defines the mechanism of the remodeling of HDL by PLTP and determines why it is enhanced in TG-enriched HDL, Homogeneous populations of spherical reconstituted HDL (rHDL) containing apoA-I and either cholesteryl esters only (CE-rHDL; diameter 9.3 nm) or CE and TG in their core (TG-rHDL; diameter 9.5 nm) were used. After 24 h of incubation with PLTP, all of the TG-rHDL, but only a proportion of the CE-rHDL, were converted into large (11.3-nm diameter) and small (7.7-nm diameter) particles. Only small particles were formed during the first 6 h of incubation of CE-rHDL with PLTP, The large particles and dissociated apoA-I were apparent after 12 h. In the case of TG-rHDL, small particles appeared after 1 h of incubation, while dissociated apoA-I and large particles were apparent at 3-h, The composition of the large particles indicated that they were derived from a fusion product. Spectroscopic studies indicated that the apoA-I in TG rHDL was less stable than the apoA-I in CE-rHDL, In conclusion, these results show that: (i) PLTP mediates rHDL fusion, (ii) the fusion product rearranges by two independent processes into small and large particles, and (iii) the more rapid remodeling of TG-rHDL by PLTP may be due to the destabilization of apoA-I.	Hanson Ctr, Lipid Res Lab, Adelaide, SA 5000, Australia; Univ Adelaide, Royal Adelaide Hosp, Dept Med, Adelaide, SA 5000, Australia; Scripps Res Inst, La Jolla, CA 92037 USA; Natl Publ Hlth Inst, Dept Biochem, FIN-00300 Helsinki, Finland; Royal Adelaide Hosp, Div Cardiovasc Serv, Adelaide, SA 5000, Australia	Royal Adelaide Hospital; University of Adelaide; Scripps Research Institute; Finland National Institute for Health & Welfare; Royal Adelaide Hospital	Rye, KA (corresponding author), Hanson Ctr, Lipid Res Lab, Level 1,Frome Rd, Adelaide, SA 5000, Australia.	karye@ozemail.com.au						Albers JJ, 1996, INT J CLIN LAB RES, V26, P262, DOI 10.1007/BF02602960; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V8, P1; BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Cheung MC, 1996, BBA-LIPID LIPID MET, V1303, P103, DOI 10.1016/0005-2760(96)00082-3; Curtiss LK, 2000, BIOCHEMISTRY-US, V39, P5712, DOI 10.1021/bi992902m; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; ECKARDSTEIN A, 1996, BIOCHIM BIOPHYS ACTA, V1301, P255; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; HOPKINS GJ, 1982, METABOLISM, V31, P78, DOI 10.1016/0026-0495(82)90048-8; Huuskonen J, 1998, J LIPID RES, V39, P2021; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2000, BIOCHEMISTRY-US, V39, P16092, DOI 10.1021/bi0019287; Jauhiainen M, 1999, J LIPID RES, V40, P654; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Kawano K, 2000, J BIOL CHEM, V275, P29477, DOI 10.1074/jbc.M003523200; Korhonen A, 1998, BIOCHEM BIOPH RES CO, V249, P910, DOI 10.1006/bbrc.1998.9162; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029; LIANG HQ, 1994, J LIPID RES, V35, P1187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MAHADEVAN V, 1983, BIOCHIM BIOPHYS ACTA, V752, P89, DOI 10.1016/0005-2760(83)90236-9; MATZ CE, 1982, J BIOL CHEM, V257, P4535; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; Pace C N, 1986, Methods Enzymol, V131, P266; PIRAN U, 1979, J LIPID RES, V20, P1040; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; PUSSINEN P, 1995, J LIPID RES, V36, P975; RAJARAM OV, 1985, BIOCHIM BIOPHYS ACTA, V835, P41, DOI 10.1016/0005-2760(85)90028-1; Rao R, 1997, BIOCHEMISTRY-US, V36, P3645, DOI 10.1021/bi962776b; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Rye KA, 1998, J LIPID RES, V39, P613; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; RYE KA, 1992, J LIPID RES, V33, P215; SPARKS DL, 1995, J BIOL CHEM, V270, P26910, DOI 10.1074/jbc.270.45.26910; SPARKS DL, 1992, J LIPID RES, V33, P123; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; TU AY, 1993, J BIOL CHEM, V268, P23098; WARNICK GR, 1978, J LIPID RES, V19, P65; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	47	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26898	26905		10.1074/jbc.M010708200	http://dx.doi.org/10.1074/jbc.M010708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11325961	hybrid			2022-12-25	WOS:000169966900024
J	Michelsen, KS; Aicher, A; Mohaupt, M; Hartung, T; Dimmeler, S; Kirschning, CJ; Schumann, RR				Michelsen, KS; Aicher, A; Mohaupt, M; Hartung, T; Dimmeler, S; Kirschning, CJ; Schumann, RR			The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCs) - Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; LIPOPOLYSACCHARIDE; IMMUNITY; CD14; ACTIVATION; RESPONSIVENESS; RECOGNITION; GENERATION; INDUCTION; MUTATIONS	Toll-like receptors (TLRs) have been found to be key elements in pathogen recognition by the host immune system. Dendritic cells (DCs) are crucial for both innate immune responses and initiation of acquired immunity, Here we focus on the potential involvement of TLR ligand interaction in DC maturation. TLR2 knockout mice and mice carrying a TLR4 mutation (C3H/HeJ) were investigated for DC maturation induced by peptidoglycan (PGN), lipopolysaccharide (LPS), or lipoteichoic acids (LTAs), All stimuli induced maturation of murine bone marrow-derived DCs in control mice. TLR2(-/-) mice lacked maturation upon stimulation with PGN, as assessed by expression of major histocompatibility complex class II, CD86, cytokine, and chemokine production, fluorescein isothiocyanate-dextran uptake, and mixed lymphocyte reactions, while being completely responsive to LPS. A similar lack of maturation was observed in C3H/HeJ mice upon stimulation with LPS, DC maturation induced by LTAs from two different types of bacteria was severely impaired in TLR2(-/-), whereas C3H/HeJ mice responded to LTAs in a manner similar to wild-type mice, We demonstrate that DC maturation is induced by stimuli from Gram-positive microorganisms, such as PGN and LTA, with similar efficiency as by LPS, Finally, we provide evidence that TLR2 and TLR4 interaction with the appropriate ligand is essential for bacteria-induced maturation of DCs.	Humboldt Univ, Univ Med Ctr Charite, Inst Mikrobiol & Hyg, D-10117 Berlin, Germany; Univ Frankfurt, Zentrum Inneren Med, D-60590 Frankfurt, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Konstanz; Technical University of Munich	Schumann, RR (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Inst Mikrobiol & Hyg, Dorotheenstr 96, D-10117 Berlin, Germany.		Mohaupt, Markus/AAE-3368-2020; Aicher, Alexandra/GZK-8031-2022	Dimmeler, Stefanie/0000-0002-1045-2436; Aicher, Alexandra/0000-0002-8920-9577				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; FISCHER W, 1993, ANAL BIOCHEM, V208, P49, DOI 10.1006/abio.1993.1007; Hashimoto M, 2000, BIOCHEM BIOPH RES CO, V273, P164, DOI 10.1006/bbrc.2000.2921; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Mahnke K, 1997, ADV EXP MED BIOL, V417, P145; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 1999, J IMMUNOL, V163, P6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MORRISON DC, 1975, J BIOL CHEM, V250, P2911; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rescigno M, 1999, IMMUNOL TODAY, V20, P200, DOI 10.1016/S0167-5699(98)01427-3; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sousa CRE, 1999, CURR OPIN IMMUNOL, V11, P392, DOI 10.1016/S0952-7915(99)80066-1; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	34	230	238	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25680	25686		10.1074/jbc.M011615200	http://dx.doi.org/10.1074/jbc.M011615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316801	hybrid			2022-12-25	WOS:000169823300008
J	Bell, M; Capone, R; Pashtan, I; Levitzki, A; Engelberg, D				Bell, M; Capone, R; Pashtan, I; Levitzki, A; Engelberg, D			Isolation of hyperactive mutants of the MAPK p38/Hog1 that are independent of MAPK kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; YEAST SACCHAROMYCES-CEREVISIAE; OF-FUNCTION MUTATION; PROTEIN-KINASE; MAMMALIAN-CELLS; DUAL PHOSPHORYLATION; STRESS-RESPONSE; DIFFERENTIATION; TRANSFORMATION; SPECIFICITY	Mitogen-activated protein kinases (MAPKs) play pivotal roles in growth, development, differentiation, and apoptosis, The exact role of a given MAPK in these processes is not fully understood. This question could be addressed using active forms of these enzymes that are independent of external stimulation and upstream regulation, Yet, such molecules are not available. MAPK activation requires dual phosphorylation, on neighboring Tyr and Thr residues, catalyzed by MAPK kinases (MAPKKs). It is not known how to force MAPK activation independent of MAPKK phosphorylation, Here we describe a series of nine hyperactive (catalytically and biologically), MAPKK-independent variants of the MAPK Hog1, Each of the active molecules contains just a single point mutation. Six mutations are in the conserved L16 domain of the protein. The active Hog1 mutants were obtained through a novel genetic screen that could be applied for isolation of active MAPKs of other families. Equivalent mutations, introduced to the human p38 alpha, rendered the enzyme active even when produced in Escherichia coli, showing that the mutations increased the intrinsic catalytic activity of p38, It implies that the activating mutations could be directly used for production of active forms of MAPKs from yeasts to humans and could open the way to revealing their biological functions.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.		Capone, Ricardo F/D-1943-2010	Capone, Ricardo F/0000-0002-7327-9837				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKENS M, 1997, SCIENCE, V277, P963; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang Y, 1997, J BIOL CHEM, V272, P11096; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SILHAVY TJ, 1984, COLD SPRING HARBOR L, P75; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	46	65	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25351	25358		10.1074/jbc.M101818200	http://dx.doi.org/10.1074/jbc.M101818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309396	hybrid			2022-12-25	WOS:000169800700122
J	Clark, PL; King, J				Clark, PL; King, J			A newly synthesized, ribosome-bound polypeptide chain adopts conformations dissimilar from early in vitro refolding intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-P22 TAILSPIKE PROTEIN; TAIL SPIKE ENDORHAMNOSIDASE; HEAD-BINDING DOMAIN; FOLDING IN-VIVO; MONOCLONAL-ANTIBODIES; MOLECULAR CHAPERONES; TRIGGER FACTOR; SALMONELLA PHAGE-P22; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE	Little is known about the conformations of newly synthesized polypeptide chains as they emerge from the large ribosomal subunit, or how these conformations compare with those populated immediately after dilution of polypeptide chains out of denaturant in vitro. Both in vivo and in vitro, partially folded intermediates of the tailspike protein from Salmonella typhimurium phage P22 can be trapped in the cold. A subset of monoclonal antibodies raised against tailspike recognize partially folded intermediates, whereas other antibodies recognize only later intermediates and/or the native state. We have used a pair of monoclonal antibodies to probe the conformational features of full-length, newly synthesized tailspike chains recovered on ribosomes from phage-infected cells. The antibody that recognizes early intermediates in vitro also recognizes the ribosome-bound intermediates. Surprisingly, the antibody that did not recognize early in vitro intermediates did recognize ribosome-bound tailspike chains translated in vivo, Thus, the newly synthesized, ribosome-bound tailspike chains display structured epitopes not detected upon dilution of tailspike chains from denaturant. As opposed to the random ensemble first populated when polypeptide chains are diluted out of denaturant, folding in vivo from the ribosome may begin with polypeptide conformations already directed toward the productive folding and assembly pathway.	MIT, Dept Biol 68 340D, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Clark, PL (corresponding author), MIT, Dept Biol 68 340D, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	plclark@mit.edu	Clark, Patricia/C-9850-2009	Clark, Patricia/0000-0001-5462-8248	NCRR NIH HHS [S10 RR05734] Funding Source: Medline; NIGMS NIH HHS [GM19715, GM17980] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, R37GM017980] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BAZINET C, 1988, BIOCHEMISTRY-US, V27, P1849, DOI 10.1021/bi00406a009; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; Betts SD, 1998, PROTEIN SCI, V7, P1516, DOI 10.1002/pro.5560070704; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; Caldas T, 2000, J BIOL CHEM, V275, P855, DOI 10.1074/jbc.275.2.855; CAMPBELL AM, 1996, ESCHERICHIA COLI SAL, P2325; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Fedorov AN, 1999, J MOL BIOL, V294, P579, DOI 10.1006/jmbi.1999.3281; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FRIGUET B, 1994, J BIOL CHEM, V269, P15945; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; Frydman J, 1999, NAT STRUCT BIOL, V6, P697, DOI 10.1038/10754; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; FULTON AB, 1993, J CELL SCI, V105, P867; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GORDON CL, 1994, J BIOL CHEM, V269, P27941; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; King J, 1986, Methods Enzymol, V131, P250; Komar AA, 1997, J BIOL CHEM, V272, P10646; Kreisberg JF, 2000, PROTEIN SCI, V9, P2338, DOI 10.1110/ps.9.12.2338; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Miller S, 1998, BIOCHEMISTRY-US, V37, P9160, DOI 10.1021/bi980190e; Neira JL, 1999, J MOL BIOL, V285, P1309, DOI 10.1006/jmbi.1998.2249; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nicola AV, 1999, NAT CELL BIOL, V1, P341, DOI 10.1038/14032; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Pal S, 1999, J BIOL CHEM, V274, P32771, DOI 10.1074/jbc.274.46.32771; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; SATHER SK, 1994, J BIOL CHEM, V269, P25268; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SHEA RG, 1977, THESIS MIT CAMBRIDGE; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Speed MA, 1997, PROTEIN SCI, V6, P99; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SPEED MA, 1995, PROTEIN SCI, V4, P900; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YU MH, 1988, J BIOL CHEM, V263, P1424	64	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25411	25420		10.1074/jbc.M008490200	http://dx.doi.org/10.1074/jbc.M008490200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319217	hybrid			2022-12-25	WOS:000169800700131
J	Fukada, T; Tonks, NK				Fukada, T; Tonks, NK			The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATA TRANSCRIPTION FACTORS; GROWTH-FACTOR-I; SACCHAROMYCES-CEREVISIAE; PHOSPHATASE 1B; INSULIN SENSITIVITY; NEGATIVE REGULATOR; SKELETAL-MUSCLE; GENE-EXPRESSION; BINDING MOTIF; ELEMENT STRE	Protein-tyrosine phosphatase 1B (PTP1B) is an important regulator of protein-tyrosine kinase-dependent signaling pathways. Changes in expression and activity of PTP1B have been associated with various human diseases; however, the mechanisms by which PTP1B expression is regulated have yet to be characterized. Previously, we have shown that the expression of PTP1B is enhanced by p210 Bcr-Ab1 and that PTP1B is a specific antagonist of transformation induced by this oncoprotein protein-tyrosine kinase, Here we have characterized the PTP1B promoter and demonstrate that a motif with features of a stress-response element acts as a (p) under bar 210 Bcr-Ab1-(r) under bar esponsive (s) under bar equence, termed PRS. We have shown that three C2H2 zinc finger proteins, namely Sp1, Sp3, and Egr-1, bind to PRS. Whereas binding of either Spl or Sp3 induced promoter function, Egr-1 repressed Sp3-mediated PTP1B promoter activation. The binding of Egr-1 to PRS is suppressed by p210 Bcr-Ab1 due to the inhibition of Egr-1 expression, resulting in the enhancement of PTP1B promoter activity. Our data indicate that Egr-1 and Sp family proteins play a reciprocal role in the control of expression from the PTP1B promoter.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, Demerec Bldg,1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.				NATIONAL CANCER INSTITUTE [R37CA053840, P30CA045508, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840, P30 CA45508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dadke SS, 2000, BIOCHEM BIOPH RES CO, V274, P583, DOI 10.1006/bbrc.2000.3188; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Forsell PKAL, 2000, GENE, V260, P145, DOI 10.1016/S0378-1119(00)00464-9; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; KENNER KA, 1993, J BIOL CHEM, V268, P25455; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Moller N P, 2000, Curr Opin Drug Discov Devel, V3, P527; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; ZHAI YF, 1993, CANCER RES, V53, P2272	52	59	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25512	25519		10.1074/jbc.M101354200	http://dx.doi.org/10.1074/jbc.M101354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316810	hybrid			2022-12-25	WOS:000169800700142
J	Lewin, TM; Kim, JH; Granger, DA; Vance, JE; Coleman, RA				Lewin, TM; Kim, JH; Granger, DA; Vance, JE; Coleman, RA			Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLATION; SN-GLYCEROL 3-PHOSPHATE; COENZYME-A SYNTHETASE; FATTY-ACID TRANSPORT; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SELECTIVE CHANGES; PLASMA-MEMBRANE; LIPID-SYNTHESIS; EXPRESSION	Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC 6.2.1.3) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5, ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane, Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity < 10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5, Refeeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies, These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res, Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Alberta; Institute for Work & Health; University of Alberta	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NICHD NIH HHS [HD 56598, HD 08431] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; BANIS RJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P210, DOI 10.1016/0005-2760(74)90232-X; Cao Y, 2000, FEBS LETT, V467, P263, DOI 10.1016/S0014-5793(00)01159-5; CHANG YY, 1967, J LIPID RES, V8, P447; COLEMAN RA, 1980, J BIOL CHEM, V255, P7681; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; CUI Z, 1993, J BIOL CHEM, V268, P16655; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fleischer S, 1979, Methods Enzymol, V55, P32; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Gargiulo CE, 1999, J LIPID RES, V40, P881; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMIRYO T, 1979, P NATL ACAD SCI USA, V76, P4390, DOI 10.1073/pnas.76.9.4390; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Kansara MS, 1996, AM J PHYSIOL-ENDOC M, V270, pE873, DOI 10.1152/ajpendo.1996.270.5.E873; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; Li JX, 1999, NEUROCHEM RES, V24, P739, DOI 10.1023/A:1020727429052; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V275, pE64, DOI 10.1152/ajpendo.1998.275.1.E64; MERRILL AH, 1982, J LIPID RES, V23, P1368; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; Muoio DM, 2000, AM J PHYSIOL-ENDOC M, V279, pE1366, DOI 10.1152/ajpendo.2000.279.6.E1366; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; Petersen KF, 2000, DIABETES, V49, P827, DOI 10.2337/diabetes.49.5.827; Piccini M, 1998, GENOMICS, V47, P350, DOI 10.1006/geno.1997.5104; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VesLosada A, 1996, MOL CELL BIOCHEM, V159, P1; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	50	219	227	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24674	24679		10.1074/jbc.M102036200	http://dx.doi.org/10.1074/jbc.M102036200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319232	Green Published, hybrid			2022-12-25	WOS:000169800700036
J	Skov, LK; Mirza, O; Henriksen, A; De Montalk, GP; Remaud-Simeon, M; Sarcabal, P; Willemot, RM; Monsan, P; Gajhede, M				Skov, LK; Mirza, O; Henriksen, A; De Montalk, GP; Remaud-Simeon, M; Sarcabal, P; Willemot, RM; Monsan, P; Gajhede, M			Amylosucrase, a glucan-synthesizing enzyme from the alpha-amylase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEISSERIA-POLYSACCHAREA; CRYSTAL-STRUCTURE; X-RAY; ANGSTROM RESOLUTION; GLYCOSYL HYDROLASES; SEQUENCE; INSIGHTS; GLYCOGEN; RESIDUES; TOOL	Amylosucrase (E,C, 2.4.1.4) is a member of Family 13 of the glycoside hydrolases (the alpha -amylases), although its biological function is the synthesis of amylose-like polymers from sucrose. The structure of amylosucrase from Neisseria polysaccharea is divided into five domains: an all helical N-terminal domain that is not similar to any known fold, a (beta/alpha)(8)-barrel A-domain, B- and B'-domains displaying alpha/beta -structure, and a C-terminal eight-stranded beta -sheet domain. In contrast to other Family 13 hydrolases that have the active site in the bottom of a large cleft, the active site of amylosucrase is at the bottom of a pocket at the molecular surface. A substrate binding site resembling the amylase 2 subsite is not found in amylosucrase, The site is blocked by a salt bridge between residues in the second and eight loops of the (beta/alpha)(8)-barrel. The result is an exo-acting enzyme. Loop 7 in the amylosucrase barrel is prolonged compared with the loop structure found in other hydrolases, and this insertion (forming domain B') is suggested to be important for the polymer synthase activity of the enzyme. The topology of the B'-domain creates an active site entrance with several ravines in the molecular surface that could be used specifically by the substrates/ products (sucrose, glucan polymer, and fructose) that have to get in and out of the active site pocket.	Univ Copenhagen, Dept Chem, Prot Struct Grp, DK-2100 Copenhagen, Denmark; Inst Natl Sci Appl, CNRS, UMR 5504,INRA,UMR 792, Ctr Bioingn G Durand,Dept Genie Biochim & Aliment, F-31077 Toulouse 4, France	University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse	Gajhede, M (corresponding author), Univ Copenhagen, Dept Chem, Prot Struct Grp, Univ Parken 5, DK-2100 Copenhagen, Denmark.			Henriksen, Anette/0000-0003-4051-5079; Mirza, Osman Asghar/0000-0001-9435-0690; Gajhede, Michael/0000-0001-9864-2287				Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Buttcher V, 1997, J BACTERIOL, V179, P3324; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; de Montalk GP, 2000, FEMS MICROBIOL LETT, V186, P103; de Montalk GP, 2000, FEBS LETT, V471, P219, DOI 10.1016/S0014-5793(00)01406-X; De Montalk GP, 1999, J BACTERIOL, V181, P375; HEHRE EJ, 1946, J BIOL CHEM, V166, P777; HEHRE EJ, 1949, J BIOL CHEM, V177, P267; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Kim JS, 1999, J BIOL CHEM, V274, P26279, DOI 10.1074/jbc.274.37.26279; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MACKENZIE CR, 1978, CAN J MICROBIOL, V24, P357, DOI 10.1139/m78-060; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; RIOU JY, 1983, ANN INST PASTEUR MIC, VB134, P257, DOI 10.1016/S0769-2609(83)80038-6; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; Sarcabal P, 2000, FEBS LETT, V474, P33, DOI 10.1016/S0014-5793(00)01567-2; Skov LK, 2000, ACTA CRYSTALLOGR D, V56, P203, DOI 10.1107/S0907444999015887; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Watanabe K, 1997, J MOL BIOL, V269, P142, DOI 10.1006/jmbi.1997.1018; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	38	137	143	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25273	25278		10.1074/jbc.M010998200	http://dx.doi.org/10.1074/jbc.M010998200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11306569	Green Published, hybrid			2022-12-25	WOS:000169800700112
J	Williams, DD; Price, NT; Loughlin, AJ; Proud, CG				Williams, DD; Price, NT; Loughlin, AJ; Proud, CG			Characterization of the mammalian initiation factor eIF2B complex as a GDP dissociation stimulator protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GTP-BINDING; FACTOR-II; TRANSLATIONAL CONTROL; RABBIT RETICULOCYTES; KINETIC MECHANISM; ALPHA-SUBUNIT; GAMMA-SUBUNIT; FACTOR EIF-2B; FACTOR 2B	Initiation factor eIF2B mediates a key regulatory step in the initiation of mRNA translation, i.e. the regeneration of active eIF2(.)GTP complexes. It is composed of five subunits, alpha-epsilon. The largest of these (E) displays catalytic activity in the absence of the others. The catalytic mechanism of eIF2B and the functions of the other subunits remain to be clarified. Here we show that, when present at similar concentrations to eIF2, mammalian eIF2B can mediate release of eIF2-bound GDP even in the absence of free nucleotide, indicating that it acts as a GDP dissociation stimulator protein. Consistent with this, addition of GDP to purified eIF2(.)eIF2B complexes causes them to dissociate. The alternative sequential mechanism would require that eIF2B epsilon itself bind GTP. However, we show that it is the beta -subunit of eIF2B that interacts with GTP, This indicates that binding of GTP to eIF2B is not an essential element of its mechanism. eIF2B preparations that lack the alpha -subunit display reduced activity compared with the holocomplex. Supplementation of such preparations with recombinant eIF2B alpha markedly enhances activity, indicating that eIF2B alpha is required for full activity of mammalian eIF2B.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Inst Med Sci, Dundee DD1 5EH, Scotland; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Kent, Res Sch Biosci, Canterbury CT2 7NJ, Kent, England	University of Dundee; University of Bristol; University of Kent	Proud, CG (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Inst Med Sci, Dow St,Wellcome Trust Bioctr Complex, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk		Proud, Christopher/0000-0003-0704-6442; Loughlin, Alison/0000-0003-4769-3740				BOMMER U-A, 1988, Biochemistry International, V16, P549; BOMMER UA, 1989, FEBS LETT, V244, P323, DOI 10.1016/0014-5793(89)80555-1; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P4618, DOI 10.1128/MCB.13.8.4618; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; Craddock BL, 1996, BIOCHEM BIOPH RES CO, V220, P843, DOI 10.1006/bbrc.1996.0495; CRADDOCK BL, 1995, BIOCHEM J, V309, P1009, DOI 10.1042/bj3091009; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; FLOWERS KM, 1995, P NATL ACAD SCI USA, V92, P4274, DOI 10.1073/pnas.92.10.4274; FLOWERS KM, 1996, BIOCHIM BIOPHYS ACTA, V1317, P318; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hutchinson JP, 2000, BIOCHEMISTRY-US, V39, P11348, DOI 10.1021/bi0007573; HWANG YW, 1985, J BIOL CHEM, V260, P1498; KIMBALL SR, 1995, BIOCHEM BIOPH RES CO, V212, P1074, DOI 10.1006/bbrc.1995.2079; Kimball SR, 1998, J BIOL CHEM, V273, P12841, DOI 10.1074/jbc.273.21.12841; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Nika J, 2000, J BIOL CHEM, V275, P26011, DOI 10.1074/jbc.M003718200; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SINGH LP, 1995, BIOCHEM BIOPH RES CO, V212, P1007, DOI 10.1006/bbrc.1995.2070; SINGH LP, 1998, BIOCHEM BIOPH RES CO, V217, P616; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Webb BLJ, 1997, INT J BIOCHEM CELL B, V29, P1127, DOI 10.1016/S1357-2725(97)00039-3; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williams DD, 2001, J BIOL CHEM, V276, P3733, DOI 10.1074/jbc.M008041200	41	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24697	24703		10.1074/jbc.M011788200	http://dx.doi.org/10.1074/jbc.M011788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323413	hybrid			2022-12-25	WOS:000169800700039
J	Benaroudj, N; Lee, DH; Goldberg, AL				Benaroudj, N; Lee, DH; Goldberg, AL			Trehalose accumulation during cellular stress protects cells and cellular proteins from damage by oxygen radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; MAMMALIAN-CELLS; TREHALOSE-6-PHOSPHATE SYNTHASE; SELECTIVE DEGRADATION; DESICCATION TOLERANCE; TRANSIENT ADAPTATION; MOLECULAR CHAPERONES; MODIFIED HEMOGLOBIN	The disaccharide trehalose, which accumulates dramatically during heat shock and stationary phase in many organisms, enhances thermotolerance and reduces aggregation of denatured proteins. Here we re port a new role for trehalose in protecting cells against oxygen radicals. Exposure of Saccharomyces cerevisiae to a mild heat shock (38 degreesC) or to a proteasome inhibitor (MG132) induced trehalose accumulation and markedly increased the viability of the cells upon exposure to a free radical-generating system (H2O2/iron). When cells were returned to normal growth temperature (28 degreesC) or MG132 was removed from the medium, the trehalose content and resistance to oxygen radicals decreased rapidly, Furthermore, a mutant unable to synthesize trehalose was much more sensitive to killing by oxygen radicals than wild-type cells. Providing trehalose exogenously enhanced the resistance of mutant cells to H2O2. Exposure of cells to H2O2 caused oxidative damage to amino acids in cellular proteins, and trehalose accumulation was found to reduce such damage. After even brief exposure to H2O2, the trehalose-deficient mutant exhibited a much higher content of oxidatively damaged proteins than wild-type cells. Trehalose accumulation decreased the initial appearance of damaged proteins, presumably by acting as a free radical scavenger. Therefore, trehalose accumulation in stressed cells plays a major role in protecting cellular constituents from oxidative damage.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Benaroudj, Nadia/0000-0002-6475-0041				ARNES BN, 1993, P NATL ACAD SCI USA, V90, P7915; ATTFIELD PV, 1987, FEBS LETT, V225, P259, DOI 10.1016/0014-5793(87)81170-5; BEERS RF, 1952, J BIOL CHEM, V195, P133; Bell W, 1998, J BIOL CHEM, V273, P33311, DOI 10.1074/jbc.273.50.33311; BELL W, 1992, EUR J BIOCHEM, V209, P951, DOI 10.1111/j.1432-1033.1992.tb17368.x; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; CAVICCHIOLI R, 1986, FEBS LETT, V207, P149, DOI 10.1016/0014-5793(86)80030-8; Chaturvedi V, 1996, J IMMUNOL, V156, P3836; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; COSTA V, 1993, ARCH BIOCHEM BIOPHYS, V300, P608, DOI 10.1006/abbi.1993.1084; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DAVIES JMS, 1995, ARCH BIOCHEM BIOPHYS, V317, P1, DOI 10.1006/abbi.1995.1128; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEVIRGILIO C, 1993, EUR J BIOCHEM, V212, P315; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; Elliott B, 1996, GENETICS, V144, P923; Eroglu A, 2000, NAT BIOTECHNOL, V18, P163, DOI 10.1038/72608; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Guo N, 2000, NAT BIOTECHNOL, V18, P168, DOI 10.1038/72616; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hazell BW, 1995, FEBS LETT, V377, P457, DOI 10.1016/0014-5793(95)01392-X; HENGGEARONIS R, 1991, J BACTERIOL, V173, P7918, DOI 10.1128/jb.173.24.7918-7924.1991; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; HOTTIGER T, 1987, FEBS LETT, V220, P113, DOI 10.1016/0014-5793(87)80886-4; HOTTIGER T, 1994, EUR J BIOCHEM, V219, P187, DOI 10.1111/j.1432-1033.1994.tb19929.x; Jennings DB, 1998, P NATL ACAD SCI USA, V95, P15129, DOI 10.1073/pnas.95.25.15129; KIENLE I, 1993, YEAST, V9, P607, DOI 10.1002/yea.320090607; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Lee J, 1995, MICROBIOL-SGM, V141, P3127, DOI 10.1099/13500872-141-12-3127; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Li SH, 1996, J PHARM SCI, V85, P868, DOI 10.1021/js9504550; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LITCHFIELD WJ, 1978, ARCH BIOCHEM BIOPHYS, V188, P26, DOI 10.1016/0003-9861(78)90351-X; Mizisin AP, 1997, NEUROSCI LETT, V229, P53, DOI 10.1016/S0304-3940(97)00416-3; MIZISIN AP, 1996, AM J PHYSIOL, V270, P90; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Rego AC, 1996, FREE RADICAL BIO MED, V20, P175, DOI 10.1016/0891-5849(95)02029-2; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SHERMAN MY, 1998, EXPT BASEL S, V77, P57; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; TAKAHASHI R, 1990, ARCH BIOCHEM BIOPHYS, V277, P228, DOI 10.1016/0003-9861(90)90573-H; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; TAUBER AI, 1977, J CLIN INVEST, V60, P374, DOI 10.1172/JCI108786; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; WIESER R, 1991, J BIOL CHEM, V266, P12406	59	480	519	8	75	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24261	24267		10.1074/jbc.M101487200	http://dx.doi.org/10.1074/jbc.M101487200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11301331	hybrid			2022-12-25	WOS:000169531100135
J	D'Souza, SJA; Pajak, A; Balazsi, K; Dagnino, L				D'Souza, SJA; Pajak, A; Balazsi, K; Dagnino, L			Ca2+ and BMP-6 signaling regulate E2F during epidermal keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTORS; RETINOBLASTOMA FAMILY; EXPRESSION PATTERNS; HISTONE DEACETYLASE; TERMINAL REGION; DNA-BINDING; PROTEINS; GROWTH	The epidermis consists of a squamous epithelium continuously replenished by committed stem cells, which can either self-renew or differentiate. We demonstrated previously that E2F genes are differentially expressed in developing epidermis (Dagnino, L., Fry, C. J., Bartley, S. M., Farnham, P., Gallie, B. L., and Phillips, R. A. (1997) Cell Growth Differ. 8, 553-563). Thus, we hypothesized that various E2F proteins likely play distinct growth regulatory roles in the undifferentiated stem cells and in terminally differentiated keratinocytes. To further understand the function of E2F genes in epidermal morphogenesis, we have examined the expression, regulation, and protein-protein interactions of E2F factors in undifferentiated cultured murine primary keratinocytes or in cells induced to differentiate with Ca2+ or BMP-6 ((b) under bar one (m) under bar orphogenetic (p) under bar (p) under bar rotein (6) under bar). We find similar patterns of E2F regulation with both differentiating agents and demonstrate a switch in expression from E2F-1, -2, and -3 in undifferentiated, proliferating cells to E2F-5 in terminally differentiated keratinocytes. Inhibition of keratinocyte proliferation by transforming growth factor-beta did not enhance E2F-5 protein levels, suggesting that this response is specific to differentiation rather than reversible cell cycle withdrawal. E2F-5 up-regulation is also accompanied by formation of heteromeric nuclear complexes containing E2F5, p130, and histone deacetylase (HDAC) 1. Overexpression of E2F5 specifically inhibited DNA synthesis in undifferentiated keratinocytes in an HDAC-dependent manner, suggesting that E2F-5(.)p130(.)HDAC1 complexes are likely involved in the permanent withdrawal from the cell cycle of keratinocytes responding to differentiation stimuli.	Univ Western Ontario, Child Hlth Res Inst, Dept Paediat, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada; Ottawa Hosp, Inst Res, Ottawa, ON K1H 8L6, Canada; Univ Western Ontario, Chlid Hlth Res Inst, Dept Pharmacol Toxicol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Pharmacol & Toxicol, Med Sci Bldg, London, ON N6A 5C1, Canada.			Dagnino, Lina/0000-0003-1483-5159				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Advani SJ, 2000, J VIROL, V74, P7842, DOI 10.1128/JVI.74.17.7842-7850.2000; Alani RM, 1998, MOL CARCINOGEN, V23, P226, DOI 10.1002/(SICI)1098-2744(199812)23:4<226::AID-MC5>3.0.CO;2-N; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Guida P, 1999, BIOCHEM BIOPH RES CO, V258, P596, DOI 10.1006/bbrc.1999.0656; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; Hendrix SW, 1998, ARCH DERMATOL RES, V290, P420, DOI 10.1007/s004030050329; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HERTLE MD, 1991, DEVELOPMENT, V112, P193; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Magnaghi-Jaulin L, 2000, Prog Cell Cycle Res, V4, P41; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Muller H, 1997, MOL CELL BIOL, V17, P5508; Myster DL, 2000, DEVELOPMENT, V127, P3249; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Saunders NA, 1999, J INVEST DERMATOL, V112, P977, DOI 10.1046/j.1523-1747.1999.00611.x; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Stiegler P, 1998, CANCER RES, V58, P5049; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Tennenbaum T, 1996, CELL GROWTH DIFFER, V7, P615; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; van der Sman J, 1999, J BIOL CHEM, V274, P12009, DOI 10.1074/jbc.274.17.12009; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZINKEL S, 1994, SEMIN CANCER BIOL, V5, P77	65	67	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23531	23538		10.1074/jbc.M100780200	http://dx.doi.org/10.1074/jbc.M100780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319226	hybrid			2022-12-25	WOS:000169531100043
J	Hakli, M; Karvonen, U; Janne, OA; Palvimo, JJ				Hakli, M; Karvonen, U; Janne, OA; Palvimo, JJ			The RING finger protein SNURF is a bifunctional protein possessing DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY JUNCTION DNA; IN-VITRO; IDENTIFICATION; RNF4; GENE; TRANSCRIPTION; HORMONE; HMG-1; COREGULATOR; COMPONENT	The small nuclear C3HC4 finger protein (SNURF), RNF4, acts as transcriptional coactivator for both steroid-dependent and -independent promoters such as those driven by androgen response elements and GC boxes, respectively. However, SNURF does not possess intrinsic transcription activation function, and the precise molecular mechanism of its action is unknown, We have studied herein the interaction of SNURF with DNA in vitro, SNURF binds to linear double-stranded DNA with no apparent sequence specificity in a cooperative fashion that is highly dependent on the length of the DNA fragment used. SNURF interacts efficiently with both supercoiled circular and four-way junction DNA, and importantly, it also recognizes nucleosomes. An intact RING structure of SNURF is not mandatory for DNA binding, whereas mutations of specific positively charged residues in the N terminus (amino acids 8-11) abolish DNA binding. Interestingly, the ability of SNURF to interact with DNA is associated with its capability to enhance transcription from promoters containing GC box elements. Because SNURF can interact with both DNA and protein (transcription) factors, it may promote assembly of nucleoprotein structures.	Univ Helsinki, Biomedicum Helsinki, Inst Biomed Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Palvimo, JJ (corresponding author), Univ Helsinki, Biomedicum Helsinki, Inst Biomed Physiol, POB 63, FIN-00014 Helsinki, Finland.	jorma.palvimo@helsinki.fi		Palvimo, Jorma/0000-0003-2373-0578				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burden DA, 1999, J BIOL CHEM, V274, P5227, DOI 10.1074/jbc.274.8.5227; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 1999, MOL CELL BIOL, V19, P5237; BUTLER AP, 1985, J BIOL CHEM, V260, P613; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Duprez E, 1999, J CELL SCI, V112, P381; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Galili N, 2000, DEV DYNAM, V218, P102, DOI 10.1002/(SICI)1097-0177(200005)218:1<102::AID-DVDY9>3.3.CO;2-1; GOODWIN GH, 1977, FEBS LETT, V80, P413, DOI 10.1016/0014-5793(77)80488-2; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; Li Q, 1997, METHODS, V12, P96, DOI 10.1006/meth.1997.0451; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Lyngso C, 2000, J BIOL CHEM, V275, P26144, DOI 10.1074/jbc.M003405200; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nehls P, 1998, NUCLEIC ACIDS RES, V26, P1160, DOI 10.1093/nar/26.5.1160; Niessing D, 2000, MOL CELL, V5, P395, DOI 10.1016/S1097-2765(00)80434-7; PANYIM S, 1971, J BIOL CHEM, V246, P4206; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Remboutsika E, 1999, J CELL SCI, V112, P1671; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; WEISSHART K, 1994, J BIOL CHEM, V269, P22788; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zhao T, 2000, J BIOL CHEM, V275, P28332; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	48	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23653	23660		10.1074/jbc.M009891200	http://dx.doi.org/10.1074/jbc.M009891200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319220	hybrid			2022-12-25	WOS:000169531100058
J	Krupenko, SA; Vlasov, AP; Wagner, C				Krupenko, SA; Vlasov, AP; Wagner, C			On the role of conserved histidine 106 in 10-formyltetrahydrofolate dehydrogenase catalysis - Connection between hydrolase and dehydrogenase mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; DENOVO PURINE BIOSYNTHESIS; ESCHERICHIA-COLI; ACTIVE-SITE; ALDEHYDE DEHYDROGENASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; METHIONYL-TRNA(F)(MET) FORMYLTRANSFERASE; DIENELACTONE HYDROLASE; FLUORESCENCE METHODS	The enzyme, 10-formyltetrahydrofolate dehydrogenase (FDH), converts 10-formyltetrahydrofolate (10-formyl-THF) to tetrahydrofolate in an NADP(+)-dependent dehydrogenase reaction or an NADP(+)-independent hydrolase reaction. The hydrolase reaction occurs in a 310-amino acid long amino-terminal domain of FDH (N-t-FDH), whereas the dehydrogenase reaction requires the full-length enzyme. The amino-terminal, domain of FDH shares some sequence identity with several other enzymes utilizing 10-formyl-THF as a substrate. These enzymes have two strictly conserved residues, aspartate and histidine, in the putative catalytic center. We have shown recently that the conserved aspartate is involved in FDH catalysis, In the present work we studied the role of the conserved histidine, His(106), in FDH function. Site-directed mutagenesis experiments showed that replacement of the histidine with alanine, asparagine, aspartate, glutamate, glutamine, or arginine in N-t-FDH resulted in expression of insoluble proteins. Replacement of the histidine with another positively charged residue, lysine, produced a soluble mutant with no hydrolase activity, The insoluble mutants refolded from inclusion bodies adopted a conformation inherent to the wild-type N-t-FDH, but they did not exhibit any hydrolase activity, Substitution of alanine for three non-conserved histidines located close to the conserved one did not reveal any significant changes in the hydrolase activity of N-t-FDH, Expressed full-length FDH with the substitution of lysine for the His(106) completely lost both the hydrolase and dehydrogenase activities. Thus, our study showed that His(106), besides being an important structural residue, is also directly involved in both the hydrolase and dehydrogenase mechanisms of FDH. Modeling of the putative hydrolase catalytic center/folate-binding site suggested that the catalytic residues, aspartate and histidine, are unlikely to be adjacent to the catalytic cysteine in the aldehyde dehydrogenase catalytic center. We hypothesize that 10-formyl-TRF dehydrogenase reaction is not an independent reaction but is a combination of hydrolase and aldehyde dehydrogenase reactions.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Res Serv, Nashville, TN 37212 USA	Medical University of South Carolina; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.				NIDDK NIH HHS [DK15289, DK53488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015289, R37DK015289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BENKOVIC SJ, 1984, TRENDS BIOCHEM SCI, V9, P320, DOI 10.1016/0968-0004(84)90302-5; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; Blow DM, 1997, TRENDS BIOCHEM SCI, V22, P405, DOI 10.1016/S0968-0004(97)01115-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brayer GD, 2000, BIOCHEMISTRY-US, V39, P4778, DOI 10.1021/bi9921182; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEAH E, 1993, PROTEINS, V16, P64, DOI 10.1002/prot.340160108; CHEN P, 1992, J MOL BIOL, V227, P283, DOI 10.1016/0022-2836(92)90698-J; Cherbavaz DB, 2000, J MOL BIOL, V295, P377, DOI 10.1006/jmbi.1999.3195; CHOW SF, 1985, J BIOL CHEM, V260, P5516; Cobessi D, 2000, J MOL BIOL, V300, P141, DOI 10.1006/jmbi.2000.3824; COOK RJ, 1991, J BIOL CHEM, V266, P4965; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Eftink MR, 1997, METHOD ENZYMOL, V278, P258; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; Goldenberg David P., 1992, P353; Greasley SE, 1999, BIOCHEMISTRY-US, V38, P16783, DOI 10.1021/bi991888a; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P6678, DOI 10.1021/bi00480a018; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; Krokan HE, 1997, BIOCHEM J, V325, P1; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; KRUPENKO SA, 1995, J BIOL CHEM, V270, P519, DOI 10.1074/jbc.270.2.519; Krupenko SA, 1998, PROTEIN EXPRES PURIF, V14, P146, DOI 10.1006/prep.1998.0937; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; Krupenko SA, 1999, J BIOL CHEM, V274, P35777, DOI 10.1074/jbc.274.50.35777; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; NAGY PL, 1993, J BACTERIOL, V175, P7066, DOI 10.1128/jb.175.21.7066-7073.1993; NAGY PL, 1995, J BACTERIOL, V177, P1292, DOI 10.1128/jb.177.5.1292-1298.1995; Nixon AE, 1997, P NATL ACAD SCI USA, V94, P1069, DOI 10.1073/pnas.94.4.1069; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; Schultz LW, 1998, BIOCHEMISTRY-US, V37, P8886, DOI 10.1021/bi972766q; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Shim JH, 1998, BIOCHEMISTRY-US, V37, P8776, DOI 10.1021/bi980244k; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; SMITH JM, 1987, J BIOL CHEM, V262, P10565; STEBEN C, 1986, J BIOL CHEM, V261, P4629; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Su Y, 1998, J MOL BIOL, V281, P485, DOI 10.1006/jmbi.1998.1931; Wagner C, 1995, FOLATE HLTH DIS, P23; Wang S, 2000, BIOCHEMISTRY-US, V39, P1234, DOI 10.1021/bi991515+; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715; WHITEHEAD TR, 1988, J BACTERIOL, V170, P3255, DOI 10.1128/jb.170.7.3255-3261.1988; Yuan CH, 1999, BBA-MOL CELL BIOL L, V1441, P215, DOI 10.1016/S1388-1981(99)00156-0	74	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24030	24037		10.1074/jbc.M009257200	http://dx.doi.org/10.1074/jbc.M009257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320079	hybrid			2022-12-25	WOS:000169531100107
J	Suzuki, A; Hiraoka, N; Suzuki, M; Angata, K; Misra, AK; McAuliffe, J; Hindsgaul, O; Fukuda, M				Suzuki, A; Hiraoka, N; Suzuki, M; Angata, K; Misra, AK; McAuliffe, J; Hindsgaul, O; Fukuda, M			Molecular cloning and expression of a novel human beta-Gal-3-O-sulfotransferase that acts preferentially on N-acetyllactosamine in N- and O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CORE 2; LINKED OLIGOSACCHARIDES; CARBOHYDRATE UNITS; HNK-1 SULFOTRANSFERASE; MUTANT DEFICIENT; L-SELECTIN; SULFATE; GALACTOSE; RESIDUES	A novel cDNA-encoding galactose 3-O-sulfotransferase was cloned by screening the expressed sequence tag data base using the previously cloned cDNA encoding a galactosyl ceramide 3-O-sulfotransferase, which we term Gal3ST-1, The newly isolated cDNA encodes a novel 3-O-sulfotransferase, termed Ga13ST-3, that acts exclusively on N-acetyllactosamine present in N-glycans and core2-branched O-glycans, These conclusions were confirmed by analyzing CD43 chimeric proteins in Chinese hamster ovary cells expressing corea beta1,6-N-acetylglucosaminyl-transferase. The acceptor specificity of Ga13ST-3 contrasts with that of the recently cloned galactose 3-O-sulfotransferase (Honke, It, Tsuda, M, Koyota, S,, Wada, P,, Iida-Tanaka N., Ishizuka, I., Nakayama, J,, and Taniguchi, N. (2001) J, Biol Chem 276, 267-274), which we term Ga13ST-2 in the present study because the latter enzyme can also act on core1 O-glycan and type 1 oligosaccharides, Gal beta1 --> 3GlcNAc. Moreover, Ga13ST-3 but not Ga13ST-2 can act on Gal beta1 -->4(sulfo -->6)GlcNAc, indicating that disulfated sulfo --> 3Gal beta1 -->4(sulfo -->6) GlcNAc -->R may be formed by Gal3ST-3 in combination with GlcNAc 6-O-sulfotransferase. Although both Ga13ST-2 and Ga13ST-3 do not act on galactosyl ceramide, Ga13ST-3 is only moderately more homologous to Ga13ST-2 (40.1%) than to Gal3ST-1 (38.0%) at the amino acid level, Northern blot analysis demonstrated that transcripts for Ga13ST-3 are predominantly expressed in the brain, kidney, and thyroid where the presence of 3 ' -sulfation of N-acetyllactosamine has been reported. These results indicate that the newly cloned Ga13ST-3 plays a critical role in 3 ' -sulfation of N-acetyllactosamine in both O- and N-glycans.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham.org	Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [R01CA048737, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Ding YL, 1998, BIOORG MED CHEM LETT, V8, P1903, DOI 10.1016/S0960-894X(98)00332-1; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; Edge ASB, 1997, ARCH BIOCHEM BIOPHYS, V343, P73, DOI 10.1006/abbi.1997.0143; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; HIRAOKA N, 2001, IN PRESS GLYCOBIOLOG; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KATO Y, 1989, J BIOL CHEM, V264, P3364; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; Misra AK, 2000, BIOORG MED CHEM LETT, V10, P1505, DOI 10.1016/S0960-894X(00)00207-9; MISRA AK, 2001, IN PRESS BIOORG MED; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; Tsuboi S, 2000, ARCH BIOCHEM BIOPHYS, V374, P100, DOI 10.1006/abbi.1999.1614; Tsuiji H, 1998, BIOCHEM BIOPH RES CO, V253, P374, DOI 10.1006/bbrc.1998.9726; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Ujita M, 2000, J BIOL CHEM, V275, P15868, DOI 10.1074/jbc.M001034200; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; WAARD PD, 1991, J BIOL CHEM, V266, P4237; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	50	26	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24388	24395		10.1074/jbc.M103135200	http://dx.doi.org/10.1074/jbc.M103135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323440	hybrid			2022-12-25	WOS:000169531100153
J	Hagedoorn, PL; Schmidt, PP; Andersson, KK; Hagen, WR; Flatmark, T; Martinez, A				Hagedoorn, PL; Schmidt, PP; Andersson, KK; Hagen, WR; Flatmark, T; Martinez, A			The effect of substrate, dihydrobiopterin, and dopamine on the EPR spectroscopic properties and the midpoint potential of the catalytic iron in recombinant human phenylalanine hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID HYDROXYLASES; H-1-NMR PARAMAGNETIC RELAXATION; HUMAN TYROSINE-HYDROXYLASE; NITRIC-OXIDE SYNTHASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; KINETIC-PROPERTIES; ENZYMATIC-ACTIVITY	Phenylalanine hydroxylase (PAH) is a tetrahydrobiopterin (BH4) and non-heme iron-dependent enzyme that hydroxylates L-Phe to L-Tyr. The paramagnetic ferric iron at the active site of recombinant human PAH (hPAH) and its midpoint potential at pH 7.25 (E-m(Fe(III)/Fe(II))) were studied by EPR spectroscopy. Similar EPR spectra were obtained for the tetrameric wild-type (wt-hPAH) and the dimeric truncated hpAH(Gly(103)-Gln(428)) corresponding to the "catalytic domain." A rhombic high spin Fe(III) signal with a g value of 4.3 dominates the EPR spectra at 3.6 K of both enzyme forms. An E-m +207 +/- 10 mV was measured for the iron in wt-hPAH, which seems to be adequate for a thermodynamically feasible electron transfer from BH4 (E-m (quinonoid-BH2/BH4) = +174 mV). The broad EPR features from g = 9.7-4.3 in the spectra of the ligand-free enzyme de creased in intensity upon the addition of L-Phe, whereas more axial type signals were observed upon binding of 7,8-dihydrobiopterin (BH2), the stable oxidized form of BH2, and of dopamine. Ah three ligands induced a decrease in the E-m value of the iron to +123 +/- 4 mV (L-Phe), +110 +/- 20 mV (BH2), and -8 +/- 9 mV (dopamine). On the basis of these data we have calculated that the binding affinities of L-Phe, BH2, and dopamine decrease by 28-, 47-, and 5040-fold, respectively, for the reduced ferrous form of the enzyme, with respect to the ferric form. Interestingly, an E-m value comparable with that of the ligand-free, resting form of wt-hPAH, i.e. +191 +/- 11 mV, was measured upon the simultaneous binding of both L-Phe and BH2, representing an inactive model for the iron environment under turnover conditions. Our findings provide new information on the redox properties of the active site iron relevant for the understanding of the reductive activation of the enzyme and the catalytic mechanism.	Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway; Delft Univ Technol, Kluyver Dept Biotechnol, NL-2628 BC Delft, Netherlands; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway	University of Bergen; University of Oslo; Delft University of Technology; University of Oslo	Martinez, A (corresponding author), Univ Bergen, Dept Biochem & Mol Biol, Arstadveien 19, N-5009 Bergen, Norway.		Martinez, Aurora/M-3088-2019; Hagedoorn, Peter-Leon/C-8535-2014; Andersson, K Kristoffer/F-9624-2010	Martinez, Aurora/0000-0003-1643-6506; Hagedoorn, Peter-Leon/0000-0001-6342-2022; 				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ANDERSSON KK, 1989, FEBS LETT, V258, P9, DOI 10.1016/0014-5793(89)81603-5; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ARCHER MC, 1972, CAN J BIOCHEM CELL B, V50, P1174, DOI 10.1139/o72-160; ARCHER MC, 1970, CAN J BIOCHEM CELL B, V48, P526, DOI 10.1139/o70-086; BAILEY SW, 1983, BIOCHEMISTRY-US, V22, P1790, DOI 10.1021/bi00277a008; BLOOM LM, 1986, BIOCHEMISTRY-US, V25, P4204, DOI 10.1021/bi00363a006; BUBLITZ C, 1971, BIOCHEM PHARMACOL, V20, P2543, DOI 10.1016/0006-2952(71)90162-6; CITRON BA, 1992, PROTEIN EXPRES PURIF, V3, P93, DOI 10.1016/S1046-5928(05)80024-5; COX DD, 1988, J AM CHEM SOC, V110, P2026, DOI 10.1021/ja00215a002; DAVIS MD, 1989, J BIOL CHEM, V264, P8585; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; EHRENBER.A, 1970, EUR J BIOCHEM, V16, P584, DOI 10.1111/j.1432-1033.1970.tb01121.x; Ellis HR, 2000, BIOCHEMISTRY-US, V39, P4174, DOI 10.1021/bi9928546; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Erlandsen H, 1998, BIOCHEMISTRY-US, V37, P15638, DOI 10.1021/bi9815290; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Flatmark T, 1999, EUR J BIOCHEM, V262, P840, DOI 10.1046/j.1432-1327.1999.00445.x; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; Francisco WA, 1998, J AM CHEM SOC, V120, P4057, DOI 10.1021/ja973543q; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; Goodwill KE, 1998, BIOCHEMISTRY-US, V37, P13437, DOI 10.1021/bi981462g; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; HAAVIK J, 1990, FEBS LETT, V262, P363, DOI 10.1016/0014-5793(90)80230-G; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1986, EUR J BIOCHEM, V160, P1, DOI 10.1111/j.1432-1033.1986.tb09932.x; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Kappock TJ, 1995, J BIOL CHEM, V270, P30532, DOI 10.1074/jbc.270.51.30532; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; Kemsley JN, 1999, J AM CHEM SOC, V121, P1528, DOI 10.1021/ja9833063; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Kumer SC, 1996, J NEUROCHEM, V67, P443; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MARTINEZ A, 1991, EUR J BIOCHEM, V198, P675, DOI 10.1111/j.1432-1033.1991.tb16066.x; MARTINEZ A, 1990, EUR J BIOCHEM, V193, P211, DOI 10.1111/j.1432-1033.1990.tb19325.x; MARTINEZ A, 1993, EUR J BIOCHEM, V211, P259, DOI 10.1111/j.1432-1033.1993.tb19894.x; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; MICHAUDSORET I, 1995, BIOCHEMISTRY-US, V34, P5504, DOI 10.1021/bi00016a022; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Olafsdottir S, 1999, J BIOL CHEM, V274, P6280, DOI 10.1074/jbc.274.10.6280; PARNIAK MA, 1981, J BIOL CHEM, V256, P6876; PHILLIPS RS, 1984, J BIOL CHEM, V259, P271; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Que L, 2000, NAT STRUCT BIOL, V7, P182, DOI 10.1038/73270; Ramsey AJ, 1998, BIOCHEMISTRY-US, V37, P8980, DOI 10.1021/bi980582l; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; SHIMAN R, 1994, J BIOL CHEM, V269, P24647; SHIMAN R, 1994, J BIOL CHEM, V269, P24637; Teigen K, 1999, J MOL BIOL, V294, P807, DOI 10.1006/jmbi.1999.3288; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043	57	24	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22850	22856		10.1074/jbc.M009458200	http://dx.doi.org/10.1074/jbc.M009458200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301319	hybrid			2022-12-25	WOS:000169412700116
J	Kawabe, Y; Branzei, D; Hayashi, T; Suzuki, H; Masuko, T; Onoda, F; Heo, SJ; Ikeda, H; Shimamoto, A; Furuichi, Y; Seki, M; Enomoto, T				Kawabe, Y; Branzei, D; Hayashi, T; Suzuki, H; Masuko, T; Onoda, F; Heo, SJ; Ikeda, H; Shimamoto, A; Furuichi, Y; Seki, M; Enomoto, T			A novel protein interacts with the Werner's syndrome gene product physically and functionally	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOMS-SYNDROME GENE; DNA HELICASE; SACCHAROMYCES-CEREVISIAE; SYNDROME CELLS; RECQ FAMILY; SGS1; YEAST; MUTATIONS; HOMOLOG; CLONING	Werner's syndrome (WS) is a rare autosomal recessive disorder characterized by premature aging. The gene responsible for WS encodes a protein homologous to Escherichia coli RecQ. Here we describe a novel Werner helicase interacting protein (WHIP), which interacts with the N-terminal portion of Werner protein (WRN), containing the exonuclease domain. WHIP, which shows homology to replication factor C family proteins, is conserved from E. coli to human. Ectopically expressed WHIP and WRN co-localized in granular structures in the nucleus. The functional relationship between WHIP and WRN was indicated by genetic analysis of yeast cells. Disruptants of the SGS1 gene of Saccharomyces cerevisiae, which is the WRN homologue in yeast, show an accelerated aging phenotype and high sensitivity to methyl methanesulfonate as compared with wild-type cells. Disruption of the yeast WHIP (yWHIP) gene in wild-type cells and sgs1 disruptants resulted in slightly accelerated aging and enhancement of the premature aging phenotype of sgs1 disruptants, respectively. In contrast, disruption of the yWHIP gene partially alleviated the sensitivity to methyl methanesulfonate of sgs1 disruptants.	Tohoku Univ, Grad Sch Pharmaceut Sci, Mol Cell Biol Lab, Aoba Ku, Sendai, Miyagi 9808578, Japan; AGENE Res Inst, Kamakura, Kanagawa 2470063, Japan; Kitasato Inst, Ctr Basic Res, Minato Ku, Tokyo 1088642, Japan	Tohoku University	Enomoto, T (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Mol Cell Biol Lab, Aoba Ku, Sendai, Miyagi 9808578, Japan.		Branzei, Dana/GOG-9093-2022; Branzei, Dana/A-2806-2015	Branzei, Dana/0000-0002-0544-4888; Branzei, Dana/0000-0002-0544-4888				Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Cooper MP, 2000, GENE DEV, V14, P907; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Frei C, 2000, GENE DEV, V14, P81; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; Goto M, 1997, HUM GENET, V99, P191, DOI 10.1007/s004390050336; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HISHIDA T, 2001, IN PRESS P NATL ACAD; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kusano K, 1999, GENETICS, V151, P1027; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; MARTIN GM, 1977, AM J PATHOL, V89, P484; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Miyajima A, 2000, MOL CELL BIOL, V20, P6399, DOI 10.1128/MCB.20.17.6399-6409.2000; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; ONODA S, 2000, MUTAT RES, V459, P203; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Schulz VP, 1996, HUM GENET, V97, P750; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P466; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	47	50	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20364	20369		10.1074/jbc.C100035200	http://dx.doi.org/10.1074/jbc.C100035200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11301316	hybrid			2022-12-25	WOS:000169135100094
J	Ishii, T; Kwon, H; Hiscott, J; Mosialos, G; Koromilas, AE				Ishii, T; Kwon, H; Hiscott, J; Mosialos, G; Koromilas, AE			Activation of the I kappa B alpha kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR	ONCOGENE			English	Article						cytokines; double-stranded RNA; protein phosphorylation; NF-kappa B; DNA-binding; transcription	EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; TUMOR-SUPPRESSOR P53; RIBOSOMAL S6 KINASE; MALIGNANT TRANSFORMATION; VIRAL-INFECTION; HA-RAS; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; APOPTOSIS	The interferon (IFN)-inducible double stranded (ds) RNA-activated protein kinase PKR plays an important role in protein synthesis by modulating the phosphorylation of the alpha -subunit of eukaryotic initiation fact 2 (eIF-2 alpha), In addition to translational control, PKR has been implicated in several signaling pathways leading to gene transcription. For example, PKR induces I kappaB alpha kinase (IKK) activity and I kappaB alpha phosphorylation leading to the induction of NF-kappaB-mediated gene transcription. Recent findings suggested that NF-kappaB activation by PKR does not require the catalytic activity of the kinase, Here, we provide novel evidence that induction of IKK and NF-kappaB activities proceeds independently of the dsRNA-binding properties of PKR and also verify the kinase-free role of PKR in this process. We also show that the effects of PKR mutants on IKK and NF-kappaB activation are independent of cell transformation but are dependent on the amount of the mutant PKR proteins expressed in cells. These data strongly support an indirect role of PKR in I kappaB alpha phosphorylation by modulating IKK activity through pathways that do not utilize the enzymatic and dsRNA-binding properties of PKR.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Cell Biol & Anat, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Fleming Biores Ctr, Athens, Greece	McGill University; McGill University; McGill University; McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.				NATIONAL CANCER INSTITUTE [R29CA071705] Funding Source: NIH RePORTER; NCI NIH HHS [CA71705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Campbell IK, 2000, J CLIN INVEST, V105, P1799, DOI 10.1172/JCI8298; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CLEMENS JM, 1977, J INTERFER CYTO RES, V17, P503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee R, 1997, VIROLOGY, V234, P277, DOI 10.1006/viro.1997.8642; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Nagai K, 1997, J VIROL, V71, P1718, DOI 10.1128/JVI.71.2.1718-1725.1997; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; WONG AHT, 2001, IN PRESS J BIOL CHEM; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	62	52	54	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1900	1912		10.1038/sj.onc.1204267	http://dx.doi.org/10.1038/sj.onc.1204267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313938				2022-12-25	WOS:000167908400011
J	Alberghina, L; Porro, D; Cazzador, L				Alberghina, L; Porro, D; Cazzador, L			Towards a blueprint of the cell cycle	ONCOGENE			English	Article						cell cycle; CDK; CKI; cyclin; budding yeast; cancer	YEAST SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; G1 CYCLINS; FLOW-CYTOMETRY; G2 CYCLINS; GROWTH; G(1); PROGRESSION; PATHWAY; PHASE	The understanding of the organisation of cell cycle events is of utmost importance. to devise effective therapeutic strategies for cancer, In this article we gather evidences from the literature in support of a system model of the cell cycle, in which a growth-sensitive threshold controls entry into S phase and the sequential activation of cyclin-dependent kinases, The cycle is terminated by an End function, that comprises events from the onset of mitosis to cell division and that may also be modulated by the increase of cell size, This blueprint allows quantitative predictions by computer simulations of steady and transitory states. In fact, we show that the proposed control system applies to budding yeast populations during nutritional shift-up and following hyperactivation of the cAMP signalling pathway, Besides the growth-sensitive control system it is shown to apply to mammalian cells both in the exit from quiescence and in active proliferation, The putative molecular determinants that set the threshold controlling S phase entry are consistently altered in cancer cells, Finally, we discuss an input/output analysis based on the simulated behaviour derived from the blueprint as a new tool to investigate the road to cancer.	Univ Milan, Biocca, Dept Biosci & Biotechnol, I-20126 Milan, Italy; Natl Res Council, Inst Syst Sci & Biomed Engn, I-35127 Padua, Italy	University of Milan	Alberghina, L (corresponding author), Univ Milan, Biocca, Dept Biosci & Biotechnol, Pzza Sci 2, I-20126 Milan, Italy.			Alberghina, Lilia/0000-0003-1694-931X; PORRO, DANILO/0000-0001-5723-3700				Alberghina L, 1998, J BACTERIOL, V180, P3864, DOI 10.1128/JB.180.15.3864-3872.1998; ALBERGHINA L, 1977, J THEOR BIOL, V69, P633, DOI 10.1016/0022-5193(77)90372-1; ALBERGHINA L, 1983, BIOSYSTEMS, V16, P297, DOI 10.1016/0303-2647(83)90012-6; ALBERGHINA L, 1993, YEAST, V9, P815, DOI 10.1002/yea.320090802; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Anghileri P, 1999, EXP CELL RES, V250, P510, DOI 10.1006/excr.1999.4531; BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; Baserga R., 1976, MULTIPLICATION DIVIS; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; COOPER S, 1979, NATURE, V280, P17, DOI 10.1038/280017a0; Futcher B, 1996, YEAST, V12, P1635; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUTCHISON C, 1995, CELL CYCLE CONTROL; Jeoung DI, 1998, MOL CELL BIOL, V18, P433, DOI 10.1128/MCB.18.1.433; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; MARIANI L, 1986, IEE PROC-D, V133, P210, DOI 10.1049/ip-d.1986.0035; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OConnor PM, 1997, CANCER SURV, V29, P151; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Palsson BO, 1997, NAT BIOTECHNOL, V15, P3, DOI 10.1038/nbt0197-3; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOMPAYRAC L, 1973, NATURE-NEW BIOL, V241, P133, DOI 10.1038/newbio241133a0; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; Tanaka S, 1996, GENES CELLS, V1, P905, DOI 10.1046/j.1365-2443.1996.d01-213.x; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYSON CB, 1979, J BACTERIOL, V138, P92, DOI 10.1128/JB.138.1.92-98.1979; VANONI M, 1983, J BACTERIOL, V156, P1282, DOI 10.1128/JB.156.3.1282-1291.1983; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZETTERBERG A, 1995, CELL CYCLE CONTROL	44	22	22	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1128	1134		10.1038/sj.onc.1204263	http://dx.doi.org/10.1038/sj.onc.1204263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314050				2022-12-25	WOS:000167232100013
J	Vivo, C; Levy, F; Pilatte, Y; Fleury-Feith, J; Chretien, P; Monnet, I; Kheuang, L; Jaurand, MC				Vivo, C; Levy, F; Pilatte, Y; Fleury-Feith, J; Chretien, P; Monnet, I; Kheuang, L; Jaurand, MC			Control of cell cycle progression in human mesothelioma cells treated with gamma interferon	ONCOGENE			English	Article						human mesothelioma cell lines; cell cycle control; cyclin dependent kinase inhibitors; cyclin; r-hu-IFN gamma	MAMMARY EPITHELIAL-CELLS; KINASE INHIBITOR P21; DEPENDENT KINASE; GROWTH ARREST; INDOLEAMINE 2,3-DIOXYGENASE; GENE-EXPRESSION; DNA-DAMAGE; ALPHA; INTERLEUKIN-6; TRANSCRIPTION	Recombinant human interferon gamma (r-hu-IFN gamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFN gamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFN gamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFN gamma. Except in the resistant cell line r-hu-IFN gamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a GZ-arrest in r-hu-IFN gamma -treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFN gamma seems to depend on cyclin regulation through p21(WAF1/C1P1)- and p27(KiP1)-independent mechanisms and is not directly related to the induced DNA damage.	Univ Paris 12, INSERM U99 09, EA 2345, F-94010 Creteil, France; Hop Tenon, Serv Histol & Biol Tumorale, F-75020 Paris, France; Ctr Hosp Intercommunal, Serv Immunohematol, F-94010 Creteil, France; Ctr Hosp Intercommunal, Serv Pneumol, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil	Jaurand, MC (corresponding author), Univ Paris 12, INSERM U99 09, EA 2345, 8 Rue Gen Sarrail, F-94010 Creteil, France.		JAURAND, MARIE-CLAUDE/S-3538-2017; Pilatte, Yannick/AAD-1943-2019; Pilatte, Yannick/N-4422-2018	JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; 				Astoul P, 1998, CANCER, V83, P2099, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; BIELEFELDTOHMANN H, 1995, CANCER IMMUNOL IMMUN, V40, P241, DOI 10.1007/s002620050169; BIELEFELDTOHMANN H, 1995, J INTERF CYTOK RES, V15, P213, DOI 10.1089/jir.1995.15.213; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOUTIN C, 1994, CANCER, V74, P2460, DOI 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N; BOWMAN RV, 1991, CANCER CHEMOTH PHARM, V28, P420, DOI 10.1007/BF00685817; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Buard A, 1998, CANCER RES, V58, P840; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHRISTMAS TI, 1993, J INTERFERON RES, V13, P9, DOI 10.1089/jir.1993.13.9; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FITZPATRICK DR, 1995, AM J RESP CELL MOL, V12, P455, DOI 10.1165/ajrcmb.12.5.7742009; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Grander D, 1997, EUR J HAEMATOL, V59, P129; Grousson J, 2000, J INVEST DERMATOL, V114, P581, DOI 10.1046/j.1523-1747.2000.00905.x; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; HERZINGER T, 1995, ONCOGENE, V11, P2151; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Jaiswal M, 2000, CANCER RES, V60, P184; JAURAND MC, 1986, MUTAT RES, V169, P141, DOI 10.1016/0165-1218(86)90093-5; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; KOSAKA C, 1992, ATHEROSCLEROSIS, V97, P75, DOI 10.1016/0021-9150(92)90053-J; Lazutka JR, 1996, MUTAT RES-ENVIR MUTA, V361, P95, DOI 10.1016/S0165-1161(96)00027-1; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MARTIN DM, 1993, J NEUROSCI RES, V34, P489, DOI 10.1002/jnr.490340502; MONTI G, 1994, CANCER RES, V54, P4419; Moro A, 1998, BIOCHEM BIOPH RES CO, V245, P752, DOI 10.1006/bbrc.1998.8512; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105; PhanBich L, 1997, AM J RESP CELL MOL, V16, P178, DOI 10.1165/ajrcmb.16.2.9032125; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; Ungar S, 1996, BRIT J CANCER, V74, P1534, DOI 10.1038/bjc.1996.585; Urashima M, 1997, BLOOD, V90, P279; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; XU JH, 1995, BLOOD, V86, P2774; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; ZENG L, 1993, INT J CANCER, V55, P515, DOI 10.1002/ijc.2910550331	52	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1085	1093		10.1038/sj.onc.1204199	http://dx.doi.org/10.1038/sj.onc.1204199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314045				2022-12-25	WOS:000167232100008
J	Kataoka, H; Miura, Y; Joh, T; Seno, K; Tada, T; Tamaoki, T; Nakabayashi, H; Kawaguchi, M; Asai, K; Kato, T; Itoh, M				Kataoka, H; Miura, Y; Joh, T; Seno, K; Tada, T; Tamaoki, T; Nakabayashi, H; Kawaguchi, M; Asai, K; Kato, T; Itoh, M			Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1	ONCOGENE			English	Article						AFP (Alpha-fetoprotein); AFP-GC (AFP producing gastric cancer); ATBF1 (AT motif binding factor 1); HNF1 (hepatocyte nuclear factor 1)	CELL-LINES; GASTROINTESTINAL-TRACT; CLINICOPATHOLOGICAL FEATURES; CARCINOMA; EXPRESSION; ESTABLISHMENT; PROTEIN; LIVER; GENE; DIFFERENTIATION	Alpha-fetoprotein (AFP) producing gastric cancer (AFP-GC) is very malignant and highly metastatic compared with common gastric cancer. However, the causal relationship between AFP production and the high malignancy of AFP-GC is unclear. We investigated AFP gene regulation in AFP-GC by an active transcription factor, HNF1 (hapatocyte nuclear factor 1) and a repressive transcription factor, ATBF1 (AT motif binding factor 1), RNase protection assays revealed that the production of AFP in gastric cancer cells did not directly associate with HNF1 expression. An inverse relation between the expressions of ATBF1 and AFP was clearly observed in gastric cancer cells. CAT assays showed the direct inhibition of AFP gene expression by ATBF1, Methylation analysis of the AFP promoter region in gastric cancer cells suggested that methylation itself could not explain the silencing of the AFP gene. Immunohistochemistry of resected clinical samples revealed that AFP producing cells lacked ATBF1 immunoreactivity, Our data suggests that the absence of ATBF1 is responsible for AFP gene expression in gastric cancer, and the absence of ATBF1 is a distinct characteristic of AFP-GC and might be important for its highly malignant nature.	Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuhi Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Nursing, Dept Pathol, Mizuhi Ku, Nagoya, Aichi 4678601, Japan; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Hokkaido Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 060, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Pathol, Toyama 9300194, Japan	Nagoya City University; Nagoya City University; Nagoya City University; University of Calgary; Hokkaido University; University of Toyama	Miura, Y (corresponding author), Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuhi Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.		Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251				BOURREILLE J, 1970, PRESSE MED, V78, P1277; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHANG YC, 1992, AM J GASTROENTEROL, V87, P321; CHANG YC, 1990, AM J GASTROENTEROL, V85, P1480; Chen HM, 1997, CRIT REV EUKAR GENE, V7, P11, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.20; DIGIOVANNI J, 1984, CANCER RES, V44, P2878; FUJIWARA T, 1993, INT J CANCER, V54, P965, DOI 10.1002/ijc.2910540617; GITLIN D, 1972, CANCER RES, V32, P979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; Ido A, 1996, GENE, V168, P227, DOI 10.1016/0378-1119(95)00740-7; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; KOYAMA K, 1990, JPN J CANCER RES, V81, P967, DOI 10.1111/j.1349-7006.1990.tb03332.x; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MCINTIRE KR, 1975, CANCER RES, V35, P991; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NAKATA K, 1992, J BIOL CHEM, V267, P1331; PENG SY, 1993, HEPATOLOGY, V17, P35, DOI 10.1016/0270-9139(93)90188-S; Ramsay RG, 2000, CANCER RES, V60, P1805; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; TAKETA K, 1990, GASTROENTEROLOGY, V99, P508, DOI 10.1016/0016-5085(90)91034-4; TERASHIMA M, 1991, JPN J CANCER RES, V82, P883, DOI 10.1111/j.1349-7006.1991.tb01915.x; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395	26	54	59	1	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					869	873		10.1038/sj.onc.1204160	http://dx.doi.org/10.1038/sj.onc.1204160			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314020				2022-12-25	WOS:000166924400010
J	Adamsky, K; Schilling, J; Garwood, J; Faissner, A; Peles, E				Adamsky, K; Schilling, J; Garwood, J; Faissner, A; Peles, E			Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTP beta) to tenascin C	ONCOGENE			English	Article						tyrosine phosphatase; extracellular matrix; cell adhesion molecule	CHONDROITIN SULFATE PROTEOGLYCAN; GROWTH-ASSOCIATED MOLECULE; HIGH-AFFINITY LIGAND; NERVOUS-SYSTEM; HOMOPHILIC BINDING; NEURITE OUTGROWTH; FOCAL ADHESIONS; PTP-MU; ZETA/BETA; EXPRESSION	The extracellular domain of receptor protein tyrosine phosphatase beta (RPTP beta) is composed of several domains which mediate its interactions with distinct ligands present on the surface of either neurons or glial cells. Here, we demonstrate that the fibronectin type III domain (FNIII) of RPTP beta binds to glial tumor-derived cell lines and primary astrocytes, We used affinity purification to isolate several proteins that specifically bind to the FNIII domain of RPTP beta. One of these, a 240 kDa protein that was purified from U118MG glioblastoma cell, was identified as tenascin C based on the amino acid sequence of several tryptic peptides. The interaction of RPTP beta with tenascin C was found to mediate cell adhesion. Adhesion and spreading of SF763T astrocytoma cells expressing RPTP beta on tenascin C,was specifically abolished by the addition of a soluble fragment containing the FNIII domain of the receptor, RPTP beta -dependent cell adhesion was mediated by binding to the alternatively spliced FNIII repeats A1,2,4 (TnfnA1,2,4) of tenascin C, Furthermore, COS cells expressing RPTP beta adhere to TnfnA1,2,4, while the parental cells did not. These results demonstrate that the FNIII domain of RPTP beta binds to tenascin C and suggest that RPTP beta present on glial tumor cells is a primary adhesion receptor system to the extracellular matrix.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ctr Neurochim, Unite CNRS UPR 1352, F-67084 Strasbourg, France; Sugen Inc, S San Francisco, CA 94080 USA	Weizmann Institute of Science; Pfizer	Peles, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259; Peles, Elior/0000-0002-3325-0597				Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Canoll PD, 1996, J NEUROSCI RES, V44, P199, DOI 10.1002/(SICI)1097-4547(19960501)44:3<199::AID-JNR1>3.0.CO;2-B; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; FAISSNER A, 1997, CELL TISSUE RES, V290, P385; Fashena SJ, 1997, MOL CELL BIOL, V17, P6859, DOI 10.1128/MCB.17.12.6859; Garwood J, 1999, J NEUROSCI, V19, P3888; Giese A, 1996, J CELL SCI, V109, P2161; Goldmann T, 2000, FOLIA HISTOCHEM CYTO, V38, P19; GRUMET M, 1994, J BIOL CHEM, V269, P12142; JONES FS, 2000, AM J RESP CRIT CARE, V161, P2086; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PHILLIPS GR, 1998, MOL BIOL CELL, V9, P1425; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; SAP J, 1994, MOL CELL BIOL, V14, P1; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Scholze A, 1996, INT J DEV NEUROSCI, V14, P315, DOI 10.1016/0736-5748(96)00016-0; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shenoi H, 1999, J IMMUNOL, V162, P7120; Snyder SE, 1996, MOL BRAIN RES, V40, P79; Stoker A, 1998, BIOESSAYS, V20, P463, DOI 10.1002/(SICI)1521-1878(199806)20:6<463::AID-BIES4>3.0.CO;2-N; Walzel H, 1999, IMMUNOL LETT, V67, P193, DOI 10.1016/S0165-2478(99)00012-7; Wang J, 1999, MOL CELL NEUROSCI, V14, P370, DOI 10.1006/mcne.1999.0789; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092; YOKOSAKI Y, 1998, J CELL SCI, V111, P1095; ZAGZAG D, 1995, CANCER RES, V55, P907; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203; Zondag GCM, 1997, BIOCHIMIE, V79, P477, DOI 10.1016/S0300-9084(97)82739-3	57	40	44	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					609	618		10.1038/sj.onc.1204119	http://dx.doi.org/10.1038/sj.onc.1204119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313993				2022-12-25	WOS:000166755000008
J	Poon, R; Smits, R; Li, C; Jagmohan-Changur, S; Kong, M; Cheon, S; Yu, CY; Fodde, R; Alman, BA				Poon, R; Smits, R; Li, C; Jagmohan-Changur, S; Kong, M; Cheon, S; Yu, CY; Fodde, R; Alman, BA			Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)	ONCOGENE			English	Article						aggressive fibromatosis; adenomatous polyposis coli; cyclooxygenase; beta-catenin; non-steroidal anti-inflammatory drugs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; ANTI-INFLAMMATORY DRUGS; COLON-CANCER CELLS; BETA-CATENIN; COLORECTAL-CANCER; CARCINOMA CELLS; GENE MUTATION; GROWTH-FACTOR; MOUSE MODEL	Aggressive fibromatosis is a locally invasive soft tissue lesion. Seventy-five per cent of cases harbor a somatic mutation in either the APC or beta -catenin genes, resulting in beta -catenin protein stabilization, Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin synthesis that modulates the formation of colonic neoplasia, especially in cases due to mutations resulting in beta -catenin stabilization, Human aggressive fibromatoses and lesions from the Apc+/Apc1638N mouse (a murine model for Ape-driven fibromatosis) demonstrated elevated COX-2 levels. COX-2 blockade either by the selective agent DFU or by non-selective COX blocking agents results in reduced proliferation in human tumor cell cultures. Breeding mice with Cox-2-/- mice resulted in no difference in number of aggressive fibromatoses formed, but in a smaller tumor size, while there was a decrease in number of GI lesions by 50%. Mice fed various COX blocking agents also showed a decline in tumor size. COX-2 expression was regulated by tcf-dependent transcription in this lesion, COX-2 partially regulates proliferation due to beta -catenin stabilization in aggressive fibromatosis, Although COX blockade alone does not cause tumor regression, this data suggests that it may have a role as an adjuvant therapy to slow tumor growth in this lesion.	Hosp Sick Children, Program Dev Biol, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Alman, BA (corresponding author), Hosp Sick Children, Program Dev Biol, Div Orthopaed Surg, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324				ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Alman BA, 1996, J ORTHOP RES, V14, P722, DOI 10.1002/jor.1100140507; ALMAN BA, 1992, J PEDIATR ORTHOPED, V12, P1; ALMAN BA, 1995, J ORTHOP RES, V13, P67, DOI 10.1002/jor.1100130111; BELIVEAU P, 1984, COLON RECTUM, V27, P53; Black SC, 1998, J CARDIOVASC PHARM, V32, P686, DOI 10.1097/00005344-199811000-00002; Castano E, 2000, J PHARMACOL EXP THER, V293, P509; Chan CC, 1997, EUR J PHARMACOL, V327, P221, DOI 10.1016/S0014-2999(97)89664-1; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, CANCER RES, V56, P733; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Giardiello FM, 1997, GUT, V40, P521, DOI 10.1136/gut.40.4.521; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HIAL V, 1977, J PHARMACOL EXP THER, V202, P446; Hsi LC, 1999, CARCINOGENESIS, V20, P2045, DOI 10.1093/carcin/20.11.2045; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KIRSCH WM, 1991, AM J SURG, V161, P416; Lackner H, 1997, CANCER, V80, P334, DOI 10.1002/(SICI)1097-0142(19970715)80:2<334::AID-CNCR22>3.0.CO;2-U; LATTES R, 1980, TUMORS SOFT TISSUES, P1; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Mei JM, 1999, CARCINOGENESIS, V20, P737, DOI 10.1093/carcin/20.4.737; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NGUYEN KD, 1993, EXP EYE RES, V57, P97, DOI 10.1006/exer.1993.1103; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; POSNER MC, 1989, ARCH SURG-CHICAGO, V124, P191; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Sparks AB, 1998, CANCER RES, V58, P1130; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; WADDELL WR, 1983, J SURG ONCOL, V22, P197, DOI 10.1002/jso.2930220314; Watson AJM, 1998, HISTOL HISTOPATHOL, V13, P591, DOI 10.14670/HH-13.591; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wolf Leslie A., 1999, Cell Biochemistry and Biophysics, V30, P353, DOI 10.1007/BF02738119; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	51	74	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					451	460		10.1038/sj.onc.1204107	http://dx.doi.org/10.1038/sj.onc.1204107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313976				2022-12-25	WOS:000166562500005
J	Luo, JL; Yang, Q; Tong, WM; Hergenhahn, M; Wang, ZQ; Hollstein, M				Luo, JL; Yang, Q; Tong, WM; Hergenhahn, M; Wang, ZQ; Hollstein, M			Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool	ONCOGENE			English	Article						p53 mouse model; gene targeting; mutagenesis	TUMOR-SUPPRESSOR GENE; MUTATIONS; RECOMBINATION; APOPTOSIS; THERAPY; PATHWAY; PROTEIN	The high prevalence and great diversity of p53 tumor suppressor gene mutations in human tumors call for development of therapeutic molecules that rescue function of aberrant p53 protein. P53 mutations also offer new approaches to the study of the origins of mutations in human cancer. An experimental mouse model with a genetically modified but normal functioning p53 gene harboring the human rather than the murine core domain, would be of considerable benefit to research on both cancer therapeutics and etiology; however, it is uncertain whether such mice would permit biological functions of p53 to be retained. Using a Cre/lox P gene-targeting approach, we have constructed a human p53 knock-in (hupki) mouse strain in which exons 4-9 of the endogenous mouse p53 allele were replaced with the homologous, normal human p53 gene sequence, The chimeric p53 allele (p53(KI)) is properly spliced, transcribed in various tissues at levels equivalent to wild-type mice, and yields cDNA with the anticipated sequence, that is, with a core domain matching that of humans. The hupki p53 protein binds to p53 consensus sequences in gel mobility shift assays and accumulates in the nucleus of hupki fibroblasts in response to UV irradiation, as is characteristic of wild-type p53, Induction of various p53-regulated genes in spleen of gamma -irradiated homozygous hupki mice (p53(KI/KI)), and the kinetics of p53-dependent apoptosis in thymocytes are similar to results with wild-type (p53(+/+)) mice, further indicating normal p53 pathway function in the hupki strain, The mice are phenotypically normal and do not develop spontaneous tumors at an early age, in contrast to knock-out (p53(-/-)) strains with a defective p53 gene. The chimeric (p53(KI)) allele thus appears to provide a biological equivalent to the endogenous murine (p53(+)) gene. This strain is a unique tool for examining in vivo spontaneous and induced mutations in human p53 gene sequences for comparison with published human tumor p53 mutation spectra, In addition, the hupki strain paves the way for mouse models in pre-clinical testing of pharmaceuticals designed to modulate DNA-binding activity of human p53.	Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Genet Alterat Carcinogenesis C0700, D-69120 Heidelberg, Germany; Int Agcy Res Canc, Unit Gene Environm Interact, F-69008 Lyon, France	Helmholtz Association; German Cancer Research Center (DKFZ); World Health Organization; International Agency for Research on Cancer (IARC)	Hollstein, M (corresponding author), Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Genet Alterat Carcinogenesis C0700, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.				NCI NIH HHS [R01CA79493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BAKER SJ, 1990, CANCER RES, V50, P7717; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hollstein M, 1998, MUTAT RES-FUND MOL M, V405, P145, DOI 10.1016/S0027-5107(98)00131-6; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HURSTING SD, 1995, CANCER RES, V55, P3949; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kleihues P, 1997, AM J PATHOL, V150, P1; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lane DP, 1996, ONCOGENE, V12, P2461; Lane DP, 1999, BRIT J CANCER, V80, P1; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shamsher M, 1996, GENE, V176, P259, DOI 10.1016/0378-1119(96)00000-5; USHIJIMA T, 1995, MOL CARCINOGEN, V12, P23, DOI 10.1002/mc.2940120105; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhao RB, 2000, GENE DEV, V14, P981	38	116	124	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					320	328		10.1038/sj.onc.1204080	http://dx.doi.org/10.1038/sj.onc.1204080			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313961				2022-12-25	WOS:000166411000006
J	Kang, KH; Lee, KH; Kim, MY; Choi, KH				Kang, KH; Lee, KH; Kim, MY; Choi, KH			Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; PROTEASOME PATHWAY; ALPHA PROTEOLYSIS; HEPATOMA-CELLS; INHIBITION; ACTIVATION; PHOSPHORYLATION; DEGRADATION; TNF	The transcription factor nuclear factor KB (NF-KB) plays a crucial role in immune and inflammatory response, and protects cells from apoptosis, In this report, we investigate whether the NF-KB signaling pathway is blocked during apoptosis induced by 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone (NA), an analog of naphthoquinone, It is observed that NA triggers apoptotic cell death in HeLa cells and destroys resistance to apoptosis caused by tumor necrosis factor-alpha. Bata presented in this study establish that p65/Re1A, a subunit of NF-KB, is cleaved at Asp(97) by caspase-3 during apoptosis, Caspase-3-cleaved p65 loses transcriptional activity and potentiates NA-induced apoptosis, in contrast to an uncleavable mutant of p65, which protects the cell from apoptosis, Caspase-3, which is responsible for the cleavage of p65, is activated via the cytochrome c/caspase-9 signaling pathway rather than Fas/caspase-8 pathway during NA-induced apoptosis, Our results suggest that NA induces apoptosis by the negative regulation of cell survival through caspase-3-mediated cleavage of p65.	Chung Ang Univ, Coll Nat Sci, Dept Biol, Dongjak Ku, Seoul 156756, South Korea; Chung Ang Univ, Coll Pharm, Div Biochem, Seoul 156756, South Korea	Chung Ang University; Chung Ang University	Choi, KH (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Biol, Dongjak Ku, Seoul 156756, South Korea.							Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Ham SW, 1998, BIOORG MED CHEM LETT, V8, P2507, DOI 10.1016/S0960-894X(98)00411-9; Jeong SY, 1999, J BIOL CHEM, V274, P18981, DOI 10.1074/jbc.274.27.18981; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIKAWA Y, 1995, J BIOL CHEM, V270, P28304, DOI 10.1074/jbc.270.47.28304; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PERERA CS, 1995, ARCH BIOCHEM BIOPHYS, V323, P471, DOI 10.1006/abbi.1995.0069; Ravi R, 1998, CANCER RES, V58, P882; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	32	70	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24638	24644		10.1074/jbc.M101291200	http://dx.doi.org/10.1074/jbc.M101291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320092	hybrid			2022-12-25	WOS:000169800700031
J	Levi, S; Corsi, B; Bosisio, M; Invernizzi, R; Volz, A; Sanford, D; Arosio, P; Drysdale, J				Levi, S; Corsi, B; Bosisio, M; Invernizzi, R; Volz, A; Sanford, D; Arosio, P; Drysdale, J			A human mitochondrial ferritin encoded by an intronless gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-FERRITIN; OXIDATIVE STRESS; IRON-METABOLISM; MESSENGER-RNA; L CHAINS; CELLS; OVEREXPRESSION; IDENTIFICATION; EVOLUTION	Ferritin is a ubiquitous protein that plays a critical role in regulating intracellular iron homoeostasis by storing iron inside its multimeric shell. It also plays an important role in detoxifying potentially harmful free ferrous iron to the less soluble ferric iron by virtue of the ferroxidase activity of the H subunit. Although excess iron is stored primarily in cytoplasm, most of the metabolically active iron in cells is processed in mitochondria. Little is yet known of how these organelles regulate iron homeostasis and toxicity. Here we report an unusual intronless gene on chromosome 5q23.1 that encodes a 242-amino acid precursor of a ferritin II-like protein. This 30-kDa protein is targeted to mitochondria and processed to a 22-kDa subunit that assembles into typical ferritin shells and has ferroxidase activity. Immunohistochemical analysis showed that it accumulates in high amounts in iron-loaded mitochondria of erythroblasts of subjects with impaired heme synthesis. This new ferritin may play an important role in the regulation of mitochondrial iron homeostasis and heme synthesis.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Hosp San Raffaele, Ist Ricovera & Cura Carattera Sci, I-20132 Milan, Italy; Univ Brescia, Fac Med, I-25100 Brescia, Italy; Univ Pavia, Dept Internal Med & Med Therapy, I-27100 Pavia, Italy; Univ Klinikum Humbolt, Charite, Berlin, Germany	Tufts University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Brescia; University of Pavia; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Drysdale, J (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.		arosio, paolo/S-3272-2019; levi, sonia/A-3161-2015; arosio, paolo/E-6817-2010	arosio, paolo/0000-0002-5343-8992; levi, sonia/0000-0002-5092-0847; 				Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BESSIS MC, 1962, BLOOD, V14, P423; BOTTOMLEY SS, 1999, WINTROBES CLIN HEMAT, P1071; BOYD D, 1985, J BIOL CHEM, V260, P1755; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; DRYSDALE JW, 1966, J BIOL CHEM, V241, P3630; DRYSDALE JW, 1970, BIOCHIM BIOPHYS ACTA, V207, P256, DOI 10.1016/0005-2795(70)90158-3; DUGAST IJ, 1990, GENOMICS, V6, P204, DOI 10.1016/0888-7543(90)90558-C; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; INVERNIZZI R, 1990, BRIT J HAEMATOL, V76, P427, DOI 10.1111/j.1365-2141.1990.tb06379.x; JAIN SK, 1985, J BIOL CHEM, V260, P1762; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; MAZUR A, 1950, J BIOL CHEM, V187, P473; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ponka P, 1997, BLOOD, V89, P1; Santambrogio P, 2000, PROTEIN EXPRES PURIF, V19, P212, DOI 10.1006/prep.2000.1212; VANIN EF, 1984, BIOCHIM BIOPHYS ACTA, V782, P231, DOI 10.1016/0167-4781(84)90057-5; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676	26	293	306	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24437	24440		10.1074/jbc.C100141200	http://dx.doi.org/10.1074/jbc.C100141200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323407	hybrid			2022-12-25	WOS:000169800700002
J	Saydam, N; Georgiev, O; Nakano, MY; Greber, UF; Schaffner, W				Saydam, N; Georgiev, O; Nakano, MY; Greber, UF; Schaffner, W			Nucleo-cytoplasmic trafficking of metal-regulatory transcription factor 1 is regulated by diverse stress signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-EXPRESSION; FACTOR MTF-1; NUCLEAR-LOCALIZATION; RESPONSE ELEMENTS; BINDING-ACTIVITY; DNA-BINDING; FACTOR-I; ACTIVATION; TRANSPORT; PROTEIN	The metal-regulatory transcription factor 1 (MTF-1) is a key regulator of heavy metal-induced transcription of metallothionein I and II and other genes in mammals and other metazoans. Transcriptional activation of genes by MTF-1 is mediated through binding to metal-responsive elements of consensus TGCRCNC in the target gene promoters. In an attempt to further clarify the mechanisms by which certain external signals activate MTF-1 and in turn modulate gene transcription, we show here that human MTF-1 has a dual nuclear and cytoplasmic localization in response to diverse stress stimuli. MTF-1 contains a consensus nuclear localization signal located just N-terminal to the first zinc finger that contributes to but is not essential for nuclear import. MTF-1 also harbors a leucine-rich, nuclear export signal. Under resting conditions, the nuclear export signal is required for cytoplasmic localization of MTF-1 as indicated by mutational analysis and transfer to the heterologous green fluorescent protein. Export from the nucleus was inhibited by leptomycin B, suggesting the involvement of the nuclear export protein CRM1. Our results further show that in addition to the heavy metals zinc and cadmium, heat shock, hydrogen peroxide, low extracellular pH (pH 6.0), inhibition of protein synthesis by cycloheximide, and serum induce nuclear accumulation of MTF-1. However, heavy metals alone land not the other stress conditions) induce a significant transcriptional response via metal-responsive element promoter sequences, implying that nuclear import of MTF-1 is necessary but not sufficient for transcriptional activation. Possible roles for nuclear import under nonmetal stress conditions are discussed.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Schaffner, W (corresponding author), Univ Zurich, Inst Mol Biol, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	walter.schaffner@molbio.unizh.ch	Greber, Urs F/G-9458-2015; Nakano, Michel Y/H-3528-2014	Greber, Urs F/0000-0003-2278-120X; Nakano, Michel Y/0000-0003-1838-771X				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Bittel DC, 2000, J BIOL CHEM, V275, P37194, DOI 10.1074/jbc.M003863200; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Ferrigno P, 1999, ONCOGENE, V18, P6129, DOI 10.1038/sj.onc.1203132; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Liu XD, 1997, METHODS, V11, P289, DOI 10.1006/meth.1996.0423; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; Murphy BJ, 1999, CANCER RES, V59, P1315; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713	40	107	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25487	25495		10.1074/jbc.M009154200	http://dx.doi.org/10.1074/jbc.M009154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11306562	hybrid, Green Accepted			2022-12-25	WOS:000169800700139
J	Urano, T; Ihara, H; Umemura, K; Suzuki, Y; Oike, M; Akita, S; Tsukamoto, Y; Suzuki, I; Takada, A				Urano, T; Ihara, H; Umemura, K; Suzuki, Y; Oike, M; Akita, S; Tsukamoto, Y; Suzuki, I; Takada, A			The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEGETABLE CHEESE NATTO; HUMAN-PLASMA; SERINE PROTEASES; STRUCTURAL BASIS; PAI-1 ACTIVITY; FACTOR XA; GENE; NATTOKINASE; NEUTRALIZATION; PURIFICATION	In this report, we demonstrate an interaction between subtilisin NAT (formerly designated BSP, or nattokinase), a profibrinolytic serine proteinase from Bacillus subtilis, and plasminogen activator inhibitor 1 (PAI-1), Subtilisin NAT was purified to homogeneity (molecular mass, 27.7 kDa) from a saline extract of B, subtilis (natto), Subtilisin NAT appeared to cleave active recombinant prokaryotic PAI-1 (rpPAI-1) into low molecular weight fragments. Matrix-assisted laser desorption/ionization in combination with time-of-flight mass spectroscopy and peptide sequence analysis revealed that rpPAI-1 was cleaved at its reactive site (P1-P1 ': Arg(346)-Met(347)), rpPAI-1 lost its specific activity after subtilisin NAT treatment in a dose-dependent manner (0.02-1.0 nM; half-maximal effect at similar to0.1 nM), Subtilisin NAT dose dependently (0.06-1 nM) enhanced tissue-type plasminogen activator-induced fibrin clot lysis both in the absence of rpPAI-1 (48 +/- 1.48 at 1 nM) and especially in the presence of rpPAI-1 (78 +/- 2.0% at 1 nM), The enhancement observed in the absence of PAI-1 seems to be induced through direct fibrin dissolution by subtilisin NAT, The stronger enhancement by subtilisin NAT of rpPAI-1-enriched fibrin clot lysis seems to involve the cleavage and inactivation of active rpPAI-1, This mechanism is suggested to be important for subtilisin NAT to potentiate fibrinolysis.	Hamamatsu Univ Sch Med, Dept Physiol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Pharmacol, Hamamatsu, Shizuoka 4313192, Japan; Cent Res Inst Mitsukan Grp Corp, Handa 4758585, Japan; Prefectural Univ Kumamoto, Fac Environm & Symbiot Sci, Kumamoto 8628502, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Urano, T (corresponding author), Hamamatsu Univ Sch Med, Dept Physiol, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	uranot@hama-med.ac.jp						ABE O, 1989, J BIOCHEM, V105, P66, DOI 10.1093/oxfordjournals.jbchem.a122621; AOKI N, 1995, MOL BASIS THROMBOSIS, P545; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; BERRETTINI M, 1989, J BIOL CHEM, V264, P11738; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; FUJITA M, 1995, BIOL PHARM BULL, V18, P1387; FUJITA M, 1995, FIBRINOLYSIS, V9, P157, DOI 10.1016/S0268-9499(95)80005-0; FUJITA M, 1993, BIOCHEM BIOPH RES CO, V197, P1340, DOI 10.1006/bbrc.1993.2624; HAMSTEN A, 1987, LANCET, V2, P3; Humphries SE, 1997, THROMB HAEMOSTASIS, V78, P457; HUNTINGTON JA, 1995, PROTEIN SCI, V4, P613; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Komiyama T, 1996, PROTEIN SCI, V5, P874; KRESS LF, 1983, BIOCHIM BIOPHYS ACTA, V745, P113, DOI 10.1016/0167-4838(83)90039-0; KURIHARA M, 1972, J BIOL CHEM, V247, P5619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN EG, 1987, BLOOD, V70, P1090; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NAKAMURA T, 1992, BIOSCI BIOTECH BIOCH, V56, P1869, DOI 10.1271/bbb.56.1869; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OTTONELLO L, 1994, EUR J CLIN INVEST, V24, P42, DOI 10.1111/j.1365-2362.1994.tb02058.x; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Siezen RJ, 1997, PROTEIN SCI, V6, P501; STACK MS, 1995, MOL BASIS THROMBOSIS, P479; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; SUENSON E, 1990, J BIOL CHEM, V265, P22228; SUMI H, 1987, EXPERIENTIA, V43, P1110, DOI 10.1007/BF01956052; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Urano T, 2000, SEMIN THROMB HEMOST, V26, P39, DOI 10.1055/s-2000-9801; Urano T, 1998, THROMB HAEMOSTASIS, V80, P161, DOI 10.1055/s-0037-1615156; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; Urano T, 1999, FIBRINOLYSIS PROTEOL, V13, P264, DOI 10.1054/fipr.2000.0041; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056	43	117	156	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24690	24696		10.1074/jbc.M101751200	http://dx.doi.org/10.1074/jbc.M101751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325965	hybrid			2022-12-25	WOS:000169800700038
J	Ito, J; Jacobs-Lorena, M				Ito, J; Jacobs-Lorena, M			Functional mapping of destabilizing elements in the protein-coding region of the Drosophila fushi tarazu mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PAIR-RULE TRANSCRIPTS; ALDOLASE-B GENE; TRANSLATION; INSTABILITY; DEGRADATION; SEQUENCE; TRANSFORMATION; LOCALIZATION; DETERMINANTS	The instability of the fushi tarazu (ftz) mRNA is essential for the proper development of the Drosophila embryo. Previously, we identified a 201-nucleotide instability element (FLE3) in the 3 ' untranslated region (UTR) of the ftz mRNA Here we report on the identification of two additional elements in the protein-coding region of the message: the 83-nucleotide-long FIE5-1 and the 69-nucleotide-long FLE5-2. The function of both elements was position dependent; the same elements destabilized RNAs when present within the coding region but did not when embedded in the 3 ' UTR of the hybrid mRNAs. We conclude that ftz mRNA has three redundant instability elements, two in the protein-coding region and one in the 3 ' UTR. Although each instability element is sufficient to destabilize a heterologous mRNA, the destabilizing activity of the two 5 ' -elements depended on their position within the message.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University	Jacobs-Lorena, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.							CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; Fontes AM, 1999, CURR TOP DEV BIOL, V44, P171; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; Hennigan AN, 1996, MOL CELL BIOL, V16, P3833; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; Ito JI, 1998, ARCH BIOCHEM BIOPHYS, V350, P291, DOI 10.1006/abbi.1997.0527; KELLERMAN KA, 1990, GENE DEV, V4, P1925; Lall S, 1999, CELL, V98, P171, DOI 10.1016/S0092-8674(00)81012-0; MASON JO, 1988, GENE DEV, V2, P1003, DOI 10.1101/gad.2.8.1003; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QIAN S, 1987, NUCLEIC ACIDS RES, V15, P987, DOI 10.1093/nar/15.3.987; Riedl A, 1996, MOL CELL BIOL, V16, P3047; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SERANO TL, 1994, GENE, V138, P181, DOI 10.1016/0378-1119(94)90804-4; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STELLER H, 1986, MOL CELL BIOL, V6, P1640, DOI 10.1128/MCB.6.5.1640; Surdej P, 1998, MOL CELL BIOL, V18, P2892, DOI 10.1128/MCB.18.5.2892; TSUTSUMI K, 1985, J MOL BIOL, V181, P153, DOI 10.1016/0022-2836(85)90081-6; TSUTSUMI K, 1984, J BIOL CHEM, V259, P4572; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; WEINER AJ, 1984, CELL, V37, P843, DOI 10.1016/0092-8674(84)90419-7; WEINER MP, 1985, NATURE, V318, P433; WELTE MA, 1995, GENE DEV, V9, P2240, DOI 10.1101/gad.9.18.2240; YU Y, 1995, MECH DEVELOP, V50, P163, DOI 10.1016/0925-4773(94)00333-I; ZAMBETTI G, 1987, P NATL ACAD SCI USA, V84, P2683, DOI 10.1073/pnas.84.9.2683; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	36	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23525	23530		10.1074/jbc.M102965200	http://dx.doi.org/10.1074/jbc.M102965200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11306592	hybrid			2022-12-25	WOS:000169531100042
J	Bacqueville, D; Deleris, P; Mendre, C; Pieraggi, MT; Chap, H; Guillon, G; Perret, B; Breton-Douillon, M				Bacqueville, D; Deleris, P; Mendre, C; Pieraggi, MT; Chap, H; Guillon, G; Perret, B; Breton-Douillon, M			Characterization of a G protein-activated phosphoinositide 3-kinase in vascular smooth muscle cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; BETA-GAMMA-SUBUNITS; SWISS 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; KINASE-B; LOCALIZATION SITES; PHOSPHOLIPASE-C; LIPID PRODUCTS; TRANSLOCATION	Recent studies highlight the existence of an autonomous nuclear polyphosphoinositide metabolism related to cellular proliferation and differentiation. However, only few data document the nuclear production of the putative second messengers, the 3-phosphorylated phosphoinositides, by the phosphoinositide 3-kinase (PI3K). In the present paper, we examine whether GTP-binding proteins can directly modulate 3-phosphorylated phosphoinositide metabolism in membrane-free nuclei isolated from pig aorta smooth muscle cells (VSMCs). In vitro PI3K assays performed without the addition of any exogenous substrates revealed that guanosine 5 '-(gamma -thio)triphosphate (GTP gammaS) specifically stimulated the nuclear synthesis of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), whereas guanosine 5 '-(beta -thio)diphosphate was ineffective. PI3K inhibitors wortmannin and LY294002 prevented GTP gammaS-induced PtdIns(3,4,5)P-3 synthesis. Moreover, pertussis toxin inhibited partially PtdIns(3,4,5)P-3 accumulation, suggesting that nuclear G(i)/G(0) proteins are involved in the activation of PI3K. Immunoblot experiments showed the presence of G alpha (0), proteins in VSMC nuclei. In contrast with previous reports, immunoblots and indirect immunofluorescence failed to detect the p85 alpha subunit of the heterodimeric PI3K within VSMC nuclei. By contrast, we have detected the presence of a 117-kDa protein immunologically related to the PI3K gamma. These results indicate the existence of a G protein-activated PI3K inside VSMC nucleus that might be involved in the contol of VSMC proliferation and in the pathogenesis of vascular proliferative disorders.	Hop Purpan, INSERM Unite 326, Inst Claude Preval, F-31059 Toulouse, France; CCIPE, INSERM Unite 469, F-34094 Montpellier 5, France; Hop Rangueil, INSERM Unite 466, Inst Louis Bugnard, F-31043 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Breton-Douillon, M (corresponding author), Hop Purpan, INSERM Unite 326, Inst Claude Preval, F-31059 Toulouse, France.	monique.douillon@purpan.inserm.fr						Bacqueville D, 1998, BIOCHEM BIOPH RES CO, V244, P630, DOI 10.1006/bbrc.1997.7885; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; BRETON M, 1986, EXP CELL RES, V166, P416, DOI 10.1016/0014-4827(86)90487-8; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Marchisio M, 1998, BIOCHEM BIOPH RES CO, V253, P346, DOI 10.1006/bbrc.1998.9787; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Martelli AM, 2000, J BONE MINER RES, V15, P1716, DOI 10.1359/jbmr.2000.15.9.1716; Matteucci A, 1998, CANCER RES, V58, P5057; MAZZOTTI G, 1995, J HISTOCHEM CYTOCHEM, V43, P181, DOI 10.1177/43.2.7822774; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NERI LM, 1994, CELL MOL BIOL, V40, P619; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROUOT B, 1992, MOL PHARMACOL, V41, P273; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vann LR, 1997, BIOCHEM J, V327, P569; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; WU HC, 1994, LAB INVEST, V71, P175; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; YORK JD, 1994, J BIOL CHEM, V269, P7847; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zini N, 1996, HISTOCHEM CELL BIOL, V106, P457, DOI 10.1007/BF02473307	50	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22170	22176		10.1074/jbc.M011572200	http://dx.doi.org/10.1074/jbc.M011572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11303021	hybrid			2022-12-25	WOS:000169412700028
J	Brysha, M; Zhang, JG; Bertolino, P; Corbin, JE; Alexander, WS; Nicola, NA; Hilton, DJ; Starr, R				Brysha, M; Zhang, JG; Bertolino, P; Corbin, JE; Alexander, WS; Nicola, NA; Hilton, DJ; Starr, R			Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED DISRUPTION; MICE; INHIBITOR; ACTIVATION; LIVER; GENE; CELLS; STAT1; LYMPHOCYTES; PROTEINS	Suppressor of cytokine signaling-1 (SOCS-1) is a cytokine-inducible intracellular protein that functions to negatively regulate cytokine signal transduction pathways. Studies in vitro have shown that constitutive over expression of SOCS-1 inhibits signaling in response to a range of cytokines, including interferons (IFN). Mice lacking SOCS-1 die from a complex disease characterized by liver degeneration and massive inflammation. Whereas there is clear evidence of increased IFN gamma signaling in SOCS-1(-/-) mice, it is unclear to what extent this is due to increased IFN gamma levels or to increased IFN gamma sensitivity. Here we have used SOCS-1(-/-) IFN gamma (-/-) mice, which remain healthy and produce no endogenous IFN gamma to demonstrate that in vitro and in vivo hepatocytes lacking SOCS-1 exhibit a prolonged response to IFN gamma and that this correlates with a dramatically increased sensitivity to the toxic effects of IFN gamma in vivo. Thus, SOCS-1 is required for the timely attenuation of IFN gamma signaling in vivo.	PO Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Centenary Inst Canc Med & Cell Biol, Newtown, NSW 2042, Australia	Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Sydney; Centenary Institute	Starr, R (corresponding author), PO Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia.		Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; Bertolino, Patrick/0000-0001-8244-7057	NCI NIH HHS [CA-22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bertolino P, 1998, EUR J IMMUNOL, V28, P221, DOI 10.1002/(SICI)1521-4141(199801)28:01<221::AID-IMMU221>3.3.CO;2-6; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAMELL JE, 1994, SCIENCE, V264, P1415; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GRESSER I, 1981, AM J PATHOL, V102, P396; Gresser I, 1982, Interferon, V4, P95; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Losman JA, 1999, J IMMUNOL, V162, P3770; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	30	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22086	22089		10.1074/jbc.M102737200	http://dx.doi.org/10.1074/jbc.M102737200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306591	hybrid			2022-12-25	WOS:000169412700015
J	Gil, J; Rullas, J; Garcia, MA; Alcami, J; Esteban, M				Gil, J; Rullas, J; Garcia, MA; Alcami, J; Esteban, M			The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappa B activation	ONCOGENE			English	Article						PKR; IKK; NF-kappa B; dsRNA	DOUBLE-STRANDED-RNA; IKK-BETA; IN-VIVO; INTERFERON; EXPRESSION; ALPHA; PHOSPHORYLATION; REPLICATION; INHIBITION; COMPLEX	The double stranded RNA-dependent protein kinase (PKR), in addition to its role as a translational controlling factor, is a key transcriptional regulator exerting antiviral and antitumoral activities. We have previously shown that induction of NF-kappaB by PKR is involved in apoptosis commitment and this process is mediated through activation of the IKK complex. To gain insights into the mechanism of activation of NF-kappaB by PKR, we have analysed the domains of PKR involved in IKK activation and subsequent NF-kappaB induction. In PKR0/0 cells infected with a collection of vaccinia virus (VV) recombinants expressing different mutant forms of PKR, we found that only PKR forms conserving the catalytic activity are able to activate NF-kappaB. An inactive PKR mutant (K296R), was unable to induce NF-kappaB activation despite full expression of the protein in a wide range of concentrations, as defined by Western blot, EMSA, IKK kinase activity and NF-kappaB transactivation assays. Moreover, the mutant PKR (K296R) acts as a dominant negative of PKR-induced eIF-2 alpha phosphorylation and NF-kappaB activation. However, PKR mutants unable to activate NF-kappaB still retain their ability to associate with the IKK complex, as confirmed by immunoprecipitation analysis. We conclude that the catalytic activity of PKR and not only a protein-protein interaction with the IKK complex, is needed for activation of the transcription factor NF-kappaB.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, E-28049 Madrid, Spain; Inst Salud Carlos III, Ctr Biol Fundamental, AIDS Immunopathogenesis Unit, Madrid 28220, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Instituto de Salud Carlos III	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, E-28049 Madrid, Spain.		Esteban, Mariano/ABG-5375-2020; Gil, Jesus/C-7739-2012; Garcia, Maria Angel MA/I-5116-2016; Alcami, Pepe/T-2242-2018	Esteban, Mariano/0000-0003-0846-2827; Gil, Jesus/0000-0002-4303-6260; Garcia, Maria Angel MA/0000-0003-2003-3769; Alcami, Pepe/0000-0003-0023-7377				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; DiazGuerra M, 1997, VIROLOGY, V227, P220, DOI 10.1006/viro.1996.8294; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; George CX, 1996, VIROLOGY, V221, P180, DOI 10.1006/viro.1996.0364; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rivas C, 1999, J INTERF CYTOK RES, V19, P1229, DOI 10.1089/107999099312885; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	54	56	61	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					385	394		10.1038/sj.onc.1204109	http://dx.doi.org/10.1038/sj.onc.1204109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313968	Bronze			2022-12-25	WOS:000166411000013
J	Bacus, SS; Gudkov, AV; Lowe, M; Lyass, L; Yung, Y; Komarov, AP; Keyomarsi, K; Yarden, Y; Seger, R				Bacus, SS; Gudkov, AV; Lowe, M; Lyass, L; Yung, Y; Komarov, AP; Keyomarsi, K; Yarden, Y; Seger, R			Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53	ONCOGENE			English	Article						taxol; MAP kinase; apoptosis; cell cycle; p53; Her-2	ACTIVATED PROTEIN-KINASE; INDUCED CELL-DEATH; EPIDERMAL-GROWTH-FACTOR; HUMAN TUMOR-CELLS; HUMAN BREAST; PHOSPHOINOSITIDE 3-KINASE; DIFFERENTIAL MODULATION; MEDIATED APOPTOSIS; PHOSPHORYLATION; PACLITAXEL	The anti-cancer agent paclitaxel (Taxol) stabilizes microtubules leading to G2/M cell cycle arrest and apoptotic cell death. In order to analyse the molecular mechanisms of Taxol-induced cytotoxicity, we studied the involvement of mitogen-activated protein kinases (MAPK) ERK and p38 as well as the p53 pathways in Taxol-induced apoptosis, The human breast carcinoma cell line MCF7 and its derivatives, MCF7/HER-2 and MDD2, sere used in the study. We found that Taxol treatment strongly activated ERK, p38 MAP kinase and p53 in MAP kinase MCF9 cells prior to apoptosis, PD98059 or SB203580, specific inhibitors of ERK and p38 kinase activities, significantly decreased apoptosis, leaving the surviving cells arrested in G2/M. These inhibitors did not significantly affect Taxol-induced alterations in the cell cycle regulatory proteins Rb, p53, p11/Waf1 and Cdk-2, In addition, inactivation of p53 did not affect cellular sensitivity to Taxol killing. However, cells with inactivated p53, unlike cells harboring wild type p53, failed to arrest in G2/M after treatment with Taxol and continued to divide or go into apoptosis, Our data show that both ERK and p38 MAP kinase cascades are essential for apoptotic response to Taxol-induced cellular killing and are independent of p53 activity, However, p53 may serve as a survival factor in breast carcinoma cells treated with Taxol by blocking cells in G2/M phase of the cell cycle.	Quantitat Diagnost Labs Inc, Elmhurst, IL 60126 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; Weizmann Inst Sci, IL-76100 Rehovot, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Weizmann Institute of Science	Bacus, SS (corresponding author), Quantitat Diagnost Labs Inc, Elmhurst, IL 60126 USA.		YARDEN, YOSEF/K-1467-2012; Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179, CA60730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179, R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 1996, ONCOGENE, V12, P2535; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blagosklonny MV, 2000, CANCER RES, V60, P3425; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fang M, 2000, ANTICANCER RES, V20, P103; Goldspiel BR, 1997, PHARMACOTHERAPY, V17, pS110; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Kandioler-Eckersberger D, 2000, CLIN CANCER RES, V6, P50; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KEYOMARSI K, 1994, CANCER RES, V54, P380; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lieu CH, 1998, CELL GROWTH DIFFER, V9, P767; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Torres K, 1998, CANCER RES, V58, P3620; TURNER PF, 1984, J CELL BIOL, V99, P940, DOI 10.1083/jcb.99.3.940; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WANG X, 2000, J BIOL CHEM, V10, P1074; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu DH, 1996, ONCOGENE, V13, P1359; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0	60	315	326	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					147	155		10.1038/sj.onc.1204062	http://dx.doi.org/10.1038/sj.onc.1204062			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313944				2022-12-25	WOS:000166410900002
J	Ni, YS; McPhie, P; Deacon, A; Ealick, S; Coleman, WG				Ni, YS; McPhie, P; Deacon, A; Ealick, S; Coleman, WG			Evidence that NADP(+) is the physiological cofactor of ADP-L-glycero-D-mannoheptose 6-epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; DEPENDENT GLUTAMATE-DEHYDROGENASE; AMINO-ACID-SEQUENCE; COENZYME SPECIFICITY; NUCLEOTIDE-SEQUENCE; RFAD GENE; BINDING; PURIFICATION; PROTEINS	ADP-L-glycero-D-mannoheptose 6-epimerase is required for lipopolysaccharide inner core biosynthesis in several genera of Gram-negative bacteria. The enzyme contains both fingerprint sequences Gly-X-Gly-X-X-Gly and Gly-X-X-Gly-X-X-Gly near its N terminus, which is indicative of an ADP binding fold. Previous studies of this ADP-L-glycero-D-mannoheptose 6-epimerase (ADP-hep 6-epimerase) were consistent with an NAD(+) cofactor. However, the crystal structure of this ADP-hep 6-epimerase showed bound NADP (Deacon, A. M., Ni, Y. S., Coleman, W. G., Jr., and Ealick, S. E. (2000) Structure 5, 453-462). In present studies, apo-ADP-hep 6-epimerase was reconstituted with NAD(+), NADP(+), and FAD. In this report we provide data that shows NAD(+) and NADP(+) both restored enzymatic activity, but FAD could not. Furthermore, ADP-hep 6-epimerase exhibited a preference for binding of NADP(+) over NAD(+). The K-d value for NADP(+) was 26 muM whereas that for NAD(+) was 45 muM. Ultraviolet circular dichroism spectra showed that apo-ADP-hep 6-epimerase reconstituted with NADP(+) had more secondary structure than apo-ADP-hep 6-epimerase reconstituted with NAD(+). Perchloric acid extracts of the purified enzyme were assayed with NAD(+)-specific alcohol dehydrogenase and NADP(+)- specific isocitric dehydrogenase. A sample of the same perchloric acid extract was analyzed in chromatographic studies, which demonstrated that ADP-hep 6-epimerase binds NADP(+) in vivo. A structural comparison of ADP-hep 6-epimerase with UDP-galactose 4-epimerase, which utilizes an NAD(+) cofactor, has identified the regions of ADP-hep 6-epimerase, which defines its specificity for NADP(+).	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; Stanford Univ, Stanford Linear Accelerator Ctr, Stanford, CA 94309 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Cornell University	Coleman, WG (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK023330, Z01DK024942, ZIADK023330] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS GA, 1967, CAN J MICROBIOL, V13, P1605, DOI 10.1139/m67-210; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAUER AJ, 1992, PROTEIN-STRUCT FUNCT, V9, P135; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; COLEMAN WG, 1992, PSEUDOMONAS : MOLECULAR BIOLOGY AND BIOTECHNOLOGY, P161; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; Daussmann T, 1997, EUR J BIOCHEM, V248, P889, DOI 10.1111/j.1432-1033.1997.00889.x; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; DING L, 1994, J BIOL CHEM, V269, P24384; Ding L, 1999, ACTA CRYSTALLOGR D, V55, P685, DOI 10.1107/S0907444998014723; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LILLEY KS, 1991, BIOCHIM BIOPHYS ACTA, V1080, P191, DOI 10.1016/0167-4838(91)90001-G; MCPHERSON MJ, 1983, NUCLEIC ACIDS RES, V11, P5257, DOI 10.1093/nar/11.15.5257; MOYE WS, 1985, J BIOL CHEM, V260, P8502; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	21	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27329	27334		10.1074/jbc.M102258200	http://dx.doi.org/10.1074/jbc.M102258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313358	hybrid			2022-12-25	WOS:000169966900080
J	Kim, JH; Lewin, TM; Coleman, RA				Kim, JH; Lewin, TM; Coleman, RA			Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5 - Selective inhibition by triacsin C and thiazolidinediones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; FATTY-ACID; TRIACYLGLYCEROL SYNTHESIS; INSULIN-SENSITIVITY; LIVER; TROGLITAZONE; ENZYMES; ESTERS; CELLS; PPAR	Inhibition by triacsins and troglitazone of long chain fatty acid incorporation into cellular lipids suggests the existence of inhibitor-sensitive and -resistant acyl-CoA synthetases (ACS, EC 6.2.1.3) that are linked to specific metabolic pathways. In order to test this hypothesis, we cloned and purified rat ACS1, ACS4, and ACS5, the isoforms present in liver and fat cells, expressed the isoforms as ACS-Flag fusion proteins in Escherichia coli, and purified them by Flag affinity chromatography, The Flag epitope at the C terminus did not alter the kinetic properties of the enzyme. Purified ACS1-, 4-, and 8-Flag isoforms differed in their apparent K-m values for ATP, thermolability, pH optima, requirement for Triton X-100, and sensitivity to N-ethylmaleimide and phenylglyoxal, The ACS inhibitor triacsin C strongly inhibited ACS1 and ACS4, but not ACS5, The thiazolidinedione (TZD) insulin-sensitizing drugs and peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands, troglitazone, rosiglitazone, and pioglitazone, strongly and specifically inhibited only ACS(4), with an IC50 of less than 1.5 muM. Troglitazone exhibited a mixed type inhibition of ACS4. alpha -Tocopherol, whose ring structure forms the non-TZD portion of troglitazone, did not inhibit ACS4, indicating that the thiazolidine-2,4-dione moiety is the critical component for inhibition. A non-TZD PPAR gamma ligand, GW1929, which is 7-fold more potent than rosiglitazone, inhibited ACS1 and ACS4 poorly with an IC50 of greater than 50 muM, more than 100-fold higher than was required for rosiglitazone, thereby demonstrating the specificity of TZD inhibition. Further, the PPAR alpha ligands, clofibrate and GW4647, and various xenobiotic carboxylic acids known to be incorporated into complex lipids had no effect on ACS1, -4, or -5, These results, together with previous data showing that triacsin C and troglitazone strongly inhibit triacylglycerol synthesis compared with other metabolic pathways, suggest that ACS1 and ACS4 catalyze the synthesis of acyl-Coks used for triacylglycerol synthesis and that lack of inhibition of a metabolic pathway by triacsin C does not prove lack of acyl-CoA involvement. The results further suggest the possibility that the insulin-sensitizing effects of the thiazolidinedione drugs might be achieved, in part, through direct interaction with ACS4 in a PPAR gamma -independent manner.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056598] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08431] Funding Source: Medline; NIDDK NIH HHS [DK56598] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AAS M, 1971, BIOCHIM BIOPHYS ACTA, V239, P208, DOI 10.1016/0005-2760(71)90166-4; BANIS RJ, 1976, ANAL BIOCHEM, V73, P1, DOI 10.1016/0003-2697(76)90135-4; BERGE RK, 1987, ARCH BIOCHEM BIOPHYS, V252, P269, DOI 10.1016/0003-9861(87)90031-2; Brown KK, 1999, DIABETES, V48, P1415, DOI 10.2337/diabetes.48.7.1415; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cho YY, 2000, BIOCHEM BIOPH RES CO, V274, P741, DOI 10.1006/bbrc.2000.3207; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; CUNNANE SC, 1988, LIPIDS, V23, P372, DOI 10.1007/BF02537353; DODDS PF, 1995, PROG LIPID RES, V34, P219, DOI 10.1016/0163-7827(95)00007-M; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Fukui Y, 2000, DIABETES, V49, P759, DOI 10.2337/diabetes.49.5.759; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; KORNBERG A, 1953, J BIOL CHEM, V204, P329; LAWSON N, 1981, BIOCHEM J, V200, P285, DOI 10.1042/bj2000285; LEE MK, 1995, METABOLISM, V44, P1166, DOI 10.1016/0026-0495(95)90010-1; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; LIPPEL K, 1972, BIOCHIM BIOPHYS ACTA, V280, P531, DOI 10.1016/0005-2760(72)90132-4; LIPPEL K, 1971, BIOCHIM BIOPHYS ACTA, V239, P384, DOI 10.1016/0005-2760(71)90031-2; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Muoio DM, 2000, AM J PHYSIOL-ENDOC M, V279, pE1366, DOI 10.1152/ajpendo.2000.279.6.E1366; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; POLOKOFF MA, 1977, J BIOL CHEM, V252, P1161; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoonjans K, 1996, J LIPID RES, V37, P907; Segel IH, 1975, ENZYME KINETICS BEHA; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; Wang ZW, 1999, BIOCHEM BIOPH RES CO, V260, P653, DOI 10.1006/bbrc.1999.0918; Wu XJ, 1996, J LIPID RES, V37, P1198	40	171	178	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24667	24673		10.1074/jbc.M010793200	http://dx.doi.org/10.1074/jbc.M010793200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319222	hybrid			2022-12-25	WOS:000169800700035
J	Sola, M; Kneussel, M; Heck, IS; Betz, H; Weissenhorn, W				Sola, M; Kneussel, M; Heck, IS; Betz, H; Weissenhorn, W			X-ray crystal structure of the trimeric N-terminal domain of gephyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; RECEPTOR-BETA-SUBUNIT; GLYCINE RECEPTOR; ESCHERICHIA-COLI; PROTEIN GEPHYRIN; MOLYBDOPTERIN BIOSYNTHESIS; STRUCTURE REFINEMENT; SPLICE VARIANTS; SPINAL-CORD; IDENTIFICATION	Gephyrin is a ubiquitously expressed protein that, in the central nervous system, forms a submembraneous scaffold for anchoring inhibitory neurotransmitter receptors in the postsynaptic membrane. The N- and C-terminal domains of gephyrin are homologous to the Escherichia coli enzymes MogA and MoeA, respectively, both of which are involved in molybdenum cofactor biosynthesis. This enzymatic pathway is highly conserved from bacteria to mammals, as underlined by the ability of gephyrin to rescue molybdenum cofactor deficiencies in different organisms. Here we report the x-ray crystal structure of the N-terminal domain (amino acids 2-188) of rat gephyrin at 1.9-Angstrom resolution. Gephyrin-(2-188) forms trimers in solution, and a sequence motif thought to be involved in molybdopterin binding is highly conserved between gephyrin and the E, coli protein. The atomic structure of gephyrin-(2-188) resembles MogA, albeit with two major differences. The path of the C-terminal ends of gephyrin-(2-188) indicates that the central and C-terminal domains, absent in this structure, should follow a similar 3-fold arrangement as the N-terminal region. In addition, a central beta -hairpin loop found in MogA is lacking in gephyrin-(2-188). Despite these differences, both structures show a high degree of surface charge conservation, which is consistent with their common catalytic function.	European Mol Biol Lab, F-38042 Grenoble 9, France; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany; Univ Tubingen, Inst Plant Biochem, D-72076 Tubingen, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society; Eberhard Karls University of Tubingen	Weissenhorn, W (corresponding author), European Mol Biol Lab, 6 Rue Jules Horowitz, F-38042 Grenoble 9, France.			Kneussel, Matthias/0000-0003-4900-366X; Sola, Maria/0000-0002-0838-9706				ALTSCHULER RA, 1986, BRAIN RES, V369, P316, DOI 10.1016/0006-8993(86)90542-1; BROWN GK, 1989, NEUROLOGY, V39, P252; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CPP4, 1994, ACTA CRYSTALLOGR D, V50, P760; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; GRAHAM D, 1985, BIOCHEMISTRY-US, V24, P990, DOI 10.1021/bi00325a027; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; Kamdar KP, 1997, BIOCHEM SOC T, V25, P778, DOI 10.1042/bst0250778; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; LANGOSCH D, 1992, FEBS LETT, V298, P113, DOI 10.1016/0014-5793(92)80034-E; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	45	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25294	25301		10.1074/jbc.M101923200	http://dx.doi.org/10.1074/jbc.M101923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325967	hybrid			2022-12-25	WOS:000169800700115
J	Stam, JC; Geerts, WJC; Versteeg, HH; Verkleij, AJ; van Bergen, PMP				Stam, JC; Geerts, WJC; Versteeg, HH; Verkleij, AJ; van Bergen, PMP			The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FAMILY ADAPTER PROTEINS; FOCAL ADHESION KINASE; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; BREAST-CANCER; PC12 CELLS; APOPTOSIS; TRANSFORMATION	The v-Crk oncogene encodes an adaptor protein containing an SH2 domain and an SH3 domain. v-Crk-transformed fibroblast cells display enhanced tyrosine phosphorylation levels, and the v-Crk protein localizes in focal adhesions, suggesting that transformation may be due to enhanced focal complex signaling. Here we investigated the mechanism of transformation and found that v-Crk-transformed NIH 3T3 cells display growth rates and serum requirements similar to control cells. However, v-Crk enhanced survival in conditions of serum starvation, Both an intact SH2 and SH3 domain are required; moreover, SH2 mutants displayed dominant interfering properties, enhancing cell death. Using other cell death-inducing stimuli, it appeared that v-Crk in general inhibits apoptosis and enhances cell survival. In search of the signaling pathways involved, we found that v-Crk-transformed cells show constitutively higher levels of phospho-protein kinase B (PKB)/Akt and PKB/ Akt activity, especially in conditions of serum starvation, These data strongly suggest involvement of the phosphatidylinositol 5-kinase/PKB survival pathway in the v-Crk-induced protection against apoptosis, In accordance, inhibition of this pathway by wortmannin or LY924002 reduced protection against starvation-induced apoptosis. In addition to the phosphatidylinositol 5-kinase/PKB pathway, a MEK-dependent pathway and an unknown additional pathway are also implicated in resistance against apoptosis, Activation of survival pathways may be the most important function of v-Crk in its oncogenic properties.	Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands	Utrecht University	van Bergen, PMP (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Versteeg, Henri/G-1783-2018; Geerts, Willie J.C./B-7640-2011; van Bergen en Henegouwen, Paul/B-8870-2011	Versteeg, Henri/0000-0003-4294-175X; Geerts, Willie J.C./0000-0002-4530-7458; van Bergen en Henegouwen, Paul/0000-0001-6050-9042				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Glassman RH, 1997, CELL DEATH DIFFER, V4, P82, DOI 10.1038/sj.cdd.4400203; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nievers MG, 1997, J CELL SCI, V110, P389; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; TENHOEVE J, 1993, ONCOGENE, V8, P2469; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	42	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25176	25183		10.1074/jbc.M009825200	http://dx.doi.org/10.1074/jbc.M009825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323409	hybrid			2022-12-25	WOS:000169800700100
J	Barbero, P; Buell, E; Zulley, S; Pfeffer, SR				Barbero, P; Buell, E; Zulley, S; Pfeffer, SR			TIP47 is not a component of lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; CYTOPLASMIC DOMAIN; ENDOSOMES; TRAFFICKING; TAIL	TIP47 functions in the delivery of mannose 6-phosphate receptors from endosomes to the trans-Golgi network both in vitro and in, vivo, It binds directly and very specifically to the cytoplasmic domains of both the cation-independent and cation-dependent mannose 6-phosphate receptors, TIP47 is 43% identical to a Lipid droplet-associated protein named adipophilin; much of the identity resides near the N termini of these proteins. It was recently reported in this journal, in a study using antiserum from this laboratory, that TIP47 is a constituent of lipid droplets (Wolins, N, E,, Rubin, B,, and Brasaemle, D. L, (2001) J, BioL Chem, 278, 5101-5108). We show here that the findings of Wolins et al. were likely due to either a cross-reactive, unidentified protein in HeLa cells that is recognized by our antiserum and/or the fact that our serum also cross-reacts with the adipophilin protein itself, shown directly by expression of adipophilin in Escherichia coli, Using antibodies specific for residues 152-434 of TIP47, me show that TIP47 is not st constituent of lipid droplets.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 95307 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Sch Med, Dept Biochem, 279 Campus Dr, Stanford, CA 95307 USA.	pfeffer@cmgm.stanford.edu			NIDDK NIH HHS [DK37336] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DUDEN R, 1991, CELL, V64, P9; Krise JP, 2000, J BIOL CHEM, V275, P25188, DOI 10.1074/jbc.M001138200; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	11	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24348	24351		10.1074/jbc.M102468200	http://dx.doi.org/10.1074/jbc.M102468200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313361	hybrid			2022-12-25	WOS:000169531100147
J	Gerber, J; Muhlenhoff, U; Hofhaus, G; Lill, R; Lisowsky, T				Gerber, J; Muhlenhoff, U; Hofhaus, G; Lill, R; Lisowsky, T			Yeast Erv2p is the first microsomal FAD-linked sulfhydryl oxidase of the Erv1p/Alrp protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; REGENERATION ALR GENE; ENDOPLASMIC-RETICULUM; LIVER-REGENERATION; EGG-WHITE; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL; TRANSFORMATION; EXPRESSION; AUGMENTOR	Saccharomyces cerevisiae Erv2p was identified previously as a distant homologue of Erv1p, an essential mitachondrial protein exhibiting sulfhydryl oxidase activity. Expression of the ERV2 (essential for respiration and vegetative growth 2) gene from a high-copy plasmid cannot substitute for the lack of ERV1, suggesting that the two proteins perform nonredundant functions. Here, we show that the deletion of the ERV2 gene or the depletion of Erv2p by regulated gene expression is not associated with any detectable growth defects. Erv2p is located in the microsomal fraction, distinguishing it from the mitochondrial Erv1p, Despite their distinct subcellular localization, the two proteins exhibit functional similarities. Both form dimers in vivo and in vitro, contain a conserved YPCXXC motif in their carboxyl-terminal part, bind flavin adenine dinucleotide (FAD) as a cofactor, and catalyze the formation of disulfide bonds in protein substrates. The catalytic activity, the ability to form dimers, and the binding of FAD are associated with the carboxyl-terminal domain of the protein. Our findings identify Erv2p as the first microsomal member of the Erv1p/Alrp protein family of FAD-linked sulfhydryl oxidases, We propose that Erv2p functions in the generation of microsomal disulfide bonds acting in parallel with Ero1p, the essential, FAD-dependent oxidase of protein disulfide isomerase.	Univ Dusseldorf, Inst Bot, D-40225 Dusseldorf, Germany; Univ Marburg, Inst Zytobiol, D-35033 Marburg, Germany; Univ Dusseldorf, Med Forschungszentrum, Inst Biochem & Biol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Philipps University Marburg; Heinrich Heine University Dusseldorf	Lisowsky, T (corresponding author), Univ Dusseldorf, Inst Bot, Univ Str 1, D-40225 Dusseldorf, Germany.	lisowsky@uni-duesseldorf.de		Lill, Roland/0000-0002-8345-6518				Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; DAUM G, 1982, J BIOL CHEM, V257, P3028; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Giorda R, 1996, MOL MED, V2, P97, DOI 10.1007/BF03402206; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harlow E., 1988, ANTIBODIES LAB MANUA; Hofhaus G, 1999, EUR J CELL BIOL, V78, P349, DOI 10.1016/S0171-9335(99)80069-7; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hoober KL, 1999, J BIOL CHEM, V274, P22147, DOI 10.1074/jbc.274.32.22147; Innis MA, 1990, PCR PROTOCOLS GUIDE; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; LISOWSKY T, 1995, GENOMICS, V29, P690, DOI 10.1006/geno.1995.9950; LISOWSKY T, 1992, MOL GEN GENET, V232, P58, DOI 10.1007/BF00299137; Lisowsky T, 2001, DIGEST LIVER DIS, V33, P173, DOI 10.1016/S1590-8658(01)80074-8; Polimeno L, 1999, ITAL J GASTROENTEROL, V31, P494; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Senkevich TG, 1997, VIROLOGY, V233, P19, DOI 10.1006/viro.1997.8607; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Stein G, 1998, YEAST, V14, P171, DOI 10.1002/(SICI)1097-0061(19980130)14:2<171::AID-YEA209>3.0.CO;2-U; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Woycechowsky KJ, 2000, CURR OPIN CHEM BIOL, V4, P533, DOI 10.1016/S1367-5931(00)00128-9; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149	39	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23486	23491		10.1074/jbc.M100134200	http://dx.doi.org/10.1074/jbc.M100134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313344	hybrid			2022-12-25	WOS:000169531100036
J	Schmidt, A; MacColl, R; Lindau-Shepard, B; Buckler, DR; Dias, JA				Schmidt, A; MacColl, R; Lindau-Shepard, B; Buckler, DR; Dias, JA			Hormone-induced conformational change of the purified soluble hormone binding domain of follitropin receptor complexed with single chain follitropin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CHORIONIC-GONADOTROPIN RECEPTOR; PROTEIN SECONDARY STRUCTURE; AMINO-ACID-RESIDUES; EXTRACELLULAR DOMAIN; CIRCULAR-DICHROISM; LUTROPIN RECEPTOR; FSH RECEPTOR; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL-PROPERTIES	Human follicle-stimulating hormone receptor (hFSHR) belongs to family I of G protein-coupled receptors. FSHR extracellular domain (ECD) is predicted to have 8-9 alpha beta or leucine-rich repeat motif elements. The objective of this study was to identify elements of the FSHR ECD involved in ligand binding. Preincubation of recombinant hFSHR ECD with rabbit antisera raised against synthetic peptides of hFSHR ECD primary sequence abolished follitropin binding primarily in the region of amino acids 150-254. Accessibility of hFSHR ECD after hormone binding, captured by monoclonal antibodies against either ECD or FSH, was decreased for the region of amino acids 150-220 but additionally for amino acids 15-100. Thus, when hFSH bound first, accessibility of antibody binding was decreased to a much larger extent than if antibody was bound first. This suggestion of a conformational change upon binding was examined further. Circular dichroism spectra were recorded for purified single chain hFSH, hFSHR ECD, and hFSHR ECD-single chain hFSH complex. A spectral change indicated a small but consistent conformational change in the ECD FSH complex after hormone binding. Taken together, these data demonstrate that FSH binding requires elements within the leucine-rich repeat motifs that form a central region of hFSHR ECD, and a conformational change occurs upon hormone binding.	New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst Publ Hlth, Albany, NY 12208 USA; Ares Adv Technol, Randolph, MA 02368 USA	State University of New York (SUNY) System; Wadsworth Center	Dias, JA (corresponding author), New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst Publ Hlth, 120 New Scotland Ave, Albany, NY 12208 USA.	James.Dias@wadsworth.org		Dias, James A/0000-0002-9792-5469; Schmidt, Anja/0000-0002-2304-8774	NICHD NIH HHS [HD18407] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018407] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; BOZON V, 1995, J MOL ENDOCRINOL, V14, P277, DOI 10.1677/jme.0.0140277; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; CHEN WY, 1993, MOL CELL ENDOCRINOL, V91, P35, DOI 10.1016/0303-7207(93)90252-F; Clement-Collin V, 1999, EUR J BIOCHEM, V264, P358, DOI 10.1046/j.1432-1327.1999.00608.x; DATTATREYAMURTY B, 1993, ENDOCRINOLOGY, V133, P1593, DOI 10.1210/en.133.4.1593; DATTATREYAMURTY B, 1992, MOL CELL ENDOCRINOL, V87, P9, DOI 10.1016/0303-7207(92)90228-X; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Hong SH, 1999, MOL ENDOCRINOL, V13, P1285, DOI 10.1210/me.13.8.1285; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Lin SS, 1996, BIOCHEMISTRY-US, V35, P14445, DOI 10.1021/bi961619+; Lindau-Shepard B, 2001, J REPROD IMMUNOL, V49, P1, DOI 10.1016/S0165-0378(00)00079-6; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; Liu XX, 2000, ENDOCRINE, V13, P361, DOI 10.1385/ENDO:13:3:361; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MURPHY CI, 1993, PROTEIN EXPRES PURIF, V4, P349, DOI 10.1006/prep.1993.1046; Nechamen CA, 2000, MOL CELL ENDOCRINOL, V166, P101, DOI 10.1016/S0303-7207(00)00281-1; Pajot-Augy E, 1999, EUR J BIOCHEM, V260, P635, DOI 10.1046/j.1432-1327.1999.00241.x; Peterson AJ, 2000, MOL CELL ENDOCRINOL, V160, P203, DOI 10.1016/S0303-7207(99)00204-X; Possee RD., 1992, BACULOVIRUS EXPRESSI; Purohit S, 1997, BIOCHEMISTRY-US, V36, P12355, DOI 10.1021/bi970303e; REICHERT LE, 1989, BIOL REPROD, V40, P13, DOI 10.1095/biolreprod40.1.13; ROTH KE, 1995, MOL CELL ENDOCRINOL, V109, P143, DOI 10.1016/0303-7207(95)03494-R; Roth KE, 1996, BIOCHEMISTRY-US, V35, P7928, DOI 10.1021/bi952566j; Shao K, 1999, MOL CELL ENDOCRINOL, V150, P47, DOI 10.1016/S0303-7207(99)00026-X; SHARMA SC, 1995, MOL CELL ENDOCRINOL, V115, P87, DOI 10.1016/0303-7207(95)03673-U; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stevis PE, 1999, ENDOCRINE, V10, P153, DOI 10.1385/ENDO:10:2:153; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; Woo SB, 1998, PROTEIN SCI, V7, P1006; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722	49	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23373	23381		10.1074/jbc.M100057200	http://dx.doi.org/10.1074/jbc.M100057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313343	hybrid			2022-12-25	WOS:000169531100022
J	Daniels, M; Brown, DR				Daniels, M; Brown, DR			Astrocytes regulate N-methyl-D-aspartate receptor subunit composition increasing neuronal sensitivity to excitotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; GLIAL GLUTAMATE TRANSPORTERS; PRION PROTEIN-FRAGMENT; RAT-BRAIN; COCULTURE SYSTEM; NMDA ANTAGONISTS; EXPRESSION; NEUROTOXICITY; CULTURE; TOXICITY	We have examined the dependence of rat cerebellar granule neurons (CGNs) for protection against glutamate toxicity. Under co-culture conditions, rat CGNs require astrocytes to protect against glutamate. The CGNs become more sensitive to glutamate toxicity in co culture than when grown in cultures with only low numbers of astrocytes. If the protection of the astroyctes was withdrawn or blocked, this sensitivity led to neuronal death. Differing changes in NMDA receptor subunit subtype composition were noted depending on the conditions in which the CGNs were grown. Suppression of individual NMDA subunit subtypes by oligonucleotide knockdown resulted in inhibition of toxicity. This result implies that astrocytes regulate the expression of NMDA receptor subunit subtypes which influence neuronal sensitivity to glutamate toxicity.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Brown, DR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.							AUDINAT E, 1994, EUR J NEUROSCI, V6, P1792, DOI 10.1111/j.1460-9568.1994.tb00572.x; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Beaman-Hall CM, 1998, J NEUROCHEM, V71, P1993; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1999, J NEUROCHEM, V72, P943, DOI 10.1046/j.1471-4159.1999.0720943.x; Brown DR, 1996, GLIA, V18, P59, DOI 10.1002/(SICI)1098-1136(199609)18:1<59::AID-GLIA6>3.0.CO;2-Z; Brown DR, 2000, MOL CELL NEUROSCI, V15, P465, DOI 10.1006/mcne.2000.0840; Brown DR, 1999, MOL CELL NEUROSCI, V13, P379, DOI 10.1006/mcne.1999.0751; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHOI DW, 1988, J NEUROSCI, V8, P185; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; GOTTSCHALL PE, 1994, BRAIN RES, V637, P197, DOI 10.1016/0006-8993(94)91233-5; Kreutz MR, 1998, J NEUROSCI, V18, P8278; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; MCLENNAN H, 1976, BRAIN RES, V115, P139, DOI 10.1016/0006-8993(76)90828-3; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; OKADA S, 1994, NEUROSCIENCE, V63, P691; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHMAN SM, 1993, NEUROPHARMACOLOGY, V32, P1279, DOI 10.1016/0028-3908(93)90022-U; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Schinder AF, 1996, J NEUROSCI, V16, P6125; SPELIOTES EK, 1994, J NEUROCHEM, V63, P879; Standaert DG, 1996, J PHARMACOL EXP THER, V276, P342; Swanson RA, 1997, J NEUROSCI, V17, P932; Vallano ML, 1996, J NEUROSCI, V16, P631; Ward MW, 2000, J NEUROSCI, V20, P7208; WATANABE M, 1994, J COMP NEUROL, V343, P513, DOI 10.1002/cne.903430402; WESTERGAARD N, 1994, J NEUROCHEM, V62, P1727; Ye ZC, 1998, GLIA, V22, P237, DOI 10.1002/(SICI)1098-1136(199803)22:3<237::AID-GLIA3>3.0.CO;2-2	37	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22446	22452		10.1074/jbc.M101740200	http://dx.doi.org/10.1074/jbc.M101740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11306581	hybrid			2022-12-25	WOS:000169412700064
J	Moog-Lutz, C; Peterson, EJ; Lutz, PG; Eliason, S; Cave-Riant, F; Singer, A; Di Gioia, Y; Dmowski, S; Kamens, J; Cayre, YE; Koretzky, G				Moog-Lutz, C; Peterson, EJ; Lutz, PG; Eliason, S; Cave-Riant, F; Singer, A; Di Gioia, Y; Dmowski, S; Kamens, J; Cayre, YE; Koretzky, G			PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; T-CELLS; GRANULOCYTIC DIFFERENTIATION; MOLECULAR-CLONING; MAMMALIAN-CELLS; SLP-76; GENE; EXPRESSION; BINDING; TRANSLOCATION	The t(15;17) translocation, found in 95% of acute promyelocytic leukemia, encodes a promyelocytic leukemia (PML)-retinoic acid receptor alpha (RAR alpha) fusion protein. Complete remission of acute promyelocytic leukemia can be obtained by treating patients with all-trans retinoic acid, and PML-RAR alpha plays a major role in mediating retinoic acid effects in leukemia cells. A main model proposed for acute promyelocytic leukemia is that PML-RAR alpha exerts its oncogenic effects by repressing the expression of retinoic acid-inducible genes critical to myeloid differentiation. By applying subtraction cloning to acute promyelocytic leukemia cells, we identified a retinoic acid-induced gene, PRAM-1 ((P) under bar ML-RAR alpha target gene encoding an (A) under bar daptor (M) under bar olecule-1), which encodes a novel adaptor protein sharing structural homologies with the SLAP-130/fyb adaptor. PRAM-1 is expressed and regulated during normal human myelopoiesis. In U937 myeloid precursor cells, PRAM-1 expression is inhibited by expression of PML-RAR alpha in the absence of ligand and de novo superinduced by retinoic acid. PRAM-1 associates with other adaptors, SLP-76 and SKAP-55HOM, in myeloid cell lines and with protein tyrosine kinase lyn. By providing the first evidence that PML-RAR alpha dysregulates expression of an adaptor protein, our data open new insights into signaling events that are disrupted during transformation by PML-RAR alpha and induced by retinoic acid during de novo differentiation of acute promyelocytic leukemia cells.	Hop St Antoine, INSERM U417, F-75012 Paris, France; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; BASF Biores Corp, Worcester, MA 01605 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Immunol Microbiol, Philadelphia, PA 19107 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; BASF; Jefferson University	Cayre, YE (corresponding author), Hop St Antoine, INSERM U417, F-75012 Paris, France.	cayre@st-antoine.inserm.fr	MOOG-LUTZ, Christel/F-1975-2011; Koretzky, Gary/AAU-5381-2021; Peterson, Erik/M-9365-2013; Lutz, Pierre/B-8822-2009	Kamens, Joanne/0000-0002-7000-1477; Lutz, Pierre/0000-0003-0590-9101				Boerth NJ, 2000, J BIOL CHEM, V275, P5143, DOI 10.1074/jbc.275.7.5143; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Botling J, 1997, J BIOL CHEM, V272, P9443; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Geng LP, 1999, J IMMUNOL, V163, P5753; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Kouroku Y, 1998, BIOCHEM BIOPH RES CO, V252, P738, DOI 10.1006/bbrc.1998.9637; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; LANOTTE M, 1991, BLOOD, V77, P1080; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lutz P, 1997, J VIROL, V71, P5102, DOI 10.1128/JVI.71.7.5102-5109.1997; Lutz PG, 2000, P NATL ACAD SCI USA, V97, P1601, DOI 10.1073/pnas.97.4.1601; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; ROWLEY JD, 1977, LANCET, V1, P549; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	40	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22375	22381		10.1074/jbc.M011683200	http://dx.doi.org/10.1074/jbc.M011683200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11301322	hybrid			2022-12-25	WOS:000169412700055
J	Lin, F; Monaco, G; Sun, T; Liu, JX; Lin, H; Stephens, C; Belmont, J; Arlinghaus, RB				Lin, F; Monaco, G; Sun, T; Liu, JX; Lin, H; Stephens, C; Belmont, J; Arlinghaus, RB			BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model	ONCOGENE			English	Article						Bcr; Bcr-Abl; chronic myelogenous leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; 1ST EXON; P160 BCR; IN-VIVO; C-ABL; MICE; SEQUENCES; ONCOGENE	It is well accepted that the Bcr-Abl oncoprotein encoded by the Philadelphia chromosome is responsible for causing chronic myelogenous leukemia (CML), We have previously demonstrated that expression of Bcr interferes with the oncogenic effects of Bcr-Abl, To examine the effects of increased Bcr expression on Bcr-Abl oncogenic effects in a more physiological system, we tested the leukemogenic potential of a clone of K562 cells (K6 K562) containing an inducible BCR gene in NOD/scid mice. In this clone, the BCR gene was placed under the control of a tetracycline (Tet) repression system with a cytomegalovirus (CMV) promoter. Induction of exogenous Bcr protein by removal of Tet from the culture medium caused a dramatic increase in Bcr serine kinase activity, yielding predominantly phosphoserine Bcr, despite the presence of Bcr-Abl in the kinase reaction mixture. Prior to induction, the endogenous Bcr was predominantly in the phosphotyrosine form because of phosphorylation by Bcr-Abl, which we previously have shown suppresses Bcr serine/threonine kinase activity, Injection of K6 K562 cells into NOD/scid mice under conditions where BCR expression was suppressed resulted in death or terminal illness in 100% of the mice within 35 days after injection. These mice had a severe wasting syndrome characterized by atrophy of bone marrow hematopoiesis, and/or neoplasia of liver, bone marrow and spleen. Neoplastic spleens from these mice usually contained b3a2 Bcr-Abl transcripts. In contrast, induction of BCR expression at the time of injection allowed 80% survival; these healthy mice had no detectable microscopic lesions in blood forming organs. This difference in survival was significant with P<0.0001, Of interest, mire that were fed Tet for 19 days to initiate the disease syndrome and then released from the BCR transcriptional block had a significantly better survival pattern than mice exposed to Tet throughout the entire period. Moreover, 30% of these mice (three mice) survived through day 50, We conclude from these findings that BCR gene expression strongly inhibits the oncogenic effects of Bcr-Abl in NOD/scid mice, yielding healthy mice in most cases.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.		Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019	Belmont, John W/0000-0001-7409-3578	NCI NIH HHS [CA49639] Funding Source: Medline; PHS HHS [A16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CAMPBELL ML, 1990, ONCOGENE, V5, P773; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dazzi F, 1998, BLOOD, V92, P1390, DOI 10.1182/blood.V92.4.1390.416k09_1390_1396; DAZZI F, 1997, BLOOD S1, V90, P8; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hawk N., 1997, Blood, V90, p277B; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HU AZX, 1997, CANCER RES, V57, P3339; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; LI WJ, 1989, ONCOGENE, V4, P127; Lin F, 1996, BLOOD, V87, P4473, DOI 10.1182/blood.V87.10.4473.bloodjournal87104473; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524	26	24	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1873	1881		10.1038/sj.onc.1204409	http://dx.doi.org/10.1038/sj.onc.1204409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313935				2022-12-25	WOS:000167908400008
J	Michael, D; Rajewsky, MF				Michael, D; Rajewsky, MF			Induction of the common fragile site FRA3B does not affect FHIT expression	ONCOGENE			English	Article						FHIT gene; FRA3B; fragile sites; human chromosome 3	CANCER; GENE; TUMORIGENICITY; PROTEIN; CELLS; REPLICATION; 3P14.2; P53	A long-standing issue concerns the extent to which fragile sites predispose to cancer-associated chromosomal rearrangements. The FHIT gene at chromosome 3p14.2 spans the most common fragile site, FRA3B, in the human genome. Although the FHIT gene is altered in many human cancers, its status as a tumor suppressor gene has remained controversial, particularly since functional studies provided contradictory results. It had been suggested the FHIT alterations result from FRA3B induction promoted by the interference of carcinogens with DNA replication. Here we investigated the effect of FRA3B induction on FHIT expression. Common fragile sites were induced by treatment with aphidicolin and scored cytogenetically, FHIT transcription was analysed by RT-PCR and RNase protection analysis. Unexpectedly, FHIT transcription proceeded unchanged after fragile site induction. Aberrant FHIT transcripts lacking one or more exons were not observed. Morevover, Western blots revealed that the levels of FHIT prior to and following fragile site induction was unchanged, whereas p53 was found at elevated levels after induction. FRA3B induction thus has no direct effect on FHIT transcription and translation.	Univ Essen, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Univ Essen, Sch Med, Dept Internal Med Canc Res, D-45122 Essen, Germany; W German Canc Ctr, D-45122 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Michael, D (corresponding author), Univ Essen, Sch Med, Inst Cell Biol Canc Res, Hufeland Str 55, D-45122 Essen, Germany.							Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; GILMANN M, 1993, CURRENT PROTOCOLS MO; GLOVER TW, 1987, AM J HUM GENET, V41, P882; Gustashaw KM., 1991, ACT CYTOGENETICS LAB, V2; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; MOSNER J, 1994, ONCOGENE, V9, P3321; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Thiagalingam S, 1996, CANCER RES, V56, P2936; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; WENGER SL, 1987, AM J MED GENET, V26, P909, DOI 10.1002/ajmg.1320260419; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	24	6	6	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1798	1801		10.1038/sj.onc.1204243	http://dx.doi.org/10.1038/sj.onc.1204243			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313927				2022-12-25	WOS:000167750900013
J	Park, SH; Kim, YS; Park, BK; Hougaard, S; Kim, SJ				Park, SH; Kim, YS; Park, BK; Hougaard, S; Kim, SJ			Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TCF-beta type II receptor expression	ONCOGENE			English	Article						TGF-beta type II receptor; ets transcription factor; promoter; enhancer; gastric cancer	GROWTH-FACTOR-BETA; ETS TRANSCRIPTION FACTOR; TGF-BETA; MICROSATELLITE INSTABILITY; GENOMIC ORGANIZATION; FAMILY; MEMBER; INACTIVATION; REPRESSION; RESISTANCE	Transcriptional repression of the TGF-beta type II receptor (RII) is one of the mechanisms leading to TGF-beta resistance. The newly identified epithelium-specific ets transcription factor ERT/ESX/ELF-3/ESE-1/jen binds to the TGF-beta RII promoter and induces promoter activity. The human gastric cancer cell lines, which show undetectable level of TGF-beta RII mRNA, do not express ERT mRNA, To study the molecular mechanisms of loss of ERT expression, we have cloned and characterized the human ERT promoter, DNA transfection experiments and electrophoretic mobility shift assays have revealed the existence of a distinct enhancer element (-186 to -177) which we named ESE ((E) under bar RT promoter Specific element). Deletion of the ESE markedly decreased expression of the target gene. ESE interacts with two distinct nuclear protein complexes, at least one of which appears to be inactivated in a cell line which does not express the ERT mRNA, compared to a cell line expressing the ERT mRNA, These results suggest the possibility that inactivation of the sequence-specific DNA binding protein to the region from -186 to -177 contributes to the loss of ERT expression, leading to the loss of TGF-beta type II receptor mRNA in human gastric cancer cell lines.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Gyeongsang Natl Univ, Coll Med, Dept Pediat, Chinju 660702, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gyeongsang National University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.							Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Horie K, 1998, J CELL PHYSIOL, V175, P305, DOI 10.1002/(SICI)1097-4652(199806)175:3<305::AID-JCP8>3.0.CO;2-S; Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161; KADIN M, 1994, P NATL ACAD SCI USA, V9, P6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim DH, 1997, J BIOL CHEM, V272, P688; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MYEROFF LL, 1995, CANCER RES, V55, P5545; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Reiss M, 1997, ONCOL RES, V9, P447; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535	32	17	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1235	1245		10.1038/sj.onc.1204227	http://dx.doi.org/10.1038/sj.onc.1204227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313868				2022-12-25	WOS:000167570100011
J	Baker, SJ; Sumerson, R; Reddy, CD; Berrebi, AS; Flynn, DC; Reddy, EP				Baker, SJ; Sumerson, R; Reddy, CD; Berrebi, AS; Flynn, DC; Reddy, EP			Characterization of an alternatively spliced AATYK mRNA: Expression pattern of AATYK in the brain and neuronal cells	ONCOGENE			English	Article						AATYK; alternative splicing; brain; neuron; differentiation; P19 cells	APOPTOSIS; KINASE; DEATH; ORGANIZATION; PROTEINS; GROWTH; SYSTEM	The AATYK gene encodes a tyrosine kinase whose expression is up-regulated during the apoptosis and differentiation of 32Dcl3 myelobalstic cells. Because high levels of AATYK mRNA have also been detected in the brain, and because these transcripts differ in size from that observed in the 32Dcl3 cell line, it was of interest to determine whether this gene encodes mRNAs that are alternatively spliced and whether these mRNAs are expressed in a tissue-specific manner. We have isolated a novel, alternatively spliced AATYK mRNA using cDNA library screening and RT-PCR, whose expression is readily detected in the brain but not myeloid cells. Western blot analysis revealed that the AATYK protein was expressed in virtually all regions of the adult rat brain in which neurons are present, including olfactory bulb, forebrain, cortex, midbrain, cerebellum and pens. Immunohistochemical labeling of adult brain sections showed the highest levels of AATYK expression in the cerebellum and olfactory bulb. Expression of AATYK was also up-regulated as a function of RA-induced neuronal differentiation of p19 embryonal carcinoma cells, supporting a role for this protein in mature neurons and neuronal differentiation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurooncol, Philadelphia, PA 19104 USA; W Virginia Univ, Sch Med, Dept Otolaryngol, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Anat Head & Neck Surg, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; West Virginia University; West Virginia University; West Virginia University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09225] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTMAN J, 1975, J COMP NEUROL, V163, P427, DOI 10.1002/cne.901630404; Berrebi AS, 1998, NEUROSCIENCE, V83, P535, DOI 10.1016/S0306-4522(97)00407-7; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; Palay S. L., 1974, CEREBELLAR CORTEX CY; Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6	14	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1015	1021		10.1038/sj.onc.1204209	http://dx.doi.org/10.1038/sj.onc.1204209			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314039				2022-12-25	WOS:000167232100001
J	Tomomura, M; Fernandez-Gonzales, A; Yano, R; Yuzaki, M				Tomomura, M; Fernandez-Gonzales, A; Yano, R; Yuzaki, M			Characterization of the apoptosis-associated tyrosine kinase (AATYK) expressed in the CNS	ONCOGENE			English	Article						apoptosis; tyrosine kinase; phosphorylation; brain; cerebellum; Purkinje cells	CEREBELLAR GRANULE NEURONS; CELL-DEATH; C-JUN; PURKINJE-CELLS; MESSENGER-RNA; GROWTH-FACTOR; SURVIVAL; PROTEIN; DEPOLARIZATION; ACTIVATION	We isolated three related cDNA clones from a mouse cerebellar library; the type I cDNA was identical to the gene encoding the apoptosis-associated tyrosine kinase (AATYK), whose expression in myeloid precursor cells is increased during growth arrest or apoptosis, Low levels of AATYK mRNA expression mere seen in adult mouse brains but not in embryos. In situ hybridization confirmed the widespread expression of AATYK mRNA in neurons throughout the adult brain. AATYK possessed tyrosine kinase activity and was autophosphorylated when expressed in 293 cells. AATYK mRNA expression was rapidly induced in cultured cerebellar granule cells during apoptosis induced by a low concentration of KCl (5 mid). Levels of endogenous AATYK protein were increased only slightly, but they were accompanied by an increase in molecular weight during apoptosis, Results of the tyrosine phosphatase treatments indicated that the increase in molecular weight was partly caused by tyrosine phosphorylation, The number of apoptotic granule cells overexpressing mild-type AATYK protein was significantly greater than the number of apoptotic granule cells overexpressing a mutant AATYK that lacked tyrosine kinase activity in low concentrations of RCl. These findings suggest that through its tyrosine kinase activity, AATYK is involved in the apoptosis of mature neurons.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; RIKEN, Brain Sci Inst, Lab Cellular Informat Proc, Wako, Saitama 35101, Japan	St Jude Children's Research Hospital; RIKEN	Yuzaki, M (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Yuzaki, Michisuke/K-5328-2013	Yuzaki, Michisuke/0000-0002-5750-3544	NCI NIH HHS [CA21765] Funding Source: Medline; NINDS NIH HHS [NS36925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; BORASIO GD, 1989, NEURON, V2, P1087; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Damgaard I, 1996, NEUROCHEM RES, V21, P267, DOI 10.1007/BF02529144; DRISCOLL BF, 1991, J NEUROCHEM, V56, P1201, DOI 10.1111/j.1471-4159.1991.tb11411.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eilers A, 1998, J NEUROSCI, V18, P1713; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLO V, 1987, J NEUROSCI, V7, P2203; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Gilmore EC, 2000, TRENDS NEUROSCI, V23, P100, DOI 10.1016/S0166-2236(99)01503-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Kurschner C, 1999, J NEUROSCI, V19, P7770; LI Y, 1995, STROKE, V26, P1252, DOI 10.1161/01.STR.26.7.1252; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; Miller TM, 1996, J NEUROSCI, V16, P7487; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P543; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Watson A, 1998, J NEUROSCI, V18, P751; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; YUZAKI M, 1992, J NEUROSCI, V12, P4253; Yuzaki M, 1996, J NEUROSCI, V16, P4651; YUZAKI M, 1994, LEARN MEMORY, V1, P230	44	34	36	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1022	1032		10.1038/sj.onc.1204210	http://dx.doi.org/10.1038/sj.onc.1204210			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314040				2022-12-25	WOS:000167232100002
J	Zvara, A; Fajardo, JE; Escalante, M; Cotton, G; Muir, T; Kirsch, KH; Birge, RB				Zvara, A; Fajardo, JE; Escalante, M; Cotton, G; Muir, T; Kirsch, KH; Birge, RB			Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II	ONCOGENE			English	Article						Crk; adaptor proteins; SH3 linker region; C-terminal SH3 domain; tyrosine phosphorylation; focal adhesion kinase	MEDIATED CELL-ADHESION; TYROSINE-PHOSPHORYLATION; ADAPTER PROTEIN; SH3 DOMAIN; PTP-PEST; V-CRK; SRC; P130(CAS); SUBSTRATE; RAS	The Crk II adaptor protein encodes an SH2/SH3-domain containing adaptor protein with an SH2-SH3-SH3 domain structure that transmits signals from tyrosine kinases, The two SH3 domains are separated by a 54 amino acid linker region, whose length is highly conserved in xenopus, chicken, and mamalian Crk II proteins. To gain a better understanding into the role of the C-terminal region of Crk, we generated a series of C-terminal SH3 domain and SH3 linker mutants and examined their role in tyrosine kinase pathways. Expression of point mutations in the C-terminal SH3 domain (W276K Crk), at the tyrosine phosphorylation site (Y222F Crk II), or truncation of the entire C-terminus (Crk I or Crk Delta 242), all increased c-Abl binding to the N-terminal SH3 domain of Crk and, where relevant, increased Tyr(222) phosphorylation, Deletion analysis of c-Crk II also revealed the presence of a C-terminal segment important for transactivation of FAK. Such mutants, Crk Delta 255 or Crk Delta 242 Extended Linker (Crk Delta 242([EL])), characterized by a disruption in the SH3 linker/C-terminal SH3 boundary, induced robust hyperphosphorylation of focal adhesion kinase (FAK) on Tyr(397), hyperphosphorylation of focal adhesion proteins p130(cas) and paxillin and increased focal adhesion formation in NIH3T3 cells. The effects of Crk Delta 242([EL]) could be abrogated by co-expression of dominant negative c-Src or the protein tyrosine phosphatase PTP - PEST, but not by dominant negative Abl. Our results suggest that the C-terminal region of Crk contains negative regulatory elements important for both Abl and FAK dependent signal pathways, and offers a paradigm for an autoinhibitory region in the SH3 linker/C-terminal SH3 domain.	Rockefeller Univ, Oncol Mol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Birge, RB (corresponding author), Rockefeller Univ, Oncol Mol Lab, 1230 York Ave, New York, NY 10021 USA.		Muir, Tom/AHD-0860-2022	Muir, Tom/0000-0001-9635-0344; Kirsch, Kathrin/0000-0003-1532-1715	NIGMS NIH HHS [GM55760] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Ling P, 1999, MOL CELL BIOL, V19, P1359; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4	53	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					951	961		10.1038/sj.onc.1204173	http://dx.doi.org/10.1038/sj.onc.1204173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314030				2022-12-25	WOS:000167097000006
J	Karayan, L; Riou, JF; Seite, P; Migeon, J; Cantereau, A; Larsen, CJ				Karayan, L; Riou, JF; Seite, P; Migeon, J; Cantereau, A; Larsen, CJ			Human ARF protein interacts with Topoisomerase I and stimulates its activity	ONCOGENE			English	Article						p14(ARF); Topoisomerase I; protein interactions	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; BETA-TRANSCRIPT; DNA; P19(ARF); MDM2; GENE; LOCUS; PRODUCT	The ARF gene (p19(ARF) in mouse and p14(ARF) in man) has become a central actor of the cell cycle regulation process as it participates to the ARF-MDM2-p53 pathway and the Rh-E2F-1 pathway. By use of immunoprecipitation and Western blotting (IP/WB), we now show that ARF physically associates with Topoisomerase I(Topo I), ARF-Topo I immune complexes were detected in SF9 insect cells infected with recombinant baculoviruses encoding the two genes as well as in 293 cells that express endogeneously these proteins. Preparations of a GST-ARF recombinant protein stimulated the DNA relaxation activity of Topo I but, in contrast, had no effect an the decatenation activity of Topo TT, The Topo I stimulation was also detected in cell extracts of SF9 cells expressing both proteins, A confocal microscopy study indicated that part of ARF and Topo I colocalized in the granular component structure of the nucleolus. As a whole, our data indicate that Topo I is a new partner of ARF and suggest that ARF is involved in cell reactions that require Topo I.	CHU Poitiers, Lab Biochim Prot, Poitiers, France; Oncol Mol Lab, CNRS, FRE 2224, Poitiers, France; IFR Commun Intercellulaire, CNRS, UMR 6558, Serv Cytofluorometrie, F-86021 Poitiers, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Aventis Pharma, F-94403 Vitry Sur Seine, France	CHU Poitiers; Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Sanofi-Aventis; Sanofi France	Larsen, CJ (corresponding author), CHU Poitiers, Lab Biochim Prot, Poitiers, France.			riou, jean-francois/0000-0002-0055-6506; Seite, Paule/0000-0002-7809-7610				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Becker T., 1902, MITTEILUNGEN ZOOLOGI, V2, P1, DOI [10.1002/mmnz.4830020237, DOI 10.1002/MMNZ.4830020237]; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DURO D, 1995, ONCOGENE, V11, P21; EYMIN B, 2000, IN PRESS ONCOGENE; Gazzeri S, 1998, CANCER RES, V58, P3926; Gimenez-Abian JF, 2000, CHROMOSOMA, V109, P235, DOI 10.1007/s004120000065; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hao YW, 1997, BIOCHEM BIOPH RES CO, V234, P194, DOI 10.1006/bbrc.1997.6539; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kill IR, 1996, J CELL SCI, V109, P1253; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Kwon Y, 2000, J BIOL CHEM, V275, P18503, DOI 10.1074/jbc.M002081200; Larsen A K, 1999, Pathol Oncol Res, V5, P171, DOI 10.1053/paor.1999.0209; LARSEN CJ, 1997, PROGR CELL CYCLE RES, P109; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MAO L, 1995, CANCER RES, V55, P2995; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; NITISS JL, 1996, DNA TOPOISOMERASE DN; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; RUAS, 1998, BIOCH BIPHYS ACTA, V1378, P115; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; TAN KB, 1992, CANCER RES, V52, P231; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tazi J, 1997, J MOL MED, V75, P786, DOI 10.1007/s001090050168; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	77	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					836	848		10.1038/sj.onc.1204170	http://dx.doi.org/10.1038/sj.onc.1204170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314011				2022-12-25	WOS:000166924400007
J	Benaud, CM; Dickson, RB				Benaud, CM; Dickson, RB			Regulation of the expression of c-Myc by beta 1 integrins in epithelial cells	ONCOGENE			English	Article						c-Myc; adhesion; integrin; Src; PKC; MAPK	ACTIVATED PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; BETA(1C) INTEGRIN; EGF RECEPTOR; CYCLIN D1; IN-VIVO; ADHESION; SRC; GROWTH; INDUCTION	Cell adhesion promotes cellular proliferation through the regulation of gene expression, including the immediate early genes. However, the precise role of cell adhesion in the regulation of the c-Myc proto-oncogene is not clear, and the adhesion-dependent signaling pathway(s) regulating the expression of c-Myc has yet to be defined. We now show that integrin signaling directly regulates the expression of c-Myc in the mammary epithelial cell line 184A1N4 (A1N4), Adhesion of quiescent A1N4 cells to fibronectin, and to collagen types IV or I, induces the expression of c-Myc in an ECM concentration-dependent fashion. Cytoskeletal rearrangement, and integrin engagement and integrin clustering are required for the induction of c-Myc by fibronectin. Furthermore, beta1 integrin function-blocking antibodies prevent the adhesion-dependent induction of c-Myc. Adhesion of A1N4 cells results in the activation both of c-Src and of the Erk 1/2 mitogen-activated protein kinase (MAPK), each of which precedes the induction of c-Myc. Pharmacological inhibitors specific for either the c-Src family of kinases or for MEK1 block the adhesion-dependent induction of c-Myc. These observations indicate that pi integrins regulate the expression of c-Myc through the activation of the Src family of tyrosine kinases and the MAI( kinase pathway.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.		Benaud, Christelle/M-1178-2018		NIA NIH HHS [R01AG1496] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aziz N, 1999, MOL CELL BIOL, V19, P1101; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dike LE, 1996, J CELL SCI, V109, P2855; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faraldo MM, 1998, EMBO J, V17, P2139, DOI 10.1093/emboj/17.8.2139; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Fornaro M, 1998, AM J PATHOL, V153, P1079, DOI 10.1016/S0002-9440(10)65652-0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; Manzotti M, 2000, AM J PATHOL, V156, P169, DOI 10.1016/S0002-9440(10)64716-5; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MORTARINI R, 1995, CANCER RES, V55, P4702; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; UDAGAWA T, 1995, CLIN EXP METASTAS, V13, P427, DOI 10.1007/BF00118182; VUORI K, 1993, J BIOL CHEM, V268, P21459; WATT R, 1983, NATURE, V303, P231; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; YAMADA KM, 1990, CANCER RES, V50, P4485	43	24	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					759	768		10.1038/sj.onc.1204152	http://dx.doi.org/10.1038/sj.onc.1204152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314009				2022-12-25	WOS:000166806000011
J	Reiss, K; Wang, JY; Romano, G; Tu, X; Peruzzi, F; Baserga, R				Reiss, K; Wang, JY; Romano, G; Tu, X; Peruzzi, F; Baserga, R			Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; cell adhesion; cell motility; signal transduction	GROWTH-FACTOR-I; SERINE KINASE PHOSPHORYLATES; DOMINANT-NEGATIVE MUTANT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; RETROVIRAL VECTORS; LIGAND OCCUPANCY; BINDING-PROTEINS	LNCaP cells are human prostatic cancer cells that have a frame-shift mutation of the tumor suppressor gene PTEN and do not express the insulin receptor substrate-1 (IRS-I), a major substrate of the type 1 insulin-like growth factor receptor (IGF-IR). Ectopic expression of IRS-1 in LNCaP cells increases cell adhesion and decreases cell motility by an IGF-I-independent mechanism. We show nom that these effects of IRS-1 are accompanied by serine phosphorylation of IRS-1 and are inhibited by inhibitors of phosphatidylinositol 3-kinase (PI3K), We have confirmed the requirement for PI3K activity and serine phosphorylation by the use of IRS-1 mutants, expressed in LNCaP cells. Serine phosphorylation inhibits IGF-I-induced tyrosyl phosphorylation of IRS-1, which is restored by the expression of wild-type PTEN or by inhibition of PI3K activity. Finally, IRS-1 in LNCaP cells co-immunoprecipitates with integrin alpha 5 beta 1, and the association is again IGF-I-independent. We conclude that in LNCaP cells, IRS-1 is serine phosphorylated by PI3K, generating effects that are different, and even opposite, from those generated by IGF-I.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 624 Biol Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.		Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NINDS NIH HHS [P0-1 NS 36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baserga R, 1999, CONT ENDOCRINOL, V17, P329; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Carson JP, 1999, CANCER RES, V59, P1449; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Davies MA, 1999, CANCER RES, V59, P2551; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; Furnari FB, 1998, CANCER RES, V58, P5002; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HAWLEY RG, 1994, GENE THER, V1, P136; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; LAM K, 1994, J BIOL CHEM, V269, P20648; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zheng DQ, 1999, CANCER RES, V59, P1655	61	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					490	500		10.1038/sj.onc.1204112	http://dx.doi.org/10.1038/sj.onc.1204112			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313980				2022-12-25	WOS:000166562500009
